DrugMAP Full Data Download File Title - DrugMAP drug to drug therapeutic target (DTT) mapping with mode of action information in raw format Version 1.01 (2022.07.20) Provided by Lab of Innovative Drug Reasearch and Bioinformatics (IDRB) College of Pharmaceutical Sciences Zhejiang University https://idrblab.org/ Any question about data provided here, please contact with: Dr. Li (lifengcheng@zju.edu.cn) and Dr. Yin (yinjiayi@zju.edu.cn) DI: Drug_ID DN: Drug_Name TI: DTT_ID TN: DTT_Name MA: MOA RN: Reference_Name RU: Reference_URL DM02A65 DI DM02A65 DM02A65 DN Temazepam DM02A65 TI TTPTXIN DM02A65 TN Translocator protein (TSPO) DM02A65 MA Modulator DM02A65 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM02A65 RU https://www.fda.gov/ DM02AWV DI DM02AWV DM02AWV DN Tolbutamide DM02AWV TI TTEF5MJ DM02AWV TN ATP-binding cassette transporter C9 (ABCC9) DM02AWV MA Blocker DM02AWV RN Expression of an activating mutation in the gene encoding the KATP channel subunit Kir6.2 in mouse pancreatic beta cells recapitulates neonatal diabetes. J Clin Invest. 2009 Jan;119(1):80-90. DM02AWV RU https://pubmed.ncbi.nlm.nih.gov/19065048 DM02AWV DI DM02AWV DM02AWV DN Tolbutamide DM02AWV TI TTP835K DM02AWV TN ATP-binding cassette transporter C8 (ABCC8) DM02AWV MA Blocker DM02AWV RN Expression of an activating mutation in the gene encoding the KATP channel subunit Kir6.2 in mouse pancreatic beta cells recapitulates neonatal diabetes. J Clin Invest. 2009 Jan;119(1):80-90. DM02AWV RU https://pubmed.ncbi.nlm.nih.gov/19065048 DM03CP7 DI DM03CP7 DM03CP7 DN Calcipotriol DM03CP7 TI TTK59TV DM03CP7 TN Vitamin D3 receptor (VDR) DM03CP7 MA Antagonist DM03CP7 RN Cellular and molecular mechanisms involved in the action of vitamin D analogs targeting vitiligo depigmentation. Curr Drug Targets. 2008 Apr;9(4):345-59. DM03CP7 RU https://pubmed.ncbi.nlm.nih.gov/18393827 DM04LR2 DI DM04LR2 DM04LR2 DN Floxuridine DM04LR2 TI TTU6BFZ DM04LR2 TN Candida Thymidylate synthase (Candi TMP1) DM04LR2 MA Inhibitor DM04LR2 RN Antisense down-regulation of thymidylate synthase to suppress growth and enhance cytotoxicity of 5-FUdR, 5-FU and Tomudex in HeLa cells. Br J Pharmacol. 1999 Aug;127(8):1777-86. DM04LR2 RU https://pubmed.ncbi.nlm.nih.gov/10482907 DM053KT DI DM053KT DM053KT DN Aprepitant DM053KT TI TTZPO1L DM053KT TN Substance-P receptor (TACR1) DM053KT MA Antagonist DM053KT RN Potent, brain-penetrant, hydroisoindoline-based human neurokinin-1 receptor antagonists. J Med Chem. 2009 May 14;52(9):3039-46. DM053KT RU https://pubmed.ncbi.nlm.nih.gov/19354254 DM05968 DI DM05968 DM05968 DN Otilonium bromide DM05968 TI TTXHYV6 DM05968 TN Voltage-gated L-type calcium channel (L-CaC) DM05968 MA Blocker DM05968 RN Emerging drugs for irritable bowel syndrome. Expert Opin Emerg Drugs. 2006 May;11(2):293-313. DM05968 RU https://pubmed.ncbi.nlm.nih.gov/16634703 DM05FXR DI DM05FXR DM05FXR DN Meclofenamic acid DM05FXR TI TTK0943 DM05FXR TN Prostaglandin G/H synthase (COX) DM05FXR MA Inhibitor DM05FXR RN Interactions of PGH synthase isozymes-1 and -2 with NSAIDs. Ann N Y Acad Sci. 1994 Nov 15;744:50-7. DM05FXR RU https://pubmed.ncbi.nlm.nih.gov/7825862 DM0659E DI DM0659E DM0659E DN Cannabidiol DM0659E TI TT94IAG DM0659E TN Cannabinoid receptor (CB) DM0659E MA Binder DM0659E RN (-)-Cannabidiol antagonizes cannabinoid receptor agonists and noradrenaline in the mouse vas deferens. Eur J Pharmacol. 2002 Dec 5;456(1-3):99-106. DM0659E RU https://pubmed.ncbi.nlm.nih.gov/12450575 DM06HG5 DI DM06HG5 DM06HG5 DN Levomethadyl Acetate DM06HG5 TI TTKWM86 DM06HG5 TN Opioid receptor mu (MOP) DM06HG5 MA Agonist DM06HG5 RN Methadone-related opioid agonist pharmacotherapy for heroin addiction. History, recent molecular and neurochemical research and future in mainstream medicine. Ann N Y Acad Sci. 2000;909:186-216. DM06HG5 RU https://pubmed.ncbi.nlm.nih.gov/10911931 DM07K2I DI DM07K2I DM07K2I DN Eprosartan DM07K2I TI TT8DBY3 DM07K2I TN Angiotensin II receptor type-1 (AGTR1) DM07K2I MA Antagonist DM07K2I RN Clinical profile of eprosartan: a different angiotensin II receptor blocker. Cardiovasc Hematol Agents Med Chem. 2008 Oct;6(4):253-7. DM07K2I RU https://pubmed.ncbi.nlm.nih.gov/18855637 DM07TX3 DI DM07TX3 DM07TX3 DN Cefotetan DM07TX3 TI TTJP4SM DM07TX3 TN Bacterial Penicillin binding protein (Bact PBP) DM07TX3 MA Binder DM07TX3 RN In-vitro profile of a new beta-lactam, ceftobiprole, with activity against methicillin-resistant Staphylococcus aureus. Clin Microbiol Infect. 2007 Jun;13 Suppl 2:17-24. DM07TX3 RU https://pubmed.ncbi.nlm.nih.gov/17488372 DM07U2A DI DM07U2A DM07U2A DN Estradiol acetate DM07U2A TI TTZAYWL DM07U2A TN Estrogen receptor (ESR) DM07U2A MA Modulator DM07U2A RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM07U2A RU https://www.fda.gov/ DM08E9O DI DM08E9O DM08E9O DN Diazepam DM08E9O TI TTPTXIN DM08E9O TN Translocator protein (TSPO) DM08E9O MA Agonist DM08E9O RN Translocator protein (18 kDa) mediates the pro-growth effects of diazepam on Ehrlich tumor cells in vivo. Eur J Pharmacol. 2010 Jan 25;626(2-3):131-8. DM08E9O RU https://pubmed.ncbi.nlm.nih.gov/19782064 DM0AQ83 DI DM0AQ83 DM0AQ83 DN Emicizumab DM0AQ83 TI TTFEZ5Q DM0AQ83 TN Coagulation factor IX (F9) DM0AQ83 MA Modulator DM0AQ83 RN 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85. DM0AQ83 RU https://pubmed.ncbi.nlm.nih.gov/29348678 DM0AQ83 DI DM0AQ83 DM0AQ83 DN Emicizumab DM0AQ83 TI TTCIHJA DM0AQ83 TN Coagulation factor Xa (F10) DM0AQ83 MA Modulator DM0AQ83 RN 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85. DM0AQ83 RU https://pubmed.ncbi.nlm.nih.gov/29348678 DM0AUCH DI DM0AUCH DM0AUCH DN Reslizumab DM0AUCH TI TTPREZD DM0AUCH TN Interleukin-5 (IL5) DM0AUCH MA Modulator DM0AUCH RN The potential of biologics for the treatment of asthma. Nat Rev Drug Discov. 2012 Dec;11(12):958-72. DM0AUCH RU https://www.ncbi.nlm.nih.gov/pubmed/23197041 DM0BQRS DI DM0BQRS DM0BQRS DN Spinosad DM0BQRS TI TT9JZPU DM0BQRS TN Pediculus humanus Nicotinic acetylcholine receptor (Pedhc nAChR) DM0BQRS MA Modulator DM0BQRS RN 2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4. DM0BQRS RU https://pubmed.ncbi.nlm.nih.gov/22293555 DM0C9IL DI DM0C9IL DM0C9IL DN Ranolazine DM0C9IL TI TTP86E2 DM0C9IL TN Plasminogen (PLG) DM0C9IL MA Modulator DM0C9IL RN Tranexamic acid in trauma: how should we use it. J Trauma Acute Care Surg. 2013 Jun;74(6):1575-86. DM0C9IL RU https://pubmed.ncbi.nlm.nih.gov/23694890 DM0CVXA DI DM0CVXA DM0CVXA DN Mechlorethamine DM0CVXA TI TTUTN1I DM0CVXA TN Human Deoxyribonucleic acid (hDNA) DM0CVXA MA Intercalator DM0CVXA RN Proteomic analysis of DNA-protein cross-linking by antitumor nitrogen mustards. Chem Res Toxicol. 2009 Jun;22(6):1151-62. DM0CVXA RU https://pubmed.ncbi.nlm.nih.gov/19480393 DM0D9YJ DI DM0D9YJ DM0D9YJ DN Dirithromycin DM0D9YJ TI TTUWYEA DM0D9YJ TN Bacterial 50S ribosomal RNA (Bact 50S rRNA) DM0D9YJ MA Binder DM0D9YJ RN Review of macrolides and ketolides: focus on respiratory tract infections. Drugs. 2001;61(4):443-98. DM0D9YJ RU https://pubmed.ncbi.nlm.nih.gov/11324679 DM0DQM5 DI DM0DQM5 DM0DQM5 DN Amlexanox DM0DQM5 TI TT78R5H DM0DQM5 TN Heat shock protein 90 alpha (HSP90A) DM0DQM5 MA Inhibitor DM0DQM5 RN Hsp90 is a direct target of the anti-allergic drugs disodium cromoglycate and amlexanox. Biochem J. 2003 Sep 1;374(Pt 2):433-41. DM0DQM5 RU https://pubmed.ncbi.nlm.nih.gov/12803546 DM0DTF7 DI DM0DTF7 DM0DTF7 DN Zonisamide DM0DTF7 TI TTRK8B9 DM0DTF7 TN Sodium channel unspecific (NaC) DM0DTF7 MA Blocker DM0DTF7 RN Antiepileptic drugs and relapse after epilepsy surgery. Epileptic Disord. 2008 Sep;10(3):193-8. DM0DTF7 RU https://pubmed.ncbi.nlm.nih.gov/18782687 DM0DXA8 DI DM0DXA8 DM0DXA8 DN Droperidol DM0DXA8 TI TTEX248 DM0DXA8 TN Dopamine D2 receptor (D2R) DM0DXA8 MA Binder DM0DXA8 RN Alpha-adrenergic blockade: a possible mechanism of tocolytic action of certain benzodiazepines in a postpartum rat model in vivo. Life Sci. 2003 Jan 24;72(10):1093-102. DM0DXA8 RU https://pubmed.ncbi.nlm.nih.gov/12505540 DM0E6S3 DI DM0E6S3 DM0E6S3 DN Suvorexant DM0E6S3 TI TT9N02I DM0E6S3 TN Orexin receptor type 2 (HCRTR2) DM0E6S3 MA Modulator DM0E6S3 RN 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81. DM0E6S3 RU https://pubmed.ncbi.nlm.nih.gov/25633781 DM0EP7M DI DM0EP7M DM0EP7M DN Minaprine DM0EP7M TI TT0K1SC DM0EP7M TN 5-HT 2B receptor (HTR2B) DM0EP7M MA Antagonist DM0EP7M RN Privileged structures: a useful concept for the rational design of new lead drug candidates. Mini Rev Med Chem. 2007 Nov;7(11):1108-19. DM0EP7M RU https://pubmed.ncbi.nlm.nih.gov/18045214 DM0EZ9Q DI DM0EZ9Q DM0EZ9Q DN Pramlintide DM0EZ9Q TI TTVIMDE DM0EZ9Q TN Glucagon-like peptide 1 receptor (GLP1R) DM0EZ9Q MA Agonist DM0EZ9Q RN Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60. DM0EZ9Q RU https://pubmed.ncbi.nlm.nih.gov/16083333 DM0FB1J DI DM0FB1J DM0FB1J DN Sertraline DM0FB1J TI TT3ROYC DM0FB1J TN Serotonin transporter (SERT) DM0FB1J MA Inhibitor DM0FB1J RN Psychopharmacological treatment of dermatological patients--when simply talking does not help. J Dtsch Dermatol Ges. 2007 Dec;5(12):1101-6. DM0FB1J RU https://pubmed.ncbi.nlm.nih.gov/17877739 DM0FSIM DI DM0FSIM DM0FSIM DN Diphtheria-tetanus vaccine DM0FSIM TI TTXT4D5 DM0FSIM TN Bacterial Cell membrane (Bact CM) DM0FSIM RN 2006 drug approvals: finding the niche. Nat Rev Drug Discov. 2007 Feb;6(2):99-101. DM0FSIM RU https://pubmed.ncbi.nlm.nih.gov/17342860 DM0GOUD DI DM0GOUD DM0GOUD DN Urokinase DM0GOUD TI TTGY7WI DM0GOUD TN Urokinase-type plasminogen activator (PLAU) DM0GOUD MA Modulator DM0GOUD RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM0GOUD RU https://www.fda.gov/ DM0GQ8N DI DM0GQ8N DM0GQ8N DN Amobarbital DM0GQ8N TI TT1MPAY DM0GQ8N TN GABA(A) receptor alpha-1 (GABRA1) DM0GQ8N MA Antagonist DM0GQ8N RN DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6. DM0GQ8N RU https://pubmed.ncbi.nlm.nih.gov/18048412 DM0GUSX DI DM0GUSX DM0GUSX DN Ranitidine DM0GUSX TI TTQHJ1K DM0GUSX TN Histamine H2 receptor (H2R) DM0GUSX MA Antagonist DM0GUSX RN Knockouts model the 100 best-selling drugs--will they model the next 100 Nat Rev Drug Discov. 2003 Jan;2(1):38-51. DM0GUSX RU https://pubmed.ncbi.nlm.nih.gov/12509758 DM0HAC8 DI DM0HAC8 DM0HAC8 DN Cerliponase Alfa DM0HAC8 TI TTOVYPT DM0HAC8 TN Tripeptidyl-peptidase I (TPP1) DM0HAC8 MA Modulator DM0HAC8 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM0HAC8 RU https://www.fda.gov/ DM0HS92 DI DM0HS92 DM0HS92 DN Merimepodib DM0HS92 TI TT6EO5L DM0HS92 TN Erbb2 tyrosine kinase receptor (HER2) DM0HS92 MA Inhibitor DM0HS92 RN Clinical pipeline report, company report or official report of GlaxoSmithKline (2009). DM0HS92 RU http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf DM0HS92 DI DM0HS92 DM0HS92 DN Merimepodib DM0HS92 TI TTGKNB4 DM0HS92 TN Epidermal growth factor receptor (EGFR) DM0HS92 MA Inhibitor DM0HS92 RN Clinical pipeline report, company report or official report of GlaxoSmithKline (2009). DM0HS92 RU http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf DM0HS92 DI DM0HS92 DM0HS92 DN Merimepodib DM0HS92 TI TTL7C8Q DM0HS92 TN Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1) DM0HS92 MA Inhibitor DM0HS92 RN VX-497: a novel, selective IMPDH inhibitor and immunosuppressive agent. J Pharm Sci. 2001 May;90(5):625-37. DM0HS92 RU https://pubmed.ncbi.nlm.nih.gov/11288107 DM0HXDS DI DM0HXDS DM0HXDS DN Pentostatin DM0HXDS TI TTLP57V DM0HXDS TN Adenosine deaminase (ADA) DM0HXDS MA Inhibitor DM0HXDS RN Purine nucleoside analogs in indolent non-Hodgkin's lymphoma. Oncology (Williston Park). 2000 Jun;14(6 Suppl 2):13-5. DM0HXDS RU https://pubmed.ncbi.nlm.nih.gov/10887639 DM0J2ZT DI DM0J2ZT DM0J2ZT DN Safinamide mesylate DM0J2ZT TI TTGP7BY DM0J2ZT TN Monoamine oxidase type B (MAO-B) DM0J2ZT MA Inhibitor DM0J2ZT RN 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85. DM0J2ZT RU https://pubmed.ncbi.nlm.nih.gov/29348678 DM0JE6N DI DM0JE6N DM0JE6N DN Metixene DM0JE6N TI TTZ9SOR DM0JE6N TN Muscarinic acetylcholine receptor M1 (CHRM1) DM0JE6N MA Modulator DM0JE6N RN Roles of the M1 muscarinic acetylcholine receptor subtype in the regulation of basal ganglia function and implications for the treatment of Parkinson's disease.J Pharmacol Exp Ther.2012 Mar;340(3):595-603. DM0JE6N RU https://www.ncbi.nlm.nih.gov/pubmed/22135383 DM0JXFL DI DM0JXFL DM0JXFL DN Temocapril hydrochloride DM0JXFL TI TTL69WB DM0JXFL TN Angiotensin-converting enzyme (ACE) DM0JXFL MA Modulator DM0JXFL RN Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. DM0JXFL RU https://pubmed.ncbi.nlm.nih.gov/17309302 DM0KAE6 DI DM0KAE6 DM0KAE6 DN Kombiglyze XR/Komboglyze FDC DM0KAE6 TI TTDIGC1 DM0KAE6 TN Dipeptidyl peptidase 4 (DPP-4) DM0KAE6 MA Modulator DM0KAE6 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1612). DM0KAE6 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1612 DM0KYI4 DI DM0KYI4 DM0KYI4 DN Mebutamate DM0KYI4 TI TTEX6LM DM0KYI4 TN GABA(A) receptor gamma-3 (GABRG3) DM0KYI4 MA Modulator DM0KYI4 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM0KYI4 RU https://www.fda.gov/ DM0L594 DI DM0L594 DM0L594 DN Ivabradine DM0L594 TI TTFCQYU DM0L594 TN Sinus node I(f) channel (SA node IfC) DM0L594 MA Modulator DM0L594 RN Ivabradine - the first selective sinus node If channel inhibitor in the treatment of stable angina. Int J Clin Pract. 2006 February; 60(2): 222-228. DM0L594 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1448693/ DM0L594 DI DM0L594 DM0L594 DN Ivabradine DM0L594 TI TTKLW9S DM0L594 TN Hyperpolarization cyclic nucleotide-gated channel (HCN) DM0L594 MA Inhibitor DM0L594 RN Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357. DM0L594 RU https://pubmed.ncbi.nlm.nih.gov/30728472 DM0LPI9 DI DM0LPI9 DM0LPI9 DN Netarsudil DM0LPI9 TI TTAWNKZ DM0LPI9 TN Norepinephrine transporter (NET) DM0LPI9 MA Modulator DM0LPI9 RN Effect of 0.04% AR-13324, a ROCK, and norepinephrine transporter inhibitor, on aqueous humor dynamics in normotensive monkey eyes. J Glaucoma. 2015 Jan;24(1):51-4. DM0LPI9 RU https://pubmed.ncbi.nlm.nih.gov/25535688 DM0LPI9 DI DM0LPI9 DM0LPI9 DN Netarsudil DM0LPI9 TI TTMQO60 DM0LPI9 TN Rho-associated protein kinase (ROCK) DM0LPI9 MA Modulator DM0LPI9 RN Effect of 0.04% AR-13324, a ROCK, and norepinephrine transporter inhibitor, on aqueous humor dynamics in normotensive monkey eyes. J Glaucoma. 2015 Jan;24(1):51-4. DM0LPI9 RU https://pubmed.ncbi.nlm.nih.gov/25535688 DM0LPI9 DI DM0LPI9 DM0LPI9 DN Netarsudil DM0LPI9 TI TTZN7RP DM0LPI9 TN Rho-associated protein kinase 1 (ROCK1) DM0LPI9 MA Inhibitor DM0LPI9 RN 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85. DM0LPI9 RU https://pubmed.ncbi.nlm.nih.gov/29348678 DM0LRU9 DI DM0LRU9 DM0LRU9 DN Fendrix DM0LRU9 TI TT3J5ZI DM0LRU9 TN Cell mediated immunity response (CMIR) DM0LRU9 RN Revaccination with Fendrix or HBVaxPro results in better response rates than does revaccination with three doses of Engerix-B in previous non-responders. Vaccine. 2012 Nov 6;30(48):6734-7. DM0LRU9 RU https://pubmed.ncbi.nlm.nih.gov/22981848 DM0MQ35 DI DM0MQ35 DM0MQ35 DN Spectinomycin DM0MQ35 TI TTQ8KVI DM0MQ35 TN Staphylococcus 30S ribosomal subunit (Stap-coc pbp2) DM0MQ35 MA Binder DM0MQ35 RN Functional insights from the structure of the 30S ribosomal subunit and its interactions with antibiotics. Nature. 2000 Sep 21;407(6802):340-8. DM0MQ35 RU https://pubmed.ncbi.nlm.nih.gov/11014183 DM0N3L7 DI DM0N3L7 DM0N3L7 DN Ethopropazine DM0N3L7 TI TTTIBOJ DM0N3L7 TN Histamine H1 receptor (H1R) DM0N3L7 MA Modulator DM0N3L7 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM0N3L7 RU https://www.fda.gov/ DM0N85H DI DM0N85H DM0N85H DN Vidarabine DM0N85H TI TTNE7KG DM0N85H TN Adenosine A2b receptor (ADORA2B) DM0N85H MA Modulator DM0N85H RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM0N85H RU https://www.fda.gov/ DM0N9WA DI DM0N9WA DM0N9WA DN Calcitonin Human DM0N9WA TI TTLWS2O DM0N9WA TN Calcitonin receptor (CALCR) DM0N9WA MA Modulator DM0N9WA RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM0N9WA RU https://www.fda.gov/ DM0NATE DI DM0NATE DM0NATE DN Insulin Susp Protamine Zinc Beef/Pork DM0NATE TI TTZOPHG DM0NATE TN Insulin (INS) DM0NATE MA Modulator DM0NATE RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM0NATE RU https://www.fda.gov/ DM0P63W DI DM0P63W DM0P63W DN Guanidine Hydrochloride DM0P63W TI TTQ8AFT DM0P63W TN Adrenergic receptor Alpha-2 (ADRA2) DM0P63W MA Modulator DM0P63W RN Guanidine-based 2-adrenoceptor ligands: Towards selective antagonist activity.Eur J Med Chem.2014 Jul 23;82:242-54. DM0P63W RU https://www.ncbi.nlm.nih.gov/pubmed/24908653 DM0PMGJ DI DM0PMGJ DM0PMGJ DN Polyestradiol Phosphate DM0PMGJ TI TT2A0DR DM0PMGJ TN Oxo-5-alpha-steroid 4-dehydrogenase (SRD5A) DM0PMGJ MA Modulator DM0PMGJ RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM0PMGJ RU https://www.fda.gov/ DM0Q8MZ DI DM0Q8MZ DM0Q8MZ DN Trimethadione DM0Q8MZ TI TT729IR DM0Q8MZ TN Voltage-gated calcium channel alpha Cav3.1 (CACNA1G) DM0Q8MZ MA Blocker DM0Q8MZ RN Prophylactic and therapeutic functions of T-type calcium blockers against noise-induced hearing loss. Hear Res. 2007 Apr;226(1-2):52-60. DM0Q8MZ RU https://pubmed.ncbi.nlm.nih.gov/17291698 DM0QD4W DI DM0QD4W DM0QD4W DN Aprotinin DM0QD4W TI TTEMV5X DM0QD4W TN Serine protease unspecific (SP) DM0QD4W MA Modulator DM0QD4W RN Randomized controlled trials of aprotinin in cardiac surgery: could clinical equipoise have stopped the bleeding Clin Trials. 2005;2(3):218-29; discussion 229-32. DM0QD4W RU https://pubmed.ncbi.nlm.nih.gov/16279145 DM0QJDC DI DM0QJDC DM0QJDC DN Lixisenatide DM0QJDC TI TTVIMDE DM0QJDC TN Glucagon-like peptide 1 receptor (GLP1R) DM0QJDC MA Modulator DM0QJDC RN GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus.Nat Rev Endocrinol.2012 Dec;8(12):728-42. DM0QJDC RU https://www.ncbi.nlm.nih.gov/pubmed/22945360 DM0QV1J DI DM0QV1J DM0QV1J DN Baclofen DM0QV1J TI TTDCVZW DM0QV1J TN Gamma-aminobutyric acid B receptor (GABBR) DM0QV1J MA Modulator DM0QV1J RN Synthesis and pharmacology of the baclofen homologues 5-amino-4-(4-chlorophenyl)pentanoic acid and the R- and S-enantiomers of 5-amino-3-(4-chlorop... J Med Chem. 1999 Jun 3;42(11):2053-9. DM0QV1J RU https://pubmed.ncbi.nlm.nih.gov/10354414 DM0QZBN DI DM0QZBN DM0QZBN DN Ibandronate DM0QZBN TI TTIKWV4 DM0QZBN TN Geranyltranstransferase (FDPS) DM0QZBN MA Modulator DM0QZBN RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM0QZBN RU https://www.fda.gov/ DM0R4Z5 DI DM0R4Z5 DM0R4Z5 DN MCB-3837 DM0R4Z5 TI TT9SL3Q DM0R4Z5 TN Polypeptide deformylase (PDF) DM0R4Z5 MA Inhibitor DM0R4Z5 RN The fight against drug-resistant malaria: novel plasmodial targets and antimalarial drugs. Curr Med Chem. 2008;15(2):161-71. DM0R4Z5 RU https://pubmed.ncbi.nlm.nih.gov/18220771 DM0REZS DI DM0REZS DM0REZS DN Virulizin DM0REZS TI TTD2MLN DM0REZS TN Natural killer cell activation (NKA) DM0REZS MA Modulator DM0REZS RN Virulizin, a novel immunotherapy agent, activates NK cells through induction of IL-12 expression in macrophages. Cancer Immunol Immunother. 2005 Nov;54(11):1115-26. DM0REZS RU https://pubmed.ncbi.nlm.nih.gov/15891881 DM0RKS4 DI DM0RKS4 DM0RKS4 DN Bepridil DM0RKS4 TI TT5HONZ DM0RKS4 TN Calcium channel unspecific (CaC) DM0RKS4 MA Modulator DM0RKS4 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM0RKS4 RU https://www.fda.gov/ DM0RXF5 DI DM0RXF5 DM0RXF5 DN Hyqvia DM0RXF5 TI TTXFI1K DM0RXF5 TN Hyaluronidase (HYAL) DM0RXF5 MA Modulator DM0RXF5 RN 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81. DM0RXF5 RU https://pubmed.ncbi.nlm.nih.gov/25633781 DM0S9Z1 DI DM0S9Z1 DM0S9Z1 DN Nemonoxacin DM0S9Z1 TI TTN6J5F DM0S9Z1 TN Bacterial DNA gyrase (Bact gyrase) DM0S9Z1 MA Inhibitor DM0S9Z1 RN Nemonoxacin: first global approval. Drugs. 2014 Aug;74(12):1445-53. DM0S9Z1 RU https://pubmed.ncbi.nlm.nih.gov/25079302 DM0SYAN DI DM0SYAN DM0SYAN DN Almitrine DM0SYAN TI TTWK8D0 DM0SYAN TN Sodium pump subunit alpha-1 (ATP1A1) DM0SYAN MA Binder DM0SYAN RN Almitrine, a new kind of energy-transduction inhibitor acting on mitochondrial ATP synthase. Biochim Biophys Acta. 1989 Aug 3;975(3):325-9. DM0SYAN RU https://pubmed.ncbi.nlm.nih.gov/2527061 DM0T3YH DI DM0T3YH DM0T3YH DN Indinavir DM0T3YH TI TT5FNQT DM0T3YH TN Human immunodeficiency virus Protease (HIV PR) DM0T3YH MA Inhibitor DM0T3YH RN Quantification of HIV protease inhibitors and non-nucleoside reverse transcriptase inhibitors in peripheral blood mononuclear cell lysate using liq... J Chromatogr B Analyt Technol Biomed Life Sci. 2009 Feb 15;877(5-6):575-80. DM0T3YH RU https://pubmed.ncbi.nlm.nih.gov/19168402 DM0TI4U DI DM0TI4U DM0TI4U DN Acebutolol DM0TI4U TI TTR6W5O DM0TI4U TN Adrenergic receptor beta-1 (ADRB1) DM0TI4U MA Antagonist DM0TI4U RN Prediction and experimental validation of acute toxicity of beta-blockers in Ceriodaphnia dubia. Environ Toxicol Chem. 2005 Oct;24(10):2470-6. DM0TI4U RU https://pubmed.ncbi.nlm.nih.gov/16268148 DM0VEC1 DI DM0VEC1 DM0VEC1 DN Ergonovine DM0VEC1 TI TTEX248 DM0VEC1 TN Dopamine D2 receptor (D2R) DM0VEC1 MA Agonist DM0VEC1 RN Agonist profile of ergometrine (ergonovine) on a population of postsynaptic alpha-adrenoceptors. J Pharm Pharmacol. 1988 Feb;40(2):137-9. DM0VEC1 RU https://pubmed.ncbi.nlm.nih.gov/2897449 DM0VQN3 DI DM0VQN3 DM0VQN3 DN Ofloxacin DM0VQN3 TI TTN6J5F DM0VQN3 TN Bacterial DNA gyrase (Bact gyrase) DM0VQN3 MA Modulator DM0VQN3 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM0VQN3 RU https://www.fda.gov/ DM0WX6I DI DM0WX6I DM0WX6I DN Primidone DM0WX6I TI TT1MPAY DM0WX6I TN GABA(A) receptor alpha-1 (GABRA1) DM0WX6I MA Antagonist DM0WX6I RN DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6. DM0WX6I RU https://pubmed.ncbi.nlm.nih.gov/18048412 DM0Y49P DI DM0Y49P DM0Y49P DN Olanzapine/fluoxetine combination DM0Y49P TI TT8G3Z7 DM0Y49P TN Serotoninnorepinephrinedopamine reuptake (SNDR) DM0Y49P MA Antagonist DM0Y49P RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DM0Y49P RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DM0YJSB DI DM0YJSB DM0YJSB DN Enflurane DM0YJSB TI TTAN6JD DM0YJSB TN Glutamate receptor AMPA (GRIA) DM0YJSB MA Suppressor DM0YJSB RN Enflurane directly depresses glutamate AMPA and NMDA currents in mouse spinal cord motor neurons independent of actions on GABAA or glycine receptors. Anesthesiology. 2000 Oct;93(4):1075-84. DM0YJSB RU https://pubmed.ncbi.nlm.nih.gov/11020764 DM0YWJC DI DM0YWJC DM0YWJC DN Safinamide DM0YWJC TI TTGP7BY DM0YWJC TN Monoamine oxidase type B (MAO-B) DM0YWJC MA Inhibitor DM0YWJC RN Emerging drugs for epilepsy. Expert Opin Emerg Drugs. 2007 Sep;12(3):407-22. DM0YWJC RU https://pubmed.ncbi.nlm.nih.gov/17874969 DM0YZC6 DI DM0YZC6 DM0YZC6 DN Fulvestrant DM0YZC6 TI TTZAYWL DM0YZC6 TN Estrogen receptor (ESR) DM0YZC6 MA Antagonist DM0YZC6 RN Beta3-tubulin is induced by estradiol in human breast carcinoma cells through an estrogen-receptor dependent pathway. Cell Motil Cytoskeleton. 2009 Jul;66(7):378-88. DM0YZC6 RU https://pubmed.ncbi.nlm.nih.gov/19466750 DM0ZRMQ DI DM0ZRMQ DM0ZRMQ DN Clomocycline DM0ZRMQ TI TTQ8KVI DM0ZRMQ TN Staphylococcus 30S ribosomal subunit (Stap-coc pbp2) DM0ZRMQ MA Binder DM0ZRMQ RN Molecular dynamics simulations of the 30S ribosomal subunit reveal a preferred tetracycline binding site. J Am Chem Soc. 2008 Jan 30;130(4):1114-5. DM0ZRMQ RU https://pubmed.ncbi.nlm.nih.gov/18219717 DM13495 DI DM13495 DM13495 DN Fesoterodine fumarate DM13495 TI TTZ9SOR DM13495 TN Muscarinic acetylcholine receptor M1 (CHRM1) DM13495 MA Modulator DM13495 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DM13495 RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DM13P4C DI DM13P4C DM13P4C DN Salsalate DM13P4C TI TT8NGED DM13P4C TN Prostaglandin G/H synthase 1 (COX-1) DM13P4C MA Inhibitor DM13P4C RN New non-steroidal anti-rheumatic drugs: selective inhibitors of inducible cyclooxygenase. Med Klin (Munich). 1998 Jul 15;93(7):407-15. DM13P4C RU https://pubmed.ncbi.nlm.nih.gov/9711054 DM13PQW DI DM13PQW DM13PQW DN Rilmenidine DM13PQW TI TT2NUT5 DM13PQW TN Adrenergic receptor alpha-2C (ADRA2C) DM13PQW MA Modulator DM13PQW RN Rilmenidine-induced ocular hypotension: role of imidazoline1 and alpha 2 receptors. Curr Eye Res. 1996 Sep;15(9):943-50. DM13PQW RU https://pubmed.ncbi.nlm.nih.gov/8921215 DM13VTW DI DM13VTW DM13VTW DN Flucytosine DM13VTW TI TTU6BFZ DM13VTW TN Candida Thymidylate synthase (Candi TMP1) DM13VTW MA Inhibitor DM13VTW RN Antifungal agents: mode of action in yeast cells. Rev Esp Quimioter. 2006 Jun;19(2):130-9. DM13VTW RU https://pubmed.ncbi.nlm.nih.gov/16964330 DM14MAE DI DM14MAE DM14MAE DN Pergolide DM14MAE TI TTZFYLI DM14MAE TN Dopamine D1 receptor (D1R) DM14MAE MA Modulator DM14MAE RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM14MAE RU https://www.fda.gov/ DM14MAE DI DM14MAE DM14MAE DN Pergolide DM14MAE TI TTEX248 DM14MAE TN Dopamine D2 receptor (D2R) DM14MAE MA Modulator DM14MAE RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM14MAE RU https://www.fda.gov/ DM14RF5 DI DM14RF5 DM14RF5 DN Secobarbital DM14RF5 TI TT1MPAY DM14RF5 TN GABA(A) receptor alpha-1 (GABRA1) DM14RF5 MA Antagonist DM14RF5 RN DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6. DM14RF5 RU https://pubmed.ncbi.nlm.nih.gov/18048412 DM154EB DI DM154EB DM154EB DN Lypressin DM154EB TI TTPFZJ1 DM154EB TN Vasopressin V1 receptor (V1R) DM154EB MA Modulator DM154EB RN Human pain thresholds after the application of lypressin, a vasopressin analogue. Pharmacol Toxicol. 1987 Jul;61(1):16-9. DM154EB RU https://pubmed.ncbi.nlm.nih.gov/3628176 DM15F0X DI DM15F0X DM15F0X DN Gefitinib DM15F0X TI TTGKNB4 DM15F0X TN Epidermal growth factor receptor (EGFR) DM15F0X MA Inhibitor DM15F0X RN Gefitinib ('Iressa', ZD1839) and new epidermal growth factor receptor inhibitors. Br J Cancer. 2004 Feb 9;90(3):566-72. DM15F0X RU https://pubmed.ncbi.nlm.nih.gov/14760365 DM15HAT DI DM15HAT DM15HAT DN Leuprorelin acetate DM15HAT TI TT8R70G DM15HAT TN Gonadotropin-releasing hormone receptor (GNRHR) DM15HAT MA Agonist DM15HAT RN Clinical pipeline report, company report or official report of Takeda (2009). DM15HAT RU http://www.takeda.com/pdf/usr/default/10_1_34992_2.pdf DM15HL8 DI DM15HL8 DM15HL8 DN Clindamycin DM15HL8 TI TTUWYEA DM15HL8 TN Bacterial 50S ribosomal RNA (Bact 50S rRNA) DM15HL8 MA Binder DM15HL8 RN Structural basis for the interaction of antibiotics with the peptidyl transferase centre in eubacteria. Nature. 2001 Oct 25;413(6858):814-21. DM15HL8 RU https://pubmed.ncbi.nlm.nih.gov/11677599 DM17ONX DI DM17ONX DM17ONX DN Fexofenadine DM17ONX TI TTTIBOJ DM17ONX TN Histamine H1 receptor (H1R) DM17ONX MA Antagonist DM17ONX RN Update on prescription and over-the-counter histamine inverse agonists in rhinitis therapy. Curr Allergy Asthma Rep. 2009 Mar;9(2):140-8. DM17ONX RU https://pubmed.ncbi.nlm.nih.gov/19210904 DM1A6RV DI DM1A6RV DM1A6RV DN Interferon beta-1a DM1A6RV TI TT4TZ8J DM1A6RV TN Interferon-beta (IFNB1) DM1A6RV MA Modulator DM1A6RV RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM1A6RV RU https://www.fda.gov/ DM1A9W3 DI DM1A9W3 DM1A9W3 DN Drospirenone DM1A9W3 TI TT26PHO DM1A9W3 TN Mineralocorticoid receptor (MR) DM1A9W3 MA Binder DM1A9W3 RN Biochemical mechanisms of New Molecular Entities (NMEs) approved by United States FDA during 2001-2004: mechanisms leading to optimal efficacy and ... Curr Top Med Chem. 2006;6(5):461-78. DM1A9W3 RU https://pubmed.ncbi.nlm.nih.gov/16719803 DM1A9XO DI DM1A9XO DM1A9XO DN Sertaconazole DM1A9XO TI TTTSOUD DM1A9XO TN Candida Cytochrome P450 51 (Candi ERG11) DM1A9XO MA Inhibitor DM1A9XO RN Sertaconazole: a review of its use in the management of superficial mycoses in dermatology and gynaecology. Drugs. 2009;69(3):339-59. DM1A9XO RU https://pubmed.ncbi.nlm.nih.gov/19275277 DM1AF5U DI DM1AF5U DM1AF5U DN Acetazolamide DM1AF5U TI TTHQPL7 DM1AF5U TN Carbonic anhydrase I (CA-I) DM1AF5U MA Modulator DM1AF5U RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM1AF5U RU https://www.fda.gov/ DM1AGXN DI DM1AGXN DM1AGXN DN Paromomycin DM1AGXN TI TTQ8KVI DM1AGXN TN Staphylococcus 30S ribosomal subunit (Stap-coc pbp2) DM1AGXN MA Binder DM1AGXN RN Aminoglycoside association pathways with the 30S ribosomal subunit. J Phys Chem B. 2009 May 21;113(20):7322-30. DM1AGXN RU https://pubmed.ncbi.nlm.nih.gov/19438282 DM1BKA6 DI DM1BKA6 DM1BKA6 DN Opicapone DM1BKA6 TI TTKWFB8 DM1BKA6 TN Catechol-O-methyl-transferase (COMT) DM1BKA6 MA Inhibitor DM1BKA6 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020 DM1BKA6 RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212489s000lbl.pdf DM1BS03 DI DM1BS03 DM1BS03 DN Sifalimumab DM1BS03 TI TTMQB37 DM1BS03 TN Interferon alpha/beta receptor 2 (IFNAR2) DM1BS03 RN Clinical pipeline report, company report or official report of AstraZeneca (2009). DM1BS03 RU http://www.astrazeneca.com/_mshost3690701/content/resources/media/investors/AZN-Q2-2009/AZN-Q2-2009-Pipeline.pdf DM1BV7W DI DM1BV7W DM1BV7W DN Aliskiren DM1BV7W TI TTB2MXP DM1BV7W TN Angiotensinogenase renin (REN) DM1BV7W MA Inhibitor DM1BV7W RN Comparative effects of aliskiren-based and ramipril-based therapy on the renin system during long-term (6 months) treatment and withdrawal in patie... J Renin Angiotensin Aldosterone Syst. 2009 Sep;10(3):157-67. DM1BV7W RU https://pubmed.ncbi.nlm.nih.gov/19617271 DM1CI9R DI DM1CI9R DM1CI9R DN Bempedoic acid DM1CI9R TI TTRA79S DM1CI9R TN Cholesterol synthesis (Chole synth) DM1CI9R MA Inhibitor DM1CI9R RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020 DM1CI9R RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/211616s000lbl.pdf DM1CI9R DI DM1CI9R DM1CI9R DN Bempedoic acid DM1CI9R TI TT0Z6Y2 DM1CI9R TN ATP-citrate synthase (ACLY) DM1CI9R MA Inhibitor DM1CI9R RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020 DM1CI9R RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/211616s000lbl.pdf DM1D8XY DI DM1D8XY DM1D8XY DN Dantrolene DM1D8XY TI TT9YXM1 DM1D8XY TN Ryanodine receptor (RYR) DM1D8XY MA Modulator DM1D8XY RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM1D8XY RU https://www.fda.gov/ DM1D90W DI DM1D90W DM1D90W DN Tropicamide DM1D90W TI TTQ3JTF DM1D90W TN Muscarinic acetylcholine receptor M4 (CHRM4) DM1D90W MA Antagonist DM1D90W RN The muscarinic receptor antagonist tropicamide suppresses tremulous jaw movements in a rodent model of parkinsonian tremor: possible role of M4 rec... Psychopharmacology (Berl). 2007 Oct;194(3):347-59. DM1D90W RU https://pubmed.ncbi.nlm.nih.gov/17594079 DM1DBV5 DI DM1DBV5 DM1DBV5 DN Dexlansoprazole DM1DBV5 TI TTF1QVM DM1DBV5 TN Gastric H(+)/K(+) ATPase alpha (ATP4A) DM1DBV5 MA Inhibitor DM1DBV5 RN Clinical pipeline report, company report or official report of Takeda (2009). DM1DBV5 RU http://www.takeda.com/pdf/usr/default/10_1_34992_2.pdf DM1DBV5 DI DM1DBV5 DM1DBV5 DN Dexlansoprazole DM1DBV5 TI TTLOKXP DM1DBV5 TN Gastric H(+)/K(+) ATPase (Proton pump) DM1DBV5 MA Modulator DM1DBV5 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM1DBV5 RU https://www.fda.gov/ DM1DP7T DI DM1DP7T DM1DP7T DN Levonorgestrel DM1DP7T TI TTUV8G9 DM1DP7T TN Progesterone receptor (PGR) DM1DP7T MA Binder DM1DP7T RN Met909 plays a key role in the activation of the progesterone receptor and also in the high potency of 13-ethyl progestins. Mol Pharmacol. 2009 Jun;75(6):1317-24. DM1DP7T RU https://pubmed.ncbi.nlm.nih.gov/19289570 DM1DX4Q DI DM1DX4Q DM1DX4Q DN Eribulin DM1DX4Q TI TTML2WA DM1DX4Q TN Tubulin (TUB) DM1DX4Q MA Inhibitor DM1DX4Q RN Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5. DM1DX4Q RU https://pubmed.ncbi.nlm.nih.gov/21283092 DM1ECNJ DI DM1ECNJ DM1ECNJ DN GS-7340 DM1ECNJ TI TT84ETX DM1ECNJ TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DM1ECNJ MA Inhibitor DM1ECNJ RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2020 DM1ECNJ RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208464s008lbl.pdf DM1EF73 DI DM1EF73 DM1EF73 DN Methysergide DM1EF73 TI TTWJBZ5 DM1EF73 TN 5-HT 2C receptor (HTR2C) DM1EF73 MA Antagonist DM1EF73 RN Spinal serotonin receptor activation modulates the exercise ventilatory response with increased dead space in goats. Respir Physiol Neurobiol. 2008 May 31;161(3):230-8. DM1EF73 RU https://pubmed.ncbi.nlm.nih.gov/18396470 DM1F42Z DI DM1F42Z DM1F42Z DN Oxatomide DM1F42Z TI TTTIBOJ DM1F42Z TN Histamine H1 receptor (H1R) DM1F42Z MA Antagonist DM1F42Z RN Intact cell binding for in vitro prediction of sedative and non-sedative histamine H1-receptor antagonists based on receptor internalization. J Pharmacol Sci. 2008 May;107(1):66-79. DM1F42Z RU https://pubmed.ncbi.nlm.nih.gov/18446005 DM1FDN8 DI DM1FDN8 DM1FDN8 DN Mizolastine DM1FDN8 TI TTTIBOJ DM1FDN8 TN Histamine H1 receptor (H1R) DM1FDN8 MA Antagonist DM1FDN8 RN Histamine H1-receptor antagonists inhibit nuclear factor-kappaB and activator protein-1 activities via H1-receptor-dependent and -independent mechanisms. Clin Exp Allergy. 2008 Jun;38(6):947-56. DM1FDN8 RU https://pubmed.ncbi.nlm.nih.gov/18498541 DM1FX74 DI DM1FX74 DM1FX74 DN Bretylium DM1FX74 TI TTR6W5O DM1FX74 TN Adrenergic receptor beta-1 (ADRB1) DM1FX74 MA Antagonist DM1FX74 RN Components of functional sympathetic control of heart rate in neonatal rats. Am J Physiol. 1985 May;248(5 Pt 2):R601-10. DM1FX74 RU https://pubmed.ncbi.nlm.nih.gov/2859811 DM1I3D5 DI DM1I3D5 DM1I3D5 DN Lepirudin DM1I3D5 TI TT6L509 DM1I3D5 TN Coagulation factor IIa (F2) DM1I3D5 MA Inhibitor DM1I3D5 RN Recombinant hirudin (lepirudin) as anticoagulant in intensive care patients treated with continuous hemodialysis. Kidney Int Suppl. 1999 Nov;(72):S46-50. DM1I3D5 RU https://pubmed.ncbi.nlm.nih.gov/10560805 DM1I93C DI DM1I93C DM1I93C DN SMT-D002 DM1I93C TI TTQ13Z5 DM1I93C TN Muscarinic acetylcholine receptor M3 (CHRM3) DM1I93C MA Agonist DM1I93C RN Demonstration of bladder selective muscarinic receptor binding by intravesical oxybutynin to treat overactive bladder. J Urol. 2004 Nov;172(5 Pt 1):2059-64. DM1I93C RU https://pubmed.ncbi.nlm.nih.gov/15540789 DM1I93C DI DM1I93C DM1I93C DN SMT-D002 DM1I93C TI TTZ9SOR DM1I93C TN Muscarinic acetylcholine receptor M1 (CHRM1) DM1I93C MA Agonist DM1I93C RN Demonstration of bladder selective muscarinic receptor binding by intravesical oxybutynin to treat overactive bladder. J Urol. 2004 Nov;172(5 Pt 1):2059-64. DM1I93C RU https://pubmed.ncbi.nlm.nih.gov/15540789 DM1I93C DI DM1I93C DM1I93C DN SMT-D002 DM1I93C TI TTYEG6Q DM1I93C TN Muscarinic acetylcholine receptor M2 (CHRM2) DM1I93C MA Agonist DM1I93C RN Demonstration of bladder selective muscarinic receptor binding by intravesical oxybutynin to treat overactive bladder. J Urol. 2004 Nov;172(5 Pt 1):2059-64. DM1I93C RU https://pubmed.ncbi.nlm.nih.gov/15540789 DM1IB4Q DI DM1IB4Q DM1IB4Q DN Zolmitriptan DM1IB4Q TI TTK8CXU DM1IB4Q TN 5-HT 1B receptor (HTR1B) DM1IB4Q MA Modulator DM1IB4Q RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM1IB4Q RU https://www.fda.gov/ DM1IB4Q DI DM1IB4Q DM1IB4Q DN Zolmitriptan DM1IB4Q TI TT6MSOK DM1IB4Q TN 5-HT 1D receptor (HTR1D) DM1IB4Q MA Modulator DM1IB4Q RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM1IB4Q RU https://www.fda.gov/ DM1IFGT DI DM1IFGT DM1IFGT DN Chlorproguanil DM1IFGT TI TT9SL3Q DM1IFGT TN Polypeptide deformylase (PDF) DM1IFGT MA Inhibitor DM1IFGT RN The fight against drug-resistant malaria: novel plasmodial targets and antimalarial drugs. Curr Med Chem. 2008;15(2):161-71. DM1IFGT RU https://pubmed.ncbi.nlm.nih.gov/18220771 DM1IQRP DI DM1IQRP DM1IQRP DN Udenafil DM1IQRP TI TTJ0IQB DM1IQRP TN Phosphodiesterase 5A (PDE5A) DM1IQRP MA Inhibitor DM1IQRP RN Increased expression of the nitric oxide synthase gene and protein in corpus cavernosum by repeated dosing of udenafil in a rat model of chemical d... Asian J Androl. 2009 Jul;11(4):435-42. DM1IQRP RU https://pubmed.ncbi.nlm.nih.gov/19465935 DM1IS6U DI DM1IS6U DM1IS6U DN Tenofovir DM1IS6U TI TT84ETX DM1IS6U TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DM1IS6U MA Inhibitor DM1IS6U RN Antiviral drugs in current clinical use. J Clin Virol. 2004 Jun;30(2):115-33. DM1IS6U RU https://pubmed.ncbi.nlm.nih.gov/15125867 DM1JEGF DI DM1JEGF DM1JEGF DN Albiglutide DM1JEGF TI TTVIMDE DM1JEGF TN Glucagon-like peptide 1 receptor (GLP1R) DM1JEGF MA Modulator DM1JEGF RN GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus.Nat Rev Endocrinol.2012 Dec;8(12):728-42. DM1JEGF RU https://www.ncbi.nlm.nih.gov/pubmed/22945360 DM1KS78 DI DM1KS78 DM1KS78 DN Talazoparib DM1KS78 TI TTEBCY8 DM1KS78 TN Poly [ADP-ribose] polymerase (PARP) DM1KS78 MA Inhibitor DM1KS78 RN 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. DM1KS78 RU https://pubmed.ncbi.nlm.nih.gov/30710142 DM1M0Q4 DI DM1M0Q4 DM1M0Q4 DN Procaterol DM1M0Q4 TI TT2CJVK DM1M0Q4 TN Adrenergic receptor beta-2 (ADRB2) DM1M0Q4 MA Agonist DM1M0Q4 RN Inhalation and incubation with procaterol increases diaphragm muscle contractility in mice. Allergol Int. 2007 Sep;56(3):285-91. DM1M0Q4 RU https://pubmed.ncbi.nlm.nih.gov/17646734 DM1MBYQ DI DM1MBYQ DM1MBYQ DN Ganciclovir DM1MBYQ TI TTIU7X1 DM1MBYQ TN Herpes simplex virus DNA polymerase UL30 (HSV UL30) DM1MBYQ MA Inhibitor DM1MBYQ RN Application of real time polymerase chain reaction to the diagnosis and treatment of cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation. Zhonghua Xue Ye Xue Za Zhi. 2009 Feb;30(2):77-81. DM1MBYQ RU https://pubmed.ncbi.nlm.nih.gov/19563015 DM1N62C DI DM1N62C DM1N62C DN Quetiapine DM1N62C TI TTEX248 DM1N62C TN Dopamine D2 receptor (D2R) DM1N62C MA Agonist DM1N62C RN Receptor reserve-dependent properties of antipsychotics at human dopamine D2 receptors. Eur J Pharmacol. 2009 Apr 1;607(1-3):35-40. DM1N62C RU https://pubmed.ncbi.nlm.nih.gov/19217900 DM1NG5W DI DM1NG5W DM1NG5W DN Hydrogen peroxide DM1NG5W TI TTELIN2 DM1NG5W TN PTPN1 messenger RNA (PTPN1 mRNA) DM1NG5W MA Inhibitor DM1NG5W RN Periodinates: a new class of protein tyrosine phosphatase inhibitors. Bioorg Med Chem Lett. 1999 Feb 8;9(3):353-6. DM1NG5W RU https://pubmed.ncbi.nlm.nih.gov/10091683 DM1NOEK DI DM1NOEK DM1NOEK DN Metreleptin DM1NOEK TI TT0HD6V DM1NOEK TN Leptin receptor (LEPR) DM1NOEK MA Modulator DM1NOEK RN 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81. DM1NOEK RU https://pubmed.ncbi.nlm.nih.gov/25633781 DM1O3BY DI DM1O3BY DM1O3BY DN Mecasermin DM1O3BY TI TTHRID2 DM1O3BY TN Insulin-like growth factor I receptor (IGF1R) DM1O3BY MA Inhibitor DM1O3BY RN IGF-1R, IGF-1 and IGF-2 expression as potential prognostic and predictive markers in colorectal-cancer. Virchows Arch. 2003 Aug;443(2):139-45. DM1O3BY RU https://pubmed.ncbi.nlm.nih.gov/12845531 DM1OFHN DI DM1OFHN DM1OFHN DN Meglitinides DM1OFHN TI TTCBFJO DM1OFHN TN Insulin receptor (INSR) DM1OFHN MA Stimulator DM1OFHN RN New drugs for type 2 diabetes mellitus: what is their place in therapy Drugs. 2008;68(15):2131-62. DM1OFHN RU https://pubmed.ncbi.nlm.nih.gov/18840004 DM1OFHN DI DM1OFHN DM1OFHN DN Meglitinides DM1OFHN TI TTEX248 DM1OFHN TN Dopamine D2 receptor (D2R) DM1OFHN MA Antagonist DM1OFHN RN Specific in vitro and in vivo binding of 3H-raclopride. A potent substituted benzamide drug with high affinity for dopamine D-2 receptors in the rat brain. Biochem Pharmacol. 1985 Jul 1;34(13):2251-9. DM1OFHN RU https://pubmed.ncbi.nlm.nih.gov/4015674 DM1P6FR DI DM1P6FR DM1P6FR DN Arry-162 DM1P6FR TI TTROQ37 DM1P6FR TN MAPK/ERK kinase kinase (MAP3K) DM1P6FR MA Modulator DM1P6FR RN MEK and the inhibitors: from bench to bedside. J Hematol Oncol. 2013; 6: 27. DM1P6FR RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3626705/ DM1P6FR DI DM1P6FR DM1P6FR DN Arry-162 DM1P6FR TI TTZCRP3 DM1P6FR TN ERK activator kinase (MEK) DM1P6FR MA Inhibitor DM1P6FR RN 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. DM1P6FR RU https://pubmed.ncbi.nlm.nih.gov/30710142 DM1QLST DI DM1QLST DM1QLST DN Trimazosin DM1QLST TI TT34BHT DM1QLST TN Adrenergic receptor alpha-1D (ADRA1D) DM1QLST MA Modulator DM1QLST RN The hypotensive effect of trimazosin is not caused solely by alpha 1-adrenoceptor blockade. J Cardiovasc Pharmacol. 1984 Jan-Feb;6(1):142-50. DM1QLST RU https://pubmed.ncbi.nlm.nih.gov/6199597 DM1R5X4 DI DM1R5X4 DM1R5X4 DN Becaplermin DM1R5X4 TI TTI7421 DM1R5X4 TN Platelet-derived growth factor receptor beta (PDGFRB) DM1R5X4 MA Modulator DM1R5X4 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM1R5X4 RU https://www.fda.gov/ DM1RBYG DI DM1RBYG DM1RBYG DN Nitric Oxide DM1RBYG TI TT6HPVC DM1RBYG TN Guanylate cyclase (GC) DM1RBYG MA Stimulator DM1RBYG RN Nitric oxide and nitric oxide synthase isoforms in the normal, hypertrophic, and failing heart. Mol Cell Biochem. 2010 Jan;333(1-2):191-201. DM1RBYG RU https://pubmed.ncbi.nlm.nih.gov/19618122 DM1RBYG DI DM1RBYG DM1RBYG DN Nitric Oxide DM1RBYG TI TT23PYC DM1RBYG TN Soluble guanylate cyclase (GCS) DM1RBYG MA Stimulator DM1RBYG RN Nitric oxide and nitrovasodilators: similarities, differences, and interactions. Am J Cardiol. 1996 May 30;77(13):2C-7C. DM1RBYG RU https://pubmed.ncbi.nlm.nih.gov/8638522 DM1S4AG DI DM1S4AG DM1S4AG DN Lumiracoxib DM1S4AG TI TTVKILB DM1S4AG TN Prostaglandin G/H synthase 2 (COX-2) DM1S4AG MA Inhibitor DM1S4AG RN Dissociation of airway inflammation and hyperresponsiveness by cyclooxygenase inhibition in allergen challenged mice. Eur Respir J. 2009 Jul;34(1):200-8. DM1S4AG RU https://pubmed.ncbi.nlm.nih.gov/19251789 DM1SC8M DI DM1SC8M DM1SC8M DN Trimipramine DM1SC8M TI TTAWNKZ DM1SC8M TN Norepinephrine transporter (NET) DM1SC8M MA Inhibitor DM1SC8M RN Antidepressants suppress production of the Th1 cytokine interferon-gamma, independent of monoamine transporter blockade. Eur Neuropsychopharmacol. 2006 Oct;16(7):481-90. DM1SC8M RU https://pubmed.ncbi.nlm.nih.gov/16388933 DM1SRQT DI DM1SRQT DM1SRQT DN Aceprometazine DM1SRQT TI TTTIBOJ DM1SRQT TN Histamine H1 receptor (H1R) DM1SRQT MA Antagonist DM1SRQT RN Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. DM1SRQT RU https://pubmed.ncbi.nlm.nih.gov/17016423 DM1TJ8F DI DM1TJ8F DM1TJ8F DN Diethylcarbamazine DM1TJ8F TI TT2J34L DM1TJ8F TN Arachidonate 5-lipoxygenase (5-LOX) DM1TJ8F MA Inhibitor DM1TJ8F RN Inhibition of leukotriene formation by diethylcarbamazine modifies the acid-base balance in the rabbits with blast injuries of the lungs. Vojnosanit Pregl. 1999 May-Jun;56(3):243-7. DM1TJ8F RU https://pubmed.ncbi.nlm.nih.gov/10518442 DM1TMA3 DI DM1TMA3 DM1TMA3 DN Imiquimod DM1TMA3 TI TTRJ1K4 DM1TMA3 TN Toll-like receptor 7 (TLR7) DM1TMA3 MA Agonist DM1TMA3 RN Imiquimod enhances IFN-gamma production and effector function of T cells infiltrating human squamous cell carcinomas of the skin. J Invest Dermatol. 2009 Nov;129(11):2676-85. DM1TMA3 RU https://pubmed.ncbi.nlm.nih.gov/19516264 DM1UE67 DI DM1UE67 DM1UE67 DN TOCOTRIENOL DM1UE67 TI TTPADOQ DM1UE67 TN HMG-CoA reductase (HMGCR) DM1UE67 MA Inhibitor DM1UE67 RN Inhibitory effect of delta-tocotrienol, a HMG CoA reductase inhibitor, on monocyte-endothelial cell adhesion. J Nutr Sci Vitaminol (Tokyo). 2002 Oct;48(5):332-7. DM1UE67 RU https://pubmed.ncbi.nlm.nih.gov/12656204 DM1UJO0 DI DM1UJO0 DM1UJO0 DN Pitavastatin calcium DM1UJO0 TI TTPADOQ DM1UJO0 TN HMG-CoA reductase (HMGCR) DM1UJO0 MA Inhibitor DM1UJO0 RN Cholesterol-lowering effect of NK-104, a 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor, in guinea pig model of hyperlipidemia. Arzneimittelforschung. 2001;51(3):197-203. DM1UJO0 RU https://pubmed.ncbi.nlm.nih.gov/11304935 DM1UV7F DI DM1UV7F DM1UV7F DN Baloxavir marboxil DM1UV7F TI TTWORX6 DM1UV7F TN Influenza Polymerase acidic endonuclease (Influ PA) DM1UV7F MA Inhibitor DM1UV7F RN 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. DM1UV7F RU https://pubmed.ncbi.nlm.nih.gov/30710142 DM1V329 DI DM1V329 DM1V329 DN Conivaptan DM1V329 TI TTK8R02 DM1V329 TN Vasopressin V2 receptor (V2R) DM1V329 MA Modulator DM1V329 RN Acute hemodynamic effects of conivaptan, a dual V(1A) and V(2) vasopressin receptor antagonist, in patients with advanced heart failure. Circulation. 2001 Nov 13;104(20):2417-23. DM1V329 RU https://pubmed.ncbi.nlm.nih.gov/11705818 DM1V329 DI DM1V329 DM1V329 DN Conivaptan DM1V329 TI TT4TFGN DM1V329 TN Vasopressin V1a receptor (V1AR) DM1V329 MA Modulator DM1V329 RN Acute hemodynamic effects of conivaptan, a dual V(1A) and V(2) vasopressin receptor antagonist, in patients with advanced heart failure. Circulation. 2001 Nov 13;104(20):2417-23. DM1V329 RU https://pubmed.ncbi.nlm.nih.gov/11705818 DM1V5ZS DI DM1V5ZS DM1V5ZS DN Felbamate DM1V5ZS TI TT9IK2Z DM1V5ZS TN N-methyl-D-aspartate receptor (NMDAR) DM1V5ZS MA Antagonist DM1V5ZS RN Molecular determinants of the anticonvulsant felbamate binding site in the N-methyl-D-aspartate receptor. J Med Chem. 2008 Mar 27;51(6):1534-45. DM1V5ZS RU https://pubmed.ncbi.nlm.nih.gov/18311896 DM1WL9O DI DM1WL9O DM1WL9O DN Glycodiazine DM1WL9O TI TTG140O DM1WL9O TN Inward rectifier potassium channel Kir1.2 (KCNJ10) DM1WL9O MA Binder DM1WL9O RN Coupling between proximal tubular transport processes. Studies with ouabain, SITS and HCO3-free solutions. Pflugers Arch. 1977 Apr 25;368(3):245-52. DM1WL9O RU https://pubmed.ncbi.nlm.nih.gov/141035 DM1WXA6 DI DM1WXA6 DM1WXA6 DN Lofexidine DM1WXA6 TI TTQ8AFT DM1WXA6 TN Adrenergic receptor Alpha-2 (ADRA2) DM1WXA6 MA Agonist DM1WXA6 RN Clinical pharmacokinetics of lofexidine, the alpha 2-adrenergic receptor agonist, in opiate addicts plasma using a highly sensitive liquid chromatography tandem mass spectrometric analysis. Am J DrugAlcohol Abuse. 2008;34(5):611-6. DM1WXA6 RU https://pubmed.ncbi.nlm.nih.gov/18821454 DM1WXA6 DI DM1WXA6 DM1WXA6 DN Lofexidine DM1WXA6 TI TTWG9A4 DM1WXA6 TN Adrenergic receptor alpha-2A (ADRA2A) DM1WXA6 MA Agonist DM1WXA6 RN 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. DM1WXA6 RU https://pubmed.ncbi.nlm.nih.gov/30710142 DM1XBHS DI DM1XBHS DM1XBHS DN Pentazocine DM1XBHS TI TTN4QDT DM1XBHS TN Opioid receptor (OPR) DM1XBHS MA Antagonist DM1XBHS RN Functional characterization of a sigma receptor and its gene expression by haloperidol. Nippon Yakurigaku Zasshi. 1999 Jul;114(1):61-8. DM1XBHS RU https://pubmed.ncbi.nlm.nih.gov/10562966 DM1XBWR DI DM1XBWR DM1XBWR DN N-acetyl-D-glucosamine DM1XBWR TI TTDM6HZ DM1XBWR TN Alpha-N-acetylglucosaminidase (NAGLU) DM1XBWR MA Activator DM1XBWR RN Development of bFGF-Chitosan Matrices and Their Interactions with Human Dermal Fibroblast Cells. J Biomater Sci Polym Ed. 2009;20(10):1335-51. DM1XBWR RU https://pubmed.ncbi.nlm.nih.gov/19622275 DM1XHYJ DI DM1XHYJ DM1XHYJ DN Etidronic acid DM1XHYJ TI TTCWXFA DM1XHYJ TN Protein-tyrosine phosphatase sigma (R-PTP-sigma) DM1XHYJ MA Inhibitor DM1XHYJ RN Human protein tyrosine phosphatase-sigma: alternative splicing and inhibition by bisphosphonates. J Bone Miner Res. 1996 Apr;11(4):535-43. DM1XHYJ RU https://pubmed.ncbi.nlm.nih.gov/8992885 DM1XT4N DI DM1XT4N DM1XT4N DN Tafenoquine DM1XT4N TI TTB8JQ7 DM1XT4N TN Electron transport complex III (Complex III) DM1XT4N MA Inhibitor DM1XT4N RN Tafenoquine: First Global Approval.Drugs. 2018 Sep;78(14):1517-1523. DM1XT4N RU https://pubmed.ncbi.nlm.nih.gov/30229442 DM1XT4N DI DM1XT4N DM1XT4N DN Tafenoquine DM1XT4N TI TTULV0X DM1XT4N TN Reactive oxygen species (ROS) DM1XT4N MA Modulator DM1XT4N RN Tafenoquine: First Global Approval.Drugs. 2018 Sep;78(14):1517-1523. DM1XT4N RU https://pubmed.ncbi.nlm.nih.gov/30229442 DM1Y2JH DI DM1Y2JH DM1Y2JH DN Inulin DM1Y2JH TI TTZOPHG DM1Y2JH TN Insulin (INS) DM1Y2JH MA Modulator DM1Y2JH RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM1Y2JH RU https://www.fda.gov/ DM1Y69Q DI DM1Y69Q DM1Y69Q DN Interleukin-3 DM1Y69Q TI TT5TQ2W DM1Y69Q TN Granulocyte colony-stimulating factor (CSF3) DM1Y69Q MA Modulator DM1Y69Q RN Interleukin 3: from colony-stimulating factor to pluripotent immunoregulatory cytokine. Int J Immunopharmacol. 1992 Apr;14(3):421-30. DM1Y69Q RU https://pubmed.ncbi.nlm.nih.gov/1618595 DM1YA7M DI DM1YA7M DM1YA7M DN Sulfonamides DM1YA7M TI TT4ILYC DM1YA7M TN Bacterial Dihydropteroate synthetase (Bact folP) DM1YA7M MA Binder DM1YA7M RN Has nature already identified all useful antibacterial targets Curr Opin Microbiol. 2008 Oct;11(5):387-92. DM1YA7M RU https://pubmed.ncbi.nlm.nih.gov/18804175 DM1YB0R DI DM1YB0R DM1YB0R DN OZ277 DM1YB0R TI TTZVSJ2 DM1YB0R TN Sarcoplasmic/endoplasmic reticulum calcium ATPase (ATP2A) DM1YB0R MA Inhibitor DM1YB0R RN The fight against drug-resistant malaria: novel plasmodial targets and antimalarial drugs. Curr Med Chem. 2008;15(2):161-71. DM1YB0R RU https://pubmed.ncbi.nlm.nih.gov/18220771 DM1YBHK DI DM1YBHK DM1YBHK DN Rifabutin DM1YBHK TI TTHKJLN DM1YBHK TN DNA-directed RNA polymerase (RNAP) DM1YBHK MA Modulator DM1YBHK RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM1YBHK RU https://www.fda.gov/ DM1YBRM DI DM1YBRM DM1YBRM DN Cyclobenzaprine DM1YBRM TI TTYSN63 DM1YBRM TN 5-HT 2 receptor (5HT2R) DM1YBRM MA Antagonist DM1YBRM RN Torticollis under Cyclobenzaprine. Pharmacology. 2009 Jul 8;84(2):91-92. DM1YBRM RU https://pubmed.ncbi.nlm.nih.gov/19590258 DM1YEPS DI DM1YEPS DM1YEPS DN Volanesorsen DM1YEPS TI TTXOZQ1 DM1YEPS TN ApoC-III messenger RNA (APOC3 mRNA) DM1YEPS MA Inhibitor DM1YEPS RN Metabolism and Disposition of Volanesorsen, a 2'- O-(2 methoxyethyl) Antisense Oligonucleotide, Across Species. Drug Metab Dispos. 2019 Oct;47(10):1164-1173. DM1YEPS RU https://pubmed.ncbi.nlm.nih.gov/31350288 DM1YVZT DI DM1YVZT DM1YVZT DN Rituximab DM1YVZT TI TTUE541 DM1YVZT TN Leukocyte surface antigen Leu-16 (CD20) DM1YVZT RN Clinical pipeline report, company report or official report of Genentech (2009). DM1YVZT RU http://www.gene.com/gene/pipeline/status/ DM20K91 DI DM20K91 DM20K91 DN Travoprost DM20K91 TI TTT2ZAR DM20K91 TN Prostaglandin F2-alpha receptor (PTGFR) DM20K91 MA Agonist DM20K91 RN Prostaglandin subtype-selective and non-selective IOP-lowering comparison in monkeys. J Ocul Pharmacol Ther. 2009 Feb;25(1):1-8. DM20K91 RU https://pubmed.ncbi.nlm.nih.gov/19232013 DM20LIM DI DM20LIM DM20LIM DN Bremelanotide DM20LIM TI TT0MV2T DM20LIM TN Melanocortin receptor 1 (MC1R) DM20LIM MA Agonist DM20LIM RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019 DM20LIM RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf DM20LIM DI DM20LIM DM20LIM DN Bremelanotide DM20LIM TI TTD0CIQ DM20LIM TN Melanocortin receptor 4 (MC4R) DM20LIM MA Agonist DM20LIM RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019 DM20LIM RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf DM20R5F DI DM20R5F DM20R5F DN Spiramycin DM20R5F TI TTLFGBV DM20R5F TN Bacterial 23S ribosomal RNA (Bact 23S rRNA) DM20R5F MA Binder DM20R5F RN The apicoplast as an antimalarial drug target. Drug Resist Updat. 2001 Jun;4(3):145-51. DM20R5F RU https://pubmed.ncbi.nlm.nih.gov/11768328 DM20VMW DI DM20VMW DM20VMW DN Ethylestrenol DM20VMW TI TTS64P2 DM20VMW TN Androgen receptor (AR) DM20VMW MA Modulator DM20VMW RN Relative binding affinity of anabolic-androgenic steroids: comparison of the binding to the androgen receptors in skeletal muscle and in prostate, ... Endocrinology. 1984 Jun;114(6):2100-6. DM20VMW RU https://www.ncbi.nlm.nih.gov/pubmed/6539197 DM20VSK DI DM20VSK DM20VSK DN Istradefylline DM20VSK TI TTM2AOE DM20VSK TN Adenosine A2a receptor (ADORA2A) DM20VSK MA Modulator DM20VSK RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019 DM20VSK RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022075s000lbl.pdf DM214Q8 DI DM214Q8 DM214Q8 DN Talbutal DM214Q8 TI TTEX6LM DM214Q8 TN GABA(A) receptor gamma-3 (GABRG3) DM214Q8 MA Modulator DM214Q8 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM214Q8 RU https://www.fda.gov/ DM215WE DI DM215WE DM215WE DN MK-1439 DM215WE TI TT84ETX DM215WE TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DM215WE MA Inhibitor DM215WE RN 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. DM215WE RU https://pubmed.ncbi.nlm.nih.gov/30710142 DM21C09 DI DM21C09 DM21C09 DN Nitrendipine DM21C09 TI TTFK1JQ DM21C09 TN Voltage-gated calcium channel alpha-2/delta-1 (CACNA2D1) DM21C09 MA Blocker DM21C09 RN Sulfobutyl ether-alkyl ether mixed cyclodextrin derivatives with enhanced inclusion ability. J Pharm Sci. 2009 Dec;98(12):4769-80. DM21C09 RU https://pubmed.ncbi.nlm.nih.gov/19408308 DM23D7J DI DM23D7J DM23D7J DN Tiaprofenic acid DM23D7J TI TTVKILB DM23D7J TN Prostaglandin G/H synthase 2 (COX-2) DM23D7J MA Inhibitor DM23D7J RN Effects of tiaprofenic acid on the concentration and metabolism of proteoglycans in normal and degenerating canine articular cartilage. J Clin Pharmacol. 1990 Sep;30(9):808-14. DM23D7J RU https://pubmed.ncbi.nlm.nih.gov/2277128 DM23HCX DI DM23HCX DM23HCX DN Dextropropoxyphene DM23HCX TI TTN4QDT DM23HCX TN Opioid receptor (OPR) DM23HCX MA Agonist DM23HCX RN Retrospective diagnosis of an adverse drug reaction in a breastfed neonate: liquid chromatography-tandem mass spectrometry quantification of dextropropoxyphene and norpropoxyphene in newborn and maternal hair. J Anal Toxicol. 2008 Nov-Dec;39(9):787-9. DM23HCX RU https://pubmed.ncbi.nlm.nih.gov/19021937 DM25FL8 DI DM25FL8 DM25FL8 DN Methimazole DM25FL8 TI TT52XDZ DM25FL8 TN Thyroid peroxidase (TPO) DM25FL8 MA Inhibitor DM25FL8 RN Diagnosis and treatment of thyrotoxicosis in childhood. A European questionnaire study. Eur J Endocrinol. 1994 Nov;131(5):467-73. DM25FL8 RU https://pubmed.ncbi.nlm.nih.gov/7952157 DM25HP1 DI DM25HP1 DM25HP1 DN Sermorelin DM25HP1 TI TTG4R8V DM25HP1 TN Growth hormone-releasing hormone receptor (GHRHR) DM25HP1 MA Binder DM25HP1 RN Sermorelin: a better approach to management of adult-onset growth hormone insufficiency Clin Interv Aging. 2006;1(4):307-8. DM25HP1 RU https://pubmed.ncbi.nlm.nih.gov/18046908 DM264B3 DI DM264B3 DM264B3 DN Dimenhydrinate DM264B3 TI TTTIBOJ DM264B3 TN Histamine H1 receptor (H1R) DM264B3 MA Antagonist DM264B3 RN Histamine 1 receptor antagonist in symptomatic treatment of renal colic accompanied by nausea: two birds with one stone Urology. 2009 Jan;73(1):32-6. DM264B3 RU https://pubmed.ncbi.nlm.nih.gov/18849063 DM26CQR DI DM26CQR DM26CQR DN Larotrectinib DM26CQR TI TTTDVOJ DM26CQR TN Tropomyosin-related kinase A (TrkA) DM26CQR MA Inhibitor DM26CQR RN 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. DM26CQR RU https://pubmed.ncbi.nlm.nih.gov/30710142 DM26CQR DI DM26CQR DM26CQR DN Larotrectinib DM26CQR TI TTXABCW DM26CQR TN NT-3 growth factor receptor (TrkC) DM26CQR MA Inhibitor DM26CQR RN 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. DM26CQR RU https://pubmed.ncbi.nlm.nih.gov/30710142 DM26CQR DI DM26CQR DM26CQR DN Larotrectinib DM26CQR TI TTKN7QR DM26CQR TN BDNF/NT-3 growth factors receptor (TrkB) DM26CQR MA Inhibitor DM26CQR RN 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. DM26CQR RU https://pubmed.ncbi.nlm.nih.gov/30710142 DM26E4B DI DM26E4B DM26E4B DN Moexipril DM26E4B TI TTL69WB DM26E4B TN Angiotensin-converting enzyme (ACE) DM26E4B MA Inhibitor DM26E4B RN Moexipril for treatment of primary biliary cirrhosis in patients with an incomplete response to ursodeoxycholic acid. Dig Dis Sci. 2010 Feb;55(2):476-83. DM26E4B RU https://pubmed.ncbi.nlm.nih.gov/19255851 DM26KR1 DI DM26KR1 DM26KR1 DN Copper dotatate Cu-64 DM26KR1 TI TTZ6T9E DM26KR1 TN Somatostatin receptor type 2 (SSTR2) DM26KR1 MA Binder DM26KR1 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020 DM26KR1 RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213227s000lbl.pdf DM26PRD DI DM26PRD DM26PRD DN Reboxetine DM26PRD TI TTAWNKZ DM26PRD TN Norepinephrine transporter (NET) DM26PRD MA Inhibitor DM26PRD RN Reboxetine: the first selective noradrenaline re-uptake inhibitor. Expert Opin Pharmacother. 2000 May;1(4):771-82. DM26PRD RU https://pubmed.ncbi.nlm.nih.gov/11249515 DM27U4Y DI DM27U4Y DM27U4Y DN Desogestrel DM27U4Y TI TTUV8G9 DM27U4Y TN Progesterone receptor (PGR) DM27U4Y MA Modulator DM27U4Y RN Preclinical experience with two selective progesterone receptor modulators on breast and endometrium. Steroids. 2000 Oct-Nov;65(10-11):733-40. DM27U4Y RU https://pubmed.ncbi.nlm.nih.gov/11108884 DM27Z5T DI DM27Z5T DM27Z5T DN Estradiol cypionate DM27Z5T TI TTZAYWL DM27Z5T TN Estrogen receptor (ESR) DM27Z5T MA Modulator DM27Z5T RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM27Z5T RU https://www.fda.gov/ DM28D05 DI DM28D05 DM28D05 DN Oritavancin DM28D05 TI TT4ILYC DM28D05 TN Bacterial Dihydropteroate synthetase (Bact folP) DM28D05 MA Inhibitor DM28D05 RN Emerging drugs for bacterial urinary tract infections. Expert Opin Emerg Drugs. 2005 May;10(2):275-98. DM28D05 RU https://pubmed.ncbi.nlm.nih.gov/15934867 DM28MU7 DI DM28MU7 DM28MU7 DN Tolnaftate DM28MU7 TI TTE14XG DM28MU7 TN Squalene monooxygenase (SQLE) DM28MU7 MA Inhibitor DM28MU7 RN Effects of squalene epoxidase inhibitors on Candida albicans. Antimicrob Agents Chemother. 1992 Aug;36(8):1779-81. DM28MU7 RU https://pubmed.ncbi.nlm.nih.gov/1416865 DM28UJG DI DM28UJG DM28UJG DN Dapagliflozin DM28UJG TI TTLWPVF DM28UJG TN Sodium/glucose cotransporter 2 (SGLT2) DM28UJG MA Modulator DM28UJG RN 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81. DM28UJG RU https://pubmed.ncbi.nlm.nih.gov/25633781 DM295PR DI DM295PR DM295PR DN Ofatumumab DM295PR TI TTUE541 DM295PR TN Leukocyte surface antigen Leu-16 (CD20) DM295PR RN Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92. DM295PR RU https://pubmed.ncbi.nlm.nih.gov/20118952 DM29GAD DI DM29GAD DM29GAD DN Lumefantrine DM29GAD TI TTWK8D0 DM29GAD TN Sodium pump subunit alpha-1 (ATP1A1) DM29GAD MA Binder DM29GAD RN The fight against drug-resistant malaria: novel plasmodial targets and antimalarial drugs. Curr Med Chem. 2008;15(2):161-71. DM29GAD RU https://pubmed.ncbi.nlm.nih.gov/18220771 DM2AOTZ DI DM2AOTZ DM2AOTZ DN Perazine DM2AOTZ TI TTEX248 DM2AOTZ TN Dopamine D2 receptor (D2R) DM2AOTZ MA Modulator DM2AOTZ RN Synthesis and in vitro binding of N-phenyl piperazine analogs as potential dopamine D3 receptor ligands. Bioorg Med Chem. 2005 Jan 3;13(1):77-87. DM2AOTZ RU https://pubmed.ncbi.nlm.nih.gov/15582454 DM2AQ5N DI DM2AQ5N DM2AQ5N DN Spironolactone DM2AQ5N TI TT26PHO DM2AQ5N TN Mineralocorticoid receptor (MR) DM2AQ5N MA Modulator DM2AQ5N RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM2AQ5N RU https://www.fda.gov/ DM2AR7L DI DM2AR7L DM2AR7L DN Meloxicam DM2AR7L TI TTVKILB DM2AR7L TN Prostaglandin G/H synthase 2 (COX-2) DM2AR7L MA Inhibitor DM2AR7L RN Meloxicam: selective COX-2 inhibition in clinical practice. Semin Arthritis Rheum. 1997 Jun;26(6 Suppl 1):21-7. DM2AR7L RU https://pubmed.ncbi.nlm.nih.gov/9219316 DM2BTFN DI DM2BTFN DM2BTFN DN Desirudin Recombinant DM2BTFN TI TT6L509 DM2BTFN TN Coagulation factor IIa (F2) DM2BTFN MA Modulator DM2BTFN RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM2BTFN RU https://www.fda.gov/ DM2C48U DI DM2C48U DM2C48U DN Anisindione DM2C48U TI TT6L509 DM2C48U TN Coagulation factor IIa (F2) DM2C48U MA Modulator DM2C48U RN Anticoagulation with anisindione in a patient with a warfarin-induced skin eruption. Pharmacotherapy. 2003 Apr;23(4):533-6. DM2C48U RU https://pubmed.ncbi.nlm.nih.gov/12680483 DM2C4RF DI DM2C4RF DM2C4RF DN Betrixaban DM2C4RF TI TTCIHJA DM2C4RF TN Coagulation factor Xa (F10) DM2C4RF MA Modulator DM2C4RF RN Company report (Portola) DM2C4RF RU https://www.portola.com/clinical-development/betrixaban-fxa-inhibitor/ DM2DMPO DI DM2DMPO DM2DMPO DN Kanamycin DM2DMPO TI TTQ8KVI DM2DMPO TN Staphylococcus 30S ribosomal subunit (Stap-coc pbp2) DM2DMPO MA Binder DM2DMPO RN SsrA-mediated protein tagging in the presence of miscoding drugs and its physiological role in Escherichia coli. Genes Cells. 2002 Jul;7(7):629-38. DM2DMPO RU https://pubmed.ncbi.nlm.nih.gov/12081641 DM2EN6G DI DM2EN6G DM2EN6G DN Propantheline DM2EN6G TI TTZ9SOR DM2EN6G TN Muscarinic acetylcholine receptor M1 (CHRM1) DM2EN6G MA Antagonist DM2EN6G RN Involvement of the peripheral cholinergic muscarinic system in the compensatory ovarian hypertrophy in the rat. Exp Biol Med (Maywood). 2004 Sep;229(8):793-805. DM2EN6G RU https://pubmed.ncbi.nlm.nih.gov/15337834 DM2ET1M DI DM2ET1M DM2ET1M DN Succinylcholine DM2ET1M TI TTQ13Z5 DM2ET1M TN Muscarinic acetylcholine receptor M3 (CHRM3) DM2ET1M MA Antagonist DM2ET1M RN The involvement of histaminic and muscarinic receptors in the bronchoconstriction induced by myorelaxant administration in sensitized rabbits. Anesth Analg. 2008 Dec;107(6):1899-906. DM2ET1M RU https://pubmed.ncbi.nlm.nih.gov/19020136 DM2EXC5 DI DM2EXC5 DM2EXC5 DN BOL-303259-X DM2EXC5 TI TTT2ZAR DM2EXC5 TN Prostaglandin F2-alpha receptor (PTGFR) DM2EXC5 MA Agonist DM2EXC5 RN Ocular hypotensive activity of BOL-303259-X, a nitric oxide donating prostaglandin F2alpha agonist, in preclinical models. Exp Eye Res. 2011 Sep;93(3):250-5. DM2EXC5 RU https://pubmed.ncbi.nlm.nih.gov/21396362 DM2F8XZ DI DM2F8XZ DM2F8XZ DN Salicyclic acid DM2F8XZ TI TT8NGED DM2F8XZ TN Prostaglandin G/H synthase 1 (COX-1) DM2F8XZ MA Inhibitor DM2F8XZ RN The C50T polymorphism of the cyclooxygenase-1 gene and the risk of thrombotic events during low-dose therapy with acetyl salicylic acid. Thromb Haemost. 2008 Jul;100(1):70-5. DM2F8XZ RU https://pubmed.ncbi.nlm.nih.gov/18612540 DM2F8XZ DI DM2F8XZ DM2F8XZ DN Salicyclic acid DM2F8XZ TI TTCFSPE DM2F8XZ TN Carbonic anhydrase VI (CA-VI) DM2F8XZ MA Inhibitor DM2F8XZ RN Carbonic anhydrase inhibitors: inhibition of mammalian isoforms I-XIV with a series of substituted phenols including paracetamol and salicylic acid. Bioorg Med Chem. 2008 Aug 1;16(15):7424-8. DM2F8XZ RU https://pubmed.ncbi.nlm.nih.gov/18579385 DM2F8XZ DI DM2F8XZ DM2F8XZ DN Salicyclic acid DM2F8XZ TI TTSYM0R DM2F8XZ TN Carbonic anhydrase XII (CA-XII) DM2F8XZ MA Inhibitor DM2F8XZ RN Carbonic anhydrase inhibitors: inhibition of mammalian isoforms I-XIV with a series of substituted phenols including paracetamol and salicylic acid. Bioorg Med Chem. 2008 Aug 1;16(15):7424-8. DM2F8XZ RU https://pubmed.ncbi.nlm.nih.gov/18579385 DM2F8XZ DI DM2F8XZ DM2F8XZ DN Salicyclic acid DM2F8XZ TI TTANPDJ DM2F8XZ TN Carbonic anhydrase II (CA-II) DM2F8XZ MA Inhibitor DM2F8XZ RN Carbonic anhydrase inhibitors: inhibition of mammalian isoforms I-XIV with a series of substituted phenols including paracetamol and salicylic acid. Bioorg Med Chem. 2008 Aug 1;16(15):7424-8. DM2F8XZ RU https://pubmed.ncbi.nlm.nih.gov/18579385 DM2F8XZ DI DM2F8XZ DM2F8XZ DN Salicyclic acid DM2F8XZ TI TTUNARX DM2F8XZ TN Carbonic anhydrase (CA) DM2F8XZ MA Inhibitor DM2F8XZ RN Carbonic anhydrase inhibitors: Inhibition of the new membrane-associated isoform XV with phenols. Bioorg Med Chem Lett. 2008 Jun 15;18(12):3593-6. DM2F8XZ RU https://pubmed.ncbi.nlm.nih.gov/18501600 DM2F8XZ DI DM2F8XZ DM2F8XZ DN Salicyclic acid DM2F8XZ TI TTZHA0O DM2F8XZ TN Carbonic anhydrase IV (CA-IV) DM2F8XZ MA Inhibitor DM2F8XZ RN Carbonic anhydrase inhibitors: inhibition of mammalian isoforms I-XIV with a series of substituted phenols including paracetamol and salicylic acid. Bioorg Med Chem. 2008 Aug 1;16(15):7424-8. DM2F8XZ RU https://pubmed.ncbi.nlm.nih.gov/18579385 DM2F8XZ DI DM2F8XZ DM2F8XZ DN Salicyclic acid DM2F8XZ TI TTHQPL7 DM2F8XZ TN Carbonic anhydrase I (CA-I) DM2F8XZ MA Inhibitor DM2F8XZ RN Carbonic anhydrase inhibitors: inhibition of mammalian isoforms I-XIV with a series of substituted phenols including paracetamol and salicylic acid. Bioorg Med Chem. 2008 Aug 1;16(15):7424-8. DM2F8XZ RU https://pubmed.ncbi.nlm.nih.gov/18579385 DM2FGRT DI DM2FGRT DM2FGRT DN Clavulanate DM2FGRT TI TTHI19T DM2FGRT TN Staphylococcus Beta-lactamase (Stap-coc blaZ) DM2FGRT MA Inhibitor DM2FGRT RN A sensitive coupled HPLC/electrospray mass spectrometry assay for SPM-1 metallo-beta-lactamase inhibitors. Assay Drug Dev Technol. 2009 Apr;7(2):170-9. DM2FGRT RU https://pubmed.ncbi.nlm.nih.gov/19505232 DM2FHG3 DI DM2FHG3 DM2FHG3 DN Pramiracetam DM2FHG3 TI TTH18TF DM2FHG3 TN Muscarinic acetylcholine receptor M5 (CHRM5) DM2FHG3 MA Modulator DM2FHG3 RN Some neurochemical properties of pramiracetam (CI-879), a new cognition-enhancing agent. Article first published online: 5 OCT 2004. DM2FHG3 RU http://onlinelibrary.wiley.com/doi/10.1002/ddr.430030503/abstract DM2G9AE DI DM2G9AE DM2G9AE DN Citalopram DM2G9AE TI TT3ROYC DM2G9AE TN Serotonin transporter (SERT) DM2G9AE MA Modulator DM2G9AE RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM2G9AE RU https://www.fda.gov/ DM2HG4X DI DM2HG4X DM2HG4X DN Prednisone DM2HG4X TI TTYRL6O DM2HG4X TN Glucocorticoid receptor (NR3C1) DM2HG4X MA Agonist DM2HG4X RN Cytochromes P450 (CYP) in the Poeciliopsis lucida hepatocellular carcinoma cell line (PLHC-1): dose- and time-dependent glucocorticoid potentiation of CYP1A induction without induction of CYP3A. ArchBiochem Biophys. 1996 May 1;329(1):113-22. DM2HG4X RU https://pubmed.ncbi.nlm.nih.gov/8619627 DM2HKC4 DI DM2HKC4 DM2HKC4 DN Fluorometholone DM2HKC4 TI TTYRL6O DM2HKC4 TN Glucocorticoid receptor (NR3C1) DM2HKC4 MA Binder DM2HKC4 RN Loteprednol etabonate: a soft steroid for the treatment of allergic diseases of the airways. Drugs Today (Barc). 2000 May;36(5):313-20. DM2HKC4 RU https://pubmed.ncbi.nlm.nih.gov/12861354 DM2HRKE DI DM2HRKE DM2HRKE DN Pentosan polysulfate DM2HRKE TI TTCEKVZ DM2HRKE TN Fibroblast growth factor-4 (FGF4) DM2HRKE MA Modulator DM2HRKE RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM2HRKE RU https://www.fda.gov/ DM2HU9I DI DM2HU9I DM2HU9I DN Triamterene DM2HU9I TI TTQM7TE DM2HU9I TN Amiloride-sensitive sodium channel (ENaC) DM2HU9I MA Blocker DM2HU9I RN Effects of the serine/threonine kinase SGK1 on the epithelial Na(+) channel (ENaC) and CFTR: implications for cystic fibrosis. Cell Physiol Biochem. 2001;11(4):209-18. DM2HU9I RU https://pubmed.ncbi.nlm.nih.gov/11509829 DM2JGQ3 DI DM2JGQ3 DM2JGQ3 DN Trametinib DM2JGQ3 TI TTROQ37 DM2JGQ3 TN MAPK/ERK kinase kinase (MAP3K) DM2JGQ3 MA Modulator DM2JGQ3 RN Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651. DM2JGQ3 RU https://pubmed.ncbi.nlm.nih.gov/28919714 DM2JTS5 DI DM2JTS5 DM2JTS5 DN Follitropin beta DM2JTS5 TI TTZFDBT DM2JTS5 TN Follicle-stimulating hormone receptor (FSHR) DM2JTS5 MA Binder DM2JTS5 RN Follitropin-alpha (Gonal-F) versus follitropin-beta (Puregon) in controlled ovarian hyperstimulation for in vitro fertilization: is there any diffe... Fertil Steril. 2009 Apr;91(4 Suppl):1522-5. DM2JTS5 RU https://pubmed.ncbi.nlm.nih.gov/18851846 DM2L3D5 DI DM2L3D5 DM2L3D5 DN Tertatolol DM2L3D5 TI TTSQIFT DM2L3D5 TN 5-HT 1A receptor (HTR1A) DM2L3D5 MA Inhibitor DM2L3D5 RN Synthesis of new derivatives of 8-OH-DPAT: Influence of substitution on the aromatic ring on the pharmacological profile, Bioorg. Med. Chem. Lett. 3(10):2035-2038 (1993). DM2L3D5 RU http://www.sciencedirect.com/science/article/pii/S0960894X0181009X DM2M3ZA DI DM2M3ZA DM2M3ZA DN Glycopyrrolate DM2M3ZA TI TTZ9SOR DM2M3ZA TN Muscarinic acetylcholine receptor M1 (CHRM1) DM2M3ZA MA Antagonist DM2M3ZA RN Autonomic cardiovascular control during a novel pharmacologic alternative to ganglionic blockade. Clin Pharmacol Ther. 2008 May;83(5):692-701. DM2M3ZA RU https://pubmed.ncbi.nlm.nih.gov/17687267 DM2NA4K DI DM2NA4K DM2NA4K DN Ciclesonide DM2NA4K TI TTJL8VG DM2NA4K TN Corticosteroid-binding globulin (SERPINA6) DM2NA4K MA Binder DM2NA4K RN Novel human corticosteroid-binding globulin variant with low cortisol-binding affinity. J Clin Endocrinol Metab. 2000 Jan;85(1):361-7. DM2NA4K RU https://pubmed.ncbi.nlm.nih.gov/10634411 DM2NLS9 DI DM2NLS9 DM2NLS9 DN Ciprofloxacin XR DM2NLS9 TI TTJP4SM DM2NLS9 TN Bacterial Penicillin binding protein (Bact PBP) DM2NLS9 MA Inhibitor DM2NLS9 RN Emerging drugs for bacterial urinary tract infections. Expert Opin Emerg Drugs. 2005 May;10(2):275-98. DM2NLS9 RU https://pubmed.ncbi.nlm.nih.gov/15934867 DM2NLS9 DI DM2NLS9 DM2NLS9 DN Ciprofloxacin XR DM2NLS9 TI TTU6BFZ DM2NLS9 TN Candida Thymidylate synthase (Candi TMP1) DM2NLS9 MA Inhibitor DM2NLS9 RN Loss of folylpoly-gamma-glutamate synthetase activity is a dominant mechanism of resistance to polyglutamylation-dependent novel antifolates in multiple human leukemia sublines. Int J Cancer. 2003 Feb 20;103(5):587-99. DM2NLS9 RU https://pubmed.ncbi.nlm.nih.gov/12494465 DM2NLS9 DI DM2NLS9 DM2NLS9 DN Ciprofloxacin XR DM2NLS9 TI TTN6J5F DM2NLS9 TN Bacterial DNA gyrase (Bact gyrase) DM2NLS9 MA Modulator DM2NLS9 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM2NLS9 RU https://www.fda.gov/ DM2NLS9 DI DM2NLS9 DM2NLS9 DN Ciprofloxacin XR DM2NLS9 TI TTIXTO3 DM2NLS9 TN Staphylococcus Topoisomerase IV (Stap-coc parC) DM2NLS9 MA Modulator DM2NLS9 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM2NLS9 RU https://www.fda.gov/ DM2NUH3 DI DM2NUH3 DM2NUH3 DN Imipramine DM2NUH3 TI TTAWNKZ DM2NUH3 TN Norepinephrine transporter (NET) DM2NUH3 MA Inhibitor DM2NUH3 RN Invivo antioxidant status: a putative target of antidepressant action. Prog Neuropsychopharmacol Biol Psychiatry. 2009 Mar 17;33(2):220-8. DM2NUH3 RU https://pubmed.ncbi.nlm.nih.gov/19059298 DM2OVDT DI DM2OVDT DM2OVDT DN Tecfidera DM2OVDT TI TTK3Q4W DM2OVDT TN NFE2-related factor 2 pathway (Nrf2 pathway) DM2OVDT MA Inhibitor DM2OVDT RN Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651. DM2OVDT RU https://pubmed.ncbi.nlm.nih.gov/28919714 DM2OZ3G DI DM2OZ3G DM2OZ3G DN Ixabepilone DM2OZ3G TI TTML2WA DM2OZ3G TN Tubulin (TUB) DM2OZ3G MA Stablizer DM2OZ3G RN Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5. DM2OZ3G RU https://pubmed.ncbi.nlm.nih.gov/21283092 DM2P6VD DI DM2P6VD DM2P6VD DN Thrombin/fibrinogen matrix patch DM2P6VD TI TTWODQF DM2P6VD TN Fibrin (FG) DM2P6VD MA Modulator DM2P6VD RN Fibrin sealant patch for repair of acute type a aortic dissection. J Card Surg. 2013 Nov;28(6):736-41. DM2P6VD RU https://pubmed.ncbi.nlm.nih.gov/23957708 DM2POTE DI DM2POTE DM2POTE DN Colchicine DM2POTE TI TTML2WA DM2POTE TN Tubulin (TUB) DM2POTE MA Binder DM2POTE RN Vitamin K3 disrupts the microtubule networks by binding to tubulin: a novel mechanism of its antiproliferative activity. Biochemistry. 2009 Jul 28;48(29):6963-74. DM2POTE RU https://pubmed.ncbi.nlm.nih.gov/19527023 DM2PSBE DI DM2PSBE DM2PSBE DN Focetria A(H1N1) DM2PSBE TI TT3J5ZI DM2PSBE TN Cell mediated immunity response (CMIR) DM2PSBE RN Influenza A/H1N1 MF59 adjuvanted vaccine in pregnant women and adverse perinatal outcomes: multicentre study. BMJ. 2013 Feb 4;346:f393. DM2PSBE RU https://pubmed.ncbi.nlm.nih.gov/23381200 DM2PYNR DI DM2PYNR DM2PYNR DN Phenindione DM2PYNR TI TTEUC8H DM2PYNR TN Vitamin K epoxide reductase complex 1 (VKORC1) DM2PYNR MA Inhibitor DM2PYNR RN [Oral anticoagulation and pharmacogenetics: importance in the clinical setting]. Rev Med Suisse. 2007 Sep 12;3(124):2030, 2033-4, 2036. DM2PYNR RU https://pubmed.ncbi.nlm.nih.gov/17955831 DM2QBHP DI DM2QBHP DM2QBHP DN Eteplirsen DM2QBHP TI TTWLFXU DM2QBHP TN Dystrophin messenger RNA (DMD mRNA) DM2QBHP MA Modulator DM2QBHP RN 2016 FDA drug approvals. Nat Rev Drug Discov. 2017 Feb 2;16(2):73-76. DM2QBHP RU https://www.ncbi.nlm.nih.gov/pubmed/28148938 DM2QDX1 DI DM2QDX1 DM2QDX1 DN Oxamniquine DM2QDX1 TI TTB1TZG DM2QDX1 TN Schistosoma Deoxyribonucleic acid (Schist DNA) DM2QDX1 MA Modulator DM2QDX1 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM2QDX1 RU https://www.fda.gov/ DM2QHZU DI DM2QHZU DM2QHZU DN Sulindac DM2QHZU TI TTFBNVI DM2QHZU TN Aldose reductase (AKR1B1) DM2QHZU MA Inhibitor DM2QHZU RN Inhibition of human lens aldose reductase by flavonoids, sulindac and indomethacin. Biochem Pharmacol. 1983 Jul 1;32(13):1995-8. DM2QHZU RU https://pubmed.ncbi.nlm.nih.gov/6409111 DM2R68E DI DM2R68E DM2R68E DN Ramipril DM2R68E TI TTL69WB DM2R68E TN Angiotensin-converting enzyme (ACE) DM2R68E MA Inhibitor DM2R68E RN Knockouts model the 100 best-selling drugs--will they model the next 100 Nat Rev Drug Discov. 2003 Jan;2(1):38-51. DM2R68E RU https://pubmed.ncbi.nlm.nih.gov/12509758 DM2R86O DI DM2R86O DM2R86O DN Siponimod DM2R86O TI TT7BQRM DM2R86O TN Sphingosine-1 phosphate receptor (S1PR) DM2R86O MA Modulator DM2R86O RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019 DM2R86O RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209884s000lbl.pdf DM2R86O DI DM2R86O DM2R86O DN Siponimod DM2R86O TI TT9JZCK DM2R86O TN Sphingosine-1-phosphate receptor 1 (S1PR1) DM2R86O MA Modulator DM2R86O RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019 DM2R86O RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209884s000lbl.pdf DM2RBWK DI DM2RBWK DM2RBWK DN Belladonna DM2RBWK TI TTH18TF DM2RBWK TN Muscarinic acetylcholine receptor M5 (CHRM5) DM2RBWK MA Modulator DM2RBWK RN Plasma level of atropine after accidental ingestion of Atropa belladonna. Clin Toxicol (Phila). 2009 Jul;47(6):602-4. DM2RBWK RU https://pubmed.ncbi.nlm.nih.gov/19586361 DM2RX0I DI DM2RX0I DM2RX0I DN Abametapir DM2RX0I TI TT1GHVO DM2RX0I TN Matrix metalloproteinase (MMP) DM2RX0I MA Inhibitor DM2RX0I RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020 DM2RX0I RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/206966lbl.pdf DM2SR1J DI DM2SR1J DM2SR1J DN Meningococcal groups A, C, Y and W-135 conjugate vaccine DM2SR1J TI TTY4IQ9 DM2SR1J TN Corynebacterium Mutated CRM197 (Cory mTOX) DM2SR1J MA Binder DM2SR1J RN Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5. DM2SR1J RU https://pubmed.ncbi.nlm.nih.gov/21283092 DM2TEOL DI DM2TEOL DM2TEOL DN Methotrexate DM2TEOL TI TTY8Z2E DM2TEOL TN Proton-coupled folate transporter (SLC46A1) DM2TEOL MA Modulator DM2TEOL RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1213). DM2TEOL RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1213 DM2TEOL DI DM2TEOL DM2TEOL DN Methotrexate DM2TEOL TI TT09I7D DM2TEOL TN Solute carrier family 19 member 1 (SLC19A1) DM2TEOL MA Modulator DM2TEOL RN Increased activity of a novel low pH folate transporter associated with lipophilic antifolate resistance in chinese hamster ovary cells. J Biol Chem. 1998 Apr 3;273(14):8106-11. DM2TEOL RU https://pubmed.ncbi.nlm.nih.gov/9525913 DM2TO9R DI DM2TO9R DM2TO9R DN Desflurane DM2TO9R TI TTAN6JD DM2TO9R TN Glutamate receptor AMPA (GRIA) DM2TO9R MA Antagonist DM2TO9R RN Modulation of NMDA receptor function by ketamine and magnesium. Part II: interactions with volatile anesthetics. Anesth Analg. 2001 May;92(5):1182-91. DM2TO9R RU https://pubmed.ncbi.nlm.nih.gov/11323344 DM2U4XQ DI DM2U4XQ DM2U4XQ DN ALCURONIUM DM2U4XQ TI TTLA931 DM2U4XQ TN Neuronal acetylcholine receptor alpha-7 (CHRNA7) DM2U4XQ MA Inhibitor DM2U4XQ RN Pharmacological characteristics and binding modes of caracurine V analogues and related compounds at the neuronal alpha7 nicotinic acetylcholine re... J Med Chem. 2007 Sep 20;50(19):4616-29. DM2U4XQ RU https://pubmed.ncbi.nlm.nih.gov/17722904 DM2WE5K DI DM2WE5K DM2WE5K DN Ceruletide DM2WE5K TI TTVFO0U DM2WE5K TN Gastrin/cholecystokinin type B receptor (CCKBR) DM2WE5K MA Agonist DM2WE5K RN Comparison of postprandial and ceruletide serum bile acid stimulation in dogs. J Vet Intern Med. 2008 Jul-Aug;22(4):873-8. DM2WE5K RU https://pubmed.ncbi.nlm.nih.gov/18537882 DM2XVNI DI DM2XVNI DM2XVNI DN Levormeloxifene DM2XVNI TI TTZAYWL DM2XVNI TN Estrogen receptor (ESR) DM2XVNI MA Modulator DM2XVNI RN Centchroman, a selective estrogen receptor modulator, as a contraceptive and for the management of hormone-related clinical disorders. Med Res Rev. 2001 Jul;21(4):302-47. DM2XVNI RU https://pubmed.ncbi.nlm.nih.gov/11410933 DM2YGNW DI DM2YGNW DM2YGNW DN Dactinomycin DM2YGNW TI TTUTN1I DM2YGNW TN Human Deoxyribonucleic acid (hDNA) DM2YGNW MA Breaker DM2YGNW RN Structural studies of atom-specific anticancer drugs acting on DNA. Pharmacol Ther. 1999 Sep;83(3):181-215. DM2YGNW RU https://pubmed.ncbi.nlm.nih.gov/10576292 DM2ZGAN DI DM2ZGAN DM2ZGAN DN Mesoridazine DM2ZGAN TI TTEX248 DM2ZGAN TN Dopamine D2 receptor (D2R) DM2ZGAN MA Agonist DM2ZGAN RN Intrinsic efficacy of antipsychotics at human D2, D3, and D4 dopamine receptors: identification of the clozapine metabolite N-desmethylclozapine as... J Pharmacol Exp Ther. 2005 Dec;315(3):1278-87. DM2ZGAN RU https://pubmed.ncbi.nlm.nih.gov/16135699 DM30SGU DI DM30SGU DM30SGU DN Simvastatin DM30SGU TI TTPADOQ DM30SGU TN HMG-CoA reductase (HMGCR) DM30SGU MA Inhibitor DM30SGU RN Equally potent inhibitors of cholesterol synthesis in human hepatocytes have distinguishable effects on different cytochrome P450 enzymes. Biopharm Drug Dispos. 2000 Dec;21(9):353-64. DM30SGU RU https://pubmed.ncbi.nlm.nih.gov/11523064 DM30SXV DI DM30SXV DM30SXV DN Idursulfase DM30SXV TI TTNY2AP DM30SXV TN Iduronate 2-sulfatase (IDS) DM30SXV MA Modulator DM30SXV RN 2006 drug approvals: finding the niche. Nat Rev Drug Discov. 2007 Feb;6(2):99-101. DM30SXV RU https://pubmed.ncbi.nlm.nih.gov/17342860 DM32B5U DI DM32B5U DM32B5U DN Upadacitinib DM32B5U TI TT6DM01 DM32B5U TN Janus kinase 1 (JAK-1) DM32B5U MA Modulator DM32B5U RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019 DM32B5U RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211675s000lbl.pdf DM32GSJ DI DM32GSJ DM32GSJ DN Incruse ellipta DM32GSJ TI TTOXS3C DM32GSJ TN Muscarinic acetylcholine receptor (CHRM) DM32GSJ MA Antagonist DM32GSJ RN Clinical pipeline report, company report or official report of GlaxoSmithKline. DM32GSJ RU http://www.gsk.ca/english/html/media-centre/2014-04-17.html DM32YAI DI DM32YAI DM32YAI DN Dimethindene DM32YAI TI TTTIBOJ DM32YAI TN Histamine H1 receptor (H1R) DM32YAI MA Antagonist DM32YAI RN Analytical method for simultaneously measuring ex vivo drug receptor occupancy and dissociation rate: application to (R)-dimethindene occupancy of central histamine H1 receptors. J Recept Signal Transduct Res. 2009;29(2):84-93. DM32YAI RU https://pubmed.ncbi.nlm.nih.gov/19308787 DM346QI DI DM346QI DM346QI DN Capreomycin Sulfate DM346QI TI TTIA0J5 DM346QI TN Bacterial 70S ribosomal RNA (Bact 70S rRNA) DM346QI MA Modulator DM346QI RN The structures of the anti-tuberculosis antibiotics viomycin and capreomycin bound to the 70S ribosome.Nat Struct Mol Biol.2010 Mar;17(3):289-93. DM346QI RU https://www.ncbi.nlm.nih.gov/pubmed/20154709 DM34TXO DI DM34TXO DM34TXO DN Dapagliflozin Propanediol; Saxagliptin Hydrochloride DM34TXO TI TTDIGC1 DM34TXO TN Dipeptidyl peptidase 4 (DPP-4) DM34TXO MA Modulator DM34TXO RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM34TXO RU https://www.fda.gov/ DM34TXO DI DM34TXO DM34TXO DN Dapagliflozin Propanediol; Saxagliptin Hydrochloride DM34TXO TI TTLWPVF DM34TXO TN Sodium/glucose cotransporter 2 (SGLT2) DM34TXO MA Modulator DM34TXO RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM34TXO RU https://www.fda.gov/ DM35M8J DI DM35M8J DM35M8J DN Thioridazine DM35M8J TI TTEX248 DM35M8J TN Dopamine D2 receptor (D2R) DM35M8J MA Antagonist DM35M8J RN Antipsychotics lack alpha 1A/B adrenoceptor subtype selectivity in the rat. Eur Neuropsychopharmacol. 2005 Mar;15(2):231-4. DM35M8J RU https://pubmed.ncbi.nlm.nih.gov/15695070 DM36LAJ DI DM36LAJ DM36LAJ DN Emedastine DM36LAJ TI TTTIBOJ DM36LAJ TN Histamine H1 receptor (H1R) DM36LAJ MA Antagonist DM36LAJ RN Emedastine difumarate: a review of its potential ameliorating effect for tissue remodeling in allergic diseases. Expert Opin Pharmacother. 2009 Aug;10(11):1859-67. DM36LAJ RU https://pubmed.ncbi.nlm.nih.gov/19558341 DM38VYQ DI DM38VYQ DM38VYQ DN Pentolinium DM38VYQ TI TT4H1MQ DM38VYQ TN Neuronal acetylcholine receptor alpha-4 (CHRNA4) DM38VYQ MA Antagonist DM38VYQ RN Nicotinic and nonnicotinic receptor-mediated actions of vinblastine. Proc Soc Exp Biol Med. 1993 Jul;203(3):372-6. DM38VYQ RU https://pubmed.ncbi.nlm.nih.gov/8516349 DM3906J DI DM3906J DM3906J DN Bedaquiline DM3906J TI TT19K0L DM3906J TN Mycobacterium Proton pump (MycB Prop) DM3906J MA Modulator DM3906J RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DM3906J RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DM3ADGP DI DM3ADGP DM3ADGP DN Rhucin DM3ADGP TI TTJ0IQB DM3ADGP TN Phosphodiesterase 5A (PDE5A) DM3ADGP MA Inhibitor DM3ADGP RN cGMP-hydrolytic activity and its inhibition by sildenafil in normal and failing human and mouse myocardium. J Pharmacol Exp Ther. 2009 Sep;330(3):884-91. DM3ADGP RU https://pubmed.ncbi.nlm.nih.gov/19546307 DM3ADGP DI DM3ADGP DM3ADGP DN Rhucin DM3ADGP TI TTVQ6R9 DM3ADGP TN C1 esterase inhibitor (SERPING1) DM3ADGP MA Modulator DM3ADGP RN Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5. DM3ADGP RU https://pubmed.ncbi.nlm.nih.gov/21283092 DM3BH1Y DI DM3BH1Y DM3BH1Y DN Lapatinib DM3BH1Y TI TTGKNB4 DM3BH1Y TN Epidermal growth factor receptor (EGFR) DM3BH1Y MA Inhibitor DM3BH1Y RN Triple negative breast cancer--current status and prospective targeted treatment based on HER1 (EGFR), TOP2A and C-MYC gene assessment. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2009 Mar;153(1):13-7. DM3BH1Y RU https://pubmed.ncbi.nlm.nih.gov/19365520 DM3BH1Y DI DM3BH1Y DM3BH1Y DN Lapatinib DM3BH1Y TI TT6EO5L DM3BH1Y TN Erbb2 tyrosine kinase receptor (HER2) DM3BH1Y MA Inhibitor DM3BH1Y RN Triple negative breast cancer--current status and prospective targeted treatment based on HER1 (EGFR), TOP2A and C-MYC gene assessment. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2009 Mar;153(1):13-7. DM3BH1Y RU https://pubmed.ncbi.nlm.nih.gov/19365520 DM3BH1Y DI DM3BH1Y DM3BH1Y DN Lapatinib DM3BH1Y TI TT1QFLA DM3BH1Y TN Eukaryotic elongation factor 2 kinase (eEF-2K) DM3BH1Y MA Inhibitor DM3BH1Y RN Inhibition of eEF-2 kinase sensitizes human nasopharyngeal carcinoma cells to lapatinib-induced apoptosis through the Src and Erk pathways.BMC Cancer. 2016 Oct 19;16(1):813. DM3BH1Y RU https://pubmed.ncbi.nlm.nih.gov/27756261 DM3BS97 DI DM3BS97 DM3BS97 DN Macrolides DM3BS97 TI TTLFGBV DM3BS97 TN Bacterial 23S ribosomal RNA (Bact 23S rRNA) DM3BS97 MA Binder DM3BS97 RN Has nature already identified all useful antibacterial targets Curr Opin Microbiol. 2008 Oct;11(5):387-92. DM3BS97 RU https://pubmed.ncbi.nlm.nih.gov/18804175 DM3BVAE DI DM3BVAE DM3BVAE DN Obinutuzumab DM3BVAE TI TTUE541 DM3BVAE TN Leukocyte surface antigen Leu-16 (CD20) DM3BVAE RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2628). DM3BVAE RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2628 DM3C5GZ DI DM3C5GZ DM3C5GZ DN FADROZOLE DM3C5GZ TI TTSZLWK DM3C5GZ TN Aromatase (CYP19A1) DM3C5GZ MA Inhibitor DM3C5GZ RN Enantioselective nonsteroidal aromatase inhibitors identified through a multidisciplinary medicinal chemistry approach. J Med Chem. 2005 Nov 17;48(23):7282-9. DM3C5GZ RU https://pubmed.ncbi.nlm.nih.gov/16279787 DM3C5GZ DI DM3C5GZ DM3C5GZ DN FADROZOLE DM3C5GZ TI TTIQUX7 DM3C5GZ TN Steroid 11-beta-hydroxylase (CYP11B1) DM3C5GZ MA Inhibitor DM3C5GZ RN Synthesis, biological evaluation, and molecular modeling of 1-benzyl-1H-imidazoles as selective inhibitors of aldosterone synthase (CYP11B2). J Med Chem. 2010 Feb 25;53(4):1712-25. DM3C5GZ RU https://pubmed.ncbi.nlm.nih.gov/20121113 DM3DSVJ DI DM3DSVJ DM3DSVJ DN Incadronate DM3DSVJ TI TTIKWV4 DM3DSVJ TN Geranyltranstransferase (FDPS) DM3DSVJ MA Inhibitor DM3DSVJ RN Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther. 2001 Feb;296(2):235-42. DM3DSVJ RU https://pubmed.ncbi.nlm.nih.gov/11160603 DM3ED1A DI DM3ED1A DM3ED1A DN Tavaborole DM3ED1A TI TT37GL6 DM3ED1A TN Staphylococcus Leucyl-tRNA synthetase (Stap-coc leuS) DM3ED1A MA Inhibitor DM3ED1A RN An antifungal agent inhibits an aminoacyl-tRNA synthetase by trapping tRNA in the editing site. Science. 2007 Jun 22;316(5832):1759-61. DM3ED1A RU https://pubmed.ncbi.nlm.nih.gov/17588934 DM3FXMA DI DM3FXMA DM3FXMA DN Naloxone DM3FXMA TI TTKWM86 DM3FXMA TN Opioid receptor mu (MOP) DM3FXMA MA Antagonist DM3FXMA RN OxyContin abuse and overdose. Postgrad Med. 2009 Mar;121(2):163-7. DM3FXMA RU https://pubmed.ncbi.nlm.nih.gov/19332974 DM3FXPS DI DM3FXPS DM3FXPS DN Liraglutide DM3FXPS TI TTVIMDE DM3FXPS TN Glucagon-like peptide 1 receptor (GLP1R) DM3FXPS MA Agonist DM3FXPS RN Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60. DM3FXPS RU https://pubmed.ncbi.nlm.nih.gov/16083333 DM3GB6S DI DM3GB6S DM3GB6S DN Halobetasol propionate DM3GB6S TI TTP3UTW DM3GB6S TN Steroid hormone receptor ERR (ESRR) DM3GB6S MA Modulator DM3GB6S RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM3GB6S RU https://www.fda.gov/ DM3JCVS DI DM3JCVS DM3JCVS DN Terazosin DM3JCVS TI TT34BHT DM3JCVS TN Adrenergic receptor alpha-1D (ADRA1D) DM3JCVS MA Antagonist DM3JCVS RN Induction of prostate apoptosis by alpha1-adrenoceptor antagonists: mechanistic significance of the quinazoline component. Prostate Cancer Prostatic Dis. 2002;5(2):88-95. DM3JCVS RU https://pubmed.ncbi.nlm.nih.gov/12496995 DM3JDRP DI DM3JDRP DM3JDRP DN Cladribine DM3JDRP TI TTLP57V DM3JDRP TN Adenosine deaminase (ADA) DM3JDRP MA Inhibitor DM3JDRP RN Cladribine: from the bench to the bedside--focus on hairy cell leukemia. Expert Rev Anticancer Ther. 2004 Oct;4(5):745-57. DM3JDRP RU https://pubmed.ncbi.nlm.nih.gov/15485311 DM3KJBC DI DM3KJBC DM3KJBC DN Epinephrine DM3KJBC TI TTR6W5O DM3KJBC TN Adrenergic receptor beta-1 (ADRB1) DM3KJBC MA Agonist DM3KJBC RN Adrenergic activation of electrogenic K+ secretion in guinea pig distal colonic epithelium: involvement of beta1- and beta2-adrenergic receptors. Am J Physiol Gastrointest Liver Physiol. 2009 Aug;297(2):G269-77. DM3KJBC RU https://pubmed.ncbi.nlm.nih.gov/19460844 DM3KN7V DI DM3KN7V DM3KN7V DN Bifonazole DM3KN7V TI TTTSOUD DM3KN7V TN Candida Cytochrome P450 51 (Candi ERG11) DM3KN7V MA Inhibitor DM3KN7V RN Investigation of the role of cytochrome P450 2B4 active site residues in substrate metabolism based on crystal structures of the ligand-bound enzyme. Arch Biochem Biophys. 2006 Nov 1;455(1):61-7. DM3KN7V RU https://pubmed.ncbi.nlm.nih.gov/17027909 DM3NC4M DI DM3NC4M DM3NC4M DN Quercetin DM3NC4M TI TTPOI4B DM3NC4M TN Acetyl-CoA:lyso-PAF acetyltransferase (PCAT) DM3NC4M MA Inhibitor DM3NC4M RN Modulation by flavonoids of PAF and related phospholipids in endothelial cells during oxidative stress. J Lipid Res. 2003 Feb;44(2):380-7. DM3NC4M RU https://pubmed.ncbi.nlm.nih.gov/12576520 DM3NF5G DI DM3NF5G DM3NF5G DN Delavirdine DM3NF5G TI TT84ETX DM3NF5G TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DM3NF5G MA Modulator DM3NF5G RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM3NF5G RU https://www.fda.gov/ DM3NUMH DI DM3NUMH DM3NUMH DN Aripiprazole DM3NUMH TI TTEX248 DM3NUMH TN Dopamine D2 receptor (D2R) DM3NUMH MA Agonist DM3NUMH RN Aripiprazole acts as a selective dopamine D2 receptor partial agonist. Expert Opin Investig Drugs. 2007 Jun;16(6):771-5. DM3NUMH RU https://pubmed.ncbi.nlm.nih.gov/17501690 DM3NXRU DI DM3NXRU DM3NXRU DN Timolol DM3NXRU TI TTR6W5O DM3NXRU TN Adrenergic receptor beta-1 (ADRB1) DM3NXRU MA Antagonist DM3NXRU RN Topical dorzolamide 2%/timolol 0.5% ophthalmic solution: a review of its use in the treatment of glaucoma and ocular hypertension. Drugs Aging. 2006;23(12):977-95. DM3NXRU RU https://pubmed.ncbi.nlm.nih.gov/17154662 DM3O6CY DI DM3O6CY DM3O6CY DN Micardis telmisartan DM3O6CY TI TT8DBY3 DM3O6CY TN Angiotensin II receptor type-1 (AGTR1) DM3O6CY MA Antagonist DM3O6CY RN The angiotensin II receptor antagonist telmisartan reduces urinary albumin excretion in patients with isolated systolic hypertension: results of a randomized, double-blind, placebo-controlled trial. J Hypertens. 2005 Nov;23(11):2055-61. DM3O6CY RU https://pubmed.ncbi.nlm.nih.gov/16208149 DM3O8QY DI DM3O8QY DM3O8QY DN Degarelix DM3O8QY TI TT8R70G DM3O8QY TN Gonadotropin-releasing hormone receptor (GNRHR) DM3O8QY MA Inhibitor DM3O8QY RN Iterative approach to the discovery of novel degarelix analogues: substitutions at positions 3, 7, and 8. Part II. J Med Chem. 2005 Jul 28;48(15):4851-60. DM3O8QY RU https://pubmed.ncbi.nlm.nih.gov/16033265 DM3OBQF DI DM3OBQF DM3OBQF DN Belimumab DM3OBQF TI TTWMIDN DM3OBQF TN B-cell-activating factor (TNFSF13B) DM3OBQF RN Clinical pipeline report, company report or official report of GlaxoSmithKline (2009). DM3OBQF RU http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf DM3P5DA DI DM3P5DA DM3P5DA DN Rofecoxib DM3P5DA TI TTVKILB DM3P5DA TN Prostaglandin G/H synthase 2 (COX-2) DM3P5DA MA Inhibitor DM3P5DA RN Privileged structures: a useful concept for the rational design of new lead drug candidates. Mini Rev Med Chem. 2007 Nov;7(11):1108-19. DM3P5DA RU https://pubmed.ncbi.nlm.nih.gov/18045214 DM3P6V7 DI DM3P6V7 DM3P6V7 DN Furazolidone DM3P6V7 TI TTS1W4A DM3P6V7 TN Bacterial Deoxyribonucleic acid (Bact DNA) DM3P6V7 MA Modulator DM3P6V7 RN Interaction of furazolidone with DNA. Biochim Biophys Acta. 1975 Aug 21;402(2):161-5. DM3P6V7 RU https://www.ncbi.nlm.nih.gov/pubmed/1174533 DM3PD2C DI DM3PD2C DM3PD2C DN Fluoxetine DM3PD2C TI TT3ROYC DM3PD2C TN Serotonin transporter (SERT) DM3PD2C MA Modulator DM3PD2C RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM3PD2C RU https://www.fda.gov/ DM3PZXN DI DM3PZXN DM3PZXN DN Taliglucerase alfa DM3PZXN TI TT1B5PU DM3PZXN TN Glucosylceramidase (GBA) DM3PZXN MA Modulator DM3PZXN RN Nat Rev Drug Discov. 2013 Feb;12(2):87-90. DM3PZXN RU https://pubmed.ncbi.nlm.nih.gov/23370234 DM3Q1SM DI DM3Q1SM DM3Q1SM DN Obeticholic acid DM3Q1SM TI TTS4UGC DM3Q1SM TN Farnesoid X-activated receptor (FXR) DM3Q1SM MA Modulator DM3Q1SM RN 2016 FDA drug approvals. Nat Rev Drug Discov. 2017 Feb 2;16(2):73-76. DM3Q1SM RU https://www.ncbi.nlm.nih.gov/pubmed/28148938 DM3SRJZ DI DM3SRJZ DM3SRJZ DN Belotecan hydrocholoride DM3SRJZ TI TTGTQHC DM3SRJZ TN DNA topoisomerase I (TOP1) DM3SRJZ MA Modulator DM3SRJZ RN Impact of natural products on developing new anti-cancer agents. Chem Rev. 2009 Jul;109(7):3012-43. DM3SRJZ RU https://pubmed.ncbi.nlm.nih.gov/19422222 DM3TABW DI DM3TABW DM3TABW DN Oxyphencyclimine DM3TABW TI TTH18TF DM3TABW TN Muscarinic acetylcholine receptor M5 (CHRM5) DM3TABW MA Binder DM3TABW RN Stereoselective interaction of procyclidine, hexahydro-difenidol, hexbutinol and oxyphencyclimine, and of related antagonists, with four muscarinic receptors. Eur J Pharmacol. 1992 Sep 1;227(1):33-42. DM3TABW RU https://pubmed.ncbi.nlm.nih.gov/1426023 DM3TPY8 DI DM3TPY8 DM3TPY8 DN Interferon Alfa-2b, Recombinant DM3TPY8 TI TTMQB37 DM3TPY8 TN Interferon alpha/beta receptor 2 (IFNAR2) DM3TPY8 MA Binder DM3TPY8 RN Successful treatment of relapsed Philadelphia chromosome-positive acute lymphoblastic leukemia with T315I mutation after haplo-identical hematopoie... Leuk Res. 2009 Aug;33(8):e111-3. DM3TPY8 RU https://pubmed.ncbi.nlm.nih.gov/19362369 DM3U7SZ DI DM3U7SZ DM3U7SZ DN Romiplostim DM3U7SZ TI TTI7421 DM3U7SZ TN Platelet-derived growth factor receptor beta (PDGFRB) DM3U7SZ MA Inhibitor DM3U7SZ RN Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel... J Med Chem. 2003 Mar 27;46(7):1116-9. DM3U7SZ RU https://pubmed.ncbi.nlm.nih.gov/12646019 DM3U7SZ DI DM3U7SZ DM3U7SZ DN Romiplostim DM3U7SZ TI TTRLW2X DM3U7SZ TN Fibroblast growth factor receptor 1 (FGFR1) DM3U7SZ MA Inhibitor DM3U7SZ RN Anthranilic acid amides: a novel class of antiangiogenic VEGF receptor kinase inhibitors. J Med Chem. 2002 Dec 19;45(26):5687-93. DM3U7SZ RU https://pubmed.ncbi.nlm.nih.gov/12477352 DM3U7SZ DI DM3U7SZ DM3U7SZ DN Romiplostim DM3U7SZ TI TT8FYO9 DM3U7SZ TN Platelet-derived growth factor receptor alpha (PDGFRA) DM3U7SZ MA Inhibitor DM3U7SZ RN Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel... J Med Chem. 2003 Mar 27;46(7):1116-9. DM3U7SZ RU https://pubmed.ncbi.nlm.nih.gov/12646019 DM3U7SZ DI DM3U7SZ DM3U7SZ DN Romiplostim DM3U7SZ TI TTX41N9 DM3U7SZ TN Tyrosine-protein kinase Kit (KIT) DM3U7SZ MA Inhibitor DM3U7SZ RN New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor-driven a... J Med Chem. 2000 Jun 15;43(12):2310-23. DM3U7SZ RU https://pubmed.ncbi.nlm.nih.gov/10882357 DM3U7SZ DI DM3U7SZ DM3U7SZ DN Romiplostim DM3U7SZ TI TTUTJGQ DM3U7SZ TN Vascular endothelial growth factor receptor 2 (KDR) DM3U7SZ MA Inhibitor DM3U7SZ RN Anthranilic acid amides: a novel class of antiangiogenic VEGF receptor kinase inhibitors. J Med Chem. 2002 Dec 19;45(26):5687-93. DM3U7SZ RU https://pubmed.ncbi.nlm.nih.gov/12477352 DM3U7SZ DI DM3U7SZ DM3U7SZ DN Romiplostim DM3U7SZ TI TT1VAUK DM3U7SZ TN VEGFR1 messenger RNA (VEGFR1 mRNA) DM3U7SZ MA Inhibitor DM3U7SZ RN New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor-driven a... J Med Chem. 2000 Jun 15;43(12):2310-23. DM3U7SZ RU https://pubmed.ncbi.nlm.nih.gov/10882357 DM3U7SZ DI DM3U7SZ DM3U7SZ DN Romiplostim DM3U7SZ TI TT4DXQT DM3U7SZ TN Proto-oncogene c-Ret (RET) DM3U7SZ MA Inhibitor DM3U7SZ RN Synthesis, structure-activity relationship and crystallographic studies of 3-substituted indolin-2-one RET inhibitors. Bioorg Med Chem. 2010 Feb 15;18(4):1482-96. DM3U7SZ RU https://pubmed.ncbi.nlm.nih.gov/20117004 DM3U7SZ DI DM3U7SZ DM3U7SZ DN Romiplostim DM3U7SZ TI TTIHYA4 DM3U7SZ TN Thrombopoietin receptor (MPL) DM3U7SZ MA Modulator DM3U7SZ RN 2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6. DM3U7SZ RU https://pubmed.ncbi.nlm.nih.gov/19180096 DM3U7SZ DI DM3U7SZ DM3U7SZ DN Romiplostim DM3U7SZ TI TT037IE DM3U7SZ TN Aryl hydrocarbon receptor (AHR) DM3U7SZ MA Modulator DM3U7SZ RN A Phase I study of the angiogenesis inhibitor SU5416 (semaxanib) in solid tumours, incorporating dynamic contrast MR pharmacodynamic end points. Br J Cancer. 2005 Oct 17;93(8):876-83. DM3U7SZ RU https://pubmed.ncbi.nlm.nih.gov/16222321 DM3UZ95 DI DM3UZ95 DM3UZ95 DN Bisoprolol DM3UZ95 TI TTR6W5O DM3UZ95 TN Adrenergic receptor beta-1 (ADRB1) DM3UZ95 MA Antagonist DM3UZ95 RN Antiarrhythmic effect of bisoprolol, a highly selective beta1-blocker, in patients with paroxysmal atrial fibrillation. Int Heart J. 2008 May;49(3):281-93. DM3UZ95 RU https://pubmed.ncbi.nlm.nih.gov/18612186 DM3VFPD DI DM3VFPD DM3VFPD DN Troglitazone DM3VFPD TI TTZMAO3 DM3VFPD TN Peroxisome proliferator-activated receptor gamma (PPAR-gamma) DM3VFPD MA Agonist DM3VFPD RN Expression of peroxisome proliferator-activated receptors (PPARs) in human urinary bladder carcinoma and growth inhibition by its agonists. Int J Cancer. 2003 May 1;104(5):597-602. DM3VFPD RU https://pubmed.ncbi.nlm.nih.gov/12594814 DM3VOGS DI DM3VOGS DM3VOGS DN Ceftizoxime DM3VOGS TI TTJP4SM DM3VOGS TN Bacterial Penicillin binding protein (Bact PBP) DM3VOGS MA Binder DM3VOGS RN Role of penicillin-binding protein 2 (PBP2) in the antibiotic susceptibility and cell wall cross-linking of Staphylococcus aureus: evidence for the cooperative functioning of PBP2, PBP4, and PBP2A. JBacteriol. 2005 Mar;187(5):1815-24. DM3VOGS RU https://pubmed.ncbi.nlm.nih.gov/15716453 DM3VR1L DI DM3VR1L DM3VR1L DN Selegiline hydrochloride DM3VR1L TI TTGP7BY DM3VR1L TN Monoamine oxidase type B (MAO-B) DM3VR1L MA Modulator DM3VR1L RN Emerging drugs for Parkinson's disease. Expert Opin Emerg Drugs. 2006 Sep;11(3):403-17. DM3VR1L RU https://pubmed.ncbi.nlm.nih.gov/16939381 DM3VS7Z DI DM3VS7Z DM3VS7Z DN Imidazole salicylate DM3VS7Z TI TTTEJMY DM3VS7Z TN Tromboxane A2 synthesis (TA2 synth) DM3VS7Z MA Modulator DM3VS7Z RN Tolerability of imidazole salycilate in aspirin-sensitive patients. Allergy Proc. 1995 Sep-Oct;16(5):251-4. DM3VS7Z RU https://pubmed.ncbi.nlm.nih.gov/8566739 DM3W15N DI DM3W15N DM3W15N DN Calcium carbimide DM3W15N TI TTCTAOJ DM3W15N TN Acetaldehyde dehydrogenase (ALDH) DM3W15N MA Inhibitor DM3W15N RN Disulfiram and calcium carbimide. Mode of action, adverse effects and clinical use. Tidsskr Nor Laegeforen. 1990 Apr 10;110(10):1224-8. DM3W15N RU https://pubmed.ncbi.nlm.nih.gov/2185581 DM3WKQ4 DI DM3WKQ4 DM3WKQ4 DN Rasagiline DM3WKQ4 TI TTGP7BY DM3WKQ4 TN Monoamine oxidase type B (MAO-B) DM3WKQ4 MA Inhibitor DM3WKQ4 RN Glyceraldehyde-3-phosphate dehydrogenase-monoamine oxidase B-mediated cell death-induced by ethanol is prevented by rasagiline and 1-R-aminoindan. Neurotox Res. 2009 Aug;16(2):148-59. DM3WKQ4 RU https://pubmed.ncbi.nlm.nih.gov/19526291 DM3XNUI DI DM3XNUI DM3XNUI DN Tazobactam DM3XNUI TI TTHI19T DM3XNUI TN Staphylococcus Beta-lactamase (Stap-coc blaZ) DM3XNUI MA Inhibitor DM3XNUI RN Selection of TNF-alpha binding affibody molecules using a beta-lactamase protein fragment complementation assay. N Biotechnol. 2009 Nov 30;26(5):251-9. DM3XNUI RU https://pubmed.ncbi.nlm.nih.gov/19576305 DM3XU74 DI DM3XU74 DM3XU74 DN Dornase Alfa DM3XU74 TI TTUTN1I DM3XU74 TN Human Deoxyribonucleic acid (hDNA) DM3XU74 MA Breaker DM3XU74 RN Dornase alfa. BioDrugs. 1997 Dec;8(6):439-45. DM3XU74 RU https://pubmed.ncbi.nlm.nih.gov/18031106 DM3XYD1 DI DM3XYD1 DM3XYD1 DN Tegaserod DM3XYD1 TI TT07C3Y DM3XYD1 TN 5-HT 4 receptor (HTR4) DM3XYD1 MA Agonist DM3XYD1 RN Emerging drugs for irritable bowel syndrome. Expert Opin Emerg Drugs. 2006 May;11(2):293-313. DM3XYD1 RU https://pubmed.ncbi.nlm.nih.gov/16634703 DM4087K DI DM4087K DM4087K DN Saprisartan DM4087K TI TT8DBY3 DM4087K TN Angiotensin II receptor type-1 (AGTR1) DM4087K MA Antagonist DM4087K RN Pharmacological properties of angiotensin II receptor antagonists. Can J Cardiol. 1999 Nov;15 Suppl F:26F-8F. DM4087K RU https://pubmed.ncbi.nlm.nih.gov/10579749 DM40EF6 DI DM40EF6 DM40EF6 DN Penicillamine DM40EF6 TI TTT3ZC9 DM40EF6 TN Human immunodeficiency virus Tat protein (HIV tat) DM40EF6 MA Inhibitor DM40EF6 RN Docking studies reveal a selective binding of D-penicillamine to the transactivator protein of human immunodeficiency virus type 1. FEBS Lett. 2002 Apr 10;516(1-3):43-6. DM40EF6 RU https://pubmed.ncbi.nlm.nih.gov/11959100 DM41GRA DI DM41GRA DM41GRA DN Ceftazidime DM41GRA TI TTJP4SM DM41GRA TN Bacterial Penicillin binding protein (Bact PBP) DM41GRA MA Binder DM41GRA RN New and emerging treatment of Staphylococcus aureus infections in the hospital setting. Clin Microbiol Infect. 2008 Apr;14 Suppl 3:32-41. DM41GRA RU https://pubmed.ncbi.nlm.nih.gov/18318877 DM42HXN DI DM42HXN DM42HXN DN Atracurium DM42HXN TI TTJSZTB DM42HXN TN Nicotinic acetylcholine receptor (nAChR) DM42HXN MA Antagonist DM42HXN RN Pharmacological characteristics of the inhibition of nondepolarizing neuromuscular blocking agents at human adult muscle nicotinic acetylcholine receptor. Anesthesiology. 2009 Jun;110(6):1244-52. DM42HXN RU https://pubmed.ncbi.nlm.nih.gov/19417616 DM42W1B DI DM42W1B DM42W1B DN Cefmetazole DM42W1B TI TT85JMW DM42W1B TN Bacterial Penicillin binding protein 3 (Bact mrcA) DM42W1B MA Binder DM42W1B RN Clinical relevance of antibiotic-induced endotoxin release in patients undergoing hepatic resection. World J Surg. 1999 Jan;23(1):75-9. DM42W1B RU https://pubmed.ncbi.nlm.nih.gov/9841767 DM43AN2 DI DM43AN2 DM43AN2 DN Fructose DM43AN2 TI TTMS54D DM43AN2 TN Fragile histidine triad protein (FHIT) DM43AN2 MA Inhibitor DM43AN2 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM43AN2 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM458UM DI DM458UM DM458UM DN Captopril DM458UM TI TTL69WB DM458UM TN Angiotensin-converting enzyme (ACE) DM458UM MA Inhibitor DM458UM RN Using ACE inhibitors appropriately. Am Fam Physician. 2002 Aug 1;66(3):461-8. DM458UM RU https://pubmed.ncbi.nlm.nih.gov/12182524 DM45OJN DI DM45OJN DM45OJN DN Mometasone DM45OJN TI TTYRL6O DM45OJN TN Glucocorticoid receptor (NR3C1) DM45OJN MA Agonist DM45OJN RN Mometasone furoate is a less specific glucocorticoid than fluticasone propionate. Eur Respir J. 2002 Dec;20(6):1386-92. DM45OJN RU https://pubmed.ncbi.nlm.nih.gov/12503693 DM471KJ DI DM471KJ DM471KJ DN Omeprazole DM471KJ TI TTLOKXP DM471KJ TN Gastric H(+)/K(+) ATPase (Proton pump) DM471KJ MA Modulator DM471KJ RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM471KJ RU https://www.fda.gov/ DM473VD DI DM473VD DM473VD DN Mivacurium DM473VD TI TTF4E0J DM473VD TN Neuronal acetylcholine receptor alpha-2 (CHRNA2) DM473VD MA Antagonist DM473VD RN Pharmacological characteristics of the inhibition of nondepolarizing neuromuscular blocking agents at human adult muscle nicotinic acetylcholine receptor. Anesthesiology. 2009 Jun;110(6):1244-52. DM473VD RU https://pubmed.ncbi.nlm.nih.gov/19417616 DM48K0X DI DM48K0X DM48K0X DN Carfilzomib DM48K0X TI TTU7ZMG DM48K0X TN Proteasome (PS) DM48K0X MA Modulator DM48K0X RN Nat Rev Drug Discov. 2013 Feb;12(2):87-90. DM48K0X RU https://pubmed.ncbi.nlm.nih.gov/23370234 DM48QOT DI DM48QOT DM48QOT DN Artemether DM48QOT TI TTWK8D0 DM48QOT TN Sodium pump subunit alpha-1 (ATP1A1) DM48QOT MA Binder DM48QOT RN The fight against drug-resistant malaria: novel plasmodial targets and antimalarial drugs. Curr Med Chem. 2008;15(2):161-71. DM48QOT RU https://pubmed.ncbi.nlm.nih.gov/18220771 DM49DUI DI DM49DUI DM49DUI DN Tretinoin DM49DUI TI TTOD7B3 DM49DUI TN Retinoic acid receptor (RAR) DM49DUI MA Binder DM49DUI RN Retinoids--which dermatological indications will benefit in the near future Skin Pharmacol Appl Skin Physiol. 2001 Sep-Oct;14(5):303-15. DM49DUI RU https://pubmed.ncbi.nlm.nih.gov/11586072 DM49DUI DI DM49DUI DM49DUI DN Tretinoin DM49DUI TI TT1Q3IE DM49DUI TN Retinoic acid receptor gamma (RARG) DM49DUI MA Agonist DM49DUI RN Targacept active conformation search: a new method for predicting the conformation of a ligand bound to its protein target. J Med Chem. 2004 Dec 30;47(27):6831-9. DM49DUI RU https://pubmed.ncbi.nlm.nih.gov/15615532 DM49IGF DI DM49IGF DM49IGF DN Pefloxacin DM49IGF TI TT0IHXV DM49IGF TN DNA topoisomerase II (TOP2) DM49IGF MA Inhibitor DM49IGF RN Clinical pharmacokinetics of the newer antibacterial 4-quinolones. Clin Pharmacokinet. 1988 Feb;14(2):96-121. DM49IGF RU https://pubmed.ncbi.nlm.nih.gov/3282749 DM49VEW DI DM49VEW DM49VEW DN Penicillin G Benzathine DM49VEW TI TTJP4SM DM49VEW TN Bacterial Penicillin binding protein (Bact PBP) DM49VEW MA Modulator DM49VEW RN Bacterial Resistance to Penicillin G by Decreased Affinity of Penicillin-Binding Proteins: A Mathematical Model DM49VEW RU https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2957969 DM4AK0Q DI DM4AK0Q DM4AK0Q DN Interferon alfa-n1 DM4AK0Q TI TTMQB37 DM4AK0Q TN Interferon alpha/beta receptor 2 (IFNAR2) DM4AK0Q MA Binder DM4AK0Q RN Lymphoblastoid interferon alfa-n1 improves the long-term response to a 6-month course of treatment in chronic hepatitis C compared with recombinant interferon alfa-2b: results of an international randomized controlled trial. Clinical Advisory Group for the Hepatitis C Comparative Study. Hepatology. 1998 Apr;27(4):1121-7. DM4AK0Q RU https://pubmed.ncbi.nlm.nih.gov/9537453 DM4AMQZ DI DM4AMQZ DM4AMQZ DN Crofelemer DM4AMQZ TI TTOJI4S DM4AMQZ TN Calcium-dependent chloride channel anoctamin (ANO) DM4AMQZ MA Modulator DM4AMQZ RN Nat Rev Drug Discov. 2013 Feb;12(2):87-90. DM4AMQZ RU https://pubmed.ncbi.nlm.nih.gov/23370234 DM4AMQZ DI DM4AMQZ DM4AMQZ DN Crofelemer DM4AMQZ TI TTRLZHP DM4AMQZ TN cAMP-dependent chloride channel (CFTR) DM4AMQZ MA Modulator DM4AMQZ RN Nat Rev Drug Discov. 2013 Feb;12(2):87-90. DM4AMQZ RU https://pubmed.ncbi.nlm.nih.gov/23370234 DM4BDON DI DM4BDON DM4BDON DN Methylprednisolone DM4BDON TI TTYRL6O DM4BDON TN Glucocorticoid receptor (NR3C1) DM4BDON MA Modulator DM4BDON RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM4BDON RU https://www.fda.gov/ DM4BOAS DI DM4BOAS DM4BOAS DN Velaglucerase alfa DM4BOAS TI TT1B5PU DM4BOAS TN Glucosylceramidase (GBA) DM4BOAS MA Modulator DM4BOAS RN Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5. DM4BOAS RU https://pubmed.ncbi.nlm.nih.gov/21283092 DM4CF18 DI DM4CF18 DM4CF18 DN Menotropins DM4CF18 TI TTZFDBT DM4CF18 TN Follicle-stimulating hormone receptor (FSHR) DM4CF18 MA Binder DM4CF18 RN The role of gonadotropins in ovulation induction. Am J Obstet Gynecol. 1995 Feb;172(2 Pt 2):759-65. DM4CF18 RU https://pubmed.ncbi.nlm.nih.gov/7872378 DM4DMBT DI DM4DMBT DM4DMBT DN Chlorthalidone DM4DMBT TI TTS087L DM4DMBT TN Solute carrier family 12 member 1 (SLC12A1) DM4DMBT MA Blocker DM4DMBT RN The 45-year story of the development of an anti-aldosterone more specific than spironolactone. Mol Cell Endocrinol. 2004 Mar 31;217(1-2):45-52. DM4DMBT RU https://pubmed.ncbi.nlm.nih.gov/15134800 DM4E8O9 DI DM4E8O9 DM4E8O9 DN Umeclidinium DM4E8O9 TI TTH18TF DM4E8O9 TN Muscarinic acetylcholine receptor M5 (CHRM5) DM4E8O9 MA Modulator DM4E8O9 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7354). DM4E8O9 RU http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7354 DM4EGV0 DI DM4EGV0 DM4EGV0 DN Linaclotide DM4EGV0 TI TTLDPRG DM4EGV0 TN Guanylyl cyclase C (GUCY2C) DM4EGV0 MA Activator DM4EGV0 RN Emerging drugs for postoperative ileus. Expert Opin Emerg Drugs. 2007 Nov;12(4):619-26. DM4EGV0 RU https://pubmed.ncbi.nlm.nih.gov/17979603 DM4ES8F DI DM4ES8F DM4ES8F DN Penbutolol DM4ES8F TI TTR6W5O DM4ES8F TN Adrenergic receptor beta-1 (ADRB1) DM4ES8F MA Antagonist DM4ES8F RN beta-Adrenergic receptor blockers--a group of chiral drugs: different effects of each enantiomer. Ceska Slov Farm. 2002 May;51(3):121-8. DM4ES8F RU https://pubmed.ncbi.nlm.nih.gov/12058352 DM4EWNS DI DM4EWNS DM4EWNS DN Cinoxacin DM4EWNS TI TT0IHXV DM4EWNS TN DNA topoisomerase II (TOP2) DM4EWNS MA Inhibitor DM4EWNS RN The interaction and transport of beta-lactam antibiotics with the cloned rat renal organic anion transporter 1. J Pharmacol Exp Ther. 1999 Aug;290(2):672-7. DM4EWNS RU https://pubmed.ncbi.nlm.nih.gov/10411577 DM4F29C DI DM4F29C DM4F29C DN Crizotinib DM4F29C TI TTNDSF4 DM4F29C TN Proto-oncogene c-Met (MET) DM4F29C MA Modulator DM4F29C RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DM4F29C RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DM4F29C DI DM4F29C DM4F29C DN Crizotinib DM4F29C TI TTSZ6Y3 DM4F29C TN Proto-oncogene c-Ros (ROS1) DM4F29C MA Modulator DM4F29C RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DM4F29C RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DM4F29C DI DM4F29C DM4F29C DN Crizotinib DM4F29C TI TTPMQSO DM4F29C TN ALK tyrosine kinase receptor (ALK) DM4F29C MA Modulator DM4F29C RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DM4F29C RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DM4F29C DI DM4F29C DM4F29C DN Crizotinib DM4F29C TI TTKA5LP DM4F29C TN HGF/Met signaling pathway (HGF/Met pathway) DM4F29C MA Inhibitor DM4F29C RN Met tyrosine kinase inhibitor, PF-2341066, suppresses growth and invasion of nasopharyngeal carcinoma.Drug Des Devel Ther. 2015 Aug 26;9:4897-907. DM4F29C RU https://pubmed.ncbi.nlm.nih.gov/26345996 DM4I8O7 DI DM4I8O7 DM4I8O7 DN Bunazosin DM4I8O7 TI TT34BHT DM4I8O7 TN Adrenergic receptor alpha-1D (ADRA1D) DM4I8O7 MA Modulator DM4I8O7 RN Bunazosin, a selective alpha1-adrenoceptor antagonist, as an anti-glaucoma drug: effects on ocular circulation and retinal neuronal damage. Cardiovasc Drug Rev. 2005 Spring;23(1):43-56. DM4I8O7 RU https://pubmed.ncbi.nlm.nih.gov/15867947 DM4IAKR DI DM4IAKR DM4IAKR DN MD-1100 DM4IAKR TI TTLDPRG DM4IAKR TN Guanylyl cyclase C (GUCY2C) DM4IAKR MA Activator DM4IAKR RN Emerging drugs for irritable bowel syndrome. Expert Opin Emerg Drugs. 2006 May;11(2):293-313. DM4IAKR RU https://pubmed.ncbi.nlm.nih.gov/16634703 DM4IF32 DI DM4IF32 DM4IF32 DN Pyrazinamide DM4IF32 TI TTVTX4N DM4IF32 TN Bacterial Fatty acid synthetase I (Bact inhA) DM4IF32 MA Inhibitor DM4IF32 RN Pyrazinamide inhibits the eukaryotic-like fatty acid synthetase I (FASI) of Mycobacterium tuberculosis. Nat Med. 2000 Sep;6(9):1043-7. DM4IF32 RU https://pubmed.ncbi.nlm.nih.gov/10973326 DM4K7GQ DI DM4K7GQ DM4K7GQ DN Erythromycin DM4K7GQ TI TTUWYEA DM4K7GQ TN Bacterial 50S ribosomal RNA (Bact 50S rRNA) DM4K7GQ MA Binder DM4K7GQ RN A synthetic alanyl-initiator tRNA with initiator tRNA properties as determined by fluorescence measurements: comparison to a synthetic alanyl-elongator tRNA. Nucleic Acids Res. 1991 Oct 25;19(20):5749-54. DM4K7GQ RU https://pubmed.ncbi.nlm.nih.gov/1945852 DM4KDYJ DI DM4KDYJ DM4KDYJ DN Nortriptyline DM4KDYJ TI TT3ROYC DM4KDYJ TN Serotonin transporter (SERT) DM4KDYJ MA Modulator DM4KDYJ RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM4KDYJ RU https://www.fda.gov/ DM4KI7O DI DM4KI7O DM4KI7O DN Zidovudine DM4KI7O TI TT84ETX DM4KI7O TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DM4KI7O MA Inhibitor DM4KI7O RN Antiviral drugs in current clinical use. J Clin Virol. 2004 Jun;30(2):115-33. DM4KI7O RU https://pubmed.ncbi.nlm.nih.gov/15125867 DM4KI7O DI DM4KI7O DM4KI7O DN Zidovudine DM4KI7O TI TTGJCWZ DM4KI7O TN Fms-like tyrosine kinase 3 (FLT-3) DM4KI7O MA Binder DM4KI7O RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1807). DM4KI7O RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1807 DM4L59B DI DM4L59B DM4L59B DN Teprotumumab DM4L59B TI TTHRID2 DM4L59B TN Insulin-like growth factor I receptor (IGF1R) DM4L59B MA Antagonist DM4L59B RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020 DM4L59B RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761143s000lbl.pdf DM4L6EU DI DM4L6EU DM4L6EU DN Trandolapril DM4L6EU TI TTL69WB DM4L6EU TN Angiotensin-converting enzyme (ACE) DM4L6EU MA Inhibitor DM4L6EU RN Selective reduction of central pulse pressure under angiotensin blockage in SHR: role of the fibronectin-alpha5beta1 integrin complex. Am J Hypertens. 2009 Jul;22(7):711-7. DM4L6EU RU https://pubmed.ncbi.nlm.nih.gov/19424161 DM4L8H3 DI DM4L8H3 DM4L8H3 DN Loracarbef DM4L8H3 TI TTJP4SM DM4L8H3 TN Bacterial Penicillin binding protein (Bact PBP) DM4L8H3 MA Binder DM4L8H3 RN Amino acid substitutions in mosaic penicillin-binding protein 2 associated with reduced susceptibility to cefixime in clinical isolates of Neisseri... Antimicrob Agents Chemother. 2006 Nov;50(11):3638-45. DM4L8H3 RU https://pubmed.ncbi.nlm.nih.gov/16940068 DM4LECQ DI DM4LECQ DM4LECQ DN Vilazodone DM4LECQ TI TT3ROYC DM4LECQ TN Serotonin transporter (SERT) DM4LECQ MA Modulator DM4LECQ RN 2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4. DM4LECQ RU https://pubmed.ncbi.nlm.nih.gov/22293555 DM4LECQ DI DM4LECQ DM4LECQ DN Vilazodone DM4LECQ TI TTSQIFT DM4LECQ TN 5-HT 1A receptor (HTR1A) DM4LECQ MA Modulator DM4LECQ RN 2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4. DM4LECQ RU https://pubmed.ncbi.nlm.nih.gov/22293555 DM4LOD0 DI DM4LOD0 DM4LOD0 DN Alglucosidase alfa DM4LOD0 TI TT95ICL DM4LOD0 TN Mannose-6-phosphate receptor (M6PR) DM4LOD0 MA Binder DM4LOD0 RN Early treatment with alglucosidase alpha prolongs long-term survival of infants with Pompe disease. Pediatr Res. 2009 Sep;66(3):329-35. DM4LOD0 RU https://pubmed.ncbi.nlm.nih.gov/19542901 DM4LSNE DI DM4LSNE DM4LSNE DN Procaine DM4LSNE TI TTPC4TU DM4LSNE TN 5-HT 3A receptor (HTR3A) DM4LSNE MA Antagonist DM4LSNE RN Local anesthetics have different mechanisms and sites of action at recombinant 5-HT3 receptors. Reg Anesth Pain Med. 2007 Nov-Dec;32(6):462-70. DM4LSNE RU https://pubmed.ncbi.nlm.nih.gov/18035290 DM4LSPN DI DM4LSPN DM4LSPN DN Ibudilast DM4LSPN TI TTV5CGO DM4LSPN TN Phosphodiesterase 4 (PDE4) DM4LSPN MA Inhibitor DM4LSPN RN Therapeutic targeting of 3',5'-cyclic nucleotide phosphodiesterases: inhibition and beyond. Nat Rev Drug Discov. 2019 Oct;18(10):770-796. DM4LSPN RU https://pubmed.ncbi.nlm.nih.gov/31388135 DM4LSPN DI DM4LSPN DM4LSPN DN Ibudilast DM4LSPN TI TTZCG4L DM4LSPN TN Phosphodiesterase 3 (PDE3) DM4LSPN MA Inhibitor DM4LSPN RN Therapeutic targeting of 3',5'-cyclic nucleotide phosphodiesterases: inhibition and beyond. Nat Rev Drug Discov. 2019 Oct;18(10):770-796. DM4LSPN RU https://pubmed.ncbi.nlm.nih.gov/31388135 DM4LT8A DI DM4LT8A DM4LT8A DN Dapsone DM4LT8A TI TT6NHYC DM4LT8A TN Pneumocystis carinii Dihydropteroate synthase (PC DHPS) DM4LT8A MA Modulator DM4LT8A RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM4LT8A RU https://www.fda.gov/ DM4LTKV DI DM4LTKV DM4LTKV DN Dalfopristin DM4LTKV TI TTUWYEA DM4LTKV TN Bacterial 50S ribosomal RNA (Bact 50S rRNA) DM4LTKV MA Binder DM4LTKV RN The streptogramin antibiotics: update on their mechanism of action. Expert Opin Investig Drugs. 1998 Apr;7(4):591-9. DM4LTKV RU https://pubmed.ncbi.nlm.nih.gov/15991995 DM4M1SG DI DM4M1SG DM4M1SG DN Clarithromycin DM4M1SG TI TTUWYEA DM4M1SG TN Bacterial 50S ribosomal RNA (Bact 50S rRNA) DM4M1SG MA Binder DM4M1SG RN Structural basis for the interaction of antibiotics with the peptidyl transferase centre in eubacteria. Nature. 2001 Oct 25;413(6858):814-21. DM4M1SG RU https://pubmed.ncbi.nlm.nih.gov/11677599 DM4MDJY DI DM4MDJY DM4MDJY DN Fluvastatin DM4MDJY TI TTPADOQ DM4MDJY TN HMG-CoA reductase (HMGCR) DM4MDJY MA Inhibitor DM4MDJY RN Equally potent inhibitors of cholesterol synthesis in human hepatocytes have distinguishable effects on different cytochrome P450 enzymes. Biopharm Drug Dispos. 2000 Dec;21(9):353-64. DM4MDJY RU https://pubmed.ncbi.nlm.nih.gov/11523064 DM4ME02 DI DM4ME02 DM4ME02 DN Ticarcillin DM4ME02 TI TTJP4SM DM4ME02 TN Bacterial Penicillin binding protein (Bact PBP) DM4ME02 MA Binder DM4ME02 RN Activities of antibiotics against methicillin-resistant Staphylococcus aureus with particular reference to synergetic effect between ticarcillin and fosfomycin on penicillinase non-producing methicillin-resistant S. aureus. Jpn J Antibiot. 1993 Jun;46(6):421-7. DM4ME02 RU https://pubmed.ncbi.nlm.nih.gov/8360977 DM4NTMO DI DM4NTMO DM4NTMO DN TRYPAN BLUE DM4NTMO TI TTELIN2 DM4NTMO TN PTPN1 messenger RNA (PTPN1 mRNA) DM4NTMO MA Inhibitor DM4NTMO RN Evans Blue and other dyes as protein tyrosine phosphatase inhibitors. Bioorg Med Chem Lett. 2004 Apr 19;14(8):1923-6. DM4NTMO RU https://pubmed.ncbi.nlm.nih.gov/15050628 DM4O2Z7 DI DM4O2Z7 DM4O2Z7 DN Cyclophosphamide DM4O2Z7 TI TTUTN1I DM4O2Z7 TN Human Deoxyribonucleic acid (hDNA) DM4O2Z7 MA Modulator DM4O2Z7 RN O6-methylguanine-DNA methyltransferase activity and sensitivity to cyclophosphamide and cisplatin in human lung tumor xenografts. Int J Cancer. 1998 Sep 11;77(6):919-22. DM4O2Z7 RU https://www.ncbi.nlm.nih.gov/pubmed/9714064 DM4O90W DI DM4O90W DM4O90W DN Insulin-lispro DM4O90W TI TTCBFJO DM4O90W TN Insulin receptor (INSR) DM4O90W MA Binder DM4O90W RN Hope for insulin mimetic oral antidiabetic drugs. Eur J Endocrinol. 1999 Dec;141(6):561-2. DM4O90W RU https://pubmed.ncbi.nlm.nih.gov/10601956 DM4ONW5 DI DM4ONW5 DM4ONW5 DN Baricitinib DM4ONW5 TI TTRMX3V DM4ONW5 TN Janus kinase 2 (JAK-2) DM4ONW5 MA Modulator DM4ONW5 RN Selective JAK inhibitors in development for rheumatoid arthritis. Expert Opin Investig Drugs. 2014 Aug;23(8):1067-77. DM4ONW5 RU https://pubmed.ncbi.nlm.nih.gov/24818516 DM4ONW5 DI DM4ONW5 DM4ONW5 DN Baricitinib DM4ONW5 TI TT6DM01 DM4ONW5 TN Janus kinase 1 (JAK-1) DM4ONW5 MA Modulator DM4ONW5 RN Selective JAK inhibitors in development for rheumatoid arthritis. Expert Opin Investig Drugs. 2014 Aug;23(8):1067-77. DM4ONW5 RU https://pubmed.ncbi.nlm.nih.gov/24818516 DM4ONW5 DI DM4ONW5 DM4ONW5 DN Baricitinib DM4ONW5 TI TTJSQEF DM4ONW5 TN Tyrosine-protein kinase (PTK) DM4ONW5 MA Inhibitor DM4ONW5 RN 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. DM4ONW5 RU https://pubmed.ncbi.nlm.nih.gov/30710142 DM4PF81 DI DM4PF81 DM4PF81 DN Mitomycin A DM4PF81 TI TTUTN1I DM4PF81 TN Human Deoxyribonucleic acid (hDNA) DM4PF81 RN Selective activation of mitomycin A by thiols to form DNA cross-links and monoadducts: biochemical basis for the modulation of mitomycin cytotoxicity by the quinone redox potential. J Med Chem. 2001 Aug 16;44(17):2834-42. DM4PF81 RU https://pubmed.ncbi.nlm.nih.gov/11495594 DM4PRFC DI DM4PRFC DM4PRFC DN Bupivacaine DM4PRFC TI TT90XZ8 DM4PRFC TN Voltage-gated sodium channel alpha Nav1.8 (SCN10A) DM4PRFC MA Modulator DM4PRFC RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM4PRFC RU https://www.fda.gov/ DM4PUDW DI DM4PUDW DM4PUDW DN L-glutamic acid DM4PUDW TI TT9IK2Z DM4PUDW TN N-methyl-D-aspartate receptor (NMDAR) DM4PUDW MA Antagonist DM4PUDW RN Altered expression of genes involved in GABAergic transmission and neuromodulation of granule cell activity in the cerebellum of schizophrenia pati... Am J Psychiatry. 2008 Dec;165(12):1594-603. DM4PUDW RU https://pubmed.ncbi.nlm.nih.gov/18923069 DM4PVDY DI DM4PVDY DM4PVDY DN Durvalumab DM4PVDY TI TT8ZLTI DM4PVDY TN Programmed cell death 1 ligand 1 (PD-L1) DM4PVDY MA Modulator DM4PVDY RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM4PVDY RU https://www.fda.gov/ DM4PXF6 DI DM4PXF6 DM4PXF6 DN Desoximetasone DM4PXF6 TI TTP3UTW DM4PXF6 TN Steroid hormone receptor ERR (ESRR) DM4PXF6 MA Modulator DM4PXF6 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM4PXF6 RU https://www.fda.gov/ DM4QFXJ DI DM4QFXJ DM4QFXJ DN Sodium Tetradecyl Sulfate DM4QFXJ TI TTZUXYS DM4QFXJ TN Vitamin K-dependent protein C (PROC) DM4QFXJ MA Inhibitor DM4QFXJ RN Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. DM4QFXJ RU https://pubmed.ncbi.nlm.nih.gov/17016423 DM4QTBN DI DM4QTBN DM4QTBN DN Isotretinoin DM4QTBN TI TTOD7B3 DM4QTBN TN Retinoic acid receptor (RAR) DM4QTBN MA Agonist DM4QTBN RN Retinoid agonist isotretinoin ameliorates obstructive renal injury. J Urol. 2003 Oct;170(4 Pt 1):1398-402. DM4QTBN RU https://pubmed.ncbi.nlm.nih.gov/14501777 DM4RK0G DI DM4RK0G DM4RK0G DN Divalproex sodium DM4RK0G TI TTT2LD9 DM4RK0G TN GABA transaminase (ABAT) DM4RK0G MA Inhibitor DM4RK0G RN DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6. DM4RK0G RU https://pubmed.ncbi.nlm.nih.gov/18048412 DM4S3O8 DI DM4S3O8 DM4S3O8 DN Ertapenem DM4S3O8 TI TTJP4SM DM4S3O8 TN Bacterial Penicillin binding protein (Bact PBP) DM4S3O8 MA Binder DM4S3O8 RN Role of penicillin-binding protein 2 (PBP2) in the antibiotic susceptibility and cell wall cross-linking of Staphylococcus aureus: evidence for the cooperative functioning of PBP2, PBP4, and PBP2A. JBacteriol. 2005 Mar;187(5):1815-24. DM4S3O8 RU https://pubmed.ncbi.nlm.nih.gov/15716453 DM4UHZF DI DM4UHZF DM4UHZF DN Vestronidase alfa DM4UHZF TI TTHS7CM DM4UHZF TN Beta-glucuronidase (GUSB) DM4UHZF MA Modulator DM4UHZF RN 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85. DM4UHZF RU https://pubmed.ncbi.nlm.nih.gov/29348678 DM4V6JA DI DM4V6JA DM4V6JA DN Cilazapril DM4V6JA TI TTL69WB DM4V6JA TN Angiotensin-converting enzyme (ACE) DM4V6JA MA Inhibitor DM4V6JA RN Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial. Am J Kidney Dis. 2008 Sep;52(3):486-93. DM4V6JA RU https://pubmed.ncbi.nlm.nih.gov/18423812 DM4V6RL DI DM4V6RL DM4V6RL DN Ritodrine DM4V6RL TI TT2CJVK DM4V6RL TN Adrenergic receptor beta-2 (ADRB2) DM4V6RL MA Modulator DM4V6RL RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM4V6RL RU https://www.fda.gov/ DM4VAOG DI DM4VAOG DM4VAOG DN Gadobenate dimeglumine DM4VAOG TI TTFNGC9 DM4VAOG TN Serum albumin (ALB) DM4VAOG MA Binder DM4VAOG RN Protocol design for high relaxivity contrast agents in MR imaging of the CNS. Eur Radiol. 2006 Nov;16 Suppl 7:M3-7. DM4VAOG RU https://pubmed.ncbi.nlm.nih.gov/18655261 DM4W9B3 DI DM4W9B3 DM4W9B3 DN Fosamprenavir DM4W9B3 TI TT5FNQT DM4W9B3 TN Human immunodeficiency virus Protease (HIV PR) DM4W9B3 MA Inhibitor DM4W9B3 RN Fosamprenavir/ritonavir in advanced HIV disease (TRIAD): a randomized study of high-dose, dual-boosted or standard dose fosamprenavir/ritonavir in ... J Antimicrob Chemother. 2009 Aug;64(2):398-410. DM4W9B3 RU https://pubmed.ncbi.nlm.nih.gov/19515730 DM4WVC5 DI DM4WVC5 DM4WVC5 DN Lifitegrast DM4WVC5 TI TTCT6F7 DM4WVC5 TN Intercellular adhesion molecule ICAM-1 (ICAM1) DM4WVC5 MA Inhibitor DM4WVC5 RN Discovery and Development of Potent LFA-1/ICAM-1 Antagonist SAR 1118 as an Ophthalmic Solution for Treating Dry Eye. ACS Med Chem Lett. 2012 Jan 31;3(3):203-6. DM4WVC5 RU https://pubmed.ncbi.nlm.nih.gov/24900456 DM4WVC5 DI DM4WVC5 DM4WVC5 DN Lifitegrast DM4WVC5 TI TT48WR6 DM4WVC5 TN Integrin alpha-L (ITGAL) DM4WVC5 MA Modulator DM4WVC5 RN Corneal inflammation is inhibited by the LFA-1 antagonist, lifitegrast (SAR 1118). J Ocul Pharmacol Ther. 2013 May;29(4):395-402. DM4WVC5 RU https://pubmed.ncbi.nlm.nih.gov/23215542 DM4YMIS DI DM4YMIS DM4YMIS DN Aldesleukin DM4YMIS TI TTF89GD DM4YMIS TN Interleukin-2 (IL2) DM4YMIS MA Modulator DM4YMIS RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM4YMIS RU https://www.fda.gov/ DM4YWCZ DI DM4YWCZ DM4YWCZ DN Nalmefene DM4YWCZ TI TTN4QDT DM4YWCZ TN Opioid receptor (OPR) DM4YWCZ MA Antagonist DM4YWCZ RN Unconditioned behavioral effects of the powerful kappa-opioid hallucinogen salvinorin A in nonhuman primates: fast onset and entry into cerebrospin... J Pharmacol Exp Ther. 2009 Feb;328(2):588-97. DM4YWCZ RU https://pubmed.ncbi.nlm.nih.gov/19001155 DM4ZBK6 DI DM4ZBK6 DM4ZBK6 DN Fedratinib DM4ZBK6 TI TTRMX3V DM4ZBK6 TN Janus kinase 2 (JAK-2) DM4ZBK6 MA Inhibitor DM4ZBK6 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019 DM4ZBK6 RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212327s000lbl.pdf DM4ZLFD DI DM4ZLFD DM4ZLFD DN Glucosamine DM4ZLFD TI TTRYK0X DM4ZLFD TN Interleukin-1 beta (IL1B) DM4ZLFD MA Inhibitor DM4ZLFD RN Glucosamine inhibits IL-1beta-mediated IL-8 production in prostate cancer cells by MAPK attenuation. J Cell Biochem. 2009 Oct 1;108(2):489-98. DM4ZLFD RU https://pubmed.ncbi.nlm.nih.gov/19626664 DM4ZS8M DI DM4ZS8M DM4ZS8M DN Nefazodone DM4ZS8M TI TTWJBZ5 DM4ZS8M TN 5-HT 2C receptor (HTR2C) DM4ZS8M MA Antagonist DM4ZS8M RN Serotonin 5-HT2C receptors as a target for the treatment of depressive and anxious states: focus on novel therapeutic strategies. Therapie. 2005 Sep-Oct;60(5):441-60. DM4ZS8M RU https://pubmed.ncbi.nlm.nih.gov/16433010 DM50ILT DI DM50ILT DM50ILT DN Fostemsavir DM50ILT TI TTBYP1X DM50ILT TN Human immunodeficiency virus Envelope glycoprotein gp120 (HIV gp120) DM50ILT MA Inhibitor DM50ILT RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2020 DM50ILT RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212950s000lbl.pdf DM50PMY DI DM50PMY DM50PMY DN Minodronate DM50PMY TI TTIKWV4 DM50PMY TN Geranyltranstransferase (FDPS) DM50PMY MA Inhibitor DM50PMY RN Synthesis, chiral high performance liquid chromatographic resolution and enantiospecific activity of a potent new geranylgeranyl transferase inhibitor, 2-hydroxy-3-imidazo[1,2-a]pyridin-3-yl-2-phosphonopropionic acid. J Med Chem. 2010 May 13;53(9):3454-64. DM50PMY RU https://pubmed.ncbi.nlm.nih.gov/20394422 DM51FY6 DI DM51FY6 DM51FY6 DN Tacrine DM51FY6 TI TT1RS9F DM51FY6 TN Acetylcholinesterase (AChE) DM51FY6 MA Inhibitor DM51FY6 RN Evidence that the clinical effects of cholinesterase inhibitors are related to potency and targeting of action. Int J Clin Pract Suppl. 2002 Jun;(127):6-19. DM51FY6 RU https://pubmed.ncbi.nlm.nih.gov/12139368 DM51OQW DI DM51OQW DM51OQW DN Oxprenolol DM51OQW TI TTR6W5O DM51OQW TN Adrenergic receptor beta-1 (ADRB1) DM51OQW MA Antagonist DM51OQW RN Prediction and experimental validation of acute toxicity of beta-blockers in Ceriodaphnia dubia. Environ Toxicol Chem. 2005 Oct;24(10):2470-6. DM51OQW RU https://pubmed.ncbi.nlm.nih.gov/16268148 DM51TYR DI DM51TYR DM51TYR DN Esmolol DM51TYR TI TTR6W5O DM51TYR TN Adrenergic receptor beta-1 (ADRB1) DM51TYR MA Antagonist DM51TYR RN Beta-1 selective adrenergic antagonist landiolol and esmolol can be safely used in patients with airway hyperreactivity. Heart Lung. 2009 Jan-Feb;38(1):48-55. DM51TYR RU https://pubmed.ncbi.nlm.nih.gov/19150530 DM51Z9E DI DM51Z9E DM51Z9E DN Cephalothin sodium DM51Z9E TI TTJP4SM DM51Z9E TN Bacterial Penicillin binding protein (Bact PBP) DM51Z9E MA Modulator DM51Z9E RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM51Z9E RU https://www.fda.gov/ DM53IP1 DI DM53IP1 DM53IP1 DN Ethchlorvynol DM53IP1 TI TTZA1NY DM53IP1 TN GABA(A) receptor beta-2 (GABRB2) DM53IP1 MA Antagonist DM53IP1 RN DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6. DM53IP1 RU https://pubmed.ncbi.nlm.nih.gov/18048412 DM53IP1 DI DM53IP1 DM53IP1 DN Ethchlorvynol DM53IP1 TI TT1MPAY DM53IP1 TN GABA(A) receptor alpha-1 (GABRA1) DM53IP1 MA Antagonist DM53IP1 RN DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6. DM53IP1 RU https://pubmed.ncbi.nlm.nih.gov/18048412 DM53PV8 DI DM53PV8 DM53PV8 DN Cefoperazone DM53PV8 TI TTJP4SM DM53PV8 TN Bacterial Penicillin binding protein (Bact PBP) DM53PV8 MA Binder DM53PV8 RN Clinical relevance of antibiotic-induced endotoxin release in patients undergoing hepatic resection. World J Surg. 1999 Jan;23(1):75-9. DM53PV8 RU https://pubmed.ncbi.nlm.nih.gov/9841767 DM53SRA DI DM53SRA DM53SRA DN Prochlorperazine DM53SRA TI TTEX248 DM53SRA TN Dopamine D2 receptor (D2R) DM53SRA MA Antagonist DM53SRA RN In vitro and in vivo characteristics of prochlorperazine oral disintegrating film. Int J Pharm. 2009 Feb 23;368(1-2):98-102. DM53SRA RU https://pubmed.ncbi.nlm.nih.gov/18992311 DM560Y3 DI DM560Y3 DM560Y3 DN Morantel tartrate DM560Y3 TI TTHDSE2 DM560Y3 TN Bacterial Fumarate reductase flavoprotein (Bact frdA) DM560Y3 MA Inhibitor DM560Y3 RN Fumarate reductase is essential for Helicobacter pylori colonization of the mouse stomach. Microb Pathog. 2000 Nov;29(5):279-87. DM560Y3 RU https://pubmed.ncbi.nlm.nih.gov/11031122 DM56YN7 DI DM56YN7 DM56YN7 DN Desloratadine DM56YN7 TI TTTIBOJ DM56YN7 TN Histamine H1 receptor (H1R) DM56YN7 MA Antagonist DM56YN7 RN Examining the tolerability of the non-sedating antihistamine desloratadine: a prescription-event monitoring study in England. Drug Saf. 2009;32(2):169-79. DM56YN7 RU https://pubmed.ncbi.nlm.nih.gov/19236123 DM57O90 DI DM57O90 DM57O90 DN Zolgensma DM57O90 TI TT8QL6X DM57O90 TN Survival motor neuron protein (SMN1) DM57O90 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. DM57O90 RU https://www.fda.gov/vaccines-blood-biologics/zolgensma DM584TM DI DM584TM DM584TM DN Butacaine DM584TM TI TTRK8B9 DM584TM TN Sodium channel unspecific (NaC) DM584TM MA Modulator DM584TM RN WO patent application no. 2008,0857,11, Synergy of sodium channel blockers and calcium channel blockers. DM584TM RU http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20080717&CC=WO&NR=2008085711A1&KC=A1 DM58QS1 DI DM58QS1 DM58QS1 DN Botulinum Toxin Type B DM58QS1 TI TTG25NJ DM58QS1 TN Vesicle-associated membrane protein (VAMP) DM58QS1 MA Binder DM58QS1 RN Long-lasting benefits of botulinum toxin type B in Parkinson's disease-related drooling. J Neurol. 2009 Apr;256(4):563-7. DM58QS1 RU https://pubmed.ncbi.nlm.nih.gov/19401804 DM58VQX DI DM58VQX DM58VQX DN Telavancin DM58VQX TI TT7EFHR DM58VQX TN Corticotropin-releasing factor receptor 1 (CRHR1) DM58VQX MA Antagonist DM58VQX RN A review of drug options in age-related macular degeneration therapy and potential new agents. Expert Opin Pharmacother. 2006 Dec;7(17):2355-68. DM58VQX RU https://pubmed.ncbi.nlm.nih.gov/17109611 DM58WKG DI DM58WKG DM58WKG DN Panobinostat DM58WKG TI TT6R7JZ DM58WKG TN Histone deacetylase 1 (HDAC1) DM58WKG MA Inhibitor DM58WKG RN Protein methyltransferases as a target class for drug discovery. Nat Rev Drug Discov. 2009 Sep;8(9):724-32. DM58WKG RU https://pubmed.ncbi.nlm.nih.gov/19721445 DM59AZT DI DM59AZT DM59AZT DN Clotiazepam DM59AZT TI TTPTXIN DM59AZT TN Translocator protein (TSPO) DM59AZT MA Agonist DM59AZT RN Effects of benzodiazepines and non-benzodiazepine compounds on the GABA-induced response in frog isolated sensory neurones. Br J Pharmacol. 1989 Nov;98(3):735-40. DM59AZT RU https://pubmed.ncbi.nlm.nih.gov/2574062 DM59JCN DI DM59JCN DM59JCN DN Drotrecogin alfa DM59JCN TI TT1290U DM59JCN TN Coagulation factor VIII (F8) DM59JCN MA Inhibitor DM59JCN RN Protein C in critical illness. Am J Health Syst Pharm. 2009 Jun 15;66(12):1089-96. DM59JCN RU https://pubmed.ncbi.nlm.nih.gov/19498123 DM59JCN DI DM59JCN DM59JCN DN Drotrecogin alfa DM59JCN TI TT1O264 DM59JCN TN Coagulation factor Va (F5) DM59JCN MA Inhibitor DM59JCN RN Protein C in critical illness. Am J Health Syst Pharm. 2009 Jun 15;66(12):1089-96. DM59JCN RU https://pubmed.ncbi.nlm.nih.gov/19498123 DM5A31S DI DM5A31S DM5A31S DN TP-434 DM5A31S TI TTND3XS DM5A31S TN Bacterial Ribosome (Bact RIBS) DM5A31S MA Modulator DM5A31S RN Target- and resistance-based mechanistic studies with TP-434, a novel fluorocycline antibiotic. Antimicrob Agents Chemother. 2012 May;56(5):2559-64. DM5A31S RU https://pubmed.ncbi.nlm.nih.gov/22354310 DM5A31S DI DM5A31S DM5A31S DN TP-434 DM5A31S TI TTOVFH2 DM5A31S TN Bacterial 30S ribosomal RNA (Bact 30S rRNA) DM5A31S MA Inhibitor DM5A31S RN The antibiotic arms race: current and emerging therapy for Klebsiella pneumoniae carbapenemase (KPC) - producing bacteria.Expert Opin Pharmacother. 2018 Oct 22:1-13. DM5A31S RU https://pubmed.ncbi.nlm.nih.gov/30346216 DM5A38V DI DM5A38V DM5A38V DN Metharbital DM5A38V TI TTEX6LM DM5A38V TN GABA(A) receptor gamma-3 (GABRG3) DM5A38V MA Modulator DM5A38V RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM5A38V RU https://www.fda.gov/ DM5BS98 DI DM5BS98 DM5BS98 DN Ampiroxicam DM5BS98 TI TTK0943 DM5BS98 TN Prostaglandin G/H synthase (COX) DM5BS98 MA Modulator DM5BS98 RN Premedication with cyclooxygenase-2 inhibitor meloxicam reduced postoperative pain in patients after oral surgery. Int J Oral Maxillofac Surg. 2006 Jul;35(7):613-7. DM5BS98 RU https://pubmed.ncbi.nlm.nih.gov/16540287 DM5CL9Z DI DM5CL9Z DM5CL9Z DN Certolizumab DM5CL9Z TI TTF8CQI DM5CL9Z TN Tumor necrosis factor (TNF) DM5CL9Z MA Inhibitor DM5CL9Z RN Emerging drugs for rheumatoid arthritis. Expert Opin Emerg Drugs. 2008 Mar;13(1):175-96. DM5CL9Z RU https://pubmed.ncbi.nlm.nih.gov/18321156 DM5D6WZ DI DM5D6WZ DM5D6WZ DN Dihydroergotoxine DM5D6WZ TI TTAN6JD DM5D6WZ TN Glutamate receptor AMPA (GRIA) DM5D6WZ MA Agonist DM5D6WZ RN Pharmacologic management of Alzheimer disease, Part II: Antioxidants, antihypertensives, and ergoloid derivatives. Ann Pharmacother. 1999 Feb;33(2):188-97. DM5D6WZ RU https://pubmed.ncbi.nlm.nih.gov/10084415 DM5D6WZ DI DM5D6WZ DM5D6WZ DN Dihydroergotoxine DM5D6WZ TI TTEX248 DM5D6WZ TN Dopamine D2 receptor (D2R) DM5D6WZ MA Agonist DM5D6WZ RN Pharmacologic management of Alzheimer disease, Part II: Antioxidants, antihypertensives, and ergoloid derivatives. Ann Pharmacother. 1999 Feb;33(2):188-97. DM5D6WZ RU https://pubmed.ncbi.nlm.nih.gov/10084415 DM5DWMU DI DM5DWMU DM5DWMU DN Rimantadine DM5DWMU TI TTXT3PU DM5DWMU TN Influenza M2 protein (Influ M) DM5DWMU MA Inhibitor DM5DWMU RN Antiviral resistance of influenza A (H3N2) strains isolated in northern Greece between 2004 and 2007. Euro Surveill. 2009 Jan 29;14(4). pii: 19104. DM5DWMU RU https://pubmed.ncbi.nlm.nih.gov/19215710 DM5EN79 DI DM5EN79 DM5EN79 DN Levamisole DM5EN79 TI TTMR5UV DM5EN79 TN Alkaline phosphatase tissue-nonspecific (ALPL) DM5EN79 MA Inhibitor DM5EN79 RN Characterization of rat heart alkaline phosphatase isoenzymes and modulation of activity. Braz J Med Biol Res. 2008 Jul;41(7):600-9. DM5EN79 RU https://pubmed.ncbi.nlm.nih.gov/18719742 DM5F47O DI DM5F47O DM5F47O DN Sofosbuvir + velpatasvir + voxilaprevir DM5F47O TI TTHC7JD DM5F47O TN Hepatitis C virus Serine protease NS3/4A (HCV NS3/4A) DM5F47O MA Inhibitor DM5F47O RN 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85. DM5F47O RU https://pubmed.ncbi.nlm.nih.gov/29348678 DM5F47O DI DM5F47O DM5F47O DN Sofosbuvir + velpatasvir + voxilaprevir DM5F47O TI TTMVBWH DM5F47O TN Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B) DM5F47O MA Inhibitor DM5F47O RN 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85. DM5F47O RU https://pubmed.ncbi.nlm.nih.gov/29348678 DM5F47O DI DM5F47O DM5F47O DN Sofosbuvir + velpatasvir + voxilaprevir DM5F47O TI TTCJ2X8 DM5F47O TN Hepatitis C virus Non-structural 5A (HCV NS5A) DM5F47O MA Inhibitor DM5F47O RN 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85. DM5F47O RU https://pubmed.ncbi.nlm.nih.gov/29348678 DM5F84A DI DM5F84A DM5F84A DN Pipecuronium DM5F84A TI TTF4E0J DM5F84A TN Neuronal acetylcholine receptor alpha-2 (CHRNA2) DM5F84A MA Antagonist DM5F84A RN Synergy between pairs of competitive antagonists at adult human muscle acetylcholine receptors. Anesth Analg. 2008 Aug;107(2):525-33. DM5F84A RU https://pubmed.ncbi.nlm.nih.gov/18633030 DM5FL14 DI DM5FL14 DM5FL14 DN Amifostine DM5FL14 TI TT0C9DV DM5FL14 TN Toxic reactive metabolite (TRM) DM5FL14 MA Modulator DM5FL14 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DM5FL14 RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DM5FLTY DI DM5FLTY DM5FLTY DN Risedronate DM5FLTY TI TTIKWV4 DM5FLTY TN Geranyltranstransferase (FDPS) DM5FLTY MA Inhibitor DM5FLTY RN Activity of bisphosphonates against Trypanosoma brucei rhodesiense. J Med Chem. 2002 Jul 4;45(14):2904-14. DM5FLTY RU https://pubmed.ncbi.nlm.nih.gov/12086478 DM5FSJA DI DM5FSJA DM5FSJA DN Glimepiride DM5FSJA TI TTEF5MJ DM5FSJA TN ATP-binding cassette transporter C9 (ABCC9) DM5FSJA MA Blocker DM5FSJA RN Mechanism of disopyramide-induced hypoglycaemia in a patient with Type 2 diabetes. Diabet Med. 2009 Jan;26(1):76-8. DM5FSJA RU https://pubmed.ncbi.nlm.nih.gov/19125764 DM5FSJA DI DM5FSJA DM5FSJA DN Glimepiride DM5FSJA TI TTP835K DM5FSJA TN ATP-binding cassette transporter C8 (ABCC8) DM5FSJA MA Blocker DM5FSJA RN Mechanism of disopyramide-induced hypoglycaemia in a patient with Type 2 diabetes. Diabet Med. 2009 Jan;26(1):76-8. DM5FSJA RU https://pubmed.ncbi.nlm.nih.gov/19125764 DM5GT1M DI DM5GT1M DM5GT1M DN EVANS BLUE DM5GT1M TI TTFNGC9 DM5GT1M TN Serum albumin (ALB) DM5GT1M MA Modulator DM5GT1M RN The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954. DM5GT1M RU https://www.ncbi.nlm.nih.gov/pubmed/27899562 DM5GVHU DI DM5GVHU DM5GVHU DN Quinolones DM5GVHU TI TT0IHXV DM5GVHU TN DNA topoisomerase II (TOP2) DM5GVHU MA Inhibitor DM5GVHU RN The magic bullets and tuberculosis drug targets. Annu Rev Pharmacol Toxicol. 2005;45:529-64. DM5GVHU RU https://pubmed.ncbi.nlm.nih.gov/15822188 DM5I1CE DI DM5I1CE DM5I1CE DN Valacyclovir Hydrochloride DM5I1CE TI TTIU7X1 DM5I1CE TN Herpes simplex virus DNA polymerase UL30 (HSV UL30) DM5I1CE MA Modulator DM5I1CE RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM5I1CE RU https://www.fda.gov/ DM5I621 DI DM5I621 DM5I621 DN Methyldopa DM5I621 TI TTEX248 DM5I621 TN Dopamine D2 receptor (D2R) DM5I621 MA Agonist DM5I621 RN Centrally acting antihypertensive agents: an update. J Clin Hypertens (Greenwich). 2007 May;9(5):399-405. DM5I621 RU https://pubmed.ncbi.nlm.nih.gov/17485976 DM5IKUF DI DM5IKUF DM5IKUF DN Dihydroergotamine DM5IKUF TI TTEX248 DM5IKUF TN Dopamine D2 receptor (D2R) DM5IKUF MA Agonist DM5IKUF RN Current and prospective pharmacological targets in relation to antimigraine action. Naunyn Schmiedebergs Arch Pharmacol. 2008 Oct;378(4):371-94. DM5IKUF RU https://pubmed.ncbi.nlm.nih.gov/18626630 DM5IXKQ DI DM5IXKQ DM5IXKQ DN Vismodegib DM5IXKQ TI TT8J1S3 DM5IXKQ TN Smoothened homolog (SMO) DM5IXKQ MA Modulator DM5IXKQ RN Nat Rev Drug Discov. 2013 Feb;12(2):87-90. DM5IXKQ RU https://pubmed.ncbi.nlm.nih.gov/23370234 DM5J1NH DI DM5J1NH DM5J1NH DN Alcaftadine DM5J1NH TI TTTIBOJ DM5J1NH TN Histamine H1 receptor (H1R) DM5J1NH MA Antagonist DM5J1NH RN Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5. DM5J1NH RU https://pubmed.ncbi.nlm.nih.gov/21283092 DM5J64S DI DM5J64S DM5J64S DN Miglustat DM5J64S TI TTPHEX3 DM5J64S TN Ceramide glucosyltransferase (UGCG) DM5J64S MA Inhibitor DM5J64S RN Effect of miglustat on bone disease in adults with type 1 Gaucher disease: a pooled analysis of three multinational, open-label studies. Clin Ther. 2007 Aug;29(8):1645-54. DM5J64S RU https://pubmed.ncbi.nlm.nih.gov/17919546 DM5JQ0D DI DM5JQ0D DM5JQ0D DN Streptokinase DM5JQ0D TI TTP86E2 DM5JQ0D TN Plasminogen (PLG) DM5JQ0D MA Activator DM5JQ0D RN Acute anuric renal failure with streptokinase therapy in a patient with acute venous thromboembolic disease and the review of renal side effects of streptokinase. Tuberk Toraks. 2008;56(4):456-61. DM5JQ0D RU https://pubmed.ncbi.nlm.nih.gov/19123085 DM5JTPU DI DM5JTPU DM5JTPU DN Albumin Human DM5JTPU TI TTFNGC9 DM5JTPU TN Serum albumin (ALB) DM5JTPU MA Modulator DM5JTPU RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM5JTPU RU https://www.fda.gov/ DM5JVAN DI DM5JVAN DM5JVAN DN Fingolimod DM5JVAN TI TT9JZCK DM5JVAN TN Sphingosine-1-phosphate receptor 1 (S1PR1) DM5JVAN MA Modulator DM5JVAN RN Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5. DM5JVAN RU https://pubmed.ncbi.nlm.nih.gov/21283092 DM5JVS3 DI DM5JVS3 DM5JVS3 DN Isoniazid DM5JVS3 TI TTVTX4N DM5JVS3 TN Bacterial Fatty acid synthetase I (Bact inhA) DM5JVS3 MA Inhibitor DM5JVS3 RN Diversity in enoyl-acyl carrier protein reductases. Cell Mol Life Sci. 2009 May;66(9):1507-17. DM5JVS3 RU https://pubmed.ncbi.nlm.nih.gov/19151923 DM5JWV9 DI DM5JWV9 DM5JWV9 DN Tiazofurin DM5JWV9 TI TTL7C8Q DM5JWV9 TN Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1) DM5JWV9 MA Inhibitor DM5JWV9 RN In vitro and in vivo antiproliferative activity of IPCAR, a new pyrazole nucleoside analog. Anticancer Res. 1998 Jul-Aug;18(4A):2623-30. DM5JWV9 RU https://pubmed.ncbi.nlm.nih.gov/9703919 DM5KYPJ DI DM5KYPJ DM5KYPJ DN Butorphanol DM5KYPJ TI TT27RFC DM5KYPJ TN Opioid receptor delta (OPRD1) DM5KYPJ MA Agonist DM5KYPJ RN Butorphanol: effects of a prototypical agonist-antagonist analgesic on kappa-opioid receptors. J Pharmacol Sci. 2005 Jun;98(2):109-16. DM5KYPJ RU https://pubmed.ncbi.nlm.nih.gov/15942128 DM5L6HI DI DM5L6HI DM5L6HI DN Atomoxetine DM5L6HI TI TTAWNKZ DM5L6HI TN Norepinephrine transporter (NET) DM5L6HI MA Inhibitor DM5L6HI RN Atomoxetine reverses attentional deficits produced by noradrenergic deafferentation of medial prefrontal cortex. Psychopharmacology (Berl). 2008 Sep;200(1):39-50. DM5L6HI RU https://pubmed.ncbi.nlm.nih.gov/18568443 DM5LJCI DI DM5LJCI DM5LJCI DN Eptinezumab DM5LJCI TI TTAFORY DM5LJCI TN Calcitonin gene-related peptide (CALC) DM5LJCI MA Inhibitor DM5LJCI RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020 DM5LJCI RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761119s000lbl.pdf DM5M4NT DI DM5M4NT DM5M4NT DN Ethacrynate sodium DM5M4NT TI TTS087L DM5M4NT TN Solute carrier family 12 member 1 (SLC12A1) DM5M4NT MA Modulator DM5M4NT RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM5M4NT RU https://www.fda.gov/ DM5NM6E DI DM5NM6E DM5NM6E DN NADH DM5NM6E TI TTTJF7V DM5NM6E TN NADH dehydrogenase (MT-ND3) DM5NM6E MA Binder DM5NM6E RN Mechanism of cadmium-decreased glucuronidation in the rat. Biochem Pharmacol. 1992 Dec 1;44(11):2139-47. DM5NM6E RU https://pubmed.ncbi.nlm.nih.gov/1472079 DM5OGK0 DI DM5OGK0 DM5OGK0 DN Epalrestat DM5OGK0 TI TTFBNVI DM5OGK0 TN Aldose reductase (AKR1B1) DM5OGK0 MA Inhibitor DM5OGK0 RN Long-term effect of epalrestat, an aldose reductase inhibitor, on the development of incipient diabetic nephropathy in Type 2 diabetic patients. J Diabetes Complications. 2001 Sep-Oct;15(5):241-4. DM5OGK0 RU https://pubmed.ncbi.nlm.nih.gov/11522497 DM5OGK0 DI DM5OGK0 DM5OGK0 DN Epalrestat DM5OGK0 TI TTXHYV6 DM5OGK0 TN Voltage-gated L-type calcium channel (L-CaC) DM5OGK0 MA Blocker DM5OGK0 RN Recent updates of N-type calcium channel blockers with therapeutic potential for neuropathic pain and stroke. Curr Top Med Chem. 2009;9(4):377-95. DM5OGK0 RU https://pubmed.ncbi.nlm.nih.gov/19442208 DM5OHYE DI DM5OHYE DM5OHYE DN Bacitracin DM5OHYE TI TT2EDHU DM5OHYE TN Insulin-degrading enzyme (IDE) DM5OHYE MA Inhibitor DM5OHYE RN Brain insulin impairs amyloid-beta(1-40) clearance from the brain. J Neurosci. 2004 Oct 27;24(43):9632-7. DM5OHYE RU https://pubmed.ncbi.nlm.nih.gov/15509750 DM5OY70 DI DM5OY70 DM5OY70 DN Iron Dextran DM5OY70 TI TTQO71U DM5OY70 TN Hemoglobin (HB) DM5OY70 MA Activator DM5OY70 RN Efficacy and safety of total dose infusion of low molecular weight iron dextran in the treatment of iron deficiency anemia during pregnancy. J Coll Physicians Surg Pak. 2008 Jul;18(7):424-7. DM5OY70 RU https://pubmed.ncbi.nlm.nih.gov/18760066 DM5PCS7 DI DM5PCS7 DM5PCS7 DN Bupropion DM5PCS7 TI TT3ROYC DM5PCS7 TN Serotonin transporter (SERT) DM5PCS7 MA Inhibitor DM5PCS7 RN Clinically relevant drug interactions with new generation antidepressants and antipsychotics. Ther Umsch. 2009 Jun;66(6):485-92. DM5PCS7 RU https://pubmed.ncbi.nlm.nih.gov/19496045 DM5PCS7 DI DM5PCS7 DM5PCS7 DN Bupropion DM5PCS7 TI TTAWNKZ DM5PCS7 TN Norepinephrine transporter (NET) DM5PCS7 MA Inhibitor DM5PCS7 RN Clinically relevant drug interactions with new generation antidepressants and antipsychotics. Ther Umsch. 2009 Jun;66(6):485-92. DM5PCS7 RU https://pubmed.ncbi.nlm.nih.gov/19496045 DM5PDRB DI DM5PDRB DM5PDRB DN Amikacin DM5PDRB TI TTQ8KVI DM5PDRB TN Staphylococcus 30S ribosomal subunit (Stap-coc pbp2) DM5PDRB MA Binder DM5PDRB RN Bacterial resistance to aminoglycosides and beta-lactams: the Tn1331 transposon paradigm. Front Biosci. 2000 Jan 1;5:D20-9. DM5PDRB RU https://pubmed.ncbi.nlm.nih.gov/10702385 DM5PFIJ DI DM5PFIJ DM5PFIJ DN Givosiran DM5PFIJ TI TTG1FXO DM5PFIJ TN ALAS1 messenger RNA (ALAS1 mRNA) DM5PFIJ MA Inhibitor DM5PFIJ RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019 DM5PFIJ RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/0212194s000lbl.pdf DM5PU6O DI DM5PU6O DM5PU6O DN Oxcarbazepine DM5PU6O TI TTN9VTF DM5PU6O TN Voltage-gated sodium channel alpha Nav1.9 (SCN11A) DM5PU6O MA Blocker DM5PU6O RN Debate: Does genetic information in humans help us treat patients PRO--genetic information in humans helps us treat patients. CON--genetic information does not help at all. Epilepsia. 2008 Dec;49 Suppl 9:13-24. DM5PU6O RU https://pubmed.ncbi.nlm.nih.gov/19087113 DM5PVQE DI DM5PVQE DM5PVQE DN Paroxetine DM5PVQE TI TT3ROYC DM5PVQE TN Serotonin transporter (SERT) DM5PVQE MA Modulator DM5PVQE RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM5PVQE RU https://www.fda.gov/ DM5QF9V DI DM5QF9V DM5QF9V DN Tamsulosin DM5QF9V TI TTNGILX DM5QF9V TN Adrenergic receptor alpha-1A (ADRA1A) DM5QF9V MA Modulator DM5QF9V RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM5QF9V RU https://www.fda.gov/ DM5QWEL DI DM5QWEL DM5QWEL DN Guanabenz DM5QWEL TI TTQ8AFT DM5QWEL TN Adrenergic receptor Alpha-2 (ADRA2) DM5QWEL MA Agonist DM5QWEL RN Centrally acting sympathetic inhibitors for therapy of patients with hypertension. Nippon Rinsho. 1997 Aug;55(8):2081-5. DM5QWEL RU https://pubmed.ncbi.nlm.nih.gov/9284427 DM5SQ1G DI DM5SQ1G DM5SQ1G DN Dihydroergocristine DM5SQ1G TI TT2NUT5 DM5SQ1G TN Adrenergic receptor alpha-2C (ADRA2C) DM5SQ1G MA Modulator DM5SQ1G RN Effect of dihydroergocristine on blood pressure and activity at peripheral alpha-adrenoceptors in pithed rats. Eur J Pharmacol. 1984 Jan 13;97(1-2):21-7. DM5SQ1G RU https://pubmed.ncbi.nlm.nih.gov/6321209 DM5SXUV DI DM5SXUV DM5SXUV DN Repaglinide DM5SXUV TI TTP835K DM5SXUV TN ATP-binding cassette transporter C8 (ABCC8) DM5SXUV MA Blocker DM5SXUV RN Metformin/Repaglinide (PrandiMet) for type 2 diabetes. Med Lett Drugs Ther. 2009 Jun 1;51(1313):41-3. DM5SXUV RU https://pubmed.ncbi.nlm.nih.gov/19478691 DM5SXUV DI DM5SXUV DM5SXUV DN Repaglinide DM5SXUV TI TTEF5MJ DM5SXUV TN ATP-binding cassette transporter C9 (ABCC9) DM5SXUV MA Blocker DM5SXUV RN Metformin/Repaglinide (PrandiMet) for type 2 diabetes. Med Lett Drugs Ther. 2009 Jun 1;51(1313):41-3. DM5SXUV RU https://pubmed.ncbi.nlm.nih.gov/19478691 DM5SYZP DI DM5SYZP DM5SYZP DN Disopyramide DM5SYZP TI TTZOVE0 DM5SYZP TN Voltage-gated sodium channel alpha Nav1.5 (SCN5A) DM5SYZP MA Blocker DM5SYZP RN Effect of sodium channel blockers on ST segment, QRS duration, and corrected QT interval in patients with Brugada syndrome. J Cardiovasc Electrophysiol. 2000 Dec;11(12):1320-9. DM5SYZP RU https://pubmed.ncbi.nlm.nih.gov/11196553 DM5T6US DI DM5T6US DM5T6US DN Estrone DM5T6US TI TTZAYWL DM5T6US TN Estrogen receptor (ESR) DM5T6US MA Agonist DM5T6US RN Reprint of Are all estrogens the same Maturitas. 2008 Sep-Oct;61(1-2):195-201. DM5T6US RU https://pubmed.ncbi.nlm.nih.gov/19434891 DM5TVS3 DI DM5TVS3 DM5TVS3 DN Vinblastine DM5TVS3 TI TTJ2PTI DM5TVS3 TN Tubulin beta-2 chain (TUBB2) DM5TVS3 MA Inhibitor DM5TVS3 RN Effect of the antitumor drug vinblastine on nuclear betaII-tubulin in cultured rat kidney mesangial cells. Invest New Drugs. 2003 Feb;21(1):15-20. DM5TVS3 RU https://pubmed.ncbi.nlm.nih.gov/12795526 DM5UGDK DI DM5UGDK DM5UGDK DN Mephenytoin DM5UGDK TI TTZOVE0 DM5UGDK TN Voltage-gated sodium channel alpha Nav1.5 (SCN5A) DM5UGDK MA Blocker DM5UGDK RN Lacosamide: a new approach to target voltage-gated sodium currents in epileptic disorders. CNS Drugs. 2009;23(7):555-68. DM5UGDK RU https://pubmed.ncbi.nlm.nih.gov/19552484 DM5URA2 DI DM5URA2 DM5URA2 DN Chlorpheniramine DM5URA2 TI TTTIBOJ DM5URA2 TN Histamine H1 receptor (H1R) DM5URA2 MA Antagonist DM5URA2 RN Intact cell binding for in vitro prediction of sedative and non-sedative histamine H1-receptor antagonists based on receptor internalization. J Pharmacol Sci. 2008 May;107(1):66-79. DM5URA2 RU https://pubmed.ncbi.nlm.nih.gov/18446005 DM5V9U1 DI DM5V9U1 DM5V9U1 DN Gadofosveset DM5V9U1 TI TTFNGC9 DM5V9U1 TN Serum albumin (ALB) DM5V9U1 MA Modulator DM5V9U1 RN 2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6. DM5V9U1 RU https://pubmed.ncbi.nlm.nih.gov/19180096 DM5VWOB DI DM5VWOB DM5VWOB DN Methylscopolamine DM5VWOB TI TTYEG6Q DM5VWOB TN Muscarinic acetylcholine receptor M2 (CHRM2) DM5VWOB MA Antagonist DM5VWOB RN Methylacridinium and its cholinergic properties. Neurotox Res. 2009 Nov;16(4):372-7. DM5VWOB RU https://pubmed.ncbi.nlm.nih.gov/19565307 DM5VWOB DI DM5VWOB DM5VWOB DN Methylscopolamine DM5VWOB TI TTOXS3C DM5VWOB TN Muscarinic acetylcholine receptor (CHRM) DM5VWOB MA Antagonist DM5VWOB RN Lithocholylcholine, a bile acid/acetylcholine hybrid, is a muscarinic receptor antagonist. J Pharmacol Exp Ther. 2002 Oct;303(1):29-35. DM5VWOB RU https://pubmed.ncbi.nlm.nih.gov/12235229 DM5VWOB DI DM5VWOB DM5VWOB DN Methylscopolamine DM5VWOB TI TTQ13Z5 DM5VWOB TN Muscarinic acetylcholine receptor M3 (CHRM3) DM5VWOB MA Antagonist DM5VWOB RN Interaction of neuromuscular blocking drugs with recombinant human m1-m5 muscarinic receptors expressed in Chinese hamster ovary cells. Br J Pharmacol. 1998 Nov;125(5):1088-94. DM5VWOB RU https://pubmed.ncbi.nlm.nih.gov/9846649 DM5WFNP DI DM5WFNP DM5WFNP DN Abarelix DM5WFNP TI TT8R70G DM5WFNP TN Gonadotropin-releasing hormone receptor (GNRHR) DM5WFNP MA Modulator DM5WFNP RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM5WFNP RU https://www.fda.gov/ DM5X7VY DI DM5X7VY DM5X7VY DN Pyrimethamine DM5X7VY TI TTVC37M DM5X7VY TN Folate receptor alpha (FOLR1) DM5X7VY MA Modulator DM5X7VY RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM5X7VY RU https://www.fda.gov/ DM5XH2C DI DM5XH2C DM5XH2C DN Methotrexate Sodium DM5XH2C TI TTYZVDJ DM5XH2C TN Dihydrofolate reductase (DHFR) DM5XH2C MA Modulator DM5XH2C RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM5XH2C RU https://www.fda.gov/ DM5XHVR DI DM5XHVR DM5XHVR DN Insulin Lyspro recombinant DM5XHVR TI TTCBFJO DM5XHVR TN Insulin receptor (INSR) DM5XHVR MA Binder DM5XHVR RN Knockouts model the 100 best-selling drugs--will they model the next 100 Nat Rev Drug Discov. 2003 Jan;2(1):38-51. DM5XHVR RU https://pubmed.ncbi.nlm.nih.gov/12509758 DM5XLTY DI DM5XLTY DM5XLTY DN Spirapril DM5XLTY TI TTL69WB DM5XLTY TN Angiotensin-converting enzyme (ACE) DM5XLTY MA Inhibitor DM5XLTY RN Central angiotensin II controls alcohol consumption via its AT1 receptor. FASEB J. 2005 Sep;19(11):1474-81. DM5XLTY RU https://pubmed.ncbi.nlm.nih.gov/16126915 DM5XPIJ DI DM5XPIJ DM5XPIJ DN Leuprolide DM5XPIJ TI TT0ID4A DM5XPIJ TN Leutinizing-hormone-releasing hormone (GNRH1) DM5XPIJ MA Activator DM5XPIJ RN Increased risk of metabolic syndrome, diabetes mellitus, and cardiovascular disease in men receiving androgen deprivation therapy for prostate cancer. Pharmacotherapy. 2008 Dec;28(12):1511-22. DM5XPIJ RU https://pubmed.ncbi.nlm.nih.gov/19025432 DM5YBO1 DI DM5YBO1 DM5YBO1 DN Levalbuterol DM5YBO1 TI TT2CJVK DM5YBO1 TN Adrenergic receptor beta-2 (ADRB2) DM5YBO1 MA Antagonist DM5YBO1 RN Beta-blockers in the treatment of hypertension: are there clinically relevant differences Postgrad Med. 2009 May;121(3):90-8. DM5YBO1 RU https://pubmed.ncbi.nlm.nih.gov/19491545 DM602WT DI DM602WT DM602WT DN Idelalisib DM602WT TI TTGBPJE DM602WT TN PI3-kinase delta (PIK3CD) DM602WT MA Inhibitor DM602WT RN 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81. DM602WT RU https://pubmed.ncbi.nlm.nih.gov/25633781 DM6034S DI DM6034S DM6034S DN Selegiline DM6034S TI TTGP7BY DM6034S TN Monoamine oxidase type B (MAO-B) DM6034S MA Inhibitor DM6034S RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2490). DM6034S RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2490 DM6034S DI DM6034S DM6034S DN Selegiline DM6034S TI TTZPO1L DM6034S TN Substance-P receptor (TACR1) DM6034S MA Antagonist DM6034S RN Clinical pipeline report, company report or official report of GlaxoSmithKline (2009). DM6034S RU http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf DM6034S DI DM6034S DM6034S DN Selegiline DM6034S TI TT32XQJ DM6034S TN Monoamine oxidase (MAO) DM6034S MA Inhibitor DM6034S RN Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110. DM6034S RU https://www.ncbi.nlm.nih.gov/pubmed/25399762 DM60QMR DI DM60QMR DM60QMR DN Ethacrynic acid DM60QMR TI TTS087L DM60QMR TN Solute carrier family 12 member 1 (SLC12A1) DM60QMR MA Blocker DM60QMR RN Na-K-Cl cotransport regulates intracellular volume and monolayer permeability of trabecular meshwork cells. Am J Physiol. 1995 Apr;268(4 Pt 1):C1067-74. DM60QMR RU https://pubmed.ncbi.nlm.nih.gov/7733229 DM61TA4 DI DM61TA4 DM61TA4 DN Arsenic trioxide DM61TA4 TI TTJ3E9X DM61TA4 TN Inhibitor of nuclear factor kappa-B kinase beta (IKKB) DM61TA4 MA Inhibitor DM61TA4 RN How acute promyelocytic leukaemia revived arsenic. Nat Rev Cancer. 2002 Sep;2(9):705-13. DM61TA4 RU https://pubmed.ncbi.nlm.nih.gov/12209159 DM62B78 DI DM62B78 DM62B78 DN Olodaterol DM62B78 TI TT2CJVK DM62B78 TN Adrenergic receptor beta-2 (ADRB2) DM62B78 MA Modulator DM62B78 RN 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81. DM62B78 RU https://pubmed.ncbi.nlm.nih.gov/25633781 DM62MUZ DI DM62MUZ DM62MUZ DN Samarium Sm-153 Lexidronam Pentasodium DM62MUZ TI TTGXKP7 DM62MUZ TN Samarium (SAM) DM62MUZ MA Modulator DM62MUZ RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM62MUZ RU https://www.fda.gov/ DM62UG5 DI DM62UG5 DM62UG5 DN Vemurafenib DM62UG5 TI TTWCGQT DM62UG5 TN Serine/threonine-protein kinase B-raf (BRAF) DM62UG5 MA Modulator DM62UG5 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DM62UG5 RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DM62UHC DI DM62UHC DM62UHC DN Meropenem DM62UHC TI TTJP4SM DM62UHC TN Bacterial Penicillin binding protein (Bact PBP) DM62UHC MA Modulator DM62UHC RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM62UHC RU https://www.fda.gov/ DM63QS9 DI DM63QS9 DM63QS9 DN Nystatin DM63QS9 TI TTQKWA4 DM63QS9 TN Fungal Cell membrane ergosterol (Fung CME) DM63QS9 MA Modulator DM63QS9 RN Cholesterol and Ergosterol Influence Nystatin Surface Aggregation: Relation to Pore Formation DM63QS9 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1304795 DM65AGJ DI DM65AGJ DM65AGJ DN Oxymorphone DM65AGJ TI TTN4QDT DM65AGJ TN Opioid receptor (OPR) DM65AGJ MA Modulator DM65AGJ RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7094). DM65AGJ RU http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7094 DM65KL8 DI DM65KL8 DM65KL8 DN Fluocinonide DM65KL8 TI TTP3UTW DM65KL8 TN Steroid hormone receptor ERR (ESRR) DM65KL8 MA Modulator DM65KL8 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM65KL8 RU https://www.fda.gov/ DM671NG DI DM671NG DM671NG DN Progabide DM671NG TI TTDCVZW DM671NG TN Gamma-aminobutyric acid B receptor (GABBR) DM671NG MA Agonist DM671NG RN Interactions between dopamine and GABA in the control of ambulatory activity and neophobia in the mouse. Pharmacol Biochem Behav. 1998 Jan;59(1):239-47. DM671NG RU https://pubmed.ncbi.nlm.nih.gov/9443561 DM672AH DI DM672AH DM672AH DN Aspirin DM672AH TI TTK0943 DM672AH TN Prostaglandin G/H synthase (COX) DM672AH MA Inhibitor DM672AH RN Cyclooxygenase inhibitors: instrumental drugs to understand cardiovascular homeostasis and arterial thrombosis. Cardiovasc Hematol Disord Drug Targets. 2008 Dec;8(4):268-77. DM672AH RU https://pubmed.ncbi.nlm.nih.gov/19075637 DM672AH DI DM672AH DM672AH DN Aspirin DM672AH TI TTPADOQ DM672AH TN HMG-CoA reductase (HMGCR) DM672AH MA Inhibitor DM672AH RN Emerging drugs in peripheral arterial disease. Expert Opin Emerg Drugs. 2006 Mar;11(1):75-90. DM672AH RU https://pubmed.ncbi.nlm.nih.gov/16503827 DM67VKL DI DM67VKL DM67VKL DN Prasterone DM67VKL TI TTS64P2 DM67VKL TN Androgen receptor (AR) DM67VKL MA Antagonist DM67VKL RN Dehydroepiandrosterone, glucose-6-phosphate dehydrogenase, and longevity. Ageing Res Rev. 2004 Apr;3(2):171-87. DM67VKL RU https://pubmed.ncbi.nlm.nih.gov/15177053 DM67VKL DI DM67VKL DM67VKL DN Prasterone DM67VKL TI TTKN8W0 DM67VKL TN Glucose-6-phosphate dehydrogenase (G6PD) DM67VKL MA Inhibitor DM67VKL RN Glucose utilization and activity of glucose-6-phosphate dehydrogenase, isocitrate dehydrogenase and malate dehydrogenase in rat erythrocytes after treatment with tuberculostatic agents. Vopr Med Khim. 1986 Sep-Oct;32(5):32-5. DM67VKL RU https://pubmed.ncbi.nlm.nih.gov/3776114 DM69XMQ DI DM69XMQ DM69XMQ DN RG-7446 DM69XMQ TI TT8ZLTI DM69XMQ TN Programmed cell death 1 ligand 1 (PD-L1) DM69XMQ RN PD-1 as a potential target in cancer therapy. Cancer Med. 2013 October; 2(5): 662-673. DM69XMQ RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3892798/ DM6A0X7 DI DM6A0X7 DM6A0X7 DN Pravastatin DM6A0X7 TI TTPADOQ DM6A0X7 TN HMG-CoA reductase (HMGCR) DM6A0X7 MA Inhibitor DM6A0X7 RN A randomized, double-blind trial comparing the efficacy and safety of pitavastatin versus pravastatin in patients with primary hypercholesterolemia. Atherosclerosis. 2002 Jun;162(2):373-9. DM6A0X7 RU https://pubmed.ncbi.nlm.nih.gov/11996957 DM6A4NW DI DM6A4NW DM6A4NW DN Etoricoxib DM6A4NW TI TTVKILB DM6A4NW TN Prostaglandin G/H synthase 2 (COX-2) DM6A4NW MA Inhibitor DM6A4NW RN The effect of newer anti-rheumatic drugs on osteogenic cell proliferation: an in-vitro study. J Orthop Surg Res. 2009 May 26;4:17. DM6A4NW RU https://pubmed.ncbi.nlm.nih.gov/19470170 DM6AN32 DI DM6AN32 DM6AN32 DN Trovafloxacin DM6AN32 TI TTN6J5F DM6AN32 TN Bacterial DNA gyrase (Bact gyrase) DM6AN32 MA Modulator DM6AN32 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM6AN32 RU https://www.fda.gov/ DM6AUFY DI DM6AUFY DM6AUFY DN Iloperidone DM6AUFY TI TTJQOD7 DM6AUFY TN 5-HT 2A receptor (HTR2A) DM6AUFY MA Antagonist DM6AUFY RN Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92. DM6AUFY RU https://pubmed.ncbi.nlm.nih.gov/20118952 DM6AUFY DI DM6AUFY DM6AUFY DN Iloperidone DM6AUFY TI TTEX248 DM6AUFY TN Dopamine D2 receptor (D2R) DM6AUFY MA Antagonist DM6AUFY RN Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92. DM6AUFY RU https://pubmed.ncbi.nlm.nih.gov/20118952 DM6AUHV DI DM6AUHV DM6AUHV DN Fostamatinib DM6AUHV TI TTOU65C DM6AUHV TN Tyrosine-protein kinase SYK (SYK) DM6AUHV MA Modulator DM6AUHV RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2230). DM6AUHV RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2230 DM6AVR4 DI DM6AVR4 DM6AVR4 DN Hydroquinone DM6AVR4 TI TT38RM1 DM6AVR4 TN Glycoprotein IIb/IIIa receptor (GPIIb/IIIa) DM6AVR4 MA Antagonist DM6AVR4 RN Accutin, a new disintegrin, inhibits angiogenesis in vitro and in vivo by acting as integrin alphavbeta3 antagonist and inducing apoptosis. Blood. 1998 Nov 1;92(9):3268-76. DM6AVR4 RU https://pubmed.ncbi.nlm.nih.gov/9787163 DM6AVR4 DI DM6AVR4 DM6AVR4 DN Hydroquinone DM6AVR4 TI TTULVH8 DM6AVR4 TN Tyrosinase (TYR) DM6AVR4 MA Inhibitor DM6AVR4 RN Identification of an Alkylhydroquinone from Rhus succedanea as an Inhibitor of Tyrosinase and Melanogenesis. J Agric Food Chem. 2009 Mar 25;57(6):2200-5. DM6AVR4 RU https://pubmed.ncbi.nlm.nih.gov/19159217 DM6CLBN DI DM6CLBN DM6CLBN DN Danaparoid DM6CLBN TI TTCIHJA DM6CLBN TN Coagulation factor Xa (F10) DM6CLBN MA Inhibitor DM6CLBN RN Effect of factor X inhibition on coagulation activation and cytokine induction in human systemic inflammation. J Infect Dis. 2002 Nov 1;186(9):1270-6. DM6CLBN RU https://pubmed.ncbi.nlm.nih.gov/12402196 DM6D7N8 DI DM6D7N8 DM6D7N8 DN Propylthiouracil DM6D7N8 TI TTU3X26 DM6D7N8 TN Iodothyronine deiodinase type I (DIO1) DM6D7N8 MA Inhibitor DM6D7N8 RN Type 1 iodothyronine deiodinase is the major source of circulating T3 in hyperthyroidism: implications for therapy. Nat Clin Pract Endocrinol Metab. 2007 Nov;3(11):740-1. DM6D7N8 RU https://pubmed.ncbi.nlm.nih.gov/17712320 DM6D7N8 DI DM6D7N8 DM6D7N8 DN Propylthiouracil DM6D7N8 TI TT52XDZ DM6D7N8 TN Thyroid peroxidase (TPO) DM6D7N8 MA Inhibitor DM6D7N8 RN Bioinorganic chemistry in thyroid gland: effect of antithyroid drugs on peroxidase-catalyzed oxidation and iodination reactions. Bioinorg Chem Appl. 2006:23214. DM6D7N8 RU https://pubmed.ncbi.nlm.nih.gov/17497002 DM6DEK9 DI DM6DEK9 DM6DEK9 DN Stavudine DM6DEK9 TI TT84ETX DM6DEK9 TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DM6DEK9 MA Inhibitor DM6DEK9 RN Primer unblocking by HIV-1 reverse transcriptase and resistance to nucleoside RT inhibitors (NRTIs). Int J Biochem Cell Biol. 2004 Sep;36(9):1687-705. DM6DEK9 RU https://pubmed.ncbi.nlm.nih.gov/15183338 DM6ECN9 DI DM6ECN9 DM6ECN9 DN Aluminium DM6ECN9 TI TTWK8D0 DM6ECN9 TN Sodium pump subunit alpha-1 (ATP1A1) DM6ECN9 MA Binder DM6ECN9 RN The inhibitory effect of aluminium on the (Na+/K+)ATPase activity of rat brain cortex synaptosomes. J Inorg Biochem. 2003 Sep 15;97(1):143-50. DM6ECN9 RU https://pubmed.ncbi.nlm.nih.gov/14507470 DM6EL5Q DI DM6EL5Q DM6EL5Q DN Glucarpidase DM6EL5Q TI TTX81QL DM6EL5Q TN Toxic methotrexate (TM) DM6EL5Q MA Modulator DM6EL5Q RN Nat Rev Drug Discov. 2013 Feb;12(2):87-90. DM6EL5Q RU https://pubmed.ncbi.nlm.nih.gov/23370234 DM6EUL5 DI DM6EUL5 DM6EUL5 DN Betaxolol DM6EUL5 TI TTR6W5O DM6EUL5 TN Adrenergic receptor beta-1 (ADRB1) DM6EUL5 MA Antagonist DM6EUL5 RN beta-adrenergic enhancement of brain kynurenic acid production mediated via cAMP-related protein kinase A signaling. Prog Neuropsychopharmacol Biol Psychiatry. 2009 Apr 30;33(3):519-29. DM6EUL5 RU https://pubmed.ncbi.nlm.nih.gov/19439240 DM6F1PU DI DM6F1PU DM6F1PU DN Vortioxetine DM6F1PU TI TT3ROYC DM6F1PU TN Serotonin transporter (SERT) DM6F1PU MA Inhibitor DM6F1PU RN Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651. DM6F1PU RU https://pubmed.ncbi.nlm.nih.gov/28919714 DM6FG1P DI DM6FG1P DM6FG1P DN Doxercalciferol DM6FG1P TI TTK59TV DM6FG1P TN Vitamin D3 receptor (VDR) DM6FG1P MA Antagonist DM6FG1P RN Emerging drugs for psoriasis. Expert Opin Emerg Drugs. 2009 Mar;14(1):145-63. DM6FG1P RU https://pubmed.ncbi.nlm.nih.gov/19249988 DM6HX9B DI DM6HX9B DM6HX9B DN Nevirapine DM6HX9B TI TT84ETX DM6HX9B TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DM6HX9B MA Modulator DM6HX9B RN HIV-1 reverse transcriptase complex with DNA and nevirapine reveals non-nucleoside inhibition mechanism.Nat Struct Mol Biol.2012 Jan 22;19(2):253-9. DM6HX9B RU https://www.ncbi.nlm.nih.gov/pubmed/22266819 DM6I2WQ DI DM6I2WQ DM6I2WQ DN Amezinium DM6I2WQ TI TT2NUT5 DM6I2WQ TN Adrenergic receptor alpha-2C (ADRA2C) DM6I2WQ MA Modulator DM6I2WQ RN Pharmacology of amezinium, a novel antihypotensive drug. III. Studies on the mechanism of action. Arzneimittelforschung. 1981;31(9a):1558-65. DM6I2WQ RU https://pubmed.ncbi.nlm.nih.gov/7197970 DM6I5GR DI DM6I5GR DM6I5GR DN Promethazine DM6I5GR TI TTTIBOJ DM6I5GR TN Histamine H1 receptor (H1R) DM6I5GR MA Antagonist DM6I5GR RN Intact cell binding for in vitro prediction of sedative and non-sedative histamine H1-receptor antagonists based on receptor internalization. J Pharmacol Sci. 2008 May;107(1):66-79. DM6I5GR RU https://pubmed.ncbi.nlm.nih.gov/18446005 DM6IR3P DI DM6IR3P DM6IR3P DN Liothyronine DM6IR3P TI TTTSEPU DM6IR3P TN Thyroid hormone receptor alpha (THRA) DM6IR3P MA Antagonist DM6IR3P RN Evaluation of thyroid hormone action in a case of generalized resistance to thyroid hormone with chronic thyroiditis: discovery of a novel heterozy... Endocr J. 2007 Dec;54(5):727-32. DM6IR3P RU https://pubmed.ncbi.nlm.nih.gov/17827792 DM6KI0D DI DM6KI0D DM6KI0D DN Repirinast DM6KI0D TI TT7CXIM DM6KI0D TN Histamine receptor (HR) DM6KI0D MA Modulator DM6KI0D RN Mechanism of action of MY-1250, an active metabolite of Repirinast, in inhibiting histamine release from rat mast cells. Br J Pharmacol. 1992 Mar;105(3):587-90. DM6KI0D RU https://pubmed.ncbi.nlm.nih.gov/1378339 DM6KZMG DI DM6KZMG DM6KZMG DN Ozenoxacin DM6KZMG TI TTN6J5F DM6KZMG TN Bacterial DNA gyrase (Bact gyrase) DM6KZMG MA Modulator DM6KZMG RN In vitro and in vivo antibacterial activity of T-3912, a novel non-fluorinated topical quinolone. J Antimicrob Chemother. 2002 Mar;49(3):455-65. DM6KZMG RU https://www.ncbi.nlm.nih.gov/pubmed/11864945 DM6KZMG DI DM6KZMG DM6KZMG DN Ozenoxacin DM6KZMG TI TTIXTO3 DM6KZMG TN Staphylococcus Topoisomerase IV (Stap-coc parC) DM6KZMG MA Modulator DM6KZMG RN In vitro and in vivo antibacterial activity of T-3912, a novel non-fluorinated topical quinolone. J Antimicrob Chemother. 2002 Mar;49(3):455-65. DM6KZMG RU https://www.ncbi.nlm.nih.gov/pubmed/11864945 DM6KZMG DI DM6KZMG DM6KZMG DN Ozenoxacin DM6KZMG TI TTABD5E DM6KZMG TN DNA replication (DNA repli) DM6KZMG MA Inhibitor DM6KZMG RN 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85. DM6KZMG RU https://pubmed.ncbi.nlm.nih.gov/29348678 DM6KZMG DI DM6KZMG DM6KZMG DN Ozenoxacin DM6KZMG TI TTRVWAT DM6KZMG TN Staphylococcus DNA gyrase A (Stap-coc gyrA) DM6KZMG MA Inhibitor DM6KZMG RN 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85. DM6KZMG RU https://pubmed.ncbi.nlm.nih.gov/29348678 DM6L4H2 DI DM6L4H2 DM6L4H2 DN Cobicistat DM6L4H2 TI TTIJQ3O DM6L4H2 TN Cytochrome P450 3A (CYP3A) DM6L4H2 MA Modulator DM6L4H2 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7535). DM6L4H2 RU http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7535 DM6L5VO DI DM6L5VO DM6L5VO DN Methsuximide DM6L5VO TI TT729IR DM6L5VO TN Voltage-gated calcium channel alpha Cav3.1 (CACNA1G) DM6L5VO MA Blocker DM6L5VO RN Block of cloned human T-type calcium channels by succinimide antiepileptic drugs. Mol Pharmacol. 2001 Nov;60(5):1121-32. DM6L5VO RU https://pubmed.ncbi.nlm.nih.gov/11641441 DM6LOQU DI DM6LOQU DM6LOQU DN Celecoxib DM6LOQU TI TTVKILB DM6LOQU TN Prostaglandin G/H synthase 2 (COX-2) DM6LOQU MA Inhibitor DM6LOQU RN Pfizer. Product Development Pipeline. March 31 2009. DM6LOQU RU http://media.pfizer.com/files/research/pipeline/2009_0331/pipeline_2009_0331.pdf DM6MO9X DI DM6MO9X DM6MO9X DN Insulin Zinc Susp Recombinant Human DM6MO9X TI TTZOPHG DM6MO9X TN Insulin (INS) DM6MO9X MA Modulator DM6MO9X RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM6MO9X RU https://www.fda.gov/ DM6N4PR DI DM6N4PR DM6N4PR DN Cerulenin DM6N4PR TI TT7AOUD DM6N4PR TN Fatty acid synthase (FASN) DM6N4PR MA Inhibitor DM6N4PR RN Inhibition of fatty acid biosynthesis prevents adipocyte lipotoxicity on human osteoblasts in vitro. J Cell Mol Med. 2010 Apr;14(4):982-91. DM6N4PR RU https://pubmed.ncbi.nlm.nih.gov/19382912 DM6NZ2P DI DM6NZ2P DM6NZ2P DN Pegvaliase DM6NZ2P TI TTGSVH2 DM6NZ2P TN Phenylalanine hydroxylase (PAH) DM6NZ2P MA Modulator DM6NZ2P RN Induction, titration, and maintenance dosing regimen in a phase 2 study of pegvaliase for control of blood phenylalanine in adults with phenylketonuria.Mol Genet Metab. 2018 Nov;125(3):217-227. DM6NZ2P RU https://pubmed.ncbi.nlm.nih.gov/30146451 DM6OZQV DI DM6OZQV DM6OZQV DN Daclizumab DM6OZQV TI TTF89GD DM6OZQV TN Interleukin-2 (IL2) DM6OZQV MA Modulator DM6OZQV RN 2016 FDA drug approvals. Nat Rev Drug Discov. 2017 Feb 2;16(2):73-76. DM6OZQV RU https://www.ncbi.nlm.nih.gov/pubmed/28148938 DM6PR40 DI DM6PR40 DM6PR40 DN Paramethasone DM6PR40 TI TTJL8VG DM6PR40 TN Corticosteroid-binding globulin (SERPINA6) DM6PR40 MA Binder DM6PR40 RN Novel human corticosteroid-binding globulin variant with low cortisol-binding affinity. J Clin Endocrinol Metab. 2000 Jan;85(1):361-7. DM6PR40 RU https://pubmed.ncbi.nlm.nih.gov/10634411 DM6Q4B0 DI DM6Q4B0 DM6Q4B0 DN Anistreplase DM6Q4B0 TI TTP86E2 DM6Q4B0 TN Plasminogen (PLG) DM6Q4B0 MA Activator DM6Q4B0 RN Evaluation of thrombolytic agents. Drugs. 1997;54 Suppl 3:11-6; discussion 16-7. DM6Q4B0 RU https://pubmed.ncbi.nlm.nih.gov/9360848 DM6Q7U4 DI DM6Q7U4 DM6Q7U4 DN Lenalidomide DM6Q7U4 TI TTF8CQI DM6Q7U4 TN Tumor necrosis factor (TNF) DM6Q7U4 MA Inhibitor DM6Q7U4 RN Thalidomide and thalidomide analogues for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev. 2009 Apr 15;(2):CD007351. DM6Q7U4 RU https://pubmed.ncbi.nlm.nih.gov/19370685 DM6QFSV DI DM6QFSV DM6QFSV DN Erdosteine DM6QFSV TI TT3NKIB DM6QFSV TN Pancreatic elastase 1 (CELA1) DM6QFSV MA Modulator DM6QFSV RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DM6QFSV RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DM6RZ9Q DI DM6RZ9Q DM6RZ9Q DN Clonidine DM6RZ9Q TI TTQ8AFT DM6RZ9Q TN Adrenergic receptor Alpha-2 (ADRA2) DM6RZ9Q MA Agonist DM6RZ9Q RN Noradrenergic alpha-2 receptor agonists reverse working memory deficits induced by the anxiogenic drug, FG7142, in rats. Pharmacol Biochem Behav. 2000 Nov;67(3):397-403. DM6RZ9Q RU https://pubmed.ncbi.nlm.nih.gov/11164065 DM6RZ9Q DI DM6RZ9Q DM6RZ9Q DN Clonidine DM6RZ9Q TI TT7HC21 DM6RZ9Q TN Membrane copper amine oxidase (AOC3) DM6RZ9Q MA Inhibitor DM6RZ9Q RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DM6RZ9Q RU https://pubmed.ncbi.nlm.nih.gov/10592235 DM6S0HB DI DM6S0HB DM6S0HB DN TachoComb DM6S0HB TI TTWODQF DM6S0HB TN Fibrin (FG) DM6S0HB MA Modulator DM6S0HB RN Pancreaticojejunostomy using a fibrin adhesive sealant (TachoComb) for the prevention of pancreatic fistula after pancreaticoduodenectomy. Hepatogastroenterology. 2011 Jan-Feb;58(105):187-91. DM6S0HB RU https://pubmed.ncbi.nlm.nih.gov/21510312 DM6S157 DI DM6S157 DM6S157 DN Guanadrel Sulfate DM6S157 TI TTVIREA DM6S157 TN Adrenergic receptor (ADR) DM6S157 MA Modulator DM6S157 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM6S157 RU https://www.fda.gov/ DM6T2J3 DI DM6T2J3 DM6T2J3 DN Neostigmine DM6T2J3 TI TT1RS9F DM6T2J3 TN Acetylcholinesterase (AChE) DM6T2J3 MA Inhibitor DM6T2J3 RN Screening of acetylcholinesterase inhibitors by CE after enzymatic reaction at capillary inlet. J Sep Sci. 2009 May;32(10):1748-56. DM6T2J3 RU https://pubmed.ncbi.nlm.nih.gov/19472276 DM6T924 DI DM6T924 DM6T924 DN Gabapentin DM6T924 TI TTDCVZW DM6T924 TN Gamma-aminobutyric acid B receptor (GABBR) DM6T924 MA Antagonist DM6T924 RN Gabapentin increases a tonic inhibitory conductance in hippocampal pyramidal neurons. Anesthesiology. 2006 Aug;105(2):325-33. DM6T924 RU https://pubmed.ncbi.nlm.nih.gov/16871066 DM6TS1N DI DM6TS1N DM6TS1N DN Phendimetrazine DM6TS1N TI TTBRKXS DM6TS1N TN Adrenergic receptor alpha-1B (ADRA1B) DM6TS1N MA Antagonist DM6TS1N RN Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. DM6TS1N RU https://pubmed.ncbi.nlm.nih.gov/17016423 DM6U9CQ DI DM6U9CQ DM6U9CQ DN Pazopanib HCl DM6U9CQ TI TTI2WET DM6U9CQ TN Platelet-derived growth factor receptor (PDGFR) DM6U9CQ MA Inhibitor DM6U9CQ RN Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92. DM6U9CQ RU https://pubmed.ncbi.nlm.nih.gov/20118952 DM6U9CQ DI DM6U9CQ DM6U9CQ DN Pazopanib HCl DM6U9CQ TI TTUTJGQ DM6U9CQ TN Vascular endothelial growth factor receptor 2 (KDR) DM6U9CQ MA Inhibitor DM6U9CQ RN Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92. DM6U9CQ RU https://pubmed.ncbi.nlm.nih.gov/20118952 DM6U9CQ DI DM6U9CQ DM6U9CQ DN Pazopanib HCl DM6U9CQ TI TTX41N9 DM6U9CQ TN Tyrosine-protein kinase Kit (KIT) DM6U9CQ MA Inhibitor DM6U9CQ RN Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92. DM6U9CQ RU https://pubmed.ncbi.nlm.nih.gov/20118952 DM6VM38 DI DM6VM38 DM6VM38 DN Reserpine DM6VM38 TI TTNZRI3 DM6VM38 TN Synaptic vesicle amine transporter (SLC18A2) DM6VM38 MA Blocker DM6VM38 RN Dopamine signaling is required for depolarization-induced slow current in cerebellar Purkinje cells. J Neurosci. 2009 Jul 1;29(26):8530-8. DM6VM38 RU https://pubmed.ncbi.nlm.nih.gov/19571144 DM6VOWQ DI DM6VOWQ DM6VOWQ DN Fomepizole DM6VOWQ TI TT5AHZ0 DM6VOWQ TN Alcohol dehydrogenase 1A (ADH1A) DM6VOWQ MA Modulator DM6VOWQ RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM6VOWQ RU https://www.fda.gov/ DM6VZFQ DI DM6VZFQ DM6VZFQ DN Pirfenidone DM6VZFQ TI TTR9XHZ DM6VZFQ TN Transforming growth factor beta 1 (TGFB1) DM6VZFQ MA Modulator DM6VZFQ RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM6VZFQ RU https://www.fda.gov/ DM6W8V5 DI DM6W8V5 DM6W8V5 DN Lisdexamfetamine DM6W8V5 TI TTIU98M DM6W8V5 TN Trace amine-associated receptor-1 (TAAR1) DM6W8V5 MA Modulator DM6W8V5 RN 2007 FDA drug approvals: a year of flux. Nat Rev Drug Discov. 2008 Feb;7(2):107-9. DM6W8V5 RU https://pubmed.ncbi.nlm.nih.gov/18246607 DM6WJO9 DI DM6WJO9 DM6WJO9 DN Etodolac DM6WJO9 TI TTVKILB DM6WJO9 TN Prostaglandin G/H synthase 2 (COX-2) DM6WJO9 MA Inhibitor DM6WJO9 RN Membranous nephropathy associated with the relatively selective cyclooxygenase-2 inhibitor, etodolac, in a patient with early rheumatoid arthritis. Intern Med. 2007;46(13):1055-8. DM6WJO9 RU https://pubmed.ncbi.nlm.nih.gov/17603251 DM6XFHS DI DM6XFHS DM6XFHS DN SPI-1005 DM6XFHS TI TTFNGC9 DM6XFHS TN Serum albumin (ALB) DM6XFHS MA Binder DM6XFHS RN Transport of ebselen in plasma and its transfer to binding sites in the hepatocyte. Biochem Pharmacol. 1994 Sep 15;48(6):1137-44. DM6XFHS RU https://pubmed.ncbi.nlm.nih.gov/7945407 DM6Y3AN DI DM6Y3AN DM6Y3AN DN Micafungin DM6Y3AN TI TT0SFXH DM6Y3AN TN Fungal 1,3-beta-glucan synthase (Fung GSC2) DM6Y3AN MA Modulator DM6Y3AN RN An immunomodulatory activity of micafungin in preclinical aspergillosis. J Antimicrob Chemother. 2014 Apr;69(4):1065-74. DM6Y3AN RU https://pubmed.ncbi.nlm.nih.gov/24265229 DM6YWBF DI DM6YWBF DM6YWBF DN Herbimycin A DM6YWBF TI TT6PKBN DM6YWBF TN Proto-oncogene c-Src (SRC) DM6YWBF MA Inhibitor DM6YWBF RN In vivo antitumor activity of herbimycin A, a tyrosine kinase inhibitor, targeted against BCR/ABL oncoprotein in mice bearing BCR/ABL-transfected cells. Leuk Res. 1994 Nov;18(11):867-73. DM6YWBF RU https://pubmed.ncbi.nlm.nih.gov/7967714 DM6ZPLQ DI DM6ZPLQ DM6ZPLQ DN Novolimus DM6ZPLQ TI TTCJG29 DM6ZPLQ TN Serine/threonine-protein kinase mTOR (mTOR) DM6ZPLQ MA Inhibitor DM6ZPLQ RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2109). DM6ZPLQ RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2109 DM70BU5 DI DM70BU5 DM70BU5 DN Thalidomide DM70BU5 TI TTF8CQI DM70BU5 TN Tumor necrosis factor (TNF) DM70BU5 MA Inhibitor DM70BU5 RN Efficacy of different thalidomide regimens for patients with multiple myeloma and its relationship with TNF-alpha level. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2008 Dec;16(6):1312-5. DM70BU5 RU https://pubmed.ncbi.nlm.nih.gov/19099634 DM70DTN DI DM70DTN DM70DTN DN Flibanserin DM70DTN TI TTJQOD7 DM70DTN TN 5-HT 2A receptor (HTR2A) DM70DTN MA Modulator DM70DTN RN Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651. DM70DTN RU https://pubmed.ncbi.nlm.nih.gov/28919714 DM70DTN DI DM70DTN DM70DTN DN Flibanserin DM70DTN TI TTSQIFT DM70DTN TN 5-HT 1A receptor (HTR1A) DM70DTN MA Modulator DM70DTN RN Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651. DM70DTN RU https://pubmed.ncbi.nlm.nih.gov/28919714 DM70IK5 DI DM70IK5 DM70IK5 DN Marinol DM70IK5 TI TT6OEDT DM70IK5 TN Cannabinoid receptor 1 (CB1) DM70IK5 MA Agonist DM70IK5 RN Emerging strategies for exploiting cannabinoid receptor agonists as medicines. Br J Pharmacol. 2009 Feb;156(3):397-411. DM70IK5 RU https://pubmed.ncbi.nlm.nih.gov/19226257 DM72JXH DI DM72JXH DM72JXH DN Losartan DM72JXH TI TT8DBY3 DM72JXH TN Angiotensin II receptor type-1 (AGTR1) DM72JXH MA Antagonist DM72JXH RN Radioligand binding assays: application of [(125)I]angiotensin II receptor binding. Methods Mol Biol. 2009;552:131-41. DM72JXH RU https://pubmed.ncbi.nlm.nih.gov/19513646 DM749I3 DI DM749I3 DM749I3 DN Ubrogepant DM749I3 TI TTY6O0Q DM749I3 TN Calcitonin gene-related peptide receptor (CGRPR) DM749I3 MA Antagonist DM749I3 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019 DM749I3 RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211765s000lbl.pdf DM74LZK DI DM74LZK DM74LZK DN Cromoglicate DM74LZK TI TT78R5H DM74LZK TN Heat shock protein 90 alpha (HSP90A) DM74LZK MA Inhibitor DM74LZK RN Hsp90 is a direct target of the anti-allergic drugs disodium cromoglycate and amlexanox. Biochem J. 2003 Sep 1;374(Pt 2):433-41. DM74LZK RU https://pubmed.ncbi.nlm.nih.gov/12803546 DM74SVE DI DM74SVE DM74SVE DN Dasiglucagon DM74SVE TI TT9O6WS DM74SVE TN Glucagon receptor (GCGR) DM74SVE MA Agonist DM74SVE RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2021 DM74SVE RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214231s000lbl.pdf DM75CXN DI DM75CXN DM75CXN DN Avanafil DM75CXN TI TTJ0IQB DM75CXN TN Phosphodiesterase 5A (PDE5A) DM75CXN MA Modulator DM75CXN RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DM75CXN RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DM76VHG DI DM76VHG DM76VHG DN Regadenoson DM76VHG TI TTM2AOE DM76VHG TN Adenosine A2a receptor (ADORA2A) DM76VHG MA Modulator DM76VHG RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DM76VHG RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DM783CH DI DM783CH DM783CH DN Levobupivacaine DM783CH TI TTRK8B9 DM783CH TN Sodium channel unspecific (NaC) DM783CH MA Blocker DM783CH RN Block of neuronal tetrodotoxin-resistant Na+ currents by stereoisomers of piperidine local anesthetics. Anesth Analg. 2000 Dec;91(6):1499-505. DM783CH RU https://pubmed.ncbi.nlm.nih.gov/11094008 DM78G6F DI DM78G6F DM78G6F DN HTF 919 DM78G6F TI TT07C3Y DM78G6F TN 5-HT 4 receptor (HTR4) DM78G6F MA Agonist DM78G6F RN 5-Hydroxytryptamine mediated contractions in isolated preparations of equine ileum and pelvic flexure: pharmacological characterization of a new 5-HT(4) agonist. J Vet Pharmacol Ther. 2002 Feb;25(1):49-58. DM78G6F RU https://pubmed.ncbi.nlm.nih.gov/11874527 DM78IME DI DM78IME DM78IME DN Ergotidine DM78IME TI TTTIBOJ DM78IME TN Histamine H1 receptor (H1R) DM78IME MA Agonist DM78IME RN Cloning and pharmacological characterization of a fourth histamine receptor (H(4)) expressed in bone marrow. Mol Pharmacol. 2001 Mar;59(3):420-6. DM78IME RU https://pubmed.ncbi.nlm.nih.gov/11179434 DM78NWP DI DM78NWP DM78NWP DN Dostarlimab DM78NWP TI TTNBFWK DM78NWP TN Programmed cell death protein 1 (PD-1) DM78NWP MA Inhibitor DM78NWP RN Dostarlimab in the treatment of recurrent or primary advanced endometrial cancer. Future Oncol. 2021 Mar;17(8):877-892. DM78NWP RU https://pubmed.ncbi.nlm.nih.gov/33251877 DM79F6G DI DM79F6G DM79F6G DN Adenosine triphosphate DM79F6G TI TT3PJMV DM79F6G TN Tyrosine-protein kinase ABL1 (ABL) DM79F6G MA Inhibitor DM79F6G RN Targeted chronic myeloid leukemia therapy: Seeking a cure. Am J Health Syst Pharm. 2007 Dec 15;64(24 Suppl 15):S9-15. DM79F6G RU https://pubmed.ncbi.nlm.nih.gov/18056932 DM79NTF DI DM79NTF DM79NTF DN Propranolol DM79NTF TI TTR6W5O DM79NTF TN Adrenergic receptor beta-1 (ADRB1) DM79NTF MA Antagonist DM79NTF RN Beta-blockers in the treatment of hypertension: are there clinically relevant differences Postgrad Med. 2009 May;121(3):90-8. DM79NTF RU https://pubmed.ncbi.nlm.nih.gov/19491545 DM79NZ5 DI DM79NZ5 DM79NZ5 DN Insulin determir DM79NZ5 TI TTZOPHG DM79NZ5 TN Insulin (INS) DM79NZ5 MA Modulator DM79NZ5 RN 2005 approvals: Safety first. Nature Reviews Drug Discovery 5, 92-93 (February 2006). DM79NZ5 RU http://www.nature.com/nrd/journal/v11/n1/full/nrd3645.html DM79VXT DI DM79VXT DM79VXT DN PF-04971729 DM79VXT TI TTLWPVF DM79VXT TN Sodium/glucose cotransporter 2 (SGLT2) DM79VXT MA Modulator DM79VXT RN Dose-ranging efficacy and safety study of ertugliflozin, a sodium-glucose co-transporter 2 inhibitor, in patients with type 2 diabetes on a background of metformin.Diabetes Obes Metab.2015 Jun;17(6):591-8. DM79VXT RU https://www.ncbi.nlm.nih.gov/pubmed/25754396 DM79XDW DI DM79XDW DM79XDW DN Cephalosporin DM79XDW TI TTLP6GN DM79XDW TN Bacterial DD-carboxypeptidase (Bact vanYB) DM79XDW MA Binder DM79XDW RN A 1.2-A snapshot of the final step of bacterial cell wall biosynthesis. Proc Natl Acad Sci U S A. 2001 Feb 13;98(4):1427-31. DM79XDW RU https://pubmed.ncbi.nlm.nih.gov/11171967 DM79Y2T DI DM79Y2T DM79Y2T DN ATryn antithrombin DM79Y2T TI TT6L509 DM79Y2T TN Coagulation factor IIa (F2) DM79Y2T MA Modulator DM79Y2T RN Antithrombin III Utilization in a Large Teaching Hospital. P T. 2013 December; 38(12): 764-767, 779. DM79Y2T RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3875262/ DM7A8TW DI DM7A8TW DM7A8TW DN Ezetimibe DM7A8TW TI TTPD1CN DM7A8TW TN Niemann-Pick C1-like protein 1 (NPC1L1) DM7A8TW MA Inhibitor DM7A8TW RN Update on patented cholesterol absorption inhibitors. Expert Opin Ther Pat. 2009 Aug;19(8):1083-107. DM7A8TW RU https://pubmed.ncbi.nlm.nih.gov/19552506 DM7AVGW DI DM7AVGW DM7AVGW DN Ocriplasmin DM7AVGW TI TTPJ921 DM7AVGW TN Fibronectin (FN1) DM7AVGW MA Inhibitor DM7AVGW RN Nat Rev Drug Discov. 2013 Feb;12(2):87-90. DM7AVGW RU https://pubmed.ncbi.nlm.nih.gov/23370234 DM7BN0X DI DM7BN0X DM7BN0X DN Esomeprazole DM7BN0X TI TTLOKXP DM7BN0X TN Gastric H(+)/K(+) ATPase (Proton pump) DM7BN0X MA Modulator DM7BN0X RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM7BN0X RU https://www.fda.gov/ DM7C8YV DI DM7C8YV DM7C8YV DN Plicamycin DM7C8YV TI TTX2AYW DM7C8YV TN RNA synthesis (hRNA synth) DM7C8YV MA Modulator DM7C8YV RN Role of magnesium ion in mithramycin-DNA interaction: binding of mithramycin-Mg2+ complexes with DNA. Biochemistry. 1995 Jan 31;34(4):1376-85. DM7C8YV RU https://pubmed.ncbi.nlm.nih.gov/7827085 DM7DSYP DI DM7DSYP DM7DSYP DN Cefprozil DM7DSYP TI TTJP4SM DM7DSYP TN Bacterial Penicillin binding protein (Bact PBP) DM7DSYP MA Binder DM7DSYP RN Microbiology and antimicrobial management of sinusitis. J Laryngol Otol. 2005 Apr;119(4):251-8. DM7DSYP RU https://pubmed.ncbi.nlm.nih.gov/15949076 DM7EN8I DI DM7EN8I DM7EN8I DN Diflunisal DM7EN8I TI TTVKILB DM7EN8I TN Prostaglandin G/H synthase 2 (COX-2) DM7EN8I MA Inhibitor DM7EN8I RN Celecoxib and rofecoxib. The role of COX-2 inhibitors in dental practice. J Am Dent Assoc. 2001 Apr;132(4):451-6. DM7EN8I RU https://pubmed.ncbi.nlm.nih.gov/11315375 DM7EUK3 DI DM7EUK3 DM7EUK3 DN Delapril DM7EUK3 TI TTL69WB DM7EUK3 TN Angiotensin-converting enzyme (ACE) DM7EUK3 MA Modulator DM7EUK3 RN Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. DM7EUK3 RU https://pubmed.ncbi.nlm.nih.gov/17309302 DM7EVLC DI DM7EVLC DM7EVLC DN Bendroflumethiazide DM7EVLC TI TTP362L DM7EVLC TN Solute carrier family 12 member 3 (SLC12A3) DM7EVLC MA Blocker DM7EVLC RN DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6. DM7EVLC RU https://pubmed.ncbi.nlm.nih.gov/18048412 DM7EVLC DI DM7EVLC DM7EVLC DN Bendroflumethiazide DM7EVLC TI TTS087L DM7EVLC TN Solute carrier family 12 member 1 (SLC12A1) DM7EVLC MA Blocker DM7EVLC RN DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6. DM7EVLC RU https://pubmed.ncbi.nlm.nih.gov/18048412 DM7F1PA DI DM7F1PA DM7F1PA DN Nebivolol DM7F1PA TI TTR6W5O DM7F1PA TN Adrenergic receptor beta-1 (ADRB1) DM7F1PA MA Antagonist DM7F1PA RN Nitric oxide mechanisms of nebivolol. Ther Adv Cardiovasc Dis. 2009 Aug;3(4):317-27. DM7F1PA RU https://pubmed.ncbi.nlm.nih.gov/19443516 DM7F5OW DI DM7F5OW DM7F5OW DN Mepyramine maleate DM7F5OW TI TTTIBOJ DM7F5OW TN Histamine H1 receptor (H1R) DM7F5OW MA Antagonist DM7F5OW RN Antinociception induced by central administration of histamine in the formalin test in rats. Indian J Physiol Pharmacol. 2008 Jul-Sep;52(3):249-54. DM7F5OW RU https://pubmed.ncbi.nlm.nih.gov/19552055 DM7G0EP DI DM7G0EP DM7G0EP DN Fosmidomycin DM7G0EP TI TTLH4J3 DM7G0EP TN Plasmodium DOXP reductoisomerase (Malaria DXR) DM7G0EP MA Binder DM7G0EP RN Structural basis of fosmidomycin action revealed by the complex with 2-C-methyl-D-erythritol 4-phosphate synthase (IspC). Implications for the cata... J Biol Chem. 2003 May 16;278(20):18401-7. DM7G0EP RU https://pubmed.ncbi.nlm.nih.gov/12621040 DM7GCVW DI DM7GCVW DM7GCVW DN Acalabrutinib DM7GCVW TI TTGM6VW DM7GCVW TN Tyrosine-protein kinase BTK (ATK) DM7GCVW MA Inhibitor DM7GCVW RN 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85. DM7GCVW RU https://pubmed.ncbi.nlm.nih.gov/29348678 DM7HUNW DI DM7HUNW DM7HUNW DN Testosterone DM7HUNW TI TTS64P2 DM7HUNW TN Androgen receptor (AR) DM7HUNW MA Agonist DM7HUNW RN Molecular mechanism of androgen action. Trends Endocrinol Metab. 1998 Oct 1;9(8):317-24. DM7HUNW RU https://pubmed.ncbi.nlm.nih.gov/18406296 DM7HXWT DI DM7HXWT DM7HXWT DN Nilotinib DM7HXWT TI TTS7G69 DM7HXWT TN Fusion protein Bcr-Abl (Bcr-Abl) DM7HXWT MA Modulator DM7HXWT RN 2007 FDA drug approvals: a year of flux. Nat Rev Drug Discov. 2008 Feb;7(2):107-9. DM7HXWT RU https://pubmed.ncbi.nlm.nih.gov/18246607 DM7I64Z DI DM7I64Z DM7I64Z DN Almogran DM7I64Z TI TT6MSOK DM7I64Z TN 5-HT 1D receptor (HTR1D) DM7I64Z MA Agonist DM7I64Z RN Efficacy and tolerability of subcutaneous almotriptan for the treatment of acute migraine: a randomized, double-blind, parallel-group, dose-finding study. Clin Ther. 2001 Nov;23(11):1867-75. DM7I64Z RU https://pubmed.ncbi.nlm.nih.gov/11768838 DM7ICNU DI DM7ICNU DM7ICNU DN Doxycycline DM7ICNU TI TTOVFH2 DM7ICNU TN Bacterial 30S ribosomal RNA (Bact 30S rRNA) DM7ICNU MA Modulator DM7ICNU RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM7ICNU RU https://www.fda.gov/ DM7ISKJ DI DM7ISKJ DM7ISKJ DN Nisoldipine DM7ISKJ TI TT5HONZ DM7ISKJ TN Calcium channel unspecific (CaC) DM7ISKJ MA Blocker DM7ISKJ RN RT-PCR and pharmacological analysis of L-and T-type calcium channels in rat carotid body. Adv Exp Med Biol. 2009;648:105-12. DM7ISKJ RU https://pubmed.ncbi.nlm.nih.gov/19536471 DM7IW9J DI DM7IW9J DM7IW9J DN Ramelteon DM7IW9J TI TT0WAIE DM7IW9J TN Melatonin receptor type 1A (MTNR1A) DM7IW9J MA Modulator DM7IW9J RN MT1 and MT2 melatonin receptors: ligands, models, oligomers, and therapeutic potential. J Med Chem. 2014 Apr 24;57(8):3161-85. DM7IW9J RU https://pubmed.ncbi.nlm.nih.gov/24228714 DM7IW9J DI DM7IW9J DM7IW9J DN Ramelteon DM7IW9J TI TT32JK8 DM7IW9J TN Melatonin receptor type 1B (MTNR1B) DM7IW9J MA Modulator DM7IW9J RN MT1 and MT2 melatonin receptors: ligands, models, oligomers, and therapeutic potential. J Med Chem. 2014 Apr 24;57(8):3161-85. DM7IW9J RU https://pubmed.ncbi.nlm.nih.gov/24228714 DM7J2TA DI DM7J2TA DM7J2TA DN Methazolamide DM7J2TA TI TTHQPL7 DM7J2TA TN Carbonic anhydrase I (CA-I) DM7J2TA MA Modulator DM7J2TA RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2597). DM7J2TA RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2597 DM7J6OR DI DM7J6OR DM7J6OR DN Tocilizumab DM7J6OR TI TT0E5SK DM7J6OR TN Interleukin 6 receptor (IL6R) DM7J6OR MA Modulator DM7J6OR RN Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5. DM7J6OR RU https://pubmed.ncbi.nlm.nih.gov/21283092 DM7JHX0 DI DM7JHX0 DM7JHX0 DN Butethal DM7JHX0 TI TT1MPAY DM7JHX0 TN GABA(A) receptor alpha-1 (GABRA1) DM7JHX0 MA Antagonist DM7JHX0 RN DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6. DM7JHX0 RU https://pubmed.ncbi.nlm.nih.gov/18048412 DM7JT24 DI DM7JT24 DM7JT24 DN Acocantherin DM7JT24 TI TTWK8D0 DM7JT24 TN Sodium pump subunit alpha-1 (ATP1A1) DM7JT24 MA Binder DM7JT24 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM7JT24 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM7K5GD DI DM7K5GD DM7K5GD DN Lutropin alfa DM7K5GD TI TT2O4W9 DM7K5GD TN Luteinizing hormone receptor (LHCGR) DM7K5GD MA Binder DM7K5GD RN Lutropin alfa. Drugs. 2008;68(11):1529-40. DM7K5GD RU https://pubmed.ncbi.nlm.nih.gov/18627209 DM7MDBE DI DM7MDBE DM7MDBE DN Vericiguat DM7MDBE TI TTWNFC2 DM7MDBE TN Soluble guanylyl cyclase (GUCY2D) DM7MDBE MA Modulator DM7MDBE RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2021 DM7MDBE RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214377s000lbl.pdf DM7MT6E DI DM7MT6E DM7MT6E DN Prasugrel DM7MT6E TI TTZ1DT0 DM7MT6E TN P2Y purinoceptor 12 (P2RY12) DM7MT6E MA Inhibitor DM7MT6E RN Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92. DM7MT6E RU https://pubmed.ncbi.nlm.nih.gov/20118952 DM7NKEV DI DM7NKEV DM7NKEV DN Thioguanine DM7NKEV TI TTCAQMW DM7NKEV TN Inosine-5'-monophosphate dehydrogenase (IMPDH) DM7NKEV MA Intercalator DM7NKEV RN Immune effector cells produce lethal DNA damage in cells treated with a thiopurine. Cancer Res. 2009 Mar 15;69(6):2393-9. DM7NKEV RU https://pubmed.ncbi.nlm.nih.gov/19244103 DM7NPJS DI DM7NPJS DM7NPJS DN Paliperidone DM7NPJS TI TT85JO3 DM7NPJS TN 5-HT receptor (5HTR) DM7NPJS MA Antagonist DM7NPJS RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DM7NPJS RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DM7OKQV DI DM7OKQV DM7OKQV DN Cholic acid DM7OKQV TI TT9V5JH DM7OKQV TN Phospholipase A2 (PLA2G1B) DM7OKQV MA Inhibitor DM7OKQV RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM7OKQV RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM7OKQV DI DM7OKQV DM7OKQV DN Cholic acid DM7OKQV TI TTQ6VF4 DM7OKQV TN Ferrochelatase (FECH) DM7OKQV MA Inhibitor DM7OKQV RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM7OKQV RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM7OKQV DI DM7OKQV DM7OKQV DN Cholic acid DM7OKQV TI TTMF541 DM7OKQV TN Liver carboxylesterase (CES1) DM7OKQV MA Inhibitor DM7OKQV RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM7OKQV RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM7P1J4 DI DM7P1J4 DM7P1J4 DN Benralizumab DM7P1J4 TI TTPREZD DM7P1J4 TN Interleukin-5 (IL5) DM7P1J4 MA Modulator DM7P1J4 RN Benralizumab a humanized mAb to IL-5R with enhanced antibody-dependent cell-mediated cytotoxicity a novel approach for the treatment of asthma DM7P1J4 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3587289 DM7P1J4 DI DM7P1J4 DM7P1J4 DN Benralizumab DM7P1J4 TI TTXH9AD DM7P1J4 TN Interleukin 5 receptor alpha (IL5RA) DM7P1J4 MA Modulator DM7P1J4 RN Benralizumab--a humanized mAb to IL-5R with enhanced antibody-dependent cell-mediated cytotoxicity--a novel approach for the treatment of asthma. Expert Opin Biol Ther. 2012 Jan;12(1):113-8. DM7P1J4 RU https://www.ncbi.nlm.nih.gov/pubmed/22136436 DM7PQIK DI DM7PQIK DM7PQIK DN Nitrofurantoin DM7PQIK TI TTS1W4A DM7PQIK TN Bacterial Deoxyribonucleic acid (Bact DNA) DM7PQIK MA Breaker DM7PQIK RN On the nature of the adaptive response induced by mitomycin C in Vibrio cholerae OGAWA 154 cells. Biochem Biophys Res Commun. 1996 Mar 27;220(3):509-14. DM7PQIK RU https://pubmed.ncbi.nlm.nih.gov/8607796 DM7Q41G DI DM7Q41G DM7Q41G DN Pyruvic acid DM7Q41G TI TTT2LD9 DM7Q41G TN GABA transaminase (ABAT) DM7Q41G MA Inhibitor DM7Q41G RN DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6. DM7Q41G RU https://pubmed.ncbi.nlm.nih.gov/18048412 DM7Q98D DI DM7Q98D DM7Q98D DN Ruxolitinib DM7Q98D TI TTRMX3V DM7Q98D TN Janus kinase 2 (JAK-2) DM7Q98D MA Modulator DM7Q98D RN 2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4. DM7Q98D RU https://pubmed.ncbi.nlm.nih.gov/22293555 DM7Q98D DI DM7Q98D DM7Q98D DN Ruxolitinib DM7Q98D TI TT6DM01 DM7Q98D TN Janus kinase 1 (JAK-1) DM7Q98D MA Modulator DM7Q98D RN 2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4. DM7Q98D RU https://pubmed.ncbi.nlm.nih.gov/22293555 DM7Q98D DI DM7Q98D DM7Q98D DN Ruxolitinib DM7Q98D TI TTPRL03 DM7Q98D TN Urokinase plasminogen activator surface receptor (PLAUR) DM7Q98D MA Inhibitor DM7Q98D RN Urokinase-type plasminogen activator receptor signaling is critical in nasopharyngeal carcinoma cell growth and metastasis.Cell Cycle. 2014;13(12):1958-69. DM7Q98D RU https://pubmed.ncbi.nlm.nih.gov/24763226 DM7QG0M DI DM7QG0M DM7QG0M DN Raxibacumab DM7QG0M TI TT3YGCD DM7QG0M TN Bacterial Protective antigen (Bact pagA) DM7QG0M MA Modulator DM7QG0M RN Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550). J Immunol. 2011 Apr 1;186(7):4234-43. DM7QG0M RU https://pubmed.ncbi.nlm.nih.gov/21383241 DM7RE8P DI DM7RE8P DM7RE8P DN Frovatriptan DM7RE8P TI TTK8CXU DM7RE8P TN 5-HT 1B receptor (HTR1B) DM7RE8P MA Modulator DM7RE8P RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM7RE8P RU https://www.fda.gov/ DM7RE8P DI DM7RE8P DM7RE8P DN Frovatriptan DM7RE8P TI TT6MSOK DM7RE8P TN 5-HT 1D receptor (HTR1D) DM7RE8P MA Modulator DM7RE8P RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM7RE8P RU https://www.fda.gov/ DM7RJXL DI DM7RJXL DM7RJXL DN Imatinib DM7RJXL TI TTS7G69 DM7RJXL TN Fusion protein Bcr-Abl (Bcr-Abl) DM7RJXL MA Inhibitor DM7RJXL RN A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22. DM7RJXL RU https://pubmed.ncbi.nlm.nih.gov/17692029 DM7RJXL DI DM7RJXL DM7RJXL DN Imatinib DM7RJXL TI TTI2WET DM7RJXL TN Platelet-derived growth factor receptor (PDGFR) DM7RJXL MA Inhibitor DM7RJXL RN A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22. DM7RJXL RU https://pubmed.ncbi.nlm.nih.gov/17692029 DM7RJXL DI DM7RJXL DM7RJXL DN Imatinib DM7RJXL TI TTX41N9 DM7RJXL TN Tyrosine-protein kinase Kit (KIT) DM7RJXL MA Inhibitor DM7RJXL RN A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22. DM7RJXL RU https://pubmed.ncbi.nlm.nih.gov/17692029 DM7RJXL DI DM7RJXL DM7RJXL DN Imatinib DM7RJXL TI TTN6ORK DM7RJXL TN Mcl-1 messenger RNA (MCL-1 mRNA) DM7RJXL RN Design and development of antisense drugs. Expert Opin. Drug Discov. 2008 3(10):1189-1207. DM7RJXL RU http://www.informahealthcare.com/doi/abs/10.1517/17460441.3.10.1177 DM7RNP3 DI DM7RNP3 DM7RNP3 DN Enbrel DM7RNP3 TI TTF8CQI DM7RNP3 TN Tumor necrosis factor (TNF) DM7RNP3 MA Modulator DM7RNP3 RN Oral pentoxifylline inhibits release of tumor necrosis factor-alpha from human peripheral blood monocytes : a potential treatment for aseptic loose... J Bone Joint Surg Am. 2001 Jul;83(7):1057-61. DM7RNP3 RU https://www.ncbi.nlm.nih.gov/pubmed/11451976 DM7SJD6 DI DM7SJD6 DM7SJD6 DN Methylphenidate DM7SJD6 TI TTVBI8W DM7SJD6 TN Dopamine transporter (DAT) DM7SJD6 MA Blocker DM7SJD6 RN Imaging the effects of methylphenidate on brain dopamine: new model on its therapeutic actions for attention-deficit/hyperactivity disorder. Biol Psychiatry. 2005 Jun 1;57(11):1410-5. DM7SJD6 RU https://pubmed.ncbi.nlm.nih.gov/15950015 DM7SWIA DI DM7SWIA DM7SWIA DN Triprolidine DM7SWIA TI TTTIBOJ DM7SWIA TN Histamine H1 receptor (H1R) DM7SWIA MA Antagonist DM7SWIA RN Histamine excites rat lateral vestibular nuclear neurons through activation of post-synaptic H2 receptors. Neurosci Lett. 2008 Dec 19;448(1):15-9. DM7SWIA RU https://pubmed.ncbi.nlm.nih.gov/18938221 DM7U5QJ DI DM7U5QJ DM7U5QJ DN Cinnarizine DM7U5QJ TI TTTIBOJ DM7U5QJ TN Histamine H1 receptor (H1R) DM7U5QJ MA Antagonist DM7U5QJ RN Central effects of cinnarizine: restricted use in aircrew. Aviat Space Environ Med. 2002 Jun;73(6):570-4. DM7U5QJ RU https://pubmed.ncbi.nlm.nih.gov/12056673 DM7UP8X DI DM7UP8X DM7UP8X DN Pegfilgrastim DM7UP8X TI TTC70AJ DM7UP8X TN Granulocyte colony-stimulating factor receptor (G-CSF-R) DM7UP8X MA Binder DM7UP8X RN Evidence that the granulocyte colony-stimulating factor (G-CSF) receptor plays a role in the pharmacokinetics of G-CSF and PegG-CSF using a G-CSF-R KO model. Pharmacol Res. 2004 Jul;50(1):55-8. DM7UP8X RU https://pubmed.ncbi.nlm.nih.gov/15082029 DM7VTQO DI DM7VTQO DM7VTQO DN Entecavir DM7VTQO TI TTS5K1M DM7VTQO TN Hepatitis B virus Reverse transcriptase (HBV RT) DM7VTQO MA Modulator DM7VTQO RN Effect of hepatitis B virus reverse transcriptase variations on entecavir treatment response. J Infect Dis. 2014 Sep 1;210(5):701-7. DM7VTQO RU https://pubmed.ncbi.nlm.nih.gov/24610871 DM7W94S DI DM7W94S DM7W94S DN Brigatinib DM7W94S TI TTPMQSO DM7W94S TN ALK tyrosine kinase receptor (ALK) DM7W94S MA Inhibitor DM7W94S RN 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85. DM7W94S RU https://pubmed.ncbi.nlm.nih.gov/29348678 DM7WI4Q DI DM7WI4Q DM7WI4Q DN Quinagolide DM7WI4Q TI TTEX248 DM7WI4Q TN Dopamine D2 receptor (D2R) DM7WI4Q MA Agonist DM7WI4Q RN Effect of dopamine receptor agonists on sensory nerve activity: possible therapeutic targets for the treatment of asthma and COPD. Br J Pharmacol. 2002 Jun;136(4):620-8. DM7WI4Q RU https://pubmed.ncbi.nlm.nih.gov/12055141 DM7YCK3 DI DM7YCK3 DM7YCK3 DN Thiabendazole DM7YCK3 TI TTHDSE2 DM7YCK3 TN Bacterial Fumarate reductase flavoprotein (Bact frdA) DM7YCK3 MA Inhibitor DM7YCK3 RN Fumarate reductase is essential for Helicobacter pylori colonization of the mouse stomach. Microb Pathog. 2000 Nov;29(5):279-87. DM7YCK3 RU https://pubmed.ncbi.nlm.nih.gov/11031122 DM7YMIT DI DM7YMIT DM7YMIT DN Methohexital DM7YMIT TI TT1MPAY DM7YMIT TN GABA(A) receptor alpha-1 (GABRA1) DM7YMIT MA Antagonist DM7YMIT RN DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6. DM7YMIT RU https://pubmed.ncbi.nlm.nih.gov/18048412 DM7YPM1 DI DM7YPM1 DM7YPM1 DN Enfuvirtide DM7YPM1 TI TTG90S6 DM7YPM1 TN Human immunodeficiency virus Glycoprotein 41 (HIV gp41) DM7YPM1 MA Modulator DM7YPM1 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM7YPM1 RU https://www.fda.gov/ DM7ZWNY DI DM7ZWNY DM7ZWNY DN Porfimer Sodium DM7ZWNY TI TTH0DUS DM7ZWNY TN Low-density lipoprotein receptor (LDL-R) DM7ZWNY MA Modulator DM7ZWNY RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM7ZWNY RU https://www.fda.gov/ DM804UR DI DM804UR DM804UR DN Hyoscyamine DM804UR TI TTH18TF DM804UR TN Muscarinic acetylcholine receptor M5 (CHRM5) DM804UR MA Antagonist DM804UR RN Reconstitution of the purified porcine atrial muscarinic acetylcholine receptor with purified porcine atrial inhibitory guanine nucleotide binding protein. Biochemistry. 1987 Dec 15;26(25):8175-82. DM804UR RU https://pubmed.ncbi.nlm.nih.gov/3126798 DM80OEZ DI DM80OEZ DM80OEZ DN Iobenguane I-123 DM80OEZ TI TTAWNKZ DM80OEZ TN Norepinephrine transporter (NET) DM80OEZ MA Inhibitor DM80OEZ RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 926). DM80OEZ RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=926 DM80OZ5 DI DM80OZ5 DM80OZ5 DN Halothane DM80OZ5 TI TTAN6JD DM80OZ5 TN Glutamate receptor AMPA (GRIA) DM80OZ5 MA Antagonist DM80OZ5 RN Reduced inhibition of cortical glutamate and GABA release by halothane in mice lacking the K+ channel, TREK-1. Br J Pharmacol. 2007 Nov;152(6):939-45. DM80OZ5 RU https://pubmed.ncbi.nlm.nih.gov/17828284 DM819JF DI DM819JF DM819JF DN Pemigatinib DM819JF TI TTST7KB DM819JF TN Fibroblast growth factor receptor 3 (FGFR3) DM819JF MA Inhibitor DM819JF RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020 DM819JF RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213736s000lbl.pdf DM819JF DI DM819JF DM819JF DN Pemigatinib DM819JF TI TTRLW2X DM819JF TN Fibroblast growth factor receptor 1 (FGFR1) DM819JF MA Inhibitor DM819JF RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020 DM819JF RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213736s000lbl.pdf DM819JF DI DM819JF DM819JF DN Pemigatinib DM819JF TI TTGJVQM DM819JF TN Fibroblast growth factor receptor 2 (FGFR2) DM819JF MA Inhibitor DM819JF RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020 DM819JF RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213736s000lbl.pdf DM82Z30 DI DM82Z30 DM82Z30 DN Topiramate DM82Z30 TI TT0MYE2 DM82Z30 TN Glutamate receptor ionotropic kainate 1 (GRIK1) DM82Z30 MA Antagonist DM82Z30 RN Development of medications for alcohol use disorders: recent advances and ongoing challenges. Expert Opin Emerg Drugs. 2005 May;10(2):323-43. DM82Z30 RU https://pubmed.ncbi.nlm.nih.gov/15934870 DM83MOK DI DM83MOK DM83MOK DN Glassia DM83MOK TI TTA7UJC DM83MOK TN Alpha-1-antitrypsin (SERPINA1) DM83MOK MA Inhibitor DM83MOK RN Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5. DM83MOK RU https://pubmed.ncbi.nlm.nih.gov/21283092 DM84ZXF DI DM84ZXF DM84ZXF DN Lorazepam DM84ZXF TI TTPTXIN DM84ZXF TN Translocator protein (TSPO) DM84ZXF MA Modulator DM84ZXF RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM84ZXF RU https://www.fda.gov/ DM87XSN DI DM87XSN DM87XSN DN REGN-727 DM87XSN TI TTBRG7E DM87XSN TN Proprotein convertase subtilisin/kexin type 9 (PCSK9) DM87XSN RN Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial. Lancet. 2012 Jul 7;380(9836):29-36. DM87XSN RU https://pubmed.ncbi.nlm.nih.gov/22633824 DM89JLN DI DM89JLN DM89JLN DN Apixaban DM89JLN TI TTCIHJA DM89JLN TN Coagulation factor Xa (F10) DM89JLN MA Inhibitor DM89JLN RN Pfizer. Product Development Pipeline. March 31 2009. DM89JLN RU http://media.pfizer.com/files/research/pipeline/2009_0331/pipeline_2009_0331.pdf DM89QE1 DI DM89QE1 DM89QE1 DN Metformin DM89QE1 TI TTY84UG DM89QE1 TN Acetyl-CoA carboxylase 2 (ACACB) DM89QE1 MA Activator DM89QE1 RN AMP-activated protein kinase-dependent and -independent mechanisms underlying in vitro antiglioma action of compound C. Biochem Pharmacol. 2009 Jun 1;77(11):1684-93. DM89QE1 RU https://pubmed.ncbi.nlm.nih.gov/19428322 DM89QE1 DI DM89QE1 DM89QE1 DN Metformin DM89QE1 TI TTMHCGA DM89QE1 TN Solute carrier family 47 member 1 (SLC47A1) DM89QE1 MA Modulator DM89QE1 RN Molecular cloning, functional characterization and tissue distribution of rat H+/organic cation antiporter MATE1. Pharm Res. 2006 Aug;23(8):1696-701. DM89QE1 RU https://pubmed.ncbi.nlm.nih.gov/16850272 DM8AI9U DI DM8AI9U DM8AI9U DN Loxapine DM8AI9U TI TTEX248 DM8AI9U TN Dopamine D2 receptor (D2R) DM8AI9U MA Antagonist DM8AI9U RN Remoxipride in Parkinson's disease: differential response in patients with dyskinesias fluctuations versus psychosis. Clin Neuropharmacol. 1995 Feb;18(1):39-45. DM8AI9U RU https://pubmed.ncbi.nlm.nih.gov/8665533 DM8ANCF DI DM8ANCF DM8ANCF DN Muromonab DM8ANCF TI TTZAT79 DM8ANCF TN T-cell surface glycoprotein CD3 epsilon (CD3E) DM8ANCF MA Binder DM8ANCF RN Basiliximab: a review of its use as induction therapy in renal transplantation. Drugs. 2003;63(24):2803-35. DM8ANCF RU https://pubmed.ncbi.nlm.nih.gov/14664658 DM8BKU9 DI DM8BKU9 DM8BKU9 DN Acitretin DM8BKU9 TI TTH8FZW DM8BKU9 TN Signal transducer and activator of transcription 3 (STAT3) DM8BKU9 MA Inhibitor DM8BKU9 RN Effects of acitretin on the expression of signaling pathway-related genes in epidermal squamous-cell carcinoma cells. Zhonghua Zhong Liu Za Zhi. 2006 Jan;28(1):21-4. DM8BKU9 RU https://pubmed.ncbi.nlm.nih.gov/16737614 DM8C3GN DI DM8C3GN DM8C3GN DN Denopamine DM8C3GN TI TTEX248 DM8C3GN TN Dopamine D2 receptor (D2R) DM8C3GN MA Modulator DM8C3GN RN Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. DM8C3GN RU https://pubmed.ncbi.nlm.nih.gov/17309302 DM8C43Q DI DM8C43Q DM8C43Q DN Cycrimine DM8C43Q TI TTZ9SOR DM8C43Q TN Muscarinic acetylcholine receptor M1 (CHRM1) DM8C43Q MA Binder DM8C43Q RN Capillary gas chromatography of trihexyphenidyl, procyclidine and cycrimine in biological fluids. J Chromatogr. 1989 Sep 29;494:135-42. DM8C43Q RU https://pubmed.ncbi.nlm.nih.gov/2573609 DM8DQV9 DI DM8DQV9 DM8DQV9 DN Pelubiprofen DM8DQV9 TI TTK0943 DM8DQV9 TN Prostaglandin G/H synthase (COX) DM8DQV9 MA Modulator DM8DQV9 RN Anti-inflammatory effect of pelubiprofen, 2-[4-(oxocyclohexylidenemethyl)-phenyl]propionic acid, mediated by dual suppression of COX activity and LPS-induced inflammatory gene expression via NF- B inactivation. J Cell Biochem. 2011 Dec;112(12):3594-603. DM8DQV9 RU https://pubmed.ncbi.nlm.nih.gov/21809372 DM8DZC1 DI DM8DZC1 DM8DZC1 DN Dyphylline DM8DZC1 TI TTZ97H5 DM8DZC1 TN Phosphodiesterase 4A (PDE4A) DM8DZC1 MA Inhibitor DM8DZC1 RN Ocular hypotension induced by topical dopaminergic drugs and phosphodiesterase inhibitors. Eur J Pharmacol. 1994 Jun 2;258(1-2):85-94. DM8DZC1 RU https://pubmed.ncbi.nlm.nih.gov/7925603 DM8EU0Z DI DM8EU0Z DM8EU0Z DN Dicloxacillin DM8EU0Z TI TTJP4SM DM8EU0Z TN Bacterial Penicillin binding protein (Bact PBP) DM8EU0Z MA Binder DM8EU0Z RN Mechanisms of resistance to beta-lactam antibiotics in Staphylococcus aureus. Scand J Infect Dis Suppl. 1984;42:64-71. DM8EU0Z RU https://pubmed.ncbi.nlm.nih.gov/6335600 DM8HBJI DI DM8HBJI DM8HBJI DN Coagulation Factor IX DM8HBJI TI TTCIHJA DM8HBJI TN Coagulation factor Xa (F10) DM8HBJI MA Activator DM8HBJI RN Haemophilia B: Christmas disease. Expert Opin Pharmacother. 2005 Aug;6(9):1517-24. DM8HBJI RU https://pubmed.ncbi.nlm.nih.gov/16086639 DM8HDOL DI DM8HDOL DM8HDOL DN Phytonadione DM8HDOL TI TT76OLR DM8HDOL TN Vitamin K-dependent gamma-carboxylase (GGCX) DM8HDOL MA Cofactor DM8HDOL RN Quinone oxidoreductases and vitamin K metabolism. Vitam Horm. 2008;78:85-101. DM8HDOL RU https://pubmed.ncbi.nlm.nih.gov/18374191 DM8HJX6 DI DM8HJX6 DM8HJX6 DN Tipranavir DM8HJX6 TI TT5FNQT DM8HJX6 TN Human immunodeficiency virus Protease (HIV PR) DM8HJX6 MA Modulator DM8HJX6 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM8HJX6 RU https://www.fda.gov/ DM8HLO5 DI DM8HLO5 DM8HLO5 DN Canakinumab DM8HLO5 TI TTRYK0X DM8HLO5 TN Interleukin-1 beta (IL1B) DM8HLO5 RN Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92. DM8HLO5 RU https://pubmed.ncbi.nlm.nih.gov/20118952 DM8HO1L DI DM8HO1L DM8HO1L DN Pyridostigmine DM8HO1L TI TT1RS9F DM8HO1L TN Acetylcholinesterase (AChE) DM8HO1L MA Inhibitor DM8HO1L RN Neuromuscular blockade, reversal agent use, and operating room time: retrospective analysis of US inpatient surgeries. Curr Med Res Opin. 2009 Apr;25(4):943-50. DM8HO1L RU https://pubmed.ncbi.nlm.nih.gov/19257799 DM8JRH0 DI DM8JRH0 DM8JRH0 DN Cangrelor DM8JRH0 TI TTZ1DT0 DM8JRH0 TN P2Y purinoceptor 12 (P2RY12) DM8JRH0 MA Antagonist DM8JRH0 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 328). DM8JRH0 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=328 DM8JXPZ DI DM8JXPZ DM8JXPZ DN Glibenclamide DM8JXPZ TI TTP835K DM8JXPZ TN ATP-binding cassette transporter C8 (ABCC8) DM8JXPZ MA Modulator DM8JXPZ RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM8JXPZ RU https://www.fda.gov/ DM8K1XO DI DM8K1XO DM8K1XO DN Hydrocortamate DM8K1XO TI TTYRL6O DM8K1XO TN Glucocorticoid receptor (NR3C1) DM8K1XO MA Modulator DM8K1XO RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM8K1XO RU https://www.fda.gov/ DM8K3EI DI DM8K3EI DM8K3EI DN Ethionamide DM8K3EI TI TTVTX4N DM8K3EI TN Bacterial Fatty acid synthetase I (Bact inhA) DM8K3EI MA Inhibitor DM8K3EI RN Mechanism of thioamide drug action against tuberculosis and leprosy. J Exp Med. 2007 Jan 22;204(1):73-8. DM8K3EI RU https://pubmed.ncbi.nlm.nih.gov/17227913 DM8KSQH DI DM8KSQH DM8KSQH DN Phenoxybenzamine DM8KSQH TI TTEX248 DM8KSQH TN Dopamine D2 receptor (D2R) DM8KSQH MA Antagonist DM8KSQH RN Catecholamine-secreting neuroblastoma in a 4-month-old infant: perioperative management. J Clin Anesth. 2009 Feb;21(1):54-6. DM8KSQH RU https://pubmed.ncbi.nlm.nih.gov/19232942 DM8L9D4 DI DM8L9D4 DM8L9D4 DN Bestatin DM8L9D4 TI TTXZEAJ DM8L9D4 TN Leukotriene A-4 hydrolase (LTA4H) DM8L9D4 MA Inhibitor DM8L9D4 RN DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41. DM8L9D4 RU https://pubmed.ncbi.nlm.nih.gov/21059682 DM8LRU2 DI DM8LRU2 DM8LRU2 DN Revolade/Promacta DM8LRU2 TI TTIHYA4 DM8LRU2 TN Thrombopoietin receptor (MPL) DM8LRU2 MA Agonist DM8LRU2 RN Clinical pipeline report, company report or official report of GlaxoSmithKline (2009). DM8LRU2 RU http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf DM8LX76 DI DM8LX76 DM8LX76 DN Penicillin V Potassium DM8LX76 TI TTJP4SM DM8LX76 TN Bacterial Penicillin binding protein (Bact PBP) DM8LX76 MA Modulator DM8LX76 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM8LX76 RU https://www.fda.gov/ DM8MC6O DI DM8MC6O DM8MC6O DN Estradiol valerate DM8MC6O TI TTZAYWL DM8MC6O TN Estrogen receptor (ESR) DM8MC6O MA Modulator DM8MC6O RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM8MC6O RU https://www.fda.gov/ DM8MNVO DI DM8MNVO DM8MNVO DN Tolcapone DM8MNVO TI TTKWFB8 DM8MNVO TN Catechol-O-methyl-transferase (COMT) DM8MNVO MA Inhibitor DM8MNVO RN Catechol-O-methyltransferase inhibitors in the management of Parkinson's disease. Semin Neurol. 2001;21(1):15-22. DM8MNVO RU https://pubmed.ncbi.nlm.nih.gov/11346021 DM8QB0T DI DM8QB0T DM8QB0T DN GSK2592984A DM8QB0T TI TT3J5ZI DM8QB0T TN Cell mediated immunity response (CMIR) DM8QB0T RN Anti-influenza agents from Traditional Chinese Medicine. Nat Prod Rep. 2010 Jan;27(12):1758-80. DM8QB0T RU https://pubmed.ncbi.nlm.nih.gov/20941447 DM8QB1D DI DM8QB1D DM8QB1D DN Olaparib DM8QB1D TI TTEBCY8 DM8QB1D TN Poly [ADP-ribose] polymerase (PARP) DM8QB1D MA Modulator DM8QB1D RN 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81. DM8QB1D RU https://pubmed.ncbi.nlm.nih.gov/25633781 DM8QM5U DI DM8QM5U DM8QM5U DN Anidulafungin DM8QM5U TI TT0SFXH DM8QM5U TN Fungal 1,3-beta-glucan synthase (Fung GSC2) DM8QM5U MA Modulator DM8QM5U RN 2006 drug approvals: finding the niche. Nat Rev Drug Discov. 2007 Feb;6(2):99-101. DM8QM5U RU https://pubmed.ncbi.nlm.nih.gov/17342860 DM8QTJI DI DM8QTJI DM8QTJI DN Loteprednol etabonate DM8QTJI TI TTP3UTW DM8QTJI TN Steroid hormone receptor ERR (ESRR) DM8QTJI MA Modulator DM8QTJI RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM8QTJI RU https://www.fda.gov/ DM8RFNJ DI DM8RFNJ DM8RFNJ DN Pitolisant DM8RFNJ TI TT9JNIC DM8RFNJ TN Histamine H3 receptor (H3R) DM8RFNJ MA Agonist DM8RFNJ RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019 DM8RFNJ RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211150s000lbl.pdf DM8RZ9H DI DM8RZ9H DM8RZ9H DN Eszopiclone DM8RZ9H TI TTPTXIN DM8RZ9H TN Translocator protein (TSPO) DM8RZ9H MA Agonist DM8RZ9H RN New hypnotics: perspectives from sleep physiology. Vertex. 2007 Jul-Aug;18(74):294-9. DM8RZ9H RU https://pubmed.ncbi.nlm.nih.gov/18265473 DM8S6T7 DI DM8S6T7 DM8S6T7 DN Ivosidenib DM8S6T7 TI TTV2A1R DM8S6T7 TN Oxalosuccinate decarboxylase (IDH1) DM8S6T7 MA Inhibitor DM8S6T7 RN 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. DM8S6T7 RU https://pubmed.ncbi.nlm.nih.gov/30710142 DM8SMD1 DI DM8SMD1 DM8SMD1 DN Tazarotene DM8SMD1 TI TT1Q3IE DM8SMD1 TN Retinoic acid receptor gamma (RARG) DM8SMD1 MA Binder DM8SMD1 RN Recent developments in receptor-selective retinoids. Curr Pharm Des. 2000 Jun;6(9):919-31. DM8SMD1 RU https://pubmed.ncbi.nlm.nih.gov/10828316 DM8SXYG DI DM8SXYG DM8SXYG DN Lamotrigine DM8SXYG TI TTN9VTF DM8SXYG TN Voltage-gated sodium channel alpha Nav1.9 (SCN11A) DM8SXYG MA Blocker DM8SXYG RN The effects of lamotrigine on the acquisition and expression of morphine-induced place preference in mice. Pak J Biol Sci. 2009 Jan 1;12(1):33-9. DM8SXYG RU https://pubmed.ncbi.nlm.nih.gov/19579915 DM8SY60 DI DM8SY60 DM8SY60 DN Butoconazole DM8SY60 TI TTTSOUD DM8SY60 TN Candida Cytochrome P450 51 (Candi ERG11) DM8SY60 MA Inhibitor DM8SY60 RN Effects of terconazole and other azole antifungal agents on the sterol and carbohydrate composition of Candida albicans. Diagn Microbiol Infect Dis. 1990 Jan-Feb;13(1):31-5. DM8SY60 RU https://pubmed.ncbi.nlm.nih.gov/2184984 DM8TUPF DI DM8TUPF DM8TUPF DN Milrinone DM8TUPF TI TTZCG4L DM8TUPF TN Phosphodiesterase 3 (PDE3) DM8TUPF MA Modulator DM8TUPF RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM8TUPF RU https://www.fda.gov/ DM8V75C DI DM8V75C DM8V75C DN ABIRATERONE DM8V75C TI TTRA5BZ DM8V75C TN Steroid 17-alpha-monooxygenase (S17AH) DM8V75C MA Modulator DM8V75C RN 2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4. DM8V75C RU https://pubmed.ncbi.nlm.nih.gov/22293555 DM8VCBE DI DM8VCBE DM8VCBE DN Ibuprofen DM8VCBE TI TTVKILB DM8VCBE TN Prostaglandin G/H synthase 2 (COX-2) DM8VCBE MA Inhibitor DM8VCBE RN Maternal toxicity of nonsteroidal anti-inflammatory drugs as an important factor affecting prenatal development. Reprod Toxicol. 2009 Sep;28(2):239-44. DM8VCBE RU https://pubmed.ncbi.nlm.nih.gov/19379806 DM8VCBE DI DM8VCBE DM8VCBE DN Ibuprofen DM8VCBE TI TTMWT8Z DM8VCBE TN C-X-C chemokine receptor type 1 (CXCR1) DM8VCBE MA Inhibitor DM8VCBE RN 2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors. J Med Chem. 2005 Jun 30;48(13):4312-31. DM8VCBE RU https://pubmed.ncbi.nlm.nih.gov/15974585 DM8VCBE DI DM8VCBE DM8VCBE DN Ibuprofen DM8VCBE TI TT30C9G DM8VCBE TN C-X-C chemokine receptor type 2 (CXCR2) DM8VCBE MA Inhibitor DM8VCBE RN 2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors. J Med Chem. 2005 Jun 30;48(13):4312-31. DM8VCBE RU https://pubmed.ncbi.nlm.nih.gov/15974585 DM8VCBE DI DM8VCBE DM8VCBE DN Ibuprofen DM8VCBE TI TTCTE1G DM8VCBE TN Interleukin-8 (IL8) DM8VCBE MA Inhibitor DM8VCBE RN Structure-Activity Relationship of novel phenylacetic CXCR1 inhibitors. Bioorg Med Chem Lett. 2009 Aug 1;19(15):4026-30. DM8VCBE RU https://pubmed.ncbi.nlm.nih.gov/19560921 DM8WAHT DI DM8WAHT DM8WAHT DN Fentanyl DM8WAHT TI TTKWM86 DM8WAHT TN Opioid receptor mu (MOP) DM8WAHT MA Modulator DM8WAHT RN The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954. DM8WAHT RU https://www.ncbi.nlm.nih.gov/pubmed/27899562 DM8WBAH DI DM8WBAH DM8WBAH DN Dexmethylphenidate hydrochloride DM8WBAH TI TTVBI8W DM8WBAH TN Dopamine transporter (DAT) DM8WBAH MA Inhibitor DM8WBAH RN Synthesis and pharmacology of site-specific cocaine abuse treatment agents: restricted rotation analogues of methylphenidate. J Med Chem. 2007 May 31;50(11):2718-31. DM8WBAH RU https://pubmed.ncbi.nlm.nih.gov/17489581 DM8WCXM DI DM8WCXM DM8WCXM DN Befunolol hci DM8WCXM TI TTVIREA DM8WCXM TN Adrenergic receptor (ADR) DM8WCXM MA Modulator DM8WCXM RN Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. DM8WCXM RU https://pubmed.ncbi.nlm.nih.gov/17309302 DM8WI3R DI DM8WI3R DM8WI3R DN Alogliptin DM8WI3R TI TTDIGC1 DM8WI3R TN Dipeptidyl peptidase 4 (DPP-4) DM8WI3R MA Inhibitor DM8WI3R RN Clinical pipeline report, company report or official report of Takeda (2009). DM8WI3R RU http://www.takeda.com/pdf/usr/default/10_1_34992_2.pdf DM8X2EH DI DM8X2EH DM8X2EH DN Everolimus DM8X2EH TI TTCJG29 DM8X2EH TN Serine/threonine-protein kinase mTOR (mTOR) DM8X2EH MA Inhibitor DM8X2EH RN Mammalian target of rapamycin, its mode of action and clinical response in metastatic clear cell carcinoma. Gan To Kagaku Ryoho. 2009 Jul;36(7):1076-9. DM8X2EH RU https://pubmed.ncbi.nlm.nih.gov/19620795 DM8X4A1 DI DM8X4A1 DM8X4A1 DN Methantheline DM8X4A1 TI TTH18TF DM8X4A1 TN Muscarinic acetylcholine receptor M5 (CHRM5) DM8X4A1 MA Antagonist DM8X4A1 RN Anticholinergics for urinary symptoms in multiple sclerosis. Cochrane Database Syst Rev. 2009 Jan 21;(1):CD004193. DM8X4A1 RU https://pubmed.ncbi.nlm.nih.gov/19160231 DM8XI09 DI DM8XI09 DM8XI09 DN Methyldopate Hydrochloride DM8XI09 TI TTQ8AFT DM8XI09 TN Adrenergic receptor Alpha-2 (ADRA2) DM8XI09 MA Modulator DM8XI09 RN Effect of Antihypertensive Therapy with Alpha Methyldopa on Levels of Angiogenic Factors in Pregnancies with Hypertensive Disorders DM8XI09 RU https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2447877 DM8XP26 DI DM8XP26 DM8XP26 DN Rolapitant DM8XP26 TI TTZPO1L DM8XP26 TN Substance-P receptor (TACR1) DM8XP26 MA Antagonist DM8XP26 RN Netupitant and palonosetron trigger NK1 receptor internalization in NG108-15 cells. Exp Brain Res. 2014 Aug;232(8):2637-44. DM8XP26 RU https://pubmed.ncbi.nlm.nih.gov/24969614 DM8Y2RU DI DM8Y2RU DM8Y2RU DN Cenegermin DM8Y2RU TI TTEDJN4 DM8Y2RU TN Low-affinity nerve growth factor receptor (NGFR) DM8Y2RU MA Agonist DM8Y2RU RN 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. DM8Y2RU RU https://pubmed.ncbi.nlm.nih.gov/30710142 DM8YU2F DI DM8YU2F DM8YU2F DN Mepenzolate DM8YU2F TI TTH18TF DM8YU2F TN Muscarinic acetylcholine receptor M5 (CHRM5) DM8YU2F MA Antagonist DM8YU2F RN Isolation of cholinergic active ingredients in aqueous extracts of Mareya micrantha using the longitudinal muscle of isolated guinea-pig ileum as a pharmacological activity marker. J Ethnopharmacol. 1995 Mar;45(3):215-22. DM8YU2F RU https://pubmed.ncbi.nlm.nih.gov/7623487 DM8YXKW DI DM8YXKW DM8YXKW DN Dihydroxyaluminium DM8YXKW TI TT8RDXP DM8YXKW TN Troponin C (TN-C) DM8YXKW MA Stimulator DM8YXKW RN A retrospective analysis of changes in inflammatory markers in patients treated with bacterial viruses. Clin Exp Med. 2009 Dec;9(4):303-12. DM8YXKW RU https://pubmed.ncbi.nlm.nih.gov/19350363 DM8ZHP1 DI DM8ZHP1 DM8ZHP1 DN MCI-186 DM8ZHP1 TI TTJGNVC DM8ZHP1 TN Apoptosis regulator Bcl-2 (BCL-2) DM8ZHP1 MA Regulator (upregulator) DM8ZHP1 RN Emerging disease-modifying therapies for the treatment of motor neuron disease/amyotropic lateral sclerosis. Expert Opin Emerg Drugs. 2007 May;12(2):229-52. DM8ZHP1 RU https://pubmed.ncbi.nlm.nih.gov/17604499 DM8ZVJ7 DI DM8ZVJ7 DM8ZVJ7 DN Calcitriol DM8ZVJ7 TI TTK59TV DM8ZVJ7 TN Vitamin D3 receptor (VDR) DM8ZVJ7 MA Agonist DM8ZVJ7 RN Kaposi sarcoma is a therapeutic target for vitamin D(3) receptor agonist. Blood. 2000 Nov 1;96(9):3188-94. DM8ZVJ7 RU https://pubmed.ncbi.nlm.nih.gov/11050002 DM8ZXT6 DI DM8ZXT6 DM8ZXT6 DN Oxymetazoline DM8ZXT6 TI TTQ8AFT DM8ZXT6 TN Adrenergic receptor Alpha-2 (ADRA2) DM8ZXT6 MA Agonist DM8ZXT6 RN Potent alpha(2A)-adrenoceptor-mediated vasoconstriction by brimonidine in porcine ciliary arteries. Invest Ophthalmol Vis Sci. 2001 Aug;42(9):2049-55. DM8ZXT6 RU https://pubmed.ncbi.nlm.nih.gov/11481271 DM90TJP DI DM90TJP DM90TJP DN Sapropterin hydrochloride DM90TJP TI TTGSVH2 DM90TJP TN Phenylalanine hydroxylase (PAH) DM90TJP MA Modulator DM90TJP RN 2007 FDA drug approvals: a year of flux. Nat Rev Drug Discov. 2008 Feb;7(2):107-9. DM90TJP RU https://pubmed.ncbi.nlm.nih.gov/18246607 DM90WJH DI DM90WJH DM90WJH DN Interferon alfacon-1 DM90WJH TI TTMQB37 DM90WJH TN Interferon alpha/beta receptor 2 (IFNAR2) DM90WJH MA Binder DM90WJH RN Retreating chronic hepatitis C with daily interferon alfacon-1/ribavirin after nonresponse to pegylated interferon/ribavirin: DIRECT results. Hepatology. 2009 Jun;49(6):1838-46. DM90WJH RU https://pubmed.ncbi.nlm.nih.gov/19291790 DM92AH3 DI DM92AH3 DM92AH3 DN Cyproheptadine DM92AH3 TI TTTIBOJ DM92AH3 TN Histamine H1 receptor (H1R) DM92AH3 MA Antagonist DM92AH3 RN Cyproheptadine displays preclinical activity in myeloma and leukemia. Blood. 2008 Aug 1;112(3):760-9. DM92AH3 RU https://pubmed.ncbi.nlm.nih.gov/18502826 DM93L4X DI DM93L4X DM93L4X DN Dexmedetomidine DM93L4X TI TTQ8AFT DM93L4X TN Adrenergic receptor Alpha-2 (ADRA2) DM93L4X MA Agonist DM93L4X RN Dexmedetomidine in intensive care unit: a study of hemodynamic changes. Middle East J Anesthesiol. 2002 Oct;16(6):587-95. DM93L4X RU https://pubmed.ncbi.nlm.nih.gov/12503262 DM93VBZ DI DM93VBZ DM93VBZ DN LY2835219 DM93VBZ TI TT0PG8F DM93VBZ TN Cyclin-dependent kinase 4 (CDK4) DM93VBZ MA Modulator DM93VBZ RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DM93VBZ RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DM93VBZ DI DM93VBZ DM93VBZ DN LY2835219 DM93VBZ TI TTO0FDJ DM93VBZ TN Cyclin-dependent kinase 6 (CDK6) DM93VBZ MA Modulator DM93VBZ RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DM93VBZ RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DM958QB DI DM958QB DM958QB DN Ripretinib DM958QB TI TT8FYO9 DM958QB TN Platelet-derived growth factor receptor alpha (PDGFRA) DM958QB MA Inhibitor DM958QB RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020 DM958QB RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213973s000lbl.pdf DM958QB DI DM958QB DM958QB DN Ripretinib DM958QB TI TTX41N9 DM958QB TN Tyrosine-protein kinase Kit (KIT) DM958QB MA Inhibitor DM958QB RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020 DM958QB RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213973s000lbl.pdf DM96SE0 DI DM96SE0 DM96SE0 DN Haloperidol DM96SE0 TI TTEX248 DM96SE0 TN Dopamine D2 receptor (D2R) DM96SE0 MA Antagonist DM96SE0 RN Dopaminergic synapses in the matrix of the ventrolateral striatum after chronic haloperidol treatment. Synapse. 2002 Aug;45(2):78-85. DM96SE0 RU https://pubmed.ncbi.nlm.nih.gov/12112400 DM98IXF DI DM98IXF DM98IXF DN Triamcinolone DM98IXF TI TTYRL6O DM98IXF TN Glucocorticoid receptor (NR3C1) DM98IXF MA Modulator DM98IXF RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM98IXF RU https://www.fda.gov/ DM9BI7M DI DM9BI7M DM9BI7M DN Duloxetine DM9BI7M TI TT3ROYC DM9BI7M TN Serotonin transporter (SERT) DM9BI7M MA Inhibitor DM9BI7M RN Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug Discov Today. 2007 Jan;12(1-2):34-42. DM9BI7M RU https://pubmed.ncbi.nlm.nih.gov/17198971 DM9BI7M DI DM9BI7M DM9BI7M DN Duloxetine DM9BI7M TI TTAWNKZ DM9BI7M TN Norepinephrine transporter (NET) DM9BI7M MA Inhibitor DM9BI7M RN Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug Discov Today. 2007 Jan;12(1-2):34-42. DM9BI7M RU https://pubmed.ncbi.nlm.nih.gov/17198971 DM9CIUW DI DM9CIUW DM9CIUW DN Ribociclib succinate DM9CIUW TI TT0PG8F DM9CIUW TN Cyclin-dependent kinase 4 (CDK4) DM9CIUW MA Modulator DM9CIUW RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM9CIUW RU https://www.fda.gov/ DM9CIUW DI DM9CIUW DM9CIUW DN Ribociclib succinate DM9CIUW TI TTO0FDJ DM9CIUW TN Cyclin-dependent kinase 6 (CDK6) DM9CIUW MA Modulator DM9CIUW RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM9CIUW RU https://www.fda.gov/ DM9EQC0 DI DM9EQC0 DM9EQC0 DN Oxidized glutathione DM9EQC0 TI TTEP6RV DM9EQC0 TN Glutathione reductase (GR) DM9EQC0 MA Inhibitor DM9EQC0 RN The purification and properties of glutathione reductase from the cestode Moniezia expansa. Int J Biochem Cell Biol. 1995 Apr;27(4):393-401. DM9EQC0 RU https://pubmed.ncbi.nlm.nih.gov/7788561 DM9FKSR DI DM9FKSR DM9FKSR DN Oxitropium bromide DM9FKSR TI TTH18TF DM9FKSR TN Muscarinic acetylcholine receptor M5 (CHRM5) DM9FKSR MA Modulator DM9FKSR RN Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. DM9FKSR RU https://pubmed.ncbi.nlm.nih.gov/17309302 DM9G7BS DI DM9G7BS DM9G7BS DN Cyclizine DM9G7BS TI TTTIBOJ DM9G7BS TN Histamine H1 receptor (H1R) DM9G7BS MA Antagonist DM9G7BS RN Histamine H1-receptor antagonists, promethazine and homochlorcyclizine, increase the steady-state plasma concentrations of haloperidol and reduced haloperidol. Ther Drug Monit. 2003 Apr;25(2):192-6. DM9G7BS RU https://pubmed.ncbi.nlm.nih.gov/12657913 DM9GH25 DI DM9GH25 DM9GH25 DN Arcitumomab DM9GH25 TI TTPX7I5 DM9GH25 TN Carcinoembryonic antigen CGM1 (CD66d) DM9GH25 RN In vivo near-infrared fluorescence imaging of carcinoembryonic antigen-expressing tumor cells in mice. Radiology. 2008 Jun;247(3):779-87. DM9GH25 RU https://pubmed.ncbi.nlm.nih.gov/18413884 DM9GP85 DI DM9GP85 DM9GP85 DN Tesamorelin DM9GP85 TI TTG4R8V DM9GP85 TN Growth hormone-releasing hormone receptor (GHRHR) DM9GP85 MA Binder DM9GP85 RN Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5. DM9GP85 RU https://pubmed.ncbi.nlm.nih.gov/21283092 DM9HOKG DI DM9HOKG DM9HOKG DN Prinomastat DM9HOKG TI TTLM12X DM9HOKG TN Matrix metalloproteinase-2 (MMP-2) DM9HOKG MA Inhibitor DM9HOKG RN AG-3340 (Agouron Pharmaceuticals Inc). IDrugs. 2000 Mar;3(3):336-45. DM9HOKG RU https://pubmed.ncbi.nlm.nih.gov/16103944 DM9HOKG DI DM9HOKG DM9HOKG DN Prinomastat DM9HOKG TI TTMX39J DM9HOKG TN Matrix metalloproteinase-1 (MMP-1) DM9HOKG MA Inhibitor DM9HOKG RN AG-3340 (Agouron Pharmaceuticals Inc). IDrugs. 2000 Mar;3(3):336-45. DM9HOKG RU https://pubmed.ncbi.nlm.nih.gov/16103944 DM9HOKG DI DM9HOKG DM9HOKG DN Prinomastat DM9HOKG TI TTMTWOS DM9HOKG TN Matrix metalloproteinase-7 (MMP-7) DM9HOKG MA Inhibitor DM9HOKG RN AG-3340 (Agouron Pharmaceuticals Inc). IDrugs. 2000 Mar;3(3):336-45. DM9HOKG RU https://pubmed.ncbi.nlm.nih.gov/16103944 DM9HPW3 DI DM9HPW3 DM9HPW3 DN Exemestane DM9HPW3 TI TTSZLWK DM9HPW3 TN Aromatase (CYP19A1) DM9HPW3 MA Inhibitor DM9HPW3 RN Aromatase inhibitors--theoretical concept and present experiences in the treatment of endometriosis. Zentralbl Gynakol. 2003 Jul-Aug;125(7-8):247-51. DM9HPW3 RU https://pubmed.ncbi.nlm.nih.gov/14505258 DM9HQ5U DI DM9HQ5U DM9HQ5U DN Tagraxofusp DM9HQ5U TI TTENHJ0 DM9HQ5U TN Interleukin 3 receptor alpha (IL3RA) DM9HQ5U MA Modulator DM9HQ5U RN 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. DM9HQ5U RU https://pubmed.ncbi.nlm.nih.gov/30710142 DM9J04X DI DM9J04X DM9J04X DN Butalbital DM9J04X TI TT1MPAY DM9J04X TN GABA(A) receptor alpha-1 (GABRA1) DM9J04X MA Antagonist DM9J04X RN DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6. DM9J04X RU https://pubmed.ncbi.nlm.nih.gov/18048412 DM9J6C2 DI DM9J6C2 DM9J6C2 DN Tetracaine DM9J6C2 TI TT90XZ8 DM9J6C2 TN Voltage-gated sodium channel alpha Nav1.8 (SCN10A) DM9J6C2 MA Inhibitor DM9J6C2 RN Heterologous expression and functional analysis of rat Nav1.8 (SNS) voltage-gated sodium channels in the dorsal root ganglion neuroblastoma cell line ND7-23. Neuropharmacology. 2004 Mar;46(3):425-38. DM9J6C2 RU https://pubmed.ncbi.nlm.nih.gov/14975698 DM9JOYP DI DM9JOYP DM9JOYP DN Palifermin DM9JOYP TI TTGJVQM DM9JOYP TN Fibroblast growth factor receptor 2 (FGFR2) DM9JOYP MA Binder DM9JOYP RN Keratinocyte growth factor. Expert Opin Biol Ther. 2009 Jun;9(6):779-87. DM9JOYP RU https://pubmed.ncbi.nlm.nih.gov/19456212 DM9JXB7 DI DM9JXB7 DM9JXB7 DN Retapamulin DM9JXB7 TI TTUWYEA DM9JXB7 TN Bacterial 50S ribosomal RNA (Bact 50S rRNA) DM9JXB7 MA Inhibitor DM9JXB7 RN Retapamulin inhibition of translation and 50S ribosomal subunit formation in Staphylococcus aureus cells. Antimicrob Agents Chemother. 2007 Sep;51(9):3385-7. DM9JXB7 RU https://pubmed.ncbi.nlm.nih.gov/17562806 DM9KHZL DI DM9KHZL DM9KHZL DN Heparin Sodium DM9KHZL TI TT4QPUL DM9KHZL TN Antithrombin-III (ATIII) DM9KHZL MA Modulator DM9KHZL RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2632). DM9KHZL RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2632 DM9KJLZ DI DM9KJLZ DM9KJLZ DN Foscavir DM9KJLZ TI TTIU7X1 DM9KJLZ TN Herpes simplex virus DNA polymerase UL30 (HSV UL30) DM9KJLZ MA Inhibitor DM9KJLZ RN Drug targets in cytomegalovirus infection. Infect Disord Drug Targets. 2009 Apr;9(2):201-22. DM9KJLZ RU https://pubmed.ncbi.nlm.nih.gov/19275707 DM9KZDO DI DM9KZDO DM9KZDO DN Esterified estrogens DM9KZDO TI TTZAYWL DM9KZDO TN Estrogen receptor (ESR) DM9KZDO MA Modulator DM9KZDO RN Safety and efficacy of low-dose esterified estrogens and methyltestosterone, alone or combined, for the treatment of hot flashes in menopausal women: a randomized, double-blind, placebo-controlled study. Fertil Steril. 2011 Jan;95(1):366-8. DM9KZDO RU https://pubmed.ncbi.nlm.nih.gov/20850731 DM9NJ52 DI DM9NJ52 DM9NJ52 DN Fosinopril DM9NJ52 TI TTL69WB DM9NJ52 TN Angiotensin-converting enzyme (ACE) DM9NJ52 MA Inhibitor DM9NJ52 RN Angiotensin-converting enzyme inhibition and novel cardiovascular risk biomarkers: results from the Trial of Angiotensin Converting Enzyme Inhibition and Novel Cardiovascular Risk Factors (TRAIN) study. Am Heart J. 2009 Feb;157(2):334.e1-8. DM9NJ52 RU https://pubmed.ncbi.nlm.nih.gov/19185642 DM9NSWT DI DM9NSWT DM9NSWT DN Guanethidine DM9NSWT TI TTT04VN DM9NSWT TN Adrenergic neuron (AD neuro) DM9NSWT MA Blocker DM9NSWT RN Characterization of bradykinin-induced endothelium-independent contraction in equine basilar artery. J Vet Pharmacol Ther. 2009 Jun;32(3):264-70. DM9NSWT RU https://pubmed.ncbi.nlm.nih.gov/19646091 DM9O8DT DI DM9O8DT DM9O8DT DN L-tyrosine DM9O8DT TI TTUHP71 DM9O8DT TN Tyrosine 3-monooxygenase (TH) DM9O8DT MA Binder DM9O8DT RN Effect of metals and phenylalanine on the activity of human tryptophan hydroxylase-2: comparison with that on tyrosine hydroxylase activity. Neurosci Lett. 2006 Jul 3;401(3):261-5. DM9O8DT RU https://pubmed.ncbi.nlm.nih.gov/16581181 DM9OZWQ DI DM9OZWQ DM9OZWQ DN Lovastatin DM9OZWQ TI TTPADOQ DM9OZWQ TN HMG-CoA reductase (HMGCR) DM9OZWQ MA Inhibitor DM9OZWQ RN Microarray and biochemical analysis of lovastatin-induced apoptosis of squamous cell carcinomas. Neoplasia. 2002 Jul-Aug;4(4):337-46. DM9OZWQ RU https://pubmed.ncbi.nlm.nih.gov/12082550 DM9PLRH DI DM9PLRH DM9PLRH DN Doxazosin DM9PLRH TI TT34BHT DM9PLRH TN Adrenergic receptor alpha-1D (ADRA1D) DM9PLRH MA Antagonist DM9PLRH RN The role of combination medical therapy in benign prostatic hyperplasia. Int J Impot Res. 2008 Dec;20 Suppl 3:S33-43. DM9PLRH RU https://pubmed.ncbi.nlm.nih.gov/19002123 DM9PVX8 DI DM9PVX8 DM9PVX8 DN Rucaparib DM9PVX8 TI TTEBCY8 DM9PVX8 TN Poly [ADP-ribose] polymerase (PARP) DM9PVX8 MA Modulator DM9PVX8 RN 2016 FDA drug approvals. Nat Rev Drug Discov. 2017 Feb 2;16(2):73-76. DM9PVX8 RU https://www.ncbi.nlm.nih.gov/pubmed/28148938 DM9Q8SO DI DM9Q8SO DM9Q8SO DN Fibrinolysin DM9Q8SO TI TTWODQF DM9Q8SO TN Fibrin (FG) DM9Q8SO MA Modulator DM9Q8SO RN FIBRINOLYSIN, FIBRIN AND HYALINE MEMBRANES. Pediatrics. 1963 Nov;32:940-2. DM9Q8SO RU https://pubmed.ncbi.nlm.nih.gov/14075642 DM9QWAH DI DM9QWAH DM9QWAH DN Ceftolozane/tazobactam DM9QWAH TI TTHI19T DM9QWAH TN Staphylococcus Beta-lactamase (Stap-coc blaZ) DM9QWAH MA Modulator DM9QWAH RN 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81. DM9QWAH RU https://pubmed.ncbi.nlm.nih.gov/25633781 DM9S2JW DI DM9S2JW DM9S2JW DN Aldosterone DM9S2JW TI TTS087L DM9S2JW TN Solute carrier family 12 member 1 (SLC12A1) DM9S2JW MA Blocker DM9S2JW RN Nongenomic effect of aldosterone on ion transport pathways of red blood cells. Cell Physiol Biochem. 2008;22(1-4):269-78. DM9S2JW RU https://pubmed.ncbi.nlm.nih.gov/18769054 DM9S2JW DI DM9S2JW DM9S2JW DN Aldosterone DM9S2JW TI TT26PHO DM9S2JW TN Mineralocorticoid receptor (MR) DM9S2JW MA Agonist DM9S2JW RN Stimulation of testosterone production in rat Leydig cells by aldosterone is mineralocorticoid receptor mediated. Mol Cell Endocrinol. 2005 Nov 24;243(1-2):35-42. DM9S2JW RU https://pubmed.ncbi.nlm.nih.gov/16188378 DM9U4FO DI DM9U4FO DM9U4FO DN Benzonatate DM9U4FO TI TTZOVE0 DM9U4FO TN Voltage-gated sodium channel alpha Nav1.5 (SCN5A) DM9U4FO MA Blocker DM9U4FO RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM9U4FO RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM9UB0P DI DM9UB0P DM9UB0P DN Oxaprozin DM9UB0P TI TTK0943 DM9UB0P TN Prostaglandin G/H synthase (COX) DM9UB0P MA Inhibitor DM9UB0P RN The aryl propionic acid R-flurbiprofen selectively induces p75NTR-dependent decreased survival of prostate tumor cells. Cancer Res. 2007 Apr 1;67(7):3254-62. DM9UB0P RU https://pubmed.ncbi.nlm.nih.gov/17409433 DM9UCJK DI DM9UCJK DM9UCJK DN Doripenem DM9UCJK TI TT4ILYC DM9UCJK TN Bacterial Dihydropteroate synthetase (Bact folP) DM9UCJK MA Inhibitor DM9UCJK RN Emerging drugs for bacterial urinary tract infections. Expert Opin Emerg Drugs. 2005 May;10(2):275-98. DM9UCJK RU https://pubmed.ncbi.nlm.nih.gov/15934867 DM9UTDE DI DM9UTDE DM9UTDE DN Morniflumate DM9UTDE TI TTK0943 DM9UTDE TN Prostaglandin G/H synthase (COX) DM9UTDE MA Modulator DM9UTDE RN Modulation of arachidonic acid metabolism by orally administered morniflumate in man. Agents Actions. 1991 Jul;33(3-4):233-9. DM9UTDE RU https://pubmed.ncbi.nlm.nih.gov/1659152 DM9Y6X7 DI DM9Y6X7 DM9Y6X7 DN Clodronate DM9Y6X7 TI TTU5A6Q DM9Y6X7 TN Adenine nucleotide translocator 1 (SLC25A4) DM9Y6X7 MA Inhibitor DM9Y6X7 RN Further insight into mechanism of action of clodronate: inhibition of mitochondrial ADP/ATP translocase by a nonhydrolyzable, adenine-containing metabolite. Mol Pharmacol. 2002 May;61(5):1255-62. DM9Y6X7 RU https://pubmed.ncbi.nlm.nih.gov/11961144 DM9YSNQ DI DM9YSNQ DM9YSNQ DN Amfepramone DM9YSNQ TI TT3ROYC DM9YSNQ TN Serotonin transporter (SERT) DM9YSNQ MA Inhibitor DM9YSNQ RN Pharmacotherapy for obesity. Drugs. 2005;65(10):1391-418. DM9YSNQ RU https://pubmed.ncbi.nlm.nih.gov/15977970 DM9YSNQ DI DM9YSNQ DM9YSNQ DN Amfepramone DM9YSNQ TI TTAWNKZ DM9YSNQ TN Norepinephrine transporter (NET) DM9YSNQ MA Inhibitor DM9YSNQ RN Pharmacotherapy for obesity. Drugs. 2005;65(10):1391-418. DM9YSNQ RU https://pubmed.ncbi.nlm.nih.gov/15977970 DM9ZMQH DI DM9ZMQH DM9ZMQH DN Clocortolone DM9ZMQH TI TT9V5JH DM9ZMQH TN Phospholipase A2 (PLA2G1B) DM9ZMQH MA Inducer DM9ZMQH RN Clocortolone pivalate: a paired comparison clinical trial of a new topical steroid in eczema/atopic dermatitis. Cutis. 1980 Jan;25(1):96-8. DM9ZMQH RU https://pubmed.ncbi.nlm.nih.gov/6986236 DMA04JS DI DMA04JS DMA04JS DN Antazoline DMA04JS TI TTTIBOJ DMA04JS TN Histamine H1 receptor (H1R) DMA04JS MA Antagonist DMA04JS RN Histamine and the convulsive threshold or effectiveness of antiepileptic drugs. Przegl Lek. 2008;65(11):803-6. DMA04JS RU https://pubmed.ncbi.nlm.nih.gov/19205365 DMA13GD DI DMA13GD DMA13GD DN Cidofovir DMA13GD TI TTIU7X1 DMA13GD TN Herpes simplex virus DNA polymerase UL30 (HSV UL30) DMA13GD MA Modulator DMA13GD RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMA13GD RU https://www.fda.gov/ DMA16BR DI DMA16BR DMA16BR DN Vorapaxar DMA16BR TI TTL935N DMA16BR TN Proteinase activated receptor 1 (F2R) DMA16BR MA Antagonist DMA16BR RN In Process Citation. Pharm Unserer Zeit. 2009;38(4):320-8. DMA16BR RU https://pubmed.ncbi.nlm.nih.gov/19572350 DMA17D0 DI DMA17D0 DMA17D0 DN Dorzolamide DMA17D0 TI TTANPDJ DMA17D0 TN Carbonic anhydrase II (CA-II) DMA17D0 MA Inhibitor DMA17D0 RN Carbonic anhydrase inhibitors. Inhibition studies of a coral secretory isoform by sulfonamides. Bioorg Med Chem. 2009 Jul 15;17(14):5054-8. DMA17D0 RU https://pubmed.ncbi.nlm.nih.gov/19520577 DMA2GHJ DI DMA2GHJ DMA2GHJ DN Tolperisone DMA2GHJ TI TTN9VTF DMA2GHJ TN Voltage-gated sodium channel alpha Nav1.9 (SCN11A) DMA2GHJ MA Modulator DMA2GHJ RN Tolperisone-type drugs inhibit spinal reflexes via blockade of voltage-gated sodium and calcium channels. J Pharmacol Exp Ther. 2005 Dec;315(3):1237-46. DMA2GHJ RU https://pubmed.ncbi.nlm.nih.gov/16126840 DMA2GHJ DI DMA2GHJ DMA2GHJ DN Tolperisone DMA2GHJ TI TTCRJKY DMA2GHJ TN Voltage-gated calcium channel (Cav) DMA2GHJ MA Modulator DMA2GHJ RN Tolperisone-type drugs inhibit spinal reflexes via blockade of voltage-gated sodium and calcium channels. J Pharmacol Exp Ther. 2005 Dec;315(3):1237-46. DMA2GHJ RU https://pubmed.ncbi.nlm.nih.gov/16126840 DMA2Z4F DI DMA2Z4F DMA2Z4F DN Minoxidil DMA2Z4F TI TT1VOHK DMA2Z4F TN Potassium channel unspecific (KC) DMA2Z4F MA Modulator DMA2Z4F RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMA2Z4F RU https://www.fda.gov/ DMA47C6 DI DMA47C6 DMA47C6 DN Rimiterol DMA47C6 TI TTMXGCW DMA47C6 TN Adrenergic receptor beta-3 (ADRB3) DMA47C6 MA Modulator DMA47C6 RN Comparison of the beta2-adrenoceptor selectivity of rimiterol, salbutamol and isoprenaline by the intravenous route in man. Br J Clin Pharmacol. 1975 Feb;2(1):41-8. DMA47C6 RU https://pubmed.ncbi.nlm.nih.gov/10940 DMA4MRX DI DMA4MRX DMA4MRX DN Perphenazine DMA4MRX TI TTEX248 DMA4MRX TN Dopamine D2 receptor (D2R) DMA4MRX MA Antagonist DMA4MRX RN CYP2D6 and DRD2 genes differentially impact pharmacodynamic sensitivity and time course of prolactin response to perphenazine. Pharmacogenet Genomics. 2007 Nov;17(11):989-93. DMA4MRX RU https://pubmed.ncbi.nlm.nih.gov/18075468 DMA5OBU DI DMA5OBU DMA5OBU DN Human neutral insulin DMA5OBU TI TTCBFJO DMA5OBU TN Insulin receptor (INSR) DMA5OBU MA Binder DMA5OBU RN Knockouts model the 100 best-selling drugs--will they model the next 100 Nat Rev Drug Discov. 2003 Jan;2(1):38-51. DMA5OBU RU https://pubmed.ncbi.nlm.nih.gov/12509758 DMA5QPM DI DMA5QPM DMA5QPM DN Zemaira DMA5QPM TI TTA7UJC DMA5QPM TN Alpha-1-antitrypsin (SERPINA1) DMA5QPM MA Inhibitor DMA5QPM RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. DMA5QPM RU https://www.fda.gov/vaccines-blood-biologics/approved-blood-products/zemaira DMA5XGH DI DMA5XGH DMA5XGH DN Isradipine DMA5XGH TI TT5HONZ DMA5XGH TN Calcium channel unspecific (CaC) DMA5XGH MA Modulator DMA5XGH RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMA5XGH RU https://www.fda.gov/ DMA630M DI DMA630M DMA630M DN Vaccinia immune globulin DMA630M TI TTOP3CH DMA630M TN Immunoglobulin unspecific (Ig) DMA630M MA Modulator DMA630M RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DMA630M RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DMA65ER DI DMA65ER DMA65ER DN Nipradilol DMA65ER TI TTMXGCW DMA65ER TN Adrenergic receptor beta-3 (ADRB3) DMA65ER MA Modulator DMA65ER RN Actions of nipradilol (K-351), a new alpha- and beta-adrenoceptor blocker, on the rabbit portal vein. Jpn J Pharmacol. 1984 Aug;35(4):359-69. DMA65ER RU https://pubmed.ncbi.nlm.nih.gov/6150128 DMA6S1D DI DMA6S1D DMA6S1D DN Ropinirole DMA6S1D TI TT4C8EA DMA6S1D TN Dopamine D3 receptor (D3R) DMA6S1D MA Modulator DMA6S1D RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMA6S1D RU https://www.fda.gov/ DMA6S1D DI DMA6S1D DMA6S1D DN Ropinirole DMA6S1D TI TTEX248 DMA6S1D TN Dopamine D2 receptor (D2R) DMA6S1D MA Modulator DMA6S1D RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMA6S1D RU https://www.fda.gov/ DMA7PEW DI DMA7PEW DMA7PEW DN Verapamil DMA7PEW TI TT729IR DMA7PEW TN Voltage-gated calcium channel alpha Cav3.1 (CACNA1G) DMA7PEW MA Blocker DMA7PEW RN Mechanism of tissue-selective drug action in the cardiovascular system. Mol Interv. 2005 Apr;5(2):84-93. DMA7PEW RU https://pubmed.ncbi.nlm.nih.gov/15821157 DMA7QTC DI DMA7QTC DMA7QTC DN Lactoferrin DMA7QTC TI TTM1TDX DMA7QTC TN Tryptase alpha/beta-1 (Tryptase) DMA7QTC MA Inhibitor DMA7QTC RN Inhibitors of tryptase for the treatment of mast cell-mediated diseases. Curr Pharm Des. 1998 Oct;4(5):381-96. DMA7QTC RU https://pubmed.ncbi.nlm.nih.gov/10197050 DMA8DPN DI DMA8DPN DMA8DPN DN Dexchlorpheniramine maleate DMA8DPN TI TTTIBOJ DMA8DPN TN Histamine H1 receptor (H1R) DMA8DPN MA Modulator DMA8DPN RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMA8DPN RU https://www.fda.gov/ DMA8FS5 DI DMA8FS5 DMA8FS5 DN Dronedarone DMA8FS5 TI TTW0CMT DMA8FS5 TN Voltage-gated potassium channel Kv1.5 (KCNA5) DMA8FS5 MA Blocker DMA8FS5 RN New antiarrhythmic agents for atrial fibrillation and atrial flutter. Expert Opin Emerg Drugs. 2005 May;10(2):311-22. DMA8FS5 RU https://pubmed.ncbi.nlm.nih.gov/15934869 DMA8FS5 DI DMA8FS5 DMA8FS5 DN Dronedarone DMA8FS5 TI TT1VOHK DMA8FS5 TN Potassium channel unspecific (KC) DMA8FS5 MA Inhibitor DMA8FS5 RN Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357. DMA8FS5 RU https://pubmed.ncbi.nlm.nih.gov/30728472 DMA8J1G DI DMA8J1G DMA8J1G DN Rifampin DMA8J1G TI TTIJ5EB DMA8J1G TN Bacterial RNA polymerase switch region (Bact RNAP-SR) DMA8J1G MA Inhibitor DMA8J1G RN Bacillus subtilis tolerance of moderate concentrations of rifampin involves the sigma(B)-dependent general and multiple stress response. J Bacteriol. 2002 Jan;184(2):459-67. DMA8J1G RU https://pubmed.ncbi.nlm.nih.gov/11751823 DMA8LM5 DI DMA8LM5 DMA8LM5 DN Cyclopentolate DMA8LM5 TI TTH18TF DMA8LM5 TN Muscarinic acetylcholine receptor M5 (CHRM5) DMA8LM5 MA Antagonist DMA8LM5 RN High spatial resolution studies of muscarinic neuroeffector junctions in mouse isolated vas deferens. Neuroscience. 2009 Sep 15;162(4):1366-76. DMA8LM5 RU https://pubmed.ncbi.nlm.nih.gov/19486927 DMA9DHW DI DMA9DHW DMA9DHW DN Nalfurafine hcl DMA9DHW TI TTKWM86 DMA9DHW TN Opioid receptor mu (MOP) DMA9DHW MA Inhibitor DMA9DHW RN Drug design and synthesis of a novel kappa opioid receptor agonist with an oxabicyclo[2.2.2]octane skeleton and its pharmacology. Bioorg Med Chem Lett. 2010 Jan 1;20(1):121-4. DMA9DHW RU https://pubmed.ncbi.nlm.nih.gov/19962305 DMA9DHW DI DMA9DHW DMA9DHW DN Nalfurafine hcl DMA9DHW TI TTQW87Y DMA9DHW TN Opioid receptor kappa (OPRK1) DMA9DHW MA Inhibitor DMA9DHW RN Drug design and synthesis of a novel kappa opioid receptor agonist with an oxabicyclo[2.2.2]octane skeleton and its pharmacology. Bioorg Med Chem Lett. 2010 Jan 1;20(1):121-4. DMA9DHW RU https://pubmed.ncbi.nlm.nih.gov/19962305 DMA9REV DI DMA9REV DMA9REV DN Elosulfase alfa DMA9REV TI TTT9YPO DMA9REV TN N-acetylgalactosamine 6 sulfatase (GALNS) DMA9REV MA Modulator DMA9REV RN 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81. DMA9REV RU https://pubmed.ncbi.nlm.nih.gov/25633781 DMAB6PM DI DMAB6PM DMAB6PM DN Factor 8 DMAB6PM TI TT1290U DMAB6PM TN Coagulation factor VIII (F8) DMAB6PM MA Modulator DMAB6PM RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2607). DMAB6PM RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2607 DMAB9QE DI DMAB9QE DMAB9QE DN Nivolumab DMAB9QE TI TTNBFWK DMAB9QE TN Programmed cell death protein 1 (PD-1) DMAB9QE MA Modulator DMAB9QE RN 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81. DMAB9QE RU https://pubmed.ncbi.nlm.nih.gov/25633781 DMABVE9 DI DMABVE9 DMABVE9 DN Sulfanilamide DMABVE9 TI TT4ILYC DMABVE9 TN Bacterial Dihydropteroate synthetase (Bact folP) DMABVE9 MA Modulator DMABVE9 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMABVE9 RU https://www.fda.gov/ DMAC130 DI DMAC130 DMAC130 DN Inotuzumab ozogamicin DMAC130 TI TTM6QSK DMAC130 TN B-cell receptor CD22 (CD22) DMAC130 RN Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia. Cancer. 2013 Aug 1;119(15):2728-36. DMAC130 RU https://pubmed.ncbi.nlm.nih.gov/23633004 DMAE6LK DI DMAE6LK DMAE6LK DN Topetecan DMAE6LK TI TTGTQHC DMAE6LK TN DNA topoisomerase I (TOP1) DMAE6LK MA Inhibitor DMAE6LK RN Clinical pipeline report, company report or official report of GlaxoSmithKline (2009). DMAE6LK RU http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf DMAE84F DI DMAE84F DMAE84F DN Alclometasone DMAE84F TI TTJL8VG DMAE84F TN Corticosteroid-binding globulin (SERPINA6) DMAE84F MA Binder DMAE84F RN The anti-inflammatory effects of LY178002 and LY256548. Agents Actions. 1989 Jun;27(3-4):300-2. DMAE84F RU https://pubmed.ncbi.nlm.nih.gov/2508442 DMAF1NB DI DMAF1NB DMAF1NB DN Isocarboxazid DMAF1NB TI TT3WG5C DMAF1NB TN Monoamine oxidase type A (MAO-A) DMAF1NB MA Inhibitor DMAF1NB RN MAOIs in the contemporary treatment of depression. Neuropsychopharmacology. 1995 May;12(3):185-219. DMAF1NB RU https://pubmed.ncbi.nlm.nih.gov/7612154 DMAFBCY DI DMAFBCY DMAFBCY DN Mequitazine DMAFBCY TI TTTIBOJ DMAFBCY TN Histamine H1 receptor (H1R) DMAFBCY MA Antagonist DMAFBCY RN Efficiency of mequitazine in the treatment of allergic rhinitis and chronic urticaria in children. A bibliographic systematic review. Rev Alerg Mex. 2008 Jan-Feb;55(1):3-9. DMAFBCY RU https://pubmed.ncbi.nlm.nih.gov/18697448 DMAGFOD DI DMAGFOD DMAGFOD DN Semaglutide DMAGFOD TI TTVIMDE DMAGFOD TN Glucagon-like peptide 1 receptor (GLP1R) DMAGFOD MA Agonist DMAGFOD RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 249). DMAGFOD RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=249 DMAH70G DI DMAH70G DMAH70G DN Molindone DMAH70G TI TTEX248 DMAH70G TN Dopamine D2 receptor (D2R) DMAH70G MA Binder DMAH70G RN Molindone for schizophrenia and severe mental illness. Cochrane Database Syst Rev. 2007 Jan 24;(1):CD002083. DMAH70G RU https://pubmed.ncbi.nlm.nih.gov/17253473 DMAHEFY DI DMAHEFY DMAHEFY DN Nafarelin DMAHEFY TI TT8R70G DMAHEFY TN Gonadotropin-releasing hormone receptor (GNRHR) DMAHEFY MA Agonist DMAHEFY RN Reversible downregulation of endocrine and germinative testicular function (hormonal castration) in the dog with the GnRH-agonist azagly-nafarelin ... Theriogenology. 2009 Apr 15;71(7):1037-45. DMAHEFY RU https://pubmed.ncbi.nlm.nih.gov/19233456 DMAHJEF DI DMAHJEF DMAHJEF DN Betamethasone DMAHJEF TI TTYRL6O DMAHJEF TN Glucocorticoid receptor (NR3C1) DMAHJEF MA Agonist DMAHJEF RN The cannabinoid CB2 receptor inverse agonist JTE-907 suppresses spontaneous itch-associated responses of NC mice, a model of atopic dermatitis. Eur J Pharmacol. 2006 Aug 7;542(1-3):179-83. DMAHJEF RU https://pubmed.ncbi.nlm.nih.gov/16824511 DMAHMT9 DI DMAHMT9 DMAHMT9 DN Glutathione DMAHMT9 TI TT3C1VN DMAHMT9 TN Enzyme unspecific (Enz) DMAHMT9 MA Modulator DMAHMT9 RN Methionine and cysteine affect glutathione level, glutathione-related enzyme activities and the expression of glutathione S-transferase isozymes in rat hepatocytes. J Nutr. 1997 Nov;127(11):2135-41. DMAHMT9 RU https://pubmed.ncbi.nlm.nih.gov/9372907 DMAHOVJ DI DMAHOVJ DMAHOVJ DN Crizanlizumab DMAHOVJ TI TTE5VG0 DMAHOVJ TN P-selectin (SELP) DMAHOVJ MA Inhibitor DMAHOVJ RN Crizanlizumab: First Approval. Drugs. 2020 Jan;80(1):79-84. DMAHOVJ RU https://pubmed.ncbi.nlm.nih.gov/31933169 DMAHSU0 DI DMAHSU0 DMAHSU0 DN Selexipag DMAHSU0 TI TTOFYT1 DMAHSU0 TN Prostacyclin receptor (PTGIR) DMAHSU0 MA Agonist DMAHSU0 RN Selexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension. Eur Respir J. 2012 Oct;40(4):874-80. DMAHSU0 RU https://pubmed.ncbi.nlm.nih.gov/22362844 DMAHZKR DI DMAHZKR DMAHZKR DN Protokylol Hydrochloride DMAHZKR TI TTR6W5O DMAHZKR TN Adrenergic receptor beta-1 (ADRB1) DMAHZKR MA Modulator DMAHZKR RN N-Aralkyl substitution increases the affinity of adrenergic drugs for the alpha-adrenoceptor in rat liver. DMAHZKR RU https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1668481 DMAI7ZV DI DMAI7ZV DMAI7ZV DN Diltiazem DMAI7ZV TI TTFK1JQ DMAI7ZV TN Voltage-gated calcium channel alpha-2/delta-1 (CACNA2D1) DMAI7ZV MA Blocker DMAI7ZV RN Egr-1, the potential target of calcium channel blockers in cardioprotection with ischemia/reperfusion injury in rats. Cell Physiol Biochem. 2009;24(1-2):17-24. DMAI7ZV RU https://pubmed.ncbi.nlm.nih.gov/19590189 DMAKIDV DI DMAKIDV DMAKIDV DN Dydrogesterone DMAKIDV TI TTUV8G9 DMAKIDV TN Progesterone receptor (PGR) DMAKIDV MA Agonist DMAKIDV RN Dienogest is a selective progesterone receptor agonist in transactivation analysis with potent oral endometrial activity due to its efficient pharm... Steroids. 2008 Feb;73(2):222-31. DMAKIDV RU https://pubmed.ncbi.nlm.nih.gov/18061638 DMAKXW9 DI DMAKXW9 DMAKXW9 DN PLEGRIDY DMAKXW9 TI TT4TZ8J DMAKXW9 TN Interferon-beta (IFNB1) DMAKXW9 MA Modulator DMAKXW9 RN 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81. DMAKXW9 RU https://pubmed.ncbi.nlm.nih.gov/25633781 DMAL4G0 DI DMAL4G0 DMAL4G0 DN Flurazepam DMAL4G0 TI TTPTXIN DMAL4G0 TN Translocator protein (TSPO) DMAL4G0 MA Modulator DMAL4G0 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMAL4G0 RU https://www.fda.gov/ DMALNG0 DI DMALNG0 DMALNG0 DN RHuEPO DMALNG0 TI TTAUX24 DMALNG0 TN Erythropoietin Receptor (EPOR) DMALNG0 MA Stimulator DMALNG0 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1718). DMALNG0 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1718 DMANBR7 DI DMANBR7 DMANBR7 DN L-alanyl-l-glutamine DMANBR7 TI TTI7S12 DMANBR7 TN Glutamine receptor (GluR) DMANBR7 MA Modulator DMANBR7 RN Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. DMANBR7 RU https://pubmed.ncbi.nlm.nih.gov/17309302 DMANBZI DI DMANBZI DMANBZI DN Abiraterone acetate DMANBZI TI TTRA5BZ DMANBZI TN Steroid 17-alpha-monooxygenase (S17AH) DMANBZI MA Modulator DMANBZI RN CYP17A1 inhibitors in castration-resistant prostate cancer.Steroids.2015 Mar;95:80-7. DMANBZI RU https://www.ncbi.nlm.nih.gov/pubmed/25560485 DMANL0D DI DMANL0D DMANL0D DN Latamoxef DMANL0D TI TT85JMW DMANL0D TN Bacterial Penicillin binding protein 3 (Bact mrcA) DMANL0D MA Binder DMANL0D RN Clinical relevance of antibiotic-induced endotoxin release in patients undergoing hepatic resection. World J Surg. 1999 Jan;23(1):75-9. DMANL0D RU https://pubmed.ncbi.nlm.nih.gov/9841767 DMAO80I DI DMAO80I DMAO80I DN Pralatrexate DMAO80I TI TT9SL3Q DMAO80I TN Polypeptide deformylase (PDF) DMAO80I MA Inhibitor DMAO80I RN Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92. DMAO80I RU https://pubmed.ncbi.nlm.nih.gov/20118952 DMAOL2S DI DMAOL2S DMAOL2S DN Voriconazole DMAOL2S TI TTTSOUD DMAOL2S TN Candida Cytochrome P450 51 (Candi ERG11) DMAOL2S MA Modulator DMAOL2S RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMAOL2S RU https://www.fda.gov/ DMAP58Y DI DMAP58Y DMAP58Y DN Peginterferon alfa-2b DMAP58Y TI TTSIUJ9 DMAP58Y TN Interferon-alpha 2 (IFNA2) DMAP58Y MA Modulator DMAP58Y RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMAP58Y RU https://www.fda.gov/ DMAP8MV DI DMAP8MV DMAP8MV DN Iron DMAP8MV TI TTQO71U DMAP8MV TN Hemoglobin (HB) DMAP8MV MA Activator DMAP8MV RN Efficacy and safety of total dose infusion of low molecular weight iron dextran in the treatment of iron deficiency anemia during pregnancy. J Coll Physicians Surg Pak. 2008 Jul;18(7):424-7. DMAP8MV RU https://pubmed.ncbi.nlm.nih.gov/18760066 DMAPV1B DI DMAPV1B DMAPV1B DN Glatiramer acetate DMAPV1B TI TTLCMWF DMAPV1B TN MHC class II antigen DRB1*1 (HLA-DRB1) DMAPV1B MA Binder DMAPV1B RN Mechanism of action of glatiramer acetate in multiple sclerosis and its potential for the development of new applications. Proc Natl Acad Sci U S A. 2004 Oct 5;101 Suppl 2:14593-8. DMAPV1B RU https://pubmed.ncbi.nlm.nih.gov/15371592 DMAQ2LK DI DMAQ2LK DMAQ2LK DN Teicoplanin DMAQ2LK TI TTXT4D5 DMAQ2LK TN Bacterial Cell membrane (Bact CM) DMAQ2LK MA Inhibitor DMAQ2LK RN 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81. DMAQ2LK RU https://pubmed.ncbi.nlm.nih.gov/25633781 DMAQ469 DI DMAQ469 DMAQ469 DN Gonadorelin DMAQ469 TI TT8R70G DMAQ469 TN Gonadotropin-releasing hormone receptor (GNRHR) DMAQ469 MA Agonist DMAQ469 RN Use of cognitive behavior therapy for functional hypothalamic amenorrhea. Ann N Y Acad Sci. 2006 Dec;1092:114-29. DMAQ469 RU https://pubmed.ncbi.nlm.nih.gov/17308138 DMAS02L DI DMAS02L DMAS02L DN Alpha-acetyldigoxin DMAS02L TI TTYHPRQ DMAS02L TN Sodium pump (NaP) DMAS02L MA Modulator DMAS02L RN Medicinal plants in therapy. Bull World Health Organ. 1985;63(6):965-81. DMAS02L RU https://pubmed.ncbi.nlm.nih.gov/3879679 DMASDQ6 DI DMASDQ6 DMASDQ6 DN Brodalumab DMASDQ6 TI TTG0MT6 DMASDQ6 TN Interleukin-17 (IL17) DMASDQ6 MA Modulator DMASDQ6 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMASDQ6 RU https://www.fda.gov/ DMASDQ6 DI DMASDQ6 DMASDQ6 DN Brodalumab DMASDQ6 TI TT69OHW DMASDQ6 TN Interleukin 17 receptor (IL17R) DMASDQ6 MA Antagonist DMASDQ6 RN 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85. DMASDQ6 RU https://pubmed.ncbi.nlm.nih.gov/29348678 DMAT2XH DI DMAT2XH DMAT2XH DN Nabumetone DMAT2XH TI TTVKILB DMAT2XH TN Prostaglandin G/H synthase 2 (COX-2) DMAT2XH MA Inhibitor DMAT2XH RN Renal effects of nabumetone, a COX-2 antagonist: impairment of function in isolated perfused rat kidneys contrasts with preserved renal function in vivo. Exp Nephrol. 2001;9(6):387-96. DMAT2XH RU https://pubmed.ncbi.nlm.nih.gov/11701998 DMAT8CG DI DMAT8CG DMAT8CG DN Goserelin DMAT8CG TI TT0ID4A DMAT8CG TN Leutinizing-hormone-releasing hormone (GNRH1) DMAT8CG MA Activator DMAT8CG RN Long-term effectiveness of adjuvant goserelin in premenopausal women with early breast cancer. J Natl Cancer Inst. 2009 Mar 4;101(5):341-9. DMAT8CG RU https://pubmed.ncbi.nlm.nih.gov/19244174 DMAUHQX DI DMAUHQX DMAUHQX DN Methdilazine DMAUHQX TI TTTIBOJ DMAUHQX TN Histamine H1 receptor (H1R) DMAUHQX MA Antagonist DMAUHQX RN Effect of H1 blockers alone and in combination with morphine to produce antinociception in mice. Neuropharmacology. 1985 Jan;24(1):1-4. DMAUHQX RU https://pubmed.ncbi.nlm.nih.gov/2858829 DMAWJIN DI DMAWJIN DMAWJIN DN Etidronate Disodium DMAWJIN TI TTUDR0C DMAWJIN TN Iron (Fe) DMAWJIN MA Modulator DMAWJIN RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMAWJIN RU https://www.fda.gov/ DMAWJIN DI DMAWJIN DMAWJIN DN Etidronate Disodium DMAWJIN TI TT8X5NO DMAWJIN TN Calcium (Ca) DMAWJIN MA Modulator DMAWJIN RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMAWJIN RU https://www.fda.gov/ DMAWU35 DI DMAWU35 DMAWU35 DN Amtolmetin guacil DMAWU35 TI TTK0943 DMAWU35 TN Prostaglandin G/H synthase (COX) DMAWU35 MA Modulator DMAWU35 RN Gastrointestinal safety of amtolmetin guacyl in comparison with celecoxib in patients with rheumatoid arthritis. Clin Exp Rheumatol. 2005 Nov-Dec;23(6):809-18. DMAWU35 RU https://pubmed.ncbi.nlm.nih.gov/16396699 DMAY7H4 DI DMAY7H4 DMAY7H4 DN Valdecoxib DMAY7H4 TI TTVKILB DMAY7H4 TN Prostaglandin G/H synthase 2 (COX-2) DMAY7H4 MA Inhibitor DMAY7H4 RN Biochemical mechanisms of New Molecular Entities (NMEs) approved by United States FDA during 2001-2004: mechanisms leading to optimal efficacy and ... Curr Top Med Chem. 2006;6(5):461-78. DMAY7H4 RU https://pubmed.ncbi.nlm.nih.gov/16719803 DMAY96V DI DMAY96V DMAY96V DN Methacycline DMAY96V TI TTQ8KVI DMAY96V TN Staphylococcus 30S ribosomal subunit (Stap-coc pbp2) DMAY96V MA Binder DMAY96V RN Tetracyclines and pulmonary inflammation. Endocr Metab Immune Disord Drug Targets. 2007 Dec;7(4):232-6. DMAY96V RU https://pubmed.ncbi.nlm.nih.gov/18220943 DMAYEU1 DI DMAYEU1 DMAYEU1 DN Demecarium bromide DMAYEU1 TI TT1RS9F DMAYEU1 TN Acetylcholinesterase (AChE) DMAYEU1 MA Inhibitor DMAYEU1 RN The effects of topical ocular application of 0.25% demecarium bromide on serum acetylcholinesterase levels in normal dogs. Vet Ophthalmol. 2003 Mar;6(1):23-5. DMAYEU1 RU https://pubmed.ncbi.nlm.nih.gov/12641839 DMAYL0T DI DMAYL0T DMAYL0T DN Phenylbutazone DMAYL0T TI TTVKILB DMAYL0T TN Prostaglandin G/H synthase 2 (COX-2) DMAYL0T MA Inhibitor DMAYL0T RN COX-1 and COX-2 inhibition in horse blood by phenylbutazone, flunixin, carprofen and meloxicam: an in vitro analysis. Pharmacol Res. 2005 Oct;52(4):302-6. DMAYL0T RU https://pubmed.ncbi.nlm.nih.gov/15939622 DMAYX6P DI DMAYX6P DMAYX6P DN Sulfoxone DMAYX6P TI TT915ZD DMAYX6P TN Candida Mannose-6-phosphate isomerase (Candi PMI1) DMAYX6P MA Inhibitor DMAYX6P RN Antifungal Activity of Ag(I) and Zn(II) Complexes of Sulfacetamide Derivatives. Met Based Drugs. 2000;7(1):49-54. DMAYX6P RU https://pubmed.ncbi.nlm.nih.gov/18475922 DMB08GE DI DMB08GE DMB08GE DN Sulfamethoxazole DMB08GE TI TT4ILYC DMB08GE TN Bacterial Dihydropteroate synthetase (Bact folP) DMB08GE MA Inhibitor DMB08GE RN In vitro activities of novel antifolate drug combinations against Plasmodium falciparum and human granulocyte CFUs. Antimicrob Agents Chemother. 1995 Apr;39(4):948-52. DMB08GE RU https://pubmed.ncbi.nlm.nih.gov/7786001 DMB0EUX DI DMB0EUX DMB0EUX DN Gliquidone DMB0EUX TI TTG140O DMB0EUX TN Inward rectifier potassium channel Kir1.2 (KCNJ10) DMB0EUX MA Binder DMB0EUX RN Hydroxyl-substituted sulfonylureas as potent inhibitors of specific [3H]glyburide binding to rat brain synaptosomes. Bioorg Med Chem. 2003 May 1;11(9):2099-113. DMB0EUX RU https://pubmed.ncbi.nlm.nih.gov/12670661 DMB0VY8 DI DMB0VY8 DMB0VY8 DN Pancuronium DMB0VY8 TI TTJSZTB DMB0VY8 TN Nicotinic acetylcholine receptor (nAChR) DMB0VY8 MA Antagonist DMB0VY8 RN Pharmacological characteristics of the inhibition of nondepolarizing neuromuscular blocking agents at human adult muscle nicotinic acetylcholine receptor. Anesthesiology. 2009 Jun;110(6):1244-52. DMB0VY8 RU https://pubmed.ncbi.nlm.nih.gov/19417616 DMB19L8 DI DMB19L8 DMB19L8 DN Trihexyphenidyl DMB19L8 TI TTZ9SOR DMB19L8 TN Muscarinic acetylcholine receptor M1 (CHRM1) DMB19L8 MA Antagonist DMB19L8 RN The role of M1 muscarinic cholinergic receptors in the discriminative stimulus properties of N-desmethylclozapine and the atypical antipsychotic dr... Psychopharmacology (Berl). 2009 Apr;203(2):295-301. DMB19L8 RU https://pubmed.ncbi.nlm.nih.gov/18685832 DMB19L8 DI DMB19L8 DMB19L8 DN Trihexyphenidyl DMB19L8 TI TTMXGCW DMB19L8 TN Adrenergic receptor beta-3 (ADRB3) DMB19L8 MA Agonist DMB19L8 RN Obesity: pathophysiology and clinical management. Curr Med Chem. 2009;16(4):506-21. DMB19L8 RU https://pubmed.ncbi.nlm.nih.gov/19199918 DMB1CZ8 DI DMB1CZ8 DMB1CZ8 DN Guanfacine extended release DMB1CZ8 TI TTQ8AFT DMB1CZ8 TN Adrenergic receptor Alpha-2 (ADRA2) DMB1CZ8 MA Agonist DMB1CZ8 RN Emerging drugs for attention-deficit/hyperactivity disorder. Expert Opin Emerg Drugs. 2007 Sep;12(3):423-34. DMB1CZ8 RU https://pubmed.ncbi.nlm.nih.gov/17874970 DMB1CZ8 DI DMB1CZ8 DMB1CZ8 DN Guanfacine extended release DMB1CZ8 TI TT7QNVC DMB1CZ8 TN Glucose-dependent insulinotropic receptor (GPR119) DMB1CZ8 MA Agonist DMB1CZ8 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 126). DMB1CZ8 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=126 DMB1CZ8 DI DMB1CZ8 DMB1CZ8 DN Guanfacine extended release DMB1CZ8 TI TTNET8J DMB1CZ8 TN G-protein coupled receptor 55 (GPR55) DMB1CZ8 MA Agonist DMB1CZ8 RN The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol. 2007 Dec;152(7):1092-101. DMB1CZ8 RU https://pubmed.ncbi.nlm.nih.gov/17876302 DMB1CZ8 DI DMB1CZ8 DMB1CZ8 DN Guanfacine extended release DMB1CZ8 TI TTMSFAW DMB1CZ8 TN Cannabinoid receptor 2 (CB2) DMB1CZ8 MA Agonist DMB1CZ8 RN Posttraining activation of CB1 cannabinoid receptors in the CA1 region of the dorsal hippocampus impairs object recognition long-term memory. Neurobiol Learn Mem. 2008 Sep;90(2):374-81. DMB1CZ8 RU https://pubmed.ncbi.nlm.nih.gov/18524639 DMB1IU4 DI DMB1IU4 DMB1IU4 DN Lenvatinib DMB1IU4 TI TTUTJGQ DMB1IU4 TN Vascular endothelial growth factor receptor 2 (KDR) DMB1IU4 MA Inhibitor DMB1IU4 RN Emerging drugs for ovarian cancer. Expert Opin Emerg Drugs. 2008 Sep;13(3):523-36. DMB1IU4 RU https://pubmed.ncbi.nlm.nih.gov/18764727 DMB39LO DI DMB39LO DMB39LO DN Metolazone DMB39LO TI TTP362L DMB39LO TN Solute carrier family 12 member 3 (SLC12A3) DMB39LO MA Blocker DMB39LO RN The renal thiazide-sensitive Na-Cl cotransporter as mediator of the aldosterone-escape phenomenon. J Clin Invest. 2001 Jul;108(2):215-22. DMB39LO RU https://pubmed.ncbi.nlm.nih.gov/11457874 DMB3ZSK DI DMB3ZSK DMB3ZSK DN Deslanoside DMB3ZSK TI TTWK8D0 DMB3ZSK TN Sodium pump subunit alpha-1 (ATP1A1) DMB3ZSK MA Binder DMB3ZSK RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMB3ZSK RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMB47TQ DI DMB47TQ DMB47TQ DN Alseroxylon DMB47TQ TI TTNZRI3 DMB47TQ TN Synaptic vesicle amine transporter (SLC18A2) DMB47TQ MA Blocker DMB47TQ RN Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. DMB47TQ RU https://pubmed.ncbi.nlm.nih.gov/17016423 DMB4AVP DI DMB4AVP DMB4AVP DN Pamidronate DMB4AVP TI TTIKWV4 DMB4AVP TN Geranyltranstransferase (FDPS) DMB4AVP MA Inhibitor DMB4AVP RN Detection of nonsterol isoprenoids by HPLC-MS/MS. Anal Biochem. 2008 Dec 1;383(1):18-24. DMB4AVP RU https://pubmed.ncbi.nlm.nih.gov/18782552 DMB4HCT DI DMB4HCT DMB4HCT DN Sparfloxacin DMB4HCT TI TTN6J5F DMB4HCT TN Bacterial DNA gyrase (Bact gyrase) DMB4HCT MA Modulator DMB4HCT RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMB4HCT RU https://www.fda.gov/ DMB4HCT DI DMB4HCT DMB4HCT DN Sparfloxacin DMB4HCT TI TTIXTO3 DMB4HCT TN Staphylococcus Topoisomerase IV (Stap-coc parC) DMB4HCT MA Modulator DMB4HCT RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMB4HCT RU https://www.fda.gov/ DMB4HFI DI DMB4HFI DMB4HFI DN Alkavervir DMB4HFI TI TTNZRI3 DMB4HFI TN Synaptic vesicle amine transporter (SLC18A2) DMB4HFI MA Modulator DMB4HFI RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMB4HFI RU https://www.fda.gov/ DMB4OLE DI DMB4OLE DMB4OLE DN Propofol DMB4OLE TI TTDP1UC DMB4OLE TN Fatty acid amide hydrolase (FAAH) DMB4OLE MA Inhibitor DMB4OLE RN Glutamate- and GABA-based CNS therapeutics. Curr Opin Pharmacol. 2006 Feb;6(1):7-17. DMB4OLE RU https://pubmed.ncbi.nlm.nih.gov/16377242 DMB4SFH DI DMB4SFH DMB4SFH DN Mepyramine DMB4SFH TI TTTIBOJ DMB4SFH TN Histamine H1 receptor (H1R) DMB4SFH MA Antagonist DMB4SFH RN Antinociception induced by central administration of histamine in the formalin test in rats. Indian J Physiol Pharmacol. 2008 Jul-Sep;52(3):249-54. DMB4SFH RU https://pubmed.ncbi.nlm.nih.gov/19552055 DMB6VEG DI DMB6VEG DMB6VEG DN Nelarabine DMB6VEG TI TTUBNVO DMB6VEG TN DNA synthesis (DNA synth) DMB6VEG MA Binder DMB6VEG RN Nelarabine. Drugs. 2008;68(4):439-47. DMB6VEG RU https://pubmed.ncbi.nlm.nih.gov/18318562 DMB8CNL DI DMB8CNL DMB8CNL DN Lindane DMB8CNL TI TTAN6JD DMB8CNL TN Glutamate receptor AMPA (GRIA) DMB8CNL MA Antagonist DMB8CNL RN NMDA-induced seizure intensity is enhanced in COX-2 deficient mice. Neurotoxicology. 2008 Nov;29(6):1114-20. DMB8CNL RU https://pubmed.ncbi.nlm.nih.gov/18834901 DMB8PF3 DI DMB8PF3 DMB8PF3 DN CT-102 DMB8PF3 TI TTI2WET DMB8PF3 TN Platelet-derived growth factor receptor (PDGFR) DMB8PF3 MA Activator DMB8PF3 RN Emerging drugs for diabetic foot ulcers. Expert Opin Emerg Drugs. 2006 Nov;11(4):709-24. DMB8PF3 RU https://pubmed.ncbi.nlm.nih.gov/17064227 DMB920Z DI DMB920Z DMB920Z DN Ceritinib DMB920Z TI TTPMQSO DMB920Z TN ALK tyrosine kinase receptor (ALK) DMB920Z MA Modulator DMB920Z RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7397). DMB920Z RU http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7397 DMBAPFG DI DMBAPFG DMBAPFG DN Brinzolamide DMBAPFG TI TTZHA0O DMBAPFG TN Carbonic anhydrase IV (CA-IV) DMBAPFG MA Modulator DMBAPFG RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMBAPFG RU https://www.fda.gov/ DMBAUED DI DMBAUED DMBAUED DN Anileridine DMBAUED TI TTKWM86 DMBAUED TN Opioid receptor mu (MOP) DMBAUED MA Agonist DMBAUED RN Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. DMBAUED RU https://pubmed.ncbi.nlm.nih.gov/17016423 DMBCM8L DI DMBCM8L DMBCM8L DN Nicergoline DMBCM8L TI TTQ8AFT DMBCM8L TN Adrenergic receptor Alpha-2 (ADRA2) DMBCM8L MA Antagonist DMBCM8L RN Effect of non-selective alpha-adrenergic receptor antagonist nicergoline on the activity of neurons in the ventral lateral thalamic nucleus. Fiziol Zh. 2005;51(4):29-35. DMBCM8L RU https://pubmed.ncbi.nlm.nih.gov/16201147 DMBCYF5 DI DMBCYF5 DMBCYF5 DN Pirmenol DMBCYF5 TI TTRK8B9 DMBCYF5 TN Sodium channel unspecific (NaC) DMBCYF5 MA Modulator DMBCYF5 RN Pirmenol, a new antiarrhythmic drug with potassium- and sodium-channel blocking activity; a voltage-clamp study in rabbit Purkinje fibres. Naunyn Schmiedebergs Arch Pharmacol. 1990 May;341(5):462-71. DMBCYF5 RU https://pubmed.ncbi.nlm.nih.gov/2164163 DMBDAZV DI DMBDAZV DMBDAZV DN Amlodipine DMBDAZV TI TTFK1JQ DMBDAZV TN Voltage-gated calcium channel alpha-2/delta-1 (CACNA2D1) DMBDAZV MA Blocker DMBDAZV RN A first drug combination for the treatment of arterial hypertension with a calcium channel antagonist (amlodipine besylate) and an angiotensin receptor blocker (valsartan): Exforge. Rev Med Liege. 2007 Nov;62(11):688-94. DMBDAZV RU https://pubmed.ncbi.nlm.nih.gov/18217647 DMBDPY0 DI DMBDPY0 DMBDPY0 DN Domperidone DMBDPY0 TI TTEX248 DMBDPY0 TN Dopamine D2 receptor (D2R) DMBDPY0 MA Antagonist DMBDPY0 RN Screening of domperidone in wastewater by high performance liquid chromatography and solid phase extraction methods. Talanta. 2006 Jan 15;68(3):928-31. DMBDPY0 RU https://pubmed.ncbi.nlm.nih.gov/18970411 DMBEP7G DI DMBEP7G DMBEP7G DN Fomivirsen sodium DMBEP7G TI TT4SCBE DMBEP7G TN Cytomegalovirus IE2 region messenger RNA (CMV IE2 mRNA) DMBEP7G MA Modulator DMBEP7G RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMBEP7G RU https://www.fda.gov/ DMBESUA DI DMBESUA DMBESUA DN Tucatinib DMBESUA TI TT6EO5L DMBESUA TN Erbb2 tyrosine kinase receptor (HER2) DMBESUA MA Inhibitor DMBESUA RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020 DMBESUA RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213411s000lbl.pdf DMBEX4O DI DMBEX4O DMBEX4O DN Methylergonovine DMBEX4O TI TTZFYLI DMBEX4O TN Dopamine D1 receptor (D1R) DMBEX4O MA Antagonist DMBEX4O RN Reinforcement in an in vitro analog of appetitive classical conditioning of feeding behavior in Aplysia: blockade by a dopamine antagonist. Learn Mem. 2005 May-Jun;12(3):216-20. DMBEX4O RU https://pubmed.ncbi.nlm.nih.gov/15930499 DMBFE74 DI DMBFE74 DMBFE74 DN Milnacipran DMBFE74 TI TTAWNKZ DMBFE74 TN Norepinephrine transporter (NET) DMBFE74 MA Inhibitor DMBFE74 RN Milnacipran: beyond a role of antidepressant. Clin Neuropharmacol. 2009 Nov-Dec;32(6):355-63. DMBFE74 RU https://pubmed.ncbi.nlm.nih.gov/19620845 DMBFZ6L DI DMBFZ6L DMBFZ6L DN Remdesivir DMBFZ6L TI TTV1095 DMBFZ6L TN COVID-19 RNA-directed RNA polymerase (RdRp) DMBFZ6L MA Inhibitor DMBFZ6L RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020 DMBFZ6L RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/214787Orig1s000lbl.pdf DMBGWPH DI DMBGWPH DMBGWPH DN Medroxyprogesterone DMBGWPH TI TTUV8G9 DMBGWPH TN Progesterone receptor (PGR) DMBGWPH MA Agonist DMBGWPH RN Dienogest is a selective progesterone receptor agonist in transactivation analysis with potent oral endometrial activity due to its efficient pharm... Steroids. 2008 Feb;73(2):222-31. DMBGWPH RU https://pubmed.ncbi.nlm.nih.gov/18061638 DMBGZI3 DI DMBGZI3 DMBGZI3 DN Chlorpromazine DMBGZI3 TI TTEX248 DMBGZI3 TN Dopamine D2 receptor (D2R) DMBGZI3 MA Antagonist DMBGZI3 RN Modulatory role of dopamine D2 receptors and fundamental role of L-type Ca2+ channels in the induction of long-term potentiation in the basolateral... Eur J Pharmacol. 2009 Mar 15;606(1-3):90-3. DMBGZI3 RU https://pubmed.ncbi.nlm.nih.gov/19374860 DMBHMOX DI DMBHMOX DMBHMOX DN Palonosetron DMBHMOX TI TTPC4TU DMBHMOX TN 5-HT 3A receptor (HTR3A) DMBHMOX MA Antagonist DMBHMOX RN Management of postoperative nausea and vomiting: focus on palonosetron. Ther Clin Risk Manag. 2009 Feb;5(1):21-34. DMBHMOX RU https://pubmed.ncbi.nlm.nih.gov/19436621 DMBHO9Y DI DMBHO9Y DMBHO9Y DN Adinazolam DMBHO9Y TI TTPTXIN DMBHO9Y TN Translocator protein (TSPO) DMBHO9Y MA Agonist DMBHO9Y RN Effects of antidepressants and benzodiazepine treatments on the dendritic structure of CA3 pyramidal neurons after chronic stress. Eur J Pharmacol. 1999 Apr 29;371(2-3):113-22. DMBHO9Y RU https://pubmed.ncbi.nlm.nih.gov/10357248 DMBI4JG DI DMBI4JG DMBI4JG DN Isosorbide dinitrate DMBI4JG TI TT6HPVC DMBI4JG TN Guanylate cyclase (GC) DMBI4JG MA Stimulator DMBI4JG RN Nitric oxide and nitric oxide synthase isoforms in the normal, hypertrophic, and failing heart. Mol Cell Biochem. 2010 Jan;333(1-2):191-201. DMBI4JG RU https://pubmed.ncbi.nlm.nih.gov/19618122 DMBI9ZJ DI DMBI9ZJ DMBI9ZJ DN Falecalcitrol DMBI9ZJ TI TTK59TV DMBI9ZJ TN Vitamin D3 receptor (VDR) DMBI9ZJ MA Agonist DMBI9ZJ RN Synthesis and biological evaluations of A-ring isomers of 26,26,26,27,27,27-hexafluoro-1,25-dihydroxyvitamin D3. Bioorg Med Chem. 2000 Aug;8(8):2157-66. DMBI9ZJ RU https://pubmed.ncbi.nlm.nih.gov/11003160 DMBIYNH DI DMBIYNH DMBIYNH DN ETI-204 DMBIYNH TI TTRLPUB DMBIYNH TN Bacillus anthracis Protective antigen (Anthrax PA) DMBIYNH RN Efficacy of ETI-204 monoclonal antibody as an adjunct therapy in a New Zealand white rabbit partial survival model for inhalational anthrax. Antimicrob Agents Chemother. 2015 Apr;59(4):2206-14. DMBIYNH RU https://pubmed.ncbi.nlm.nih.gov/25645849 DMBKX3C DI DMBKX3C DMBKX3C DN VESNARINONE DMBKX3C TI TT06AWU DMBKX3C TN Phosphodiesterase 3A (PDE3A) DMBKX3C MA Inhibitor DMBKX3C RN Design, synthesis and biological evaluation of 6-(benzyloxy)-4-methylquinolin-2(1H)-one derivatives as PDE3 inhibitors. Bioorg Med Chem. 2010 Jan 15;18(2):855-62. DMBKX3C RU https://pubmed.ncbi.nlm.nih.gov/20005117 DMBKX3C DI DMBKX3C DMBKX3C DN VESNARINONE DMBKX3C TI TTQ6VDM DMBKX3C TN Voltage-gated potassium channel Kv11.1 (KCNH2) DMBKX3C MA Inhibitor DMBKX3C RN Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods. Bioorg Med Chem Lett. 2003 Aug 18;13(16):2773-5. DMBKX3C RU https://pubmed.ncbi.nlm.nih.gov/12873512 DMBL79I DI DMBL79I DMBL79I DN Proguanil DMBL79I TI TT9SL3Q DMBL79I TN Polypeptide deformylase (PDF) DMBL79I MA Inhibitor DMBL79I RN Transformation with human dihydrofolate reductase renders malaria parasites insensitive to WR99210 but does not affect the intrinsic activity of proguanil. Proc Natl Acad Sci U S A. 1997 Sep 30;94(20):10931-6. DMBL79I RU https://pubmed.ncbi.nlm.nih.gov/9380737 DMBLX7U DI DMBLX7U DMBLX7U DN Evinacumab DMBLX7U TI TTUO98L DMBLX7U TN Angiopoietin-related protein 3 (ANGPTL3) DMBLX7U MA Inhibitor DMBLX7U RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2021 DMBLX7U RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761181s000lbl.pdf DMBMUWZ DI DMBMUWZ DMBMUWZ DN Emtricitabine DMBMUWZ TI TT84ETX DMBMUWZ TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMBMUWZ MA Modulator DMBMUWZ RN Nat Rev Drug Discov. 2013 Feb;12(2):87-90. DMBMUWZ RU https://pubmed.ncbi.nlm.nih.gov/23370234 DMBNI20 DI DMBNI20 DMBNI20 DN Ulipristal DMBNI20 TI TTUV8G9 DMBNI20 TN Progesterone receptor (PGR) DMBNI20 MA Modulator DMBNI20 RN Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5. DMBNI20 RU https://pubmed.ncbi.nlm.nih.gov/21283092 DMBNKST DI DMBNKST DMBNKST DN Nadroparin calcium DMBNKST TI TTCIHJA DMBNKST TN Coagulation factor Xa (F10) DMBNKST MA Modulator DMBNKST RN Serum zinc concentrations: contamination from laboratory equipment. JPEN J Parenter Enteral Nutr. 1979 May-Jun;3(3):179-81. DMBNKST RU https://pubmed.ncbi.nlm.nih.gov/113585 DMBP5N3 DI DMBP5N3 DMBP5N3 DN Cantharidin DMBP5N3 TI TTFLH0E DMBP5N3 TN Serine/threonine PP1-alpha (PPP1CA) DMBP5N3 MA Inhibitor DMBP5N3 RN Serine-threonine protein phosphatase inhibitors: development of potential therapeutic strategies. J Med Chem. 2002 Mar 14;45(6):1151-75. DMBP5N3 RU https://pubmed.ncbi.nlm.nih.gov/11881984 DMBQEGT DI DMBQEGT DMBQEGT DN Buprenorphine + naloxone DMBQEGT TI TTKWM86 DMBQEGT TN Opioid receptor mu (MOP) DMBQEGT MA Agonist DMBQEGT RN Abstracts of Poster Presentations: CNS Summit 2013: November 14-17, 2013 Boca Raton, Florida. Innov Clin Neurosci. 2013 Nov-Dec; 10(11-12 Suppl B): 1-18. DMBQEGT RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4051412/ DMBR01X DI DMBR01X DMBR01X DN Brilinta DMBR01X TI TTZ1DT0 DMBR01X TN P2Y purinoceptor 12 (P2RY12) DMBR01X MA Antagonist DMBR01X RN Clinical pipeline report, company report or official report of AstraZeneca (2009). DMBR01X RU http://www.astrazeneca.com/_mshost3690701/content/resources/media/investors/AZN-Q2-2009/AZN-Q2-2009-Pipeline.pdf DMBR5Q7 DI DMBR5Q7 DMBR5Q7 DN Rolitetracycline DMBR5Q7 TI TTQ8KVI DMBR5Q7 TN Staphylococcus 30S ribosomal subunit (Stap-coc pbp2) DMBR5Q7 MA Binder DMBR5Q7 RN Reversed-phase high-performance liquid chromatography coupled to ultraviolet and electrospray time-of-flight mass spectrometry on-line detection fo... J Chromatogr A. 2008 Jun 27;1195(1-2):107-16. DMBR5Q7 RU https://pubmed.ncbi.nlm.nih.gov/18501371 DMBS370 DI DMBS370 DMBS370 DN Tofacitinib DMBS370 TI TTT7PJU DMBS370 TN Janus kinase 3 (JAK-3) DMBS370 MA Modulator DMBS370 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DMBS370 RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DMBS632 DI DMBS632 DMBS632 DN Buspirone DMBS632 TI TTSQIFT DMBS632 TN 5-HT 1A receptor (HTR1A) DMBS632 MA Agonist DMBS632 RN Interactions between corticotropin-releasing hormone and serotonin: implications for the aetiology and treatment of anxiety disorders. Handb Exp Pharmacol. 2005;(169):181-204. DMBS632 RU https://pubmed.ncbi.nlm.nih.gov/16594259 DMBSHMF DI DMBSHMF DMBSHMF DN Boceprevir DMBSHMF TI TTHC7JD DMBSHMF TN Hepatitis C virus Serine protease NS3/4A (HCV NS3/4A) DMBSHMF MA Modulator DMBSHMF RN 2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4. DMBSHMF RU https://pubmed.ncbi.nlm.nih.gov/22293555 DMBSK7X DI DMBSK7X DMBSK7X DN Isoflurophate DMBSK7X TI TT1RS9F DMBSK7X TN Acetylcholinesterase (AChE) DMBSK7X MA Inhibitor DMBSK7X RN Rational design of alkylene-linked bis-pyridiniumaldoximes as improved acetylcholinesterase reactivators. Chem Biol. 2003 Jun;10(6):491-502. DMBSK7X RU https://pubmed.ncbi.nlm.nih.gov/12837382 DMBSXI0 DI DMBSXI0 DMBSXI0 DN Dienestrol DMBSXI0 TI TTZAYWL DMBSXI0 TN Estrogen receptor (ESR) DMBSXI0 MA Agonist DMBSXI0 RN Potential use of an estrogen-glucocorticoid receptor chimera as a drug screen for tissue selective estrogenic activity. Bone. 2009 Jan;44(1):102-12. DMBSXI0 RU https://pubmed.ncbi.nlm.nih.gov/18976723 DMBT3AI DI DMBT3AI DMBT3AI DN Belantamab mafodotin DMBT3AI TI TTZ3P4W DMBT3AI TN B-cell maturation protein (TNFRSF17) DMBT3AI RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020 DMBT3AI RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761158s000lbl.pdf DMBT7MI DI DMBT7MI DMBT7MI DN Gentamicine sulfate DMBT7MI TI TTUWYEA DMBT7MI TN Bacterial 50S ribosomal RNA (Bact 50S rRNA) DMBT7MI MA Binder DMBT7MI RN The protein synthesis inhibitors, oxazolidinones and chloramphenicol, cause extensive translational inaccuracy in vivo. J Mol Biol. 2002 Sep 13;322(2):273-9. DMBT7MI RU https://pubmed.ncbi.nlm.nih.gov/12217690 DMBUH26 DI DMBUH26 DMBUH26 DN Rituximab DMBUH26 TI TTUE541 DMBUH26 TN Leukocyte surface antigen Leu-16 (CD20) DMBUH26 RN [Contribution of radioimmunotherapy to the treatment of lymphoma]. Ann Pharm Fr. 2008 Nov-Dec;66(5-6):300-8. DMBUH26 RU https://pubmed.ncbi.nlm.nih.gov/19061730 DMBUNVW DI DMBUNVW DMBUNVW DN Prednicarbate DMBUNVW TI TTP3UTW DMBUNVW TN Steroid hormone receptor ERR (ESRR) DMBUNVW MA Modulator DMBUNVW RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMBUNVW RU https://www.fda.gov/ DMBVEC7 DI DMBVEC7 DMBVEC7 DN Dextrothyroxine Sodium DMBVEC7 TI TTTSEPU DMBVEC7 TN Thyroid hormone receptor alpha (THRA) DMBVEC7 MA Modulator DMBVEC7 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMBVEC7 RU https://www.fda.gov/ DMBVEC7 DI DMBVEC7 DMBVEC7 DN Dextrothyroxine Sodium DMBVEC7 TI TTGER3L DMBVEC7 TN Thyroid hormone receptor beta (THRB) DMBVEC7 MA Modulator DMBVEC7 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMBVEC7 RU https://www.fda.gov/ DMBW7VH DI DMBW7VH DMBW7VH DN Methyprylon DMBW7VH TI TT1MPAY DMBW7VH TN GABA(A) receptor alpha-1 (GABRA1) DMBW7VH MA Antagonist DMBW7VH RN DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6. DMBW7VH RU https://pubmed.ncbi.nlm.nih.gov/18048412 DMBXVMZ DI DMBXVMZ DMBXVMZ DN Dihydroartemisinin DMBXVMZ TI TTZVSJ2 DMBXVMZ TN Sarcoplasmic/endoplasmic reticulum calcium ATPase (ATP2A) DMBXVMZ MA Inhibitor DMBXVMZ RN The fight against drug-resistant malaria: novel plasmodial targets and antimalarial drugs. Curr Med Chem. 2008;15(2):161-71. DMBXVMZ RU https://pubmed.ncbi.nlm.nih.gov/18220771 DMBXWU8 DI DMBXWU8 DMBXWU8 DN Aprindine DMBXWU8 TI TTV3NH6 DMBXWU8 TN Calmodulin (CALM) DMBXWU8 MA Inhibitor DMBXWU8 RN Aprindine inhibits calmodulin-stimulated phosphodiesterase and Ca-ATPase activities. J Cardiovasc Pharmacol. 1983 Jan-Feb;5(1):151-6. DMBXWU8 RU https://pubmed.ncbi.nlm.nih.gov/6186851 DMBYCU0 DI DMBYCU0 DMBYCU0 DN Metyrosine DMBYCU0 TI TTUHP71 DMBYCU0 TN Tyrosine 3-monooxygenase (TH) DMBYCU0 MA Binder DMBYCU0 RN Dopamine beta-hydroxylase deficiency. A genetic disorder of cardiovascular regulation. Hypertension. 1991 Jul;18(1):1-8. DMBYCU0 RU https://pubmed.ncbi.nlm.nih.gov/1677640 DMBYNW0 DI DMBYNW0 DMBYNW0 DN MK-3475 DMBYNW0 TI TTNBFWK DMBYNW0 TN Programmed cell death protein 1 (PD-1) DMBYNW0 RN 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81. DMBYNW0 RU https://pubmed.ncbi.nlm.nih.gov/25633781 DMBZIVP DI DMBZIVP DMBZIVP DN Tubocurarine DMBZIVP TI TTF4E0J DMBZIVP TN Neuronal acetylcholine receptor alpha-2 (CHRNA2) DMBZIVP MA Antagonist DMBZIVP RN Pharmacological characteristics of the inhibition of nondepolarizing neuromuscular blocking agents at human adult muscle nicotinic acetylcholine receptor. Anesthesiology. 2009 Jun;110(6):1244-52. DMBZIVP RU https://pubmed.ncbi.nlm.nih.gov/19417616 DMBZWQL DI DMBZWQL DMBZWQL DN Clemastine DMBZWQL TI TTTIBOJ DMBZWQL TN Histamine H1 receptor (H1R) DMBZWQL MA Antagonist DMBZWQL RN Histamine upregulates keratinocyte MMP-9 production via the histamine H1 receptor. J Invest Dermatol. 2008 Dec;128(12):2783-91. DMBZWQL RU https://pubmed.ncbi.nlm.nih.gov/18548114 DMC0GSJ DI DMC0GSJ DMC0GSJ DN Efavirenz DMC0GSJ TI TT84ETX DMC0GSJ TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMC0GSJ MA Modulator DMC0GSJ RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMC0GSJ RU https://www.fda.gov/ DMC128O DI DMC128O DMC128O DN Anileridine Hydrochloride DMC128O TI TTKWM86 DMC128O TN Opioid receptor mu (MOP) DMC128O MA Modulator DMC128O RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMC128O RU https://www.fda.gov/ DMC1NBW DI DMC1NBW DMC1NBW DN Thiazolidinedione DMC1NBW TI TTZMAO3 DMC1NBW TN Peroxisome proliferator-activated receptor gamma (PPAR-gamma) DMC1NBW MA Agonist DMC1NBW RN Functional PPAR-gamma receptor is a novel therapeutic target for ACTH-secreting pituitary adenomas. Nat Med. 2002 Nov;8(11):1281-7. DMC1NBW RU https://pubmed.ncbi.nlm.nih.gov/12379847 DMC3JST DI DMC3JST DMC3JST DN Clorazepate DMC3JST TI TTPTXIN DMC3JST TN Translocator protein (TSPO) DMC3JST MA Modulator DMC3JST RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMC3JST RU https://www.fda.gov/ DMC3YUA DI DMC3YUA DMC3YUA DN Benzbromarone DMC3YUA TI TTOI92F DMC3YUA TN Multidrug resistance-associated protein 1 (ABCC1) DMC3YUA MA Stimulator DMC3YUA RN Transport of diclofenac by breast cancer resistance protein (ABCG2) and stimulation of multidrug resistance protein 2 (ABCC2)-mediated drug transpo... Drug Metab Dispos. 2009 Jan;37(1):129-36. DMC3YUA RU https://pubmed.ncbi.nlm.nih.gov/18845662 DMC3YUA DI DMC3YUA DMC3YUA DN Benzbromarone DMC3YUA TI TTOJI4S DMC3YUA TN Calcium-dependent chloride channel anoctamin (ANO) DMC3YUA MA Antagonist DMC3YUA RN Anoctamin Channels in Human Myometrium: A Novel Target for Tocolysis.Reprod Sci. 2018 Nov;25(11):1589-1600. DMC3YUA RU https://pubmed.ncbi.nlm.nih.gov/29471754 DMC4GEI DI DMC4GEI DMC4GEI DN Ospemifene DMC4GEI TI TTZAYWL DMC4GEI TN Estrogen receptor (ESR) DMC4GEI MA Modulator DMC4GEI RN Clinical pipeline report, company report or official report of Shionogi (2011). DMC4GEI RU http://www.shionogi.co.jp/index_e.html DMC50ME DI DMC50ME DMC50ME DN Debrisoquin DMC50ME TI TTT04VN DMC50ME TN Adrenergic neuron (AD neuro) DMC50ME MA Blocker DMC50ME RN Guanethidine and related agents. 3. Antagonism by drugs which inhibit the norepinephrine pump in man. J Clin Invest. 1970 Aug;49(8):1596-604. DMC50ME RU https://pubmed.ncbi.nlm.nih.gov/5431666 DMC5AST DI DMC5AST DMC5AST DN Butabarbital DMC5AST TI TT1MPAY DMC5AST TN GABA(A) receptor alpha-1 (GABRA1) DMC5AST MA Antagonist DMC5AST RN DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6. DMC5AST RU https://pubmed.ncbi.nlm.nih.gov/18048412 DMC7XDN DI DMC7XDN DMC7XDN DN Alprazolam DMC7XDN TI TTPTXIN DMC7XDN TN Translocator protein (TSPO) DMC7XDN MA Agonist DMC7XDN RN Comparison of five benzodiazepine-receptor agonists on buprenorphine-induced mu-opioid receptor regulation. J Pharmacol Sci. 2009 May;110(1):36-46. DMC7XDN RU https://pubmed.ncbi.nlm.nih.gov/19443999 DMC8VNH DI DMC8VNH DMC8VNH DN Flufenamic Acid DMC8VNH TI TTS64P2 DMC8VNH TN Androgen receptor (AR) DMC8VNH MA Inhibitor DMC8VNH RN Ouellet M, Percival MD: Effect of inhibitor time-dependency on selectivity towards cyclooxygenase isoforms. Biochem J. 1995 Feb 15;306 ( Pt 1):247-51. DMC8VNH RU https://pubmed.ncbi.nlm.nih.gov/7864817 DMC8VNH DI DMC8VNH DMC8VNH DN Flufenamic Acid DMC8VNH TI TTVKILB DMC8VNH TN Prostaglandin G/H synthase 2 (COX-2) DMC8VNH MA Inhibitor DMC8VNH RN Ouellet M, Percival MD: Effect of inhibitor time-dependency on selectivity towards cyclooxygenase isoforms. Biochem J. 1995 Feb 15;306 ( Pt 1):247-51. DMC8VNH RU https://pubmed.ncbi.nlm.nih.gov/7864817 DMC8VNH DI DMC8VNH DMC8VNH DN Flufenamic Acid DMC8VNH TI TT8NGED DMC8VNH TN Prostaglandin G/H synthase 1 (COX-1) DMC8VNH MA Inhibitor DMC8VNH RN Ouellet M, Percival MD: Effect of inhibitor time-dependency on selectivity towards cyclooxygenase isoforms. Biochem J. 1995 Feb 15;306 ( Pt 1):247-51. DMC8VNH RU https://pubmed.ncbi.nlm.nih.gov/7864817 DMC8VNH DI DMC8VNH DMC8VNH DN Flufenamic Acid DMC8VNH TI TT5ZWB6 DMC8VNH TN Dihydrodiol dehydrogenase type I (AKR1C3) DMC8VNH MA Inhibitor DMC8VNH RN Ouellet M, Percival MD: Effect of inhibitor time-dependency on selectivity towards cyclooxygenase isoforms. Biochem J. 1995 Feb 15;306 ( Pt 1):247-51. DMC8VNH RU https://pubmed.ncbi.nlm.nih.gov/7864817 DMC9O43 DI DMC9O43 DMC9O43 DN Sevoflurane DMC9O43 TI TTAN6JD DMC9O43 TN Glutamate receptor AMPA (GRIA) DMC9O43 MA Antagonist DMC9O43 RN Effects of sevoflurane on carrageenan- and fentanyl-induced pain hypersensitivity in Sprague-Dawley rats. Can J Anaesth. 2009 Feb;56(2):126-35. DMC9O43 RU https://pubmed.ncbi.nlm.nih.gov/19247760 DMCA9QP DI DMCA9QP DMCA9QP DN Papaverine DMCA9QP TI TTJ0IQB DMCA9QP TN Phosphodiesterase 5A (PDE5A) DMCA9QP MA Inhibitor DMCA9QP RN Effects of icariin on cGMP-specific PDE5 and cAMP-specific PDE4 activities. Asian J Androl. 2003 Mar;5(1):15-8. DMCA9QP RU https://pubmed.ncbi.nlm.nih.gov/12646997 DMCA9QP DI DMCA9QP DMCA9QP DN Papaverine DMCA9QP TI TTSKMI8 DMCA9QP TN Phosphodiesterase 4D (PDE4D) DMCA9QP MA Inhibitor DMCA9QP RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMCA9QP RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMCBJSR DI DMCBJSR DMCBJSR DN Sunitinib DMCBJSR TI TTUTJGQ DMCBJSR TN Vascular endothelial growth factor receptor 2 (KDR) DMCBJSR MA Modulator DMCBJSR RN 2006 drug approvals: finding the niche. Nat Rev Drug Discov. 2007 Feb;6(2):99-101. DMCBJSR RU https://pubmed.ncbi.nlm.nih.gov/17342860 DMCD9YG DI DMCD9YG DMCD9YG DN Prazosin DMCD9YG TI TTG28O6 DMCD9YG TN Adrenergic receptor Alpha-1 (ADRA1) DMCD9YG MA Antagonist DMCD9YG RN Adventitia removal does not modify the alphaID-adrenoceptors response in aorta during hypertension and ageing. Auton Autacoid Pharmacol. 2009 Jul;29(3):117-33. DMCD9YG RU https://pubmed.ncbi.nlm.nih.gov/19566752 DMCDYW7 DI DMCDYW7 DMCDYW7 DN Nicardipine DMCDYW7 TI TT5HONZ DMCDYW7 TN Calcium channel unspecific (CaC) DMCDYW7 MA Blocker DMCDYW7 RN Effect of intracoronary nicardipine on cardiac enzymes after elective percutaneous coronary intervention. Clin Cardiol. 2009 Jun;32(6):315-20. DMCDYW7 RU https://pubmed.ncbi.nlm.nih.gov/19569065 DMCEUJD DI DMCEUJD DMCEUJD DN Clorgyline DMCEUJD TI TT3WG5C DMCEUJD TN Monoamine oxidase type A (MAO-A) DMCEUJD MA Inhibitor DMCEUJD RN Further investigation into the mechanism of tachykinin NK(2) receptor-triggered serotonin release from guinea-pig proximal colon. J Pharmacol Sci. 2009 May;110(1):122-6. DMCEUJD RU https://pubmed.ncbi.nlm.nih.gov/19423952 DMCEUJD DI DMCEUJD DMCEUJD DN Clorgyline DMCEUJD TI TT32XQJ DMCEUJD TN Monoamine oxidase (MAO) DMCEUJD MA Inhibitor DMCEUJD RN Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110. DMCEUJD RU https://www.ncbi.nlm.nih.gov/pubmed/25399762 DMCEW64 DI DMCEW64 DMCEW64 DN Ceftriaxone DMCEW64 TI TTJP4SM DMCEW64 TN Bacterial Penicillin binding protein (Bact PBP) DMCEW64 MA Modulator DMCEW64 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMCEW64 RU https://www.fda.gov/ DMCEZ1B DI DMCEZ1B DMCEZ1B DN Cotinine DMCEZ1B TI TTJSZTB DMCEZ1B TN Nicotinic acetylcholine receptor (nAChR) DMCEZ1B MA Modulator DMCEZ1B RN Functional versus chemical diversity: is biodiversity important for drug discovery. Trends Pharmacol Sci. 2002 May;23(5):225-31. DMCEZ1B RU https://pubmed.ncbi.nlm.nih.gov/12008000 DMCFE9I DI DMCFE9I DMCFE9I DN Valproate DMCFE9I TI TTRZQE3 DMCFE9I TN Glycogen synthase kinase-3 alpha (GSK-3A) DMCFE9I MA Inhibitor DMCFE9I RN Challenges and new opportunities in the investigation of new drug therapies to treat frontotemporal dementia. Expert Opin Ther Targets. 2008 Nov;12(11):1367-76. DMCFE9I RU https://pubmed.ncbi.nlm.nih.gov/18851693 DMCFE9I DI DMCFE9I DMCFE9I DN Valproate DMCFE9I TI TTBH0VX DMCFE9I TN Histone deacetylase (HDAC) DMCFE9I MA Inhibitor DMCFE9I RN Transcription-independent heritability of induced histone modifications in the mouse preimplantation embryo. PLoS One. 2009 Jun 30;4(6):e6086. DMCFE9I RU https://pubmed.ncbi.nlm.nih.gov/19564914 DMCH7RU DI DMCH7RU DMCH7RU DN Pheniramine DMCH7RU TI TTTIBOJ DMCH7RU TN Histamine H1 receptor (H1R) DMCH7RU MA Antagonist DMCH7RU RN Role of central histaminergic system in lorazepam withdrawal syndrome in rats. Pharmacol Biochem Behav. 2001 Apr;68(4):777-82. DMCH7RU RU https://pubmed.ncbi.nlm.nih.gov/11526976 DMCH80F DI DMCH80F DMCH80F DN Polythiazide DMCH80F TI TTP362L DMCH80F TN Solute carrier family 12 member 3 (SLC12A3) DMCH80F MA Blocker DMCH80F RN The renal thiazide-sensitive Na-Cl cotransporter as mediator of the aldosterone-escape phenomenon. J Clin Invest. 2001 Jul;108(2):215-22. DMCH80F RU https://pubmed.ncbi.nlm.nih.gov/11457874 DMCHV4I DI DMCHV4I DMCHV4I DN Rifapentine DMCHV4I TI TTHKJLN DMCHV4I TN DNA-directed RNA polymerase (RNAP) DMCHV4I MA Binder DMCHV4I RN Contribution of rpoB mutations to development of rifamycin cross-resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother. 1998 Jul;42(7):1853-7. DMCHV4I RU https://pubmed.ncbi.nlm.nih.gov/9661035 DMCIJBH DI DMCIJBH DMCIJBH DN DU-176B DMCIJBH TI TTCIHJA DMCIJBH TN Coagulation factor Xa (F10) DMCIJBH MA Modulator DMCIJBH RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2359). DMCIJBH RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2359 DMCJN1P DI DMCJN1P DMCJN1P DN Plerixafor DMCJN1P TI TTBID49 DMCJN1P TN C-X-C chemokine receptor type 4 (CXCR4) DMCJN1P MA Antagonist DMCJN1P RN Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127. DMCJN1P RU https://pubmed.ncbi.nlm.nih.gov/19249983 DMCKL5V DI DMCKL5V DMCKL5V DN Efalizumab DMCKL5V TI TT48WR6 DMCKL5V TN Integrin alpha-L (ITGAL) DMCKL5V RN [Successful therapy of discoid lupus erythematosus with efalizumab]. Hautarzt. 2010 Mar;61(3):246-9. DMCKL5V RU https://pubmed.ncbi.nlm.nih.gov/19436973 DMCKPUR DI DMCKPUR DMCKPUR DN Alfaferone DMCKPUR TI TT95SOA DMCKPUR TN Interferon alpha (IFNA) DMCKPUR MA Modulator DMCKPUR RN Natural leukocyte interferon alpha (Alfaferone) combined with ribavirin in the treatment of patients with HCV-related cirrhosis: our experience. Infection. 2011 Oct;39(5):433-7. DMCKPUR RU https://pubmed.ncbi.nlm.nih.gov/21739360 DMCKYZ5 DI DMCKYZ5 DMCKYZ5 DN Clenbuterol DMCKYZ5 TI TT2CJVK DMCKYZ5 TN Adrenergic receptor beta-2 (ADRB2) DMCKYZ5 MA Agonist DMCKYZ5 RN Postischemic brain injury is attenuated in mice lacking the beta2-adrenergic receptor. Anesth Analg. 2009 Jan;108(1):280-7. DMCKYZ5 RU https://pubmed.ncbi.nlm.nih.gov/19095863 DMCL2OK DI DMCL2OK DMCL2OK DN Disulfiram DMCL2OK TI TTB6UM0 DMCL2OK TN Fatty aldehyde dehydrogenase (ALDH3A2) DMCL2OK MA Inhibitor DMCL2OK RN Pharmacological treatment of alcohol dependence: target symptoms and target mechanisms. Pharmacol Ther. 2006 Sep;111(3):855-76. DMCL2OK RU https://pubmed.ncbi.nlm.nih.gov/16545872 DMCLHO0 DI DMCLHO0 DMCLHO0 DN Bethanechol DMCLHO0 TI TTH18TF DMCLHO0 TN Muscarinic acetylcholine receptor M5 (CHRM5) DMCLHO0 MA Agonist DMCLHO0 RN Loss of Ca-mediated ion transport during colitis correlates with reduced ion transport responses to a Ca-activated K channel opener. Br J Pharmacol. 2009 Apr;156(7):1085-97. DMCLHO0 RU https://pubmed.ncbi.nlm.nih.gov/19298254 DMCLR6G DI DMCLR6G DMCLR6G DN Pegloticase DMCLR6G TI TTZ1SWF DMCLR6G TN Uric acid (URA) DMCLR6G MA Modulator DMCLR6G RN Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5. DMCLR6G RU https://pubmed.ncbi.nlm.nih.gov/21283092 DMCMBHA DI DMCMBHA DMCMBHA DN Erlotinib DMCMBHA TI TTGKNB4 DMCMBHA TN Epidermal growth factor receptor (EGFR) DMCMBHA MA Inhibitor DMCMBHA RN Quantitative prediction of fold resistance for inhibitors of EGFR. Biochemistry. 2009 Sep 8;48(35):8435-48. DMCMBHA RU https://pubmed.ncbi.nlm.nih.gov/19627157 DMCME17 DI DMCME17 DMCME17 DN Lisuride DMCME17 TI TTEX248 DMCME17 TN Dopamine D2 receptor (D2R) DMCME17 MA Agonist DMCME17 RN Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease. Lancet Neurol. 2007 Sep;6(9):826-9. DMCME17 RU https://pubmed.ncbi.nlm.nih.gov/17706566 DMCMETN DI DMCMETN DMCMETN DN MLN9708 DMCMETN TI TTU7ZMG DMCMETN TN Proteasome (PS) DMCMETN MA Modulator DMCMETN RN Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer. Cancer Res. 2010 Mar 1;70(5):1970-80. DMCMETN RU https://pubmed.ncbi.nlm.nih.gov/20160034 DMCN61Z DI DMCN61Z DMCN61Z DN Interferon beta-1b DMCN61Z TI TTMQB37 DMCN61Z TN Interferon alpha/beta receptor 2 (IFNAR2) DMCN61Z MA Binder DMCN61Z RN Interferon-beta(1b) Treatment in Neuromyelitis Optica. Eur Neurol. 2009 Jul 7;62(3):167-170. DMCN61Z RU https://pubmed.ncbi.nlm.nih.gov/19590215 DMCO5JZ DI DMCO5JZ DMCO5JZ DN SR141716A DMCO5JZ TI TT6OEDT DMCO5JZ TN Cannabinoid receptor 1 (CB1) DMCO5JZ MA Antagonist DMCO5JZ RN Anti-obesity drugs. Expert Opin Pharmacother. 2008 Jun;9(8):1339-50. DMCO5JZ RU https://pubmed.ncbi.nlm.nih.gov/18473708 DMCOAVT DI DMCOAVT DMCOAVT DN Emepronium DMCOAVT TI TTH18TF DMCOAVT TN Muscarinic acetylcholine receptor M5 (CHRM5) DMCOAVT MA Modulator DMCOAVT RN Classification of the presynaptic muscarinic receptor subtype that regulates 3H-acetylcholine secretion in the guinea pig urinary bladder in vitro. J Pharmacol Exp Ther. 1995 Jul;274(1):458-68. DMCOAVT RU https://pubmed.ncbi.nlm.nih.gov/7616431 DMCOLUP DI DMCOLUP DMCOLUP DN Levallorphan DMCOLUP TI TTF4E0J DMCOLUP TN Neuronal acetylcholine receptor alpha-2 (CHRNA2) DMCOLUP MA Antagonist DMCOLUP RN Synergy between pairs of competitive antagonists at adult human muscle acetylcholine receptors. Anesth Analg. 2008 Aug;107(2):525-33. DMCOLUP RU https://pubmed.ncbi.nlm.nih.gov/18633030 DMCOZJY DI DMCOZJY DMCOZJY DN Tenapanor DMCOZJY TI TTFZVPO DMCOZJY TN Sodium/hydrogen exchanger 3 (SLC9A3) DMCOZJY MA Modulator DMCOZJY RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019 DMCOZJY RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211801s000lbl.pdf DMCR1MV DI DMCR1MV DMCR1MV DN Itraconazole DMCR1MV TI TTTSOUD DMCR1MV TN Candida Cytochrome P450 51 (Candi ERG11) DMCR1MV MA Modulator DMCR1MV RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMCR1MV RU https://www.fda.gov/ DMCR1MV DI DMCR1MV DMCR1MV DN Itraconazole DMCR1MV TI TT4LXBC DMCR1MV TN Hedgehog signaling pathway (HS pathway) DMCR1MV MA Inhibitor DMCR1MV RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMCR1MV RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMCRQHB DI DMCRQHB DMCRQHB DN Edrophonium DMCRQHB TI TT1RS9F DMCRQHB TN Acetylcholinesterase (AChE) DMCRQHB MA Inhibitor DMCRQHB RN Screening of acetylcholinesterase inhibitors by CE after enzymatic reaction at capillary inlet. J Sep Sci. 2009 May;32(10):1748-56. DMCRQHB RU https://pubmed.ncbi.nlm.nih.gov/19472276 DMCS6M5 DI DMCS6M5 DMCS6M5 DN Voxelotor DMCS6M5 TI TTQO71U DMCS6M5 TN Hemoglobin (HB) DMCS6M5 MA Modulator DMCS6M5 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019 DMCS6M5 RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/213137s000lbl.pdf DMCSLZ4 DI DMCSLZ4 DMCSLZ4 DN Sodium zirconium cyclosilicate DMCSLZ4 TI TTB0SC6 DMCSLZ4 TN Potassium (K) DMCSLZ4 MA Binder DMCSLZ4 RN 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. DMCSLZ4 RU https://pubmed.ncbi.nlm.nih.gov/30710142 DMCT31R DI DMCT31R DMCT31R DN Carbinoxamine DMCT31R TI TTTIBOJ DMCT31R TN Histamine H1 receptor (H1R) DMCT31R MA Antagonist DMCT31R RN Comparison of the effects of eleven histamine H1-receptor antagonists on monoamine turnover in the mouse brain. Naunyn Schmiedebergs Arch Pharmacol. 1994 Feb;349(2):140-4. DMCT31R RU https://pubmed.ncbi.nlm.nih.gov/7513381 DMCT3I8 DI DMCT3I8 DMCT3I8 DN Ifosfamide DMCT3I8 TI TTUTN1I DMCT3I8 TN Human Deoxyribonucleic acid (hDNA) DMCT3I8 MA Modulator DMCT3I8 RN Pharmacokinetics and metabolism of ifosfamide in relation to DNA damage assessed by the COMET assay in children with cancer. Br J Cancer. 2005 May 9;92(9):1626-35. DMCT3I8 RU https://www.ncbi.nlm.nih.gov/pubmed/15827549 DMCTE9R DI DMCTE9R DMCTE9R DN Mexiletine DMCTE9R TI TTZOVE0 DMCTE9R TN Voltage-gated sodium channel alpha Nav1.5 (SCN5A) DMCTE9R MA Blocker DMCTE9R RN Effect of sodium channel blockers on ST segment, QRS duration, and corrected QT interval in patients with Brugada syndrome. J Cardiovasc Electrophysiol. 2000 Dec;11(12):1320-9. DMCTE9R RU https://pubmed.ncbi.nlm.nih.gov/11196553 DMCUT21 DI DMCUT21 DMCUT21 DN Ursodeoxycholic acid DMCUT21 TI TTOP832 DMCUT21 TN Solute carrier family 23 member 2 (SLC23A2) DMCUT21 MA Activator DMCUT21 RN Role of vitamin C transporters and biliverdin reductase in the dual pro-oxidant and anti-oxidant effect of biliary compounds on the placental-fetal... Toxicol Appl Pharmacol. 2008 Oct 15;232(2):327-36. DMCUT21 RU https://pubmed.ncbi.nlm.nih.gov/18706437 DMCUT21 DI DMCUT21 DMCUT21 DN Ursodeoxycholic acid DMCUT21 TI TTJBPN3 DMCUT21 TN Biliverdin reductase A (BLVRA) DMCUT21 MA Activator DMCUT21 RN Role of vitamin C transporters and biliverdin reductase in the dual pro-oxidant and anti-oxidant effect of biliary compounds on the placental-fetal... Toxicol Appl Pharmacol. 2008 Oct 15;232(2):327-36. DMCUT21 RU https://pubmed.ncbi.nlm.nih.gov/18706437 DMCV109 DI DMCV109 DMCV109 DN Etanercept DMCV109 TI TTF8CQI DMCV109 TN Tumor necrosis factor (TNF) DMCV109 MA Modulator DMCV109 RN The potential of biologics for the treatment of asthma. Nat Rev Drug Discov. 2012 Dec;11(12):958-72. DMCV109 RU https://www.ncbi.nlm.nih.gov/pubmed/23197041 DMCVJ86 DI DMCVJ86 DMCVJ86 DN Clofarabine DMCVJ86 TI TTX09M4 DMCVJ86 TN Ribonucleotide reductase (RIR) DMCVJ86 MA Inhibitor DMCVJ86 RN Clofarabine: past, present, and future. Leuk Lymphoma. 2007 Oct;48(10):1922-30. DMCVJ86 RU https://pubmed.ncbi.nlm.nih.gov/17852710 DMCVJ86 DI DMCVJ86 DMCVJ86 DN Clofarabine DMCVJ86 TI TTJP4SM DMCVJ86 TN Bacterial Penicillin binding protein (Bact PBP) DMCVJ86 MA Binder DMCVJ86 RN Clofarabine: past, present, and future. Leuk Lymphoma. 2007 Oct;48(10):1922-30. DMCVJ86 RU https://pubmed.ncbi.nlm.nih.gov/17852710 DMCVPXO DI DMCVPXO DMCVPXO DN Lurasidone hydrochloride DMCVPXO TI TTJQOD7 DMCVPXO TN 5-HT 2A receptor (HTR2A) DMCVPXO MA Modulator DMCVPXO RN Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5. DMCVPXO RU https://pubmed.ncbi.nlm.nih.gov/21283092 DMCVPXO DI DMCVPXO DMCVPXO DN Lurasidone hydrochloride DMCVPXO TI TTEX248 DMCVPXO TN Dopamine D2 receptor (D2R) DMCVPXO MA Modulator DMCVPXO RN Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5. DMCVPXO RU https://pubmed.ncbi.nlm.nih.gov/21283092 DMCX0K3 DI DMCX0K3 DMCX0K3 DN Cinacalcet DMCX0K3 TI TTBUYHA DMCX0K3 TN Extracellular calcium-sensing receptor (CASR) DMCX0K3 MA Agonist DMCX0K3 RN Clinical pipeline report, company report or official report of Amgen (2009). DMCX0K3 RU http://www.amgen.com/science/pipe.jsp DMCY0TI DI DMCY0TI DMCY0TI DN Carglumic acid DMCY0TI TI TT42M75 DMCY0TI TN Carbamoyl-phosphate synthetase I (CPS1) DMCY0TI MA Activator DMCY0TI RN Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5. DMCY0TI RU https://pubmed.ncbi.nlm.nih.gov/21283092 DMCY8AF DI DMCY8AF DMCY8AF DN Arbutamine DMCY8AF TI TTR6W5O DMCY8AF TN Adrenergic receptor beta-1 (ADRB1) DMCY8AF MA Stimulator DMCY8AF RN Characterization of the adrenergic activity of arbutamine, a novel agent for pharmacological stress testing. Cardiovasc Drugs Ther. 1996 Mar;10(1):39-47. DMCY8AF RU https://pubmed.ncbi.nlm.nih.gov/8723169 DMCYANK DI DMCYANK DMCYANK DN Doxapram DMCYANK TI TT6EYVN DMCYANK TN Peripheral carotid chemoreceptor (PCC) DMCYANK MA Stimulator DMCYANK RN Ovalbumin sensitization alters the ventilatory responses to chemical challenges in guinea pigs. J Appl Physiol (1985). 2005 Nov;99(5):1782-8. DMCYANK RU https://pubmed.ncbi.nlm.nih.gov/16024517 DMCYVDT DI DMCYVDT DMCYVDT DN Chlorzoxazone DMCYVDT TI TTMNI76 DMCYVDT TN Calcium-activated potassium channel (KCN) DMCYVDT MA Activator DMCYVDT RN Chlorzoxazone inhibits contraction of rat thoracic aorta. Eur J Pharmacol. 2006 Sep 18;545(2-3):161-6. DMCYVDT RU https://pubmed.ncbi.nlm.nih.gov/16859676 DMCZGRE DI DMCZGRE DMCZGRE DN Dolutegravir DMCZGRE TI TT5FH9Y DMCZGRE TN Human immunodeficiency virus Integrase (HIV IN) DMCZGRE MA Modulator DMCZGRE RN Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651. DMCZGRE RU https://pubmed.ncbi.nlm.nih.gov/28919714 DMCZIHT DI DMCZIHT DMCZIHT DN Asasantin DMCZIHT TI TTK0943 DMCZIHT TN Prostaglandin G/H synthase (COX) DMCZIHT MA Inhibitor DMCZIHT RN Emerging drugs in peripheral arterial disease. Expert Opin Emerg Drugs. 2006 Mar;11(1):75-90. DMCZIHT RU https://pubmed.ncbi.nlm.nih.gov/16503827 DMCZQGK DI DMCZQGK DMCZQGK DN Demecolcine DMCZQGK TI TT1EDJZ DMCZQGK TN Microtubule-associated protein (MAP) DMCZQGK MA Modulator DMCZQGK RN Medicinal plants in therapy. Bull World Health Organ. 1985;63(6):965-81. DMCZQGK RU https://pubmed.ncbi.nlm.nih.gov/3879679 DMD072M DI DMD072M DMD072M DN Fosfestrol DMD072M TI TTZAYWL DMD072M TN Estrogen receptor (ESR) DMD072M MA Modulator DMD072M RN Impact of natural products on developing new anti-cancer agents. Chem Rev. 2009 Jul;109(7):3012-43. DMD072M RU https://pubmed.ncbi.nlm.nih.gov/19422222 DMD157S DI DMD157S DMD157S DN Montelukast DMD157S TI TTGKOY9 DMD157S TN Leukotriene CysLT1 receptor (CYSLTR1) DMD157S MA Antagonist DMD157S RN Protective potential of montelukast against hepatic ischemia/reperfusion injury in rats. J Surg Res. 2010 Mar;159(1):588-94. DMD157S RU https://pubmed.ncbi.nlm.nih.gov/19515388 DMD1B8Z DI DMD1B8Z DMD1B8Z DN Dobutamine DMD1B8Z TI TTR6W5O DMD1B8Z TN Adrenergic receptor beta-1 (ADRB1) DMD1B8Z MA Agonist DMD1B8Z RN Beta-adrenoceptor alterations coupled with secretory response and experimental periodontitis in rat submandibular glands. Arch Oral Biol. 2008 Jun;53(6):509-16. DMD1B8Z RU https://pubmed.ncbi.nlm.nih.gov/18275933 DMD1QXW DI DMD1QXW DMD1QXW DN Ambrisentan DMD1QXW TI TTKRD0G DMD1QXW TN Endothelin A receptor (EDNRA) DMD1QXW MA Antagonist DMD1QXW RN Clinical pipeline report, company report or official report of GlaxoSmithKline (2009). DMD1QXW RU http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf DMD1VZL DI DMD1VZL DMD1VZL DN Pemafibrate DMD1VZL TI TTJ584C DMD1VZL TN Peroxisome proliferator-activated receptor alpha (PPARA) DMD1VZL MA Agonist DMD1VZL RN Pemafibrate: First Global Approval. Drugs. 2017 Oct;77(16):1805-1810. DMD1VZL RU https://pubmed.ncbi.nlm.nih.gov/28929345 DMD2K4I DI DMD2K4I DMD2K4I DN Fludiazepam DMD2K4I TI TTPTXIN DMD2K4I TN Translocator protein (TSPO) DMD2K4I MA Agonist DMD2K4I RN Benzodiazepines and their metabolites: relationship between binding affinity to the benzodiazepine receptor and pharmacological activity. Life Sci. 1985 Jan 14;36(2):113-9. DMD2K4I RU https://pubmed.ncbi.nlm.nih.gov/2857046 DMD2NV7 DI DMD2NV7 DMD2NV7 DN Pindolol DMD2NV7 TI TTR6W5O DMD2NV7 TN Adrenergic receptor beta-1 (ADRB1) DMD2NV7 MA Antagonist DMD2NV7 RN Are we misunderstanding beta-blockers. Int J Cardiol. 2007 Aug 9;120(1):10-27. DMD2NV7 RU https://pubmed.ncbi.nlm.nih.gov/17433471 DMD2WPG DI DMD2WPG DMD2WPG DN Trientine DMD2WPG TI TTEYTKG DMD2WPG TN Carbonic anhydrase XIV (CA-XIV) DMD2WPG MA Inhibitor DMD2WPG RN Polyamines inhibit carbonic anhydrases by anchoring to the zinc-coordinated water molecule. J Med Chem. 2010 Aug 12;53(15):5511-22. DMD2WPG RU https://pubmed.ncbi.nlm.nih.gov/20590092 DMD4381 DI DMD4381 DMD4381 DN Terbutaline DMD4381 TI TT2CJVK DMD4381 TN Adrenergic receptor beta-2 (ADRB2) DMD4381 MA Agonist DMD4381 RN Evaluation of a new oral beta2-adrenoceptor stimulant bronchodilator, terbutaline. Pharmacology. 1975;13(3):201-11. DMD4381 RU https://pubmed.ncbi.nlm.nih.gov/239414 DMD59GI DI DMD59GI DMD59GI DN Urapidil DMD59GI TI TTG28O6 DMD59GI TN Adrenergic receptor Alpha-1 (ADRA1) DMD59GI MA Antagonist DMD59GI RN Urapidil. A reappraisal of its use in the management of hypertension. Drugs. 1998 Nov;56(5):929-55. DMD59GI RU https://pubmed.ncbi.nlm.nih.gov/9829161 DMD59GI DI DMD59GI DMD59GI DN Urapidil DMD59GI TI TTSQIFT DMD59GI TN 5-HT 1A receptor (HTR1A) DMD59GI MA Agonist DMD59GI RN Urapidil. A reappraisal of its use in the management of hypertension. Drugs. 1998 Nov;56(5):929-55. DMD59GI RU https://pubmed.ncbi.nlm.nih.gov/9829161 DMD5JU8 DI DMD5JU8 DMD5JU8 DN Cephalexin DMD5JU8 TI TTJP4SM DMD5JU8 TN Bacterial Penicillin binding protein (Bact PBP) DMD5JU8 MA Binder DMD5JU8 RN Relationship between penicillin-binding protein patterns and beta-lactamases in clinical isolates of Bacteroides fragilis with different susceptibility to beta-lactam antibiotics. J Med Microbiol. 2004 Mar;53(Pt 3):213-21. DMD5JU8 RU https://pubmed.ncbi.nlm.nih.gov/14970246 DMD5LBX DI DMD5LBX DMD5LBX DN Celiprolol HCL DMD5LBX TI TTVIREA DMD5LBX TN Adrenergic receptor (ADR) DMD5LBX MA Modulator DMD5LBX RN Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. DMD5LBX RU https://pubmed.ncbi.nlm.nih.gov/17309302 DMD7L94 DI DMD7L94 DMD7L94 DN Palbociclib DMD7L94 TI TT0PG8F DMD7L94 TN Cyclin-dependent kinase 4 (CDK4) DMD7L94 MA Modulator DMD7L94 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2017 DMD7L94 RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/207103s004lbl.pdf DMD7L94 DI DMD7L94 DMD7L94 DN Palbociclib DMD7L94 TI TTO0FDJ DMD7L94 TN Cyclin-dependent kinase 6 (CDK6) DMD7L94 MA Modulator DMD7L94 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2017 DMD7L94 RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/207103s004lbl.pdf DMD7X1O DI DMD7X1O DMD7X1O DN Dexrazoxane DMD7X1O TI TT4NVEM DMD7X1O TN DNA topoisomerase II beta (TOP2B) DMD7X1O MA Inhibitor DMD7X1O RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMD7X1O RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMD7X1O DI DMD7X1O DMD7X1O DN Dexrazoxane DMD7X1O TI TT0IHXV DMD7X1O TN DNA topoisomerase II (TOP2) DMD7X1O MA Modulator DMD7X1O RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMD7X1O RU https://www.fda.gov/ DMD8Q3J DI DMD8Q3J DMD8Q3J DN Gemfibrozil DMD8Q3J TI TTOF3WZ DMD8Q3J TN Lipoprotein lipase (LPL) DMD8Q3J MA Activator DMD8Q3J RN Mode of action of fibrates in the regulation of triglyceride and HDL-cholesterol metabolism. Drugs Today (Barc). 2006 Jan;42(1):39-64. DMD8Q3J RU https://pubmed.ncbi.nlm.nih.gov/16511610 DMD9WSC DI DMD9WSC DMD9WSC DN Memantine DMD9WSC TI TT9IK2Z DMD9WSC TN N-methyl-D-aspartate receptor (NMDAR) DMD9WSC MA Modulator DMD9WSC RN The NMDA receptor antagonist memantine as a symptomatological and neuroprotective treatment for Alzheimer's disease: preclinical evidence. Int J Geriatr Psychiatry. 2003 Sep;18(Suppl 1):S23-32. DMD9WSC RU https://pubmed.ncbi.nlm.nih.gov/12973747 DMDBX5F DI DMDBX5F DMDBX5F DN Ivermectin DMDBX5F TI TTSNVHO DMDBX5F TN Onchocerca Glutamate-gated chloride channel (Onchoc GluCl) DMDBX5F MA Activator DMDBX5F RN Inhibitory neurotransmission and olfactory memory in honeybees. Neurobiol Learn Mem. 2008 Nov;90(4):589-95. DMDBX5F RU https://pubmed.ncbi.nlm.nih.gov/18755283 DMDBZMV DI DMDBZMV DMDBZMV DN Vitamin B6 DMDBZMV TI TTN451K DMDBZMV TN Aromatic-L-amino-acid decarboxylase (DDC) DMDBZMV MA Cofactor DMDBZMV RN Functional COMT variant predicts response to high dose pyridoxine in Parkinson's disease. Am J Med Genet B Neuropsychiatr Genet. 2005 Aug 5;137B(1):1-4. DMDBZMV RU https://pubmed.ncbi.nlm.nih.gov/15965967 DMDEA85 DI DMDEA85 DMDEA85 DN Trimetrexate DMDEA85 TI TT9SL3Q DMDEA85 TN Polypeptide deformylase (PDF) DMDEA85 MA Inhibitor DMDEA85 RN Expression and characterization of recombinant human-derived Pneumocystis carinii dihydrofolate reductase. Antimicrob Agents Chemother. 2000 Nov;44(11):3092-6. DMDEA85 RU https://pubmed.ncbi.nlm.nih.gov/11036028 DMDEXQ0 DI DMDEXQ0 DMDEXQ0 DN Febuxostat DMDEXQ0 TI TT7RJY8 DMDEXQ0 TN Xanthine dehydrogenase/oxidase (XDH) DMDEXQ0 MA Inhibitor DMDEXQ0 RN Clinical pipeline report, company report or official report of Takeda (2009). DMDEXQ0 RU http://www.takeda.com/pdf/usr/default/10_1_34992_2.pdf DMDEZI3 DI DMDEZI3 DMDEZI3 DN Pegvisomant DMDEZI3 TI TTKMAZ6 DMDEZI3 TN Growth hormone receptor (GHR) DMDEZI3 MA Antagonist DMDEZI3 RN Growth hormone receptor antagonist treatment reduces exercise performance in young males. J Clin Endocrinol Metab. 2009 Sep;94(9):3265-72. DMDEZI3 RU https://pubmed.ncbi.nlm.nih.gov/19549743 DMDF79Z DI DMDF79Z DMDF79Z DN Acetylcholine DMDF79Z TI TTOXS3C DMDF79Z TN Muscarinic acetylcholine receptor (CHRM) DMDF79Z MA Agonist DMDF79Z RN Thiochrome enhances acetylcholine affinity at muscarinic M4 receptors: receptor subtype selectivity via cooperativity rather than affinity. Mol Pharmacol. 2004 Jan;65(1):257-66. DMDF79Z RU https://pubmed.ncbi.nlm.nih.gov/14722259 DMDH9KX DI DMDH9KX DMDH9KX DN Megestrol DMDH9KX TI TTUV8G9 DMDH9KX TN Progesterone receptor (PGR) DMDH9KX MA Binder DMDH9KX RN Focus on anastrozole and breast cancer. Curr Med Res Opin. 2003;19(8):683-8. DMDH9KX RU https://pubmed.ncbi.nlm.nih.gov/14687437 DMDHCK9 DI DMDHCK9 DMDHCK9 DN Trumenba DMDHCK9 TI TTUW6OP DMDHCK9 TN Complement factor H (CFH) DMDHCK9 RN 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81. DMDHCK9 RU https://pubmed.ncbi.nlm.nih.gov/25633781 DMDI269 DI DMDI269 DMDI269 DN Docetaxel DMDI269 TI TTML2WA DMDI269 TN Tubulin (TUB) DMDI269 MA Inhibitor DMDI269 RN Docetaxel: a review of its use in metastatic breast cancer. Drugs. 2005;65(17):2513-31. DMDI269 RU https://pubmed.ncbi.nlm.nih.gov/16296875 DMDI6R4 DI DMDI6R4 DMDI6R4 DN Dabigatran DMDI6R4 TI TT6L509 DMDI6R4 TN Coagulation factor IIa (F2) DMDI6R4 MA Inhibitor DMDI6R4 RN Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5. DMDI6R4 RU https://pubmed.ncbi.nlm.nih.gov/21283092 DMDIC39 DI DMDIC39 DMDIC39 DN Fosfosal DMDIC39 TI TTK0943 DMDIC39 TN Prostaglandin G/H synthase (COX) DMDIC39 MA Modulator DMDIC39 RN Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. DMDIC39 RU https://pubmed.ncbi.nlm.nih.gov/17309302 DMDINC4 DI DMDINC4 DMDINC4 DN Thiothixene DMDINC4 TI TTEX248 DMDINC4 TN Dopamine D2 receptor (D2R) DMDINC4 MA Antagonist DMDINC4 RN Dopaminergic stimulation of cAMP accumulation in cultured rat mesangial cells. Am J Physiol. 1987 Aug;253(2 Pt 2):H358-64. DMDINC4 RU https://pubmed.ncbi.nlm.nih.gov/3039860 DMDINFS DI DMDINFS DMDINFS DN Sanguinarine DMDINFS TI TTQ38E9 DMDINFS TN Sodium/potassium-transporting ATPase (SPT ATPase) DMDINFS MA Modulator DMDINFS RN Medicinal plants in therapy. Bull World Health Organ. 1985;63(6):965-81. DMDINFS RU https://pubmed.ncbi.nlm.nih.gov/3879679 DMDIYFZ DI DMDIYFZ DMDIYFZ DN Telotristat ethyl DMDIYFZ TI TTDJBV3 DMDIYFZ TN Tryptophan hydroxylase (TPH) DMDIYFZ MA Modulator DMDIYFZ RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMDIYFZ RU https://www.fda.gov/ DMDJMA3 DI DMDJMA3 DMDJMA3 DN Rizatriptan DMDJMA3 TI TT6MSOK DMDJMA3 TN 5-HT 1D receptor (HTR1D) DMDJMA3 MA Agonist DMDJMA3 RN An introduction to migraine: from ancient treatment to functional pharmacology and antimigraine therapy. Proc West Pharmacol Soc. 2002;45:199-210. DMDJMA3 RU https://pubmed.ncbi.nlm.nih.gov/12434581 DMDK7T9 DI DMDK7T9 DMDK7T9 DN SBC-102 DMDK7T9 TI TTS8T1M DMDK7T9 TN Lysosomal acid lipase (LIPA) DMDK7T9 MA Modulator DMDK7T9 RN A Phase 3 Trial of Sebelipase Alfa in Lysosomal Acid Lipase Deficiency. N Engl J Med. 2015 Sep 10;373(11):1010-20. DMDK7T9 RU https://pubmed.ncbi.nlm.nih.gov/26352813 DMDKE4N DI DMDKE4N DMDKE4N DN Secretin DMDKE4N TI TTOBVIN DMDKE4N TN Secretin receptor (SCT) DMDKE4N MA Binder DMDKE4N RN False-positive secretin stimulation test for gastrinoma associated with the use of proton pump inhibitor therapy. Clin Gastroenterol Hepatol. 2009 May;7(5):600-2. DMDKE4N RU https://pubmed.ncbi.nlm.nih.gov/19245850 DMDKF3M DI DMDKF3M DMDKF3M DN Raloxifene DMDKF3M TI TTZAYWL DMDKF3M TN Estrogen receptor (ESR) DMDKF3M MA Modulator DMDKF3M RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 620). DMDKF3M RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=620 DMDKXTO DI DMDKXTO DMDKXTO DN Cobicistat/darunavir DMDKXTO TI TTIJQ3O DMDKXTO TN Cytochrome P450 3A (CYP3A) DMDKXTO MA Modulator DMDKXTO RN Cobicistat: a review of its use as a pharmacokinetic enhancer of atazanavir and darunavir in patients with HIV-1 infection. Drugs. 2014 Feb;74(2):195-206. DMDKXTO RU https://pubmed.ncbi.nlm.nih.gov/24343782 DMDL27I DI DMDL27I DMDL27I DN Oxytocin DMDL27I TI TTSCIUP DMDL27I TN Oxytocin receptor (OTR) DMDL27I MA Modulator DMDL27I RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 369). DMDL27I RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=369 DMDL27I DI DMDL27I DMDL27I DN Oxytocin DMDL27I TI TT4TFGN DMDL27I TN Vasopressin V1a receptor (V1AR) DMDL27I MA Agonist DMDL27I RN Mapping peptide-binding domains of the human V1a vasopressin receptor with a photoactivatable linear peptide antagonist. J Biol Chem. 1997 Oct 17;272(42):26536-44. DMDL27I RU https://pubmed.ncbi.nlm.nih.gov/9334232 DMDL27I DI DMDL27I DMDL27I DN Oxytocin DMDL27I TI TTL9MHW DMDL27I TN Vasopressin V1b receptor (V1BR) DMDL27I MA Agonist DMDL27I RN The human V3 pituitary vasopressin receptor: ligand binding profile and density-dependent signaling pathways. Endocrinology. 1997 Oct;138(10):4109-22. DMDL27I RU https://pubmed.ncbi.nlm.nih.gov/9322919 DMDL27I DI DMDL27I DMDL27I DN Oxytocin DMDL27I TI TTK8R02 DMDL27I TN Vasopressin V2 receptor (V2R) DMDL27I MA Agonist DMDL27I RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 368). DMDL27I RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=368 DMDNJHG DI DMDNJHG DMDNJHG DN Aztreonam DMDNJHG TI TT85JMW DMDNJHG TN Bacterial Penicillin binding protein 3 (Bact mrcA) DMDNJHG MA Binder DMDNJHG RN Penicillin-binding protein PBP2 of Escherichia coli localizes preferentially in the lateral wall and at mid-cell in comparison with the old cell pole. Mol Microbiol. 2003 Jan;47(2):539-47. DMDNJHG RU https://pubmed.ncbi.nlm.nih.gov/12519203 DMDO279 DI DMDO279 DMDO279 DN Phenprocoumon DMDO279 TI TTEUC8H DMDO279 TN Vitamin K epoxide reductase complex 1 (VKORC1) DMDO279 MA Inhibitor DMDO279 RN [Oral anticoagulation and pharmacogenetics: importance in the clinical setting]. Rev Med Suisse. 2007 Sep 12;3(124):2030, 2033-4, 2036. DMDO279 RU https://pubmed.ncbi.nlm.nih.gov/17955831 DMDPM7R DI DMDPM7R DMDPM7R DN Y-25130 DMDPM7R TI TTNXLKE DMDPM7R TN 5-HT 3 receptor (5HT3R) DMDPM7R MA Antagonist DMDPM7R RN The antiemetic profile of Y-25130, a new selective 5-HT3 receptor antagonist. Eur J Pharmacol. 1991 Apr 24;196(3):299-305. DMDPM7R RU https://pubmed.ncbi.nlm.nih.gov/1654255 DMDPYI5 DI DMDPYI5 DMDPYI5 DN Benzyl benzoate DMDPYI5 TI TTLUQ8E DMDPYI5 TN Hormone sensitive lipase (LIPE) DMDPYI5 MA Modulator DMDPYI5 RN The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954. DMDPYI5 RU https://www.ncbi.nlm.nih.gov/pubmed/27899562 DMDRKH2 DI DMDRKH2 DMDRKH2 DN Thiamphenicol DMDRKH2 TI TTLFGBV DMDRKH2 TN Bacterial 23S ribosomal RNA (Bact 23S rRNA) DMDRKH2 MA Modulator DMDRKH2 RN The fused TrpEG from Streptomyces venezuelae is an anthranilate synthase, not a 2-amino-2-deoxyisochorismate [corrected] (ADIC) synthase. Ethn Dis. 2008 Spring;18(2 Suppl 2):S2-9-13. DMDRKH2 RU https://pubmed.ncbi.nlm.nih.gov/18646313 DMDRQZU DI DMDRQZU DMDRQZU DN Ethanol DMDRQZU TI TT1MPAY DMDRQZU TN GABA(A) receptor alpha-1 (GABRA1) DMDRQZU MA Antagonist DMDRQZU RN DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6. DMDRQZU RU https://pubmed.ncbi.nlm.nih.gov/18048412 DMDRT0E DI DMDRT0E DMDRT0E DN Idoxuridine DMDRT0E TI TT4823K DMDRT0E TN Virus Deoxyribonucleic acid (Viru DNA) DMDRT0E MA Binder DMDRT0E RN Radiopharmaceuticals (Strontium 89) and radiosensitizers (idoxuridine). J Intraven Nurs. 1998 Nov-Dec;21(6):335-7. DMDRT0E RU https://pubmed.ncbi.nlm.nih.gov/10392098 DMDSWAG DI DMDSWAG DMDSWAG DN Methylphenobarbital DMDSWAG TI TT1MPAY DMDSWAG TN GABA(A) receptor alpha-1 (GABRA1) DMDSWAG MA Antagonist DMDSWAG RN DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6. DMDSWAG RU https://pubmed.ncbi.nlm.nih.gov/18048412 DMDTC7R DI DMDTC7R DMDTC7R DN Phenindamine DMDTC7R TI TTTIBOJ DMDTC7R TN Histamine H1 receptor (H1R) DMDTC7R MA Antagonist DMDTC7R RN The histamine H1-receptor antagonist binding site. A stereoselective pharmacophoric model based upon (semi-)rigid H1-antagonists and including a known interaction site on the receptor. J Med Chem. 1995 Aug 18;38(17):3351-60. DMDTC7R RU https://pubmed.ncbi.nlm.nih.gov/7650688 DMDU0BV DI DMDU0BV DMDU0BV DN Pivmecillinam DMDU0BV TI TTJP4SM DMDU0BV TN Bacterial Penicillin binding protein (Bact PBP) DMDU0BV MA Binder DMDU0BV RN Association between antimicrobial consumption and resistance in Escherichia coli. Antimicrob Agents Chemother. 2009 Mar;53(3):912-7. DMDU0BV RU https://pubmed.ncbi.nlm.nih.gov/19104012 DMDVP3B DI DMDVP3B DMDVP3B DN Pregabalin DMDVP3B TI TTFK1JQ DMDVP3B TN Voltage-gated calcium channel alpha-2/delta-1 (CACNA2D1) DMDVP3B MA Modulator DMDVP3B RN Pregabalin reduces the release of synaptic vesicles from cultured hippocampal neurons. Mol Pharmacol. 2006 Aug;70(2):467-76. DMDVP3B RU https://pubmed.ncbi.nlm.nih.gov/16641316 DMDWICP DI DMDWICP DMDWICP DN Succinic acid DMDWICP TI TTJUWVB DMDWICP TN Succinate-semialdehyde dehydrogenase (ALDH5A1) DMDWICP MA Inhibitor DMDWICP RN Redox-switch modulation of human SSADH by dynamic catalytic loop. EMBO J. 2009 Apr 8;28(7):959-68. DMDWICP RU https://pubmed.ncbi.nlm.nih.gov/19300440 DMDX1ZC DI DMDX1ZC DMDX1ZC DN Cinolazepam DMDX1ZC TI TTPTXIN DMDX1ZC TN Translocator protein (TSPO) DMDX1ZC MA Binder DMDX1ZC RN Short-term sleep laboratory studies with cinolazepam in situational insomnia induced by traffic noise. Int J Clin Pharmacol Res. 1987;7(5):407-18. DMDX1ZC RU https://pubmed.ncbi.nlm.nih.gov/2889679 DMDYA31 DI DMDYA31 DMDYA31 DN Pretomanid DMDYA31 TI TT08ESN DMDYA31 TN Mycobacterium Mycolic acid synthase (MycB cma) DMDYA31 MA Inhibitor DMDYA31 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019 DMDYA31 RU https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212862Orig1s000Lbl.pdf DMDZ9LT DI DMDZ9LT DMDZ9LT DN Ethosuximide DMDZ9LT TI TT729IR DMDZ9LT TN Voltage-gated calcium channel alpha Cav3.1 (CACNA1G) DMDZ9LT MA Blocker DMDZ9LT RN Maladaptive homeostatic plasticity in a rodent model of central pain syndrome: thalamic hyperexcitability after spinothalamic tract lesions. J Neurosci. 2008 Nov 12;28(46):11959-69. DMDZ9LT RU https://pubmed.ncbi.nlm.nih.gov/19005061 DMDZY54 DI DMDZY54 DMDZY54 DN Fremanezumab DMDZY54 TI TTY6O0Q DMDZY54 TN Calcitonin gene-related peptide receptor (CGRPR) DMDZY54 MA Modulator DMDZY54 RN 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. DMDZY54 RU https://pubmed.ncbi.nlm.nih.gov/30710142 DME0F98 DI DME0F98 DME0F98 DN Ovine corticotropin-releasing hormone DME0F98 TI TTVIREA DME0F98 TN Adrenergic receptor (ADR) DME0F98 MA Modulator DME0F98 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DME0F98 RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DME0TC8 DI DME0TC8 DME0TC8 DN Lomerizine DME0TC8 TI TTZOVE0 DME0TC8 TN Voltage-gated sodium channel alpha Nav1.5 (SCN5A) DME0TC8 MA Inhibitor DME0TC8 RN Medicinal chemistry of neuronal voltage-gated sodium channel blockers. J Med Chem. 2001 Jan 18;44(2):115-37. DME0TC8 RU https://pubmed.ncbi.nlm.nih.gov/11170622 DME0TC8 DI DME0TC8 DME0TC8 DN Lomerizine DME0TC8 TI TT4FDG6 DME0TC8 TN Voltage-gated calcium channel alpha Cav2.2 (CACNA1B) DME0TC8 MA Inhibitor DME0TC8 RN Synthesis and SAR of novel 2-arylthiazolidinones as selective analgesic N-type calcium channel blockers. Bioorg Med Chem Lett. 2007 Feb 1;17(3):662-7. DME0TC8 RU https://pubmed.ncbi.nlm.nih.gov/17134896 DME0TC8 DI DME0TC8 DME0TC8 DN Lomerizine DME0TC8 TI TTRK8B9 DME0TC8 TN Sodium channel unspecific (NaC) DME0TC8 MA Inhibitor DME0TC8 RN Medicinal chemistry of neuronal voltage-gated sodium channel blockers. J Med Chem. 2001 Jan 18;44(2):115-37. DME0TC8 RU https://pubmed.ncbi.nlm.nih.gov/11170622 DME1DJX DI DME1DJX DME1DJX DN Baquting DME1DJX TI TTWODQF DME1DJX TN Fibrin (FG) DME1DJX MA Modulator DME1DJX RN Baquting, enable our sales and marketing team to effectively promote our principal products and help to stimulate the sales of our other pharmaceuticals. DME1DJX RU http://www.sec.gov/Archives/edgar/data/1474952/000119312509239183/df1.htm DME1LQN DI DME1LQN DME1LQN DN Streptomycin DME1LQN TI TTQ8KVI DME1LQN TN Staphylococcus 30S ribosomal subunit (Stap-coc pbp2) DME1LQN MA Binder DME1LQN RN Functional insights from the structure of the 30S ribosomal subunit and its interactions with antibiotics. Nature. 2000 Sep 21;407(6802):340-8. DME1LQN RU https://pubmed.ncbi.nlm.nih.gov/11014183 DME2H5T DI DME2H5T DME2H5T DN Cilastatin DME2H5T TI TTYUENF DME2H5T TN Dehydropeptidase I (DPEP1) DME2H5T MA Inhibitor DME2H5T RN Pharmacokinetic study of pleural fluid penetration of carbapenem antibiotic agents in chemical pleurisy. Respir Med. 2006 Feb;100(2):324-31. DME2H5T RU https://pubmed.ncbi.nlm.nih.gov/16493791 DME2PY5 DI DME2PY5 DME2PY5 DN Midodrine DME2PY5 TI TTG28O6 DME2PY5 TN Adrenergic receptor Alpha-1 (ADRA1) DME2PY5 MA Agonist DME2PY5 RN Orthostatic hypotension in patients with Parkinson's disease: pathophysiology and management. Drugs Aging. 2001;18(7):495-505. DME2PY5 RU https://pubmed.ncbi.nlm.nih.gov/11482743 DME2XG3 DI DME2XG3 DME2XG3 DN Carbenicillin Indanyl Sodium DME2XG3 TI TTJP4SM DME2XG3 TN Bacterial Penicillin binding protein (Bact PBP) DME2XG3 MA Modulator DME2XG3 RN Carbenicillin resistance of Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1982 Aug;22(2):255-61. DME2XG3 RU https://www.ncbi.nlm.nih.gov/pubmed/6821456 DME4RA8 DI DME4RA8 DME4RA8 DN Amodiaquine DME4RA8 TI TT2B6EV DME4RA8 TN Histamine N-methyltransferase (HNMT) DME4RA8 MA Inhibitor DME4RA8 RN Effect of amodiaquine, a histamine N-methyltransferase inhibitor, on, Propionibacterium acnes and lipopolysaccharide-induced hepatitis in mice. Eur J Pharmacol. 2007 Mar 8;558(1-3):179-84. DME4RA8 RU https://pubmed.ncbi.nlm.nih.gov/17222819 DME5Y64 DI DME5Y64 DME5Y64 DN Tranilast DME5Y64 TI TTTIBOJ DME5Y64 TN Histamine H1 receptor (H1R) DME5Y64 MA Antagonist DME5Y64 RN Emerging drugs for ocular allergy. Expert Opin Emerg Drugs. 2005 Aug;10(3):505-20. DME5Y64 RU https://pubmed.ncbi.nlm.nih.gov/16083326 DME5Y64 DI DME5Y64 DME5Y64 DN Tranilast DME5Y64 TI TTHM0R1 DME5Y64 TN Steryl-sulfatase (STS) DME5Y64 MA Inhibitor DME5Y64 RN Review of estrone sulfatase and its inhibitors--an important new target against hormone dependent breast cancer. Curr Med Chem. 2002 Jan;9(2):263-73. DME5Y64 RU https://pubmed.ncbi.nlm.nih.gov/11860358 DME6G97 DI DME6G97 DME6G97 DN Lefamulin DME6G97 TI TTLFGBV DME6G97 TN Bacterial 23S ribosomal RNA (Bact 23S rRNA) DME6G97 MA Inhibitor DME6G97 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019 DME6G97 RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211672s000,211673s000lbl.pdf DME78OA DI DME78OA DME78OA DN Biperiden DME78OA TI TTZ9SOR DME78OA TN Muscarinic acetylcholine receptor M1 (CHRM1) DME78OA MA Antagonist DME78OA RN Evaluation of in vivo binding properties of 3H-NMPB and 3H-QNB in mouse brain. J Neural Transm. 1999;106(7-8):583-92. DME78OA RU https://pubmed.ncbi.nlm.nih.gov/10907719 DME7KRM DI DME7KRM DME7KRM DN Oxiconazole DME7KRM TI TTTSOUD DME7KRM TN Candida Cytochrome P450 51 (Candi ERG11) DME7KRM MA Inhibitor DME7KRM RN Antifungal agents: mechanisms of action. Trends Microbiol. 2003 Jun;11(6):272-9. DME7KRM RU https://pubmed.ncbi.nlm.nih.gov/12823944 DME8FZ9 DI DME8FZ9 DME8FZ9 DN Methoxsalen DME8FZ9 TI TTAQ6ZW DME8FZ9 TN Cytochrome P450 2A6 (CYP2A6) DME8FZ9 MA Binder DME8FZ9 RN Mutagenicity and carcinogenicity of methoxsalen plus UV-A. Arch Dermatol. 1984 May;120(5):662-9. DME8FZ9 RU https://pubmed.ncbi.nlm.nih.gov/6372701 DME9JNL DI DME9JNL DME9JNL DN Propericiazine DME9JNL TI TTBRKXS DME9JNL TN Adrenergic receptor alpha-1B (ADRA1B) DME9JNL MA Binder DME9JNL RN Interaction of neuroleptics and antidepressants with rat brain alpha 2-receptors: a possible relationship between alpha 2-receptor antagonism and antidepressant action. Biol Psychiatry. 1984 Sep;19(9):1283-91. DME9JNL RU https://pubmed.ncbi.nlm.nih.gov/6149771 DMEADRK DI DMEADRK DMEADRK DN Hexylcaine DMEADRK TI TTZOVE0 DMEADRK TN Voltage-gated sodium channel alpha Nav1.5 (SCN5A) DMEADRK MA Blocker DMEADRK RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMEADRK RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMEAOYJ DI DMEAOYJ DMEAOYJ DN Ponesimod DMEAOYJ TI TT9JZCK DMEAOYJ TN Sphingosine-1-phosphate receptor 1 (S1PR1) DMEAOYJ MA Agonist DMEAOYJ RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2021 DMEAOYJ RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/213498s000lbl.pdf DMEBOFW DI DMEBOFW DMEBOFW DN Clofazimine DMEBOFW TI TTS1W4A DMEBOFW TN Bacterial Deoxyribonucleic acid (Bact DNA) DMEBOFW MA Modulator DMEBOFW RN The mode of action of clofazimine DNA binding studies. Int J Lepr Other Mycobact Dis. 1976 Jan-Jun;44(1-2):133-4. DMEBOFW RU https://www.ncbi.nlm.nih.gov/pubmed/945233 DMEBQAO DI DMEBQAO DMEBQAO DN Lumasiran DMEBQAO TI TTS58YO DMEBQAO TN HAO1 messenger RNA (HAO1 mRNA) DMEBQAO MA Inhibitor DMEBQAO RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020 DMEBQAO RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/214103lbl.pdf DMEBY2D DI DMEBY2D DMEBY2D DN Beriplast-P DMEBY2D TI TTWODQF DMEBY2D TN Fibrin (FG) DMEBY2D MA Modulator DMEBY2D RN Wound healing and degradation of the fibrin sealant Beriplast P following partial liver resection in rabbits. Wound Repair Regen. 2005 May-Jun;13(3):318-23. DMEBY2D RU https://pubmed.ncbi.nlm.nih.gov/15953052 DMECB4H DI DMECB4H DMECB4H DN Levopropoxyphene Napsylate Anhydrous DMECB4H TI TTKWM86 DMECB4H TN Opioid receptor mu (MOP) DMECB4H MA Modulator DMECB4H RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMECB4H RU https://www.fda.gov/ DMECB4H DI DMECB4H DMECB4H DN Levopropoxyphene Napsylate Anhydrous DMECB4H TI TT35UGH DMECB4H TN Neuronal acetylcholine receptor alpha-3/beta-4 (CHRNA3/B4) DMECB4H MA Modulator DMECB4H RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMECB4H RU https://www.fda.gov/ DMECBWN DI DMECBWN DMECBWN DN Riluzole DMECBWN TI TTN9VTF DMECBWN TN Voltage-gated sodium channel alpha Nav1.9 (SCN11A) DMECBWN MA Blocker DMECBWN RN Secondary injury mechanisms of spinal cord trauma: a novel therapeutic approach for the management of secondary pathophysiology with the sodium channel blocker riluzole. Prog Brain Res. 2002;137:177-90. DMECBWN RU https://pubmed.ncbi.nlm.nih.gov/12440368 DMECRX1 DI DMECRX1 DMECRX1 DN Bivalirudin DMECRX1 TI TT6L509 DMECRX1 TN Coagulation factor IIa (F2) DMECRX1 MA Inhibitor DMECRX1 RN New anticoagulants. Am Heart J. 2001 Aug;142(2 Suppl):S3-8. DMECRX1 RU https://pubmed.ncbi.nlm.nih.gov/11479484 DMECRX1 DI DMECRX1 DMECRX1 DN Bivalirudin DMECRX1 TI TTRTKPV DMECRX1 TN Trypanosoma Trypanothione reductase (Trypano TPR) DMECRX1 MA Inhibitor DMECRX1 RN 8-Methoxy-naphtho[2,3-b]thiophen-4,9-quinone, a non-competitive inhibitor of trypanothione reductase. Mem Inst Oswaldo Cruz. 2003 Jun;98(4):565-8. DMECRX1 RU https://pubmed.ncbi.nlm.nih.gov/12937775 DMEDU7B DI DMEDU7B DMEDU7B DN NERATINIB MALEATE DMEDU7B TI TT6EO5L DMEDU7B TN Erbb2 tyrosine kinase receptor (HER2) DMEDU7B MA Antagonist DMEDU7B RN 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85. DMEDU7B RU https://pubmed.ncbi.nlm.nih.gov/29348678 DMEDU7B DI DMEDU7B DMEDU7B DN NERATINIB MALEATE DMEDU7B TI TTGKNB4 DMEDU7B TN Epidermal growth factor receptor (EGFR) DMEDU7B MA Antagonist DMEDU7B RN 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85. DMEDU7B RU https://pubmed.ncbi.nlm.nih.gov/29348678 DMEFRTZ DI DMEFRTZ DMEFRTZ DN Lurbinectedin DMEFRTZ TI TTOVXHF DMEFRTZ TN Human Deoxyribonucleic acid minor groove (hDNA min) DMEFRTZ MA Inhibitor DMEFRTZ RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020 DMEFRTZ RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213702s000lbl.pdf DMEFRTZ DI DMEFRTZ DMEFRTZ DN Lurbinectedin DMEFRTZ TI TTUTN1I DMEFRTZ TN Human Deoxyribonucleic acid (hDNA) DMEFRTZ MA Inhibitor DMEFRTZ RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020 DMEFRTZ RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213702s000lbl.pdf DMEGIQ6 DI DMEGIQ6 DMEGIQ6 DN Nitrazepam DMEGIQ6 TI TT1MPAY DMEGIQ6 TN GABA(A) receptor alpha-1 (GABRA1) DMEGIQ6 MA Antagonist DMEGIQ6 RN DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6. DMEGIQ6 RU https://pubmed.ncbi.nlm.nih.gov/18048412 DMEH3O7 DI DMEH3O7 DMEH3O7 DN Rifamycin DMEH3O7 TI TTR6YA2 DMEH3O7 TN Bacterial RNA polymerase sigma factor SigA (Bact sigA) DMEH3O7 MA Modulator DMEH3O7 RN NCBI report DMEH3O7 RU http://www.ncbi.nlm.nih.gov/Structure/mmdb/mmdbsrv.cgi?uid=4OIR DMEH3O7 DI DMEH3O7 DMEH3O7 DN Rifamycin DMEH3O7 TI TTS31JH DMEH3O7 TN Staphylococcus Plastid RNA polymerase beta (Stap-coc rpoB) DMEH3O7 MA Modulator DMEH3O7 RN NCBI report DMEH3O7 RU http://www.ncbi.nlm.nih.gov/Structure/mmdb/mmdbsrv.cgi?uid=4OIR DMEH3O7 DI DMEH3O7 DMEH3O7 DN Rifamycin DMEH3O7 TI TT79JGK DMEH3O7 TN Mycobacterium RNA polymerase (MycB RNAP) DMEH3O7 MA Inhibitor DMEH3O7 RN Rifamycin action on RNA polymerase in antibiotic-tolerant Mycobacterium tuberculosis results in differentially detectable populations.Proc Natl Acad Sci U S A. 2017 Jun 13;114(24):E4832-E4840. DMEH3O7 RU https://pubmed.ncbi.nlm.nih.gov/28559332 DMEH7YU DI DMEH7YU DMEH7YU DN Lanadelumab DMEH7YU TI TTMF8H9 DMEH7YU TN Plasma kallikrein (KLKB1) DMEH7YU MA Modulator DMEH7YU RN 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. DMEH7YU RU https://pubmed.ncbi.nlm.nih.gov/30710142 DMEHCY5 DI DMEHCY5 DMEHCY5 DN Dextromethorphan polistirex DMEHCY5 TI TT3ROYC DMEHCY5 TN Serotonin transporter (SERT) DMEHCY5 MA Modulator DMEHCY5 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMEHCY5 RU https://www.fda.gov/ DMEHCY5 DI DMEHCY5 DMEHCY5 DN Dextromethorphan polistirex DMEHCY5 TI TT5TPI6 DMEHCY5 TN Opioid receptor sigma 1 (OPRS1) DMEHCY5 MA Modulator DMEHCY5 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMEHCY5 RU https://www.fda.gov/ DMEJKRF DI DMEJKRF DMEJKRF DN Motexafin gadolinium DMEJKRF TI TTLPJWH DMEJKRF TN Thioredoxin reductase (PRDX5) DMEJKRF MA Modulator DMEJKRF RN Mechanism of inhibition of ribonucleotide reductase with motexafin gadolinium (MGd). Biochem Biophys Res Commun. 2009 Feb 13;379(3):775-9. DMEJKRF RU https://pubmed.ncbi.nlm.nih.gov/19121624 DMEMBJC DI DMEMBJC DMEMBJC DN Folic acid DMEMBJC TI TTQOD3G DMEMBJC TN Folate receptor (FOLR) DMEMBJC MA Binder DMEMBJC RN Gamma-glutamyl hydrolase and drug resistance. Clin Chim Acta. 2006 Dec;374(1-2):25-32. DMEMBJC RU https://pubmed.ncbi.nlm.nih.gov/16859665 DMEMBJC DI DMEMBJC DMEMBJC DN Folic acid DMEMBJC TI TTY8Z2E DMEMBJC TN Proton-coupled folate transporter (SLC46A1) DMEMBJC MA Modulator DMEMBJC RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1213). DMEMBJC RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1213 DMEMBJC DI DMEMBJC DMEMBJC DN Folic acid DMEMBJC TI TT09I7D DMEMBJC TN Solute carrier family 19 member 1 (SLC19A1) DMEMBJC MA Modulator DMEMBJC RN Increased activity of a novel low pH folate transporter associated with lipophilic antifolate resistance in chinese hamster ovary cells. J Biol Chem. 1998 Apr 3;273(14):8106-11. DMEMBJC RU https://pubmed.ncbi.nlm.nih.gov/9525913 DMEMV9D DI DMEMV9D DMEMV9D DN Trimeprazine DMEMV9D TI TTTIBOJ DMEMV9D TN Histamine H1 receptor (H1R) DMEMV9D MA Antagonist DMEMV9D RN Effectiveness of alimemazine in controlling retching after Nissen fundoplication. J Pediatr Surg. 2005 Nov;40(11):1737-40. DMEMV9D RU https://pubmed.ncbi.nlm.nih.gov/16291162 DMEN6X7 DI DMEN6X7 DMEN6X7 DN Atropine DMEN6X7 TI TTH18TF DMEN6X7 TN Muscarinic acetylcholine receptor M5 (CHRM5) DMEN6X7 MA Antagonist DMEN6X7 RN Additive protective effects of donepezil and nicotine against salsolinol-induced cytotoxicity in SH-SY5Y cells. Neurotox Res. 2009 Oct;16(3):194-204. DMEN6X7 RU https://pubmed.ncbi.nlm.nih.gov/19526284 DMENSL5 DI DMENSL5 DMENSL5 DN Aminosalicylic acid DMENSL5 TI TT8NGED DMENSL5 TN Prostaglandin G/H synthase 1 (COX-1) DMENSL5 MA Modulator DMENSL5 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMENSL5 RU https://www.fda.gov/ DMENSL5 DI DMENSL5 DMENSL5 DN Aminosalicylic acid DMENSL5 TI TTVKILB DMENSL5 TN Prostaglandin G/H synthase 2 (COX-2) DMENSL5 MA Modulator DMENSL5 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMENSL5 RU https://www.fda.gov/ DMENSL5 DI DMENSL5 DMENSL5 DN Aminosalicylic acid DMENSL5 TI TTYZVDJ DMENSL5 TN Dihydrofolate reductase (DHFR) DMENSL5 MA Modulator DMENSL5 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMENSL5 RU https://www.fda.gov/ DMEO794 DI DMEO794 DMEO794 DN Galantamine DMEO794 TI TT1RS9F DMEO794 TN Acetylcholinesterase (AChE) DMEO794 MA Inhibitor DMEO794 RN [From symptomatic to disease modifying therapy Recent developments in the pharmacotherapy of Alzheimer's disease]. Fortschr Neurol Psychiatr. 2009 Jun;77(6):326-33. DMEO794 RU https://pubmed.ncbi.nlm.nih.gov/19504422 DMEPWYA DI DMEPWYA DMEPWYA DN THIOCOLCHICOSIDE DMEPWYA TI TTF45NW DMEPWYA TN Strychnine-binding glycine receptor (GLRA1) DMEPWYA MA Inhibitor DMEPWYA RN 3-demethoxy-3-glycosylaminothiocolchicines: Synthesis of a new class of putative muscle relaxant compounds. J Med Chem. 2006 Sep 7;49(18):5571-7. DMEPWYA RU https://pubmed.ncbi.nlm.nih.gov/16942030 DMEPWYA DI DMEPWYA DMEPWYA DN THIOCOLCHICOSIDE DMEPWYA TI TT1MPAY DMEPWYA TN GABA(A) receptor alpha-1 (GABRA1) DMEPWYA MA Inhibitor DMEPWYA RN 3-demethoxy-3-glycosylaminothiocolchicines: Synthesis of a new class of putative muscle relaxant compounds. J Med Chem. 2006 Sep 7;49(18):5571-7. DMEPWYA RU https://pubmed.ncbi.nlm.nih.gov/16942030 DMEPWYA DI DMEPWYA DMEPWYA DN THIOCOLCHICOSIDE DMEPWYA TI TTZA1NY DMEPWYA TN GABA(A) receptor beta-2 (GABRB2) DMEPWYA MA Inhibitor DMEPWYA RN 3-demethoxy-3-glycosylaminothiocolchicines: Synthesis of a new class of putative muscle relaxant compounds. J Med Chem. 2006 Sep 7;49(18):5571-7. DMEPWYA RU https://pubmed.ncbi.nlm.nih.gov/16942030 DMEPWYA DI DMEPWYA DMEPWYA DN THIOCOLCHICOSIDE DMEPWYA TI TTZ8EM9 DMEPWYA TN Glycine receptor (GlyR) DMEPWYA MA Inhibitor DMEPWYA RN 3-demethoxy-3-glycosylaminothiocolchicines: Synthesis of a new class of putative muscle relaxant compounds. J Med Chem. 2006 Sep 7;49(18):5571-7. DMEPWYA RU https://pubmed.ncbi.nlm.nih.gov/16942030 DMEPWYA DI DMEPWYA DMEPWYA DN THIOCOLCHICOSIDE DMEPWYA TI TTNJYV2 DMEPWYA TN Gamma-aminobutyric acid receptor (GAR) DMEPWYA MA Inhibitor DMEPWYA RN 3-demethoxy-3-glycosylaminothiocolchicines: Synthesis of a new class of putative muscle relaxant compounds. J Med Chem. 2006 Sep 7;49(18):5571-7. DMEPWYA RU https://pubmed.ncbi.nlm.nih.gov/16942030 DMEPWYA DI DMEPWYA DMEPWYA DN THIOCOLCHICOSIDE DMEPWYA TI TT06RH5 DMEPWYA TN GABA(A) receptor gamma-2 (GABRG2) DMEPWYA MA Inhibitor DMEPWYA RN 3-demethoxy-3-glycosylaminothiocolchicines: Synthesis of a new class of putative muscle relaxant compounds. J Med Chem. 2006 Sep 7;49(18):5571-7. DMEPWYA RU https://pubmed.ncbi.nlm.nih.gov/16942030 DMER9YA DI DMER9YA DMER9YA DN Galsulfase DMER9YA TI TTESQTG DMER9YA TN N-acetylgalactosamine-4-sulfatase (G4S) DMER9YA MA Modulator DMER9YA RN Enzyme replacement therapy for mucopolysaccharidosis VI: long-term cardiac effects of galsulfase (Naglazyme ) therapy. J Inherit Metab Dis. 2013 Mar;36(2):385-94. DMER9YA RU https://pubmed.ncbi.nlm.nih.gov/22669363 DMETVFJ DI DMETVFJ DMETVFJ DN Omalizumab DMETVFJ TI TTDGEC0 DMETVFJ TN Immunoglobulin epsilon Fc receptor gamma (FCERG) DMETVFJ MA Modulator DMETVFJ RN The potential of biologics for the treatment of asthma. Nat Rev Drug Discov. 2012 Dec;11(12):958-72. DMETVFJ RU https://www.ncbi.nlm.nih.gov/pubmed/23197041 DMETWAU DI DMETWAU DMETWAU DN Hyaluronidase (ovine) DMETWAU TI TTYTVXF DMETWAU TN Hyaluronic acid (HA) DMETWAU MA Modulator DMETWAU RN Safety results of two phase III trials of an intravitreous injection of highly purified ovine hyaluronidase (Vitrase) for the management of vitreous hemorrhage. Am J Ophthalmol. 2005 Oct;140(4):585-97. DMETWAU RU https://pubmed.ncbi.nlm.nih.gov/16226510 DMETYK5 DI DMETYK5 DMETYK5 DN Triazolam DMETYK5 TI TTPTXIN DMETYK5 TN Translocator protein (TSPO) DMETYK5 MA Modulator DMETYK5 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMETYK5 RU https://www.fda.gov/ DMEV954 DI DMEV954 DMEV954 DN Sulfinpyrazone DMEV954 TI TTOI92F DMEV954 TN Multidrug resistance-associated protein 1 (ABCC1) DMEV954 MA Modulator DMEV954 RN Species-dependent transport and modulation properties of human and mouse multidrug resistance protein 2 (MRP2/Mrp2, ABCC2/Abcc2). Drug Metab Dispos. 2008 Apr;36(4):631-40. DMEV954 RU https://pubmed.ncbi.nlm.nih.gov/18180270 DMEVXY6 DI DMEVXY6 DMEVXY6 DN Heparin Calcium DMEVXY6 TI TT4QPUL DMEVXY6 TN Antithrombin-III (ATIII) DMEVXY6 MA Modulator DMEVXY6 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMEVXY6 RU https://www.fda.gov/ DMEWC7N DI DMEWC7N DMEWC7N DN Prazepam DMEWC7N TI TTPTXIN DMEWC7N TN Translocator protein (TSPO) DMEWC7N MA Modulator DMEWC7N RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMEWC7N RU https://www.fda.gov/ DMEWUPF DI DMEWUPF DMEWUPF DN Salmon Calcitonin DMEWUPF TI TTLWS2O DMEWUPF TN Calcitonin receptor (CALCR) DMEWUPF MA Binder DMEWUPF RN Improved absorption of salmon calcitonin by ultraflexible liposomes through intranasal delivery. Peptides. 2009 Jul;30(7):1288-95. DMEWUPF RU https://pubmed.ncbi.nlm.nih.gov/19540427 DMEXMYK DI DMEXMYK DMEXMYK DN Alpelisib DMEXMYK TI TTEUNMR DMEXMYK TN PI3-kinase alpha (PIK3CA) DMEXMYK MA Inhibitor DMEXMYK RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019 DMEXMYK RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212526s000lbl.pdf DMEYHG9 DI DMEYHG9 DMEYHG9 DN Elotuzumab DMEYHG9 TI TT7ILZ1 DMEYHG9 TN SLAM family member 7 SLAMF7 (CS1) DMEYHG9 RN Market watch: Upcoming catalysts in Q2 2015. Nat Rev Drug Discov. 2015 Apr;14(4):228. DMEYHG9 RU https://pubmed.ncbi.nlm.nih.gov/25764988 DMEYLH9 DI DMEYLH9 DMEYLH9 DN Ribavirin DMEYLH9 TI TTL7C8Q DMEYLH9 TN Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1) DMEYLH9 MA Inhibitor DMEYLH9 RN Treating HCV with ribavirin analogues and ribavirin-like molecules. J Antimicrob Chemother. 2006 Jan;57(1):8-13. DMEYLH9 RU https://pubmed.ncbi.nlm.nih.gov/16293677 DMEZ2KH DI DMEZ2KH DMEZ2KH DN Ocrelizumab DMEZ2KH TI TTUE541 DMEZ2KH TN Leukocyte surface antigen Leu-16 (CD20) DMEZ2KH RN Emerging drugs for rheumatoid arthritis. Expert Opin Emerg Drugs. 2008 Mar;13(1):175-96. DMEZ2KH RU https://pubmed.ncbi.nlm.nih.gov/18321156 DMEZFXR DI DMEZFXR DMEZFXR DN Desoxyribonuclease DMEZFXR TI TT3C1VN DMEZFXR TN Enzyme unspecific (Enz) DMEZFXR MA Modulator DMEZFXR RN Preparation of the bifunctional enzyme ribonuclease-deoxyribonuclease by cross-linkage. Biochemistry. 1979 Oct 2;18(20):4449-52. DMEZFXR RU https://pubmed.ncbi.nlm.nih.gov/486431 DMF0NQR DI DMF0NQR DMF0NQR DN Eplerenone DMF0NQR TI TT26PHO DMF0NQR TN Mineralocorticoid receptor (MR) DMF0NQR MA Modulator DMF0NQR RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMF0NQR RU https://www.fda.gov/ DMF1X5P DI DMF1X5P DMF1X5P DN Proflavine DMF1X5P TI TTS1W4A DMF1X5P TN Bacterial Deoxyribonucleic acid (Bact DNA) DMF1X5P MA Binder DMF1X5P RN Interaction of small molecules with double-stranded RNA: spectroscopic, viscometric, and calorimetric study of hoechst and proflavine binding to PolyCG structures. DNA Cell Biol. 2009 Apr;28(4):209-19. DMF1X5P RU https://pubmed.ncbi.nlm.nih.gov/19364280 DMF28YC DI DMF28YC DMF28YC DN Atorvastatin DMF28YC TI TTPADOQ DMF28YC TN HMG-CoA reductase (HMGCR) DMF28YC MA Inhibitor DMF28YC RN Equally potent inhibitors of cholesterol synthesis in human hepatocytes have distinguishable effects on different cytochrome P450 enzymes. Biopharm Drug Dispos. 2000 Dec;21(9):353-64. DMF28YC RU https://pubmed.ncbi.nlm.nih.gov/11523064 DMF29Q5 DI DMF29Q5 DMF29Q5 DN Connexyn DMF29Q5 TI TTWG9A4 DMF29Q5 TN Adrenergic receptor alpha-2A (ADRA2A) DMF29Q5 MA Agonist DMF29Q5 RN alpha2A-adrenergic receptors heterosynaptically regulate glutamatergic transmission in the bed nucleus of the stria terminalis. Neuroscience. 2009 Sep 29;163(1):339-51. DMF29Q5 RU https://pubmed.ncbi.nlm.nih.gov/19527774 DMF2JDG DI DMF2JDG DMF2JDG DN Dromostanolone DMF2JDG TI TTS64P2 DMF2JDG TN Androgen receptor (AR) DMF2JDG MA Binder DMF2JDG RN Endocrinological and pathological effects of anabolic-androgenic steroid in male rats. Endocr J. 2004 Aug;51(4):425-34. DMF2JDG RU https://pubmed.ncbi.nlm.nih.gov/15351799 DMF2KLU DI DMF2KLU DMF2KLU DN Oxybutynin hydrochloride DMF2KLU TI TTOXS3C DMF2KLU TN Muscarinic acetylcholine receptor (CHRM) DMF2KLU MA Modulator DMF2KLU RN Effects of propiverine hydrochloride (propiverine) on the muscarinic receptor binding affinity in guinea pig tissues and on salivation in conscious dogs. Nihon Yakurigaku Zasshi. 1999 Mar;113(3):157-66. DMF2KLU RU https://pubmed.ncbi.nlm.nih.gov/10347840 DMF3AN7 DI DMF3AN7 DMF3AN7 DN Loratadine DMF3AN7 TI TTTIBOJ DMF3AN7 TN Histamine H1 receptor (H1R) DMF3AN7 MA Antagonist DMF3AN7 RN Clinical research of Ibudilast on treating the steroid resistant allergic rhinitis. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2009 Jan;23(2):63-6. DMF3AN7 RU https://pubmed.ncbi.nlm.nih.gov/19452709 DMF3GM2 DI DMF3GM2 DMF3GM2 DN Somatropin recombinant DMF3GM2 TI TTKMAZ6 DMF3GM2 TN Growth hormone receptor (GHR) DMF3GM2 MA Binder DMF3GM2 RN Cost-utility of somatropin (rDNA origin) in the treatment of growth hormone deficiency in children. Curr Med Res Opin. 2006 Feb;22(2):351-7. DMF3GM2 RU https://pubmed.ncbi.nlm.nih.gov/16466607 DMF3VXA DI DMF3VXA DMF3VXA DN Zotepine DMF3VXA TI TTJQOD7 DMF3VXA TN 5-HT 2A receptor (HTR2A) DMF3VXA MA Inhibitor DMF3VXA RN Current and novel approaches to the drug treatment of schizophrenia. J Med Chem. 2001 Feb 15;44(4):477-501. DMF3VXA RU https://pubmed.ncbi.nlm.nih.gov/11170639 DMF54ZG DI DMF54ZG DMF54ZG DN Sulpiride DMF54ZG TI TTEX248 DMF54ZG TN Dopamine D2 receptor (D2R) DMF54ZG MA Antagonist DMF54ZG RN The treatment of Tourette's syndrome: current opinions. Expert Opin Pharmacother. 2002 Jul;3(7):899-914. DMF54ZG RU https://pubmed.ncbi.nlm.nih.gov/12083990 DMF5EK1 DI DMF5EK1 DMF5EK1 DN Vilanterol DMF5EK1 TI TT2CJVK DMF5EK1 TN Adrenergic receptor beta-2 (ADRB2) DMF5EK1 MA Modulator DMF5EK1 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7353). DMF5EK1 RU http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7353 DMF5HU6 DI DMF5HU6 DMF5HU6 DN Cefotiam DMF5HU6 TI TT85JMW DMF5HU6 TN Bacterial Penicillin binding protein 3 (Bact mrcA) DMF5HU6 MA Binder DMF5HU6 RN Genetic analyses of beta-lactamase negative ampicillin-resistant strains of Haemophilus influenzae isolated in Okinawa, Japan. Jpn J Infect Dis. 2006 Feb;59(1):36-41. DMF5HU6 RU https://pubmed.ncbi.nlm.nih.gov/16495632 DMF5XQH DI DMF5XQH DMF5XQH DN Methoxamine DMF5XQH TI TTBRKXS DMF5XQH TN Adrenergic receptor alpha-1B (ADRA1B) DMF5XQH MA Stimulator DMF5XQH RN Activation of alpha1-adrenoceptors inhibits growth hormone secretion in humans. Exp Clin Endocrinol Diabetes. 2009 Oct;117(9):460-2. DMF5XQH RU https://pubmed.ncbi.nlm.nih.gov/19373756 DMF5ZB3 DI DMF5ZB3 DMF5ZB3 DN OspA lipoprotein DMF5ZB3 TI TTM6QSK DMF5ZB3 TN B-cell receptor CD22 (CD22) DMF5ZB3 MA Binder DMF5ZB3 RN Safety and immunogenicity of recombinant Bacille Calmette-Gu |rin (rBCG) expressing Borrelia burgdorferi outer surface protein A (OspA) lipoprotein in adult volunteers: a candidate Lyme disease vaccine. Vaccine. 1999 Feb 26;17(7-8):904-14. DMF5ZB3 RU https://pubmed.ncbi.nlm.nih.gov/10067697 DMF6Y0L DI DMF6Y0L DMF6Y0L DN Polatuzumab vedotin DMF6Y0L TI TTBN5I7 DMF6Y0L TN B-cell-specific glycoprotein B29 (CD79B) DMF6Y0L RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019 DMF6Y0L RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761121s000lbl.pdf DMF6Z5T DI DMF6Z5T DMF6Z5T DN Glecaprevir; pibrentasvir DMF6Z5T TI TTHC7JD DMF6Z5T TN Hepatitis C virus Serine protease NS3/4A (HCV NS3/4A) DMF6Z5T MA Inhibitor DMF6Z5T RN 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85. DMF6Z5T RU https://pubmed.ncbi.nlm.nih.gov/29348678 DMF6Z5T DI DMF6Z5T DMF6Z5T DN Glecaprevir; pibrentasvir DMF6Z5T TI TTCJ2X8 DMF6Z5T TN Hepatitis C virus Non-structural 5A (HCV NS5A) DMF6Z5T MA Inhibitor DMF6Z5T RN 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85. DMF6Z5T RU https://pubmed.ncbi.nlm.nih.gov/29348678 DMF8DNE DI DMF8DNE DMF8DNE DN Framycetin DMF8DNE TI TTQ8KVI DMF8DNE TN Staphylococcus 30S ribosomal subunit (Stap-coc pbp2) DMF8DNE MA Binder DMF8DNE RN Characterization of a 30S ribosomal subunit assembly intermediate found in Escherichia coli cells growing with neomycin or paromomycin. Arch Microbiol. 2008 May;189(5):441-9. DMF8DNE RU https://pubmed.ncbi.nlm.nih.gov/18060665 DMF8DNE DI DMF8DNE DMF8DNE DN Framycetin DMF8DNE TI TT38DW5 DMF8DNE TN Bacterial 16S ribosomal RNA (Bact 16S rRNA) DMF8DNE MA Binder DMF8DNE RN Antistaphylococcal activity of gentamicin. Minerva Med. 1975 Dec 8;66(84):4505-26. DMF8DNE RU https://pubmed.ncbi.nlm.nih.gov/1105242 DMF8Y74 DI DMF8Y74 DMF8Y74 DN Hydroxyzine DMF8Y74 TI TTTIBOJ DMF8Y74 TN Histamine H1 receptor (H1R) DMF8Y74 MA Antagonist DMF8Y74 RN Hydroxyzine, a first generation H(1)-receptor antagonist, inhibits human ether-a-go-go-related gene (HERG) current and causes syncope in a patient ... J Pharmacol Sci. 2008 Dec;108(4):462-71. DMF8Y74 RU https://pubmed.ncbi.nlm.nih.gov/19057127 DMF9G7L DI DMF9G7L DMF9G7L DN Dibucaine DMF9G7L TI TTZOVE0 DMF9G7L TN Voltage-gated sodium channel alpha Nav1.5 (SCN5A) DMF9G7L MA Blocker DMF9G7L RN Halothane attenuates the cerebroprotective action of several Na+ and Ca2+ channel blockers via reversal of their ion channel blockade. Eur J Pharmacol. 2002 Oct 4;452(2):175-81. DMF9G7L RU https://pubmed.ncbi.nlm.nih.gov/12354567 DMF9O6B DI DMF9O6B DMF9O6B DN Gallium nitrate DMF9O6B TI TTRYK0X DMF9O6B TN Interleukin-1 beta (IL1B) DMF9O6B MA Inhibitor DMF9O6B RN Elimination of arthritis pain and inflammation for over 2 years with a single 90 min, topical 14% gallium nitrate treatment: case reports and revie... Med Hypotheses. 2005;65(6):1136-41. DMF9O6B RU https://pubmed.ncbi.nlm.nih.gov/16122880 DMFA5MY DI DMFA5MY DMFA5MY DN Metoclopramide DMFA5MY TI TTEX248 DMFA5MY TN Dopamine D2 receptor (D2R) DMFA5MY MA Antagonist DMFA5MY RN Mechanisms for metoclopramide-mediated sensitization and haloperidol-induced catalepsy in rats. Eur J Pharmacol. 2008 Jun 10;587(1-3):181-6. DMFA5MY RU https://pubmed.ncbi.nlm.nih.gov/18457824 DMFA9MV DI DMFA9MV DMFA9MV DN Efinaconazole DMFA9MV TI TTTSOUD DMFA9MV TN Candida Cytochrome P450 51 (Candi ERG11) DMFA9MV MA Inhibitor DMFA9MV RN Efinaconazole: Developmental and reproductive toxicity potential of a novel antifungal azole. Reprod Toxicol. 2015 Apr;52:18-25. DMFA9MV RU https://pubmed.ncbi.nlm.nih.gov/25527861 DMFAOKP DI DMFAOKP DMFAOKP DN Fenoldopam DMFAOKP TI TTZFYLI DMFAOKP TN Dopamine D1 receptor (D1R) DMFAOKP MA Agonist DMFAOKP RN Etiology of iodinated radiocontrast nephrotoxicity and its attenuation by beraprost. Yakugaku Zasshi. 2008 Jul;128(7):1023-9. DMFAOKP RU https://pubmed.ncbi.nlm.nih.gov/18591870 DMFB97P DI DMFB97P DMFB97P DN Dihydrotachysterol DMFB97P TI TTK59TV DMFB97P TN Vitamin D3 receptor (VDR) DMFB97P MA Antagonist DMFB97P RN In vivo metabolism of the vitamin D analog, dihydrotachysterol. Evidence for formation of 1 alpha,25- and 1 beta,25-dihydroxy-dihydrotachysterol metabolites and studies of their biological activity. J Biol Chem. 1993 Jan 5;268(1):282-92. DMFB97P RU https://pubmed.ncbi.nlm.nih.gov/8380156 DMFC41K DI DMFC41K DMFC41K DN Tafluprost DMFC41K TI TTT2ZAR DMFC41K TN Prostaglandin F2-alpha receptor (PTGFR) DMFC41K MA Modulator DMFC41K RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DMFC41K RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DMFC71L DI DMFC71L DMFC71L DN Clozapine DMFC71L TI TTE0A2F DMFC71L TN Dopamine D4 receptor (D4R) DMFC71L MA Modulator DMFC71L RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMFC71L RU https://www.fda.gov/ DMFCLYW DI DMFCLYW DMFCLYW DN Moxisylyte DMFCLYW TI TT34BHT DMFCLYW TN Adrenergic receptor alpha-1D (ADRA1D) DMFCLYW MA Modulator DMFCLYW RN Pharmacokinetics of moxisylyte in healthy volunteers after intracavernous injection of increasing doses. Eur J Clin Pharmacol. 1996;49(5):411-5. DMFCLYW RU https://pubmed.ncbi.nlm.nih.gov/8866639 DMFD9Q6 DI DMFD9Q6 DMFD9Q6 DN Cetrorelix DMFD9Q6 TI TT8R70G DMFD9Q6 TN Gonadotropin-releasing hormone receptor (GNRHR) DMFD9Q6 MA Antagonist DMFD9Q6 RN Gonadotropin releasing hormone analogs induce apoptosis by extrinsic pathway involving p53 phosphorylation in primary cell cultures of human prostatic adenocarcinomas. Prostate. 2009 Jul 1;69(10):1025-33. DMFD9Q6 RU https://pubmed.ncbi.nlm.nih.gov/19301301 DMFDC0Q DI DMFDC0Q DMFDC0Q DN Tiotropium DMFDC0Q TI TTQ13Z5 DMFDC0Q TN Muscarinic acetylcholine receptor M3 (CHRM3) DMFDC0Q MA Antagonist DMFDC0Q RN DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6. DMFDC0Q RU https://pubmed.ncbi.nlm.nih.gov/18048412 DMFDC0Q DI DMFDC0Q DMFDC0Q DN Tiotropium DMFDC0Q TI TTOXS3C DMFDC0Q TN Muscarinic acetylcholine receptor (CHRM) DMFDC0Q MA Antagonist DMFDC0Q RN Pharmacological characterization of GSK573719 (umeclidinium): a novel, long-acting, inhaled antagonist of the muscarinic cholinergic receptors for treatment of pulmonary diseases. J Pharmacol Exp Ther. 2013 May;345(2):260-70. DMFDC0Q RU https://pubmed.ncbi.nlm.nih.gov/23435542 DMFEGB0 DI DMFEGB0 DMFEGB0 DN Segesterone acetate; ethinyl estradiol DMFEGB0 TI TTUV8G9 DMFEGB0 TN Progesterone receptor (PGR) DMFEGB0 MA Modulator DMFEGB0 RN 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. DMFEGB0 RU https://pubmed.ncbi.nlm.nih.gov/30710142 DMFEGB0 DI DMFEGB0 DMFEGB0 DN Segesterone acetate; ethinyl estradiol DMFEGB0 TI TTDSB34 DMFEGB0 TN G-protein coupled estrogen receptor 1 (GPER1) DMFEGB0 MA Modulator DMFEGB0 RN 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. DMFEGB0 RU https://pubmed.ncbi.nlm.nih.gov/30710142 DMFEHXD DI DMFEHXD DMFEHXD DN Natamycin DMFEHXD TI TTAH0B3 DMFEHXD TN Fungal Cell membrane (Fung CM) DMFEHXD MA Binder DMFEHXD RN Natamycin blocks fungal growth by binding specifically to ergosterol without permeabilizing the membrane. J Biol Chem. 2008 Mar 7;283(10):6393-401. DMFEHXD RU https://pubmed.ncbi.nlm.nih.gov/18165687 DMFETDK DI DMFETDK DMFETDK DN Artemisinin SP DMFETDK TI TTZVSJ2 DMFETDK TN Sarcoplasmic/endoplasmic reticulum calcium ATPase (ATP2A) DMFETDK MA Inhibitor DMFETDK RN The fight against drug-resistant malaria: novel plasmodial targets and antimalarial drugs. Curr Med Chem. 2008;15(2):161-71. DMFETDK RU https://pubmed.ncbi.nlm.nih.gov/18220771 DMFETDK DI DMFETDK DMFETDK DN Artemisinin SP DMFETDK TI TTAN6JD DMFETDK TN Glutamate receptor AMPA (GRIA) DMFETDK MA Agonist DMFETDK RN GABA(A) receptor ligands and their therapeutic potentials. Curr Top Med Chem. 2002 Aug;2(8):817-32. DMFETDK RU https://pubmed.ncbi.nlm.nih.gov/12171573 DMFGND4 DI DMFGND4 DMFGND4 DN Aminocaproic acid DMFGND4 TI TTP86E2 DMFGND4 TN Plasminogen (PLG) DMFGND4 MA Inhibitor DMFGND4 RN The blockage of the high-affinity lysine binding sites of plasminogen by EACA significantly inhibits prourokinase-induced plasminogen activation. Biochim Biophys Acta. 2002 Apr 29;1596(2):182-92. DMFGND4 RU https://pubmed.ncbi.nlm.nih.gov/12007600 DMFGND4 DI DMFGND4 DMFGND4 DN Aminocaproic acid DMFGND4 TI TTXAGYU DMFGND4 TN Tissue-type plasminogen activator (PLAT) DMFGND4 MA Inhibitor DMFGND4 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMFGND4 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMFGQ2S DI DMFGQ2S DMFGQ2S DN Erythrityl Tetranitrate DMFGQ2S TI TT6HPVC DMFGQ2S TN Guanylate cyclase (GC) DMFGQ2S MA Stimulator DMFGQ2S RN Nitric oxide and nitric oxide synthase isoforms in the normal, hypertrophic, and failing heart. Mol Cell Biochem. 2010 Jan;333(1-2):191-201. DMFGQ2S RU https://pubmed.ncbi.nlm.nih.gov/19618122 DMFH15Z DI DMFH15Z DMFH15Z DN Bendamustine hydrochloride DMFH15Z TI TTUTN1I DMFH15Z TN Human Deoxyribonucleic acid (hDNA) DMFH15Z MA Modulator DMFH15Z RN 2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6. DMFH15Z RU https://pubmed.ncbi.nlm.nih.gov/19180096 DMFI46A DI DMFI46A DMFI46A DN Argatroban DMFI46A TI TT6L509 DMFI46A TN Coagulation factor IIa (F2) DMFI46A MA Inhibitor DMFI46A RN Studies on the different modes of action of the anticoagulant protease inhibitors DX-9065a and Argatroban. I. Effects on thrombin generation. J Biol Chem. 2002 Dec 27;277(52):50439-44. DMFI46A RU https://pubmed.ncbi.nlm.nih.gov/12496240 DMFI8A7 DI DMFI8A7 DMFI8A7 DN Tranexamic acid DMFI8A7 TI TTP86E2 DMFI8A7 TN Plasminogen (PLG) DMFI8A7 MA Inhibitor DMFI8A7 RN Evaluation of aprotinin and tranexamic acid in different in vitro and in vivo models of fibrinolysis, coagulation and thrombus formation. J Thromb Haemost. 2007 Oct;5(10):2113-8. DMFI8A7 RU https://pubmed.ncbi.nlm.nih.gov/17666018 DMFIC0M DI DMFIC0M DMFIC0M DN Cinalukast DMFIC0M TI TTGKOY9 DMFIC0M TN Leukotriene CysLT1 receptor (CYSLTR1) DMFIC0M MA Antagonist DMFIC0M RN Prolonged protection against exercise-induced bronchoconstriction by the leukotriene D4-receptor antagonist cinalukast. J Allergy Clin Immunol. 1997 Feb;99(2):210-5. DMFIC0M RU https://pubmed.ncbi.nlm.nih.gov/9042047 DMFIQ2H DI DMFIQ2H DMFIQ2H DN Migalastat DMFIQ2H TI TTIS03D DMFIQ2H TN Alpha-galactosidase A (GLA) DMFIQ2H MA Modulator DMFIQ2H RN AT-1001: a high-affinity alpha3beta4 nAChR ligand with novel nicotine-suppressive pharmacology. Br J Pharmacol. 2015 Apr;172(7):1834-45. DMFIQ2H RU https://pubmed.ncbi.nlm.nih.gov/25440006 DMFJ2OG DI DMFJ2OG DMFJ2OG DN Collagenase DMFJ2OG TI TTK982E DMFJ2OG TN Collagen (CO) DMFJ2OG MA Breaker DMFJ2OG RN Contact dermatitis with clostridiopeptidase A contained in Noruxol ointment. Contact Dermatitis. 2007 Jun;56(6):361-2. DMFJ2OG RU https://pubmed.ncbi.nlm.nih.gov/17577383 DMFJ8LT DI DMFJ8LT DMFJ8LT DN Ibutamoren DMFJ8LT TI TTWDC17 DMFJ8LT TN Growth hormone secretagogue receptor 1 (GHSR) DMFJ8LT MA Modulator DMFJ8LT RN Design and biological activities of L-163,191 (MK-0677): a potent, orally active growth hormone secretagogue. Proc Natl Acad Sci U S A. 1995 Jul 18;92(15):7001-5. DMFJ8LT RU https://www.ncbi.nlm.nih.gov/pubmed/7624358 DMFJH5Q DI DMFJH5Q DMFJH5Q DN Mephentermine DMFJH5Q TI TTEX248 DMFJH5Q TN Dopamine D2 receptor (D2R) DMFJH5Q MA Agonist DMFJH5Q RN Present state of alpha- and beta-adrenergic drugs I. The adrenergic receptor. Am Heart J. 1976 Nov;92(5):661-4. DMFJH5Q RU https://pubmed.ncbi.nlm.nih.gov/10722 DMFJTDI DI DMFJTDI DMFJTDI DN Sibutramine DMFJTDI TI TTAWNKZ DMFJTDI TN Norepinephrine transporter (NET) DMFJTDI MA Modulator DMFJTDI RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMFJTDI RU https://www.fda.gov/ DMFJTDI DI DMFJTDI DMFJTDI DN Sibutramine DMFJTDI TI TT3ROYC DMFJTDI TN Serotonin transporter (SERT) DMFJTDI MA Modulator DMFJTDI RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMFJTDI RU https://www.fda.gov/ DMFJZN0 DI DMFJZN0 DMFJZN0 DN Romosozumab DMFJZN0 TI TTYRO4F DMFJZN0 TN Sclerostin (SOST) DMFJZN0 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019 DMFJZN0 RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761062s000lbl.pdf DMFK9HG DI DMFK9HG DMFK9HG DN Escitalopram DMFK9HG TI TT3ROYC DMFK9HG TN Serotonin transporter (SERT) DMFK9HG MA Inhibitor DMFK9HG RN Antidepressants and sleep: a review. Perspect Psychiatr Care. 2009 Jul;45(3):191-7. DMFK9HG RU https://pubmed.ncbi.nlm.nih.gov/19566691 DMFKXDY DI DMFKXDY DMFKXDY DN Fenofibrate DMFKXDY TI TTJ584C DMFKXDY TN Peroxisome proliferator-activated receptor alpha (PPARA) DMFKXDY MA Agonist DMFKXDY RN Peroxisome proliferator-activated receptor alpha activators improve insulin sensitivity and reduce adiposity. J Biol Chem. 2000 Jun 2;275(22):16638-42. DMFKXDY RU https://pubmed.ncbi.nlm.nih.gov/10828060 DMFLUTR DI DMFLUTR DMFLUTR DN Glucagon recombinant DMFLUTR TI TT9O6WS DMFLUTR TN Glucagon receptor (GCGR) DMFLUTR MA Binder DMFLUTR RN Glucagon receptor expression and glucagon stimulation of ghrelin secretion in rat stomach. Biochem Biophys Res Commun. 2007 Jun 15;357(4):865-70. DMFLUTR RU https://pubmed.ncbi.nlm.nih.gov/17462598 DMFMBZ4 DI DMFMBZ4 DMFMBZ4 DN Zanamivir DMFMBZ4 TI TT50QJ3 DMFMBZ4 TN Influenza Neuraminidase (Influ NA) DMFMBZ4 MA Inhibitor DMFMBZ4 RN Current and future antiviral therapy of severe seasonal and avian influenza. Antiviral Res. 2008 Apr;78(1):91-102. DMFMBZ4 RU https://pubmed.ncbi.nlm.nih.gov/18328578 DMFMDOB DI DMFMDOB DMFMDOB DN Carteolol DMFMDOB TI TTR6W5O DMFMDOB TN Adrenergic receptor beta-1 (ADRB1) DMFMDOB MA Agonist DMFMDOB RN Partial agonistic effects of carteolol on atypical beta-adrenoceptors in the guinea pig gastric fundus. Jpn J Pharmacol. 2000 Nov;84(3):287-92. DMFMDOB RU https://pubmed.ncbi.nlm.nih.gov/11138729 DMFMZ3G DI DMFMZ3G DMFMZ3G DN Choriogonadotropin alfa DMFMZ3G TI TT2O4W9 DMFMZ3G TN Luteinizing hormone receptor (LHCGR) DMFMZ3G MA Modulator DMFMZ3G RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMFMZ3G RU https://www.fda.gov/ DMFN07X DI DMFN07X DMFN07X DN Nilutamide DMFN07X TI TTS64P2 DMFN07X TN Androgen receptor (AR) DMFN07X MA Antagonist DMFN07X RN CX3CR1 is expressed by prostate epithelial cells and androgens regulate the levels of CX3CL1/fractalkine in the bone marrow: potential role in prostate cancer bone tropism. Cancer Res. 2008 Mar 15;68(6):1715-22. DMFN07X RU https://pubmed.ncbi.nlm.nih.gov/18339851 DMFNAEM DI DMFNAEM DMFNAEM DN Sulfaphenazole DMFNAEM TI TTR40YJ DMFNAEM TN S-mephenytoin 4-hydroxylase (CYP2C9) DMFNAEM MA Modulator DMFNAEM RN Identification of amino acid substitutions that confer a high affinity for sulfaphenazole binding and a high catalytic efficiency for warfarin meta... Biochemistry. 1998 Nov 17;37(46):16270-9. DMFNAEM RU https://www.ncbi.nlm.nih.gov/pubmed/9819219 DMFNH7L DI DMFNH7L DMFNH7L DN Pentobarbital DMFNH7L TI TT1MPAY DMFNH7L TN GABA(A) receptor alpha-1 (GABRA1) DMFNH7L MA Antagonist DMFNH7L RN DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6. DMFNH7L RU https://pubmed.ncbi.nlm.nih.gov/18048412 DMFO843 DI DMFO843 DMFO843 DN Fluspirilene DMFO843 TI TTEX248 DMFO843 TN Dopamine D2 receptor (D2R) DMFO843 MA Antagonist DMFO843 RN Inhibition of glutamate release by fluspirilene in cerebrocortical nerve terminals (synaptosomes). Synapse. 2002 Apr;44(1):36-41. DMFO843 RU https://pubmed.ncbi.nlm.nih.gov/11842444 DMFOIA8 DI DMFOIA8 DMFOIA8 DN Nesiritide DMFOIA8 TI TTJME02 DMFOIA8 TN Atrial natriuretic peptide receptor A (NPR1) DMFOIA8 MA Binder DMFOIA8 RN The efficacy and safety of B-type natriuretic peptide (nesiritide) in patients with renal insufficiency and acutely decompensated congestive heart failure. Nephrol Dial Transplant. 2004 Feb;19(2):391-9. DMFOIA8 RU https://pubmed.ncbi.nlm.nih.gov/14736964 DMFOTZ7 DI DMFOTZ7 DMFOTZ7 DN Racecadotril DMFOTZ7 TI TT8CYO4 DMFOTZ7 TN Endopeptidase (ENP) DMFOTZ7 MA Modulator DMFOTZ7 RN A comprehensive review of the pharmacodynamics, pharmacokinetics, and clinical effects of the neutral endopeptidase inhibitor racecadotril. Front Pharmacol. 2012 May 30;3:93. DMFOTZ7 RU https://pubmed.ncbi.nlm.nih.gov/22661949 DMFOVSD DI DMFOVSD DMFOVSD DN Brompheniramine DMFOVSD TI TTTIBOJ DMFOVSD TN Histamine H1 receptor (H1R) DMFOVSD MA Antagonist DMFOVSD RN Histamine-induced venodilation in human beings involves both H1 and H2 receptor subtypes. J Allergy Clin Immunol. 1994 Mar;93(3):606-14. DMFOVSD RU https://pubmed.ncbi.nlm.nih.gov/8151062 DMFP6MV DI DMFP6MV DMFP6MV DN Fidaxomicin DMFP6MV TI TTIJ5EB DMFP6MV TN Bacterial RNA polymerase switch region (Bact RNAP-SR) DMFP6MV MA Modulator DMFP6MV RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DMFP6MV RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DMFQ320 DI DMFQ320 DMFQ320 DN Ipratropium DMFQ320 TI TTQ13Z5 DMFQ320 TN Muscarinic acetylcholine receptor M3 (CHRM3) DMFQ320 MA Modulator DMFQ320 RN Role of parasympathetic nerves and muscarinic receptors in allergy and asthma.Chem Immunol Allergy.2012;98:48-69. DMFQ320 RU https://www.ncbi.nlm.nih.gov/pubmed/22767057 DMFQCB1 DI DMFQCB1 DMFQCB1 DN Dicumarol DMFQCB1 TI TTEUC8H DMFQCB1 TN Vitamin K epoxide reductase complex 1 (VKORC1) DMFQCB1 MA Inhibitor DMFQCB1 RN Vitamin K antagonism of coumarin intoxication in the rat. Thromb Haemost. 1986 Apr 30;55(2):235-9. DMFQCB1 RU https://pubmed.ncbi.nlm.nih.gov/2424118 DMFQEA6 DI DMFQEA6 DMFQEA6 DN Pembrolizumab DMFQEA6 TI TTNBFWK DMFQEA6 TN Programmed cell death protein 1 (PD-1) DMFQEA6 RN Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730. DMFQEA6 RU https://pubmed.ncbi.nlm.nih.gov/30247903 DMFR201 DI DMFR201 DMFR201 DN Vibegron DMFR201 TI TTMXGCW DMFR201 TN Adrenergic receptor beta-3 (ADRB3) DMFR201 MA Agonist DMFR201 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020 DMFR201 RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213006s000lbl.pdf DMFRM1I DI DMFRM1I DMFRM1I DN Canagliflozin DMFRM1I TI TTLWPVF DMFRM1I TN Sodium/glucose cotransporter 2 (SGLT2) DMFRM1I MA Modulator DMFRM1I RN Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651. DMFRM1I RU https://pubmed.ncbi.nlm.nih.gov/28919714 DMFS63G DI DMFS63G DMFS63G DN Enfortumab DMFS63G TI TTPO9EG DMFS63G TN Nectin cell adhesion molecule 4 (NECTIN4) DMFS63G MA Inhibitor DMFS63G RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019 DMFS63G RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761137s000lbl.pdf DMFSWGH DI DMFSWGH DMFSWGH DN Econazole DMFSWGH TI TTTSOUD DMFSWGH TN Candida Cytochrome P450 51 (Candi ERG11) DMFSWGH MA Inhibitor DMFSWGH RN Differential azole antifungal efficacies contrasted using a Saccharomyces cerevisiae strain humanized for sterol 14 alpha-demethylase at the homolo... Antimicrob Agents Chemother. 2008 Oct;52(10):3597-603. DMFSWGH RU https://pubmed.ncbi.nlm.nih.gov/18694951 DMFT73E DI DMFT73E DMFT73E DN Chorionic Gonadotropin DMFT73E TI TT2O4W9 DMFT73E TN Luteinizing hormone receptor (LHCGR) DMFT73E MA Modulator DMFT73E RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMFT73E RU https://www.fda.gov/ DMFUAXT DI DMFUAXT DMFUAXT DN H1N1 pandemic influenza A vaccine DMFUAXT TI TT3J5ZI DMFUAXT TN Cell mediated immunity response (CMIR) DMFUAXT RN How Influenza (Flu) Vaccines Are Made. FLU.gov. 2014. DMFUAXT RU http://www.flu.gov/about_the_flu/h1n1/ DMFWKG1 DI DMFWKG1 DMFWKG1 DN Nandrolone DMFWKG1 TI TTS64P2 DMFWKG1 TN Androgen receptor (AR) DMFWKG1 MA Agonist DMFWKG1 RN Expression of androgen receptor on fibroblast and hepatocyte of rats after deep second-degree burn caused by scalding. Sichuan Da Xue Xue Bao Yi Xue Ban. 2005 May;36(3):362-4. DMFWKG1 RU https://pubmed.ncbi.nlm.nih.gov/15931869 DMFX9O6 DI DMFX9O6 DMFX9O6 DN SM-101 DMFX9O6 TI TTXT21W DMFX9O6 TN Immunoglobulin gamma Fc receptor IIA (FCGR2A) DMFX9O6 MA Antagonist DMFX9O6 RN Emerging drugs for idiopathic thrombocytopenic purpura in adults. Expert Opin Emerg Drugs. 2008 Jun;13(2):237-54. DMFX9O6 RU https://pubmed.ncbi.nlm.nih.gov/18537519 DMFX9O6 DI DMFX9O6 DMFX9O6 DN SM-101 DMFX9O6 TI TTYT93M DMFX9O6 TN MAP kinase p38 (MAPK12) DMFX9O6 MA Inhibitor DMFX9O6 RN Agents in development for the treatment of diabetic nephropathy. Expert Opin Emerg Drugs. 2008 Sep;13(3):447-63. DMFX9O6 RU https://pubmed.ncbi.nlm.nih.gov/18764722 DMFXEWT DI DMFXEWT DMFXEWT DN Chloramphenicol DMFXEWT TI TTLFGBV DMFXEWT TN Bacterial 23S ribosomal RNA (Bact 23S rRNA) DMFXEWT MA Binder DMFXEWT RN Inhibition of peptide bond formation by pleuromutilins: the structure of the 50S ribosomal subunit from Deinococcus radiodurans in complex with tiamulin. Mol Microbiol. 2004 Dec;54(5):1287-94. DMFXEWT RU https://pubmed.ncbi.nlm.nih.gov/15554968 DMFY307 DI DMFY307 DMFY307 DN Hexafluronium bromide DMFY307 TI TTEB0GD DMFY307 TN Cholinesterase (BCHE) DMFY307 MA Inhibitor DMFY307 RN Synergistic effect of acidosis and succinylcholine-induced hyperkalemia in spinal cord transected rats. Acta Anaesthesiol Scand. 1984 Feb;28(1):87-90. DMFY307 RU https://pubmed.ncbi.nlm.nih.gov/6711267 DMFYBD0 DI DMFYBD0 DMFYBD0 DN Dexibuprofen DMFYBD0 TI TTK0943 DMFYBD0 TN Prostaglandin G/H synthase (COX) DMFYBD0 MA Modulator DMFYBD0 RN Comparison of the efficacy and tolerability of dexibuprofen and celecoxib in the treatment of osteoarthritis of the hip. Int J Clin Pharmacol Ther. 2003 Apr;41(4):153-64. DMFYBD0 RU https://pubmed.ncbi.nlm.nih.gov/12708604 DMFYZKN DI DMFYZKN DMFYZKN DN Enprofylline DMFYZKN TI TTZ97H5 DMFYZKN TN Phosphodiesterase 4A (PDE4A) DMFYZKN MA Inhibitor DMFYZKN RN Effects of enprofylline, a new xanthine derivate, on human pregnant myometrium. Am J Obstet Gynecol. 1987 Apr;156(4):958-62. DMFYZKN RU https://pubmed.ncbi.nlm.nih.gov/3034059 DMFZBMQ DI DMFZBMQ DMFZBMQ DN Chloroxine DMFZBMQ TI TTQW87Y DMFZBMQ TN Opioid receptor kappa (OPRK1) DMFZBMQ MA Inhibitor DMFZBMQ RN In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6. DMFZBMQ RU https://pubmed.ncbi.nlm.nih.gov/21074425 DMG0H8K DI DMG0H8K DMG0H8K DN Bictegravir, emtricitabine and tenofovir alafenamide DMG0H8K TI TT84ETX DMG0H8K TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMG0H8K MA Inhibitor DMG0H8K RN 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. DMG0H8K RU https://pubmed.ncbi.nlm.nih.gov/30710142 DMG0H8K DI DMG0H8K DMG0H8K DN Bictegravir, emtricitabine and tenofovir alafenamide DMG0H8K TI TT5FH9Y DMG0H8K TN Human immunodeficiency virus Integrase (HIV IN) DMG0H8K MA Inhibitor DMG0H8K RN 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. DMG0H8K RU https://pubmed.ncbi.nlm.nih.gov/30710142 DMG1DTE DI DMG1DTE DMG1DTE DN Penfluridol DMG1DTE TI TT729IR DMG1DTE TN Voltage-gated calcium channel alpha Cav3.1 (CACNA1G) DMG1DTE MA Blocker DMG1DTE RN Differential inhibition of T-type calcium channels by neuroleptics. J Neurosci. 2002 Jan 15;22(2):396-403. DMG1DTE RU https://pubmed.ncbi.nlm.nih.gov/11784784 DMG281S DI DMG281S DMG281S DN Carboplatin DMG281S TI TTUTN1I DMG281S TN Human Deoxyribonucleic acid (hDNA) DMG281S MA Modulator DMG281S RN Inhibition of carboplatin-induced DNA interstrand cross-link repair by gemcitabine in patients receiving these drugs for platinum-resistant ovarian cancer.Clin Cancer Res.2010 Oct 1;16(19):4899-905. DMG281S RU https://www.ncbi.nlm.nih.gov/pubmed/20719935 DMG2KI4 DI DMG2KI4 DMG2KI4 DN Fluocinolone acetonide DMG2KI4 TI TTYRL6O DMG2KI4 TN Glucocorticoid receptor (NR3C1) DMG2KI4 MA Modulator DMG2KI4 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMG2KI4 RU https://www.fda.gov/ DMG2KW7 DI DMG2KW7 DMG2KW7 DN Menthol DMG2KW7 TI TTELV3W DMG2KW7 TN Transformation-sensitive protein p120 (TRPA1) DMG2KW7 MA Activator DMG2KW7 RN TRPV1-mediated itch in seasonal allergic rhinitis. Allergy. 2009 May;64(5):807-10. DMG2KW7 RU https://pubmed.ncbi.nlm.nih.gov/19220220 DMG2KW7 DI DMG2KW7 DMG2KW7 DN Menthol DMG2KW7 TI TTXDKTO DMG2KW7 TN Long transient receptor potential channel 8 (TRPM8) DMG2KW7 MA Activator DMG2KW7 RN TRPV1-mediated itch in seasonal allergic rhinitis. Allergy. 2009 May;64(5):807-10. DMG2KW7 RU https://pubmed.ncbi.nlm.nih.gov/19220220 DMG2SKR DI DMG2SKR DMG2SKR DN Tedizolid DMG2SKR TI TTUWYEA DMG2SKR TN Bacterial 50S ribosomal RNA (Bact 50S rRNA) DMG2SKR MA Modulator DMG2SKR RN 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81. DMG2SKR RU https://pubmed.ncbi.nlm.nih.gov/25633781 DMG2YBD DI DMG2YBD DMG2YBD DN Trifluridine DMG2YBD TI TTU6BFZ DMG2YBD TN Candida Thymidylate synthase (Candi TMP1) DMG2YBD MA Inhibitor DMG2YBD RN Trifluorothymidine induces cell death independently of p53. Nucleosides Nucleotides Nucleic Acids. 2008 Jun;27(6):699-703. DMG2YBD RU https://pubmed.ncbi.nlm.nih.gov/18600528 DMG3F94 DI DMG3F94 DMG3F94 DN Mestranol DMG3F94 TI TTZAYWL DMG3F94 TN Estrogen receptor (ESR) DMG3F94 MA Agonist DMG3F94 RN Short-term effects of environmentally relevant concentrations of EDC mixtures on Mytilus galloprovincialis digestive gland. Aquat Toxicol. 2008 May 30;87(4):272-9. DMG3F94 RU https://pubmed.ncbi.nlm.nih.gov/18374427 DMG592Q DI DMG592Q DMG592Q DN Solifenacin DMG592Q TI TTQ13Z5 DMG592Q TN Muscarinic acetylcholine receptor M3 (CHRM3) DMG592Q MA Antagonist DMG592Q RN Comparison of muscarinic receptor selectivity of solifenacin and oxybutynin in the bladder and submandibular gland of muscarinic receptor knockout ... Eur J Pharmacol. 2009 Aug 1;615(1-3):201-6. DMG592Q RU https://pubmed.ncbi.nlm.nih.gov/19446545 DMG594T DI DMG594T DMG594T DN Ibritumomab DMG594T TI TTUE541 DMG594T TN Leukocyte surface antigen Leu-16 (CD20) DMG594T RN Structure of the Fab fragment of therapeutic antibody Ofatumumab provides insights into the recognition mechanism with CD20. Mol Immunol. 2009 Jul;46(11-12):2419-23. DMG594T RU https://pubmed.ncbi.nlm.nih.gov/19427037 DMG60XN DI DMG60XN DMG60XN DN Phentermine DMG60XN TI TTAWNKZ DMG60XN TN Norepinephrine transporter (NET) DMG60XN MA Inhibitor DMG60XN RN Novel anti-obesity drugs. Expert Opin Investig Drugs. 2000 Jun;9(6):1317-26. DMG60XN RU https://pubmed.ncbi.nlm.nih.gov/11060745 DMG629M DI DMG629M DMG629M DN Rivastigmine DMG629M TI TT1RS9F DMG629M TN Acetylcholinesterase (AChE) DMG629M MA Modulator DMG629M RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2465). DMG629M RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2465 DMG6OYJ DI DMG6OYJ DMG6OYJ DN Lorcaserin DMG6OYJ TI TTWJBZ5 DMG6OYJ TN 5-HT 2C receptor (HTR2C) DMG6OYJ MA Agonist DMG6OYJ RN Anti-obesity drugs. Expert Opin Pharmacother. 2008 Jun;9(8):1339-50. DMG6OYJ RU https://pubmed.ncbi.nlm.nih.gov/18473708 DMG6ZU4 DI DMG6ZU4 DMG6ZU4 DN Lanreotide acetate DMG6ZU4 TI TTZ6T9E DMG6ZU4 TN Somatostatin receptor type 2 (SSTR2) DMG6ZU4 MA Modulator DMG6ZU4 RN Treatment strategies for acromegaly. Expert Opin Emerg Drugs. 2005 Nov;10(4):875-90. DMG6ZU4 RU https://pubmed.ncbi.nlm.nih.gov/16262568 DMG7SQK DI DMG7SQK DMG7SQK DN Rescinnamine DMG7SQK TI TTL69WB DMG7SQK TN Angiotensin-converting enzyme (ACE) DMG7SQK MA Inhibitor DMG7SQK RN Colorimetric determination of indolic drugs. Pak J Pharm Sci. 2005 Apr;18(2):48-51. DMG7SQK RU https://pubmed.ncbi.nlm.nih.gov/16431399 DMG814N DI DMG814N DMG814N DN Saquinavir DMG814N TI TT5FNQT DMG814N TN Human immunodeficiency virus Protease (HIV PR) DMG814N MA Inhibitor DMG814N RN PL-100, a novel HIV-1 protease inhibitor displaying a high genetic barrier to resistance: an in vitro selection study. J Med Virol. 2008 Dec;80(12):2053-63. DMG814N RU https://pubmed.ncbi.nlm.nih.gov/19040279 DMG8K57 DI DMG8K57 DMG8K57 DN Cortisone acetate DMG8K57 TI TTP3UTW DMG8K57 TN Steroid hormone receptor ERR (ESRR) DMG8K57 MA Modulator DMG8K57 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMG8K57 RU https://www.fda.gov/ DMG8MLJ DI DMG8MLJ DMG8MLJ DN Pneumococcal 13-valent conjugate vaccine DMG8MLJ TI TTY4IQ9 DMG8MLJ TN Corynebacterium Mutated CRM197 (Cory mTOX) DMG8MLJ MA Binder DMG8MLJ RN Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5. DMG8MLJ RU https://pubmed.ncbi.nlm.nih.gov/21283092 DMG9B1U DI DMG9B1U DMG9B1U DN Elvitegravir DMG9B1U TI TT5FH9Y DMG9B1U TN Human immunodeficiency virus Integrase (HIV IN) DMG9B1U MA Modulator DMG9B1U RN Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651. DMG9B1U RU https://pubmed.ncbi.nlm.nih.gov/28919714 DMG9HIA DI DMG9HIA DMG9HIA DN Urofollitropin DMG9HIA TI TTZFDBT DMG9HIA TN Follicle-stimulating hormone receptor (FSHR) DMG9HIA MA Binder DMG9HIA RN Follicle-stimulating hormone in clinical practice: an update. Treat Endocrinol. 2004;3(3):161-71. DMG9HIA RU https://pubmed.ncbi.nlm.nih.gov/16026112 DMGA9X0 DI DMGA9X0 DMGA9X0 DN Sodium nitroprusside DMGA9X0 TI TT23PYC DMGA9X0 TN Soluble guanylate cyclase (GCS) DMGA9X0 MA Modulator DMGA9X0 RN Stimulators and activators of soluble guanylate cyclase: review and potential therapeutic indications.Crit Care Res Pract.2012;2012:290805. DMGA9X0 RU https://www.ncbi.nlm.nih.gov/pubmed/22482042 DMGAZHU DI DMGAZHU DMGAZHU DN Quattvaxem DMGAZHU TI TT3J5ZI DMGAZHU TN Cell mediated immunity response (CMIR) DMGAZHU RN Double-blind study comparing the immunogenicity of a licensed DTwPHib-CRM197 conjugate vaccine (Quattvaxem) with three investigational, liquid formulations using lower doses of Hib-CRM197 conjugate. Vaccine. 2005 Feb 25;23(14):1715-9. DMGAZHU RU https://pubmed.ncbi.nlm.nih.gov/15705477 DMGB035 DI DMGB035 DMGB035 DN Armodafinil DMGB035 TI TT34BHT DMGB035 TN Adrenergic receptor alpha-1D (ADRA1D) DMGB035 MA Agonist DMGB035 RN Mechanisms of modafinil: A review of current research. Neuropsychiatr Dis Treat. 2007 June; 3(3): 349-364. DMGB035 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2654794/ DMGB5RE DI DMGB5RE DMGB5RE DN Tranylcypromine DMGB5RE TI TT3WG5C DMGB5RE TN Monoamine oxidase type A (MAO-A) DMGB5RE MA Inhibitor DMGB5RE RN Tramadol and another atypical opioid meperidine have exaggerated serotonin syndrome behavioural effects, but decreased analgesic effects, in genetically deficient serotonin transporter (SERT) mice. Int J Neuropsychopharmacol. 2009 Mar 11:1-11. DMGB5RE RU https://pubmed.ncbi.nlm.nih.gov/19275775 DMGB5RE DI DMGB5RE DMGB5RE DN Tranylcypromine DMGB5RE TI TTGP7BY DMGB5RE TN Monoamine oxidase type B (MAO-B) DMGB5RE MA Inhibitor DMGB5RE RN Tranylcypromine: new perspectives on an "old" drug. Eur Arch Psychiatry Clin Neurosci. 2006 Aug;256(5):268-73. DMGB5RE RU https://pubmed.ncbi.nlm.nih.gov/16927039 DMGB5RE DI DMGB5RE DMGB5RE DN Tranylcypromine DMGB5RE TI TT32XQJ DMGB5RE TN Monoamine oxidase (MAO) DMGB5RE MA Inhibitor DMGB5RE RN Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110. DMGB5RE RU https://www.ncbi.nlm.nih.gov/pubmed/25399762 DMGBKVD DI DMGBKVD DMGBKVD DN Gamma hydroxybutyric acid DMGBKVD TI TTDCVZW DMGBKVD TN Gamma-aminobutyric acid B receptor (GABBR) DMGBKVD MA Modulator DMGBKVD RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMGBKVD RU https://www.fda.gov/ DMGBPSH DI DMGBPSH DMGBPSH DN Homatropine Methylbromide DMGBPSH TI TTH18TF DMGBPSH TN Muscarinic acetylcholine receptor M5 (CHRM5) DMGBPSH MA Antagonist DMGBPSH RN Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. DMGBPSH RU https://pubmed.ncbi.nlm.nih.gov/17016423 DMGC5DB DI DMGC5DB DMGC5DB DN Ciprofibrate DMGC5DB TI TTJ584C DMGC5DB TN Peroxisome proliferator-activated receptor alpha (PPARA) DMGC5DB MA Agonist DMGC5DB RN Peroxisome proliferator-activated receptor alpha activators improve insulin sensitivity and reduce adiposity. J Biol Chem. 2000 Jun 2;275(22):16638-42. DMGC5DB RU https://pubmed.ncbi.nlm.nih.gov/10828060 DMGCHDS DI DMGCHDS DMGCHDS DN Sulfamethizole DMGCHDS TI TT4ILYC DMGCHDS TN Bacterial Dihydropteroate synthetase (Bact folP) DMGCHDS MA Inhibitor DMGCHDS RN Inhibition of bioluminescence in Photobacterium phosphoreum by sulfamethizole and its stimulation by thymine. Biochim Biophys Acta. 1990 Jun 26;1017(3):229-34. DMGCHDS RU https://pubmed.ncbi.nlm.nih.gov/2372557 DMGCSVF DI DMGCSVF DMGCSVF DN Fluticasone DMGCSVF TI TTYRL6O DMGCSVF TN Glucocorticoid receptor (NR3C1) DMGCSVF MA Antagonist DMGCSVF RN Fluticasone furoate nasal spray in allergic rhinitis. Drugs Today (Barc). 2008 Apr;44(4):251-60. DMGCSVF RU https://pubmed.ncbi.nlm.nih.gov/18536783 DMGD3YH DI DMGD3YH DMGD3YH DN Naldemedine Tosylate DMGD3YH TI TTKWM86 DMGD3YH TN Opioid receptor mu (MOP) DMGD3YH MA Antagonist DMGD3YH RN 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85. DMGD3YH RU https://pubmed.ncbi.nlm.nih.gov/29348678 DMGDKXN DI DMGDKXN DMGDKXN DN Sitagliptin DMGDKXN TI TTDIGC1 DMGDKXN TN Dipeptidyl peptidase 4 (DPP-4) DMGDKXN MA Inhibitor DMGDKXN RN Novel therapeutics for type 2 diabetes: incretin hormone mimetics (glucagon-like peptide-1 receptor agonists) and dipeptidyl peptidase-4 inhibitors. Pharmacol Ther. 2009 Oct;124(1):113-38. DMGDKXN RU https://pubmed.ncbi.nlm.nih.gov/19545590 DMGE0CW DI DMGE0CW DMGE0CW DN Glutethimide DMGE0CW TI TTVG215 DMGE0CW TN Debrisoquine 4-hydroxylase (CYP2D6) DMGE0CW MA Inducer DMGE0CW RN A study of the effects of large doses of glutethimide that were used for self-poisoning during pregnancy on human fetuses. Toxicol Ind Health. 2008 Feb-Mar;24(1-2):69-78. DMGE0CW RU https://pubmed.ncbi.nlm.nih.gov/18818183 DMGEATB DI DMGEATB DMGEATB DN Siltuximab DMGEATB TI TTT1V78 DMGEATB TN Interleukin-6 (IL6) DMGEATB RN 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81. DMGEATB RU https://pubmed.ncbi.nlm.nih.gov/25633781 DMGECIJ DI DMGECIJ DMGECIJ DN Blinatumomab DMGECIJ TI TTW640A DMGECIJ TN B-lymphocyte surface antigen B4 (CD19) DMGECIJ MA Modulator DMGECIJ RN 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81. DMGECIJ RU https://pubmed.ncbi.nlm.nih.gov/25633781 DMGECIJ DI DMGECIJ DMGECIJ DN Blinatumomab DMGECIJ TI TTUN7MC DMGECIJ TN T-cell surface glycoprotein CD3 (CD3) DMGECIJ MA Modulator DMGECIJ RN 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81. DMGECIJ RU https://pubmed.ncbi.nlm.nih.gov/25633781 DMGEMB7 DI DMGEMB7 DMGEMB7 DN Hydrocortisone DMGEMB7 TI TTYRL6O DMGEMB7 TN Glucocorticoid receptor (NR3C1) DMGEMB7 MA Modulator DMGEMB7 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMGEMB7 RU https://www.fda.gov/ DMGFB0E DI DMGFB0E DMGFB0E DN MOXONIDINE DMGFB0E TI TTWG9A4 DMGFB0E TN Adrenergic receptor alpha-2A (ADRA2A) DMGFB0E MA Inhibitor DMGFB0E RN Synthesis and pharmacologic evaluation of 2-endo-amino-3-exo-isopropylbicyclo[2.2.1]heptane: a potent imidazoline1 receptor specific agent. J Med Chem. 1996 Mar 15;39(6):1193-5. DMGFB0E RU https://pubmed.ncbi.nlm.nih.gov/8632424 DMGFB0E DI DMGFB0E DMGFB0E DN MOXONIDINE DMGFB0E TI TT2NUT5 DMGFB0E TN Adrenergic receptor alpha-2C (ADRA2C) DMGFB0E MA Inhibitor DMGFB0E RN Synthesis and pharmacologic evaluation of 2-endo-amino-3-exo-isopropylbicyclo[2.2.1]heptane: a potent imidazoline1 receptor specific agent. J Med Chem. 1996 Mar 15;39(6):1193-5. DMGFB0E RU https://pubmed.ncbi.nlm.nih.gov/8632424 DMGFB0E DI DMGFB0E DMGFB0E DN MOXONIDINE DMGFB0E TI TTWM4TY DMGFB0E TN Adrenergic receptor alpha-2B (ADRA2B) DMGFB0E MA Inhibitor DMGFB0E RN Synthesis and pharmacologic evaluation of 2-endo-amino-3-exo-isopropylbicyclo[2.2.1]heptane: a potent imidazoline1 receptor specific agent. J Med Chem. 1996 Mar 15;39(6):1193-5. DMGFB0E RU https://pubmed.ncbi.nlm.nih.gov/8632424 DMGFPU2 DI DMGFPU2 DMGFPU2 DN Linezolid DMGFPU2 TI TTLFGBV DMGFPU2 TN Bacterial 23S ribosomal RNA (Bact 23S rRNA) DMGFPU2 MA Binder DMGFPU2 RN Genome sequencing of linezolid-resistant Streptococcus pneumoniae mutants reveals novel mechanisms of resistance. Genome Res. 2009 Jul;19(7):1214-23. DMGFPU2 RU https://pubmed.ncbi.nlm.nih.gov/19351617 DMGFV3Z DI DMGFV3Z DMGFV3Z DN Nizatidine DMGFV3Z TI TTQHJ1K DMGFV3Z TN Histamine H2 receptor (H2R) DMGFV3Z MA Antagonist DMGFV3Z RN Does the use of nizatidine, as a pro-kinetic agent, improve gastric emptying in patients post-oesophagectomy J Gastrointest Surg. 2009 Mar;13(3):432-7. DMGFV3Z RU https://pubmed.ncbi.nlm.nih.gov/18979143 DMGFWSM DI DMGFWSM DMGFWSM DN Zaleplon DMGFWSM TI TT1MPAY DMGFWSM TN GABA(A) receptor alpha-1 (GABRA1) DMGFWSM MA Modulator DMGFWSM RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMGFWSM RU https://www.fda.gov/ DMGIZF5 DI DMGIZF5 DMGIZF5 DN Hydroxyflutamide DMGIZF5 TI TTS64P2 DMGIZF5 TN Androgen receptor (AR) DMGIZF5 MA Antagonist DMGIZF5 RN Drug insight: role of the androgen receptor in the development and progression of prostate cancer. Nat Clin Pract Oncol. 2007 Apr;4(4):236-44. DMGIZF5 RU https://pubmed.ncbi.nlm.nih.gov/17392714 DMGKT2L DI DMGKT2L DMGKT2L DN Pro-urokinase DMGKT2L TI TTGY7WI DMGKT2L TN Urokinase-type plasminogen activator (PLAU) DMGKT2L MA Modulator DMGKT2L RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2393). DMGKT2L RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2393 DMGKV9D DI DMGKV9D DMGKV9D DN Hydroxocobalamin DMGKV9D TI TTCQ21Y DMGKV9D TN Methylmalonyl-CoA mutase (MMUT) DMGKV9D MA Cofactor DMGKV9D RN Vitamin B12. Nippon Rinsho. 1999 Oct;57(10):2205-10. DMGKV9D RU https://pubmed.ncbi.nlm.nih.gov/10540863 DMGL19D DI DMGL19D DMGL19D DN Enzalutamide DMGL19D TI TTS64P2 DMGL19D TN Androgen receptor (AR) DMGL19D MA Modulator DMGL19D RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DMGL19D RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DMGLAX1 DI DMGLAX1 DMGLAX1 DN Halcinonide DMGLAX1 TI TTP3UTW DMGLAX1 TN Steroid hormone receptor ERR (ESRR) DMGLAX1 MA Modulator DMGLAX1 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMGLAX1 RU https://www.fda.gov/ DMGLP6S DI DMGLP6S DMGLP6S DN Sarpogrelate DMGLP6S TI TTJQOD7 DMGLP6S TN 5-HT 2A receptor (HTR2A) DMGLP6S MA Antagonist DMGLP6S RN Beneficial effects of sarpogrelate hydrochloride, a 5-HT2A receptor antagonist, supplemented with pioglitazone on diabetic model mice. Endocr Res. 2009;34(1-2):18-30. DMGLP6S RU https://pubmed.ncbi.nlm.nih.gov/19557588 DMGLUQS DI DMGLUQS DMGLUQS DN Rilonacept DMGLUQS TI TTRYK0X DMGLUQS TN Interleukin-1 beta (IL1B) DMGLUQS MA Modulator DMGLUQS RN 2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6. DMGLUQS RU https://pubmed.ncbi.nlm.nih.gov/19180096 DMGLX0T DI DMGLX0T DMGLX0T DN Grepafloxacin DMGLX0T TI TTN6J5F DMGLX0T TN Bacterial DNA gyrase (Bact gyrase) DMGLX0T MA Modulator DMGLX0T RN Grepafloxacin, a dimethyl derivative of ciprofloxacin, acts preferentially through gyrase in Streptococcus pneumoniae: role of the C-5 group in tar... Antimicrob Agents Chemother. 2002 Feb;46(2):582-5. DMGLX0T RU https://www.ncbi.nlm.nih.gov/pubmed/11796384 DMGLZ26 DI DMGLZ26 DMGLZ26 DN Practolol DMGLZ26 TI TTR6W5O DMGLZ26 TN Adrenergic receptor beta-1 (ADRB1) DMGLZ26 MA Antagonist DMGLZ26 RN Prostaglandin E2 synthesis elicited by adrenergic stimuli in guinea pig trachea is mediated primarily via activation of beta 2 adrenergic receptors. Prostaglandins. 1992 Nov;44(5):399-412. DMGLZ26 RU https://pubmed.ncbi.nlm.nih.gov/1335153 DMGM2Z6 DI DMGM2Z6 DMGM2Z6 DN Lonafarnib DMGM2Z6 TI TTXQKM3 DMGM2Z6 TN Farnesyl protein transferase (Ftase) DMGM2Z6 MA Modulator DMGM2Z6 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020 DMGM2Z6 RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213969s000lbl.pdf DMGMB30 DI DMGMB30 DMGMB30 DN Ganirelix DMGMB30 TI TT8R70G DMGMB30 TN Gonadotropin-releasing hormone receptor (GNRHR) DMGMB30 MA Antagonist DMGMB30 RN Age attenuates testosterone secretion driven by amplitude-varying pulses of recombinant human luteinizing hormone during acute gonadotrope inhibiti... J Clin Endocrinol Metab. 2007 Sep;92(9):3626-32. DMGMB30 RU https://pubmed.ncbi.nlm.nih.gov/17579202 DMGMF6V DI DMGMF6V DMGMF6V DN Capsaicin DMGMF6V TI TTMI6F5 DMGMF6V TN Transient receptor potential cation channel V1 (TRPV1) DMGMF6V MA Agonist DMGMF6V RN Capsaicin receptor: TRPV1 a promiscuous TRP channel. Handb Exp Pharmacol. 2007;(179):155-71. DMGMF6V RU https://pubmed.ncbi.nlm.nih.gov/17217056 DMGMNH3 DI DMGMNH3 DMGMNH3 DN Dalbavancin DMGMNH3 TI TTXMY0J DMGMNH3 TN Pancreatic triacylglycerol lipase (PNLIP) DMGMNH3 MA Inhibitor DMGMNH3 RN Pfizer. Product Development Pipeline. March 31 2009. DMGMNH3 RU http://media.pfizer.com/files/research/pipeline/2009_0331/pipeline_2009_0331.pdf DMGN1PW DI DMGN1PW DMGN1PW DN Indapamide DMGN1PW TI TT846HF DMGN1PW TN Voltage-gated potassium channel Kv7.1 (KCNQ1) DMGN1PW MA Blocker DMGN1PW RN Indapamide induces apoptosis of GH3 pituitary cells independently of its inhibition of voltage-dependent K+ currents. Eur J Pharmacol. 2006 Apr 24;536(1-2):78-84. DMGN1PW RU https://pubmed.ncbi.nlm.nih.gov/16556441 DMGN4BY DI DMGN4BY DMGN4BY DN Flurbiprofen DMGN4BY TI TTVKILB DMGN4BY TN Prostaglandin G/H synthase 2 (COX-2) DMGN4BY MA Modulator DMGN4BY RN Flurbiprofen, a cyclooxygenase inhibitor, protects mice from hepatic ischemia/reperfusion injury by inhibiting GSK-3 signaling and mitochondrial permeability transition.Mol Med.2012 Sep 25;18:1128-35. DMGN4BY RU https://www.ncbi.nlm.nih.gov/pubmed/22714712 DMGN5QD DI DMGN5QD DMGN5QD DN Protirelin DMGN5QD TI TT4J8MF DMGN5QD TN Thyrotropin-releasing hormone receptor (TRHR) DMGN5QD MA Modulator DMGN5QD RN Company report (takeda) DMGN5QD RU https://www.takeda.com/csr/reports/pdf/index/ar2010_04_en.pdf DMGNYIH DI DMGNYIH DMGNYIH DN Retigabine DMGNYIH TI TTIVDM3 DMGNYIH TN Voltage-gated potassium channel Kv7.3 (KCNQ3) DMGNYIH MA Modulator DMGNYIH RN The urinary safety profile and secondary renal effects of retigabine (ezogabine): a first-in-class antiepileptic drug that targets KCNQ (K(v)7) potassium channels. Epilepsia. 2012 Apr;53(4):606-12. DMGNYIH RU https://pubmed.ncbi.nlm.nih.gov/22428574 DMGNYIH DI DMGNYIH DMGNYIH DN Retigabine DMGNYIH TI TTQ29KF DMGNYIH TN Voltage-gated potassium channel Kv7 (KCNQ) DMGNYIH MA Activator DMGNYIH RN Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357. DMGNYIH RU https://pubmed.ncbi.nlm.nih.gov/30728472 DMGO2MC DI DMGO2MC DMGO2MC DN Fenofibric acid DMGO2MC TI TTIV96N DMGO2MC TN Fatty acid-binding protein 1 (FABP1) DMGO2MC MA Inhibitor DMGO2MC RN Characterization of the drug binding specificity of rat liver fatty acid binding protein. J Med Chem. 2008 Jul 10;51(13):3755-64. DMGO2MC RU https://pubmed.ncbi.nlm.nih.gov/18533710 DMGO72P DI DMGO72P DMGO72P DN Oseltamivir DMGO72P TI TT50QJ3 DMGO72P TN Influenza Neuraminidase (Influ NA) DMGO72P MA Inhibitor DMGO72P RN Current and future antiviral therapy of severe seasonal and avian influenza. Antiviral Res. 2008 Apr;78(1):91-102. DMGO72P RU https://pubmed.ncbi.nlm.nih.gov/18328578 DMGOVHA DI DMGOVHA DMGOVHA DN Cenobamate DMGOVHA TI TTIG65Q DMGOVHA TN Voltage-gated sodium channel (Nav) DMGOVHA MA Inhibitor DMGOVHA RN Effects of cenobamate (YKP3089), a newly developed anti-epileptic drug, on voltage-gated sodium channels in rat hippocampal CA3 neurons. Eur J Pharmacol. 2019 Jul 15;855:175-182. DMGOVHA RU https://pubmed.ncbi.nlm.nih.gov/31063770 DMGOXPQ DI DMGOXPQ DMGOXPQ DN DP-VPA DMGOXPQ TI TTNJYV2 DMGOXPQ TN Gamma-aminobutyric acid receptor (GAR) DMGOXPQ MA Modulator DMGOXPQ RN DP-VPA D-Pharm. Curr Opin Investig Drugs. 2002 Jun;3(6):921-3. DMGOXPQ RU https://pubmed.ncbi.nlm.nih.gov/12137414 DMGP8AX DI DMGP8AX DMGP8AX DN Thiopental DMGP8AX TI TTDP1UC DMGP8AX TN Fatty acid amide hydrolase (FAAH) DMGP8AX MA Inhibitor DMGP8AX RN The general anesthetic propofol increases brain N-arachidonylethanolamine (anandamide) content and inhibits fatty acid amide hydrolase. Br J Pharmacol. 2003 Jul;139(5):1005-13. DMGP8AX RU https://pubmed.ncbi.nlm.nih.gov/12839875 DMGQ0ZI DI DMGQ0ZI DMGQ0ZI DN Pralidoxime chloride DMGQ0ZI TI TT1RS9F DMGQ0ZI TN Acetylcholinesterase (AChE) DMGQ0ZI MA Modulator DMGQ0ZI RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMGQ0ZI RU https://www.fda.gov/ DMGQFYB DI DMGQFYB DMGQFYB DN Mecamylamine DMGQFYB TI TTJSZTB DMGQFYB TN Nicotinic acetylcholine receptor (nAChR) DMGQFYB MA Antagonist DMGQFYB RN Mecamylamine (Inversine): an old antihypertensive with new research directions. J Hum Hypertens. 2002 Jul;16(7):453-7. DMGQFYB RU https://pubmed.ncbi.nlm.nih.gov/12080428 DMGQIPT DI DMGQIPT DMGQIPT DN Caspofungin DMGQIPT TI TT0SFXH DMGQIPT TN Fungal 1,3-beta-glucan synthase (Fung GSC2) DMGQIPT MA Modulator DMGQIPT RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMGQIPT RU https://www.fda.gov/ DMGQU0Y DI DMGQU0Y DMGQU0Y DN Piperacetazine DMGQU0Y TI TTEX248 DMGQU0Y TN Dopamine D2 receptor (D2R) DMGQU0Y MA Modulator DMGQU0Y RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMGQU0Y RU https://www.fda.gov/ DMGR5Z3 DI DMGR5Z3 DMGR5Z3 DN Flunitrazepam DMGR5Z3 TI TTPTXIN DMGR5Z3 TN Translocator protein (TSPO) DMGR5Z3 MA Agonist DMGR5Z3 RN Comparison of five benzodiazepine-receptor agonists on buprenorphine-induced mu-opioid receptor regulation. J Pharmacol Sci. 2009 May;110(1):36-46. DMGR5Z3 RU https://pubmed.ncbi.nlm.nih.gov/19443999 DMGS4QH DI DMGS4QH DMGS4QH DN Methacholine Chloride DMGS4QH TI TTYEG6Q DMGS4QH TN Muscarinic acetylcholine receptor M2 (CHRM2) DMGS4QH MA Inhibitor DMGS4QH RN 6beta-Acetoxynortropane: a potent muscarinic agonist with apparent selectivity toward M2-receptors. J Med Chem. 1998 Jun 4;41(12):2047-55. DMGS4QH RU https://pubmed.ncbi.nlm.nih.gov/9622546 DMGS4QH DI DMGS4QH DMGS4QH DN Methacholine Chloride DMGS4QH TI TTQ3JTF DMGS4QH TN Muscarinic acetylcholine receptor M4 (CHRM4) DMGS4QH MA Inhibitor DMGS4QH RN 6beta-Acetoxynortropane: a potent muscarinic agonist with apparent selectivity toward M2-receptors. J Med Chem. 1998 Jun 4;41(12):2047-55. DMGS4QH RU https://pubmed.ncbi.nlm.nih.gov/9622546 DMGS4QH DI DMGS4QH DMGS4QH DN Methacholine Chloride DMGS4QH TI TTQ13Z5 DMGS4QH TN Muscarinic acetylcholine receptor M3 (CHRM3) DMGS4QH MA Modulator DMGS4QH RN Muscarinic M3-receptors mediate cholinergic synergism of mitogenesis in airway smooth muscle. Am J Respir Cell Mol Biol. 2003 Feb;28(2):257-62. DMGS4QH RU https://pubmed.ncbi.nlm.nih.gov/12540494 DMGS80V DI DMGS80V DMGS80V DN Levorphanol DMGS80V TI TTN4QDT DMGS80V TN Opioid receptor (OPR) DMGS80V MA Agonist DMGS80V RN Comparison of the effects of dextromethorphan, dextrorphan, and levorphanol on the hypothalamo-pituitary-adrenal axis. J Pharmacol Exp Ther. 2004 May;309(2):515-22. DMGS80V RU https://pubmed.ncbi.nlm.nih.gov/14742749 DMGS80V DI DMGS80V DMGS80V DN Levorphanol DMGS80V TI TT9IK2Z DMGS80V TN N-methyl-D-aspartate receptor (NMDAR) DMGS80V MA Antagonist DMGS80V RN Neuroprotective agents for the treatment of acute ischemic stroke. Curr Neurol Neurosci Rep. 2003 Jan;3(1):9-20. DMGS80V RU https://pubmed.ncbi.nlm.nih.gov/12507405 DMGSRN1 DI DMGSRN1 DMGSRN1 DN Mipomersen DMGSRN1 TI TTN1IE2 DMGSRN1 TN APOB messenger RNA (APOB mRNA) DMGSRN1 RN Design and development of antisense drugs. Expert Opin. Drug Discov. 2008 3(10):1189-1207. DMGSRN1 RU http://www.informahealthcare.com/doi/abs/10.1517/17460441.3.10.1177 DMGTW1I DI DMGTW1I DMGTW1I DN Pirarubicin DMGTW1I TI TTUTN1I DMGTW1I TN Human Deoxyribonucleic acid (hDNA) DMGTW1I MA Modulator DMGTW1I RN Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. DMGTW1I RU https://pubmed.ncbi.nlm.nih.gov/17309302 DMGU74E DI DMGU74E DMGU74E DN Cholecalciferol DMGU74E TI TTK59TV DMGU74E TN Vitamin D3 receptor (VDR) DMGU74E MA Binder DMGU74E RN [Vitamin D2 or vitamin D3]. Rev Med Interne. 2008 Oct;29(10):815-20. DMGU74E RU https://pubmed.ncbi.nlm.nih.gov/18406498 DMGUC9T DI DMGUC9T DMGUC9T DN HEV-239 DMGUC9T TI TT3J5ZI DMGUC9T TN Cell mediated immunity response (CMIR) DMGUC9T RN The development of a recombinant hepatitis E vaccine HEV 239. Hum Vaccin Immunother. 2015;11(4):908-14. DMGUC9T RU https://pubmed.ncbi.nlm.nih.gov/25714510 DMGUX67 DI DMGUX67 DMGUX67 DN Ibopamine hci DMGUX67 TI TTEX248 DMGUX67 TN Dopamine D2 receptor (D2R) DMGUX67 MA Modulator DMGUX67 RN Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. DMGUX67 RU https://pubmed.ncbi.nlm.nih.gov/17309302 DMGUZ0W DI DMGUZ0W DMGUZ0W DN MELARSOPROL DMGUZ0W TI TT2SUAQ DMGUZ0W TN Cysteine protease (CYP) DMGUZ0W MA Inhibitor DMGUZ0W RN On-bead screening of a combinatorial fumaric acid derived peptide library yields antiplasmodial cysteine protease inhibitors with unusual peptide s... J Med Chem. 2009 Sep 24;52(18):5662-72. DMGUZ0W RU https://pubmed.ncbi.nlm.nih.gov/19715342 DMGV8QU DI DMGV8QU DMGV8QU DN Etravirine DMGV8QU TI TT84ETX DMGV8QU TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMGV8QU MA Modulator DMGV8QU RN 2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6. DMGV8QU RU https://pubmed.ncbi.nlm.nih.gov/19180096 DMGVH6N DI DMGVH6N DMGVH6N DN Axitinib DMGVH6N TI TTUTJGQ DMGVH6N TN Vascular endothelial growth factor receptor 2 (KDR) DMGVH6N MA Modulator DMGVH6N RN Nat Rev Drug Discov. 2013 Feb;12(2):87-90. DMGVH6N RU https://pubmed.ncbi.nlm.nih.gov/23370234 DMGVJLB DI DMGVJLB DMGVJLB DN GMA-161 DMGVJLB TI TT7KTSR DMGVJLB TN Immunoglobulin gamma Fc receptor III (FCGR3) DMGVJLB MA Antagonist DMGVJLB RN Emerging drugs for idiopathic thrombocytopenic purpura in adults. Expert Opin Emerg Drugs. 2008 Jun;13(2):237-54. DMGVJLB RU https://pubmed.ncbi.nlm.nih.gov/18537519 DMGVUO5 DI DMGVUO5 DMGVUO5 DN Tislelizumab DMGVUO5 TI TTNBFWK DMGVUO5 TN Programmed cell death protein 1 (PD-1) DMGVUO5 RN Tislelizumab: an investigational anti-PD-1 antibody for the treatment of advanced non-small cell lung cancer (NSCLC). Expert Opin Investig Drugs. 2020 Dec;29(12):1355-1364. DMGVUO5 RU https://pubmed.ncbi.nlm.nih.gov/33044117 DMGW1ID DI DMGW1ID DMGW1ID DN Sirolimus DMGW1ID TI TTCJG29 DMGW1ID TN Serine/threonine-protein kinase mTOR (mTOR) DMGW1ID MA Inhibitor DMGW1ID RN Knockouts model the 100 best-selling drugs--will they model the next 100 Nat Rev Drug Discov. 2003 Jan;2(1):38-51. DMGW1ID RU https://pubmed.ncbi.nlm.nih.gov/12509758 DMGW1ID DI DMGW1ID DMGW1ID DN Sirolimus DMGW1ID TI TTGQUFK DMGW1ID TN PI3K/AKT/mTOR pathway (PAm pathway) DMGW1ID MA Inhibitor DMGW1ID RN The genomic landscape of nasopharyngeal carcinoma.Nat Genet. 2014 Aug;46(8):866-71. DMGW1ID RU https://pubmed.ncbi.nlm.nih.gov/24952746 DMGWR0C DI DMGWR0C DMGWR0C DN Sintilimab DMGWR0C TI TTNBFWK DMGWR0C TN Programmed cell death protein 1 (PD-1) DMGWR0C MA Inhibitor DMGWR0C RN Sintilimab: First Global Approval. Drugs. 2019 Feb;79(3):341-346. DMGWR0C RU https://pubmed.ncbi.nlm.nih.gov/30742278 DMGXENV DI DMGXENV DMGXENV DN Saxagliptin DMGXENV TI TTDIGC1 DMGXENV TN Dipeptidyl peptidase 4 (DPP-4) DMGXENV MA Inhibitor DMGXENV RN Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92. DMGXENV RU https://pubmed.ncbi.nlm.nih.gov/20118952 DMGY0UT DI DMGY0UT DMGY0UT DN Estrogen DMGY0UT TI TTZAYWL DMGY0UT TN Estrogen receptor (ESR) DMGY0UT MA Agonist DMGY0UT RN Estrogen-receptor polymorphisms and effects of estrogen replacement on high-density lipoprotein cholesterol in women with coronary disease. N Engl J Med. 2002 Mar 28;346(13):967-74. DMGY0UT RU https://pubmed.ncbi.nlm.nih.gov/11919305 DMGY0UT DI DMGY0UT DMGY0UT DN Estrogen DMGY0UT TI TTOM3J0 DMGY0UT TN Estrogen receptor beta (ESR2) DMGY0UT MA Agonist DMGY0UT RN Estrogen inhibits the vascular injury response in estrogen receptor beta-deficient female mice. Proc Natl Acad Sci U S A. 1999 Dec 21;96(26):15133-6. DMGY0UT RU https://pubmed.ncbi.nlm.nih.gov/10611350 DMGZOVN DI DMGZOVN DMGZOVN DN Benztropine DMGZOVN TI TTZ9SOR DMGZOVN TN Muscarinic acetylcholine receptor M1 (CHRM1) DMGZOVN MA Antagonist DMGZOVN RN Formulation and biopharmaceutical evaluation of transdermal patch containing benztropine. Int J Pharm. 2008 Jun 5;357(1-2):55-60. DMGZOVN RU https://pubmed.ncbi.nlm.nih.gov/18417307 DMGZQEF DI DMGZQEF DMGZQEF DN Mifepristone DMGZQEF TI TTYRL6O DMGZQEF TN Glucocorticoid receptor (NR3C1) DMGZQEF MA Modulator DMGZQEF RN The glucocorticoid agonist activities of mifepristone (RU486) and progesterone are dependent on glucocorticoid receptor levels but not on EC50 values. Steroids. 2007 Jun;72(6-7):600-8. DMGZQEF RU https://pubmed.ncbi.nlm.nih.gov/17509631 DMH07Y3 DI DMH07Y3 DMH07Y3 DN Letrozole DMH07Y3 TI TTSZLWK DMH07Y3 TN Aromatase (CYP19A1) DMH07Y3 MA Inhibitor DMH07Y3 RN Aromatase inhibitors--theoretical concept and present experiences in the treatment of endometriosis. Zentralbl Gynakol. 2003 Jul-Aug;125(7-8):247-51. DMH07Y3 RU https://pubmed.ncbi.nlm.nih.gov/14505258 DMH0QKA DI DMH0QKA DMH0QKA DN GDC-0199 DMH0QKA TI TTJGNVC DMH0QKA TN Apoptosis regulator Bcl-2 (BCL-2) DMH0QKA MA Modulator DMH0QKA RN ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013 Feb;19(2):202-8. DMH0QKA RU https://pubmed.ncbi.nlm.nih.gov/23291630 DMH0ZJE DI DMH0ZJE DMH0ZJE DN Mitomycin DMH0ZJE TI TTUTN1I DMH0ZJE TN Human Deoxyribonucleic acid (hDNA) DMH0ZJE MA Binder DMH0ZJE RN Assessment of cell viability, lipid peroxidation and quantification of DNA fragmentation after the treatment of anticancerous drug mitomycin C and ... Exp Toxicol Pathol. 2010 Sep;62(5):503-8. DMH0ZJE RU https://pubmed.ncbi.nlm.nih.gov/19608391 DMH15UV DI DMH15UV DMH15UV DN Tetrahydrofolic acid DMH15UV TI TTQOD3G DMH15UV TN Folate receptor (FOLR) DMH15UV MA Binder DMH15UV RN Common mutations at the homocysteine metabolism pathway and pediatric stroke. Thromb Res. 2001 Apr 15;102(2):115-20. DMH15UV RU https://pubmed.ncbi.nlm.nih.gov/11323021 DMH1KMT DI DMH1KMT DMH1KMT DN Polidocanol DMH1KMT TI TTT6K3S DMH1KMT TN Endothelium of blood vessels (Endothelium) DMH1KMT MA Modulator DMH1KMT RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DMH1KMT RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DMH1M9B DI DMH1M9B DMH1M9B DN Benazepril DMH1M9B TI TTL69WB DMH1M9B TN Angiotensin-converting enzyme (ACE) DMH1M9B MA Inhibitor DMH1M9B RN Efficacy of benazepril hydrochloride to delay the progression of occult dilated cardiomyopathy in Doberman Pinschers. J Vet Intern Med. 2009 Sep-Oct;23(5):977-83. DMH1M9B RU https://pubmed.ncbi.nlm.nih.gov/19572914 DMH2NMY DI DMH2NMY DMH2NMY DN Mepivacaine DMH2NMY TI TTRK8B9 DMH2NMY TN Sodium channel unspecific (NaC) DMH2NMY MA Blocker DMH2NMY RN Block of neuronal tetrodotoxin-resistant Na+ currents by stereoisomers of piperidine local anesthetics. Anesth Analg. 2000 Dec;91(6):1499-505. DMH2NMY RU https://pubmed.ncbi.nlm.nih.gov/11094008 DMH4CFE DI DMH4CFE DMH4CFE DN Antithymocyte globulin DMH4CFE TI TTBGTFN DMH4CFE TN T-cell surface glycoprotein CD1a (CD1A) DMH4CFE MA Binder DMH4CFE RN Acute sensory neuropathy associated with rabbit antithymocyte globulin. Am J Transplant. 2007 Feb;7(2):484-6. DMH4CFE RU https://pubmed.ncbi.nlm.nih.gov/17283492 DMH4IVU DI DMH4IVU DMH4IVU DN Haloprogin DMH4IVU TI TTAH0B3 DMH4IVU TN Fungal Cell membrane (Fung CM) DMH4IVU MA Binder DMH4IVU RN Haloprogin: mode of action studies in Candida albicans. Can J Microbiol. 1974 Sep;20(9):1241-5. DMH4IVU RU https://pubmed.ncbi.nlm.nih.gov/4608935 DMH5W0G DI DMH5W0G DMH5W0G DN Dipivefrin DMH5W0G TI TTR6W5O DMH5W0G TN Adrenergic receptor beta-1 (ADRB1) DMH5W0G MA Antagonist DMH5W0G RN Contractile response of the isolated trabecular meshwork and ciliary muscle to cholinergic and adrenergic agents. Ger J Ophthalmol. 1996 May;5(3):146-53. DMH5W0G RU https://pubmed.ncbi.nlm.nih.gov/8803576 DMH61ZB DI DMH61ZB DMH61ZB DN Cimetidine DMH61ZB TI TTQHJ1K DMH61ZB TN Histamine H2 receptor (H2R) DMH61ZB MA Antagonist DMH61ZB RN Histamine H1 and H2 receptor antagonists accelerate skin barrier repair and prevent epidermal hyperplasia induced by barrier disruption in a dry environment. J Invest Dermatol. 2001 Feb;116(2):261-5. DMH61ZB RU https://pubmed.ncbi.nlm.nih.gov/11180002 DMH6IKO DI DMH6IKO DMH6IKO DN Lusutrombopag DMH6IKO TI TTIHYA4 DMH6IKO TN Thrombopoietin receptor (MPL) DMH6IKO MA Agonist DMH6IKO RN 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. DMH6IKO RU https://pubmed.ncbi.nlm.nih.gov/30710142 DMH75KV DI DMH75KV DMH75KV DN Acenocoumarol DMH75KV TI TTEUC8H DMH75KV TN Vitamin K epoxide reductase complex 1 (VKORC1) DMH75KV MA Inhibitor DMH75KV RN Evaluation of a reverse-hybridization StripAssay for the detection of genetic polymorphisms leading to acenocoumarol sensitivity. Mol Biol Rep. 2010 Apr;37(4):1693-7. DMH75KV RU https://pubmed.ncbi.nlm.nih.gov/19562511 DMH7GN8 DI DMH7GN8 DMH7GN8 DN Ramosetron DMH7GN8 TI TT85JO3 DMH7GN8 TN 5-HT receptor (5HTR) DMH7GN8 MA Modulator DMH7GN8 RN Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. DMH7GN8 RU https://pubmed.ncbi.nlm.nih.gov/17309302 DMH7GN8 DI DMH7GN8 DMH7GN8 DN Ramosetron DMH7GN8 TI TTNXLKE DMH7GN8 TN 5-HT 3 receptor (5HT3R) DMH7GN8 MA Modulator DMH7GN8 RN Inhibitory effect of YM060 on 5-HT3 receptor-mediated depolarization in colonic myenteric neurons of the guinea pig. Eur J Pharmacol. 1995 Sep 5;283(1-3):107-12. DMH7GN8 RU https://pubmed.ncbi.nlm.nih.gov/7498299 DMH7IDQ DI DMH7IDQ DMH7IDQ DN Dichlorphenamide DMH7IDQ TI TTANPDJ DMH7IDQ TN Carbonic anhydrase II (CA-II) DMH7IDQ MA Inhibitor DMH7IDQ RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMH7IDQ RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMH7IDQ DI DMH7IDQ DMH7IDQ DN Dichlorphenamide DMH7IDQ TI TTHQPL7 DMH7IDQ TN Carbonic anhydrase I (CA-I) DMH7IDQ MA Modulator DMH7IDQ RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMH7IDQ RU https://www.fda.gov/ DMH7MUV DI DMH7MUV DMH7MUV DN Zalcitabine DMH7MUV TI TT84ETX DMH7MUV TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMH7MUV MA Inhibitor DMH7MUV RN A peptide inhibitor of HIV-1 reverse transcriptase using alpha,beta-dehydro residues: a structure-based computer model. J Biomol Struct Dyn. 1998 Oct;16(2):347-54. DMH7MUV RU https://pubmed.ncbi.nlm.nih.gov/9833673 DMH7OIA DI DMH7OIA DMH7OIA DN Infliximab DMH7OIA TI TTF8CQI DMH7OIA TN Tumor necrosis factor (TNF) DMH7OIA RN Drug insight: tumor necrosis factor-converting enzyme as a pharmaceutical target for rheumatoid arthritis. Nat Clin Pract Rheumatol. 2008 Jun;4(6):300-9. DMH7OIA RU https://pubmed.ncbi.nlm.nih.gov/18414459 DMHA18P DI DMHA18P DMHA18P DN Lasofoxifene DMHA18P TI TTZAYWL DMHA18P TN Estrogen receptor (ESR) DMHA18P MA Modulator DMHA18P RN Pfizer. Product Development Pipeline. March 31 2009. DMHA18P RU http://media.pfizer.com/files/research/pipeline/2009_0331/pipeline_2009_0331.pdf DMHA18P DI DMHA18P DMHA18P DN Lasofoxifene DMHA18P TI TT57ID8 DMHA18P TN Respiratory syncytial virus protein F (RSV F) DMHA18P MA Modulator DMHA18P RN Prospects for the development of fusion inhibitors to treat human respiratory syncytial virus infection. Curr Opin Drug Discov Devel. 2009 Jul;12(4):479-87. DMHA18P RU https://pubmed.ncbi.nlm.nih.gov/19562644 DMHAQCO DI DMHAQCO DMHAQCO DN Trichlormethiazide DMHAQCO TI TTS087L DMHAQCO TN Solute carrier family 12 member 1 (SLC12A1) DMHAQCO MA Blocker DMHAQCO RN Function and regulation of epithelial sodium transporters in the kidney of a salt-sensitive hypertensive rat model. J Hypertens. 2007 May;25(5):1065-72. DMHAQCO RU https://pubmed.ncbi.nlm.nih.gov/17414671 DMHAUO0 DI DMHAUO0 DMHAUO0 DN Acetyldigitoxin DMHAUO0 TI TTWK8D0 DMHAUO0 TN Sodium pump subunit alpha-1 (ATP1A1) DMHAUO0 MA Modulator DMHAUO0 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMHAUO0 RU https://www.fda.gov/ DMHCI9S DI DMHCI9S DMHCI9S DN Flurandrenolide DMHCI9S TI TTP3UTW DMHCI9S TN Steroid hormone receptor ERR (ESRR) DMHCI9S MA Modulator DMHCI9S RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMHCI9S RU https://www.fda.gov/ DMHCTAL DI DMHCTAL DMHCTAL DN Cryptenamine Acetates DMHCTAL TI TTH18TF DMHCTAL TN Muscarinic acetylcholine receptor M5 (CHRM5) DMHCTAL MA Modulator DMHCTAL RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMHCTAL RU https://www.fda.gov/ DMHD4PE DI DMHD4PE DMHD4PE DN Desvenlafaxine DMHD4PE TI TT3ROYC DMHD4PE TN Serotonin transporter (SERT) DMHD4PE MA Modulator DMHD4PE RN 2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6. DMHD4PE RU https://pubmed.ncbi.nlm.nih.gov/19180096 DMHDF7B DI DMHDF7B DMHDF7B DN Thiamylal DMHDF7B TI TTEX6LM DMHDF7B TN GABA(A) receptor gamma-3 (GABRG3) DMHDF7B MA Modulator DMHDF7B RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMHDF7B RU https://www.fda.gov/ DMHERIJ DI DMHERIJ DMHERIJ DN Capromab DMHERIJ TI TT9G4N0 DMHERIJ TN Glutamate carboxypeptidase II (GCPII) DMHERIJ RN Synergistic value of single-photon emission computed tomography/computed tomography fusion to radioimmunoscintigraphic imaging of prostate cancer. Semin Nucl Med. 2007 Jan;37(1):17-28. DMHERIJ RU https://pubmed.ncbi.nlm.nih.gov/17161036 DMHF4IQ DI DMHF4IQ DMHF4IQ DN Trimethaphan DMHF4IQ TI TT4H1MQ DMHF4IQ TN Neuronal acetylcholine receptor alpha-4 (CHRNA4) DMHF4IQ MA Antagonist DMHF4IQ RN Mechanism of long-lasting block of ganglion nicotinic receptors by mono-ammonium compounds with long aliphatic chain. J Auton Nerv Syst. 1994 Aug;48(3):231-40. DMHF4IQ RU https://pubmed.ncbi.nlm.nih.gov/7963258 DMHFJDT DI DMHFJDT DMHFJDT DN Procyclidine DMHFJDT TI TTH18TF DMHFJDT TN Muscarinic acetylcholine receptor M5 (CHRM5) DMHFJDT MA Antagonist DMHFJDT RN Protection against soman-induced seizures in rats: relationship among doses of prophylactics, soman, and adjuncts. Toxicol Appl Pharmacol. 2004 May 1;196(3):327-36. DMHFJDT RU https://pubmed.ncbi.nlm.nih.gov/15094303 DMHG57U DI DMHG57U DMHG57U DN OPC-34712 DMHG57U TI TTSQIFT DMHG57U TN 5-HT 1A receptor (HTR1A) DMHG57U MA Modulator DMHG57U RN Effects of brexpiprazole, a novel serotonin-dopamine activity modulator, on phencyclidine-induced cognitive deficits in mice: a role for serotonin 5-HT1A receptors.Pharmacol Biochem Behav.2014 Sep;124:245-9. DMHG57U RU https://www.ncbi.nlm.nih.gov/pubmed/24955861 DMHG57U DI DMHG57U DMHG57U DN OPC-34712 DMHG57U TI TTEX248 DMHG57U TN Dopamine D2 receptor (D2R) DMHG57U MA Modulator DMHG57U RN Effects of brexpiprazole, a novel serotonin-dopamine activity modulator, on phencyclidine-induced cognitive deficits in mice: a role for serotonin 5-HT1A receptors.Pharmacol Biochem Behav.2014 Sep;124:245-9. DMHG57U RU https://www.ncbi.nlm.nih.gov/pubmed/24955861 DMHIDCJ DI DMHIDCJ DMHIDCJ DN Octreotide DMHIDCJ TI TTZ6T9E DMHIDCJ TN Somatostatin receptor type 2 (SSTR2) DMHIDCJ MA Binder DMHIDCJ RN Versatile conjugation of octreotide to dendrimers by cycloaddition ("click") chemistry to yield high-affinity multivalent cyclic Peptide dendrimers. Bioconjug Chem. 2009 Jul;20(7):1323-31. DMHIDCJ RU https://pubmed.ncbi.nlm.nih.gov/19537708 DMHIDUE DI DMHIDUE DMHIDUE DN Phenelzine DMHIDUE TI TTGP7BY DMHIDUE TN Monoamine oxidase type B (MAO-B) DMHIDUE MA Inhibitor DMHIDUE RN Limitation of adipose tissue enlargement in rats chronically treated with semicarbazide-sensitive amine oxidase and monoamine oxidase inhibitors. Pharmacol Res. 2008 Jun;57(6):426-34. DMHIDUE RU https://pubmed.ncbi.nlm.nih.gov/18539478 DMHIDUE DI DMHIDUE DMHIDUE DN Phenelzine DMHIDUE TI TT32XQJ DMHIDUE TN Monoamine oxidase (MAO) DMHIDUE MA Inhibitor DMHIDUE RN Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110. DMHIDUE RU https://www.ncbi.nlm.nih.gov/pubmed/25399762 DMHJV0X DI DMHJV0X DMHJV0X DN Pertuzumab DMHJV0X TI TT6EO5L DMHJV0X TN Erbb2 tyrosine kinase receptor (HER2) DMHJV0X MA Inhibitor DMHJV0X RN Clinical pipeline report, company report or official report of Roche (2009). DMHJV0X RU http://www.roche.com/research_and_development/pipeline/roche_pharma_pipeline.htm DMHJVOL DI DMHJVOL DMHJVOL DN Nabi-HB DMHJVOL TI TT6KSF7 DMHJVOL TN Hepatitis B virus Large envelope protein (HBV S) DMHJVOL MA Modulator DMHJVOL RN Hepatitis B Immune Globulin (Human) Nabi-HB . US Food and Drug Administration report. DMHJVOL RU http://www.fda.gov/downloads/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/FractionatedPlasmaProducts/ucm117658.pdf DMHKS94 DI DMHKS94 DMHKS94 DN Valaciclovir DMHKS94 TI TTIU7X1 DMHKS94 TN Herpes simplex virus DNA polymerase UL30 (HSV UL30) DMHKS94 MA Inhibitor DMHKS94 RN Extensive oral shedding of human herpesvirus 8 in a renal allograft recipient. Oral Microbiol Immunol. 2009 Apr;24(2):109-15. DMHKS94 RU https://pubmed.ncbi.nlm.nih.gov/19239637 DMHL7OB DI DMHL7OB DMHL7OB DN Uracil mustard DMHL7OB TI TTUTN1I DMHL7OB TN Human Deoxyribonucleic acid (hDNA) DMHL7OB MA Modulator DMHL7OB RN Excision of DNA adducts of nitrogen mustards by bacterial and mammalian 3-methyladenine-DNA glycosylases. Carcinogenesis. 1996 Apr;17(4):643-8. DMHL7OB RU https://pubmed.ncbi.nlm.nih.gov/8625472 DMHLP9C DI DMHLP9C DMHLP9C DN Felypressin DMHLP9C TI TT4TFGN DMHLP9C TN Vasopressin V1a receptor (V1AR) DMHLP9C MA Agonist DMHLP9C RN Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin V1a, V1b, V2 and OT receptors: research tools and potential therapeutic agents. Prog Brain Res. 2008;170:473-512. DMHLP9C RU https://pubmed.ncbi.nlm.nih.gov/18655903 DMHM7JS DI DMHM7JS DMHM7JS DN Pasireotide DMHM7JS TI TTJX3UE DMHM7JS TN Somatostatin receptor type 3 (SSTR3) DMHM7JS MA Inhibitor DMHM7JS RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 357). DMHM7JS RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=357 DMHM7JS DI DMHM7JS DMHM7JS DN Pasireotide DMHM7JS TI TTIND6G DMHM7JS TN Somatostatin receptor type 1 (SSTR1) DMHM7JS MA Inhibitor DMHM7JS RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 355). DMHM7JS RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=355 DMHM7JS DI DMHM7JS DMHM7JS DN Pasireotide DMHM7JS TI TTZ6T9E DMHM7JS TN Somatostatin receptor type 2 (SSTR2) DMHM7JS MA Inhibitor DMHM7JS RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 356). DMHM7JS RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=356 DMHM7JS DI DMHM7JS DMHM7JS DN Pasireotide DMHM7JS TI TT2BC4G DMHM7JS TN Somatostatin receptor type 5 (SSTR5) DMHM7JS MA Inhibitor DMHM7JS RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 359). DMHM7JS RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=359 DMHM93Y DI DMHM93Y DMHM93Y DN Meprobamate DMHM93Y TI TT9SL3Q DMHM93Y TN Polypeptide deformylase (PDF) DMHM93Y MA Inhibitor DMHM93Y RN The fight against drug-resistant malaria: novel plasmodial targets and antimalarial drugs. Curr Med Chem. 2008;15(2):161-71. DMHM93Y RU https://pubmed.ncbi.nlm.nih.gov/18220771 DMHM93Y DI DMHM93Y DMHM93Y DN Meprobamate DMHM93Y TI TT1MPAY DMHM93Y TN GABA(A) receptor alpha-1 (GABRA1) DMHM93Y MA Antagonist DMHM93Y RN DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6. DMHM93Y RU https://pubmed.ncbi.nlm.nih.gov/18048412 DMHM93Y DI DMHM93Y DMHM93Y DN Meprobamate DMHM93Y TI TTBZ7OD DMHM93Y TN Protein kinase C epsilon (PRKCE) DMHM93Y MA Stimulator DMHM93Y RN Protein kinase C, an elusive therapeutic target . Nat Rev Drug Discov. 2012 December; 11(12): 937-957. DMHM93Y RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3760692/ DMHMP05 DI DMHMP05 DMHMP05 DN Carprofen DMHMP05 TI TTVKILB DMHMP05 TN Prostaglandin G/H synthase 2 (COX-2) DMHMP05 MA Inhibitor DMHMP05 RN Scaffold of the cyclooxygenase-2 (COX-2) inhibitor carprofen provides Alzheimer gamma-secretase modulators. J Med Chem. 2006 Dec 28;49(26):7588-91. DMHMP05 RU https://pubmed.ncbi.nlm.nih.gov/17181139 DMHN027 DI DMHN027 DMHN027 DN Levothyroxine DMHN027 TI TTTSEPU DMHN027 TN Thyroid hormone receptor alpha (THRA) DMHN027 MA Antagonist DMHN027 RN Thyroid hormone resistance and pituitary enlargement after thyroid ablation in a woman on levothyroxine treatment. Thyroid. 2008 Oct;18(10):1119-23. DMHN027 RU https://pubmed.ncbi.nlm.nih.gov/18816177 DMHNQOG DI DMHNQOG DMHNQOG DN Zafirlukast DMHNQOG TI TTGKOY9 DMHNQOG TN Leukotriene CysLT1 receptor (CYSLTR1) DMHNQOG MA Antagonist DMHNQOG RN Inhibitory effects of zafirlukast on respiratory bursts of human neutrophils. Drugs Exp Clin Res. 2002;28(4):133-45. DMHNQOG RU https://pubmed.ncbi.nlm.nih.gov/12512231 DMHO0AR DI DMHO0AR DMHO0AR DN Ergocalciferol DMHO0AR TI TTK59TV DMHO0AR TN Vitamin D3 receptor (VDR) DMHO0AR MA Antagonist DMHO0AR RN Vitamin D in health and disease. Clin J Am Soc Nephrol. 2008 Sep;3(5):1535-41. DMHO0AR RU https://pubmed.ncbi.nlm.nih.gov/18525006 DMHOAUG DI DMHOAUG DMHOAUG DN Rimegepant DMHOAUG TI TTY6O0Q DMHOAUG TN Calcitonin gene-related peptide receptor (CGRPR) DMHOAUG MA Antagonist DMHOAUG RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020 DMHOAUG RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212728s000lbl.pdf DMHP21E DI DMHP21E DMHP21E DN Hydromorphone DMHP21E TI TT27RFC DMHP21E TN Opioid receptor delta (OPRD1) DMHP21E MA Binder DMHP21E RN Identification of opioid ligands possessing mixed micro agonist/delta antagonist activity among pyridomorphinans derived from naloxone, oxymorphone, and hydromorphone [correction of hydropmorphone]. J Med Chem. 2004 Mar 11;47(6):1400-12. DMHP21E RU https://pubmed.ncbi.nlm.nih.gov/14998329 DMHP21E DI DMHP21E DMHP21E DN Hydromorphone DMHP21E TI TTKWM86 DMHP21E TN Opioid receptor mu (MOP) DMHP21E MA Inhibitor DMHP21E RN Clinical pipeline report, company report or official report of signaturerx. DMHP21E RU http://www.signaturerx.com/view.cfm/59/Abuse-Resistant-Opioids DMHP8FI DI DMHP8FI DMHP8FI DN Methscopolamine bromide DMHP8FI TI TTQ13Z5 DMHP8FI TN Muscarinic acetylcholine receptor M3 (CHRM3) DMHP8FI MA Modulator DMHP8FI RN Agonist-regulated alteration of the affinity of pancreatic muscarinic cholinergic receptors. J Biol Chem. 1993 Oct 25;268(30):22436-43. DMHP8FI RU https://www.ncbi.nlm.nih.gov/pubmed/7693670 DMHP9BL DI DMHP9BL DMHP9BL DN Etelcalcetide DMHP9BL TI TTBUYHA DMHP9BL TN Extracellular calcium-sensing receptor (CASR) DMHP9BL MA Modulator DMHP9BL RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMHP9BL RU https://www.fda.gov/ DMHPRWG DI DMHPRWG DMHPRWG DN Exjade DMHPRWG TI TTUDR0C DMHPRWG TN Iron (Fe) DMHPRWG MA Modulator DMHPRWG RN Deferasirox : a review of its use in the management of transfusional chronic iron overload. Drugs. 2007;67(15):2211-30. DMHPRWG RU https://pubmed.ncbi.nlm.nih.gov/17927285 DMHPWOM DI DMHPWOM DMHPWOM DN Diphenidol DMHPWOM TI TTQ3JTF DMHPWOM TN Muscarinic acetylcholine receptor M4 (CHRM4) DMHPWOM MA Antagonist DMHPWOM RN Diphenidol-related diamines as novel muscarinic M4 receptor antagonists. Bioorg Med Chem Lett. 2008 May 1;18(9):2972-6. DMHPWOM RU https://pubmed.ncbi.nlm.nih.gov/18395442 DMHR8KW DI DMHR8KW DMHR8KW DN Alvimopan DMHR8KW TI TTKWM86 DMHR8KW TN Opioid receptor mu (MOP) DMHR8KW MA Antagonist DMHR8KW RN Alvimopan for postoperative ileus. Am J Health Syst Pharm. 2009 Jul 15;66(14):1267-77. DMHR8KW RU https://pubmed.ncbi.nlm.nih.gov/19574601 DMHRG8Q DI DMHRG8Q DMHRG8Q DN Carbidopa DMHRG8Q TI TTN451K DMHRG8Q TN Aromatic-L-amino-acid decarboxylase (DDC) DMHRG8Q MA Inhibitor DMHRG8Q RN Catechol-O-methyltransferase inhibitors in the management of Parkinson's disease. Semin Neurol. 2001;21(1):15-22. DMHRG8Q RU https://pubmed.ncbi.nlm.nih.gov/11346021 DMHSJB4 DI DMHSJB4 DMHSJB4 DN Cyclacillin DMHSJB4 TI TTJP4SM DMHSJB4 TN Bacterial Penicillin binding protein (Bact PBP) DMHSJB4 MA Binder DMHSJB4 RN Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. DMHSJB4 RU https://pubmed.ncbi.nlm.nih.gov/17016423 DMHSY1I DI DMHSY1I DMHSY1I DN Regorafenib DMHSY1I TI TT4DXQT DMHSY1I TN Proto-oncogene c-Ret (RET) DMHSY1I MA Modulator DMHSY1I RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DMHSY1I RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DMHSY1I DI DMHSY1I DMHSY1I DN Regorafenib DMHSY1I TI TTUTJGQ DMHSY1I TN Vascular endothelial growth factor receptor 2 (KDR) DMHSY1I MA Modulator DMHSY1I RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DMHSY1I RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DMHSY1I DI DMHSY1I DMHSY1I DN Regorafenib DMHSY1I TI TTX41N9 DMHSY1I TN Tyrosine-protein kinase Kit (KIT) DMHSY1I MA Modulator DMHSY1I RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DMHSY1I RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DMHT34O DI DMHT34O DMHT34O DN Gemifloxacin DMHT34O TI TTN6J5F DMHT34O TN Bacterial DNA gyrase (Bact gyrase) DMHT34O MA Modulator DMHT34O RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMHT34O RU https://www.fda.gov/ DMHT34O DI DMHT34O DMHT34O DN Gemifloxacin DMHT34O TI TTIXTO3 DMHT34O TN Staphylococcus Topoisomerase IV (Stap-coc parC) DMHT34O MA Modulator DMHT34O RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMHT34O RU https://www.fda.gov/ DMHTB31 DI DMHTB31 DMHTB31 DN Carphenazine DMHTB31 TI TTEX248 DMHTB31 TN Dopamine D2 receptor (D2R) DMHTB31 MA Antagonist DMHTB31 RN Atypical antipsychotics: mechanism of action. Can J Psychiatry. 2002 Feb;47(1):27-38. DMHTB31 RU https://pubmed.ncbi.nlm.nih.gov/11873706 DMHTEAO DI DMHTEAO DMHTEAO DN Carvedilol DMHTEAO TI TTG28O6 DMHTEAO TN Adrenergic receptor Alpha-1 (ADRA1) DMHTEAO MA Antagonist DMHTEAO RN Beta-blockers in the treatment of hypertension: are there clinically relevant differences Postgrad Med. 2009 May;121(3):90-8. DMHTEAO RU https://pubmed.ncbi.nlm.nih.gov/19491545 DMHTXSL DI DMHTXSL DMHTXSL DN Arbekacin DMHTXSL TI TTA4FIU DMHTXSL TN Ribosome A (hRA) DMHTXSL MA Modulator DMHTXSL RN Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. DMHTXSL RU https://pubmed.ncbi.nlm.nih.gov/17309302 DMHTYK3 DI DMHTYK3 DMHTYK3 DN Ustekinumab DMHTYK3 TI TTC1GLB DMHTYK3 TN Interleukin-23 (IL23) DMHTYK3 RN Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92. DMHTYK3 RU https://pubmed.ncbi.nlm.nih.gov/20118952 DMHTYK3 DI DMHTYK3 DMHTYK3 DN Ustekinumab DMHTYK3 TI TTRTK6Y DMHTYK3 TN Interleukin-12 alpha (IL12A) DMHTYK3 RN Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92. DMHTYK3 RU https://pubmed.ncbi.nlm.nih.gov/20118952 DMHTYK3 DI DMHTYK3 DMHTYK3 DN Ustekinumab DMHTYK3 TI TT9SL3Q DMHTYK3 TN Polypeptide deformylase (PDF) DMHTYK3 MA Inhibitor DMHTYK3 RN Novel Saccharomyces cerevisiae screen identifies WR99210 analogues that inhibit Mycobacterium tuberculosis dihydrofolate reductase. Antimicrob Agents Chemother. 2002 Nov;46(11):3362-9. DMHTYK3 RU https://pubmed.ncbi.nlm.nih.gov/12384337 DMHVBG1 DI DMHVBG1 DMHVBG1 DN Naftifine DMHVBG1 TI TTE14XG DMHVBG1 TN Squalene monooxygenase (SQLE) DMHVBG1 MA Inhibitor DMHVBG1 RN Characterization of squalene epoxidase activity from the dermatophyte Trichophyton rubrum and its inhibition by terbinafine and other antimycotic agents. Antimicrob Agents Chemother. 1996 Feb;40(2):443-7. DMHVBG1 RU https://pubmed.ncbi.nlm.nih.gov/8834895 DMHVJFK DI DMHVJFK DMHVJFK DN Misoprostol DMHVJFK TI TTOFYT1 DMHVJFK TN Prostacyclin receptor (PTGIR) DMHVJFK MA Antagonist DMHVJFK RN Palmitoylation of the human prostacyclin receptor. Functional implications of palmitoylation and isoprenylation. J Biol Chem. 2003 Feb 28;278(9):6947-58. DMHVJFK RU https://pubmed.ncbi.nlm.nih.gov/12488443 DMHVL0J DI DMHVL0J DMHVL0J DN Azelaic Acid DMHVL0J TI TT2A0DR DMHVL0J TN Oxo-5-alpha-steroid 4-dehydrogenase (SRD5A) DMHVL0J MA Inhibitor DMHVL0J RN Inhibition of 5 alpha-reductase activity in human skin by zinc and azelaic acid. Br J Dermatol. 1988 Nov;119(5):627-32. DMHVL0J RU https://pubmed.ncbi.nlm.nih.gov/3207614 DMHVWIK DI DMHVWIK DMHVWIK DN Cefepime DMHVWIK TI TTHWB7G DMHVWIK TN Bacterial Penicillin binding protein 2 (Bact mrdA) DMHVWIK MA Modulator DMHVWIK RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMHVWIK RU https://www.fda.gov/ DMHWE7P DI DMHWE7P DMHWE7P DN Ampicillin DMHWE7P TI TTJP4SM DMHWE7P TN Bacterial Penicillin binding protein (Bact PBP) DMHWE7P MA Binder DMHWE7P RN Effects of amino acid alterations in penicillin-binding proteins (PBPs) 1a, 2b, and 2x on PBP affinities of penicillin, ampicillin, amoxicillin, cefditoren, cefuroxime, cefprozil, and cefaclor in 18 clinical isolates of penicillin-susceptible, -intermediate, and -resistant pneumococci. Antimicrob Agents Chemother. 2002 May;46(5):1273-80. DMHWE7P RU https://pubmed.ncbi.nlm.nih.gov/11959556 DMHY3IP DI DMHY3IP DMHY3IP DN Lobeglitazone DMHY3IP TI TTJ584C DMHY3IP TN Peroxisome proliferator-activated receptor alpha (PPARA) DMHY3IP MA Agonist DMHY3IP RN Tolerability and pharmacokinetics of lobeglitazone, a novel peroxisome proliferator-activated receptor-gamma agonist, after a single oral administration in healthy female subjects. Clin Drug Investig. 2014 Jul;34(7):467-74. DMHY3IP RU https://pubmed.ncbi.nlm.nih.gov/24802657 DMHY3IP DI DMHY3IP DMHY3IP DN Lobeglitazone DMHY3IP TI TTZMAO3 DMHY3IP TN Peroxisome proliferator-activated receptor gamma (PPAR-gamma) DMHY3IP MA Agonist DMHY3IP RN Tolerability and pharmacokinetics of lobeglitazone, a novel peroxisome proliferator-activated receptor-gamma agonist, after a single oral administration in healthy female subjects. Clin Drug Investig. 2014 Jul;34(7):467-74. DMHY3IP RU https://pubmed.ncbi.nlm.nih.gov/24802657 DMHZCPO DI DMHZCPO DMHZCPO DN Ibrutinib DMHZCPO TI TTGM6VW DMHZCPO TN Tyrosine-protein kinase BTK (ATK) DMHZCPO MA Inhibitor DMHZCPO RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1948). DMHZCPO RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1948 DMHZJCG DI DMHZJCG DMHZJCG DN Pentamidine DMHZJCG TI TTM1TDX DMHZJCG TN Tryptase alpha/beta-1 (Tryptase) DMHZJCG MA Inhibitor DMHZJCG RN Inhibitors of tryptase for the treatment of mast cell-mediated diseases. Curr Pharm Des. 1998 Oct;4(5):381-96. DMHZJCG RU https://pubmed.ncbi.nlm.nih.gov/10197050 DMHZV7X DI DMHZV7X DMHZV7X DN Golimumab DMHZV7X TI TTF8CQI DMHZV7X TN Tumor necrosis factor (TNF) DMHZV7X RN Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92. DMHZV7X RU https://pubmed.ncbi.nlm.nih.gov/20118952 DMI0GDH DI DMI0GDH DMI0GDH DN Oxybuprocaine DMI0GDH TI TTRK8B9 DMI0GDH TN Sodium channel unspecific (NaC) DMI0GDH MA Blocker DMI0GDH RN Intrathecal oxybuprocaine and proxymetacaine produced potent and long-lasting spinal anesthesia in rats. Neurosci Lett. 2009 May 1;454(3):249-53. DMI0GDH RU https://pubmed.ncbi.nlm.nih.gov/19429093 DMI0RHA DI DMI0RHA DMI0RHA DN Inebilizumab DMI0RHA TI TTW640A DMI0RHA TN B-lymphocyte surface antigen B4 (CD19) DMI0RHA MA Inhibitor DMI0RHA RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020 DMI0RHA RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761142s000lbl.pdf DMI18HW DI DMI18HW DMI18HW DN Benzocaine DMI18HW TI TTRK8B9 DMI18HW TN Sodium channel unspecific (NaC) DMI18HW MA Blocker DMI18HW RN Electrostatic contributions of aromatic residues in the local anesthetic receptor of voltage-gated sodium channels. Circ Res. 2008 Jan 4;102(1):86-94. DMI18HW RU https://pubmed.ncbi.nlm.nih.gov/17967784 DMI2QPE DI DMI2QPE DMI2QPE DN Didanosine DMI2QPE TI TT84ETX DMI2QPE TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMI2QPE MA Inhibitor DMI2QPE RN The effect of individual antiretroviral drugs on body composition in HIV-infected persons initiating highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2009 Jul 1;51(3):298-304. DMI2QPE RU https://pubmed.ncbi.nlm.nih.gov/19412117 DMI347A DI DMI347A DMI347A DN Lamivudine DMI347A TI TT84ETX DMI347A TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMI347A MA Modulator DMI347A RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMI347A RU https://www.fda.gov/ DMI40NL DI DMI40NL DMI40NL DN Tolazoline DMI40NL TI TTEX248 DMI40NL TN Dopamine D2 receptor (D2R) DMI40NL MA Antagonist DMI40NL RN Comparative effects of tolazoline and nitroprusside on human isolated radial artery. Ann Thorac Surg. 2006 Jan;81(1):125-31. DMI40NL RU https://pubmed.ncbi.nlm.nih.gov/16368348 DMI4EL5 DI DMI4EL5 DMI4EL5 DN Ketorolac DMI4EL5 TI TTK0943 DMI4EL5 TN Prostaglandin G/H synthase (COX) DMI4EL5 MA Inhibitor DMI4EL5 RN Cyclooxygenase and nitric oxide synthase dependence of cutaneous reactive hyperemia in humans. Am J Physiol Heart Circ Physiol. 2007 Jul;293(1):H425-32. DMI4EL5 RU https://pubmed.ncbi.nlm.nih.gov/17369458 DMI53FU DI DMI53FU DMI53FU DN Gaboxadol DMI53FU TI TTGXH6N DMI53FU TN GABA(A) receptor delta (GABRD) DMI53FU MA Modulator DMI53FU RN Gaboxadol--a new awakening in sleep.Curr Opin Pharmacol.2006 Feb;6(1):30-6. DMI53FU RU https://www.ncbi.nlm.nih.gov/pubmed/16368265 DMI5678 DI DMI5678 DMI5678 DN Pirbuterol DMI5678 TI TT2CJVK DMI5678 TN Adrenergic receptor beta-2 (ADRB2) DMI5678 MA Agonist DMI5678 RN Inhaled beta agonists. Respir Care. 2007 Jul;52(7):820-32. DMI5678 RU https://pubmed.ncbi.nlm.nih.gov/17594727 DMI5DW1 DI DMI5DW1 DMI5DW1 DN Hesperidin DMI5DW1 TI TT4FDG6 DMI5DW1 TN Voltage-gated calcium channel alpha Cav2.2 (CACNA1B) DMI5DW1 MA Inhibitor DMI5DW1 RN In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6. DMI5DW1 RU https://pubmed.ncbi.nlm.nih.gov/21074425 DMI5OXG DI DMI5OXG DMI5OXG DN Latanoprost DMI5OXG TI TTT2ZAR DMI5OXG TN Prostaglandin F2-alpha receptor (PTGFR) DMI5OXG MA Agonist DMI5OXG RN PGF(2alpha) FP receptor contributes to brain damage following transient focal brain ischemia. Neurotox Res. 2009 Jan;15(1):62-70. DMI5OXG RU https://pubmed.ncbi.nlm.nih.gov/19384589 DMI6E0R DI DMI6E0R DMI6E0R DN Midostaurin DMI6E0R TI TTGJCWZ DMI6E0R TN Fms-like tyrosine kinase 3 (FLT-3) DMI6E0R MA Inhibitor DMI6E0R RN A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22. DMI6E0R RU https://pubmed.ncbi.nlm.nih.gov/17692029 DMI6E0R DI DMI6E0R DMI6E0R DN Midostaurin DMI6E0R TI TTRFOXJ DMI6E0R TN Protein kinase C gamma (PRKCG) DMI6E0R MA Inhibitor DMI6E0R RN A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22. DMI6E0R RU https://pubmed.ncbi.nlm.nih.gov/17692029 DMI6GKT DI DMI6GKT DMI6GKT DN Beta-acetyldigoxin DMI6GKT TI TTYHPRQ DMI6GKT TN Sodium pump (NaP) DMI6GKT MA Modulator DMI6GKT RN Medicinal plants in therapy. Bull World Health Organ. 1985;63(6):965-81. DMI6GKT RU https://pubmed.ncbi.nlm.nih.gov/3879679 DMI6HUW DI DMI6HUW DMI6HUW DN Terbinafine DMI6HUW TI TTM9XSU DMI6HUW TN Candida Squalene epoxidase (Candi ERG1) DMI6HUW MA Modulator DMI6HUW RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMI6HUW RU https://www.fda.gov/ DMI782S DI DMI782S DMI782S DN Erdafitinib DMI782S TI TT0LF7H DMI782S TN Fibroblast growth factor receptor (FGFR) DMI782S MA Inhibitor DMI782S RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019 DMI782S RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212018s000lbl.pdf DMI783H DI DMI783H DMI783H DN Vonvendi DMI783H TI TT3SZBT DMI783H TN von Willebrand factor (VWF) DMI783H MA Replacement DMI783H RN Clinical pipeline report, company report or official report of Vonvendi. DMI783H RU https://www.vonvendi.com/ DMI7DZ2 DI DMI7DZ2 DMI7DZ2 DN Prilocaine DMI7DZ2 TI TTZOVE0 DMI7DZ2 TN Voltage-gated sodium channel alpha Nav1.5 (SCN5A) DMI7DZ2 MA Blocker DMI7DZ2 RN Monoamine transporter and sodium channel mechanisms in the rapid pressor response to cocaine. Pharmacol Biochem Behav. 1998 Feb;59(2):305-12. DMI7DZ2 RU https://pubmed.ncbi.nlm.nih.gov/9476974 DMI7FVQ DI DMI7FVQ DMI7FVQ DN Metyrapone DMI7FVQ TI TTIQUX7 DMI7FVQ TN Steroid 11-beta-hydroxylase (CYP11B1) DMI7FVQ MA Inhibitor DMI7FVQ RN Effects of 3-MeSO2-DDE and some CYP inhibitors on glucocorticoid steroidogenesis in the H295R human adrenocortical carcinoma cell line. Toxicol In Vitro. 2002 Apr;16(2):113-21. DMI7FVQ RU https://pubmed.ncbi.nlm.nih.gov/11869873 DMI9FBP DI DMI9FBP DMI9FBP DN Imipenem DMI9FBP TI TTHWB7G DMI9FBP TN Bacterial Penicillin binding protein 2 (Bact mrdA) DMI9FBP MA Binder DMI9FBP RN A comparative trial of imipenem versus ceftazidime in the release of endotoxin and cytokine generation in patients with gram-negative urosepsis. Urosepsis Study Group. J Endotoxin Res. 2000;6(1):25-31. DMI9FBP RU https://pubmed.ncbi.nlm.nih.gov/11061029 DMI9PRJ DI DMI9PRJ DMI9PRJ DN Diflorasone DMI9PRJ TI TT9V5JH DMI9PRJ TN Phospholipase A2 (PLA2G1B) DMI9PRJ MA Inhibitor DMI9PRJ RN Structures from powders: diflorasone diacetate. Steroids. 2009 Jan;74(1):102-11. DMI9PRJ RU https://pubmed.ncbi.nlm.nih.gov/19013475 DMIBH7M DI DMIBH7M DMIBH7M DN L-tryptophan DMIBH7M TI TTZJYKH DMIBH7M TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMIBH7M MA Binder DMIBH7M RN Interactions between nitric oxide and indoleamine 2,3-dioxygenase. Biochemistry. 2006 Jul 18;45(28):8527-38. DMIBH7M RU https://pubmed.ncbi.nlm.nih.gov/16834326 DMIBNG2 DI DMIBNG2 DMIBNG2 DN Picrotoxin DMIBNG2 TI TT1MPAY DMIBNG2 TN GABA(A) receptor alpha-1 (GABRA1) DMIBNG2 MA Antagonist DMIBNG2 RN DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6. DMIBNG2 RU https://pubmed.ncbi.nlm.nih.gov/18048412 DMICA9H DI DMICA9H DMICA9H DN Sulfasalazine DMICA9H TI TTIMJ02 DMICA9H TN ATP-binding cassette transporter G2 (ABCG2) DMICA9H MA Inhibitor DMICA9H RN The anti-inflammatory mechanism of sulfasalazine is related to adenosine release at inflamed sites. J Immunol. 1996 Mar 1;156(5):1937-41. DMICA9H RU https://pubmed.ncbi.nlm.nih.gov/8596047 DMICA9H DI DMICA9H DMICA9H DN Sulfasalazine DMICA9H TI TTSXVID DMICA9H TN Nuclear factor NF-kappa-B (NFKB) DMICA9H MA Activator DMICA9H RN Emerging drugs for rheumatoid arthritis. Expert Opin Emerg Drugs. 2008 Mar;13(1):175-96. DMICA9H RU https://pubmed.ncbi.nlm.nih.gov/18321156 DMICDLV DI DMICDLV DMICDLV DN Lorlatinib DMICDLV TI TTPMQSO DMICDLV TN ALK tyrosine kinase receptor (ALK) DMICDLV MA Inhibitor DMICDLV RN 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. DMICDLV RU https://pubmed.ncbi.nlm.nih.gov/30710142 DMICDLV DI DMICDLV DMICDLV DN Lorlatinib DMICDLV TI TTSZ6Y3 DMICDLV TN Proto-oncogene c-Ros (ROS1) DMICDLV MA Inhibitor DMICDLV RN 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. DMICDLV RU https://pubmed.ncbi.nlm.nih.gov/30710142 DMIEU69 DI DMIEU69 DMIEU69 DN Salmeterol DMIEU69 TI TT2CJVK DMIEU69 TN Adrenergic receptor beta-2 (ADRB2) DMIEU69 MA Agonist DMIEU69 RN Pharmacogenetic tests in asthma therapy. Clin Lab Med. 2008 Dec;28(4):645-65. DMIEU69 RU https://pubmed.ncbi.nlm.nih.gov/19059068 DMIFYLX DI DMIFYLX DMIFYLX DN Bopindolol DMIFYLX TI TTMXGCW DMIFYLX TN Adrenergic receptor beta-3 (ADRB3) DMIFYLX MA Modulator DMIFYLX RN Effect of propranolol, alprenolol, pindolol, and bopindolol on beta 2-adrenoceptor density in human lymphocytes. J Cardiovasc Pharmacol. 1986;8 Suppl 6:S70-3. DMIFYLX RU https://pubmed.ncbi.nlm.nih.gov/2439825 DMIG6FY DI DMIG6FY DMIG6FY DN Amdinocillin DMIG6FY TI TTHWB7G DMIG6FY TN Bacterial Penicillin binding protein 2 (Bact mrdA) DMIG6FY MA Inhibitor DMIG6FY RN Growth of Escherichia coli: significance of peptidoglycan degradation during elongation and septation. J Bacteriol. 2008 Jun;190(11):3914-22. DMIG6FY RU https://pubmed.ncbi.nlm.nih.gov/18390656 DMIG8DW DI DMIG8DW DMIG8DW DN Dexamethasone sodium phosphate DMIG8DW TI TTYRL6O DMIG8DW TN Glucocorticoid receptor (NR3C1) DMIG8DW MA Agonist DMIG8DW RN Dexamethasone rapidly increases GABA release in the dorsal motor nucleus of the vagus via retrograde messenger-mediated enhancement of TRPV1 activity. PLoS One. 2013 Jul 30;8(7):e70505. DMIG8DW RU https://pubmed.ncbi.nlm.nih.gov/23936221 DMIHRNA DI DMIHRNA DMIHRNA DN Tolazamide DMIHRNA TI TTG140O DMIHRNA TN Inward rectifier potassium channel Kir1.2 (KCNJ10) DMIHRNA MA Blocker DMIHRNA RN Inhibition of ATP-activated potassium channels exerts pressor effects and improves survival in a rat model of severe hemorrhagic shock. Shock. 1996 Jun;5(6):391-4. DMIHRNA RU https://pubmed.ncbi.nlm.nih.gov/8799949 DMIJATC DI DMIJATC DMIJATC DN Benzphetamine DMIJATC TI TT9IK2Z DMIJATC TN N-methyl-D-aspartate receptor (NMDAR) DMIJATC MA Antagonist DMIJATC RN Amphetamine inhibits the N-methyl-D-aspartate receptor-mediated responses by directly interacting with the receptor/channel complex. J Pharmacol Exp Ther. 2002 Mar;300(3):1008-16. DMIJATC RU https://pubmed.ncbi.nlm.nih.gov/11861810 DMIJC9X DI DMIJC9X DMIJC9X DN Osilodrostat DMIJC9X TI TTIQUX7 DMIJC9X TN Steroid 11-beta-hydroxylase (CYP11B1) DMIJC9X MA Modulator DMIJC9X RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020 DMIJC9X RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212801s000lbl.pdf DMIJRF0 DI DMIJRF0 DMIJRF0 DN Anisotropine Methylbromide DMIJRF0 TI TTH18TF DMIJRF0 TN Muscarinic acetylcholine receptor M5 (CHRM5) DMIJRF0 MA Binder DMIJRF0 RN Anisotropine methylbromide: a new antispasmodic for gastrointestinal disorders. Curr Ther Res Clin Exp. 1963 May;5:213-8. DMIJRF0 RU https://pubmed.ncbi.nlm.nih.gov/13966843 DMIK367 DI DMIK367 DMIK367 DN Procarbazine DMIK367 TI TTUTN1I DMIK367 TN Human Deoxyribonucleic acid (hDNA) DMIK367 RN Brca2/Xrcc2 dependent HR, but not NHEJ, is required for protection against O(6)-methylguanine triggered apoptosis, DSBs and chromosomal aberrations... DNA Repair (Amst). 2009 Jan 1;8(1):72-86. DMIK367 RU https://pubmed.ncbi.nlm.nih.gov/18840549 DMIKFEL DI DMIKFEL DMIKFEL DN Levomepromazine DMIKFEL TI TTEX248 DMIKFEL TN Dopamine D2 receptor (D2R) DMIKFEL MA Modulator DMIKFEL RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMIKFEL RU https://www.fda.gov/ DMIKHN0 DI DMIKHN0 DMIKHN0 DN Meticillin DMIKHN0 TI TTJP4SM DMIKHN0 TN Bacterial Penicillin binding protein (Bact PBP) DMIKHN0 MA Binder DMIKHN0 RN A link in transcription between the native pbpB and the acquired mecA gene in a strain of Staphylococcus aureus. Microbiology. 2006 Sep;152(Pt 9):2549-58. DMIKHN0 RU https://pubmed.ncbi.nlm.nih.gov/16946250 DMINO7Z DI DMINO7Z DMINO7Z DN Perhexiline DMINO7Z TI TTDL0NY DMINO7Z TN Carnitine O-palmitoyltransferase I (CPT1B) DMINO7Z MA Inhibitor DMINO7Z RN Perhexiline. Cardiovasc Drug Rev. 2007 Spring;25(1):76-97. DMINO7Z RU https://pubmed.ncbi.nlm.nih.gov/17445089 DMINOX3 DI DMINOX3 DMINOX3 DN Vincristine DMINOX3 TI TTYFKSZ DMINOX3 TN Tubulin beta (TUBB) DMINOX3 MA Modulator DMINOX3 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMINOX3 RU https://www.fda.gov/ DMINRKW DI DMINRKW DMINRKW DN Clomipramine DMINRKW TI TT3ROYC DMINRKW TN Serotonin transporter (SERT) DMINRKW MA Inhibitor DMINRKW RN Efficacy of treatments for patients with obsessive-compulsive disorder: a systematic review. J Am Acad Nurse Pract. 2009 Apr;21(4):207-13. DMINRKW RU https://pubmed.ncbi.nlm.nih.gov/19366379 DMINZ4W DI DMINZ4W DMINZ4W DN Tetrahydrobiopterin DMINZ4W TI TTUHP71 DMINZ4W TN Tyrosine 3-monooxygenase (TH) DMINZ4W MA Cofactor DMINZ4W RN Biochemistry of postmortem brains in Parkinson's disease: historical overview and future prospects. J Neural Transm Suppl. 2007;(72):113-20. DMINZ4W RU https://pubmed.ncbi.nlm.nih.gov/17982884 DMIO1K0 DI DMIO1K0 DMIO1K0 DN Sulfamylon DMIO1K0 TI TTANPDJ DMIO1K0 TN Carbonic anhydrase II (CA-II) DMIO1K0 MA Inhibitor DMIO1K0 RN Sulfonamide linked neoglycoconjugates--a new class of inhibitors for cancer-associated carbonic anhydrases. J Med Chem. 2010 Apr 8;53(7):2913-26. DMIO1K0 RU https://pubmed.ncbi.nlm.nih.gov/20201556 DMIO1K0 DI DMIO1K0 DMIO1K0 DN Sulfamylon DMIO1K0 TI TTSYM0R DMIO1K0 TN Carbonic anhydrase XII (CA-XII) DMIO1K0 MA Inhibitor DMIO1K0 RN Sulfonamide linked neoglycoconjugates--a new class of inhibitors for cancer-associated carbonic anhydrases. J Med Chem. 2010 Apr 8;53(7):2913-26. DMIO1K0 RU https://pubmed.ncbi.nlm.nih.gov/20201556 DMIO1K0 DI DMIO1K0 DMIO1K0 DN Sulfamylon DMIO1K0 TI TTCFSPE DMIO1K0 TN Carbonic anhydrase VI (CA-VI) DMIO1K0 MA Inhibitor DMIO1K0 RN Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV. J Med Chem. 2009 Feb 12;52(3):646-54. DMIO1K0 RU https://pubmed.ncbi.nlm.nih.gov/19193158 DMIO1K0 DI DMIO1K0 DMIO1K0 DN Sulfamylon DMIO1K0 TI TTEYTKG DMIO1K0 TN Carbonic anhydrase XIV (CA-XIV) DMIO1K0 MA Inhibitor DMIO1K0 RN Carbonic anhydrase inhibitors: inhibition of the transmembrane isozyme XIV with sulfonamides. Bioorg Med Chem Lett. 2005 Sep 1;15(17):3828-33. DMIO1K0 RU https://pubmed.ncbi.nlm.nih.gov/16039848 DMIO1K0 DI DMIO1K0 DMIO1K0 DN Sulfamylon DMIO1K0 TI TTZHA0O DMIO1K0 TN Carbonic anhydrase IV (CA-IV) DMIO1K0 MA Inhibitor DMIO1K0 RN Carbonic anhydrase inhibitors. Inhibition of the membrane-bound human and bovine isozymes IV with sulfonamides. Bioorg Med Chem Lett. 2005 Feb 15;15(4):1149-54. DMIO1K0 RU https://pubmed.ncbi.nlm.nih.gov/15686931 DMIO1K0 DI DMIO1K0 DMIO1K0 DN Sulfamylon DMIO1K0 TI TTUNARX DMIO1K0 TN Carbonic anhydrase (CA) DMIO1K0 MA Inhibitor DMIO1K0 RN Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV. J Med Chem. 2009 Feb 12;52(3):646-54. DMIO1K0 RU https://pubmed.ncbi.nlm.nih.gov/19193158 DMIO4V5 DI DMIO4V5 DMIO4V5 DN VRX496 DMIO4V5 TI TTXVOJ5 DMIO4V5 TN Human immunodeficiency virus Envelope messenger RNA (HIV env mRNA) DMIO4V5 RN Design and development of antisense drugs. Expert Opin. Drug Discov. 2008 3(10):1189-1207. DMIO4V5 RU http://www.informahealthcare.com/doi/abs/10.1517/17460441.3.10.1177 DMIOGBU DI DMIOGBU DMIOGBU DN Bosentan DMIOGBU TI TTKRD0G DMIOGBU TN Endothelin A receptor (EDNRA) DMIOGBU MA Modulator DMIOGBU RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMIOGBU RU https://www.fda.gov/ DMIOGBU DI DMIOGBU DMIOGBU DN Bosentan DMIOGBU TI TT3ZTGU DMIOGBU TN Endothelin B receptor (EDNRB) DMIOGBU MA Modulator DMIOGBU RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMIOGBU RU https://www.fda.gov/ DMIOZ29 DI DMIOZ29 DMIOZ29 DN Glycine DMIOZ29 TI TTKJEMQ DMIOZ29 TN Glutamate receptor ionotropic NMDA 2A (NMDAR2A) DMIOZ29 MA Antagonist DMIOZ29 RN Glycine transport inhibitors for the treatment of schizophrenia: Symptom and disease modification. Curr Opin Drug Discov Devel. 2009 Jul;12(4):468-78. DMIOZ29 RU https://pubmed.ncbi.nlm.nih.gov/19562643 DMIP3ZV DI DMIP3ZV DMIP3ZV DN Fenoterol DMIP3ZV TI TT2CJVK DMIP3ZV TN Adrenergic receptor beta-2 (ADRB2) DMIP3ZV MA Agonist DMIP3ZV RN Functional alpha1- and beta2-adrenergic receptors in human osteoblasts. J Cell Physiol. 2009 Jul;220(1):267-75. DMIP3ZV RU https://pubmed.ncbi.nlm.nih.gov/19334040 DMIR5QP DI DMIR5QP DMIR5QP DN Azlocillin DMIR5QP TI TTJP4SM DMIR5QP TN Bacterial Penicillin binding protein (Bact PBP) DMIR5QP MA Binder DMIR5QP RN Reactivation of peptidoglycan synthesis in ether-permeabilized Escherichia coli after inhibition by beta-lactam antibiotics. Antimicrob Agents Chemother. 1989 Dec;33(12):2101-8. DMIR5QP RU https://pubmed.ncbi.nlm.nih.gov/2515794 DMIRMVB DI DMIRMVB DMIRMVB DN Methadyl Acetate DMIRMVB TI TTKWM86 DMIRMVB TN Opioid receptor mu (MOP) DMIRMVB MA Agonist DMIRMVB RN Acetylmethadol metabolites influence opiate receptors and adenylate cyclase in amygdala. Eur J Pharmacol. 1981 Jul 10;72(4):343-9. DMIRMVB RU https://pubmed.ncbi.nlm.nih.gov/6268422 DMISH0Z DI DMISH0Z DMISH0Z DN Mogamulizumab DMISH0Z TI TT7HQD0 DMISH0Z TN C-C chemokine receptor type 4 (CCR4) DMISH0Z MA Inhibitor DMISH0Z RN Mogamulizumab, a humanized mAb against C-C chemokine receptor 4 for the potential treatment of T-cell lymphomas and asthma. Curr Opin Mol Ther. 2010 Dec;12(6):770-9. DMISH0Z RU https://pubmed.ncbi.nlm.nih.gov/21154168 DMIT8LX DI DMIT8LX DMIT8LX DN Fluphenazine DMIT8LX TI TTK8CXU DMIT8LX TN 5-HT 1B receptor (HTR1B) DMIT8LX MA Modulator DMIT8LX RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMIT8LX RU https://www.fda.gov/ DMITQS0 DI DMITQS0 DMITQS0 DN Lopinavir DMITQS0 TI TTLFGBV DMITQS0 TN Bacterial 23S ribosomal RNA (Bact 23S rRNA) DMITQS0 MA Modulator DMITQS0 RN Company report (JMI Laboratories) DMITQS0 RU http://www.jmilabs.com/data/posters/ICAAC2013%5CE-144.pdf DMITSEH DI DMITSEH DMITSEH DN Isoetharine DMITSEH TI TT2CJVK DMITSEH TN Adrenergic receptor beta-2 (ADRB2) DMITSEH MA Modulator DMITSEH RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMITSEH RU https://www.fda.gov/ DMIUW25 DI DMIUW25 DMIUW25 DN Granisetron DMIUW25 TI TTNXLKE DMIUW25 TN 5-HT 3 receptor (5HT3R) DMIUW25 MA Antagonist DMIUW25 RN New approaches to chemotherapy-induced nausea and vomiting: from neuropharmacology to clinical investigations. Cancer J. 2006 Sep-Oct;12(5):341-7. DMIUW25 RU https://pubmed.ncbi.nlm.nih.gov/17034670 DMIUX3D DI DMIUX3D DMIUX3D DN Methyl aminolevulinate DMIUX3D TI TTQ6VF4 DMIUX3D TN Ferrochelatase (FECH) DMIUX3D MA Activator DMIUX3D RN Low-dose methotrexate enhances aminolevulinate-based photodynamic therapy in skin carcinoma cells in vitro and in vivo. Clin Cancer Res. 2009 May 15;15(10):3333-43. DMIUX3D RU https://pubmed.ncbi.nlm.nih.gov/19447864 DMIUYFH DI DMIUYFH DMIUYFH DN Sulfapyridine DMIUYFH TI TT4ILYC DMIUYFH TN Bacterial Dihydropteroate synthetase (Bact folP) DMIUYFH MA Inhibitor DMIUYFH RN A confirmatory method for the simultaneous extraction, separation, identification and quantification of Tetracycline, Sulphonamide, Trimethoprim an... J Chromatogr A. 2009 Nov 13;1216(46):8110-6. DMIUYFH RU https://pubmed.ncbi.nlm.nih.gov/19586630 DMIVJ0D DI DMIVJ0D DMIVJ0D DN Pseudoephedrine DMIVJ0D TI TTEX248 DMIVJ0D TN Dopamine D2 receptor (D2R) DMIVJ0D MA Stimulator DMIVJ0D RN Cetirizine/pseudoephedrine. Drugs. 2001;61(15):2231-40; discussion 2241-2. DMIVJ0D RU https://pubmed.ncbi.nlm.nih.gov/11772135 DMIWFRL DI DMIWFRL DMIWFRL DN Tolvaptan DMIWFRL TI TTK8R02 DMIWFRL TN Vasopressin V2 receptor (V2R) DMIWFRL MA Antagonist DMIWFRL RN Antibody-mediated disruption of the interaction between PCSK9 and the low-density lipoprotein receptor. Biochem J. 2009 May 1;419(3):577-84. DMIWFRL RU https://pubmed.ncbi.nlm.nih.gov/19196236 DMIXC7G DI DMIXC7G DMIXC7G DN Zoledronate DMIXC7G TI TTIKWV4 DMIXC7G TN Geranyltranstransferase (FDPS) DMIXC7G MA Modulator DMIXC7G RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMIXC7G RU https://www.fda.gov/ DMIYDT4 DI DMIYDT4 DMIYDT4 DN Cabozantinib DMIYDT4 TI TTUTJGQ DMIYDT4 TN Vascular endothelial growth factor receptor 2 (KDR) DMIYDT4 MA Inhibitor DMIYDT4 RN Clinical pipeline report, company report or official report of Exelixis (2011). DMIYDT4 RU http://www.exelixis.com/pipeline DMIYDT4 DI DMIYDT4 DMIYDT4 DN Cabozantinib DMIYDT4 TI TTNDSF4 DMIYDT4 TN Proto-oncogene c-Met (MET) DMIYDT4 MA Inhibitor DMIYDT4 RN Clinical pipeline report, company report or official report of Exelixis (2011). DMIYDT4 RU http://www.exelixis.com/pipeline DMIYG7Z DI DMIYG7Z DMIYG7Z DN Donepezil DMIYG7Z TI TT1RS9F DMIYG7Z TN Acetylcholinesterase (AChE) DMIYG7Z MA Modulator DMIYG7Z RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2465). DMIYG7Z RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2465 DMIYJFV DI DMIYJFV DMIYJFV DN Nicorandil DMIYJFV TI TTEF5MJ DMIYJFV TN ATP-binding cassette transporter C9 (ABCC9) DMIYJFV MA Activator DMIYJFV RN A functional role of the C-terminal 42 amino acids of SUR2A and SUR2B in the physiology and pharmacology of cardiovascular ATP-sensitive K(+) chann... J Mol Cell Cardiol. 2005 Jul;39(1):1-6. DMIYJFV RU https://pubmed.ncbi.nlm.nih.gov/15978900 DMIZ1E8 DI DMIZ1E8 DMIZ1E8 DN Galcanezumab DMIZ1E8 TI TTY6O0Q DMIZ1E8 TN Calcitonin gene-related peptide receptor (CGRPR) DMIZ1E8 MA Modulator DMIZ1E8 RN 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. DMIZ1E8 RU https://pubmed.ncbi.nlm.nih.gov/30710142 DMIZ6W2 DI DMIZ6W2 DMIZ6W2 DN Norfloxacin DMIZ6W2 TI TTN6J5F DMIZ6W2 TN Bacterial DNA gyrase (Bact gyrase) DMIZ6W2 MA Modulator DMIZ6W2 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMIZ6W2 RU https://www.fda.gov/ DMJ01D8 DI DMJ01D8 DMJ01D8 DN Colforsin daropate hci DMJ01D8 TI TTULOB6 DMJ01D8 TN Cathelicidin antimicrobial peptide (CAMP) DMJ01D8 MA Modulator DMJ01D8 RN Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. DMJ01D8 RU https://pubmed.ncbi.nlm.nih.gov/17309302 DMJ0QOW DI DMJ0QOW DMJ0QOW DN Rilpivirine DMJ0QOW TI TT84ETX DMJ0QOW TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMJ0QOW MA Inhibitor DMJ0QOW RN Emerging antiviral drugs. Expert Opin Emerg Drugs. 2008 Sep;13(3):393-416. DMJ0QOW RU https://pubmed.ncbi.nlm.nih.gov/18764719 DMJ0QOW DI DMJ0QOW DMJ0QOW DN Rilpivirine DMJ0QOW TI TT90XZ8 DMJ0QOW TN Voltage-gated sodium channel alpha Nav1.8 (SCN10A) DMJ0QOW MA Inhibitor DMJ0QOW RN Structures of muO-conotoxins from Conus marmoreus. I nhibitors of tetrodotoxin (TTX)-sensitive and TTX-resistant sodium channels in mammalian senso... J Biol Chem. 2004 Jun 11;279(24):25774-82. DMJ0QOW RU https://pubmed.ncbi.nlm.nih.gov/15044438 DMJ13KI DI DMJ13KI DMJ13KI DN Terconazole DMJ13KI TI TTTSOUD DMJ13KI TN Candida Cytochrome P450 51 (Candi ERG11) DMJ13KI MA Inhibitor DMJ13KI RN Mode of action of anti-Candida drugs: focus on terconazole and other ergosterol biosynthesis inhibitors. Am J Obstet Gynecol. 1991 Oct;165(4 Pt 2):1193-9. DMJ13KI RU https://pubmed.ncbi.nlm.nih.gov/1951574 DMJ2AH4 DI DMJ2AH4 DMJ2AH4 DN Vitamin A DMJ2AH4 TI TTH029C DMJ2AH4 TN Retinoic acid receptor RXR-gamma (RXRG) DMJ2AH4 MA Binder DMJ2AH4 RN Vitamins and cofactors: highlights of ESBOC 2009. Nat Chem Biol. 2009 Aug;5(8):530-3. DMJ2AH4 RU https://pubmed.ncbi.nlm.nih.gov/19620989 DMJ2AH4 DI DMJ2AH4 DMJ2AH4 DN Vitamin A DMJ2AH4 TI TTOD7B3 DMJ2AH4 TN Retinoic acid receptor (RAR) DMJ2AH4 MA Binder DMJ2AH4 RN Vitamins and cofactors: highlights of ESBOC 2009. Nat Chem Biol. 2009 Aug;5(8):530-3. DMJ2AH4 RU https://pubmed.ncbi.nlm.nih.gov/19620989 DMJ2AH4 DI DMJ2AH4 DMJ2AH4 DN Vitamin A DMJ2AH4 TI TTRTKPV DMJ2AH4 TN Trypanosoma Trypanothione reductase (Trypano TPR) DMJ2AH4 MA Binder DMJ2AH4 RN Opportunities and challenges in antiparasitic drug discovery. Nat Rev Drug Discov. 2005 Sep;4(9):727-40. DMJ2AH4 RU https://pubmed.ncbi.nlm.nih.gov/16138106 DMJ2O7B DI DMJ2O7B DMJ2O7B DN Gemtuzumab ozogamicin DMJ2O7B TI TTJVYO3 DMJ2O7B TN Myeloid cell surface antigen CD33 (CD33) DMJ2O7B RN Targeted treatment of acute myeloid leukemia in older adults: role of gemtuzumab ozogamicin. Clin Interv Aging. 2009;4:197-205. DMJ2O7B RU https://pubmed.ncbi.nlm.nih.gov/19503782 DMJ3I1Q DI DMJ3I1Q DMJ3I1Q DN Niflumic acid DMJ3I1Q TI TTVKILB DMJ3I1Q TN Prostaglandin G/H synthase 2 (COX-2) DMJ3I1Q MA Inhibitor DMJ3I1Q RN Rat ovulation, implantation and decidualization are severely compromised by COX-2 inhibitors. Front Biosci. 2007 May 1;12:3333-42. DMJ3I1Q RU https://pubmed.ncbi.nlm.nih.gov/17485303 DMJ47QC DI DMJ47QC DMJ47QC DN Thyrotropin DMJ47QC TI TT6NYJA DMJ47QC TN Thyrotropin receptor (TSHR) DMJ47QC MA Modulator DMJ47QC RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMJ47QC RU https://www.fda.gov/ DMJ4AWC DI DMJ4AWC DMJ4AWC DN Cyclothiazide DMJ4AWC TI TTANPDJ DMJ4AWC TN Carbonic anhydrase II (CA-II) DMJ4AWC MA Inhibitor DMJ4AWC RN Selective effect of thiazides on the human osteoblast-like cell line MG-63. Kidney Int. 1996 Nov;50(5):1476-82. DMJ4AWC RU https://pubmed.ncbi.nlm.nih.gov/8914012 DMJ6H1Z DI DMJ6H1Z DMJ6H1Z DN Quinestrol DMJ6H1Z TI TTZAYWL DMJ6H1Z TN Estrogen receptor (ESR) DMJ6H1Z MA Modulator DMJ6H1Z RN The antioxidant effect of estrogen and Selective Estrogen Receptor Modulators in the inhibition of osteocyte apoptosis in vitro. Bone. 2007 Mar;40(3):674-84. DMJ6H1Z RU https://pubmed.ncbi.nlm.nih.gov/17174166 DMJ7A0H DI DMJ7A0H DMJ7A0H DN Cefdinir DMJ7A0H TI TTJP4SM DMJ7A0H TN Bacterial Penicillin binding protein (Bact PBP) DMJ7A0H MA Binder DMJ7A0H RN Decreased affinity of mosaic-structure recombinant penicillin-binding protein 2 for oral cephalosporins in Neisseria gonorrhoeae. J Antimicrob Chemother. 2007 Jul;60(1):54-60. DMJ7A0H RU https://pubmed.ncbi.nlm.nih.gov/17540669 DMJ7IQX DI DMJ7IQX DMJ7IQX DN Crestor/TriLipix DMJ7IQX TI TTPADOQ DMJ7IQX TN HMG-CoA reductase (HMGCR) DMJ7IQX MA Inhibitor DMJ7IQX RN Clinical pipeline report, company report or official report of AstraZeneca (2009). DMJ7IQX RU http://www.astrazeneca.com/_mshost3690701/content/resources/media/investors/AZN-Q2-2009/AZN-Q2-2009-Pipeline.pdf DMJ8A3Z DI DMJ8A3Z DMJ8A3Z DN Florbetapir F-18 DMJ8A3Z TI TTE4KHA DMJ8A3Z TN Amyloid beta A4 protein (APP) DMJ8A3Z MA Modulator DMJ8A3Z RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DMJ8A3Z RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DMJ8NMC DI DMJ8NMC DMJ8NMC DN Barbital DMJ8NMC TI TT1MPAY DMJ8NMC TN GABA(A) receptor alpha-1 (GABRA1) DMJ8NMC MA Antagonist DMJ8NMC RN DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6. DMJ8NMC RU https://pubmed.ncbi.nlm.nih.gov/18048412 DMJ90O5 DI DMJ90O5 DMJ90O5 DN Medrysone DMJ90O5 TI TTP3UTW DMJ90O5 TN Steroid hormone receptor ERR (ESRR) DMJ90O5 MA Modulator DMJ90O5 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMJ90O5 RU https://www.fda.gov/ DMJ93CT DI DMJ93CT DMJ93CT DN Inotersen DMJ93CT TI TTC1I86 DMJ93CT TN Transthyretin (TTR) DMJ93CT MA Antisense DMJ93CT RN 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. DMJ93CT RU https://pubmed.ncbi.nlm.nih.gov/30710142 DMJ9G23 DI DMJ9G23 DMJ9G23 DN ISIS 1570 DMJ9G23 TI TTA1L39 DMJ9G23 TN ICAM1 messenger RNA (ICAM1 mRNA) DMJ9G23 RN US patent application no. 6,300,491, Oligonucleotide inhibition of cell adhesion. DMJ9G23 RU http://www.patentbuddy.com/Patent/6300491?ft=true&sr=true DMJAOT1 DI DMJAOT1 DMJAOT1 DN Polyoxidonium DMJAOT1 TI TT3J5ZI DMJAOT1 TN Cell mediated immunity response (CMIR) DMJAOT1 MA Modulator DMJAOT1 RN Effect of polyoxidonium on the phagocytic activity of human peripheral blood leukocytes. Russ J Immunol. 2003 Apr;8(1):53-60. DMJAOT1 RU https://pubmed.ncbi.nlm.nih.gov/12717555 DMJAPE7 DI DMJAPE7 DMJAPE7 DN Methylene blue DMJAPE7 TI TT32XQJ DMJAPE7 TN Monoamine oxidase (MAO) DMJAPE7 RN Photoluminescence of CdTe nanocrystals modulated by methylene blue and DNA. A label-free luminescent signaling nanohybrid platform. Phys Chem Chem Phys. 2009 Jul 7;11(25):5062-9. DMJAPE7 RU https://pubmed.ncbi.nlm.nih.gov/19562136 DMJAPE7 DI DMJAPE7 DMJAPE7 DN Methylene blue DMJAPE7 TI TT6HPVC DMJAPE7 TN Guanylate cyclase (GC) DMJAPE7 MA Inhibitor DMJAPE7 RN Curcumin ameliorates high glucose-induced acute vascular endothelial dysfunction in rat thoracic aorta. Clin Exp Pharmacol Physiol. 2009 Dec;36(12):1177-82. DMJAPE7 RU https://pubmed.ncbi.nlm.nih.gov/19473193 DMJBOCR DI DMJBOCR DMJBOCR DN Levacecarnine HCL DMJBOCR TI TTDL0NY DMJBOCR TN Carnitine O-palmitoyltransferase I (CPT1B) DMJBOCR MA Activator DMJBOCR RN Central ghrelin regulates peripheral lipid metabolism in a growth hormone-independent fashion. Endocrinology. 2009 Oct;150(10):4562-74. DMJBOCR RU https://pubmed.ncbi.nlm.nih.gov/19608647 DMJCP1Y DI DMJCP1Y DMJCP1Y DN Yohimbine DMJCP1Y TI TTQ8AFT DMJCP1Y TN Adrenergic receptor Alpha-2 (ADRA2) DMJCP1Y MA Antagonist DMJCP1Y RN Acute neurotoxicity after yohimbine ingestion by a body builder. Clin Toxicol (Phila). 2009 Sep;47(8):827-9. DMJCP1Y RU https://pubmed.ncbi.nlm.nih.gov/19640235 DMJDB0Y DI DMJDB0Y DMJDB0Y DN Dezocine DMJDB0Y TI TTQW87Y DMJDB0Y TN Opioid receptor kappa (OPRK1) DMJDB0Y MA Antagonist DMJDB0Y RN Pharmacological profiles of opioid ligands at kappa opioid receptors. BMC Pharmacol. 2006 Jan 25;6:3. DMJDB0Y RU https://pubmed.ncbi.nlm.nih.gov/16433932 DMJDYNQ DI DMJDYNQ DMJDYNQ DN E-2007 DMJDYNQ TI TTAN6JD DMJDYNQ TN Glutamate receptor AMPA (GRIA) DMJDYNQ MA Modulator DMJDYNQ RN Nat Rev Drug Discov. 2013 Feb;12(2):87-90. DMJDYNQ RU https://pubmed.ncbi.nlm.nih.gov/23370234 DMJDYNQ DI DMJDYNQ DMJDYNQ DN E-2007 DMJDYNQ TI TTVPQTF DMJDYNQ TN Glutamate receptor AMPA 1 (GRIA1) DMJDYNQ MA Inhibitor DMJDYNQ RN Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357. DMJDYNQ RU https://pubmed.ncbi.nlm.nih.gov/30728472 DMJDYNQ DI DMJDYNQ DMJDYNQ DN E-2007 DMJDYNQ TI TT9HLZ0 DMJDYNQ TN Glutamate receptor AMPA 2 (GRIA2) DMJDYNQ MA Inhibitor DMJDYNQ RN Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357. DMJDYNQ RU https://pubmed.ncbi.nlm.nih.gov/30728472 DMJDYNQ DI DMJDYNQ DMJDYNQ DN E-2007 DMJDYNQ TI TT82EZV DMJDYNQ TN Glutamate receptor AMPA 3 (GRIA3) DMJDYNQ MA Inhibitor DMJDYNQ RN Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357. DMJDYNQ RU https://pubmed.ncbi.nlm.nih.gov/30728472 DMJDYNQ DI DMJDYNQ DMJDYNQ DN E-2007 DMJDYNQ TI TTPJR0G DMJDYNQ TN Glutamate receptor AMPA 4 (GRIA4) DMJDYNQ MA Inhibitor DMJDYNQ RN Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357. DMJDYNQ RU https://pubmed.ncbi.nlm.nih.gov/30728472 DMJE6KO DI DMJE6KO DMJE6KO DN Desvenalfaxine succinate DMJE6KO TI TTAWNKZ DMJE6KO TN Norepinephrine transporter (NET) DMJE6KO MA Inhibitor DMJE6KO RN Emerging therapies for fibromyalgia. Expert Opin Emerg Drugs. 2008 Mar;13(1):53-62. DMJE6KO RU https://pubmed.ncbi.nlm.nih.gov/18321148 DMJFP6G DI DMJFP6G DMJFP6G DN Metergolin DMJFP6G TI TT85JO3 DMJFP6G TN 5-HT receptor (5HTR) DMJFP6G MA Modulator DMJFP6G RN Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. DMJFP6G RU https://pubmed.ncbi.nlm.nih.gov/17309302 DMJFP6G DI DMJFP6G DMJFP6G DN Metergolin DMJFP6G TI TTWJBZ5 DMJFP6G TN 5-HT 2C receptor (HTR2C) DMJFP6G MA Antagonist DMJFP6G RN Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors. Naunyn Schmiedebergs Arch Pharmacol. 2004 Aug;370(2):114-23. DMJFP6G RU https://pubmed.ncbi.nlm.nih.gov/15322733 DMJFP6G DI DMJFP6G DMJFP6G DN Metergolin DMJFP6G TI TTK8CXU DMJFP6G TN 5-HT 1B receptor (HTR1B) DMJFP6G MA Antagonist DMJFP6G RN Two amino acid differences in the sixth transmembrane domain are partially responsible for the pharmacological differences between the 5-HT1D beta and 5-HT1E 5-hydroxytryptamine receptors. J Neurochem. 1996 Nov;67(5):2096-103. DMJFP6G RU https://pubmed.ncbi.nlm.nih.gov/8863519 DMJFP6G DI DMJFP6G DMJFP6G DN Metergolin DMJFP6G TI TTCPG9S DMJFP6G TN 5-HT 1E receptor (HTR1E) DMJFP6G MA Antagonist DMJFP6G RN Molecular cloning and pharmacological characterization of the guinea pig 5-HT1E receptor. Eur J Pharmacol. 2004 Jan 26;484(2-3):127-39. DMJFP6G RU https://pubmed.ncbi.nlm.nih.gov/14744596 DMJFP6G DI DMJFP6G DMJFP6G DN Metergolin DMJFP6G TI TT0MI3F DMJFP6G TN 5-HT 1F receptor (HTR1F) DMJFP6G MA Antagonist DMJFP6G RN Cloning and characterization of the guinea pig 5-HT1F receptor subtype: a comparison of the pharmacological profile to the human species homolog. Neuropharmacology. 1997 Apr-May;36(4-5):569-76. DMJFP6G RU https://pubmed.ncbi.nlm.nih.gov/9225282 DMJFP6G DI DMJFP6G DMJFP6G DN Metergolin DMJFP6G TI TTRUFDT DMJFP6G TN 5-HT 5A receptor (HTR5A) DMJFP6G MA Antagonist DMJFP6G RN Cloning and characterisation of the human 5-HT5A serotonin receptor. FEBS Lett. 1994 Dec 5;355(3):242-6. DMJFP6G RU https://pubmed.ncbi.nlm.nih.gov/7988681 DMJFP6G DI DMJFP6G DMJFP6G DN Metergolin DMJFP6G TI TT6MSOK DMJFP6G TN 5-HT 1D receptor (HTR1D) DMJFP6G MA Antagonist DMJFP6G RN Primary structure and functional characterization of a human 5-HT1D-type serotonin receptor. Mol Pharmacol. 1991 Aug;40(2):143-8. DMJFP6G RU https://pubmed.ncbi.nlm.nih.gov/1652050 DMJFP6G DI DMJFP6G DMJFP6G DN Metergolin DMJFP6G TI TT0K1SC DMJFP6G TN 5-HT 2B receptor (HTR2B) DMJFP6G MA Antagonist DMJFP6G RN Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors. Naunyn Schmiedebergs Arch Pharmacol. 2004 Aug;370(2):114-23. DMJFP6G RU https://pubmed.ncbi.nlm.nih.gov/15322733 DMJFP6G DI DMJFP6G DMJFP6G DN Metergolin DMJFP6G TI TTJQOD7 DMJFP6G TN 5-HT 2A receptor (HTR2A) DMJFP6G MA Antagonist DMJFP6G RN Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors. Naunyn Schmiedebergs Arch Pharmacol. 2004 Aug;370(2):114-23. DMJFP6G RU https://pubmed.ncbi.nlm.nih.gov/15322733 DMJFZDL DI DMJFZDL DMJFZDL DN Naphazoline DMJFZDL TI TTEX248 DMJFZDL TN Dopamine D2 receptor (D2R) DMJFZDL MA Agonist DMJFZDL RN Decongestants in treatment of nasal obstruction. Otolaryngol Pol. 1999;53(3):347-52. DMJFZDL RU https://pubmed.ncbi.nlm.nih.gov/10481510 DMJHLSD DI DMJHLSD DMJHLSD DN Famciclovir DMJHLSD TI TTIU7X1 DMJHLSD TN Herpes simplex virus DNA polymerase UL30 (HSV UL30) DMJHLSD MA Inhibitor DMJHLSD RN Penciclovir cream--improved topical treatment for herpes simplex infections. Skin Pharmacol Physiol. 2004 Sep-Oct;17(5):214-8. DMJHLSD RU https://pubmed.ncbi.nlm.nih.gov/15452407 DMJHN0A DI DMJHN0A DMJHN0A DN Icosapent DMJHN0A TI TTK0943 DMJHN0A TN Prostaglandin G/H synthase (COX) DMJHN0A MA Binder DMJHN0A RN Differential modulation of Toll-like receptors by fatty acids: preferential inhibition by n-3 polyunsaturated fatty acids. J Lipid Res. 2003 Mar;44(3):479-86. DMJHN0A RU https://pubmed.ncbi.nlm.nih.gov/12562875 DMJI3BA DI DMJI3BA DMJI3BA DN Peginterferon alfa-2a DMJI3BA TI TTSIUJ9 DMJI3BA TN Interferon-alpha 2 (IFNA2) DMJI3BA MA Modulator DMJI3BA RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMJI3BA RU https://www.fda.gov/ DMJIA6T DI DMJIA6T DMJIA6T DN Barbiturate DMJIA6T TI TTAN6JD DMJIA6T TN Glutamate receptor AMPA (GRIA) DMJIA6T MA Agonist DMJIA6T RN Anaesthetic drugs: linking molecular actions to clinical effects. Curr Pharm Des. 2006;12(28):3665-79. DMJIA6T RU https://pubmed.ncbi.nlm.nih.gov/17073666 DMJIA6T DI DMJIA6T DMJIA6T DN Barbiturate DMJIA6T TI TT1MPAY DMJIA6T TN GABA(A) receptor alpha-1 (GABRA1) DMJIA6T MA Antagonist DMJIA6T RN DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6. DMJIA6T RU https://pubmed.ncbi.nlm.nih.gov/18048412 DMJIBAW DI DMJIBAW DMJIBAW DN Budesonide DMJIBAW TI TTYRL6O DMJIBAW TN Glucocorticoid receptor (NR3C1) DMJIBAW MA Antagonist DMJIBAW RN PXR-mediated induction of human CYP3A4 and mouse Cyp3a11 by the glucocorticoid budesonide. Eur J Pharm Sci. 2009 Mar 2;36(4-5):565-71. DMJIBAW RU https://pubmed.ncbi.nlm.nih.gov/19138736 DMJKROX DI DMJKROX DMJKROX DN Luvox DMJKROX TI TT3ROYC DMJKROX TN Serotonin transporter (SERT) DMJKROX MA Modulator DMJKROX RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMJKROX RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMJL10P DI DMJL10P DMJL10P DN Isoxyl DMJL10P TI TT6RIOV DMJL10P TN Acyl-CoA desaturase (SCD) DMJL10P MA Binder DMJL10P RN Has nature already identified all useful antibacterial targets Curr Opin Microbiol. 2008 Oct;11(5):387-92. DMJL10P RU https://pubmed.ncbi.nlm.nih.gov/18804175 DMJMVKI DI DMJMVKI DMJMVKI DN Metipranolol DMJMVKI TI TTR6W5O DMJMVKI TN Adrenergic receptor beta-1 (ADRB1) DMJMVKI MA Antagonist DMJMVKI RN Invited review: Neuroprotective properties of certain beta-adrenoceptor antagonists used for the treatment of glaucoma. J Ocul Pharmacol Ther. 2005 Jun;21(3):175-81. DMJMVKI RU https://pubmed.ncbi.nlm.nih.gov/15969634 DMJNV4O DI DMJNV4O DMJNV4O DN Tirbanibulin DMJNV4O TI TTHVQ4N DMJNV4O TN Tubulin polymerization (TubP) DMJNV4O MA Inhibitor DMJNV4O RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020 DMJNV4O RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213189s000lbl.pdf DMJO6GV DI DMJO6GV DMJO6GV DN Abciximab DMJO6GV TI TT38RM1 DMJO6GV TN Glycoprotein IIb/IIIa receptor (GPIIb/IIIa) DMJO6GV MA Modulator DMJO6GV RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMJO6GV RU https://www.fda.gov/ DMJOQM3 DI DMJOQM3 DMJOQM3 DN Eflornithine DMJOQM3 TI TTUMGNO DMJOQM3 TN Ornithine decarboxylase (ODC1) DMJOQM3 MA Inhibitor DMJOQM3 RN Plasmodium falciparum and Plasmodium berghei: effects of ornithine decarboxylase inhibitors on erythrocytic schizogony. Exp Parasitol. 1987 Oct;64(2):237-43. DMJOQM3 RU https://pubmed.ncbi.nlm.nih.gov/3115816 DMJPD06 DI DMJPD06 DMJPD06 DN Lmw heparin DMJPD06 TI TTCIHJA DMJPD06 TN Coagulation factor Xa (F10) DMJPD06 MA Modulator DMJPD06 RN Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. DMJPD06 RU https://pubmed.ncbi.nlm.nih.gov/17309302 DMJPR2B DI DMJPR2B DMJPR2B DN Glisoxepide DMJPR2B TI TTG140O DMJPR2B TN Inward rectifier potassium channel Kir1.2 (KCNJ10) DMJPR2B MA Blocker DMJPR2B RN Bepridil, an antiarrhythmic drug, opens mitochondrial KATP channels, blocks sarcolemmal KATP channels, and confers cardioprotection. J Pharmacol Exp Ther. 2006 Jan;316(1):182-8. DMJPR2B RU https://pubmed.ncbi.nlm.nih.gov/16174795 DMJSBT6 DI DMJSBT6 DMJSBT6 DN Silodosin DMJSBT6 TI TTNGILX DMJSBT6 TN Adrenergic receptor alpha-1A (ADRA1A) DMJSBT6 MA Inhibitor DMJSBT6 RN Pharmacophore identification of alpha(1A)-adrenoceptor antagonists. Bioorg Med Chem Lett. 2005 Feb 1;15(3):657-64. DMJSBT6 RU https://pubmed.ncbi.nlm.nih.gov/15664832 DMJTEMW DI DMJTEMW DMJTEMW DN Lubiprostone DMJTEMW TI TT30NW6 DMJTEMW TN Chloride channel protein 2 (CLC-2) DMJTEMW MA Activator DMJTEMW RN Lubiprostone stimulates secretion from tracheal submucosal glands of sheep, pigs, and humans. Am J Physiol Lung Cell Mol Physiol. 2009 May;296(5):L811-24. DMJTEMW RU https://pubmed.ncbi.nlm.nih.gov/19233902 DMJTIYK DI DMJTIYK DMJTIYK DN Ipilimumab DMJTIYK TI TTI2S1D DMJTIYK TN Cytotoxic T-lymphocyte protein 4 (CTLA-4) DMJTIYK RN Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5. DMJTIYK RU https://pubmed.ncbi.nlm.nih.gov/21283092 DMJUNY5 DI DMJUNY5 DMJUNY5 DN Cefpodoxime DMJUNY5 TI TTJP4SM DMJUNY5 TN Bacterial Penicillin binding protein (Bact PBP) DMJUNY5 MA Binder DMJUNY5 RN Amino acid substitutions in mosaic penicillin-binding protein 2 associated with reduced susceptibility to cefixime in clinical isolates of Neisseri... Antimicrob Agents Chemother. 2006 Nov;50(11):3638-45. DMJUNY5 RU https://pubmed.ncbi.nlm.nih.gov/16940068 DMJUVE6 DI DMJUVE6 DMJUVE6 DN Bulevirtide DMJUVE6 TI TTWZRY5 DMJUVE6 TN Sodium/bile acid cotransporter (SLC10A1) DMJUVE6 MA Inhibitor DMJUVE6 RN Bulevirtide: First Approval. Drugs. 2020 Oct;80(15):1601-1605. DMJUVE6 RU https://pubmed.ncbi.nlm.nih.gov/32926353 DMJV2EK DI DMJV2EK DMJV2EK DN Dasatinib DMJV2EK TI TT6PKBN DMJV2EK TN Proto-oncogene c-Src (SRC) DMJV2EK MA Inhibitor DMJV2EK RN A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22. DMJV2EK RU https://pubmed.ncbi.nlm.nih.gov/17692029 DMJV2EK DI DMJV2EK DMJV2EK DN Dasatinib DMJV2EK TI TTS7G69 DMJV2EK TN Fusion protein Bcr-Abl (Bcr-Abl) DMJV2EK MA Inhibitor DMJV2EK RN A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22. DMJV2EK RU https://pubmed.ncbi.nlm.nih.gov/17692029 DMJV2EK DI DMJV2EK DMJV2EK DN Dasatinib DMJV2EK TI TT860QF DMJV2EK TN LCK tyrosine protein kinase (LCK) DMJV2EK MA Inhibitor DMJV2EK RN A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22. DMJV2EK RU https://pubmed.ncbi.nlm.nih.gov/17692029 DMJV2EK DI DMJV2EK DMJV2EK DN Dasatinib DMJV2EK TI TT2B9KF DMJV2EK TN Fyn tyrosine protein kinase (FYN) DMJV2EK MA Inhibitor DMJV2EK RN A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22. DMJV2EK RU https://pubmed.ncbi.nlm.nih.gov/17692029 DMJW0VS DI DMJW0VS DMJW0VS DN Tilidine DMJW0VS TI TTN4QDT DMJW0VS TN Opioid receptor (OPR) DMJW0VS MA Modulator DMJW0VS RN Actions of tilidine and nortilidine on cloned opioid receptors. Eur J Pharmacol. 2005 Jan 4;506(3):205-8. DMJW0VS RU https://pubmed.ncbi.nlm.nih.gov/15627429 DMJWRQP DI DMJWRQP DMJWRQP DN Zanubrutinib DMJWRQP TI TTGM6VW DMJWRQP TN Tyrosine-protein kinase BTK (ATK) DMJWRQP MA Inhibitor DMJWRQP RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019 DMJWRQP RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/213217s000lbl.pdf DMJX6ZG DI DMJX6ZG DMJX6ZG DN Codeine DMJX6ZG TI TT27RFC DMJX6ZG TN Opioid receptor delta (OPRD1) DMJX6ZG MA Agonist DMJX6ZG RN Butorphanol: effects of a prototypical agonist-antagonist analgesic on kappa-opioid receptors. J Pharmacol Sci. 2005 Jun;98(2):109-16. DMJX6ZG RU https://pubmed.ncbi.nlm.nih.gov/15942128 DMJXDGC DI DMJXDGC DMJXDGC DN Cefaclor DMJXDGC TI TTJP4SM DMJXDGC TN Bacterial Penicillin binding protein (Bact PBP) DMJXDGC MA Binder DMJXDGC RN Antibacterial activity of oral cephems against various clinically isolated strains and evaluation of efficacy based on the pharmacokinetics/pharmacodynamics theory. Jpn J Antibiot. 2004 Dec;57(6):465-74. DMJXDGC RU https://pubmed.ncbi.nlm.nih.gov/15747584 DMJXIC9 DI DMJXIC9 DMJXIC9 DN Anagliptin DMJXIC9 TI TTDIGC1 DMJXIC9 TN Dipeptidyl peptidase 4 (DPP-4) DMJXIC9 MA Modulator DMJXIC9 RN Diabetes Treatment. Diabetes Care. 2009 March; 32(3): e25-e30. DMJXIC9 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2646042/ DMJYCVW DI DMJYCVW DMJYCVW DN Warfarin DMJYCVW TI TTEUC8H DMJYCVW TN Vitamin K epoxide reductase complex 1 (VKORC1) DMJYCVW MA Inhibitor DMJYCVW RN [Oral anticoagulation and pharmacogenetics: importance in the clinical setting]. Rev Med Suisse. 2007 Sep 12;3(124):2030, 2033-4, 2036. DMJYCVW RU https://pubmed.ncbi.nlm.nih.gov/17955831 DMJYDVK DI DMJYDVK DMJYDVK DN Cariprazine DMJYDVK TI TT4C8EA DMJYDVK TN Dopamine D3 receptor (D3R) DMJYDVK MA Modulator DMJYDVK RN Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651. DMJYDVK RU https://pubmed.ncbi.nlm.nih.gov/28919714 DMJYDVK DI DMJYDVK DMJYDVK DN Cariprazine DMJYDVK TI TTEX248 DMJYDVK TN Dopamine D2 receptor (D2R) DMJYDVK MA Modulator DMJYDVK RN Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651. DMJYDVK RU https://pubmed.ncbi.nlm.nih.gov/28919714 DMJYN25 DI DMJYN25 DMJYN25 DN Tenecteplase DMJYN25 TI TTP86E2 DMJYN25 TN Plasminogen (PLG) DMJYN25 MA Activator DMJYN25 RN Thrombolytic therapies: the current state of affairs. J Endovasc Ther. 2005 Apr;12(2):224-32. DMJYN25 RU https://pubmed.ncbi.nlm.nih.gov/15823070 DMJZHT1 DI DMJZHT1 DMJZHT1 DN Tadalafil DMJZHT1 TI TTJ0IQB DMJZHT1 TN Phosphodiesterase 5A (PDE5A) DMJZHT1 MA Inhibitor DMJZHT1 RN Pulmonary arterial hypertension: the most devastating vascular complication of systemic sclerosis. Rheumatology (Oxford). 2009 Jun;48 Suppl 3:iii25-31. DMJZHT1 RU https://pubmed.ncbi.nlm.nih.gov/19487219 DMK08L3 DI DMK08L3 DMK08L3 DN Amifampridine DMK08L3 TI TT1VOHK DMK08L3 TN Potassium channel unspecific (KC) DMK08L3 MA Blocker DMK08L3 RN 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. DMK08L3 RU https://pubmed.ncbi.nlm.nih.gov/30710142 DMK0O7U DI DMK0O7U DMK0O7U DN Flutamide DMK0O7U TI TTS64P2 DMK0O7U TN Androgen receptor (AR) DMK0O7U MA Antagonist DMK0O7U RN Androgen receptor as a target in androgen-independent prostate cancer. Urology. 2002 Sep;60(3 Suppl 1):132-8; discussion 138-9. DMK0O7U RU https://pubmed.ncbi.nlm.nih.gov/12231070 DMK1GBJ DI DMK1GBJ DMK1GBJ DN Trazodone DMK1GBJ TI TT3ROYC DMK1GBJ TN Serotonin transporter (SERT) DMK1GBJ MA Modulator DMK1GBJ RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMK1GBJ RU https://www.fda.gov/ DMK1GBJ DI DMK1GBJ DMK1GBJ DN Trazodone DMK1GBJ TI TTSQIFT DMK1GBJ TN 5-HT 1A receptor (HTR1A) DMK1GBJ MA Modulator DMK1GBJ RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMK1GBJ RU https://www.fda.gov/ DMK1LZD DI DMK1LZD DMK1LZD DN Methoxy polyethylene glycol-epoetin beta DMK1LZD TI TTAUX24 DMK1LZD TN Erythropoietin Receptor (EPOR) DMK1LZD MA Activator DMK1LZD RN 2007 FDA drug approvals: a year of flux. Nat Rev Drug Discov. 2008 Feb;7(2):107-9. DMK1LZD RU https://pubmed.ncbi.nlm.nih.gov/18246607 DMK2GZX DI DMK2GZX DMK2GZX DN Avapritinib DMK2GZX TI TT8FYO9 DMK2GZX TN Platelet-derived growth factor receptor alpha (PDGFRA) DMK2GZX MA Inhibitor DMK2GZX RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020 DMK2GZX RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212608s000lbl.pdf DMK2PBD DI DMK2PBD DMK2PBD DN Palonosetron + fosnetupitant DMK2PBD TI TTZPO1L DMK2PBD TN Substance-P receptor (TACR1) DMK2PBD MA Antagonist DMK2PBD RN 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. DMK2PBD RU https://pubmed.ncbi.nlm.nih.gov/30710142 DMK2PBD DI DMK2PBD DMK2PBD DN Palonosetron + fosnetupitant DMK2PBD TI TTPC4TU DMK2PBD TN 5-HT 3A receptor (HTR3A) DMK2PBD MA Antagonist DMK2PBD RN 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. DMK2PBD RU https://pubmed.ncbi.nlm.nih.gov/30710142 DMK4OL7 DI DMK4OL7 DMK4OL7 DN Zinostatin stimalamer DMK4OL7 TI TTUTN1I DMK4OL7 TN Human Deoxyribonucleic acid (hDNA) DMK4OL7 MA Modulator DMK4OL7 RN Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. DMK4OL7 RU https://pubmed.ncbi.nlm.nih.gov/17309302 DMK54YG DI DMK54YG DMK54YG DN Griseofulvin DMK54YG TI TT7PBUD DMK54YG TN Fungal Microtubule (Fung MicroTU) DMK54YG MA Inducer DMK54YG RN Dermatophyte infections. Am Fam Physician. 2003 Jan 1;67(1):101-8. DMK54YG RU https://pubmed.ncbi.nlm.nih.gov/12537173 DMK57GB DI DMK57GB DMK57GB DN Ethinamate DMK57GB TI TTANPDJ DMK57GB TN Carbonic anhydrase II (CA-II) DMK57GB MA Inhibitor DMK57GB RN Inhibition of carbonic anhydrases I and II by N-unsubstituted carbamate esters. J Biol Chem. 1992 Dec 15;267(35):25044-50. DMK57GB RU https://pubmed.ncbi.nlm.nih.gov/1460006 DMK659W DI DMK659W DMK659W DN Enteric-coated mycophenolate sodium DMK659W TI TTCAQMW DMK659W TN Inosine-5'-monophosphate dehydrogenase (IMPDH) DMK659W MA Inhibitor DMK659W RN Mycophenolate mofetil, an inhibitor of inosine monophosphate dehydrogenase, causes a paradoxical elevation of GTP in erythrocytes of renal transplant patients. Clin Sci (Lond). 2004 Jul;107(1):63-8. DMK659W RU https://pubmed.ncbi.nlm.nih.gov/14723604 DMK6XAV DI DMK6XAV DMK6XAV DN Bitolterol DMK6XAV TI TTMXGCW DMK6XAV TN Adrenergic receptor beta-3 (ADRB3) DMK6XAV MA Modulator DMK6XAV RN Bitolterol mesylate: a beta-adrenergic agent. Chemistry, pharmacokinetics, pharmacodynamics, adverse effects and clinical efficacy in asthma. Pharmacotherapy. 1985 May-Jun;5(3):127-37. DMK6XAV RU https://pubmed.ncbi.nlm.nih.gov/3895171 DMK7F9S DI DMK7F9S DMK7F9S DN Amitriptyline DMK7F9S TI TTAWNKZ DMK7F9S TN Norepinephrine transporter (NET) DMK7F9S MA Inhibitor DMK7F9S RN Treatment of comorbid pain with serotonin norepinephrine reuptake inhibitors. CNS Spectr. 2008 Jul;13(7 Suppl 11):22-6. DMK7F9S RU https://pubmed.ncbi.nlm.nih.gov/18622371 DMK7F9S DI DMK7F9S DMK7F9S DN Amitriptyline DMK7F9S TI TT3ROYC DMK7F9S TN Serotonin transporter (SERT) DMK7F9S MA Inhibitor DMK7F9S RN Treatment of comorbid pain with serotonin norepinephrine reuptake inhibitors. CNS Spectr. 2008 Jul;13(7 Suppl 11):22-6. DMK7F9S RU https://pubmed.ncbi.nlm.nih.gov/18622371 DMK7HFI DI DMK7HFI DMK7HFI DN Mefenamic acid DMK7HFI TI TTVKILB DMK7HFI TN Prostaglandin G/H synthase 2 (COX-2) DMK7HFI MA Inhibitor DMK7HFI RN Systematic pharmacological approach to the characterization of NSAIDs. Prostaglandins Leukot Essent Fatty Acids. 1998 Jul;59(1):55-62. DMK7HFI RU https://pubmed.ncbi.nlm.nih.gov/9758208 DMK7IWL DI DMK7IWL DMK7IWL DN Relugolix DMK7IWL TI TT8R70G DMK7IWL TN Gonadotropin-releasing hormone receptor (GNRHR) DMK7IWL MA Antagonist DMK7IWL RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020 DMK7IWL RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/214621s000lbl.pdf DMK7MEY DI DMK7MEY DMK7MEY DN Isoproterenol DMK7MEY TI TTR6W5O DMK7MEY TN Adrenergic receptor beta-1 (ADRB1) DMK7MEY MA Agonist DMK7MEY RN Current therapeutic uses and potential of beta-adrenoceptor agonists and antagonists. Eur J Clin Pharmacol. 1998 Feb;53(6):389-404. DMK7MEY RU https://pubmed.ncbi.nlm.nih.gov/9551698 DMK7MEY DI DMK7MEY DMK7MEY DN Isoproterenol DMK7MEY TI TT2CJVK DMK7MEY TN Adrenergic receptor beta-2 (ADRB2) DMK7MEY MA Modulator DMK7MEY RN Current therapeutic uses and potential of beta-adrenoceptor agonists and antagonists. Eur J Clin Pharmacol. 1998 Feb;53(6):389-404. DMK7MEY RU https://pubmed.ncbi.nlm.nih.gov/9551698 DMK7MEY DI DMK7MEY DMK7MEY DN Isoproterenol DMK7MEY TI TTGW72V DMK7MEY TN Interleukin-12 beta (IL12B) DMK7MEY MA Modulator DMK7MEY RN A phase 1 study of AS1409, a novel antibody-cytokine fusion protein, in patients with malignant melanoma or renal cell carcinoma. Clin Cancer Res. 2011 Apr 1;17(7):1998-2005. DMK7MEY RU https://pubmed.ncbi.nlm.nih.gov/21447719 DMK8U72 DI DMK8U72 DMK8U72 DN Labetalol DMK8U72 TI TTG28O6 DMK8U72 TN Adrenergic receptor Alpha-1 (ADRA1) DMK8U72 MA Antagonist DMK8U72 RN Beta-blockers in the treatment of hypertension: are there clinically relevant differences Postgrad Med. 2009 May;121(3):90-8. DMK8U72 RU https://pubmed.ncbi.nlm.nih.gov/19491545 DMKA8J4 DI DMKA8J4 DMKA8J4 DN Etonogestrel DMKA8J4 TI TTUV8G9 DMKA8J4 TN Progesterone receptor (PGR) DMKA8J4 MA Binder DMKA8J4 RN Pharmacological profile of progestins. Maturitas. 2008 Sep-Oct;61(1-2):151-7. DMKA8J4 RU https://pubmed.ncbi.nlm.nih.gov/19434887 DMKAEQW DI DMKAEQW DMKAEQW DN Phenyltoloxamine DMKAEQW TI TTZFYLI DMKAEQW TN Dopamine D1 receptor (D1R) DMKAEQW MA Inhibitor DMKAEQW RN Dopamine/serotonin receptor ligands. 9. Oxygen-containing midsized heterocyclic ring systems and nonrigidized analogues. A step toward dopamine D5 ... J Med Chem. 2004 Aug 12;47(17):4155-8. DMKAEQW RU https://pubmed.ncbi.nlm.nih.gov/15293986 DMKAEQW DI DMKAEQW DMKAEQW DN Phenyltoloxamine DMKAEQW TI TTE0A2F DMKAEQW TN Dopamine D4 receptor (D4R) DMKAEQW MA Inhibitor DMKAEQW RN Dopamine/serotonin receptor ligands. 9. Oxygen-containing midsized heterocyclic ring systems and nonrigidized analogues. A step toward dopamine D5 ... J Med Chem. 2004 Aug 12;47(17):4155-8. DMKAEQW RU https://pubmed.ncbi.nlm.nih.gov/15293986 DMKAEQW DI DMKAEQW DMKAEQW DN Phenyltoloxamine DMKAEQW TI TTEX248 DMKAEQW TN Dopamine D2 receptor (D2R) DMKAEQW MA Inhibitor DMKAEQW RN Dopamine/serotonin receptor ligands. 9. Oxygen-containing midsized heterocyclic ring systems and nonrigidized analogues. A step toward dopamine D5 ... J Med Chem. 2004 Aug 12;47(17):4155-8. DMKAEQW RU https://pubmed.ncbi.nlm.nih.gov/15293986 DMKAEQW DI DMKAEQW DMKAEQW DN Phenyltoloxamine DMKAEQW TI TTS2PH3 DMKAEQW TN Dopamine D5 receptor (D5R) DMKAEQW MA Inhibitor DMKAEQW RN Dopamine/serotonin receptor ligands. 9. Oxygen-containing midsized heterocyclic ring systems and nonrigidized analogues. A step toward dopamine D5 ... J Med Chem. 2004 Aug 12;47(17):4155-8. DMKAEQW RU https://pubmed.ncbi.nlm.nih.gov/15293986 DMKB79O DI DMKB79O DMKB79O DN Bromfenac DMKB79O TI TT8NGED DMKB79O TN Prostaglandin G/H synthase 1 (COX-1) DMKB79O MA Inhibitor DMKB79O RN Comparison of cyclooxygenase inhibitory activity and ocular anti-inflammatory effects of ketorolac tromethamine and bromfenac sodium. Curr Med Res Opin. 2006 Jun;22(6):1133-40. DMKB79O RU https://pubmed.ncbi.nlm.nih.gov/16846546 DMKB9FI DI DMKB9FI DMKB9FI DN Benzoic acid DMKB9FI TI TT958S6 DMKB9FI TN Ras-related protein Rab-9A (RAB9A) DMKB9FI MA Inhibitor DMKB9FI RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMKB9FI RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMKBJWP DI DMKBJWP DMKBJWP DN Caffeine DMKBJWP TI TTK25J1 DMKBJWP TN Adenosine A1 receptor (ADORA1) DMKBJWP MA Antagonist DMKBJWP RN Caffeine as a psychomotor stimulant: mechanism of action. Cell Mol Life Sci. 2004 Apr;61(7-8):857-72. DMKBJWP RU https://pubmed.ncbi.nlm.nih.gov/15095008 DMKBJWP DI DMKBJWP DMKBJWP DN Caffeine DMKBJWP TI TTM2AOE DMKBJWP TN Adenosine A2a receptor (ADORA2A) DMKBJWP MA Antagonist DMKBJWP RN Caffeine as a psychomotor stimulant: mechanism of action. Cell Mol Life Sci. 2004 Apr;61(7-8):857-72. DMKBJWP RU https://pubmed.ncbi.nlm.nih.gov/15095008 DMKBOS2 DI DMKBOS2 DMKBOS2 DN Levosimendan DMKBOS2 TI TT8RDXP DMKBOS2 TN Troponin C (TN-C) DMKBOS2 MA Stimulator DMKBOS2 RN Timing of levosimendan in cardiac surgery. Anadolu Kardiyol Derg. 2009 Jun;9(3):223-30. DMKBOS2 RU https://pubmed.ncbi.nlm.nih.gov/19520657 DMKBTFG DI DMKBTFG DMKBTFG DN Cefozopran DMKBTFG TI TT4ILYC DMKBTFG TN Bacterial Dihydropteroate synthetase (Bact folP) DMKBTFG MA Inhibitor DMKBTFG RN Emerging drugs for bacterial urinary tract infections. Expert Opin Emerg Drugs. 2005 May;10(2):275-98. DMKBTFG RU https://pubmed.ncbi.nlm.nih.gov/15934867 DMKBW5C DI DMKBW5C DMKBW5C DN Talimogene Laherparepvec DMKBW5C TI TTNYZG2 DMKBW5C TN Granulocyte-macrophage colony-stimulating factor (CSF2) DMKBW5C MA Modulator DMKBW5C RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMKBW5C RU https://www.fda.gov/ DMKBYWI DI DMKBYWI DMKBYWI DN Trifluoperazine DMKBYWI TI TTV3NH6 DMKBYWI TN Calmodulin (CALM) DMKBYWI MA Inhibitor DMKBYWI RN Inhibitory effect of jujuboside A on glutamate-mediated excitatory signal pathway in hippocampus. Planta Med. 2003 Aug;69(8):692-5. DMKBYWI RU https://pubmed.ncbi.nlm.nih.gov/14531016 DMKCIUZ DI DMKCIUZ DMKCIUZ DN Daratumumab DMKCIUZ TI TTPURFN DMKCIUZ TN Cyclic ADP-ribose hydrolase 1 (CD38) DMKCIUZ RN Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma. N Engl J Med. 2015 Sep 24;373(13):1207-19. DMKCIUZ RU https://pubmed.ncbi.nlm.nih.gov/26308596 DMKDU16 DI DMKDU16 DMKDU16 DN Daptomycin DMKDU16 TI TT4ILYC DMKDU16 TN Bacterial Dihydropteroate synthetase (Bact folP) DMKDU16 MA Binder DMKDU16 RN Structural transitions as determinants of the action of the calcium-dependent antibiotic daptomycin. Chem Biol. 2004 Jul;11(7):949-57. DMKDU16 RU https://pubmed.ncbi.nlm.nih.gov/15271353 DMKE6YT DI DMKE6YT DMKE6YT DN Incobotulinum toxin A DMKE6YT TI TTZJD1B DMKE6YT TN Acetylcholine release (Ach rele) DMKE6YT MA Modulator DMKE6YT RN Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5. DMKE6YT RU https://pubmed.ncbi.nlm.nih.gov/21283092 DMKE7L9 DI DMKE7L9 DMKE7L9 DN Doxacurium DMKE7L9 TI TTS5WZF DMKE7L9 TN Neuronal acetylcholine receptor alpha (NACHRA) DMKE7L9 MA Antagonist DMKE7L9 RN Interaction of nondepolarizing muscle relaxants with M2 and M3 muscarinic receptors in guinea pig lung and heart. Anesthesiology. 1996 Jan;84(1):155-61. DMKE7L9 RU https://pubmed.ncbi.nlm.nih.gov/8572329 DMKECZD DI DMKECZD DMKECZD DN Temozolomide DMKECZD TI TTUTN1I DMKECZD TN Human Deoxyribonucleic acid (hDNA) DMKECZD MA Modulator DMKECZD RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMKECZD RU https://www.fda.gov/ DMKER83 DI DMKER83 DMKER83 DN Hesperetin DMKER83 TI TTF8P9I DMKER83 TN Diacylglycerol acyltransferase 1 (DGAT1) DMKER83 MA Inhibitor DMKER83 RN In vitro inhibition of diacylglycerol acyltransferase by prenylflavonoids from Sophora flavescens. Planta Med. 2004 Mar;70(3):258-60. DMKER83 RU https://pubmed.ncbi.nlm.nih.gov/15114505 DMKEX7O DI DMKEX7O DMKEX7O DN Plecanatide DMKEX7O TI TTLDPRG DMKEX7O TN Guanylyl cyclase C (GUCY2C) DMKEX7O MA Modulator DMKEX7O RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMKEX7O RU https://www.fda.gov/ DMKEY6S DI DMKEY6S DMKEY6S DN Margetuximab DMKEY6S TI TT6EO5L DMKEY6S TN Erbb2 tyrosine kinase receptor (HER2) DMKEY6S RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020 DMKEY6S RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761150s000lbl.pdf DMKFQJP DI DMKFQJP DMKFQJP DN Triflupromazine DMKFQJP TI TT0K1SC DMKFQJP TN 5-HT 2B receptor (HTR2B) DMKFQJP MA Antagonist DMKFQJP RN Some properties of 5-hydroxytryptamine receptors in the hindquarters of the rat. Br J Pharmacol. 1979 Sep;67(1):79-85. DMKFQJP RU https://pubmed.ncbi.nlm.nih.gov/497523 DMKGH0R DI DMKGH0R DMKGH0R DN GHRP-2 DMKGH0R TI TTZ3IFB DMKGH0R TN Phosphogluconate dehydrogenase (PGD) DMKGH0R MA Inhibitor DMKGH0R RN Synthesis and biological evaluation of substrate-based inhibitors of 6-phosphogluconate dehydrogenase as potential drugs against African trypanosomiasis. Bioorg Med Chem. 2003 Jul 17;11(14):3205-14. DMKGH0R RU https://pubmed.ncbi.nlm.nih.gov/12818683 DMKGH0R DI DMKGH0R DMKGH0R DN GHRP-2 DMKGH0R TI TTWDC17 DMKGH0R TN Growth hormone secretagogue receptor 1 (GHSR) DMKGH0R MA Agonist DMKGH0R RN GH-releasing peptide-2 increases fat mass in mice lacking NPY: indication for a crucial mediating role of hypothalamic agouti-related protein. Endocrinology. 2002 Feb;143(2):558-68. DMKGH0R RU https://pubmed.ncbi.nlm.nih.gov/11796511 DMKI2XC DI DMKI2XC DMKI2XC DN Sulfacytine DMKI2XC TI TT4ILYC DMKI2XC TN Bacterial Dihydropteroate synthetase (Bact folP) DMKI2XC MA Inhibitor DMKI2XC RN Sulfacytine in uncomplicated urinary tract infections. Double-blind comparison with sulfisoxazole. Urology. 1976 Mar;7(3):267-71. DMKI2XC RU https://pubmed.ncbi.nlm.nih.gov/769287 DMKI7RB DI DMKI7RB DMKI7RB DN Clomifene DMKI7RB TI TTZAYWL DMKI7RB TN Estrogen receptor (ESR) DMKI7RB MA Modulator DMKI7RB RN The future of the new selective estrogen receptor modulators. Menopause Int. 2007 Mar;13(1):27-34. DMKI7RB RU https://pubmed.ncbi.nlm.nih.gov/17448265 DMKINJO DI DMKINJO DMKINJO DN Gentamicin DMKINJO TI TTOVFH2 DMKINJO TN Bacterial 30S ribosomal RNA (Bact 30S rRNA) DMKINJO MA Modulator DMKINJO RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMKINJO RU https://www.fda.gov/ DMKITQE DI DMKITQE DMKITQE DN Amoxapine DMKITQE TI TTAWNKZ DMKITQE TN Norepinephrine transporter (NET) DMKITQE MA Inhibitor DMKITQE RN Effects of acute and chronic treatment with amoxapine and cericlamine on the sleep-wakefulness cycle in the rat. Neuropharmacology. 1994 Aug;33(8):1017-25. DMKITQE RU https://pubmed.ncbi.nlm.nih.gov/7845548 DMKJ485 DI DMKJ485 DMKJ485 DN Pioglitazone DMKJ485 TI TTZMAO3 DMKJ485 TN Peroxisome proliferator-activated receptor gamma (PPAR-gamma) DMKJ485 MA Agonist DMKJ485 RN Functional PPAR-gamma receptor is a novel therapeutic target for ACTH-secreting pituitary adenomas. Nat Med. 2002 Nov;8(11):1281-7. DMKJ485 RU https://pubmed.ncbi.nlm.nih.gov/12379847 DMKJ8LB DI DMKJ8LB DMKJ8LB DN Josamycin DMKJ8LB TI TTUWYEA DMKJ8LB TN Bacterial 50S ribosomal RNA (Bact 50S rRNA) DMKJ8LB MA Binder DMKJ8LB RN The mechanism of action of macrolides, lincosamides and streptogramin B reveals the nascent peptide exit path in the ribosome. J Mol Biol. 2003 Jul 25;330(5):1005-14. DMKJ8LB RU https://pubmed.ncbi.nlm.nih.gov/12860123 DMKLAYG DI DMKLAYG DMKLAYG DN Altretamine DMKLAYG TI TTUTN1I DMKLAYG TN Human Deoxyribonucleic acid (hDNA) DMKLAYG MA Breaker DMKLAYG RN Synergy of irofulven in combination with other DNA damaging agents: synergistic interaction with altretamine, alkylating, and platinum-derived agen... Cancer Chemother Pharmacol. 2008 Dec;63(1):19-26. DMKLAYG RU https://pubmed.ncbi.nlm.nih.gov/18305940 DMKLJRD DI DMKLJRD DMKLJRD DN Fospropofol disodium DMKLJRD TI TTAN6JD DMKLJRD TN Glutamate receptor AMPA (GRIA) DMKLJRD MA Modulator DMKLJRD RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DMKLJRD RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DMKLSHF DI DMKLSHF DMKLSHF DN Bambuterol DMKLSHF TI TT2CJVK DMKLSHF TN Adrenergic receptor beta-2 (ADRB2) DMKLSHF MA Agonist DMKLSHF RN Enantiomeric separation of beta2-agonists on macrocyclic antibiotic chiral stationary phases in high performance liquid chromatography. Pharmazie. 2007 Nov;62(11):836-40. DMKLSHF RU https://pubmed.ncbi.nlm.nih.gov/18065099 DMKM3SX DI DMKM3SX DMKM3SX DN Sulfamerazine DMKM3SX TI TT4ILYC DMKM3SX TN Bacterial Dihydropteroate synthetase (Bact folP) DMKM3SX MA Inhibitor DMKM3SX RN A confirmatory method for the simultaneous extraction, separation, identification and quantification of Tetracycline, Sulphonamide, Trimethoprim an... J Chromatogr A. 2009 Nov 13;1216(46):8110-6. DMKM3SX RU https://pubmed.ncbi.nlm.nih.gov/19586630 DMKMBES DI DMKMBES DMKMBES DN Plazomicin DMKMBES TI TTUQ7WN DMKMBES TN Mitochondrial rRNA methyltransferase 2 (MRM2) DMKMBES MA Inhibitor DMKMBES RN In vitro activity of plazomicin against -lactamase-producing carbapenem-resistant Enterobacteriaceae (CRE).J Antimicrob Chemother. 2017 Oct 1;72(10):2792-2795. DMKMBES RU https://pubmed.ncbi.nlm.nih.gov/29091224 DMKMJHE DI DMKMJHE DMKMJHE DN Cemiplimab DMKMJHE TI TTNBFWK DMKMJHE TN Programmed cell death protein 1 (PD-1) DMKMJHE MA Modulator DMKMJHE RN 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. DMKMJHE RU https://pubmed.ncbi.nlm.nih.gov/30710142 DMKMWQG DI DMKMWQG DMKMWQG DN Olopatadine DMKMWQG TI TTTIBOJ DMKMWQG TN Histamine H1 receptor (H1R) DMKMWQG MA Antagonist DMKMWQG RN Emerging drugs for ocular allergy. Expert Opin Emerg Drugs. 2005 Aug;10(3):505-20. DMKMWQG RU https://pubmed.ncbi.nlm.nih.gov/16083326 DMKN345 DI DMKN345 DMKN345 DN Charybdotoxin DMKN345 TI TTMNI76 DMKN345 TN Calcium-activated potassium channel (KCN) DMKN345 MA Blocker DMKN345 RN Reversible inhibition of the platelet procoagulant response through manipulation of the Gardos channel. Blood. 2006 Oct 1;108(7):2223-8. DMKN345 RU https://pubmed.ncbi.nlm.nih.gov/16741254 DMKOJSN DI DMKOJSN DMKOJSN DN Necitumumab DMKOJSN TI TTGKNB4 DMKOJSN TN Epidermal growth factor receptor (EGFR) DMKOJSN MA Modulator DMKOJSN RN Rindopepimut, a 14-mer injectable peptide vaccine against EGFRvIII for the potential treatment of glioblastoma multiforme. Curr Opin Mol Ther. 2010 Dec;12(6):741-54. DMKOJSN RU https://pubmed.ncbi.nlm.nih.gov/21154166 DMKOXFE DI DMKOXFE DMKOXFE DN Doxylamine DMKOXFE TI TTTIBOJ DMKOXFE TN Histamine H1 receptor (H1R) DMKOXFE MA Antagonist DMKOXFE RN First-generation H1 antihistamines found in pilot fatalities of civil aviation accidents, 1990-2005. Aviat Space Environ Med. 2007 May;78(5):514-22. DMKOXFE RU https://pubmed.ncbi.nlm.nih.gov/17539447 DMKQTBA DI DMKQTBA DMKQTBA DN Diphenhydramine DMKQTBA TI TTTIBOJ DMKQTBA TN Histamine H1 receptor (H1R) DMKQTBA MA Antagonist DMKQTBA RN Intact cell binding for in vitro prediction of sedative and non-sedative histamine H1-receptor antagonists based on receptor internalization. J Pharmacol Sci. 2008 May;107(1):66-79. DMKQTBA RU https://pubmed.ncbi.nlm.nih.gov/18446005 DMKQTBA DI DMKQTBA DMKQTBA DN Diphenhydramine DMKQTBA TI TT2B6EV DMKQTBA TN Histamine N-methyltransferase (HNMT) DMKQTBA MA Inhibitor DMKQTBA RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMKQTBA RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMKR3C5 DI DMKR3C5 DMKR3C5 DN Ergotamine DMKR3C5 TI TTG28O6 DMKR3C5 TN Adrenergic receptor Alpha-1 (ADRA1) DMKR3C5 MA Agonist DMKR3C5 RN Reversal of ergotamine-induced vasospasm following methylprednisolone. Clin Toxicol (Phila). 2008 Dec;46(10):1074-6. DMKR3C5 RU https://pubmed.ncbi.nlm.nih.gov/18763151 DMKS1DV DI DMKS1DV DMKS1DV DN SARALASIN DMKS1DV TI TTQVOEI DMKS1DV TN Angiotensin II receptor type-2 (AGTR2) DMKS1DV MA Inhibitor DMKS1DV RN cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain... J Med Chem. 2008 Nov 27;51(22):7094-8. DMKS1DV RU https://pubmed.ncbi.nlm.nih.gov/18983139 DMKS1DV DI DMKS1DV DMKS1DV DN SARALASIN DMKS1DV TI TT8DBY3 DMKS1DV TN Angiotensin II receptor type-1 (AGTR1) DMKS1DV MA Inhibitor DMKS1DV RN Identification of a potent, selective, and orally active leukotriene a4 hydrolase inhibitor with anti-inflammatory activity. J Med Chem. 2008 Jul 24;51(14):4150-69. DMKS1DV RU https://pubmed.ncbi.nlm.nih.gov/18588282 DMKSQG0 DI DMKSQG0 DMKSQG0 DN Tiagabine DMKSQG0 TI TTV9MQG DMKSQG0 TN Gamma-aminobutyric acid uptake (GABAU) DMKSQG0 MA Inhibitor DMKSQG0 RN Glutamate- and GABA-based CNS therapeutics. Curr Opin Pharmacol. 2006 Feb;6(1):7-17. DMKSQG0 RU https://pubmed.ncbi.nlm.nih.gov/16377242 DMKSQG0 DI DMKSQG0 DMKSQG0 DN Tiagabine DMKSQG0 TI TTPRKM0 DMKSQG0 TN GABA transporter GAT-1 (SLC6A1) DMKSQG0 MA Inhibitor DMKSQG0 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 929). DMKSQG0 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=929 DMKSTWR DI DMKSTWR DMKSTWR DN L-Proline DMKSTWR TI TT6ZFQ4 DMKSTWR TN Rotamase B (PPIB) DMKSTWR MA Binder DMKSTWR RN Escherichia coli cyclophilin B binds a highly distorted form of trans-prolyl peptide isomer. Eur J Biochem. 2004 Sep;271(18):3794-803. DMKSTWR RU https://pubmed.ncbi.nlm.nih.gov/15355356 DMKSTWR DI DMKSTWR DMKSTWR DN L-Proline DMKSTWR TI TTL2ADK DMKSTWR TN Rotamase A (PPIA) DMKSTWR MA Binder DMKSTWR RN Mechanistic insight into the role of transition-state stabilization in cyclophilin A. J Am Chem Soc. 2009 Jan 14;131(1):147-52. DMKSTWR RU https://pubmed.ncbi.nlm.nih.gov/19128175 DMKUOQV DI DMKUOQV DMKUOQV DN Burosumab DMKUOQV TI TT2IZ4K DMKUOQV TN Fibroblast growth factor-23 (FGF23) DMKUOQV MA Modulator DMKUOQV RN 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. DMKUOQV RU https://pubmed.ncbi.nlm.nih.gov/30710142 DMKV4NL DI DMKV4NL DMKV4NL DN Flavoxate DMKV4NL TI TTH18TF DMKV4NL TN Muscarinic acetylcholine receptor M5 (CHRM5) DMKV4NL MA Antagonist DMKV4NL RN Brain pertussis toxin-sensitive G proteins are involved in the flavoxate hydrochloride-induced suppression of the micturition reflex in rats. Brain Res. 1996 Jul 15;727(1-2):91-8. DMKV4NL RU https://pubmed.ncbi.nlm.nih.gov/8842386 DMKVOYF DI DMKVOYF DMKVOYF DN Penicillin V DMKVOYF TI TTJP4SM DMKVOYF TN Bacterial Penicillin binding protein (Bact PBP) DMKVOYF MA Binder DMKVOYF RN Localization of penicillin-binding proteins to the splitting system of Staphylococcus aureus septa by using a mercury-penicillin V derivative. J Bacteriol. 1995 Jul;177(13):3631-40. DMKVOYF RU https://pubmed.ncbi.nlm.nih.gov/7541399 DMKVWGE DI DMKVWGE DMKVWGE DN Dexbrompheniramine DMKVWGE TI TTTIBOJ DMKVWGE TN Histamine H1 receptor (H1R) DMKVWGE MA Antagonist DMKVWGE RN H2 histaminergic control of inhibition of eating induced by intragastric NaCl in rats. Physiol Behav. 1998 Aug;65(1):105-13. DMKVWGE RU https://pubmed.ncbi.nlm.nih.gov/9811372 DMKWB73 DI DMKWB73 DMKWB73 DN Epoetin alfa DMKWB73 TI TTAUX24 DMKWB73 TN Erythropoietin Receptor (EPOR) DMKWB73 MA Agonist DMKWB73 RN 2007 Standards, Options, and Recommendations: use of erythropoiesis-stimulating agents (ESA: epoetin alfa, epoetin beta, and darbepoetin) for the management of anemia in children with cancer. PediatrBlood Cancer. 2009 Jul;53(1):7-12. DMKWB73 RU https://pubmed.ncbi.nlm.nih.gov/19229970 DMKWFBT DI DMKWFBT DMKWFBT DN Melatonin DMKWFBT TI TT0WAIE DMKWFBT TN Melatonin receptor type 1A (MTNR1A) DMKWFBT MA Binder DMKWFBT RN The human MT1 melatonin receptor stimulates cAMP production in the human neuroblastoma cell line SH-SY5Y cells via a calcium-calmodulin signal transduction pathway. J Neuroendocrinol. 2005 Mar;17(3):170-8. DMKWFBT RU https://pubmed.ncbi.nlm.nih.gov/15796769 DMKWFBT DI DMKWFBT DMKWFBT DN Melatonin DMKWFBT TI TTJLP0R DMKWFBT TN Quinone reductase 2 (NQO2) DMKWFBT MA Inhibitor DMKWFBT RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMKWFBT RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMKXJZ7 DI DMKXJZ7 DMKXJZ7 DN Suprofen DMKXJZ7 TI TT8NGED DMKXJZ7 TN Prostaglandin G/H synthase 1 (COX-1) DMKXJZ7 MA Inhibitor DMKXJZ7 RN Differential binding mode of diverse cyclooxygenase inhibitors. J Mol Graph Model. 2002 Mar;20(5):359-71. DMKXJZ7 RU https://pubmed.ncbi.nlm.nih.gov/11885959 DMKXY2R DI DMKXY2R DMKXY2R DN Ibutilide DMKXY2R TI TT1VOHK DMKXY2R TN Potassium channel unspecific (KC) DMKXY2R MA Modulator DMKXY2R RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMKXY2R RU https://www.fda.gov/ DMKY8V1 DI DMKY8V1 DMKY8V1 DN Propiomazine DMKY8V1 TI TTTIBOJ DMKY8V1 TN Histamine H1 receptor (H1R) DMKY8V1 MA Antagonist DMKY8V1 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMKY8V1 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMKYD5N DI DMKYD5N DMKYD5N DN Zuclopenthixol DMKYD5N TI TTEX248 DMKYD5N TN Dopamine D2 receptor (D2R) DMKYD5N MA Antagonist DMKYD5N RN An ethopharmacological assessment of the effects of zuclopenthixol on agonistic interactions in male mice. Methods Find Exp Clin Pharmacol. 1999 Jan-Feb;21(1):11-5. DMKYD5N RU https://pubmed.ncbi.nlm.nih.gov/10222441 DMKZEIB DI DMKZEIB DMKZEIB DN Felbinac DMKZEIB TI TTK0943 DMKZEIB TN Prostaglandin G/H synthase (COX) DMKZEIB MA Modulator DMKZEIB RN A review of the effects of fenbufen and a metabolite, biphenylacetic acid, on platelet biochemistry and function. Arzneimittelforschung. 1980;30(4A):702-7. DMKZEIB RU https://pubmed.ncbi.nlm.nih.gov/6254545 DMKZROL DI DMKZROL DMKZROL DN Saralasin Acetate DMKZROL TI TT8DBY3 DMKZROL TN Angiotensin II receptor type-1 (AGTR1) DMKZROL MA Modulator DMKZROL RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMKZROL RU https://www.fda.gov/ DML0B41 DI DML0B41 DML0B41 DN Naloxegol DML0B41 TI TTKWM86 DML0B41 TN Opioid receptor mu (MOP) DML0B41 MA Modulator DML0B41 RN 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81. DML0B41 RU https://pubmed.ncbi.nlm.nih.gov/25633781 DML0D1P DI DML0D1P DML0D1P DN Reteplase DML0D1P TI TTP86E2 DML0D1P TN Plasminogen (PLG) DML0D1P MA Activator DML0D1P RN Fibrin binding and the regulation of plasminogen activators during thrombolytic therapy. Cardiovasc Hematol Agents Med Chem. 2008 Jul;6(3):212-23. DML0D1P RU https://pubmed.ncbi.nlm.nih.gov/18673235 DML0RAE DI DML0RAE DML0RAE DN Methoxyflurane DML0RAE TI TT1MPAY DML0RAE TN GABA(A) receptor alpha-1 (GABRA1) DML0RAE MA Antagonist DML0RAE RN DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6. DML0RAE RU https://pubmed.ncbi.nlm.nih.gov/18048412 DML1538 DI DML1538 DML1538 DN Diazoxide DML1538 TI TT1VOHK DML1538 TN Potassium channel unspecific (KC) DML1538 MA Modulator DML1538 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DML1538 RU https://www.fda.gov/ DML2A03 DI DML2A03 DML2A03 DN Alosetron DML2A03 TI TTPC4TU DML2A03 TN 5-HT 3A receptor (HTR3A) DML2A03 MA Antagonist DML2A03 RN Efficacy of 5-HT3 antagonists and 5-HT4 agonists in irritable bowel syndrome: systematic review and meta-analysis. Am J Gastroenterol. 2009 Jul;104(7):1831-43; quiz 1844. DML2A03 RU https://pubmed.ncbi.nlm.nih.gov/19471254 DML2NIB DI DML2NIB DML2NIB DN Aminophylline DML2NIB TI TT06AWU DML2NIB TN Phosphodiesterase 3A (PDE3A) DML2NIB MA Inhibitor DML2NIB RN Topical fat reduction from the waist. Diabetes Obes Metab. 2007 May;9(3):300-3. DML2NIB RU https://pubmed.ncbi.nlm.nih.gov/17391155 DML4ZOT DI DML4ZOT DML4ZOT DN Lidocaine DML4ZOT TI TTN9VTF DML4ZOT TN Voltage-gated sodium channel alpha Nav1.9 (SCN11A) DML4ZOT MA Blocker DML4ZOT RN Mechanisms of analgesia of intravenous lidocaine. Rev Bras Anestesiol. 2008 May-Jun;58(3):280-6. DML4ZOT RU https://pubmed.ncbi.nlm.nih.gov/19378524 DML53ZJ DI DML53ZJ DML53ZJ DN Mirtazapine DML53ZJ TI TTWJBZ5 DML53ZJ TN 5-HT 2C receptor (HTR2C) DML53ZJ MA Antagonist DML53ZJ RN Inverse agonist and neutral antagonist actions of antidepressants at recombinant and native 5-hydroxytryptamine2C receptors: differential modulatio... Mol Pharmacol. 2008 Mar;73(3):748-57. DML53ZJ RU https://pubmed.ncbi.nlm.nih.gov/18083778 DML5VQ0 DI DML5VQ0 DML5VQ0 DN Fenoprofen DML5VQ0 TI TTK0943 DML5VQ0 TN Prostaglandin G/H synthase (COX) DML5VQ0 MA Inhibitor DML5VQ0 RN The aryl propionic acid R-flurbiprofen selectively induces p75NTR-dependent decreased survival of prostate tumor cells. Cancer Res. 2007 Apr 1;67(7):3254-62. DML5VQ0 RU https://pubmed.ncbi.nlm.nih.gov/17409433 DML60TN DI DML60TN DML60TN DN Sotalol DML60TN TI TTR6W5O DML60TN TN Adrenergic receptor beta-1 (ADRB1) DML60TN MA Antagonist DML60TN RN beta(2)-adrenoceptors are critical for antidepressant treatment of neuropathic pain. Ann Neurol. 2009 Feb;65(2):218-25. DML60TN RU https://pubmed.ncbi.nlm.nih.gov/19259968 DML6OE7 DI DML6OE7 DML6OE7 DN Tbo-Filgrastim DML6OE7 TI TTC70AJ DML6OE7 TN Granulocyte colony-stimulating factor receptor (G-CSF-R) DML6OE7 MA Modulator DML6OE7 RN Nat Rev Drug Discov. 2013 Feb;12(2):87-90. DML6OE7 RU https://pubmed.ncbi.nlm.nih.gov/23370234 DML6SRO DI DML6SRO DML6SRO DN Alacepril DML6SRO TI TTL69WB DML6SRO TN Angiotensin-converting enzyme (ACE) DML6SRO MA Modulator DML6SRO RN Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. DML6SRO RU https://pubmed.ncbi.nlm.nih.gov/17309302 DML72VJ DI DML72VJ DML72VJ DN GW685698X DML72VJ TI TTYRL6O DML72VJ TN Glucocorticoid receptor (NR3C1) DML72VJ MA Agonist DML72VJ RN Clinical pipeline report, company report or official report of GlaxoSmithKline (2009). DML72VJ RU http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf DML8KTN DI DML8KTN DML8KTN DN Danazol DML8KTN TI TTZAYWL DML8KTN TN Estrogen receptor (ESR) DML8KTN MA Antagonist DML8KTN RN Danazol suppression of luteinizing hormone in the rat: evidence for mediation by both androgen and estrogen receptors. Proc Soc Exp Biol Med. 1990 May;194(1):54-7. DML8KTN RU https://pubmed.ncbi.nlm.nih.gov/2326286 DML8QSZ DI DML8QSZ DML8QSZ DN Amosulalol DML8QSZ TI TTMXGCW DML8QSZ TN Adrenergic receptor beta-3 (ADRB3) DML8QSZ MA Modulator DML8QSZ RN Effects of amosulalol, a combined alpha 1- and beta-adrenoceptor-blocking agent, on ischemic myocardial energy metabolism in dogs. J Pharm Sci. 1993 Mar;82(3):291-5. DML8QSZ RU https://pubmed.ncbi.nlm.nih.gov/8095542 DML8QSZ DI DML8QSZ DML8QSZ DN Amosulalol DML8QSZ TI TT2NUT5 DML8QSZ TN Adrenergic receptor alpha-2C (ADRA2C) DML8QSZ MA Modulator DML8QSZ RN Effects of amosulalol, a combined alpha 1- and beta-adrenoceptor-blocking agent, on ischemic myocardial energy metabolism in dogs. J Pharm Sci. 1993 Mar;82(3):291-5. DML8QSZ RU https://pubmed.ncbi.nlm.nih.gov/8095542 DML97WV DI DML97WV DML97WV DN Pemirolast DML97WV TI TTTIBOJ DML97WV TN Histamine H1 receptor (H1R) DML97WV MA Antagonist DML97WV RN The effect of a combined therapy with a histamine H1 antagonist and a chemical mediator release inhibitor on allergic conjunctivitis. Ophthalmologica. 2008;222(4):232-9. DML97WV RU https://pubmed.ncbi.nlm.nih.gov/18463425 DML9TI0 DI DML9TI0 DML9TI0 DN Ombitasvir + paritaprevir + ritonavir DML9TI0 TI TTWXB3E DML9TI0 TN Hepatitis C virus NS3 helicase (HCV NS3) DML9TI0 MA Modulator DML9TI0 RN HCV Drug Resistance Challenges in Japan: The Role of Pre-Existing Variants and Emerging Resistant Strains in Direct Acting Antiviral Therapy DML9TI0 RU https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4632384 DMLB0EZ DI DMLB0EZ DMLB0EZ DN Tamoxifen DMLB0EZ TI TTZAYWL DMLB0EZ TN Estrogen receptor (ESR) DMLB0EZ MA Antagonist DMLB0EZ RN Modulators of vascular sex hormone receptors and their effects in estrogen-deficiency states associated with menopause. Recent Pat Cardiovasc Drug Discov. 2008 Nov;3(3):165-86. DMLB0EZ RU https://pubmed.ncbi.nlm.nih.gov/18991792 DMLBVKQ DI DMLBVKQ DMLBVKQ DN Entacapone DMLBVKQ TI TTKWFB8 DMLBVKQ TN Catechol-O-methyl-transferase (COMT) DMLBVKQ MA Inhibitor DMLBVKQ RN Entacapone: a catechol-O-methyltransferase inhibitor for the adjunctive treatment of Parkinson's disease. Clin Ther. 2001 Jun;23(6):802-32; discussion 771. DMLBVKQ RU https://pubmed.ncbi.nlm.nih.gov/11440283 DMLDQFV DI DMLDQFV DMLDQFV DN Dasotraline DMLDQFV TI TTVBI8W DMLDQFV TN Dopamine transporter (DAT) DMLDQFV MA Inhibitor DMLDQFV RN Dasotraline for the Treatment of Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Trial in Adults. Neuropsychopharmacology. 2015 Nov;40(12):2745-52. DMLDQFV RU https://pubmed.ncbi.nlm.nih.gov/25948101 DMLDQFV DI DMLDQFV DMLDQFV DN Dasotraline DMLDQFV TI TTAWNKZ DMLDQFV TN Norepinephrine transporter (NET) DMLDQFV MA Inhibitor DMLDQFV RN Dasotraline for the Treatment of Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Trial in Adults. Neuropsychopharmacology. 2015 Nov;40(12):2745-52. DMLDQFV RU https://pubmed.ncbi.nlm.nih.gov/25948101 DMLDQFV DI DMLDQFV DMLDQFV DN Dasotraline DMLDQFV TI TT3ROYC DMLDQFV TN Serotonin transporter (SERT) DMLDQFV MA Inhibitor DMLDQFV RN Dasotraline for the Treatment of Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Trial in Adults. Neuropsychopharmacology. 2015 Nov;40(12):2745-52. DMLDQFV RU https://pubmed.ncbi.nlm.nih.gov/25948101 DMLDQFV DI DMLDQFV DMLDQFV DN Dasotraline DMLDQFV TI TT8G3Z7 DMLDQFV TN Serotoninnorepinephrinedopamine reuptake (SNDR) DMLDQFV MA Inhibitor DMLDQFV RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMLDQFV RU http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf DMLE7IO DI DMLE7IO DMLE7IO DN Tigecycline DMLE7IO TI TTQ8KVI DMLE7IO TN Staphylococcus 30S ribosomal subunit (Stap-coc pbp2) DMLE7IO MA Binder DMLE7IO RN Tigecycline: first of a new class of antimicrobial agents. Pharmacotherapy. 2006 Aug;26(8):1099-110. DMLE7IO RU https://pubmed.ncbi.nlm.nih.gov/16863487 DMLEDNK DI DMLEDNK DMLEDNK DN Carbenicillin DMLEDNK TI TTJP4SM DMLEDNK TN Bacterial Penicillin binding protein (Bact PBP) DMLEDNK MA Binder DMLEDNK RN Resistance of Pseudomonas aeruginosa to cefsulodin: modification of penicillin-binding protein 3 and mapping of its chromosomal gene. J Antimicrob Chemother. 1990 Apr;25(4):513-23. DMLEDNK RU https://pubmed.ncbi.nlm.nih.gov/2112536 DMLFX7K DI DMLFX7K DMLFX7K DN LCZ696 DMLFX7K TI TT5TKPM DMLFX7K TN Neutral endopeptidase (MME) DMLFX7K MA Modulator DMLFX7K RN 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81. DMLFX7K RU https://pubmed.ncbi.nlm.nih.gov/25633781 DMLFZHD DI DMLFZHD DMLFZHD DN Aclarubicin DMLFZHD TI TT0IHXV DMLFZHD TN DNA topoisomerase II (TOP2) DMLFZHD MA Inhibitor DMLFZHD RN Linker length in podophyllotoxin-acridine conjugates determines potency in vivo and in vitro as well as specificity against MDR cell lines. Anticancer Drug Des. 2001 Dec;16(6):305-15. DMLFZHD RU https://pubmed.ncbi.nlm.nih.gov/12375883 DMLHESP DI DMLHESP DMLHESP DN Chlorothiazide DMLHESP TI TTANPDJ DMLHESP TN Carbonic anhydrase II (CA-II) DMLHESP MA Inhibitor DMLHESP RN Localization of diuretic effects along the loop of Henle: an in vivo microperfusion study in rats. Clin Sci (Lond). 2000 Apr;98(4):481-8. DMLHESP RU https://pubmed.ncbi.nlm.nih.gov/10731484 DMLHOA0 DI DMLHOA0 DMLHOA0 DN Xatral DMLHOA0 TI TTNGILX DMLHOA0 TN Adrenergic receptor alpha-1A (ADRA1A) DMLHOA0 MA Antagonist DMLHOA0 RN Pharma & Vaccines. Product Development Pipeline. April 29 2009. DMLHOA0 RU http://en.sanofi-aventis.com/binaries/RD_Phase_III_EN_tcm28-24007.pdf DMLHSE3 DI DMLHSE3 DMLHSE3 DN Oxtriphylline DMLHSE3 TI TTV5CGO DMLHSE3 TN Phosphodiesterase 4 (PDE4) DMLHSE3 MA Modulator DMLHSE3 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMLHSE3 RU https://www.fda.gov/ DMLHSE3 DI DMLHSE3 DMLHSE3 DN Oxtriphylline DMLHSE3 TI TTZCG4L DMLHSE3 TN Phosphodiesterase 3 (PDE3) DMLHSE3 MA Modulator DMLHSE3 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMLHSE3 RU https://www.fda.gov/ DMLJ634 DI DMLJ634 DMLJ634 DN Sodium lauryl sulfate DMLJ634 TI TTFNGC9 DMLJ634 TN Serum albumin (ALB) DMLJ634 MA Binder DMLJ634 RN Some properties of the interaction between 2,2'-diselenadibenzoic acid and serum albumins. J Pharm Biomed Anal. 2005 Sep 1;39(1-2):263-7. DMLJ634 RU https://pubmed.ncbi.nlm.nih.gov/16085141 DMLK2QH DI DMLK2QH DMLK2QH DN Nateglinide DMLK2QH TI TT1VOHK DMLK2QH TN Potassium channel unspecific (KC) DMLK2QH MA Modulator DMLK2QH RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMLK2QH RU https://www.fda.gov/ DMLKFC4 DI DMLKFC4 DMLKFC4 DN Quinupristin DMLKFC4 TI TTIB7O8 DMLKFC4 TN Bacterial Integral membrane LmrP (Bact lmrP) DMLKFC4 MA Modulator DMLKFC4 RN The lactococcal secondary multidrug transporter LmrP confers resistance to lincosamides, macrolides, streptogramins and tetracyclines. Microbiology. 2001 Oct;147(Pt 10):2873-80. DMLKFC4 RU https://pubmed.ncbi.nlm.nih.gov/11577166 DMLKSE0 DI DMLKSE0 DMLKSE0 DN Hexachlorophene DMLKSE0 TI TTAO7YK DMLKSE0 TN Plasmodium Glutamate dehydrogenase (Malaria gdh) DMLKSE0 MA Inhibitor DMLKSE0 RN Novel inhibitors complexed with glutamate dehydrogenase: allosteric regulation by control of protein dynamics. J Biol Chem. 2009 Aug 21;284(34):22988-3000. DMLKSE0 RU https://pubmed.ncbi.nlm.nih.gov/19531491 DMLMXE0 DI DMLMXE0 DMLMXE0 DN Amprenavir DMLMXE0 TI TT5FNQT DMLMXE0 TN Human immunodeficiency virus Protease (HIV PR) DMLMXE0 MA Inhibitor DMLMXE0 RN Darunavir: a review of its use in the management of HIV infection in adults. Drugs. 2009;69(4):477-503. DMLMXE0 RU https://pubmed.ncbi.nlm.nih.gov/19323590 DMLNCE0 DI DMLNCE0 DMLNCE0 DN Cetuximab DMLNCE0 TI TTGKNB4 DMLNCE0 TN Epidermal growth factor receptor (EGFR) DMLNCE0 RN Molecular inhibition of angiogenesis and metastatic potential in human squamous cell carcinomas after epidermal growth factor receptor blockade. Mol Cancer Ther. 2002 May;1(7):507-14. DMLNCE0 RU https://pubmed.ncbi.nlm.nih.gov/12479268 DMLNMEA DI DMLNMEA DMLNMEA DN Estradiol valerate/dienogest DMLNMEA TI TTUV8G9 DMLNMEA TN Progesterone receptor (PGR) DMLNMEA MA Modulator DMLNMEA RN Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5. DMLNMEA RU https://pubmed.ncbi.nlm.nih.gov/21283092 DMLOQ1V DI DMLOQ1V DMLOQ1V DN Tasimelteon DMLOQ1V TI TT32JK8 DMLOQ1V TN Melatonin receptor type 1B (MTNR1B) DMLOQ1V MA Agonist DMLOQ1V RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7393). DMLOQ1V RU http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7393 DMLOQ1V DI DMLOQ1V DMLOQ1V DN Tasimelteon DMLOQ1V TI TT0WAIE DMLOQ1V TN Melatonin receptor type 1A (MTNR1A) DMLOQ1V MA Agonist DMLOQ1V RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7393). DMLOQ1V RU http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7393 DMLOS5R DI DMLOS5R DMLOS5R DN Bay 80-6946 DMLOS5R TI TTHBTOP DMLOS5R TN PI3-kinase gamma (PIK3CG) DMLOS5R MA Modulator DMLOS5R RN BAY 80-6946 is a highly selective intravenous PI3K inhibitor with potent p110 and p110 activities in tumor cell lines and xenograft models.Mol Cancer Ther.2013 Nov;12(11):2319-30. DMLOS5R RU https://www.ncbi.nlm.nih.gov/pubmed/24170767 DMLOS5R DI DMLOS5R DMLOS5R DN Bay 80-6946 DMLOS5R TI TTGBPJE DMLOS5R TN PI3-kinase delta (PIK3CD) DMLOS5R MA Inhibitor DMLOS5R RN 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85. DMLOS5R RU https://pubmed.ncbi.nlm.nih.gov/29348678 DMLOS5R DI DMLOS5R DMLOS5R DN Bay 80-6946 DMLOS5R TI TTEUNMR DMLOS5R TN PI3-kinase alpha (PIK3CA) DMLOS5R MA Inhibitor DMLOS5R RN 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85. DMLOS5R RU https://pubmed.ncbi.nlm.nih.gov/29348678 DMLPAOB DI DMLPAOB DMLPAOB DN Allopurinol DMLPAOB TI TT7RJY8 DMLPAOB TN Xanthine dehydrogenase/oxidase (XDH) DMLPAOB MA Inhibitor DMLPAOB RN Allopurinol: xanthine oxidase inhibitor. Tex Med. 1966 Jan;62(1):100-1. DMLPAOB RU https://pubmed.ncbi.nlm.nih.gov/5324754 DMLPSWQ DI DMLPSWQ DMLPSWQ DN Niraparib Tosylate DMLPSWQ TI TTVDSZ0 DMLPSWQ TN Poly [ADP-ribose] polymerase 1 (PARP1) DMLPSWQ MA Modulator DMLPSWQ RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMLPSWQ RU https://www.fda.gov/ DMLS39E DI DMLS39E DMLS39E DN Proparacaine DMLS39E TI TT90XZ8 DMLS39E TN Voltage-gated sodium channel alpha Nav1.8 (SCN10A) DMLS39E MA Modulator DMLS39E RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMLS39E RU https://www.fda.gov/ DMLSUWZ DI DMLSUWZ DMLSUWZ DN PSI-7977 DMLSUWZ TI TTMVBWH DMLSUWZ TN Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B) DMLSUWZ MA Modulator DMLSUWZ RN Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651. DMLSUWZ RU https://pubmed.ncbi.nlm.nih.gov/28919714 DMLT0E1 DI DMLT0E1 DMLT0E1 DN Conjugated estrogens DMLT0E1 TI TTOM3J0 DMLT0E1 TN Estrogen receptor beta (ESR2) DMLT0E1 MA Antagonist DMLT0E1 RN Differential biochemical and cellular actions of Premarin estrogens: distinct pharmacology of bazedoxifene-conjugated estrogens combination. Mol Endocrinol. 2009 Jan;23(1):74-85. DMLT0E1 RU https://pubmed.ncbi.nlm.nih.gov/19036900 DMLUA9D DI DMLUA9D DMLUA9D DN Simeprevir DMLUA9D TI TTHC7JD DMLUA9D TN Hepatitis C virus Serine protease NS3/4A (HCV NS3/4A) DMLUA9D MA Modulator DMLUA9D RN Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651. DMLUA9D RU https://pubmed.ncbi.nlm.nih.gov/28919714 DMLVSYX DI DMLVSYX DMLVSYX DN Remimazolam DMLVSYX TI TTEX6LM DMLVSYX TN GABA(A) receptor gamma-3 (GABRG3) DMLVSYX MA Agonist DMLVSYX RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020 DMLVSYX RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212295s000lbl.pdf DMLW57T DI DMLW57T DMLW57T DN Teniposide DMLW57T TI TT0IHXV DMLW57T TN DNA topoisomerase II (TOP2) DMLW57T MA Modulator DMLW57T RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMLW57T RU https://www.fda.gov/ DMLW9HG DI DMLW9HG DMLW9HG DN Tildrakizumab DMLW9HG TI TTC1GLB DMLW9HG TN Interleukin-23 (IL23) DMLW9HG MA Modulator DMLW9HG RN 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. DMLW9HG RU https://pubmed.ncbi.nlm.nih.gov/30710142 DMLW9HG DI DMLW9HG DMLW9HG DN Tildrakizumab DMLW9HG TI TTQTX98 DMLW9HG TN Interleukin-37 (IL37) DMLW9HG MA Inhibitor DMLW9HG RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMLW9HG RU http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf DMLWQ27 DI DMLWQ27 DMLWQ27 DN Angiotensin Ii DMLWQ27 TI TT8DBY3 DMLWQ27 TN Angiotensin II receptor type-1 (AGTR1) DMLWQ27 MA Inhibitor DMLWQ27 RN The amino-terminus of angiotensin II contacts several ectodomains of the angiotensin II receptor AT1. J Med Chem. 2010 Mar 11;53(5):2063-75. DMLWQ27 RU https://pubmed.ncbi.nlm.nih.gov/20146480 DMLWQ27 DI DMLWQ27 DMLWQ27 DN Angiotensin Ii DMLWQ27 TI TTQVOEI DMLWQ27 TN Angiotensin II receptor type-2 (AGTR2) DMLWQ27 MA Inhibitor DMLWQ27 RN The preparation of (perfluoroalkyl)imidazoles as nonpeptide angiotensin II receptor antagonists, Bioorg. Med. Chem. Lett. 3(5):895-898 (1993). DMLWQ27 RU http://www.sciencedirect.com/science/article/pii/S0960894X00806885 DMLZNIQ DI DMLZNIQ DMLZNIQ DN Sarecycline DMLZNIQ TI TTOVFH2 DMLZNIQ TN Bacterial 30S ribosomal RNA (Bact 30S rRNA) DMLZNIQ MA Inhibitor DMLZNIQ RN Microbiological Profile of Sarecycline, a Novel Targeted Spectrum Tetracycline for the Treatment of Acne Vulgaris.Antimicrob Agents Chemother. 2018 Dec 21;63(1). pii: e01297-18. DMLZNIQ RU https://pubmed.ncbi.nlm.nih.gov/30397052 DMM0HR1 DI DMM0HR1 DMM0HR1 DN Pargyline DMM0HR1 TI TTGP7BY DMM0HR1 TN Monoamine oxidase type B (MAO-B) DMM0HR1 MA Inhibitor DMM0HR1 RN Dose-dependent activation of distinct hypertrophic pathways by serotonin in cardiac cells. Am J Physiol Heart Circ Physiol. 2009 Aug;297(2):H821-8. DMM0HR1 RU https://pubmed.ncbi.nlm.nih.gov/19542488 DMM0HR1 DI DMM0HR1 DMM0HR1 DN Pargyline DMM0HR1 TI TT32XQJ DMM0HR1 TN Monoamine oxidase (MAO) DMM0HR1 MA Inhibitor DMM0HR1 RN Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110. DMM0HR1 RU https://www.ncbi.nlm.nih.gov/pubmed/25399762 DMM0PDO DI DMM0PDO DMM0PDO DN Dalfampridine DMM0PDO TI TT1VOHK DMM0PDO TN Potassium channel unspecific (KC) DMM0PDO MA Modulator DMM0PDO RN Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5. DMM0PDO RU https://pubmed.ncbi.nlm.nih.gov/21283092 DMM0XGL DI DMM0XGL DMM0XGL DN Idarubicin DMM0XGL TI TT0IHXV DMM0XGL TN DNA topoisomerase II (TOP2) DMM0XGL MA Modulator DMM0XGL RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMM0XGL RU https://www.fda.gov/ DMM13DI DI DMM13DI DMM13DI DN Tasosartan DMM13DI TI TT8DBY3 DMM13DI TN Angiotensin II receptor type-1 (AGTR1) DMM13DI MA Antagonist DMM13DI RN Tasosartan, enoltasosartan, and angiotensin II receptor blockade: the confounding role of protein binding. J Pharmacol Exp Ther. 2000 Nov;295(2):649-54. DMM13DI RU https://pubmed.ncbi.nlm.nih.gov/11046101 DMM1JL9 DI DMM1JL9 DMM1JL9 DN Amcinonide DMM1JL9 TI TTP3UTW DMM1JL9 TN Steroid hormone receptor ERR (ESRR) DMM1JL9 MA Modulator DMM1JL9 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMM1JL9 RU https://www.fda.gov/ DMM2NSK DI DMM2NSK DMM2NSK DN Adenosine DMM2NSK TI TTNE7KG DMM2NSK TN Adenosine A2b receptor (ADORA2B) DMM2NSK MA Modulator DMM2NSK RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMM2NSK RU https://www.fda.gov/ DMM32GT DI DMM32GT DMM32GT DN Risankizumab DMM32GT TI TTC1GLB DMM32GT TN Interleukin-23 (IL23) DMM32GT MA Inhibitor DMM32GT RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019 DMM32GT RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761105s000lbl.pdf DMM3950 DI DMM3950 DMM3950 DN Sodium chloride DMM3950 TI TTQ8AFT DMM3950 TN Adrenergic receptor Alpha-2 (ADRA2) DMM3950 MA Agonist DMM3950 RN Noradrenergic alpha-2 receptor agonists reverse working memory deficits induced by the anxiogenic drug, FG7142, in rats. Pharmacol Biochem Behav. 2000 Nov;67(3):397-403. DMM3950 RU https://pubmed.ncbi.nlm.nih.gov/11164065 DMM39BF DI DMM39BF DMM39BF DN Mitoxantrone DMM39BF TI TT0IHXV DMM39BF TN DNA topoisomerase II (TOP2) DMM39BF MA Modulator DMM39BF RN Mitoxantrone, a topoisomerase II inhibitor, induces apoptosis of B-chronic lymphocytic leukaemia cells. Br J Haematol. 1998 Jan;100(1):142-6. DMM39BF RU https://pubmed.ncbi.nlm.nih.gov/9450803 DMM3L6Z DI DMM3L6Z DMM3L6Z DN Ketobemidone DMM3L6Z TI TTN4QDT DMM3L6Z TN Opioid receptor (OPR) DMM3L6Z MA Modulator DMM3L6Z RN The mu1 and mu2 opioid receptor binding of ketobemidone, norketobemidone and 3-dimethylamino-1,1-diphenylbutene. Pharmacol Toxicol. 1996 Aug;79(2):103-4. DMM3L6Z RU https://pubmed.ncbi.nlm.nih.gov/8878254 DMM4FXA DI DMM4FXA DMM4FXA DN Asfotase alfa DMM4FXA TI TTMR5UV DMM4FXA TN Alkaline phosphatase tissue-nonspecific (ALPL) DMM4FXA MA Modulator DMM4FXA RN Enzyme-replacement therapy in life-threatening hypophosphatasia. N Engl J Med. 2012 Mar 8;366(10):904-13. DMM4FXA RU https://pubmed.ncbi.nlm.nih.gov/22397652 DMM4QOJ DI DMM4QOJ DMM4QOJ DN Metadoxine DMM4QOJ TI TTPRKM0 DMM4QOJ TN GABA transporter GAT-1 (SLC6A1) DMM4QOJ MA Modulator DMM4QOJ RN Company report (Alcobra pharma) DMM4QOJ RU http://www.alcobra-pharma.com/products.cfm?productID=163127 DMM4U9G DI DMM4U9G DMM4U9G DN R0-93877 DMM4U9G TI TT07C3Y DMM4U9G TN 5-HT 4 receptor (HTR4) DMM4U9G MA Agonist DMM4U9G RN Irritable bowel syndrome: new agents targeting serotonin receptor subtypes. Drugs. 2001;61(3):317-32. DMM4U9G RU https://pubmed.ncbi.nlm.nih.gov/11293643 DMM58JY DI DMM58JY DMM58JY DN Ziprasidone DMM58JY TI TTEX248 DMM58JY TN Dopamine D2 receptor (D2R) DMM58JY MA Agonist DMM58JY RN Striatal and extrastriatal D2/D3-receptor-binding properties of ziprasidone: a positron emission tomography study with [18F]Fallypride and [11C]raclopride (D2/D3-receptor occupancy of ziprasidone). JClin Psychopharmacol. 2008 Dec;28(6):608-17. DMM58JY RU https://pubmed.ncbi.nlm.nih.gov/19011428 DMM58JY DI DMM58JY DMM58JY DN Ziprasidone DMM58JY TI TTLA931 DMM58JY TN Neuronal acetylcholine receptor alpha-7 (CHRNA7) DMM58JY MA Binder DMM58JY RN The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22. DMM58JY RU https://pubmed.ncbi.nlm.nih.gov/17667958 DMM765C DI DMM765C DMM765C DN Nitroprusside DMM765C TI TTC9IZL DMM765C TN Inositol 1,4,5-trisphosphate receptor (ITPR) DMM765C MA Antagonist DMM765C RN Prostacyclin and sodium nitroprusside inhibit the activity of the platelet inositol 1,4,5-trisphosphate receptor and promote its phosphorylation. J Biol Chem. 1996 Mar 8;271(10):5545-51. DMM765C RU https://pubmed.ncbi.nlm.nih.gov/8621413 DMM7CHK DI DMM7CHK DMM7CHK DN Trimethoprim DMM7CHK TI TTYZVDJ DMM7CHK TN Dihydrofolate reductase (DHFR) DMM7CHK MA Modulator DMM7CHK RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMM7CHK RU https://www.fda.gov/ DMM9BJD DI DMM9BJD DMM9BJD DN Tisagenlecleucel DMM9BJD TI TTUE541 DMM9BJD TN Leukocyte surface antigen Leu-16 (CD20) DMM9BJD MA Immunostimulant DMM9BJD RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMM9BJD RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DMM9BJD DI DMM9BJD DMM9BJD DN Tisagenlecleucel DMM9BJD TI TTW640A DMM9BJD TN B-lymphocyte surface antigen B4 (CD19) DMM9BJD MA Immunostimulant DMM9BJD RN 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85. DMM9BJD RU https://pubmed.ncbi.nlm.nih.gov/29348678 DMMAWLU DI DMMAWLU DMMAWLU DN Huperzine A DMMAWLU TI TT1RS9F DMMAWLU TN Acetylcholinesterase (AChE) DMMAWLU MA Inhibitor DMMAWLU RN Huperzine A attenuates cognitive deficits and brain injury in neonatal rats after hypoxia-ischemia. Brain Res. 2002 Sep 13;949(1-2):162-70. DMMAWLU RU https://pubmed.ncbi.nlm.nih.gov/12213312 DMMAWLU DI DMMAWLU DMMAWLU DN Huperzine A DMMAWLU TI TT9IK2Z DMMAWLU TN N-methyl-D-aspartate receptor (NMDAR) DMMAWLU MA Antagonist DMMAWLU RN Progress report on new antiepileptic drugs: a summary of the Ninth Eilat Conference (EILAT IX). Epilepsy Res. 2009 Jan;83(1):1-43. DMMAWLU RU https://pubmed.ncbi.nlm.nih.gov/19008076 DMMAWY1 DI DMMAWY1 DMMAWY1 DN Adefovir dipivoxil DMMAWY1 TI TT84ETX DMMAWY1 TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMMAWY1 MA Modulator DMMAWY1 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMMAWY1 RU https://www.fda.gov/ DMMC345 DI DMMC345 DMMC345 DN Cefadroxil DMMC345 TI TTJP4SM DMMC345 TN Bacterial Penicillin binding protein (Bact PBP) DMMC345 MA Binder DMMC345 RN Penicillin-binding protein sensitive to cephalexin in sporulation of Bacillus cereus. Microbiol Res. 1997 Sep;152(3):227-32. DMMC345 RU https://pubmed.ncbi.nlm.nih.gov/9352657 DMMC45B DI DMMC45B DMMC45B DN Teriparatide DMMC45B TI TT6F7GZ DMMC45B TN Parathyroid hormone (PTH) DMMC45B MA Modulator DMMC45B RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMMC45B RU https://www.fda.gov/ DMMD9QE DI DMMD9QE DMMD9QE DN Colistin DMMD9QE TI TT4ILYC DMMD9QE TN Bacterial Dihydropteroate synthetase (Bact folP) DMMD9QE MA Binder DMMD9QE RN Polymyxin B sulfate and colistin: old antibiotics for emerging multiresistant gram-negative bacteria. Ann Pharmacother. 1999 Sep;33(9):960-7. DMMD9QE RU https://pubmed.ncbi.nlm.nih.gov/10492501 DMME8LH DI DMME8LH DMME8LH DN Alitretinoin DMME8LH TI TTKLV96 DMME8LH TN Retinoic acid receptor RXR-beta (RXRB) DMME8LH MA Agonist DMME8LH RN Retinoic acid receptors and retinoid X receptors: interactions with endogenous retinoic acids. Proc Natl Acad Sci U S A. 1993 Jan 1;90(1):30-4. DMME8LH RU https://pubmed.ncbi.nlm.nih.gov/8380496 DMME8LH DI DMME8LH DMME8LH DN Alitretinoin DMME8LH TI TT6PEUO DMME8LH TN Retinoic acid receptor RXR-alpha (RXRA) DMME8LH MA Agonist DMME8LH RN Retinoic acid receptors and retinoid X receptors: interactions with endogenous retinoic acids. Proc Natl Acad Sci U S A. 1993 Jan 1;90(1):30-4. DMME8LH RU https://pubmed.ncbi.nlm.nih.gov/8380496 DMME8LH DI DMME8LH DMME8LH DN Alitretinoin DMME8LH TI TTISP28 DMME8LH TN Retinoic acid receptor beta (RARB) DMME8LH MA Agonist DMME8LH RN Retinoic acid receptors and retinoid X receptors: interactions with endogenous retinoic acids. Proc Natl Acad Sci U S A. 1993 Jan 1;90(1):30-4. DMME8LH RU https://pubmed.ncbi.nlm.nih.gov/8380496 DMME8LH DI DMME8LH DMME8LH DN Alitretinoin DMME8LH TI TTH029C DMME8LH TN Retinoic acid receptor RXR-gamma (RXRG) DMME8LH MA Agonist DMME8LH RN Retinoic acid receptors and retinoid X receptors: interactions with endogenous retinoic acids. Proc Natl Acad Sci U S A. 1993 Jan 1;90(1):30-4. DMME8LH RU https://pubmed.ncbi.nlm.nih.gov/8380496 DMME8LH DI DMME8LH DMME8LH DN Alitretinoin DMME8LH TI TT1Q3IE DMME8LH TN Retinoic acid receptor gamma (RARG) DMME8LH MA Modulator DMME8LH RN Retinoic acid receptors and retinoid X receptors: interactions with endogenous retinoic acids. Proc Natl Acad Sci U S A. 1993 Jan 1;90(1):30-4. DMME8LH RU https://pubmed.ncbi.nlm.nih.gov/8380496 DMMF8U0 DI DMMF8U0 DMMF8U0 DN Atezolizumab DMMF8U0 TI TT8ZLTI DMMF8U0 TN Programmed cell death 1 ligand 1 (PD-L1) DMMF8U0 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019 DMMF8U0 RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761034s018lbl.pdf DMMFCIH DI DMMFCIH DMMFCIH DN Clotrimazole DMMFCIH TI TT30C9G DMMFCIH TN C-X-C chemokine receptor type 2 (CXCR2) DMMFCIH MA Modulator DMMFCIH RN Mode of action of clotrimazole: implications for therapy. Am J Obstet Gynecol. 1985 Aug 1;152(7 Pt 2):939-44. DMMFCIH RU https://www.ncbi.nlm.nih.gov/pubmed/3895959 DMMFVB3 DI DMMFVB3 DMMFVB3 DN Difluprednate DMMFVB3 TI TTUCK4B DMMFVB3 TN Phospholipase A2 inhibitory protein (PA2IP) DMMFVB3 MA Agonist DMMFVB3 RN 2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6. DMMFVB3 RU https://pubmed.ncbi.nlm.nih.gov/19180096 DMMFWOJ DI DMMFWOJ DMMFWOJ DN Probenecid DMMFWOJ TI TTTQR47 DMMFWOJ TN Solute carrier family 22 member 8 (SLC22A8) DMMFWOJ MA Blocker DMMFWOJ RN Transport of organic anions across the basolateral membrane of proximal tubule cells. Rev Physiol Biochem Pharmacol. 2003;146:95-158. DMMFWOJ RU https://pubmed.ncbi.nlm.nih.gov/12605306 DMMG26Z DI DMMG26Z DMMG26Z DN Dolasetron DMMG26Z TI TTPC4TU DMMG26Z TN 5-HT 3A receptor (HTR3A) DMMG26Z MA Antagonist DMMG26Z RN Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, do... Lancet Oncol. 2009 Feb;10(2):115-24. DMMG26Z RU https://pubmed.ncbi.nlm.nih.gov/19135415 DMMHNU2 DI DMMHNU2 DMMHNU2 DN (S)-(+)-Dimethindene maleate DMMHNU2 TI TTTIBOJ DMMHNU2 TN Histamine H1 receptor (H1R) DMMHNU2 MA Antagonist DMMHNU2 RN Analytical method for simultaneously measuring ex vivo drug receptor occupancy and dissociation rate: application to (R)-dimethindene occupancy of central histamine H1 receptors. J Recept Signal Transduct Res. 2009;29(2):84-93. DMMHNU2 RU https://pubmed.ncbi.nlm.nih.gov/19308787 DMMHR1U DI DMMHR1U DMMHR1U DN Denileukin diftitox DMMHR1U TI TTAJU0S DMMHR1U TN Interleukin 2 receptor (IL2R) DMMHR1U MA Binder DMMHR1U RN Optimizing denileukin diftitox (Ontak) therapy. Future Oncol. 2008 Aug;4(4):457-69. DMMHR1U RU https://pubmed.ncbi.nlm.nih.gov/18684057 DMMHYLB DI DMMHYLB DMMHYLB DN H5N1 influenza vaccine DMMHYLB TI TT3J5ZI DMMHYLB TN Cell mediated immunity response (CMIR) DMMHYLB RN Comparative clinical trial of vaccines against avian influenza. Zh Mikrobiol Epidemiol Immunobiol. 2007 May-Jun;(3):10-6. DMMHYLB RU https://pubmed.ncbi.nlm.nih.gov/17672124 DMMIAXO DI DMMIAXO DMMIAXO DN Betamethasone valerate DMMIAXO TI TTYRL6O DMMIAXO TN Glucocorticoid receptor (NR3C1) DMMIAXO MA Modulator DMMIAXO RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMMIAXO RU https://www.fda.gov/ DMMIHVP DI DMMIHVP DMMIHVP DN Dextroamphetamine DMMIHVP TI TTIU98M DMMIHVP TN Trace amine-associated receptor-1 (TAAR1) DMMIHVP MA Modulator DMMIHVP RN Methamphetamine and HIV-1-induced neurotoxicity: role of trace amine associated receptor 1 cAMP signaling in astrocytes. Neuropharmacology. 2014 Oct;85:499-507. DMMIHVP RU https://pubmed.ncbi.nlm.nih.gov/24950453 DMMIQ20 DI DMMIQ20 DMMIQ20 DN Patiromer calcium DMMIQ20 TI TTB0SC6 DMMIQ20 TN Potassium (K) DMMIQ20 MA Binder DMMIQ20 RN Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial. Eur Heart J. 2011 Apr;32(7):820-8. DMMIQ20 RU https://pubmed.ncbi.nlm.nih.gov/21208974 DMMIQ7G DI DMMIQ7G DMMIQ7G DN Rosuvastatin DMMIQ7G TI TTPADOQ DMMIQ7G TN HMG-CoA reductase (HMGCR) DMMIQ7G MA Inhibitor DMMIQ7G RN New dimension of statin action on ApoB atherogenicity. Clin Cardiol. 2003 Jan;26(1 Suppl 1):I7-10. DMMIQ7G RU https://pubmed.ncbi.nlm.nih.gov/12539816 DMMJ1IS DI DMMJ1IS DMMJ1IS DN Prolixin decanoate DMMJ1IS TI TTK8CXU DMMJ1IS TN 5-HT 1B receptor (HTR1B) DMMJ1IS MA Modulator DMMJ1IS RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMMJ1IS RU https://www.fda.gov/ DMMJQSH DI DMMJQSH DMMJQSH DN Lanthanum carbonate DMMJQSH TI TTHOTF6 DMMJQSH TN Phosphate (PHO) DMMJQSH MA Modulator DMMJQSH RN 2004 approvals: the demise of the blockbuster. Nat Rev Drug Discov. 2005 Feb;4(2):93-4. DMMJQSH RU https://pubmed.ncbi.nlm.nih.gov/15756752 DMMJTYW DI DMMJTYW DMMJTYW DN Darbepoetin alfa DMMJTYW TI TTAUX24 DMMJTYW TN Erythropoietin Receptor (EPOR) DMMJTYW MA Agonist DMMJTYW RN A cytosolic domain of the erythropoietin receptor contributes to endoplasmic reticulum-associated degradation. Eur J Biochem. 1999 Jul;263(2):410-9. DMMJTYW RU https://pubmed.ncbi.nlm.nih.gov/10406949 DMMJVXZ DI DMMJVXZ DMMJVXZ DN LU302146 DMMJVXZ TI TTKRD0G DMMJVXZ TN Endothelin A receptor (EDNRA) DMMJVXZ MA Antagonist DMMJVXZ RN Influence of endothelin receptor antagonists on myocardial protein kinase C isoforms in uraemic cardiomyopathy. Clin Sci (Lond). 2002 Aug;103 Suppl 48:276S-279S. DMMJVXZ RU https://pubmed.ncbi.nlm.nih.gov/12193103 DMMKHBJ DI DMMKHBJ DMMKHBJ DN Cefotaxime DMMKHBJ TI TTLP6GN DMMKHBJ TN Bacterial DD-carboxypeptidase (Bact vanYB) DMMKHBJ MA Inhibitor DMMKHBJ RN Extended-spectrum cephalosporinases: structure, detection and epidemiology. Future Microbiol. 2007 Jun;2:297-307. DMMKHBJ RU https://pubmed.ncbi.nlm.nih.gov/17661704 DMMN36E DI DMMN36E DMMN36E DN Abacavir DMMN36E TI TT84ETX DMMN36E TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMMN36E MA Inhibitor DMMN36E RN Quadruple nucleos(t)ide reverse transcriptase inhibitors-only regimen of tenofovir plus zidovudine/lamivudine/abacavir in heavily pre-treated HIV-1 infected patients: salvage therapy or backbone only Curr HIV Res. 2009 May;7(3):320-6. DMMN36E RU https://pubmed.ncbi.nlm.nih.gov/19442129 DMMP3Y2 DI DMMP3Y2 DMMP3Y2 DN Yn-968D1 DMMP3Y2 TI TTUTJGQ DMMP3Y2 TN Vascular endothelial growth factor receptor 2 (KDR) DMMP3Y2 MA Inhibitor DMMP3Y2 RN YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo. Cancer Sci. 2011 Jul;102(7):1374-80. DMMP3Y2 RU https://pubmed.ncbi.nlm.nih.gov/21443688 DMMP5SI DI DMMP5SI DMMP5SI DN Revefenacin DMMP5SI TI TTOXS3C DMMP5SI TN Muscarinic acetylcholine receptor (CHRM) DMMP5SI MA Antagonist DMMP5SI RN 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. DMMP5SI RU https://pubmed.ncbi.nlm.nih.gov/30710142 DMMPCFX DI DMMPCFX DMMPCFX DN Recombinant human endostatin DMMPCFX TI TTRPKQG DMMPCFX TN Beta-catenin (CTNNB1) DMMPCFX MA Modulator DMMPCFX RN Endostar, a modified recombinant human endostatin, suppresses angiogenesis through inhibition of Wnt/beta-catenin signaling pathway. PLoS One. 2014 Sep 18;9(9):e107463. DMMPCFX RU https://pubmed.ncbi.nlm.nih.gov/25232946 DMMPG5V DI DMMPG5V DMMPG5V DN NERIDRONIC ACID DMMPG5V TI TTIKWV4 DMMPG5V TN Geranyltranstransferase (FDPS) DMMPG5V MA Inhibitor DMMPG5V RN Structure-activity relationships among the nitrogen containing bisphosphonates in clinical use and other analogues: time-dependent inhibition of hu... J Med Chem. 2008 Apr 10;51(7):2187-95. DMMPG5V RU https://pubmed.ncbi.nlm.nih.gov/18327899 DMMPTLH DI DMMPTLH DMMPTLH DN Entrectinib DMMPTLH TI TTSZ6Y3 DMMPTLH TN Proto-oncogene c-Ros (ROS1) DMMPTLH MA Inhibitor DMMPTLH RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019 DMMPTLH RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212725s000lbl.pdf DMMPTLH DI DMMPTLH DMMPTLH DN Entrectinib DMMPTLH TI TTPMQSO DMMPTLH TN ALK tyrosine kinase receptor (ALK) DMMPTLH MA Inhibitor DMMPTLH RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019 DMMPTLH RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212725s000lbl.pdf DMMPTLH DI DMMPTLH DMMPTLH DN Entrectinib DMMPTLH TI TTKN7QR DMMPTLH TN BDNF/NT-3 growth factors receptor (TrkB) DMMPTLH MA Inhibitor DMMPTLH RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019 DMMPTLH RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212725s000lbl.pdf DMMPTLH DI DMMPTLH DMMPTLH DN Entrectinib DMMPTLH TI TTXABCW DMMPTLH TN NT-3 growth factor receptor (TrkC) DMMPTLH MA Inhibitor DMMPTLH RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019 DMMPTLH RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212725s000lbl.pdf DMMPTLH DI DMMPTLH DMMPTLH DN Entrectinib DMMPTLH TI TTTDVOJ DMMPTLH TN Tropomyosin-related kinase A (TrkA) DMMPTLH MA Inhibitor DMMPTLH RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019 DMMPTLH RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212725s000lbl.pdf DMMQ8ZG DI DMMQ8ZG DMMQ8ZG DN Furosemide DMMQ8ZG TI TTS087L DMMQ8ZG TN Solute carrier family 12 member 1 (SLC12A1) DMMQ8ZG MA Blocker DMMQ8ZG RN Update of diuretics in the treatment of hypertension. Am J Ther. 2007 Mar-Apr;14(2):154-60. DMMQ8ZG RU https://pubmed.ncbi.nlm.nih.gov/17414583 DMMQHOZ DI DMMQHOZ DMMQHOZ DN Oxyphenonium DMMQHOZ TI TTZ9SOR DMMQHOZ TN Muscarinic acetylcholine receptor M1 (CHRM1) DMMQHOZ MA Antagonist DMMQHOZ RN Ultraviolet spectroscopic estimation of microenvironments and bitter tastes of oxyphenonium bromide in cyclodextrin solutions. J Pharm Sci. 1999 Aug;88(8):759-62. DMMQHOZ RU https://pubmed.ncbi.nlm.nih.gov/10430538 DMMRV29 DI DMMRV29 DMMRV29 DN Telaprevir DMMRV29 TI TTHC7JD DMMRV29 TN Hepatitis C virus Serine protease NS3/4A (HCV NS3/4A) DMMRV29 MA Modulator DMMRV29 RN 2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4. DMMRV29 RU https://pubmed.ncbi.nlm.nih.gov/22293555 DMMSDOY DI DMMSDOY DMMSDOY DN Stiripentol DMMSDOY TI TTEX6LM DMMSDOY TN GABA(A) receptor gamma-3 (GABRG3) DMMSDOY MA Modulator DMMSDOY RN Stiripentol, a putative antiepileptic drug, enhances the duration of opening of GABA-A receptor channels. Epilepsia. 2006 Apr;47(4):704-16. DMMSDOY RU https://pubmed.ncbi.nlm.nih.gov/16650136 DMMSOLA DI DMMSOLA DMMSOLA DN Propoxyphene Hydrochloride DMMSOLA TI TTKWM86 DMMSOLA TN Opioid receptor mu (MOP) DMMSOLA MA Modulator DMMSOLA RN Norpropoxyphene-induced cardiotoxicity is associated with changes in ion-selectivity and gating of HERG currents. Cardiovasc Res. 1999 Dec;44(3):568-78. DMMSOLA RU https://www.ncbi.nlm.nih.gov/pubmed/10690289 DMMTAJC DI DMMTAJC DMMTAJC DN Potassium chloride DMMTAJC TI TTS087L DMMTAJC TN Solute carrier family 12 member 1 (SLC12A1) DMMTAJC MA Modulator DMMTAJC RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMMTAJC RU https://www.fda.gov/ DMMU6BJ DI DMMU6BJ DMMU6BJ DN Sodium bicarbonate DMMU6BJ TI TTZPWGN DMMU6BJ TN Voltage-gated calcium channel alpha Cav3.2 (CACNA1H) DMMU6BJ MA Blocker DMMU6BJ RN Acute renal failure. Clin Evid (Online). 2008 Sep 3;2008. pii: 2001. DMMU6BJ RU https://pubmed.ncbi.nlm.nih.gov/19445797 DMMU6BJ DI DMMU6BJ DMMU6BJ DN Sodium bicarbonate DMMU6BJ TI TTPLQO0 DMMU6BJ TN Voltage-gated potassium channel Kv4.3 (KCND3) DMMU6BJ MA Blocker DMMU6BJ RN Management of cocaine-induced cardiac arrhythmias due to cardiac ion channel dysfunction. Clin Toxicol (Phila). 2009 Jan;47(1):14-23. DMMU6BJ RU https://pubmed.ncbi.nlm.nih.gov/18815938 DMMUCG4 DI DMMUCG4 DMMUCG4 DN Eicosapentaenoic acid/docosa-hexaenoic acid DMMUCG4 TI TTVKILB DMMUCG4 TN Prostaglandin G/H synthase 2 (COX-2) DMMUCG4 MA Inhibitor DMMUCG4 RN Cox-2 inhibitory effects of naturally occurring and modified fatty acids. J Nat Prod. 2001 Jun;64(6):745-9. DMMUCG4 RU https://pubmed.ncbi.nlm.nih.gov/11421736 DMMUCG4 DI DMMUCG4 DMMUCG4 DN Eicosapentaenoic acid/docosa-hexaenoic acid DMMUCG4 TI TT8NGED DMMUCG4 TN Prostaglandin G/H synthase 1 (COX-1) DMMUCG4 MA Inhibitor DMMUCG4 RN Cox-2 inhibitory effects of naturally occurring and modified fatty acids. J Nat Prod. 2001 Jun;64(6):745-9. DMMUCG4 RU https://pubmed.ncbi.nlm.nih.gov/11421736 DMMUOLJ DI DMMUOLJ DMMUOLJ DN Varenicline DMMUOLJ TI TTL1ATN DMMUOLJ TN Neuronal acetylcholine receptor alpha-4/beta-2 (CHRNA4/B2) DMMUOLJ MA Modulator DMMUOLJ RN 2006 drug approvals: finding the niche. Nat Rev Drug Discov. 2007 Feb;6(2):99-101. DMMUOLJ RU https://pubmed.ncbi.nlm.nih.gov/17342860 DMMV0KW DI DMMV0KW DMMV0KW DN Ephedrine DMMV0KW TI TTEX248 DMMV0KW TN Dopamine D2 receptor (D2R) DMMV0KW MA Agonist DMMV0KW RN The effect of alpha-2 adrenergic agonists on memory and cognitive flexibility. Cogn Behav Neurol. 2006 Dec;19(4):204-7. DMMV0KW RU https://pubmed.ncbi.nlm.nih.gov/17159617 DMMVNZ0 DI DMMVNZ0 DMMVNZ0 DN Masoprocol DMMVNZ0 TI TT6EO5L DMMVNZ0 TN Erbb2 tyrosine kinase receptor (HER2) DMMVNZ0 MA Modulator DMMVNZ0 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMMVNZ0 RU https://www.fda.gov/ DMMWSUL DI DMMWSUL DMMWSUL DN Lomustine DMMWSUL TI TTUTN1I DMMWSUL TN Human Deoxyribonucleic acid (hDNA) DMMWSUL MA Inhibitor DMMWSUL RN Synthesis and evaluation of ethylnitrosoureas of substituted naphthalimides as anticancer compounds. Acta Pol Pharm. 2007 Jan-Feb;64(1):27-33. DMMWSUL RU https://pubmed.ncbi.nlm.nih.gov/17665847 DMMWZET DI DMMWZET DMMWZET DN Dexamethasone DMMWZET TI TTYRL6O DMMWZET TN Glucocorticoid receptor (NR3C1) DMMWZET MA Agonist DMMWZET RN Interaction between the glucocorticoid and erythropoietin receptors in human erythroid cells. Exp Hematol. 2009 May;37(5):559-72. DMMWZET RU https://pubmed.ncbi.nlm.nih.gov/19375647 DMMX2E6 DI DMMX2E6 DMMX2E6 DN Pemetrexed DMMX2E6 TI TTU6BFZ DMMX2E6 TN Candida Thymidylate synthase (Candi TMP1) DMMX2E6 MA Inhibitor DMMX2E6 RN Updated clinical information on multitargeted antifolates in lung cancer. Clin Lung Cancer. 2009 Mar;10 Suppl 1:S35-40. DMMX2E6 RU https://pubmed.ncbi.nlm.nih.gov/19362945 DMMYLTI DI DMMYLTI DMMYLTI DN Thyrotropin Alfa DMMYLTI TI TT6NYJA DMMYLTI TN Thyrotropin receptor (TSHR) DMMYLTI MA Binder DMMYLTI RN Pharmacological profiles and clinical effects of recombinant human thyrotropin alfa (Thyrogen) Intramuscular Injection 0.9 mg). Nippon Yakurigaku Zasshi. 2009 Jul;134(1):28-34. DMMYLTI RU https://pubmed.ncbi.nlm.nih.gov/19602784 DMMYPWO DI DMMYPWO DMMYPWO DN Alefacept DMMYPWO TI TT5KSBY DMMYPWO TN Surface glycoprotein LFA-3 (CD58) DMMYPWO MA Modulator DMMYPWO RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMMYPWO RU https://www.fda.gov/ DMMYZ3D DI DMMYZ3D DMMYZ3D DN Tositumomab DMMYZ3D TI TTUE541 DMMYZ3D TN Leukocyte surface antigen Leu-16 (CD20) DMMYZ3D RN Structure of the Fab fragment of therapeutic antibody Ofatumumab provides insights into the recognition mechanism with CD20. Mol Immunol. 2009 Jul;46(11-12):2419-23. DMMYZ3D RU https://pubmed.ncbi.nlm.nih.gov/19427037 DMMZB0K DI DMMZB0K DMMZB0K DN Prifinium DMMZB0K TI TTH18TF DMMZB0K TN Muscarinic acetylcholine receptor M5 (CHRM5) DMMZB0K MA Modulator DMMZB0K RN Ligand binding properties of muscarinic acetylcholine receptor subtypes (m1-m5) expressed in baculovirus-infected insect cells. J Pharmacol Exp Ther. 1995 Jul;274(1):378-84. DMMZB0K RU https://pubmed.ncbi.nlm.nih.gov/7616422 DMMZPWT DI DMMZPWT DMMZPWT DN Levocabastine DMMZPWT TI TTTIBOJ DMMZPWT TN Histamine H1 receptor (H1R) DMMZPWT MA Antagonist DMMZPWT RN Contribution of alpha4beta1 integrin to the antiallergic effect of levocabastine. Biochem Pharmacol. 2008 Sep 15;76(6):751-62. DMMZPWT RU https://pubmed.ncbi.nlm.nih.gov/18680729 DMMZSXQ DI DMMZSXQ DMMZSXQ DN Azathioprine DMMZSXQ TI TTZFTY4 DMMZSXQ TN Amidophosphoribosyltransferase (PPAT) DMMZSXQ MA Inhibitor DMMZSXQ RN IMPDH activity in thiopurine-treated patients with inflammatory bowel disease - relation to TPMT activity and metabolite concentrations. Br J Clin Pharmacol. 2008 Jan;65(1):69-77. DMMZSXQ RU https://pubmed.ncbi.nlm.nih.gov/17662091 DMMZXIW DI DMMZXIW DMMZXIW DN Rabeprazole DMMZXIW TI TTF1QVM DMMZXIW TN Gastric H(+)/K(+) ATPase alpha (ATP4A) DMMZXIW MA Inhibitor DMMZXIW RN Review article: rabeprazole's tolerability profile in clinical trials. Aliment Pharmacol Ther. 1999 Oct;13 Suppl 5:17-23. DMMZXIW RU https://pubmed.ncbi.nlm.nih.gov/10555605 DMN0LP8 DI DMN0LP8 DMN0LP8 DN Polymyxin B Sulfate DMN0LP8 TI TT4ILYC DMN0LP8 TN Bacterial Dihydropteroate synthetase (Bact folP) DMN0LP8 MA Binder DMN0LP8 RN Polymyxin B sulfate and colistin: old antibiotics for emerging multiresistant gram-negative bacteria. Ann Pharmacother. 1999 Sep;33(9):960-7. DMN0LP8 RU https://pubmed.ncbi.nlm.nih.gov/10492501 DMN0S1G DI DMN0S1G DMN0S1G DN HEGF DMN0S1G TI TTGKNB4 DMN0S1G TN Epidermal growth factor receptor (EGFR) DMN0S1G MA Activator DMN0S1G RN Emerging drugs for diabetic foot ulcers. Expert Opin Emerg Drugs. 2006 Nov;11(4):709-24. DMN0S1G RU https://pubmed.ncbi.nlm.nih.gov/17064227 DMN1XVC DI DMN1XVC DMN1XVC DN Lutetium Lu 177 dotatate DMN1XVC TI TTIND6G DMN1XVC TN Somatostatin receptor type 1 (SSTR1) DMN1XVC MA Antagonist DMN1XVC RN 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. DMN1XVC RU https://pubmed.ncbi.nlm.nih.gov/30710142 DMN3E57 DI DMN3E57 DMN3E57 DN Levodopa DMN3E57 TI TTEX248 DMN3E57 TN Dopamine D2 receptor (D2R) DMN3E57 MA Modulator DMN3E57 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3639). DMN3E57 RU http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3639 DMN3GCH DI DMN3GCH DMN3GCH DN Darunavir DMN3GCH TI TT5FNQT DMN3GCH TN Human immunodeficiency virus Protease (HIV PR) DMN3GCH MA Modulator DMN3GCH RN 2006 drug approvals: finding the niche. Nat Rev Drug Discov. 2007 Feb;6(2):99-101. DMN3GCH RU https://pubmed.ncbi.nlm.nih.gov/17342860 DMN3UXQ DI DMN3UXQ DMN3UXQ DN Diethylstilbestrol DMN3UXQ TI TTZAYWL DMN3UXQ TN Estrogen receptor (ESR) DMN3UXQ MA Agonist DMN3UXQ RN Effects of diethylstilbestrol on programmed oocyte death and induction of polyovular follicles in neonatal mouse ovaries. Biol Reprod. 2009 Nov;81(5):1002-9. DMN3UXQ RU https://pubmed.ncbi.nlm.nih.gov/19553606 DMN4CV5 DI DMN4CV5 DMN4CV5 DN Calcidiol DMN4CV5 TI TTK59TV DMN4CV5 TN Vitamin D3 receptor (VDR) DMN4CV5 MA Antagonist DMN4CV5 RN Vitamin D in health and disease. Clin J Am Soc Nephrol. 2008 Sep;3(5):1535-41. DMN4CV5 RU https://pubmed.ncbi.nlm.nih.gov/18525006 DMN4H2O DI DMN4H2O DMN4H2O DN Zithromax DMN4H2O TI TTUWYEA DMN4H2O TN Bacterial 50S ribosomal RNA (Bact 50S rRNA) DMN4H2O MA Modulator DMN4H2O RN The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954. DMN4H2O RU https://www.ncbi.nlm.nih.gov/pubmed/27899562 DMN5T2A DI DMN5T2A DMN5T2A DN Ciclopirox DMN5T2A TI TTJQFBG DMN5T2A TN HIF-prolyl hydroxylase (HPH) DMN5T2A MA Modulator DMN5T2A RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMN5T2A RU https://www.fda.gov/ DMN63DZ DI DMN63DZ DMN63DZ DN Moxetumomab pasudotox DMN63DZ TI TTM6QSK DMN63DZ TN B-cell receptor CD22 (CD22) DMN63DZ MA Modulator DMN63DZ RN Antibody fusion proteins: anti-CD22 recombinant immunotoxin moxetumomab pasudotox. Clin Cancer Res. 2011 Oct 15;17(20):6398-405. DMN63DZ RU https://pubmed.ncbi.nlm.nih.gov/22003067 DMN6CAG DI DMN6CAG DMN6CAG DN Tiapride DMN6CAG TI TT90XZ8 DMN6CAG TN Voltage-gated sodium channel alpha Nav1.8 (SCN10A) DMN6CAG MA Inhibitor DMN6CAG RN Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26. DMN6CAG RU https://pubmed.ncbi.nlm.nih.gov/17355217 DMN6CAG DI DMN6CAG DMN6CAG DN Tiapride DMN6CAG TI TTEX248 DMN6CAG TN Dopamine D2 receptor (D2R) DMN6CAG MA Antagonist DMN6CAG RN The treatment of Tourette's syndrome: current opinions. Expert Opin Pharmacother. 2002 Jul;3(7):899-914. DMN6CAG RU https://pubmed.ncbi.nlm.nih.gov/12083990 DMN6DXL DI DMN6DXL DMN6DXL DN Risperidone DMN6DXL TI TTEX248 DMN6DXL TN Dopamine D2 receptor (D2R) DMN6DXL MA Antagonist DMN6DXL RN Randomized clinical comparison of perospirone and risperidone in patients with schizophrenia: Kansai Psychiatric Multicenter Study. Psychiatry Clin Neurosci. 2009 Jun;63(3):322-8. DMN6DXL RU https://pubmed.ncbi.nlm.nih.gov/19566763 DMN6QO5 DI DMN6QO5 DMN6QO5 DN Gliclazide DMN6QO5 TI TTP835K DMN6QO5 TN ATP-binding cassette transporter C8 (ABCC8) DMN6QO5 MA Blocker DMN6QO5 RN Structural basis for the interference between nicorandil and sulfonylurea action. Diabetes. 2001 Oct;50(10):2253-9. DMN6QO5 RU https://pubmed.ncbi.nlm.nih.gov/11574406 DMN7SDE DI DMN7SDE DMN7SDE DN Methyclothiazide DMN7SDE TI TTS087L DMN7SDE TN Solute carrier family 12 member 1 (SLC12A1) DMN7SDE MA Blocker DMN7SDE RN DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6. DMN7SDE RU https://pubmed.ncbi.nlm.nih.gov/18048412 DMN7Y9K DI DMN7Y9K DMN7Y9K DN Alpidem DMN7Y9K TI TTNJYV2 DMN7Y9K TN Gamma-aminobutyric acid receptor (GAR) DMN7Y9K MA Inhibitor DMN7Y9K RN Synthesis and binding affinity of 2-phenylimidazo[1,2-alpha]pyridine derivatives for both central and peripheral benzodiazepine receptors. A new se... J Med Chem. 1997 Sep 12;40(19):3109-18. DMN7Y9K RU https://pubmed.ncbi.nlm.nih.gov/9301675 DMN7Y9K DI DMN7Y9K DMN7Y9K DN Alpidem DMN7Y9K TI TTPTXIN DMN7Y9K TN Translocator protein (TSPO) DMN7Y9K MA Inhibitor DMN7Y9K RN Anxiolytic-like effects of N,N-dialkyl-2-phenylindol-3-ylglyoxylamides by modulation of translocator protein promoting neurosteroid biosynthesis. J Med Chem. 2008 Sep 25;51(18):5798-806. DMN7Y9K RU https://pubmed.ncbi.nlm.nih.gov/18729350 DMN9CWF DI DMN9CWF DMN9CWF DN Salbutamol DMN9CWF TI TT2CJVK DMN9CWF TN Adrenergic receptor beta-2 (ADRB2) DMN9CWF MA Agonist DMN9CWF RN Potential of beta2-adrenoceptor agonists as add-on therapy for multiple sclerosis: focus on salbutamol (albuterol). CNS Drugs. 2002;16(1):1-8. DMN9CWF RU https://pubmed.ncbi.nlm.nih.gov/11772115 DMN9RPO DI DMN9RPO DMN9RPO DN Nafcillin DMN9RPO TI TTJP4SM DMN9RPO TN Bacterial Penicillin binding protein (Bact PBP) DMN9RPO MA Binder DMN9RPO RN Binding affinity for penicillin-binding protein 2a correlates with in vivo activity of beta-lactam antibiotics against methicillin-resistant Staphylococcus aureus. J Infect Dis. 1990 Sep;162(3):705-10. DMN9RPO RU https://pubmed.ncbi.nlm.nih.gov/2387996 DMNA8HM DI DMNA8HM DMNA8HM DN Pyrithione Zinc DMNA8HM TI TTG5TOX DMNA8HM TN Fungal Proton pump (FPPCM) DMNA8HM MA Modulator DMNA8HM RN Mechanism of the antimicrobial action of pyrithione: effects on membrane transport, ATP levels, and protein synthesis. Antimicrob Agents Chemother. 1978 Jul;14(1):60-8. DMNA8HM RU https://www.ncbi.nlm.nih.gov/pubmed/28693 DMNAKLY DI DMNAKLY DMNAKLY DN Remikiren DMNAKLY TI TTB2MXP DMNAKLY TN Angiotensinogenase renin (REN) DMNAKLY MA Inhibitor DMNAKLY RN Functional expression of the renin-angiotensin system in human podocytes. Am J Physiol Renal Physiol. 2006 Mar;290(3):F710-9. DMNAKLY RU https://pubmed.ncbi.nlm.nih.gov/16189286 DMNARJT DI DMNARJT DMNARJT DN Ioflupane I-123 DMNARJT TI TTVBI8W DMNARJT TN Dopamine transporter (DAT) DMNARJT MA Modulator DMNARJT RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DMNARJT RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DMNC64R DI DMNC64R DMNC64R DN Antegren DMNC64R TI TT4BT06 DMNC64R TN Integrin alpha-4 (ITGA4) DMNC64R RN Very late antigen 4 (VLA4) antagonists as anti-inflammatory agents. Curr Opin Chem Biol. 1998 Aug;2(4):453-7. DMNC64R RU https://pubmed.ncbi.nlm.nih.gov/9736917 DMND304 DI DMND304 DMND304 DN Miltefosine DMND304 TI TT9V5JH DMND304 TN Phospholipase A2 (PLA2G1B) DMND304 MA Inhibitor DMND304 RN Novel antifungal agents, targets or therapeutic strategies for the treatment of invasive fungal diseases: a review of the literature (2005-2009). Rev Iberoam Micol. 2009 Mar 31;26(1):15-22. DMND304 RU https://pubmed.ncbi.nlm.nih.gov/19463273 DMNDJT5 DI DMNDJT5 DMNDJT5 DN Bromodiphenhydramine DMNDJT5 TI TTTIBOJ DMNDJT5 TN Histamine H1 receptor (H1R) DMNDJT5 MA Antagonist DMNDJT5 RN Studies on synergism between penicillins and ambodryl (bromodiphenhydramine HCl), an antihistamine with antimicrobial property. Indian J Exp Biol. 1990 Mar;28(3):253-8. DMNDJT5 RU https://pubmed.ncbi.nlm.nih.gov/1973150 DMNER5S DI DMNER5S DMNER5S DN Bleomycin DMNER5S TI TTUTN1I DMNER5S TN Human Deoxyribonucleic acid (hDNA) DMNER5S MA Breaker DMNER5S RN Bleomycin and talisomycin sequence-specific strand scission of DNA: a mechanism of double-strand cleavage. Cancer Res. 1982 Jul;42(7):2779-85. DMNER5S RU https://pubmed.ncbi.nlm.nih.gov/6177398 DMNEXZF DI DMNEXZF DMNEXZF DN Cefamandole DMNEXZF TI TTJP4SM DMNEXZF TN Bacterial Penicillin binding protein (Bact PBP) DMNEXZF MA Binder DMNEXZF RN The impact of penicillinase on cefamandole treatment and prophylaxis of experimental endocarditis due to methicillin-resistant Staphylococcus aureus. J Infect Dis. 1998 Jan;177(1):146-54. DMNEXZF RU https://pubmed.ncbi.nlm.nih.gov/9419181 DMNF0G8 DI DMNF0G8 DMNF0G8 DN Rh-alphaglucosidase DMNF0G8 TI TTXWASR DMNF0G8 TN Intestinal maltase-glucoamylase (MGAM) DMNF0G8 MA Modulator DMNF0G8 RN 2006 drug approvals: finding the niche. Nat Rev Drug Discov. 2007 Feb;6(2):99-101. DMNF0G8 RU https://pubmed.ncbi.nlm.nih.gov/17342860 DMNFUZR DI DMNFUZR DMNFUZR DN Enalapril DMNFUZR TI TTL69WB DMNFUZR TN Angiotensin-converting enzyme (ACE) DMNFUZR MA Inhibitor DMNFUZR RN Determination of bezafibrate, methotrexate, cyclophosphamide, orlistat and enalapril in waste and surface waters using on-line solid-phase extracti... J Environ Monit. 2009 Apr;11(4):830-8. DMNFUZR RU https://pubmed.ncbi.nlm.nih.gov/19557238 DMNH3PG DI DMNH3PG DMNH3PG DN Etoposide DMNH3PG TI TT0IHXV DMNH3PG TN DNA topoisomerase II (TOP2) DMNH3PG MA Modulator DMNH3PG RN Etoposide, topoisomerase II and cancer.Curr Med Chem Anticancer Agents.2005 Jul;5(4):363-72. DMNH3PG RU https://www.ncbi.nlm.nih.gov/pubmed/16101488 DMNHTZI DI DMNHTZI DMNHTZI DN Protriptyline DMNHTZI TI TTAWNKZ DMNHTZI TN Norepinephrine transporter (NET) DMNHTZI MA Inhibitor DMNHTZI RN Analgesic properties of intrathecally administered heterocyclic antidepressants. Pain. 1987 Mar;28(3):343-55. DMNHTZI RU https://pubmed.ncbi.nlm.nih.gov/3494977 DMNI0KO DI DMNI0KO DMNI0KO DN Denosumab DMNI0KO TI TT9E8HR DMNI0KO TN Osteoclast differentiation factor (ODF) DMNI0KO RN Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5. DMNI0KO RU https://pubmed.ncbi.nlm.nih.gov/21283092 DMNIJT0 DI DMNIJT0 DMNIJT0 DN Adenosine monophosphate DMNIJT0 TI TTV1ZSQ DMNIJT0 TN Adenylate cyclase type 1 (ADCY1) DMNIJT0 MA Binder DMNIJT0 RN Ecto- and cytosolic 5'-nucleotidases in normal and AMP deaminase-deficient human skeletal muscle. Biol Chem. 2006 Jan;387(1):53-8. DMNIJT0 RU https://pubmed.ncbi.nlm.nih.gov/16497164 DMNKG1Z DI DMNKG1Z DMNKG1Z DN Atenolol DMNKG1Z TI TTR6W5O DMNKG1Z TN Adrenergic receptor beta-1 (ADRB1) DMNKG1Z MA Antagonist DMNKG1Z RN Prediction and experimental validation of acute toxicity of beta-blockers in Ceriodaphnia dubia. Environ Toxicol Chem. 2005 Oct;24(10):2470-6. DMNKG1Z RU https://pubmed.ncbi.nlm.nih.gov/16268148 DMNKT8Z DI DMNKT8Z DMNKT8Z DN Pachycarpine DMNKT8Z TI TTRK8B9 DMNKT8Z TN Sodium channel unspecific (NaC) DMNKT8Z MA Modulator DMNKT8Z RN Medicinal plants in therapy. Bull World Health Organ. 1985;63(6):965-81. DMNKT8Z RU https://pubmed.ncbi.nlm.nih.gov/3879679 DMNL0E6 DI DMNL0E6 DMNL0E6 DN Pipobroman DMNL0E6 TI TTUTN1I DMNL0E6 TN Human Deoxyribonucleic acid (hDNA) DMNL0E6 MA Binder DMNL0E6 RN Effects of piposulfan (Ancyte) on protein and DNA synthesis in Ehrlich ascites carcinoma. Life Sci II. 1971 Jun 8;10(11):605-12. DMNL0E6 RU https://pubmed.ncbi.nlm.nih.gov/5556760 DMNL98G DI DMNL98G DMNL98G DN Meclofenamate sodium DMNL98G TI TT8NGED DMNL98G TN Prostaglandin G/H synthase 1 (COX-1) DMNL98G MA Modulator DMNL98G RN Role of COX-2-derived metabolites in regulation of the renal hemodynamic response to norepinephrine. Am J Physiol Renal Physiol. 2001 Nov;281(5):F975-82. DMNL98G RU https://www.ncbi.nlm.nih.gov/pubmed/11592955 DMNL98G DI DMNL98G DMNL98G DN Meclofenamate sodium DMNL98G TI TTVKILB DMNL98G TN Prostaglandin G/H synthase 2 (COX-2) DMNL98G MA Modulator DMNL98G RN Role of COX-2-derived metabolites in regulation of the renal hemodynamic response to norepinephrine. Am J Physiol Renal Physiol. 2001 Nov;281(5):F975-82. DMNL98G RU https://www.ncbi.nlm.nih.gov/pubmed/11592955 DMNLHAC DI DMNLHAC DMNLHAC DN Allopregnanolone DMNLHAC TI TTZA1NY DMNLHAC TN GABA(A) receptor beta-2 (GABRB2) DMNLHAC MA Inhibitor DMNLHAC RN Neurosteroid analogues. 10. The effect of methyl group substitution at the C-6 and C-7 positions on the GABA modulatory and anesthetic actions of (... J Med Chem. 2005 Apr 21;48(8):3051-9. DMNLHAC RU https://pubmed.ncbi.nlm.nih.gov/15828844 DMNLHAC DI DMNLHAC DMNLHAC DN Allopregnanolone DMNLHAC TI TTNJYV2 DMNLHAC TN Gamma-aminobutyric acid receptor (GAR) DMNLHAC MA Inhibitor DMNLHAC RN Neurosteroid analogues. 11. Alternative ring system scaffolds: gamma-aminobutyric acid receptor modulation and anesthetic actions of benz[f]indenes. J Med Chem. 2006 Jul 27;49(15):4595-605. DMNLHAC RU https://pubmed.ncbi.nlm.nih.gov/16854065 DMNLHAC DI DMNLHAC DMNLHAC DN Allopregnanolone DMNLHAC TI TT06RH5 DMNLHAC TN GABA(A) receptor gamma-2 (GABRG2) DMNLHAC MA Inhibitor DMNLHAC RN Neurosteroid analogues. 10. The effect of methyl group substitution at the C-6 and C-7 positions on the GABA modulatory and anesthetic actions of (... J Med Chem. 2005 Apr 21;48(8):3051-9. DMNLHAC RU https://pubmed.ncbi.nlm.nih.gov/15828844 DMNLHAC DI DMNLHAC DMNLHAC DN Allopregnanolone DMNLHAC TI TT1MPAY DMNLHAC TN GABA(A) receptor alpha-1 (GABRA1) DMNLHAC MA Inhibitor DMNLHAC RN Neurosteroid analogues. 10. The effect of methyl group substitution at the C-6 and C-7 positions on the GABA modulatory and anesthetic actions of (... J Med Chem. 2005 Apr 21;48(8):3051-9. DMNLHAC RU https://pubmed.ncbi.nlm.nih.gov/15828844 DMNLHAC DI DMNLHAC DMNLHAC DN Allopregnanolone DMNLHAC TI TTGXH6N DMNLHAC TN GABA(A) receptor delta (GABRD) DMNLHAC MA Inhibitor DMNLHAC RN Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357. DMNLHAC RU https://pubmed.ncbi.nlm.nih.gov/30728472 DMNLHAC DI DMNLHAC DMNLHAC DN Allopregnanolone DMNLHAC TI TTEX6LM DMNLHAC TN GABA(A) receptor gamma-3 (GABRG3) DMNLHAC MA Modulator DMNLHAC RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMNLHAC RU http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf DMNMHBV DI DMNMHBV DMNMHBV DN Penicillin DMNMHBV TI TTJP4SM DMNMHBV TN Bacterial Penicillin binding protein (Bact PBP) DMNMHBV MA Modulator DMNMHBV RN Bacterial Resistance to Penicillin G by Decreased Affinity of Penicillin-Binding Proteins: A Mathematical Model DMNMHBV RU https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2957969 DMNMW9R DI DMNMW9R DMNMW9R DN Pramipexole DMNMW9R TI TT4C8EA DMNMW9R TN Dopamine D3 receptor (D3R) DMNMW9R MA Modulator DMNMW9R RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMNMW9R RU https://www.fda.gov/ DMNMW9R DI DMNMW9R DMNMW9R DN Pramipexole DMNMW9R TI TTEX248 DMNMW9R TN Dopamine D2 receptor (D2R) DMNMW9R MA Modulator DMNMW9R RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMNMW9R RU https://www.fda.gov/ DMNMXR8 DI DMNMXR8 DMNMXR8 DN Procainamide DMNMXR8 TI TT05DLS DMNMXR8 TN E3 ubiquitin-protein ligase COP1 (RFWD2) DMNMXR8 MA Modulator DMNMXR8 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMNMXR8 RU https://www.fda.gov/ DMNO38U DI DMNO38U DMNO38U DN Bortezomib DMNO38U TI TT5L2VC DMNO38U TN Kallikrein-related peptidase (KLK) DMNO38U MA Inhibitor DMNO38U RN Characterization of a class of peptide boronates with neutral P1 side chains as highly selective inhibitors of thrombin. J Med Chem. 1995 Apr 28;38(9):1511-22. DMNO38U RU https://pubmed.ncbi.nlm.nih.gov/7739010 DMNO38U DI DMNO38U DMNO38U DN Bortezomib DMNO38U TI TT2WR1T DMNO38U TN Cationic trypsinogen (PRSS1) DMNO38U MA Inhibitor DMNO38U RN Characterization of a class of peptide boronates with neutral P1 side chains as highly selective inhibitors of thrombin. J Med Chem. 1995 Apr 28;38(9):1511-22. DMNO38U RU https://pubmed.ncbi.nlm.nih.gov/7739010 DMNO38U DI DMNO38U DMNO38U DN Bortezomib DMNO38U TI TTU7ZMG DMNO38U TN Proteasome (PS) DMNO38U MA Modulator DMNO38U RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMNO38U RU https://www.fda.gov/ DMNOBFQ DI DMNOBFQ DMNOBFQ DN Mebeverine DMNOBFQ TI TTH18TF DMNOBFQ TN Muscarinic acetylcholine receptor M5 (CHRM5) DMNOBFQ MA Antagonist DMNOBFQ RN Emerging drugs for irritable bowel syndrome. Expert Opin Emerg Drugs. 2006 May;11(2):293-313. DMNOBFQ RU https://pubmed.ncbi.nlm.nih.gov/16634703 DMNOKBV DI DMNOKBV DMNOKBV DN Phenytoin DMNOKBV TI TTRK8B9 DMNOKBV TN Sodium channel unspecific (NaC) DMNOKBV MA Blocker DMNOKBV RN Lacosamide: a new approach to target voltage-gated sodium currents in epileptic disorders. CNS Drugs. 2009;23(7):555-68. DMNOKBV RU https://pubmed.ncbi.nlm.nih.gov/19552484 DMNOSWU DI DMNOSWU DMNOSWU DN Anisodine DMNOSWU TI TTR6W5O DMNOSWU TN Adrenergic receptor beta-1 (ADRB1) DMNOSWU MA Modulator DMNOSWU RN Medicinal plants in therapy. Bull World Health Organ. 1985;63(6):965-81. DMNOSWU RU https://pubmed.ncbi.nlm.nih.gov/3879679 DMNOSWU DI DMNOSWU DMNOSWU DN Anisodine DMNOSWU TI TTH18TF DMNOSWU TN Muscarinic acetylcholine receptor M5 (CHRM5) DMNOSWU MA Modulator DMNOSWU RN Medicinal plants in therapy. Bull World Health Organ. 1985;63(6):965-81. DMNOSWU RU https://pubmed.ncbi.nlm.nih.gov/3879679 DMNP60F DI DMNP60F DMNP60F DN Anastrozole DMNP60F TI TTSZLWK DMNP60F TN Aromatase (CYP19A1) DMNP60F MA Inhibitor DMNP60F RN Effective aromatase inhibition by anastrozole in a patient with gonadotropin-independent precocious puberty in McCune-Albright syndrome. J Pediatr Endocrinol Metab. 2002;15 Suppl 3:945-8. DMNP60F RU https://pubmed.ncbi.nlm.nih.gov/12199354 DMNPZL4 DI DMNPZL4 DMNPZL4 DN Dacarbazine DMNPZL4 TI TTUTN1I DMNPZL4 TN Human Deoxyribonucleic acid (hDNA) DMNPZL4 MA Breaker DMNPZL4 RN Predicting the myelotoxicity of chemotherapy: the use of pretreatment O6-methylguanine-DNA methyltransferase determination in peripheral blood mono... Melanoma Res. 2011 Dec;21(6):502-8. DMNPZL4 RU https://pubmed.ncbi.nlm.nih.gov/19561552 DMNQXV8 DI DMNQXV8 DMNQXV8 DN LGX818 DMNQXV8 TI TTWCGQT DMNQXV8 TN Serine/threonine-protein kinase B-raf (BRAF) DMNQXV8 MA Modulator DMNQXV8 RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMNQXV8 RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMNSJ7V DI DMNSJ7V DMNSJ7V DN Tropisetron DMNSJ7V TI TTPC4TU DMNSJ7V TN 5-HT 3A receptor (HTR3A) DMNSJ7V MA Antagonist DMNSJ7V RN Emerging therapies for fibromyalgia. Expert Opin Emerg Drugs. 2008 Mar;13(1):53-62. DMNSJ7V RU https://pubmed.ncbi.nlm.nih.gov/18321148 DMNUC42 DI DMNUC42 DMNUC42 DN Sulodexide DMNUC42 TI TT4QPUL DMNUC42 TN Antithrombin-III (ATIII) DMNUC42 MA Activator DMNUC42 RN Review of pharmacodynamics, pharmacokinetics, and therapeutic properties of sulodexide. Med Res Rev. 1998 Jan;18(1):1-20. DMNUC42 RU https://pubmed.ncbi.nlm.nih.gov/9436179 DMNUWST DI DMNUWST DMNUWST DN Flucloxacillin DMNUWST TI TTJP4SM DMNUWST TN Bacterial Penicillin binding protein (Bact PBP) DMNUWST MA Binder DMNUWST RN Mechanisms of resistance to beta-lactam antibiotics in Staphylococcus aureus. Scand J Infect Dis Suppl. 1984;42:64-71. DMNUWST RU https://pubmed.ncbi.nlm.nih.gov/6335600 DMNVKU6 DI DMNVKU6 DMNVKU6 DN Crisaborole DMNVKU6 TI TTV5CGO DMNVKU6 TN Phosphodiesterase 4 (PDE4) DMNVKU6 MA Modulator DMNVKU6 RN 2016 FDA drug approvals. Nat Rev Drug Discov. 2017 Feb 2;16(2):73-76. DMNVKU6 RU https://www.ncbi.nlm.nih.gov/pubmed/28148938 DMNWZJG DI DMNWZJG DMNWZJG DN Leucovorin Calcium DMNWZJG TI TTYZVDJ DMNWZJG TN Dihydrofolate reductase (DHFR) DMNWZJG MA Modulator DMNWZJG RN Biochemical factors in the selectivity of leucovorin rescue: selective inhibition of leucovorin reactivation of dihydrofolate reductase and leucovorin utilization in purine and pyrimidine biosynthesis by methotrexate and dihydrofolate polyglutamates.NCI Monogr.1987;(5):17-26. DMNWZJG RU https://www.ncbi.nlm.nih.gov/pubmed/2448654 DMNXY5K DI DMNXY5K DMNXY5K DN Peramivir DMNXY5K TI TT50QJ3 DMNXY5K TN Influenza Neuraminidase (Influ NA) DMNXY5K MA Inhibitor DMNXY5K RN Developing new antiviral agents for influenza treatment: what does the future hold Clin Infect Dis. 2009 Jan 1;48 Suppl 1:S3-13. DMNXY5K RU https://pubmed.ncbi.nlm.nih.gov/19067613 DMNYOIX DI DMNYOIX DMNYOIX DN Olaratumab DMNYOIX TI TT8FYO9 DMNYOIX TN Platelet-derived growth factor receptor alpha (PDGFRA) DMNYOIX MA Modulator DMNYOIX RN A phase I study of olaratumab, an anti-platelet-derived growth factor receptor alpha (PDGFRalpha) monoclonal antibody, in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2014 Mar;73(3):595-604. DMNYOIX RU https://pubmed.ncbi.nlm.nih.gov/24452395 DMNYPGS DI DMNYPGS DMNYPGS DN Tioconazole DMNYPGS TI TTTSOUD DMNYPGS TN Candida Cytochrome P450 51 (Candi ERG11) DMNYPGS MA Inhibitor DMNYPGS RN Biological spectra analysis: Linking biological activity profiles to molecular structure. Proc Natl Acad Sci U S A. 2005 Jan 11;102(2):261-6. DMNYPGS RU https://pubmed.ncbi.nlm.nih.gov/15625110 DMNZBRY DI DMNZBRY DMNZBRY DN Capreomycin DMNZBRY TI TTIA0J5 DMNZBRY TN Bacterial 70S ribosomal RNA (Bact 70S rRNA) DMNZBRY MA Binder DMNZBRY RN Interaction between the ribosomal subunits: 16S rRNA suppressors of the lethal DeltaA1916 mutation in the 23S rRNA of Escherichia coli. Mol Genet Genomics. 2007 Sep;278(3):307-15. DMNZBRY RU https://pubmed.ncbi.nlm.nih.gov/17564727 DMNZCI1 DI DMNZCI1 DMNZCI1 DN YM443 DMNZCI1 TI TT1RS9F DMNZCI1 TN Acetylcholinesterase (AChE) DMNZCI1 MA Modulator DMNZCI1 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DMNZCI1 RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DMNZSC1 DI DMNZSC1 DMNZSC1 DN Candicidin DMNZSC1 TI TTQKWA4 DMNZSC1 TN Fungal Cell membrane ergosterol (Fung CME) DMNZSC1 MA Modulator DMNZSC1 RN Mode of Action of the Polyene Antibiotic Candicidin: Binding Factors in the Wall of Candida albicans DMNZSC1 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC429577 DMNZWL7 DI DMNZWL7 DMNZWL7 DN Moclobemide DMNZWL7 TI TT3WG5C DMNZWL7 TN Monoamine oxidase type A (MAO-A) DMNZWL7 MA Inhibitor DMNZWL7 RN Efficacy of citalopram and moclobemide in patients with social phobia: some preliminary findings. Hum Psychopharmacol. 2002 Dec;17(8):401-5. DMNZWL7 RU https://pubmed.ncbi.nlm.nih.gov/12457375 DMNZWL7 DI DMNZWL7 DMNZWL7 DN Moclobemide DMNZWL7 TI TT32XQJ DMNZWL7 TN Monoamine oxidase (MAO) DMNZWL7 MA Inhibitor DMNZWL7 RN Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110. DMNZWL7 RU https://www.ncbi.nlm.nih.gov/pubmed/25399762 DMO091F DI DMO091F DMO091F DN Balsalazide DMO091F TI TT8NGED DMO091F TN Prostaglandin G/H synthase 1 (COX-1) DMO091F MA Inhibitor DMO091F RN Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. DMO091F RU https://pubmed.ncbi.nlm.nih.gov/17016423 DMO14SG DI DMO14SG DMO14SG DN Mebendazole DMO14SG TI TTYFKSZ DMO14SG TN Tubulin beta (TUBB) DMO14SG MA Binder DMO14SG RN Flubendazole interferes with a wide spectrum of cell homeostatic mechanisms in Echinococcus granulosus protoscoleces. Parasitol Int. 2009 Sep;58(3):270-7. DMO14SG RU https://pubmed.ncbi.nlm.nih.gov/19336257 DMO2K0J DI DMO2K0J DMO2K0J DN Pyridoxal Phosphate DMO2K0J TI TTT2LD9 DMO2K0J TN GABA transaminase (ABAT) DMO2K0J MA Inhibitor DMO2K0J RN DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6. DMO2K0J RU https://pubmed.ncbi.nlm.nih.gov/18048412 DMO2K0J DI DMO2K0J DMO2K0J DN Pyridoxal Phosphate DMO2K0J TI TT6L509 DMO2K0J TN Coagulation factor IIa (F2) DMO2K0J MA Inhibitor DMO2K0J RN New antithrombotic drugs (excluding plasminogen activators. Arch Mal Coeur Vaiss. 2001 Nov;94(11 Suppl):1225-32. DMO2K0J RU https://pubmed.ncbi.nlm.nih.gov/11794963 DMO381I DI DMO381I DMO381I DN Acamprosate DMO381I TI TTAN6JD DMO381I TN Glutamate receptor AMPA (GRIA) DMO381I MA Agonist DMO381I RN Predicting the effect of naltrexone and acamprosate in alcohol-dependent patients using genetic indicators. Addict Biol. 2009 Jul;14(3):328-37. DMO381I RU https://pubmed.ncbi.nlm.nih.gov/19523047 DMO4PVE DI DMO4PVE DMO4PVE DN Apraclonidine DMO4PVE TI TTQ8AFT DMO4PVE TN Adrenergic receptor Alpha-2 (ADRA2) DMO4PVE MA Agonist DMO4PVE RN Apraclonidine attenuates the increases in spinal excitatory amino acid release in rats with adjuvant-induced inflammation. Anesth Analg. 2002 Mar;94(3):701-5; table of contents. DMO4PVE RU https://pubmed.ncbi.nlm.nih.gov/11867401 DMO50U2 DI DMO50U2 DMO50U2 DN Naratriptan DMO50U2 TI TTK8CXU DMO50U2 TN 5-HT 1B receptor (HTR1B) DMO50U2 MA Agonist DMO50U2 RN Triptans in pregnancy. Ther Drug Monit. 2008 Feb;30(1):5-9. DMO50U2 RU https://pubmed.ncbi.nlm.nih.gov/18223456 DMO5SZX DI DMO5SZX DMO5SZX DN Diphenoxylate DMO5SZX TI TTKWM86 DMO5SZX TN Opioid receptor mu (MOP) DMO5SZX MA Agonist DMO5SZX RN Loperamide: a pharmacological review. Rev Gastroenterol Disord. 2007;7 Suppl 3:S11-8. DMO5SZX RU https://pubmed.ncbi.nlm.nih.gov/18192961 DMO6315 DI DMO6315 DMO6315 DN Vonoprazan DMO6315 TI TTLOKXP DMO6315 TN Gastric H(+)/K(+) ATPase (Proton pump) DMO6315 MA Modulator DMO6315 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2008 DMO6315 RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/020973s022lbl.pdf DMO946V DI DMO946V DMO946V DN Ticlopidine DMO946V TI TTQL5VC DMO946V TN Platelet-activating factor receptor (PTAFR) DMO946V MA Modulator DMO946V RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMO946V RU https://www.fda.gov/ DMO95XI DI DMO95XI DMO95XI DN Insulin, porcine DMO95XI TI TTCBFJO DMO95XI TN Insulin receptor (INSR) DMO95XI MA Binder DMO95XI RN Acidic residues on the N-terminus of proinsulin C-Peptide are important for the folding of insulin precursor. J Biochem. 2002 Jun;131(6):855-9. DMO95XI RU https://pubmed.ncbi.nlm.nih.gov/12038982 DMO9WDS DI DMO9WDS DMO9WDS DN Altropane DMO9WDS TI TTVBI8W DMO9WDS TN Dopamine transporter (DAT) DMO9WDS MA Inhibitor DMO9WDS RN Rapid detection of Parkinson's disease by SPECT with altropane: a selective ligand for dopamine transporters. Synapse. 1998 Jun;29(2):128-41. DMO9WDS RU https://pubmed.ncbi.nlm.nih.gov/9593103 DMOA4VW DI DMOA4VW DMOA4VW DN Insulin-detemir DMOA4VW TI TTZOPHG DMOA4VW TN Insulin (INS) DMOA4VW MA Modulator DMOA4VW RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMOA4VW RU https://www.fda.gov/ DMOAD2Y DI DMOAD2Y DMOAD2Y DN Dupilumab DMOAD2Y TI TTDWHC3 DMOAD2Y TN Interleukin 4 receptor alpha (IL4R) DMOAD2Y RN Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med. 2013 Jun 27;368(26):2455-66. DMOAD2Y RU https://pubmed.ncbi.nlm.nih.gov/23688323 DMOB2F3 DI DMOB2F3 DMOB2F3 DN Heptabarbital DMOB2F3 TI TTAN6JD DMOB2F3 TN Glutamate receptor AMPA (GRIA) DMOB2F3 MA Antagonist DMOB2F3 RN A computer program using disposition decomposition analysis in pharmacodynamics. Biopharm Drug Dispos. 1997 Jan;18(1):9-15. DMOB2F3 RU https://pubmed.ncbi.nlm.nih.gov/9008265 DMOB58Q DI DMOB58Q DMOB58Q DN MK-8228 DMOB58Q TI TTOGPL1 DMOB58Q TN Cytomegalovirus Terminase UL56 (CMV TRM1) DMOB58Q MA Inhibitor DMOB58Q RN The novel anticytomegalovirus compound AIC246 (Letermovir) inhibits human cytomegalovirus replication through a specific antiviral mechanism that involves the viral terminase. J Virol. 2011 Oct;85(20):10884-93. DMOB58Q RU https://pubmed.ncbi.nlm.nih.gov/21752907 DMOB58Q DI DMOB58Q DMOB58Q DN MK-8228 DMOB58Q TI TTZHSBO DMOB58Q TN Cytomegalovirus Terminase (CMV TRM) DMOB58Q MA Inhibitor DMOB58Q RN 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85. DMOB58Q RU https://pubmed.ncbi.nlm.nih.gov/29348678 DMOBIKY DI DMOBIKY DMOBIKY DN Bexarotene DMOBIKY TI TT6PEUO DMOBIKY TN Retinoic acid receptor RXR-alpha (RXRA) DMOBIKY MA Modulator DMOBIKY RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMOBIKY RU https://www.fda.gov/ DMOBLGK DI DMOBLGK DMOBLGK DN Tromethamine DMOBLGK TI TTBFROQ DMOBLGK TN S-adenosylmethionine decarboxylase proenzyme (AMD1) DMOBLGK MA Inhibitor DMOBLGK RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMOBLGK RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMODHQI DI DMODHQI DMODHQI DN Budipine DMODHQI TI TTGP7BY DMODHQI TN Monoamine oxidase type B (MAO-B) DMODHQI MA Modulator DMODHQI RN Multiple mechanisms of action: the pharmacological profile of budipine. J Neural Transm Suppl. 1999;56:83-105. DMODHQI RU https://pubmed.ncbi.nlm.nih.gov/10370904 DMODJ40 DI DMODJ40 DMODJ40 DN Ethinyl estradiol DMODJ40 TI TTZAYWL DMODJ40 TN Estrogen receptor (ESR) DMODJ40 MA Agonist DMODJ40 RN 17alpha-Ethinylestradiol hinders nucleotide excision repair in zebrafish liver cells. Aquat Toxicol. 2009 Dec 13;95(4):273-8. DMODJ40 RU https://pubmed.ncbi.nlm.nih.gov/19237207 DMOEM2I DI DMOEM2I DMOEM2I DN Estriol DMOEM2I TI TTZAYWL DMOEM2I TN Estrogen receptor (ESR) DMOEM2I MA Agonist DMOEM2I RN Reprint of Are all estrogens the same Maturitas. 2008 Sep-Oct;61(1-2):195-201. DMOEM2I RU https://pubmed.ncbi.nlm.nih.gov/19434891 DMOERGM DI DMOERGM DMOERGM DN Abaloparatide DMOERGM TI TTFPD47 DMOERGM TN Parathyroid hormone 1 receptor (PTH1R) DMOERGM MA Modulator DMOERGM RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMOERGM RU https://www.fda.gov/ DMOF2C6 DI DMOF2C6 DMOF2C6 DN Ecallantide DMOF2C6 TI TT5L2VC DMOF2C6 TN Kallikrein-related peptidase (KLK) DMOF2C6 MA Inhibitor DMOF2C6 RN Ecallantide (DX-88), a plasma kallikrein inhibitor for the treatment of hereditary angioedema and the prevention of blood loss in on-pump cardiothoracic surgery. Expert Opin Biol Ther. 2008 Aug;8(8):1187-99. DMOF2C6 RU https://pubmed.ncbi.nlm.nih.gov/18613770 DMOF2C6 DI DMOF2C6 DMOF2C6 DN Ecallantide DMOF2C6 TI TTMF8H9 DMOF2C6 TN Plasma kallikrein (KLKB1) DMOF2C6 MA Inhibitor DMOF2C6 RN Ecallantide (DX-88), a plasma kallikrein inhibitor for the treatment of hereditary angioedema and the prevention of blood loss in on-pump cardiothoracic surgery. Expert Opin Biol Ther. 2008 Aug;8(8):1187-99. DMOF2C6 RU https://pubmed.ncbi.nlm.nih.gov/18613770 DMOF7AT DI DMOF7AT DMOF7AT DN Streptozocin DMOF7AT TI TTUTN1I DMOF7AT TN Human Deoxyribonucleic acid (hDNA) DMOF7AT MA Breaker DMOF7AT RN Hydrodynamics-based transfection of pancreatic duodenal homeobox 1 DNA improves hyperglycemia and is associated with limited complications in diabe... Endocr J. 2009;56(6):783-90. DMOF7AT RU https://pubmed.ncbi.nlm.nih.gov/19561381 DMOFP18 DI DMOFP18 DMOFP18 DN Ryzodeq DMOFP18 TI TTCBFJO DMOFP18 TN Insulin receptor (INSR) DMOFP18 MA Modulator DMOFP18 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1800). DMOFP18 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1800 DMOGFIX DI DMOGFIX DMOGFIX DN Eltrombopag DMOGFIX TI TTIHYA4 DMOGFIX TN Thrombopoietin receptor (MPL) DMOGFIX MA Agonist DMOGFIX RN Emerging drugs for idiopathic thrombocytopenic purpura in adults. Expert Opin Emerg Drugs. 2008 Jun;13(2):237-54. DMOGFIX RU https://pubmed.ncbi.nlm.nih.gov/18537519 DMOGNXY DI DMOGNXY DMOGNXY DN Sarilumab DMOGNXY TI TT0E5SK DMOGNXY TN Interleukin 6 receptor (IL6R) DMOGNXY MA Modulator DMOGNXY RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMOGNXY RU https://www.fda.gov/ DMOGREH DI DMOGREH DMOGREH DN Suplatast tosilate DMOGREH TI TTGPK5Y DMOGREH TN T(H2) cytokine production (TH2 produ) DMOGREH MA Modulator DMOGREH RN Suplatast tosilate inhibits goblet-cell metaplasia of airway epithelium in sensitized mice. J Allergy Clin Immunol. 2000 Apr;105(4):739-45. DMOGREH RU https://pubmed.ncbi.nlm.nih.gov/10756224 DMOH8VY DI DMOH8VY DMOH8VY DN Dacomitinib DMOH8VY TI TT0JESD DMOH8VY TN Erbb4 tyrosine kinase receptor (Erbb-4) DMOH8VY MA Antagonist DMOH8VY RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7422). DMOH8VY RU http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7422 DMOH8VY DI DMOH8VY DMOH8VY DN Dacomitinib DMOH8VY TI TT6EO5L DMOH8VY TN Erbb2 tyrosine kinase receptor (HER2) DMOH8VY MA Antagonist DMOH8VY RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7422). DMOH8VY RU http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7422 DMOH8VY DI DMOH8VY DMOH8VY DN Dacomitinib DMOH8VY TI TTGKNB4 DMOH8VY TN Epidermal growth factor receptor (EGFR) DMOH8VY MA Antagonist DMOH8VY RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1797). DMOH8VY RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1797 DMOHK1E DI DMOHK1E DMOHK1E DN Docosanol DMOHK1E TI TT1JL7D DMOHK1E TN Epstein-Barr virus Envelope glycoprotein gp340 (EBV BLLF1) DMOHK1E MA Modulator DMOHK1E RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMOHK1E RU https://www.fda.gov/ DMOHS9P DI DMOHS9P DMOHS9P DN Phenacemide DMOHS9P TI TTRK8B9 DMOHS9P TN Sodium channel unspecific (NaC) DMOHS9P MA Blocker DMOHS9P RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMOHS9P RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMOI1ZF DI DMOI1ZF DMOI1ZF DN Choline alfoscerate DMOI1ZF TI TTH18TF DMOI1ZF TN Muscarinic acetylcholine receptor M5 (CHRM5) DMOI1ZF MA Modulator DMOI1ZF RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 467). DMOI1ZF RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=467 DMOIFW0 DI DMOIFW0 DMOIFW0 DN Aniracetam DMOIFW0 TI TTEX248 DMOIFW0 TN Dopamine D2 receptor (D2R) DMOIFW0 MA Inhibitor DMOIFW0 RN Anxiolytic effects of aniracetam in three different mouse models of anxiety and the underlying mechanism. Eur J Pharmacol. 2001 May 18;420(1):33-43. DMOIFW0 RU https://pubmed.ncbi.nlm.nih.gov/11412837 DMOIFW0 DI DMOIFW0 DMOIFW0 DN Aniracetam DMOIFW0 TI TTJQOD7 DMOIFW0 TN 5-HT 2A receptor (HTR2A) DMOIFW0 MA Inhibitor DMOIFW0 RN Anxiolytic effects of aniracetam in three different mouse models of anxiety and the underlying mechanism. Eur J Pharmacol. 2001 May 18;420(1):33-43. DMOIFW0 RU https://pubmed.ncbi.nlm.nih.gov/11412837 DMOIX5S DI DMOIX5S DMOIX5S DN Azilsartan DMOIX5S TI TT8DBY3 DMOIX5S TN Angiotensin II receptor type-1 (AGTR1) DMOIX5S MA Modulator DMOIX5S RN 2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4. DMOIX5S RU https://pubmed.ncbi.nlm.nih.gov/22293555 DMOJ0V6 DI DMOJ0V6 DMOJ0V6 DN Metoprolol DMOJ0V6 TI TTR6W5O DMOJ0V6 TN Adrenergic receptor beta-1 (ADRB1) DMOJ0V6 MA Antagonist DMOJ0V6 RN Prediction and experimental validation of acute toxicity of beta-blockers in Ceriodaphnia dubia. Environ Toxicol Chem. 2005 Oct;24(10):2470-6. DMOJ0V6 RU https://pubmed.ncbi.nlm.nih.gov/16268148 DMOJ4ZI DI DMOJ4ZI DMOJ4ZI DN Butenafine DMOJ4ZI TI TTM9XSU DMOJ4ZI TN Candida Squalene epoxidase (Candi ERG1) DMOJ4ZI MA Modulator DMOJ4ZI RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMOJ4ZI RU https://www.fda.gov/ DMOJZQ9 DI DMOJZQ9 DMOJZQ9 DN Loperamide DMOJZQ9 TI TT27RFC DMOJZQ9 TN Opioid receptor delta (OPRD1) DMOJZQ9 MA Binder DMOJZQ9 RN Loperamide: evidence of interaction with mu and delta opioid receptors. Life Sci. 1983;33 Suppl 1:315-8. DMOJZQ9 RU https://pubmed.ncbi.nlm.nih.gov/6319884 DMOK965 DI DMOK965 DMOK965 DN Prulifloxacin DMOK965 TI TTFK8YB DMOK965 TN Bacterial DNA topoisomerase 4A (Bact parC) DMOK965 MA Inhibitor DMOK965 RN Prulifloxacin: a new antibacterial fluoroquinolone. Expert Rev Anti Infect Ther. 2006 Feb;4(1):27-41. DMOK965 RU https://pubmed.ncbi.nlm.nih.gov/16441207 DMOK965 DI DMOK965 DMOK965 DN Prulifloxacin DMOK965 TI TTN6J5F DMOK965 TN Bacterial DNA gyrase (Bact gyrase) DMOK965 MA Inhibitor DMOK965 RN Prulifloxacin: a new antibacterial fluoroquinolone. Expert Rev Anti Infect Ther. 2006 Feb;4(1):27-41. DMOK965 RU https://pubmed.ncbi.nlm.nih.gov/16441207 DMOKCVI DI DMOKCVI DMOKCVI DN ARZOXIFENE DMOKCVI TI TTZAYWL DMOKCVI TN Estrogen receptor (ESR) DMOKCVI MA Inhibitor DMOKCVI RN Benzothiophene selective estrogen receptor modulators with modulated oxidative activity and receptor affinity. J Med Chem. 2007 May 31;50(11):2682-92. DMOKCVI RU https://pubmed.ncbi.nlm.nih.gov/17489582 DMOKCVI DI DMOKCVI DMOKCVI DN ARZOXIFENE DMOKCVI TI TTOM3J0 DMOKCVI TN Estrogen receptor beta (ESR2) DMOKCVI MA Inhibitor DMOKCVI RN Benzothiophene selective estrogen receptor modulators with modulated oxidative activity and receptor affinity. J Med Chem. 2007 May 31;50(11):2682-92. DMOKCVI RU https://pubmed.ncbi.nlm.nih.gov/17489582 DMOL54H DI DMOL54H DMOL54H DN Clopidogrel DMOL54H TI TTZ1DT0 DMOL54H TN P2Y purinoceptor 12 (P2RY12) DMOL54H MA Antagonist DMOL54H RN P2Y12, a new platelet ADP receptor, target of clopidogrel. Semin Vasc Med. 2003 May;3(2):113-22. DMOL54H RU https://pubmed.ncbi.nlm.nih.gov/15199474 DMOL5IU DI DMOL5IU DMOL5IU DN Mesalazine DMOL5IU TI TT8NGED DMOL5IU TN Prostaglandin G/H synthase 1 (COX-1) DMOL5IU MA Inhibitor DMOL5IU RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMOL5IU RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMOL793 DI DMOL793 DMOL793 DN Trifarotene DMOL793 TI TT1Q3IE DMOL793 TN Retinoic acid receptor gamma (RARG) DMOL793 MA Agonist DMOL793 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019 DMOL793 RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211527s000lbl.pdf DMOLNCZ DI DMOLNCZ DMOLNCZ DN ACECLIDINE DMOLNCZ TI TTH18TF DMOLNCZ TN Muscarinic acetylcholine receptor M5 (CHRM5) DMOLNCZ MA Inhibitor DMOLNCZ RN Design, synthesis, and neurochemical evaluation of 5-(3-alkyl-1,2,4- oxadiazol-5-yl)-1,4,5,6-tetrahydropyrimidines as M1 muscarinic receptor agonists. J Med Chem. 1993 Apr 2;36(7):842-7. DMOLNCZ RU https://pubmed.ncbi.nlm.nih.gov/8464038 DMOLNCZ DI DMOLNCZ DMOLNCZ DN ACECLIDINE DMOLNCZ TI TTQ3JTF DMOLNCZ TN Muscarinic acetylcholine receptor M4 (CHRM4) DMOLNCZ MA Inhibitor DMOLNCZ RN Design, synthesis, and neurochemical evaluation of 5-(3-alkyl-1,2,4- oxadiazol-5-yl)-1,4,5,6-tetrahydropyrimidines as M1 muscarinic receptor agonists. J Med Chem. 1993 Apr 2;36(7):842-7. DMOLNCZ RU https://pubmed.ncbi.nlm.nih.gov/8464038 DMOLNCZ DI DMOLNCZ DMOLNCZ DN ACECLIDINE DMOLNCZ TI TTQ13Z5 DMOLNCZ TN Muscarinic acetylcholine receptor M3 (CHRM3) DMOLNCZ MA Inhibitor DMOLNCZ RN Design, synthesis, and neurochemical evaluation of 5-(3-alkyl-1,2,4- oxadiazol-5-yl)-1,4,5,6-tetrahydropyrimidines as M1 muscarinic receptor agonists. J Med Chem. 1993 Apr 2;36(7):842-7. DMOLNCZ RU https://pubmed.ncbi.nlm.nih.gov/8464038 DMOLNCZ DI DMOLNCZ DMOLNCZ DN ACECLIDINE DMOLNCZ TI TTZ9SOR DMOLNCZ TN Muscarinic acetylcholine receptor M1 (CHRM1) DMOLNCZ MA Inhibitor DMOLNCZ RN Design, synthesis, and neurochemical evaluation of 5-(3-alkyl-1,2,4- oxadiazol-5-yl)-1,4,5,6-tetrahydropyrimidines as M1 muscarinic receptor agonists. J Med Chem. 1993 Apr 2;36(7):842-7. DMOLNCZ RU https://pubmed.ncbi.nlm.nih.gov/8464038 DMOLNCZ DI DMOLNCZ DMOLNCZ DN ACECLIDINE DMOLNCZ TI TTYEG6Q DMOLNCZ TN Muscarinic acetylcholine receptor M2 (CHRM2) DMOLNCZ MA Inhibitor DMOLNCZ RN Design, synthesis, and neurochemical evaluation of 5-(3-alkyl-1,2,4- oxadiazol-5-yl)-1,4,5,6-tetrahydropyrimidines as M1 muscarinic receptor agonists. J Med Chem. 1993 Apr 2;36(7):842-7. DMOLNCZ RU https://pubmed.ncbi.nlm.nih.gov/8464038 DMOLNHF DI DMOLNHF DMOLNHF DN Melphalan DMOLNHF TI TTUTN1I DMOLNHF TN Human Deoxyribonucleic acid (hDNA) DMOLNHF MA Modulator DMOLNHF RN Alkylation of DNA by melphalan in relation to immunoassay of melphalan-DNA adducts: characterization of mono-alkylated and cross-linked products fr... Chem Biol Interact. 1990;73(2-3):183-94. DMOLNHF RU https://www.ncbi.nlm.nih.gov/pubmed/2155711 DMOM8AL DI DMOM8AL DMOM8AL DN Scopolamine DMOM8AL TI TTOXS3C DMOM8AL TN Muscarinic acetylcholine receptor (CHRM) DMOM8AL MA Antagonist DMOM8AL RN The amygdala modulates morphine-induced state-dependent memory retrieval via muscarinic acetylcholine receptors. Neuroscience. 2009 May 5;160(2):255-63. DMOM8AL RU https://pubmed.ncbi.nlm.nih.gov/19272427 DMOMBJW DI DMOMBJW DMOMBJW DN Moricizine DMOMBJW TI TTZOVE0 DMOMBJW TN Voltage-gated sodium channel alpha Nav1.5 (SCN5A) DMOMBJW MA Blocker DMOMBJW RN From first class to third class: recent upheaval in antiarrhythmic therapy--lessons from clinical trials. Am J Cardiol. 1996 Aug 29;78(4A):28-33. DMOMBJW RU https://pubmed.ncbi.nlm.nih.gov/8780326 DMOMK1V DI DMOMK1V DMOMK1V DN Halofantrine DMOMK1V TI TTV3NH6 DMOMK1V TN Calmodulin (CALM) DMOMK1V MA Modulator DMOMK1V RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMOMK1V RU https://www.fda.gov/ DMOMLHJ DI DMOMLHJ DMOMLHJ DN Lymecycline DMOMLHJ TI TTQ8KVI DMOMLHJ TN Staphylococcus 30S ribosomal subunit (Stap-coc pbp2) DMOMLHJ MA Binder DMOMLHJ RN Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. DMOMLHJ RU https://pubmed.ncbi.nlm.nih.gov/17016423 DMOMP9U DI DMOMP9U DMOMP9U DN Cetirizine DMOMP9U TI TTTIBOJ DMOMP9U TN Histamine H1 receptor (H1R) DMOMP9U MA Antagonist DMOMP9U RN Design, synthesis and histamine H1-receptor antagonistic activity of some novel 4-amino-2-(substituted)-5-(substituted) aryl-6-[(substituted aryl) amino] pyrimidines. Arzneimittelforschung. 2009;59(5):243-7. DMOMP9U RU https://pubmed.ncbi.nlm.nih.gov/19537525 DMOP0BL DI DMOP0BL DMOP0BL DN Ambenonium DMOP0BL TI TT1RS9F DMOP0BL TN Acetylcholinesterase (AChE) DMOP0BL MA Inhibitor DMOP0BL RN Alpha6-containing nicotinic acetylcholine receptors dominate the nicotine control of dopamine neurotransmission in nucleus accumbens. Neuropsychopharmacology. 2008 Aug;33(9):2158-66. DMOP0BL RU https://pubmed.ncbi.nlm.nih.gov/18033235 DMOPGHQ DI DMOPGHQ DMOPGHQ DN Indiplon DMOPGHQ TI TT1MPAY DMOPGHQ TN GABA(A) receptor alpha-1 (GABRA1) DMOPGHQ MA Agonist DMOPGHQ RN Emerging therapies for fibromyalgia. Expert Opin Emerg Drugs. 2008 Mar;13(1):53-62. DMOPGHQ RU https://pubmed.ncbi.nlm.nih.gov/18321148 DMOPZDT DI DMOPZDT DMOPZDT DN Perindopril DMOPZDT TI TTL69WB DMOPZDT TN Angiotensin-converting enzyme (ACE) DMOPZDT MA Inhibitor DMOPZDT RN Fixed combination perindopril-amlodipine (Coveram) in the treatment of hypertension and coronary heart disease. Rev Med Liege. 2009 Apr;64(4):223-7. DMOPZDT RU https://pubmed.ncbi.nlm.nih.gov/19514543 DMOQK8Z DI DMOQK8Z DMOQK8Z DN Arbidol DMOQK8Z TI TTF4CAM DMOQK8Z TN Influenza Hemagglutinin (Influ HA) DMOQK8Z MA Inhibitor DMOQK8Z RN Pharmacokinetic properties and bioequivalence of two formulations of arbidol: an open-label, single-dose, randomized-sequence, two-period crossover study in healthy Chinese male volunteers. Clin Ther. 2009 Apr;31(4):784-92. DMOQK8Z RU https://pubmed.ncbi.nlm.nih.gov/19446151 DMOQVU9 DI DMOQVU9 DMOQVU9 DN Hydroxyurea DMOQVU9 TI TTBWDI0 DMOQVU9 TN Ribonucleoside-diphosphate reductase M2 (RRM2) DMOQVU9 MA Modulator DMOQVU9 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMOQVU9 RU https://www.fda.gov/ DMORPBA DI DMORPBA DMORPBA DN Ergoloid mesylate DMORPBA TI TT32XQJ DMORPBA TN Monoamine oxidase (MAO) DMORPBA MA Modulator DMORPBA RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMORPBA RU https://www.fda.gov/ DMOSQGU DI DMOSQGU DMOSQGU DN Nalbuphine DMOSQGU TI TTQW87Y DMOSQGU TN Opioid receptor kappa (OPRK1) DMOSQGU MA Modulator DMOSQGU RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMOSQGU RU https://www.fda.gov/ DMOSW35 DI DMOSW35 DMOSW35 DN Felodipine DMOSW35 TI TT5HONZ DMOSW35 TN Calcium channel unspecific (CaC) DMOSW35 MA Blocker DMOSW35 RN Molecular pharmacology of human Cav3.2 T-type Ca2+ channels: block by antihypertensives, antiarrhythmics, and their analogs. J Pharmacol Exp Ther. 2009 Feb;328(2):621-7. DMOSW35 RU https://pubmed.ncbi.nlm.nih.gov/18974361 DMOTQ1I DI DMOTQ1I DMOTQ1I DN Ondansetron DMOTQ1I TI TTNXLKE DMOTQ1I TN 5-HT 3 receptor (5HT3R) DMOTQ1I MA Agonist DMOTQ1I RN Treatment of pruritus in chronic liver disease with the 5-hydroxytryptamine receptor type 3 antagonist ondansetron: a randomized, placebo-controlled, double-blind cross-over trial. Eur J Gastroenterol Hepatol. 1998 Oct;10(10):865-70. DMOTQ1I RU https://pubmed.ncbi.nlm.nih.gov/9831410 DMOU1PK DI DMOU1PK DMOU1PK DN Praziquantel DMOU1PK TI TTCYE56 DMOU1PK TN Glutathione-dependent PGD synthase (HPGDS) DMOU1PK MA Inhibitor DMOU1PK RN X-ray structure of glutathione S-transferase from Schistosoma japonicum in a new crystal form reveals flexibility of the substrate-binding site. Acta Crystallogr Sect F Struct Biol Cryst Commun. 2005 Mar 1;61(Pt 3):263-5. DMOU1PK RU https://pubmed.ncbi.nlm.nih.gov/16511012 DMOUC09 DI DMOUC09 DMOUC09 DN Norepinephrine DMOUC09 TI TTR6W5O DMOUC09 TN Adrenergic receptor beta-1 (ADRB1) DMOUC09 MA Stimulator DMOUC09 RN Impact of exogenous beta-adrenergic receptor stimulation on hepatosplanchnic oxygen kinetics and metabolic activity in septic shock. Crit Care Med. 1999 Feb;27(2):325-31. DMOUC09 RU https://pubmed.ncbi.nlm.nih.gov/10075057 DMOUMDV DI DMOUMDV DMOUMDV DN Penciclovir DMOUMDV TI TTIU7X1 DMOUMDV TN Herpes simplex virus DNA polymerase UL30 (HSV UL30) DMOUMDV MA Inhibitor DMOUMDV RN Antimicrobial strategies: inhibition of viral polymerases by 3'-hydroxyl nucleosides. Drugs. 2009;69(2):151-66. DMOUMDV RU https://pubmed.ncbi.nlm.nih.gov/19228073 DMOUMDV DI DMOUMDV DMOUMDV DN Penciclovir DMOUMDV TI TTP3QRF DMOUMDV TN Thymidine kinase 1 (TK1) DMOUMDV MA Inhibitor DMOUMDV RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMOUMDV RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMOVAIX DI DMOVAIX DMOVAIX DN Meropenem + vaborbactam DMOVAIX TI TTHI19T DMOVAIX TN Staphylococcus Beta-lactamase (Stap-coc blaZ) DMOVAIX MA Inhibitor DMOVAIX RN 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85. DMOVAIX RU https://pubmed.ncbi.nlm.nih.gov/29348678 DMOVH1M DI DMOVH1M DMOVH1M DN Oxytetracycline DMOVH1M TI TTQ8KVI DMOVH1M TN Staphylococcus 30S ribosomal subunit (Stap-coc pbp2) DMOVH1M MA Binder DMOVH1M RN Detection of tetracycline resistance genes by PCR methods. Methods Mol Biol. 2004;268:3-13. DMOVH1M RU https://pubmed.ncbi.nlm.nih.gov/15156014 DMOVY05 DI DMOVY05 DMOVY05 DN Ketotifen DMOVY05 TI TTTIBOJ DMOVY05 TN Histamine H1 receptor (H1R) DMOVY05 MA Antagonist DMOVY05 RN Intact cell binding for in vitro prediction of sedative and non-sedative histamine H1-receptor antagonists based on receptor internalization. J Pharmacol Sci. 2008 May;107(1):66-79. DMOVY05 RU https://pubmed.ncbi.nlm.nih.gov/18446005 DMOWEBU DI DMOWEBU DMOWEBU DN Pegaptanib DMOWEBU TI TTIPJCB DMOWEBU TN Neuropilin-1 (NRP1) DMOWEBU RN Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat Rev Drug Discov. 2006 Feb;5(2):123-32. DMOWEBU RU https://pubmed.ncbi.nlm.nih.gov/16518379 DMOWK6B DI DMOWK6B DMOWK6B DN Aprobarbital DMOWK6B TI TTAN6JD DMOWK6B TN Glutamate receptor AMPA (GRIA) DMOWK6B MA Binder DMOWK6B RN Determination of zidovudine/lamivudine/nevirapine in human plasma using ion-pair HPLC. J Pharm Biomed Anal. 2002 Jun 1;28(5):903-8. DMOWK6B RU https://pubmed.ncbi.nlm.nih.gov/12039632 DMOWLVG DI DMOWLVG DMOWLVG DN Nitazoxanide DMOWLVG TI TT0F5P8 DMOWLVG TN Cryptosporidium Pyruvate:ferredoxin oxidoreductase (Crypto CpPNO) DMOWLVG MA Modulator DMOWLVG RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMOWLVG RU https://www.fda.gov/ DMOWZ6B DI DMOWZ6B DMOWZ6B DN Fluconazole DMOWZ6B TI TTTSOUD DMOWZ6B TN Candida Cytochrome P450 51 (Candi ERG11) DMOWZ6B MA Modulator DMOWZ6B RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMOWZ6B RU https://www.fda.gov/ DMOX3LB DI DMOX3LB DMOX3LB DN Fosphenytoin DMOX3LB TI TTZOVE0 DMOX3LB TN Voltage-gated sodium channel alpha Nav1.5 (SCN5A) DMOX3LB MA Blocker DMOX3LB RN Lacosamide: a new approach to target voltage-gated sodium currents in epileptic disorders. CNS Drugs. 2009;23(7):555-68. DMOX3LB RU https://pubmed.ncbi.nlm.nih.gov/19552484 DMOXJKF DI DMOXJKF DMOXJKF DN Dapiprazole DMOXJKF TI TTEX248 DMOXJKF TN Dopamine D2 receptor (D2R) DMOXJKF MA Antagonist DMOXJKF RN Effect of ibopamine on aqueous humor production in normotensive humans. Invest Ophthalmol Vis Sci. 2003 Nov;44(11):4853-8. DMOXJKF RU https://pubmed.ncbi.nlm.nih.gov/14578408 DMOY7W3 DI DMOY7W3 DMOY7W3 DN Artemisinin DMOY7W3 TI TT3PQ2Y DMOY7W3 TN Plasmodium Dihydroorotate dehydrogenase (Malaria DHOdehase) DMOY7W3 MA Inhibitor DMOY7W3 RN The fight against drug-resistant malaria: novel plasmodial targets and antimalarial drugs. Curr Med Chem. 2008;15(2):161-71. DMOY7W3 RU https://pubmed.ncbi.nlm.nih.gov/18220771 DMOY7W3 DI DMOY7W3 DMOY7W3 DN Artemisinin DMOY7W3 TI TTZVSJ2 DMOY7W3 TN Sarcoplasmic/endoplasmic reticulum calcium ATPase (ATP2A) DMOY7W3 MA Inhibitor DMOY7W3 RN The fight against drug-resistant malaria: novel plasmodial targets and antimalarial drugs. Curr Med Chem. 2008;15(2):161-71. DMOY7W3 RU https://pubmed.ncbi.nlm.nih.gov/18220771 DMOYJFK DI DMOYJFK DMOYJFK DN Valrubicin DMOYJFK TI TT0IHXV DMOYJFK TN DNA topoisomerase II (TOP2) DMOYJFK MA Inhibitor DMOYJFK RN Metabolic activation of N-acylanthracyclines precedes their interaction with DNA topoisomerase II. NCI Monogr. 1987;(4):111-5. DMOYJFK RU https://pubmed.ncbi.nlm.nih.gov/3041237 DMP0OVQ DI DMP0OVQ DMP0OVQ DN Gestrinone DMP0OVQ TI TTZAYWL DMP0OVQ TN Estrogen receptor (ESR) DMP0OVQ MA Modulator DMP0OVQ RN Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. DMP0OVQ RU https://pubmed.ncbi.nlm.nih.gov/17309302 DMP0UK2 DI DMP0UK2 DMP0UK2 DN Vecuronium DMP0UK2 TI TTF4E0J DMP0UK2 TN Neuronal acetylcholine receptor alpha-2 (CHRNA2) DMP0UK2 MA Antagonist DMP0UK2 RN Pharmacological characteristics of the inhibition of nondepolarizing neuromuscular blocking agents at human adult muscle nicotinic acetylcholine receptor. Anesthesiology. 2009 Jun;110(6):1244-52. DMP0UK2 RU https://pubmed.ncbi.nlm.nih.gov/19417616 DMP1I6Y DI DMP1I6Y DMP1I6Y DN Alectinib DMP1I6Y TI TTPMQSO DMP1I6Y TN ALK tyrosine kinase receptor (ALK) DMP1I6Y MA Inhibitor DMP1I6Y RN CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant. Cancer Cell. 2011 May 17;19(5):679-90. DMP1I6Y RU https://pubmed.ncbi.nlm.nih.gov/21575866 DMP1QTS DI DMP1QTS DMP1QTS DN Idecabtagene vicleucel DMP1QTS TI TTZ3P4W DMP1QTS TN B-cell maturation protein (TNFRSF17) DMP1QTS MA CAR-T-Cell-Therapy DMP1QTS RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. DMP1QTS RU https://www.fda.gov/vaccines-blood-biologics/abecma-idecabtagene-vicleucel DMP2LZ8 DI DMP2LZ8 DMP2LZ8 DN MLN0002 DMP2LZ8 TI TT7ZMI1 DMP2LZ8 TN Integrin alpha-4/beta-7 (ITGA4/B7) DMP2LZ8 MA Modulator DMP2LZ8 RN 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81. DMP2LZ8 RU https://pubmed.ncbi.nlm.nih.gov/25633781 DMP45ME DI DMP45ME DMP45ME DN Lisocabtagene maraleucel DMP45ME TI TTW640A DMP45ME TN B-lymphocyte surface antigen B4 (CD19) DMP45ME MA CAR-T-Cell-Therapy DMP45ME RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. DMP45ME RU https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/breyanzi-lisocabtagene-maraleucel DMP54C7 DI DMP54C7 DMP54C7 DN Bacampicillin DMP54C7 TI TTJP4SM DMP54C7 TN Bacterial Penicillin binding protein (Bact PBP) DMP54C7 MA Binder DMP54C7 RN Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. DMP54C7 RU https://pubmed.ncbi.nlm.nih.gov/17016423 DMP5A4T DI DMP5A4T DMP5A4T DN Trilaciclib DMP5A4T TI TT0PG8F DMP5A4T TN Cyclin-dependent kinase 4 (CDK4) DMP5A4T MA Inhibitor DMP5A4T RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2021 DMP5A4T RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214200s000lbl.pdf DMP5A4T DI DMP5A4T DMP5A4T DN Trilaciclib DMP5A4T TI TTO0FDJ DMP5A4T TN Cyclin-dependent kinase 6 (CDK6) DMP5A4T MA Inhibitor DMP5A4T RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2021 DMP5A4T RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214200s000lbl.pdf DMP6G8T DI DMP6G8T DMP6G8T DN Topotecan DMP6G8T TI TTGTQHC DMP6G8T TN DNA topoisomerase I (TOP1) DMP6G8T MA Modulator DMP6G8T RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMP6G8T RU https://www.fda.gov/ DMP6M1N DI DMP6M1N DMP6M1N DN Pirenzepine DMP6M1N TI TTZ9SOR DMP6M1N TN Muscarinic acetylcholine receptor M1 (CHRM1) DMP6M1N MA Antagonist DMP6M1N RN Negative crosstalk between M1 and M2 muscarinic autoreceptors involves endogenous adenosine activating A1 receptors at the rat motor endplate. Neurosci Lett. 2009 Aug 14;459(3):127-31. DMP6M1N RU https://pubmed.ncbi.nlm.nih.gov/19427366 DMP6SC2 DI DMP6SC2 DMP6SC2 DN Irinotecan DMP6SC2 TI TTGTQHC DMP6SC2 TN DNA topoisomerase I (TOP1) DMP6SC2 MA Modulator DMP6SC2 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMP6SC2 RU https://www.fda.gov/ DMP79A1 DI DMP79A1 DMP79A1 DN Macitentan DMP79A1 TI TTKRD0G DMP79A1 TN Endothelin A receptor (EDNRA) DMP79A1 MA Modulator DMP79A1 RN Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651. DMP79A1 RU https://pubmed.ncbi.nlm.nih.gov/28919714 DMP79A1 DI DMP79A1 DMP79A1 DN Macitentan DMP79A1 TI TT3ZTGU DMP79A1 TN Endothelin B receptor (EDNRB) DMP79A1 MA Modulator DMP79A1 RN Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651. DMP79A1 RU https://pubmed.ncbi.nlm.nih.gov/28919714 DMP7LK1 DI DMP7LK1 DMP7LK1 DN Guggulsterone DMP7LK1 TI TTS4UGC DMP7LK1 TN Farnesoid X-activated receptor (FXR) DMP7LK1 MA Antagonist DMP7LK1 RN Effect of guggulsterone and cembranoids of Commiphora mukul on pancreatic phospholipase A(2): role in hypocholesterolemia. J Nat Prod. 2009 Jan;72(1):24-8. DMP7LK1 RU https://pubmed.ncbi.nlm.nih.gov/19102680 DMP8HEL DI DMP8HEL DMP8HEL DN Mitiglinide DMP8HEL TI TTG140O DMP8HEL TN Inward rectifier potassium channel Kir1.2 (KCNJ10) DMP8HEL MA Blocker DMP8HEL RN Carboxyl-glucuronidation of mitiglinide by human UDP-glucuronosyltransferases. Biochem Pharmacol. 2007 Jun 1;73(11):1842-51. DMP8HEL RU https://pubmed.ncbi.nlm.nih.gov/17359941 DMP9HBO DI DMP9HBO DMP9HBO DN Sucralfate DMP9HBO TI TTGKIED DMP9HBO TN Fibroblast growth factor-2 (FGF2) DMP9HBO MA Modulator DMP9HBO RN Assessment of sucralfate coating by sequential scintigraphic imaging in radiation-induced esophageal lesions. Gastrointest Endosc. 1995 Feb;41(2):109-14. DMP9HBO RU https://pubmed.ncbi.nlm.nih.gov/7720996 DMPAZHC DI DMPAZHC DMPAZHC DN Cabazitaxel DMPAZHC TI TTML2WA DMPAZHC TN Tubulin (TUB) DMPAZHC MA Inhibitor DMPAZHC RN Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5. DMPAZHC RU https://pubmed.ncbi.nlm.nih.gov/21283092 DMPC1J7 DI DMPC1J7 DMPC1J7 DN Clofibrate DMPC1J7 TI TTOF3WZ DMPC1J7 TN Lipoprotein lipase (LPL) DMPC1J7 MA Activator DMPC1J7 RN Effects of clofibrate treatment in laying hens. Poult Sci. 2007 Jun;86(6):1187-95. DMPC1J7 RU https://pubmed.ncbi.nlm.nih.gov/17495091 DMPC2QY DI DMPC2QY DMPC2QY DN CNTO-1959 DMPC2QY TI TTC1GLB DMPC2QY TN Interleukin-23 (IL23) DMPC2QY RN Interleukin-23 in the pathogenesis and treatment of psoriasis. Skin Therapy Lett. 2015 Mar-Apr;20(2):1-4. DMPC2QY RU https://pubmed.ncbi.nlm.nih.gov/25807335 DMPCG2L DI DMPCG2L DMPCG2L DN Flumazenil DMPCG2L TI TTPTXIN DMPCG2L TN Translocator protein (TSPO) DMPCG2L MA Antagonist DMPCG2L RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2879). DMPCG2L RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2879 DMPCG2L DI DMPCG2L DMPCG2L DN Flumazenil DMPCG2L TI TT37EDJ DMPCG2L TN GABA(A) receptor alpha-3 (GABRA3) DMPCG2L MA Modulator (allosteric modulator) DMPCG2L RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 406). DMPCG2L RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=406 DMPCG2L DI DMPCG2L DMPCG2L DN Flumazenil DMPCG2L TI TTNZPQ1 DMPCG2L TN GABA(A) receptor alpha-5 (GABRA5) DMPCG2L MA Modulator (allosteric modulator) DMPCG2L RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 408). DMPCG2L RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=408 DMPCG2L DI DMPCG2L DMPCG2L DN Flumazenil DMPCG2L TI TTBMV1G DMPCG2L TN GABA(A) receptor alpha-2 (GABRA2) DMPCG2L MA Modulator (allosteric modulator) DMPCG2L RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 405). DMPCG2L RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=405 DMPCG2L DI DMPCG2L DMPCG2L DN Flumazenil DMPCG2L TI TTEX6LM DMPCG2L TN GABA(A) receptor gamma-3 (GABRG3) DMPCG2L MA Modulator (allosteric modulator) DMPCG2L RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 415). DMPCG2L RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=415 DMPDW6T DI DMPDW6T DMPDW6T DN Epirubicin DMPDW6T TI TT0IHXV DMPDW6T TN DNA topoisomerase II (TOP2) DMPDW6T MA Modulator DMPDW6T RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMPDW6T RU https://www.fda.gov/ DMPDYFR DI DMPDYFR DMPDYFR DN Cefazolin DMPDYFR TI TTJP4SM DMPDYFR TN Bacterial Penicillin binding protein (Bact PBP) DMPDYFR MA Binder DMPDYFR RN Bacteriological characteristics of Staphylococcus aureus isolates from humans and bulk milk. J Dairy Sci. 2008 Feb;91(2):564-9. DMPDYFR RU https://pubmed.ncbi.nlm.nih.gov/18218742 DMPFN6Y DI DMPFN6Y DMPFN6Y DN Olanzapine DMPFN6Y TI TTEX248 DMPFN6Y TN Dopamine D2 receptor (D2R) DMPFN6Y MA Agonist DMPFN6Y RN Olanzapine: an updated review of its use in the management of schizophrenia. Drugs. 2001;61(1):111-61. DMPFN6Y RU https://pubmed.ncbi.nlm.nih.gov/11217867 DMPFWO6 DI DMPFWO6 DMPFWO6 DN Halazepam DMPFWO6 TI TTPTXIN DMPFWO6 TN Translocator protein (TSPO) DMPFWO6 MA Modulator DMPFWO6 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMPFWO6 RU https://www.fda.gov/ DMPGHY8 DI DMPGHY8 DMPGHY8 DN Roflumilast DMPGHY8 TI TTV5CGO DMPGHY8 TN Phosphodiesterase 4 (PDE4) DMPGHY8 MA Modulator DMPGHY8 RN 2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4. DMPGHY8 RU https://pubmed.ncbi.nlm.nih.gov/22293555 DMPGR1E DI DMPGR1E DMPGR1E DN Clascoterone DMPGR1E TI TTS64P2 DMPGR1E TN Androgen receptor (AR) DMPGR1E MA Antagonist DMPGR1E RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020 DMPGR1E RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213433s000lbl.pdf DMPGUCF DI DMPGUCF DMPGUCF DN Dopamine DMPGUCF TI TTEX248 DMPGUCF TN Dopamine D2 receptor (D2R) DMPGUCF MA Agonist DMPGUCF RN The Detection of Dopamine Gene Receptors (DRD1-DRD5) Expression on Human Peripheral Blood Lymphocytes by Real Time PCR. Iran J Allergy Asthma Immunol. 2004 Dec;3(4):169-74. DMPGUCF RU https://pubmed.ncbi.nlm.nih.gov/17301410 DMPHVQ1 DI DMPHVQ1 DMPHVQ1 DN Human prothrombin complex concentrate DMPHVQ1 TI TT6L509 DMPHVQ1 TN Coagulation factor IIa (F2) DMPHVQ1 MA Modulator DMPHVQ1 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2362). DMPHVQ1 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2362 DMPHWU6 DI DMPHWU6 DMPHWU6 DN Tandospirone DMPHWU6 TI TT85JO3 DMPHWU6 TN 5-HT receptor (5HTR) DMPHWU6 MA Modulator DMPHWU6 RN Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. DMPHWU6 RU https://pubmed.ncbi.nlm.nih.gov/17309302 DMPHXMI DI DMPHXMI DMPHXMI DN Besifloxacin DMPHXMI TI TTN6J5F DMPHXMI TN Bacterial DNA gyrase (Bact gyrase) DMPHXMI MA Modulator DMPHXMI RN Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92. DMPHXMI RU https://pubmed.ncbi.nlm.nih.gov/20118952 DMPHXMI DI DMPHXMI DMPHXMI DN Besifloxacin DMPHXMI TI TTIXTO3 DMPHXMI TN Staphylococcus Topoisomerase IV (Stap-coc parC) DMPHXMI MA Modulator DMPHXMI RN Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92. DMPHXMI RU https://pubmed.ncbi.nlm.nih.gov/20118952 DMPHZQE DI DMPHZQE DMPHZQE DN Chlorpropamide DMPHZQE TI TTG140O DMPHZQE TN Inward rectifier potassium channel Kir1.2 (KCNJ10) DMPHZQE MA Blocker DMPHZQE RN Effect of the chlorpropamide and fructose-1,6-bisphosphate of soluble TNF receptor II levels. Pharmacol Res. 2004 May;49(5):449-53. DMPHZQE RU https://pubmed.ncbi.nlm.nih.gov/14998554 DMPI6Z0 DI DMPI6Z0 DMPI6Z0 DN Zopiclone DMPI6Z0 TI TTAN6JD DMPI6Z0 TN Glutamate receptor AMPA (GRIA) DMPI6Z0 MA Binder DMPI6Z0 RN Eszopiclone: its use in the treatment of insomnia. Neuropsychiatr Dis Treat. 2007 Aug;3(4):441-453. DMPI6Z0 RU https://pubmed.ncbi.nlm.nih.gov/19300573 DMPI98T DI DMPI98T DMPI98T DN Doxepin DMPI98T TI TTTIBOJ DMPI98T TN Histamine H1 receptor (H1R) DMPI98T MA Inhibitor DMPI98T RN Novel therapeutic usage of low-dose doxepin hydrochloride. Expert Opin Investig Drugs. 2007 Aug;16(8):1295-305. DMPI98T RU https://pubmed.ncbi.nlm.nih.gov/17685877 DMPIBJK DI DMPIBJK DMPIBJK DN Propafenone DMPIBJK TI TT05DLS DMPIBJK TN E3 ubiquitin-protein ligase COP1 (RFWD2) DMPIBJK MA Modulator DMPIBJK RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMPIBJK RU https://www.fda.gov/ DMPIHLS DI DMPIHLS DMPIHLS DN Diclofenac DMPIHLS TI TTK0943 DMPIHLS TN Prostaglandin G/H synthase (COX) DMPIHLS MA Modulator DMPIHLS RN Diclofenac and NS-398, a selective cyclooxygenase-2 inhibitor, decrease agonist-induced contractions of the pig isolated ureter. Urol Res. 2000 Dec;28(6):376-82. DMPIHLS RU https://pubmed.ncbi.nlm.nih.gov/11221916 DMPL395 DI DMPL395 DMPL395 DN Insulin degludec DMPL395 TI TTZOPHG DMPL395 TN Insulin (INS) DMPL395 MA Modulator DMPL395 RN Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651. DMPL395 RU https://pubmed.ncbi.nlm.nih.gov/28919714 DMPLY7B DI DMPLY7B DMPLY7B DN Cefmenoxime DMPLY7B TI TT85JMW DMPLY7B TN Bacterial Penicillin binding protein 3 (Bact mrcA) DMPLY7B MA Binder DMPLY7B RN In vitro evaluation of E1040, a new cephalosporin with potent antipseudomonal activity. Antimicrob Agents Chemother. 1988 May;32(5):693-701. DMPLY7B RU https://pubmed.ncbi.nlm.nih.gov/3134847 DMPM4SK DI DMPM4SK DMPM4SK DN Methamphetamine DMPM4SK TI TTEX248 DMPM4SK TN Dopamine D2 receptor (D2R) DMPM4SK MA Agonist DMPM4SK RN Pharmacotherapy for obesity. Drugs. 2005;65(10):1391-418. DMPM4SK RU https://pubmed.ncbi.nlm.nih.gov/15977970 DMPM4SK DI DMPM4SK DMPM4SK DN Methamphetamine DMPM4SK TI TTBRKXS DMPM4SK TN Adrenergic receptor alpha-1B (ADRA1B) DMPM4SK MA Antagonist DMPM4SK RN Mirtazapine treatment after conditioning with methamphetamine alters subsequent expression of place preference. Drug Alcohol Depend. 2009 Jan 1;99(1-3):231-9. DMPM4SK RU https://pubmed.ncbi.nlm.nih.gov/18945553 DMPMYE8 DI DMPMYE8 DMPMYE8 DN Miconazole DMPMYE8 TI TTTSOUD DMPMYE8 TN Candida Cytochrome P450 51 (Candi ERG11) DMPMYE8 MA Modulator DMPMYE8 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMPMYE8 RU https://www.fda.gov/ DMPN1TW DI DMPN1TW DMPN1TW DN Dofetilide DMPN1TW TI TT1VOHK DMPN1TW TN Potassium channel unspecific (KC) DMPN1TW MA Modulator DMPN1TW RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMPN1TW RU https://www.fda.gov/ DMPO0MS DI DMPO0MS DMPO0MS DN Gallamine Triethiodide DMPO0MS TI TTYEG6Q DMPO0MS TN Muscarinic acetylcholine receptor M2 (CHRM2) DMPO0MS MA Antagonist DMPO0MS RN Cholinergic regulation of the corpora allata in adult male loreyi leafworm Mythimna loreyi. Arch Insect Biochem Physiol. 2002 Apr;49(4):215-24. DMPO0MS RU https://pubmed.ncbi.nlm.nih.gov/11921079 DMPOD47 DI DMPOD47 DMPOD47 DN Ajmalicine DMPOD47 TI TTR6W5O DMPOD47 TN Adrenergic receptor beta-1 (ADRB1) DMPOD47 MA Modulator DMPOD47 RN Medicinal plants in therapy. Bull World Health Organ. 1985;63(6):965-81. DMPOD47 RU https://pubmed.ncbi.nlm.nih.gov/3879679 DMPOU5H DI DMPOU5H DMPOU5H DN ENASIDENIB MESYLATE DMPOU5H TI TTDTWV0 DMPOU5H TN Isocitrate dehydrogenase (IDH) DMPOU5H MA Inhibitor DMPOU5H RN 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85. DMPOU5H RU https://pubmed.ncbi.nlm.nih.gov/29348678 DMPQAGE DI DMPQAGE DMPQAGE DN Mycophenolate mofetil DMPQAGE TI TTTB4UP DMPQAGE TN Inosine-5'-monophosphate dehydrogenase 2 (IMPDH2) DMPQAGE MA Inhibitor DMPQAGE RN Clinical pipeline report, company report or official report of Roche (2009). DMPQAGE RU http://www.roche.com/research_and_development/pipeline/roche_pharma_pipeline.htm DMPQAGE DI DMPQAGE DMPQAGE DN Mycophenolate mofetil DMPQAGE TI TT1ZAVI DMPQAGE TN Prostaglandin E2 receptor EP2 (PTGER2) DMPQAGE MA Modulator DMPQAGE RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 341). DMPQAGE RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=341 DMPRBQV DI DMPRBQV DMPRBQV DN Enalaprilat DMPRBQV TI TTL69WB DMPRBQV TN Angiotensin-converting enzyme (ACE) DMPRBQV MA Inhibitor DMPRBQV RN Analysis of Vancomycin in the Hindlimb Vascular Bed of the Rat. Am J Ther. 1996 Oct;3(10):681-687. DMPRBQV RU https://pubmed.ncbi.nlm.nih.gov/11862223 DMPRI8G DI DMPRI8G DMPRI8G DN Buprenorphine DMPRI8G TI TTKWM86 DMPRI8G TN Opioid receptor mu (MOP) DMPRI8G MA Agonist DMPRI8G RN Buprenorphine is a weak partial agonist that inhibits opioid receptor desensitization. J Neurosci. 2009 Jun 3;29(22):7341-8. DMPRI8G RU https://pubmed.ncbi.nlm.nih.gov/19494155 DMPSB8F DI DMPSB8F DMPSB8F DN MEPTAZINOL DMPSB8F TI TTEB0GD DMPSB8F TN Cholinesterase (BCHE) DMPSB8F MA Inhibitor DMPSB8F RN Bis-(-)-nor-meptazinols as novel nanomolar cholinesterase inhibitors with high inhibitory potency on amyloid-beta aggregation. J Med Chem. 2008 Apr 10;51(7):2027-36. DMPSB8F RU https://pubmed.ncbi.nlm.nih.gov/18333606 DMPT74U DI DMPT74U DMPT74U DN Gramicidin D DMPT74U TI TT4ILYC DMPT74U TN Bacterial Dihydropteroate synthetase (Bact folP) DMPT74U MA Binder DMPT74U RN Structures of gramicidins A, B, and C incorporated into sodium dodecyl sulfate micelles. Biochemistry. 2001 Oct 2;40(39):11676-86. DMPT74U RU https://pubmed.ncbi.nlm.nih.gov/11570868 DMPU2WX DI DMPU2WX DMPU2WX DN Omacetaxine mepesuccinate DMPU2WX TI TTA4FIU DMPU2WX TN Ribosome A (hRA) DMPU2WX MA Modulator DMPU2WX RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DMPU2WX RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DMPUKA7 DI DMPUKA7 DMPUKA7 DN Caplacizumab DMPUKA7 TI TT3SZBT DMPUKA7 TN von Willebrand factor (VWF) DMPUKA7 MA Inhibitor DMPUKA7 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019 DMPUKA7 RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761112s000lbl.pdf DMPVRN9 DI DMPVRN9 DMPVRN9 DN Setmelanotide DMPVRN9 TI TTD0CIQ DMPVRN9 TN Melanocortin receptor 4 (MC4R) DMPVRN9 MA Agonist DMPVRN9 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020 DMPVRN9 RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213793s000lbl.pdf DMPWB7T DI DMPWB7T DMPWB7T DN Maprotiline DMPWB7T TI TTAWNKZ DMPWB7T TN Norepinephrine transporter (NET) DMPWB7T MA Inhibitor DMPWB7T RN Effect of pharmacologically selective antidepressants on serotonin uptake in rat platelets. Gen Physiol Biophys. 2005 Mar;24(1):113-28. DMPWB7T RU https://pubmed.ncbi.nlm.nih.gov/15900091 DMPWCTH DI DMPWCTH DMPWCTH DN Neocarzinostatin DMPWCTH TI TTUTN1I DMPWCTH TN Human Deoxyribonucleic acid (hDNA) DMPWCTH MA Modulator DMPWCTH RN Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. DMPWCTH RU https://pubmed.ncbi.nlm.nih.gov/17309302 DMPWGBR DI DMPWGBR DMPWGBR DN Triclabendazole DMPWGBR TI TTEAID7 DMPWGBR TN Trypanosoma Cruzipain (Trypano CYSP) DMPWGBR MA Inhibitor DMPWGBR RN Colloid formation by drugs in simulated intestinal fluid. J Med Chem. 2010 May 27;53(10):4259-65. DMPWGBR RU https://pubmed.ncbi.nlm.nih.gov/20426472 DMPWNDB DI DMPWNDB DMPWNDB DN Balofloxacin DMPWNDB TI TTJP4SM DMPWNDB TN Bacterial Penicillin binding protein (Bact PBP) DMPWNDB MA Inhibitor DMPWNDB RN Emerging drugs for bacterial urinary tract infections. Expert Opin Emerg Drugs. 2005 May;10(2):275-98. DMPWNDB RU https://pubmed.ncbi.nlm.nih.gov/15934867 DMPWSEM DI DMPWSEM DMPWSEM DN Lercanidipine DMPWSEM TI TTFK1JQ DMPWSEM TN Voltage-gated calcium channel alpha-2/delta-1 (CACNA2D1) DMPWSEM MA Blocker DMPWSEM RN Treatment of essential hypertension with calcium channel blockers: what is the place of lercanidipine Expert Opin Drug Metab Toxicol. 2009 Aug;5(8):981-7. DMPWSEM RU https://pubmed.ncbi.nlm.nih.gov/19619074 DMPXITB DI DMPXITB DMPXITB DN Hetacillin DMPXITB TI TTJP4SM DMPXITB TN Bacterial Penicillin binding protein (Bact PBP) DMPXITB MA Modulator DMPXITB RN JBioWH: an open-source Java framework for bioinformatics data integration.Database (Oxford).2013 Jul 11;2013:bat051. DMPXITB RU https://www.ncbi.nlm.nih.gov/pubmed/23846595 DMPZI3Q DI DMPZI3Q DMPZI3Q DN Ketoconazole DMPZI3Q TI TTTSOUD DMPZI3Q TN Candida Cytochrome P450 51 (Candi ERG11) DMPZI3Q MA Inhibitor DMPZI3Q RN Clinical pharmacokinetics and pharmacodynamics of solifenacin. Clin Pharmacokinet. 2009;48(5):281-302. DMPZI3Q RU https://pubmed.ncbi.nlm.nih.gov/19566112 DMPZS7U DI DMPZS7U DMPZS7U DN Oxyphenbutazone DMPZS7U TI TTFNGC9 DMPZS7U TN Serum albumin (ALB) DMPZS7U MA Modulator DMPZS7U RN Effect of albumin conformation on binding of phenylbutazone and oxyphenbutazone to human serum albumin. J Pharm Sci. 1982 Feb;71(2):241-4. DMPZS7U RU https://www.ncbi.nlm.nih.gov/pubmed/7062254 DMQ0C2Z DI DMQ0C2Z DMQ0C2Z DN Prevnar DMQ0C2Z TI TT9GOIR DMQ0C2Z TN Streptococcus Diphtheria protein (Stre DIPP) DMQ0C2Z RN Patent WO2013131983 A1. DMQ0C2Z RU http://www.google.com/patents/WO2013131983A1?cl=en DMQ0RKZ DI DMQ0RKZ DMQ0RKZ DN Nimodipine DMQ0RKZ TI TT5HONZ DMQ0RKZ TN Calcium channel unspecific (CaC) DMQ0RKZ MA Blocker DMQ0RKZ RN Influence of bupropion and calcium channel antagonists on the nicotine-induced memory-related response of mice in the elevated plus maze. Pharmacol Rep. 2009 Mar-Apr;61(2):236-44. DMQ0RKZ RU https://pubmed.ncbi.nlm.nih.gov/19443934 DMQ2491 DI DMQ2491 DMQ2491 DN Nitroglycerin DMQ2491 TI TTGKNB4 DMQ2491 TN Epidermal growth factor receptor (EGFR) DMQ2491 MA Activator DMQ2491 RN Emerging drugs for diabetic foot ulcers. Expert Opin Emerg Drugs. 2006 Nov;11(4):709-24. DMQ2491 RU https://pubmed.ncbi.nlm.nih.gov/17064227 DMQ2491 DI DMQ2491 DMQ2491 DN Nitroglycerin DMQ2491 TI TT23PYC DMQ2491 TN Soluble guanylate cyclase (GCS) DMQ2491 MA Modulator DMQ2491 RN Activators of soluble guanylate cyclase for the treatment of male erectile dysfunction. Int J Impot Res. 2002 Feb;14(1):8-14. DMQ2491 RU https://pubmed.ncbi.nlm.nih.gov/11896472 DMQ2AIJ DI DMQ2AIJ DMQ2AIJ DN Lestaurtinib DMQ2AIJ TI TTGJCWZ DMQ2AIJ TN Fms-like tyrosine kinase 3 (FLT-3) DMQ2AIJ MA Modulator DMQ2AIJ RN Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with ... Blood. 2008 Jun 15;111(12):5663-71. DMQ2AIJ RU https://pubmed.ncbi.nlm.nih.gov/17984313 DMQ2FKJ DI DMQ2FKJ DMQ2FKJ DN Teriflunomide DMQ2FKJ TI TTPADOQ DMQ2FKJ TN HMG-CoA reductase (HMGCR) DMQ2FKJ MA Inhibitor DMQ2FKJ RN Emerging drugs in peripheral arterial disease. Expert Opin Emerg Drugs. 2006 Mar;11(1):75-90. DMQ2FKJ RU https://pubmed.ncbi.nlm.nih.gov/16503827 DMQ2FKJ DI DMQ2FKJ DMQ2FKJ DN Teriflunomide DMQ2FKJ TI TT3PQ2Y DMQ2FKJ TN Plasmodium Dihydroorotate dehydrogenase (Malaria DHOdehase) DMQ2FKJ MA Inhibitor DMQ2FKJ RN Expression and characterization of E. coli-produced soluble, functional human dihydroorotate dehydrogenase: a potential target for immunosuppression. J Mol Microbiol Biotechnol. 1999 Aug;1(1):183-8. DMQ2FKJ RU https://pubmed.ncbi.nlm.nih.gov/10941801 DMQ2FKJ DI DMQ2FKJ DMQ2FKJ DN Teriflunomide DMQ2FKJ TI TTLVP78 DMQ2FKJ TN Dihydroorotate dehydrogenase (DHODH) DMQ2FKJ MA Modulator DMQ2FKJ RN Nat Rev Drug Discov. 2013 Feb;12(2):87-90. DMQ2FKJ RU https://pubmed.ncbi.nlm.nih.gov/23370234 DMQ2FPC DI DMQ2FPC DMQ2FPC DN Vasopressin DMQ2FPC TI TTK8R02 DMQ2FPC TN Vasopressin V2 receptor (V2R) DMQ2FPC MA Agonist DMQ2FPC RN Vasopressin receptors: structure/function relationships and signal transduction in target cells. J Soc Biol. 2005;199(4):351-9. DMQ2FPC RU https://pubmed.ncbi.nlm.nih.gov/16738530 DMQ2JO5 DI DMQ2JO5 DMQ2JO5 DN Hydrocodone DMQ2JO5 TI TTKWM86 DMQ2JO5 TN Opioid receptor mu (MOP) DMQ2JO5 MA Modulator DMQ2JO5 RN Clinical pipeline report, company report or official report of kempharm. DMQ2JO5 RU http://www.kempharm.com/pages/pipeline/pain.php DMQ314B DI DMQ314B DMQ314B DN Hexobarbital DMQ314B TI TT1MPAY DMQ314B TN GABA(A) receptor alpha-1 (GABRA1) DMQ314B MA Antagonist DMQ314B RN DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6. DMQ314B RU https://pubmed.ncbi.nlm.nih.gov/18048412 DMQ4HIN DI DMQ4HIN DMQ4HIN DN Cabergoline DMQ4HIN TI TTEX248 DMQ4HIN TN Dopamine D2 receptor (D2R) DMQ4HIN MA Agonist DMQ4HIN RN Role of D1 and D2 receptors in the regulation of voluntary movements. Bull Exp Biol Med. 2008 Jul;146(1):14-7. DMQ4HIN RU https://pubmed.ncbi.nlm.nih.gov/19145338 DMQ4TJK DI DMQ4TJK DMQ4TJK DN Dutasteride DMQ4TJK TI TT2A0DR DMQ4TJK TN Oxo-5-alpha-steroid 4-dehydrogenase (SRD5A) DMQ4TJK MA Inhibitor DMQ4TJK RN The role of 5-alpha reductase inhibitors in prostate pathophysiology: Is there an additional advantage to inhibition of type 1 isoenzyme Can Urol Assoc J. 2009 Jun;3(3 Suppl 2):S109-14. DMQ4TJK RU https://pubmed.ncbi.nlm.nih.gov/19543428 DMQ5S6C DI DMQ5S6C DMQ5S6C DN Tebipenem pivoxil DMQ5S6C TI TTJP4SM DMQ5S6C TN Bacterial Penicillin binding protein (Bact PBP) DMQ5S6C MA Binder DMQ5S6C RN In Vitro Activity of Tebipenem (SPR859) against Penicillin-Binding Proteins of Gram-Negative and Gram-Positive Bacteria. Antimicrob Agents Chemother. 2019 Mar 27;63(4):e02181-18. DMQ5S6C RU https://pubmed.ncbi.nlm.nih.gov/30718255 DMQ8E9R DI DMQ8E9R DMQ8E9R DN SKI-758 DMQ8E9R TI TT6PKBN DMQ8E9R TN Proto-oncogene c-Src (SRC) DMQ8E9R MA Inhibitor DMQ8E9R RN Synthesis and Src kinase inhibitory activity of a series of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-7-furyl-3-quinolinecarbonitriles. J Med Chem. 2006 Dec 28;49(26):7868-76. DMQ8E9R RU https://pubmed.ncbi.nlm.nih.gov/17181170 DMQ8E9R DI DMQ8E9R DMQ8E9R DN SKI-758 DMQ8E9R TI TT3PJMV DMQ8E9R TN Tyrosine-protein kinase ABL1 (ABL) DMQ8E9R MA Inhibitor DMQ8E9R RN Synthesis and Src kinase inhibitory activity of a series of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-7-furyl-3-quinolinecarbonitriles. J Med Chem. 2006 Dec 28;49(26):7868-76. DMQ8E9R RU https://pubmed.ncbi.nlm.nih.gov/17181170 DMQ8E9R DI DMQ8E9R DMQ8E9R DN SKI-758 DMQ8E9R TI TTGKNB4 DMQ8E9R TN Epidermal growth factor receptor (EGFR) DMQ8E9R MA Inhibitor DMQ8E9R RN Synthesis and Src kinase inhibitory activity of a series of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-7-furyl-3-quinolinecarbonitriles. J Med Chem. 2006 Dec 28;49(26):7868-76. DMQ8E9R RU https://pubmed.ncbi.nlm.nih.gov/17181170 DMQ8FR2 DI DMQ8FR2 DMQ8FR2 DN Prednisolone DMQ8FR2 TI TTYRL6O DMQ8FR2 TN Glucocorticoid receptor (NR3C1) DMQ8FR2 MA Modulator DMQ8FR2 RN Aldosterone (mineralocorticoid) equivalent to prednisolone (glucocorticoid) in reversing hearing loss in MRL/MpJ-Fas1pr autoimmune mice. Laryngoscope. 2000 Nov;110(11):1902-6. DMQ8FR2 RU https://pubmed.ncbi.nlm.nih.gov/11081607 DMQ8HOJ DI DMQ8HOJ DMQ8HOJ DN lumateperone tosylate DMQ8HOJ TI TTJQOD7 DMQ8HOJ TN 5-HT 2A receptor (HTR2A) DMQ8HOJ MA Antagonist DMQ8HOJ RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019 DMQ8HOJ RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209500s000lbl.pdf DMQ8HOJ DI DMQ8HOJ DMQ8HOJ DN lumateperone tosylate DMQ8HOJ TI TTEX248 DMQ8HOJ TN Dopamine D2 receptor (D2R) DMQ8HOJ MA Antagonist DMQ8HOJ RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019 DMQ8HOJ RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209500s000lbl.pdf DMQ8JIK DI DMQ8JIK DMQ8JIK DN Chenodiol DMQ8JIK TI TTS4UGC DMQ8JIK TN Farnesoid X-activated receptor (FXR) DMQ8JIK MA Modulator DMQ8JIK RN Lithocholic acid decreases expression of bile salt export pump through farnesoid X receptor antagonist activity. J Biol Chem. 2002 Aug 30;277(35):31441-7. DMQ8JIK RU https://pubmed.ncbi.nlm.nih.gov/12052824 DMQ8R4E DI DMQ8R4E DMQ8R4E DN Naftopidil DMQ8R4E TI TTNGILX DMQ8R4E TN Adrenergic receptor alpha-1A (ADRA1A) DMQ8R4E MA Inhibitor DMQ8R4E RN Pharmacophore identification of alpha(1A)-adrenoceptor antagonists. Bioorg Med Chem Lett. 2005 Feb 1;15(3):657-64. DMQ8R4E RU https://pubmed.ncbi.nlm.nih.gov/15664832 DMQ9MVG DI DMQ9MVG DMQ9MVG DN Chlorhexidine DMQ9MVG TI TT4ILYC DMQ9MVG TN Bacterial Dihydropteroate synthetase (Bact folP) DMQ9MVG MA Breaker DMQ9MVG RN The mechanism of action of chlorhexidine. FEMS Microbiol Lett. 1992 Dec 15;79(1-3):211-5. DMQ9MVG RU https://pubmed.ncbi.nlm.nih.gov/1335944 DMQCTIH DI DMQCTIH DMQCTIH DN Digoxin DMQCTIH TI TTQ38E9 DMQCTIH TN Sodium/potassium-transporting ATPase (SPT ATPase) DMQCTIH MA Inhibitor DMQCTIH RN Fab antibody fragments: some applications in clinical toxicology. Drug Saf. 2004;27(14):1115-33. DMQCTIH RU https://pubmed.ncbi.nlm.nih.gov/15554746 DMQCTIH DI DMQCTIH DMQCTIH DN Digoxin DMQCTIH TI TTACFNR DMQCTIH TN Organic anion transporter M1 (SLCO4C1) DMQCTIH MA Modulator DMQCTIH RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1227). DMQCTIH RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1227 DMQG17S DI DMQG17S DMQG17S DN Tirofiban DMQG17S TI TT38RM1 DMQG17S TN Glycoprotein IIb/IIIa receptor (GPIIb/IIIa) DMQG17S MA Modulator DMQG17S RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMQG17S RU https://www.fda.gov/ DMQHM2D DI DMQHM2D DMQHM2D DN Benzylpenicilloyl Polylysine DMQHM2D TI TTDGEC0 DMQHM2D TN Immunoglobulin epsilon Fc receptor gamma (FCERG) DMQHM2D MA Binder DMQHM2D RN Penicillin allergy: anti-penicillin IgE antibodies and immediate hypersensitivity skin reactions employing major and minor determinants of penicillin. Arch Dis Child. 1980 Nov;55(11):857-60. DMQHM2D RU https://pubmed.ncbi.nlm.nih.gov/7436456 DMQI0FU DI DMQI0FU DMQI0FU DN Insulin-glulisine DMQI0FU TI TTCBFJO DMQI0FU TN Insulin receptor (INSR) DMQI0FU MA Binder DMQI0FU RN Insulin glulisine: a review of its use in the management of diabetes mellitus. Drugs. 2009;69(8):1035-57. DMQI0FU RU https://pubmed.ncbi.nlm.nih.gov/19496630 DMQJHR7 DI DMQJHR7 DMQJHR7 DN Indacaterol DMQJHR7 TI TT2CJVK DMQJHR7 TN Adrenergic receptor beta-2 (ADRB2) DMQJHR7 MA Agonist DMQJHR7 RN Emerging drugs in chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2009 Mar;14(1):181-94. DMQJHR7 RU https://pubmed.ncbi.nlm.nih.gov/19265487 DMQL8XJ DI DMQL8XJ DMQL8XJ DN Decitabine DMQL8XJ TI TTUTN1I DMQL8XJ TN Human Deoxyribonucleic acid (hDNA) DMQL8XJ MA Modulator DMQL8XJ RN 2006 drug approvals: finding the niche. Nat Rev Drug Discov. 2007 Feb;6(2):99-101. DMQL8XJ RU https://pubmed.ncbi.nlm.nih.gov/17342860 DMQLT4N DI DMQLT4N DMQLT4N DN Brimonidine DMQLT4N TI TT2NUT5 DMQLT4N TN Adrenergic receptor alpha-2C (ADRA2C) DMQLT4N MA Modulator DMQLT4N RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 520). DMQLT4N RU http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=520 DMQLT4N DI DMQLT4N DMQLT4N DN Brimonidine DMQLT4N TI TTQ8AFT DMQLT4N TN Adrenergic receptor Alpha-2 (ADRA2) DMQLT4N MA Agonist DMQLT4N RN Increased alpha2-adrenergic constriction of isolated arterioles in diffuse scleroderma. Arthritis Rheum. 2000 Aug;43(8):1886-90. DMQLT4N RU https://pubmed.ncbi.nlm.nih.gov/10943881 DMQLX7O DI DMQLX7O DMQLX7O DN Arteether DMQLX7O TI TT9X7H4 DMQLX7O TN Beta-hematin formation (BHF) DMQLX7O MA Modulator DMQLX7O RN Lack of association of the S769N mutation in Plasmodium falciparum SERCA (PfATP6) with resistance to artemisinins. Antimicrob Agents Chemother. 2012 May;56(5):2546-52. DMQLX7O RU https://pubmed.ncbi.nlm.nih.gov/22354307 DMQM9S0 DI DMQM9S0 DMQM9S0 DN Palivizumab DMQM9S0 TI TT57ID8 DMQM9S0 TN Respiratory syncytial virus protein F (RSV F) DMQM9S0 MA Modulator DMQM9S0 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMQM9S0 RU https://www.fda.gov/ DMQMBZ1 DI DMQMBZ1 DMQMBZ1 DN Rivaroxaban DMQMBZ1 TI TTCIHJA DMQMBZ1 TN Coagulation factor Xa (F10) DMQMBZ1 MA Modulator DMQMBZ1 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DMQMBZ1 RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DMQMGXV DI DMQMGXV DMQMGXV DN Loxoprofen gel DMQMGXV TI TTK0943 DMQMGXV TN Prostaglandin G/H synthase (COX) DMQMGXV MA Inhibitor DMQMGXV RN Comparative study of the clinical efficacy of the selective cyclooxygenase-2 inhibitor celecoxib compared with loxoprofen in patients with frozen shoulder. Mod Rheumatol. 2014 Jan;24(1):144-9. DMQMGXV RU https://pubmed.ncbi.nlm.nih.gov/24261771 DMQMV1B DI DMQMV1B DMQMV1B DN Adalimumab DMQMV1B TI TTF8CQI DMQMV1B TN Tumor necrosis factor (TNF) DMQMV1B RN Adalimumab for psoriasis patients who are non-responders to etanercept: open-label prospective evaluation. J Eur Acad Dermatol Venereol. 2009 Dec;23(12):1394-7. DMQMV1B RU https://pubmed.ncbi.nlm.nih.gov/19573024 DMQNI7O DI DMQNI7O DMQNI7O DN OTL-200 DMQNI7O TI TTYQANR DMQNI7O TN Cerebroside-sulfatase (ARSA) DMQNI7O MA Replacement DMQNI7O RN Clinical pipeline report, company report or official report of Orchard Therapeutics. DMQNI7O RU https://www.orchard-tx.com/approach/pipeline/ DMQNWRD DI DMQNWRD DMQNWRD DN Oxaliplatin DMQNWRD TI TTUTN1I DMQNWRD TN Human Deoxyribonucleic acid (hDNA) DMQNWRD MA Modulator DMQNWRD RN Structures of oxaliplatin-oligonucleotide adducts from DNA.J Mass Spectrom.2012 Oct;47(10):1282-93. DMQNWRD RU https://www.ncbi.nlm.nih.gov/pubmed/23019159 DMQPD1F DI DMQPD1F DMQPD1F DN Panitumumab DMQPD1F TI TTGKNB4 DMQPD1F TN Epidermal growth factor receptor (EGFR) DMQPD1F MA Suppressor DMQPD1F RN Integration of panitumumab into the treatment of colorectal cancer. Crit Rev Oncol Hematol. 2010 Apr;74(1):16-26. DMQPD1F RU https://pubmed.ncbi.nlm.nih.gov/19616446 DMQPTOZ DI DMQPTOZ DMQPTOZ DN Icatibant DMQPTOZ TI TTGY8IW DMQPTOZ TN B2 bradykinin receptor (BDKRB2) DMQPTOZ MA Antagonist DMQPTOZ RN Bradykinin receptor antagonists--a review of the patent literature 2005-2008. Expert Opin Ther Pat. 2009 Jul;19(7):919-41. DMQPTOZ RU https://pubmed.ncbi.nlm.nih.gov/19552510 DMQRPOS DI DMQRPOS DMQRPOS DN Chlorphentermine hydrochloride DMQRPOS TI TT3ROYC DMQRPOS TN Serotonin transporter (SERT) DMQRPOS MA Modulator DMQRPOS RN Aminorex, fenfluramine, and chlorphentermine are serotonin transporter substrates.Implications for primary pulmonary hypertension.Circulation.1999 Aug 24;100(8):869-75. DMQRPOS RU https://www.ncbi.nlm.nih.gov/pubmed/10458725 DMQSA2V DI DMQSA2V DMQSA2V DN Valbenazine tosylate DMQSA2V TI TTNZRI3 DMQSA2V TN Synaptic vesicle amine transporter (SLC18A2) DMQSA2V MA Modulator DMQSA2V RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMQSA2V RU https://www.fda.gov/ DMQSGM0 DI DMQSGM0 DMQSGM0 DN Hydroxyamphetamine Hydrobromide DMQSGM0 TI TTIU98M DMQSGM0 TN Trace amine-associated receptor-1 (TAAR1) DMQSGM0 MA Modulator DMQSGM0 RN Diagnostic pharmacology of the pupil.Clin Neuropharmacol.1985;8(1):27-37. DMQSGM0 RU https://www.ncbi.nlm.nih.gov/pubmed/3884149 DMQTAGO DI DMQTAGO DMQTAGO DN BMS-201038 DMQTAGO TI TTUS1RD DMQTAGO TN Microsomal triglyceride transfer protein (MTTP) DMQTAGO MA Inhibitor DMQTAGO RN Dyslipidemia and cardiovascular diseases. Curr Opin Lipidol. 2009 Apr;20(2):157-8. DMQTAGO RU https://pubmed.ncbi.nlm.nih.gov/19276898 DMQTFAO DI DMQTFAO DMQTFAO DN Fluorescein DMQTFAO TI TTHQZV7 DMQTFAO TN Mothers against decapentaplegic homolog 3 (SMAD3) DMQTFAO MA Inhibitor DMQTFAO RN In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6. DMQTFAO RU https://pubmed.ncbi.nlm.nih.gov/21074425 DMQTFAO DI DMQTFAO DMQTFAO DN Fluorescein DMQTFAO TI TTTQR47 DMQTFAO TN Solute carrier family 22 member 8 (SLC22A8) DMQTFAO MA Inhibitor DMQTFAO RN Structural variation governs substrate specificity for organic anion transporter (OAT) homologs. Potential remote sensing by OAT family members. J Biol Chem. 2007 Aug 17;282(33):23841-53. DMQTFAO RU https://pubmed.ncbi.nlm.nih.gov/17553798 DMQTJSX DI DMQTJSX DMQTJSX DN Fluvoxamine DMQTJSX TI TT3ROYC DMQTJSX TN Serotonin transporter (SERT) DMQTJSX MA Inhibitor DMQTJSX RN Changes of functional MRI findings in a patient whose pathological gambling improved with fluvoxamine. Yonsei Med J. 2009 Jun 30;50(3):441-4. DMQTJSX RU https://pubmed.ncbi.nlm.nih.gov/19568609 DMQTREB DI DMQTREB DMQTREB DN Uridine DMQTREB TI TTO0IB8 DMQTREB TN Thymidine phosphorylase (TYMP) DMQTREB MA Inhibitor DMQTREB RN Enzymatic activities of uridine and thymidine phosphorylase in normal and cancerous uterine cervical tissues. Hum Cell. 2007 Nov;20(4):107-10. DMQTREB RU https://pubmed.ncbi.nlm.nih.gov/17949350 DMQUSBT DI DMQUSBT DMQUSBT DN Daunorubicin DMQUSBT TI TTUTN1I DMQUSBT TN Human Deoxyribonucleic acid (hDNA) DMQUSBT MA Intercalator DMQUSBT RN 31P NMR spectra of ethidium, quinacrine, and daunomycin complexes with poly(adenylic acid).poly(uridylic acid) RNA duplex and calf thymus DNA. Biochemistry. 1989 Apr 4;28(7):2804-12. DMQUSBT RU https://pubmed.ncbi.nlm.nih.gov/2472832 DMQUSBT DI DMQUSBT DMQUSBT DN Daunorubicin DMQUSBT TI TTABD5E DMQUSBT TN DNA replication (DNA repli) DMQUSBT MA Modulator DMQUSBT RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMQUSBT RU https://www.fda.gov/ DMQVRZH DI DMQVRZH DMQVRZH DN Vitamin B3 DMQVRZH TI TTRHEQ4 DMQVRZH TN Diacylglycerol O-acyltransferase 2 (DGAT2) DMQVRZH MA Inhibitor DMQVRZH RN Hakozaki T, Minwalla L, Zhuang J, Chhoa M, Matsubara A, Miyamoto K, Greatens A, Hillebrand GG, Bissett DL, Boissy RE: The effect of niacinamide on reducing cutaneous pigmentation and suppression of melanosome transfer. Br J Dermatol. 2002 Jul;147(1):20-31. DMQVRZH RU https://pubmed.ncbi.nlm.nih.gov/12100180 DMQVRZH DI DMQVRZH DMQVRZH DN Vitamin B3 DMQVRZH TI TTWNV8U DMQVRZH TN Nicotinic acid receptor (HCAR2) DMQVRZH MA Agonist DMQVRZH RN Hakozaki T, Minwalla L, Zhuang J, Chhoa M, Matsubara A, Miyamoto K, Greatens A, Hillebrand GG, Bissett DL, Boissy RE: The effect of niacinamide on reducing cutaneous pigmentation and suppression of melanosome transfer. Br J Dermatol. 2002 Jul;147(1):20-31. DMQVRZH RU https://pubmed.ncbi.nlm.nih.gov/12100180 DMQVZJD DI DMQVZJD DMQVZJD DN Enoximone DMQVZJD TI TT06AWU DMQVZJD TN Phosphodiesterase 3A (PDE3A) DMQVZJD MA Inhibitor DMQVZJD RN Inhibitors of cyclic AMP phosphodiesterase. 2. Structural variations of N-cyclohexyl-N-methyl-4-[(1,2,3,5-tetrahydro- 2-oxoimidazo[2,1-b]quinazolin... J Med Chem. 1987 Feb;30(2):303-18. DMQVZJD RU https://pubmed.ncbi.nlm.nih.gov/3027339 DMQVZJD DI DMQVZJD DMQVZJD DN Enoximone DMQVZJD TI TTZCG4L DMQVZJD TN Phosphodiesterase 3 (PDE3) DMQVZJD MA Modulator DMQVZJD RN In vitro and in vivo effects of the phosphodiesterase-III inhibitor enoximone on malignant hyperthermia-susceptible swine. Anesthesiology. 2003 Apr;98(4):944-9. DMQVZJD RU https://www.ncbi.nlm.nih.gov/pubmed/12657857 DMQWZ0H DI DMQWZ0H DMQWZ0H DN Benzthiazide DMQWZ0H TI TTANPDJ DMQWZ0H TN Carbonic anhydrase II (CA-II) DMQWZ0H MA Inhibitor DMQWZ0H RN Nature of the inhibition of carbonic anhydrase by acetazolamide and benzthiazide. J Pharmacol Exp Ther. 1961 Mar;131:271-4. DMQWZ0H RU https://pubmed.ncbi.nlm.nih.gov/13760527 DMQXI9F DI DMQXI9F DMQXI9F DN L-Phenylalanine DMQXI9F TI TTUHP71 DMQXI9F TN Tyrosine 3-monooxygenase (TH) DMQXI9F MA Binder DMQXI9F RN Selectivity and affinity determinants for ligand binding to the aromatic amino acid hydroxylases. Curr Med Chem. 2007;14(4):455-67. DMQXI9F RU https://pubmed.ncbi.nlm.nih.gov/17305546 DMQXLD2 DI DMQXLD2 DMQXLD2 DN Cyproterone DMQXLD2 TI TTS64P2 DMQXLD2 TN Androgen receptor (AR) DMQXLD2 MA Antagonist DMQXLD2 RN Coactivator selective regulation of androgen receptor activity. Steroids. 2009 Aug;74(8):669-74. DMQXLD2 RU https://pubmed.ncbi.nlm.nih.gov/19463689 DMQXTJS DI DMQXTJS DMQXTJS DN Eptifibatide DMQXTJS TI TT38RM1 DMQXTJS TN Glycoprotein IIb/IIIa receptor (GPIIb/IIIa) DMQXTJS MA Modulator DMQXTJS RN Barbourin. A GPIIb-IIIa-specific integrin antagonist from the venom of Sistrurus m. barbouri. J Biol Chem. 1991 May 25;266(15):9359-62. DMQXTJS RU https://pubmed.ncbi.nlm.nih.gov/2033037 DMQYJIR DI DMQYJIR DMQYJIR DN Macimorelin DMQYJIR TI TTWDC17 DMQYJIR TN Growth hormone secretagogue receptor 1 (GHSR) DMQYJIR MA Agonist DMQYJIR RN National Cancer Institute Drug Dictionary (drug id 735530). DMQYJIR RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=735530 DMQYUWG DI DMQYUWG DMQYUWG DN Toremifene DMQYUWG TI TTZAYWL DMQYUWG TN Estrogen receptor (ESR) DMQYUWG MA Modulator DMQYUWG RN Effect of selective estrogen receptor modulators on cell proliferation and estrogen receptor activities in normal human prostate stromal and epithe... Prostate Cancer Prostatic Dis. 2009;12(4):375-81. DMQYUWG RU https://pubmed.ncbi.nlm.nih.gov/19468285 DMQYV60 DI DMQYV60 DMQYV60 DN Isopropamide iodide DMQYV60 TI TTOXS3C DMQYV60 TN Muscarinic acetylcholine receptor (CHRM) DMQYV60 MA Modulator DMQYV60 RN Competitive and non-competitive antagonism exhibited by 'selective' antagonists at atrial and ileal muscarinic receptor subtypes. Br J Pharmacol. 1987 Apr;90(4):701-7. DMQYV60 RU https://pubmed.ncbi.nlm.nih.gov/3580704 DMQZ9GF DI DMQZ9GF DMQZ9GF DN Trilostane DMQZ9GF TI TTOM3J0 DMQZ9GF TN Estrogen receptor beta (ESR2) DMQZ9GF MA Modulator DMQZ9GF RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMQZ9GF RU https://www.fda.gov/ DMQZBXI DI DMQZBXI DMQZBXI DN Calaspargase pegol DMQZBXI TI TT4WT91 DMQZBXI TN Asparaginase (ASRGL1) DMQZBXI MA Inhibitor DMQZBXI RN Pharmacokinetic and pharmacodynamic properties of calaspargase pegol Escherichia coli L-asparaginase in the treatment of patients with acute lymphoblastic leukemia: results from Children's Oncology Group Study AALL07P4. J Clin Oncol. 2014 Dec 1;32(34):3874-82. DMQZBXI RU https://pubmed.ncbi.nlm.nih.gov/25348002 DMR0TYK DI DMR0TYK DMR0TYK DN Fosdenopterin DMR0TYK TI TT7RJY8 DMR0TYK TN Xanthine dehydrogenase/oxidase (XDH) DMR0TYK MA Cofactor DMR0TYK RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2021 DMR0TYK RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214018s000lbl.pdf DMR27C8 DI DMR27C8 DMR27C8 DN Artesunate DMR27C8 TI TTZVSJ2 DMR27C8 TN Sarcoplasmic/endoplasmic reticulum calcium ATPase (ATP2A) DMR27C8 MA Inhibitor DMR27C8 RN The fight against drug-resistant malaria: novel plasmodial targets and antimalarial drugs. Curr Med Chem. 2008;15(2):161-71. DMR27C8 RU https://pubmed.ncbi.nlm.nih.gov/18220771 DMR2IQ4 DI DMR2IQ4 DMR2IQ4 DN Tizanidine DMR2IQ4 TI TTQ8AFT DMR2IQ4 TN Adrenergic receptor Alpha-2 (ADRA2) DMR2IQ4 MA Agonist DMR2IQ4 RN Tizanidine. A review of its pharmacology, clinical efficacy and tolerability in the management of spasticity associated with cerebral and spinal disorders. Drugs. 1997 Mar;53(3):435-52. DMR2IQ4 RU https://pubmed.ncbi.nlm.nih.gov/9074844 DMR2J95 DI DMR2J95 DMR2J95 DN Omadacycline DMR2J95 TI TTOVFH2 DMR2J95 TN Bacterial 30S ribosomal RNA (Bact 30S rRNA) DMR2J95 MA Inhibitor DMR2J95 RN Omadacycline Enters the Ring: A New Antimicrobial Contender.Pharmacotherapy. 2018 Dec;38(12):1194-1204. DMR2J95 RU https://pubmed.ncbi.nlm.nih.gov/30290000 DMR4HIW DI DMR4HIW DMR4HIW DN Insulin-glargine DMR4HIW TI TTZOPHG DMR4HIW TN Insulin (INS) DMR4HIW MA Modulator DMR4HIW RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMR4HIW RU https://www.fda.gov/ DMR5QS6 DI DMR5QS6 DMR5QS6 DN Hydroxystilbamidine Isethionate DMR5QS6 TI TTS1W4A DMR5QS6 TN Bacterial Deoxyribonucleic acid (Bact DNA) DMR5QS6 MA Modulator DMR5QS6 RN Interaction between hydroxystilbamidine and DNA. I. Binding isotherms and thermodynamics of the association. Biochim Biophys Acta. 1975 Sep 12;407(1):24-42. DMR5QS6 RU https://www.ncbi.nlm.nih.gov/pubmed/1242363 DMR5ZUP DI DMR5ZUP DMR5ZUP DN Paramethadione DMR5ZUP TI TT729IR DMR5ZUP TN Voltage-gated calcium channel alpha Cav3.1 (CACNA1G) DMR5ZUP MA Blocker DMR5ZUP RN Prophylactic and therapeutic functions of T-type calcium blockers against noise-induced hearing loss. Hear Res. 2007 Apr;226(1-2):52-60. DMR5ZUP RU https://pubmed.ncbi.nlm.nih.gov/17291698 DMR6N7H DI DMR6N7H DMR6N7H DN Acetohexamide DMR6N7H TI TTP835K DMR6N7H TN ATP-binding cassette transporter C8 (ABCC8) DMR6N7H MA Modulator DMR6N7H RN Diabetes and insulin secretion: the ATP-sensitive K+ channel (K ATP) connection.Diabetes.2005 Nov;54(11):3065-72. DMR6N7H RU https://www.ncbi.nlm.nih.gov/pubmed/16249427 DMR6QH0 DI DMR6QH0 DMR6QH0 DN Venlafaxine DMR6QH0 TI TT3ROYC DMR6QH0 TN Serotonin transporter (SERT) DMR6QH0 MA Inhibitor DMR6QH0 RN Clinically relevant drug interactions with new generation antidepressants and antipsychotics. Ther Umsch. 2009 Jun;66(6):485-92. DMR6QH0 RU https://pubmed.ncbi.nlm.nih.gov/19496045 DMR6QH0 DI DMR6QH0 DMR6QH0 DN Venlafaxine DMR6QH0 TI TTAWNKZ DMR6QH0 TN Norepinephrine transporter (NET) DMR6QH0 MA Inhibitor DMR6QH0 RN Clinically relevant drug interactions with new generation antidepressants and antipsychotics. Ther Umsch. 2009 Jun;66(6):485-92. DMR6QH0 RU https://pubmed.ncbi.nlm.nih.gov/19496045 DMR7IVC DI DMR7IVC DMR7IVC DN Pimavanserin DMR7IVC TI TTJQOD7 DMR7IVC TN 5-HT 2A receptor (HTR2A) DMR7IVC MA Modulator DMR7IVC RN Pimavanserin, a selective serotonin (5-HT)2A-inverse agonist, enhances the efficacy and safety of risperidone, 2mg/day, but does not enhance efficacy of haloperidol, 2mg/day: comparison with reference dose risperidone, 6mg/day.Schizophr Res.2012 Nov;141(2-3):144-52. DMR7IVC RU https://www.ncbi.nlm.nih.gov/pubmed/22954754 DMR87LC DI DMR87LC DMR87LC DN Ethambutol DMR87LC TI TT1Q8GP DMR87LC TN Mycobacterium Arabinosyltransferase C (MycB embC) DMR87LC MA Inhibitor DMR87LC RN The arabinosyltransferase EmbC is inhibited by ethambutol in Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2009 Oct;53(10):4138-46. DMR87LC RU https://pubmed.ncbi.nlm.nih.gov/19596878 DMR8H31 DI DMR8H31 DMR8H31 DN Quinapril DMR8H31 TI TTL69WB DMR8H31 TN Angiotensin-converting enzyme (ACE) DMR8H31 MA Inhibitor DMR8H31 RN An experimental model of encapsulating peritoneal sclerosis. Perit Dial Int. 2009 Feb;29 Suppl 2:S49-50. DMR8H31 RU https://pubmed.ncbi.nlm.nih.gov/19270231 DMR8ONJ DI DMR8ONJ DMR8ONJ DN Leflunomide DMR8ONJ TI TT3PQ2Y DMR8ONJ TN Plasmodium Dihydroorotate dehydrogenase (Malaria DHOdehase) DMR8ONJ MA Inhibitor DMR8ONJ RN Identification and characterization of potential new therapeutic targets in inflammatory and autoimmune diseases. Eur J Biochem. 1999 Dec;266(3):1184-91. DMR8ONJ RU https://pubmed.ncbi.nlm.nih.gov/10583416 DMR8YD6 DI DMR8YD6 DMR8YD6 DN B-Lactams DMR8YD6 TI TTLP6GN DMR8YD6 TN Bacterial DD-carboxypeptidase (Bact vanYB) DMR8YD6 MA Inhibitor DMR8YD6 RN Has nature already identified all useful antibacterial targets Curr Opin Microbiol. 2008 Oct;11(5):387-92. DMR8YD6 RU https://pubmed.ncbi.nlm.nih.gov/18804175 DMR8YD6 DI DMR8YD6 DMR8YD6 DN B-Lactams DMR8YD6 TI TTGTQHC DMR8YD6 TN DNA topoisomerase I (TOP1) DMR8YD6 MA Inhibitor DMR8YD6 RN Luteolin, an emerging anti-cancer flavonoid, poisons eukaryotic DNA topoisomerase I. Biochem J. 2002 Sep 1;366(Pt 2):653-61. DMR8YD6 RU https://pubmed.ncbi.nlm.nih.gov/12027807 DMR8YD6 DI DMR8YD6 DMR8YD6 DN B-Lactams DMR8YD6 TI TTPOI4B DMR8YD6 TN Acetyl-CoA:lyso-PAF acetyltransferase (PCAT) DMR8YD6 MA Inhibitor DMR8YD6 RN Inhibition of lysoPAF acetyltransferase activity by flavonoids. Inflamm Res. 1996 Nov;45(11):546-9. DMR8YD6 RU https://pubmed.ncbi.nlm.nih.gov/8951505 DMRADYL DI DMRADYL DMRADYL DN Pinacidil DMRADYL TI TT1VOHK DMRADYL TN Potassium channel unspecific (KC) DMRADYL MA Modulator DMRADYL RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMRADYL RU https://www.fda.gov/ DMRBJNZ DI DMRBJNZ DMRBJNZ DN Forasartan DMRBJNZ TI TT8DBY3 DMRBJNZ TN Angiotensin II receptor type-1 (AGTR1) DMRBJNZ MA Antagonist DMRBJNZ RN Non-peptide angiotensin II receptor antagonists: chemical feature based pharmacophore identification. J Med Chem. 2003 Feb 27;46(5):716-26. DMRBJNZ RU https://pubmed.ncbi.nlm.nih.gov/12593652 DMRCLZB DI DMRCLZB DMRCLZB DN Pentagastrin DMRCLZB TI TTVFO0U DMRCLZB TN Gastrin/cholecystokinin type B receptor (CCKBR) DMRCLZB MA Agonist DMRCLZB RN Functional interactions between endocannabinoid and CCK neurotransmitter systems may be critical for extinction learning. Neuropsychopharmacology. 2009 Jan;34(2):509-21. DMRCLZB RU https://pubmed.ncbi.nlm.nih.gov/18580872 DMRCX8K DI DMRCX8K DMRCX8K DN Eloctate DMRCX8K TI TT1290U DMRCX8K TN Coagulation factor VIII (F8) DMRCX8K MA Modulator DMRCX8K RN 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81. DMRCX8K RU https://pubmed.ncbi.nlm.nih.gov/25633781 DMRD1QK DI DMRD1QK DMRD1QK DN Netilmicin DMRD1QK TI TTQ8KVI DMRD1QK TN Staphylococcus 30S ribosomal subunit (Stap-coc pbp2) DMRD1QK MA Binder DMRD1QK RN Ribosomal resistance in the gentamicin producer organism Micromonospora purpurea. Antimicrob Agents Chemother. 1982 Aug;22(2):231-6. DMRD1QK RU https://pubmed.ncbi.nlm.nih.gov/6927285 DMRDUC0 DI DMRDUC0 DMRDUC0 DN Elagolix sodium DMRDUC0 TI TT8R70G DMRDUC0 TN Gonadotropin-releasing hormone receptor (GNRHR) DMRDUC0 MA Antagonist DMRDUC0 RN 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. DMRDUC0 RU https://pubmed.ncbi.nlm.nih.gov/30710142 DMREUQ6 DI DMREUQ6 DMREUQ6 DN Valsartan DMREUQ6 TI TT8DBY3 DMREUQ6 TN Angiotensin II receptor type-1 (AGTR1) DMREUQ6 MA Antagonist DMREUQ6 RN Radioligand binding assays: application of [(125)I]angiotensin II receptor binding. Methods Mol Biol. 2009;552:131-41. DMREUQ6 RU https://pubmed.ncbi.nlm.nih.gov/19513646 DMRF9YK DI DMRF9YK DMRF9YK DN Empagliflozin DMRF9YK TI TTLWPVF DMRF9YK TN Sodium/glucose cotransporter 2 (SGLT2) DMRF9YK MA Modulator DMRF9YK RN 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81. DMRF9YK RU https://pubmed.ncbi.nlm.nih.gov/25633781 DMRFWGK DI DMRFWGK DMRFWGK DN Novobiocin DMRFWGK TI TT0IHXV DMRFWGK TN DNA topoisomerase II (TOP2) DMRFWGK MA Inhibitor DMRFWGK RN Transcriptional responses of Bacillus subtillis and thuringiensis to antibiotics and anti-tumour drugs. Int J Mol Med. 2009 Jan;23(1):33-9. DMRFWGK RU https://pubmed.ncbi.nlm.nih.gov/19082504 DMRGZ16 DI DMRGZ16 DMRGZ16 DN Sulfamethazine DMRGZ16 TI TT4ILYC DMRGZ16 TN Bacterial Dihydropteroate synthetase (Bact folP) DMRGZ16 MA Inhibitor DMRGZ16 RN A new and simple method to determine trace levels of sulfonamides in honey by high performance liquid chromatography with fluorescence detection. J Chromatogr A. 2009 Oct 23;1216(43):7275-80. DMRGZ16 RU https://pubmed.ncbi.nlm.nih.gov/19505691 DMRH0D5 DI DMRH0D5 DMRH0D5 DN PEGylated IFN beta 1-a DMRH0D5 TI TT4TZ8J DMRH0D5 TN Interferon-beta (IFNB1) DMRH0D5 MA Modulator DMRH0D5 RN Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study. Lancet Neurol. 2014 Jul;13(7):657-65. DMRH0D5 RU https://pubmed.ncbi.nlm.nih.gov/24794721 DMRH7CV DI DMRH7CV DMRH7CV DN Deserpidine DMRH7CV TI TTL69WB DMRH7CV TN Angiotensin-converting enzyme (ACE) DMRH7CV MA Inhibitor DMRH7CV RN Angiotensin II-induced modulation of endothelium-dependent relaxation in rabbit mesenteric resistance arteries. J Physiol. 2003 May 1;548(Pt 3):893-906. DMRH7CV RU https://pubmed.ncbi.nlm.nih.gov/12651915 DMRHGI9 DI DMRHGI9 DMRHGI9 DN Cisplatin DMRHGI9 TI TTUTN1I DMRHGI9 TN Human Deoxyribonucleic acid (hDNA) DMRHGI9 MA Modulator DMRHGI9 RN Cisplatin and DNA repair in cancer chemotherapy.Trends Biochem Sci.1995 Oct;20(10):435-9. DMRHGI9 RU https://www.ncbi.nlm.nih.gov/pubmed/8533159 DMRICNP DI DMRICNP DMRICNP DN Vandetanib DMRICNP TI TTUTJGQ DMRICNP TN Vascular endothelial growth factor receptor 2 (KDR) DMRICNP MA Inhibitor DMRICNP RN A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22. DMRICNP RU https://pubmed.ncbi.nlm.nih.gov/17692029 DMRICNP DI DMRICNP DMRICNP DN Vandetanib DMRICNP TI TT4DXQT DMRICNP TN Proto-oncogene c-Ret (RET) DMRICNP MA Inhibitor DMRICNP RN A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22. DMRICNP RU https://pubmed.ncbi.nlm.nih.gov/17692029 DMRICNP DI DMRICNP DMRICNP DN Vandetanib DMRICNP TI TTGKNB4 DMRICNP TN Epidermal growth factor receptor (EGFR) DMRICNP MA Inhibitor DMRICNP RN A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22. DMRICNP RU https://pubmed.ncbi.nlm.nih.gov/17692029 DMRJ3YX DI DMRJ3YX DMRJ3YX DN Alteplase DMRJ3YX TI TTP86E2 DMRJ3YX TN Plasminogen (PLG) DMRJ3YX MA Activator DMRJ3YX RN Thrombolytic therapies: the current state of affairs. J Endovasc Ther. 2005 Apr;12(2):224-32. DMRJ3YX RU https://pubmed.ncbi.nlm.nih.gov/15823070 DMRJ7D1 DI DMRJ7D1 DMRJ7D1 DN Nomegestrol acetate DMRJ7D1 TI TTZAYWL DMRJ7D1 TN Estrogen receptor (ESR) DMRJ7D1 MA Modulator DMRJ7D1 RN Regulation of rat uterine steroid receptors by nomegestrol acetate, a new 19-nor-progesterone derivative. J Pharmacol Exp Ther. 1989 Feb;248(2):758-61. DMRJ7D1 RU https://pubmed.ncbi.nlm.nih.gov/2918478 DMRJFN9 DI DMRJFN9 DMRJFN9 DN Theophylline DMRJFN9 TI TTSLI08 DMRJFN9 TN Adenosine receptor (ADOR) DMRJFN9 MA Antagonist DMRJFN9 RN Emerging adenosine receptor agonists. Expert Opin Emerg Drugs. 2007 Sep;12(3):479-92. DMRJFN9 RU https://pubmed.ncbi.nlm.nih.gov/17874974 DMRJLAT DI DMRJLAT DMRJLAT DN Osimertinib DMRJLAT TI TTGKNB4 DMRJLAT TN Epidermal growth factor receptor (EGFR) DMRJLAT MA Inhibitor DMRJLAT RN AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov. 2014 Sep;4(9):1046-61. DMRJLAT RU https://pubmed.ncbi.nlm.nih.gov/24893891 DMRJSP8 DI DMRJSP8 DMRJSP8 DN Orlistat DMRJSP8 TI TT6OEDT DMRJSP8 TN Cannabinoid receptor 1 (CB1) DMRJSP8 MA Inhibitor DMRJSP8 RN Tetrahydrolipstatin analogues as modulators of endocannabinoid 2-arachidonoylglycerol metabolism. J Med Chem. 2008 Nov 13;51(21):6970-9. DMRJSP8 RU https://pubmed.ncbi.nlm.nih.gov/18831576 DMRJSP8 DI DMRJSP8 DMRJSP8 DN Orlistat DMRJSP8 TI TTXMY0J DMRJSP8 TN Pancreatic triacylglycerol lipase (PNLIP) DMRJSP8 MA Modulator DMRJSP8 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMRJSP8 RU https://www.fda.gov/ DMRK8OT DI DMRK8OT DMRK8OT DN Candesartan DMRK8OT TI TT8DBY3 DMRK8OT TN Angiotensin II receptor type-1 (AGTR1) DMRK8OT MA Antagonist DMRK8OT RN Candesartan: widening indications for this angiotensin II receptor blocker Expert Opin Pharmacother. 2009 Aug;10(12):1995-2007. DMRK8OT RU https://pubmed.ncbi.nlm.nih.gov/19563275 DMRKE63 DI DMRKE63 DMRKE63 DN Chlorambucil DMRKE63 TI TTABD5E DMRKE63 TN DNA replication (DNA repli) DMRKE63 MA Intercalator DMRKE63 RN Roles of DNA repair and reductase activity in the cytotoxicity of the hypoxia-activated dinitrobenzamide mustard PR-104A. Mol Cancer Ther. 2009 Jun;8(6):1714-23. DMRKE63 RU https://pubmed.ncbi.nlm.nih.gov/19509245 DMRKOS1 DI DMRKOS1 DMRKOS1 DN Oxilofrine DMRKOS1 TI TTVIREA DMRKOS1 TN Adrenergic receptor (ADR) DMRKOS1 MA Modulator DMRKOS1 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DMRKOS1 RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DMRKXPT DI DMRKXPT DMRKXPT DN Ketoprofen DMRKXPT TI TTVKILB DMRKXPT TN Prostaglandin G/H synthase 2 (COX-2) DMRKXPT MA Inhibitor DMRKXPT RN Probing the skin permeation of fish oil/EPA and ketoprofen-3. Effects on epidermal COX-2 and LOX. Prostaglandins Leukot Essent Fatty Acids. 2007 Jun;76(6):357-62. DMRKXPT RU https://pubmed.ncbi.nlm.nih.gov/17588732 DMRL3AB DI DMRL3AB DMRL3AB DN Famotidine DMRL3AB TI TTQHJ1K DMRL3AB TN Histamine H2 receptor (H2R) DMRL3AB MA Antagonist DMRL3AB RN Histamine H1 and H2 receptor antagonists accelerate skin barrier repair and prevent epidermal hyperplasia induced by barrier disruption in a dry environment. J Invest Dermatol. 2001 Feb;116(2):261-5. DMRL3AB RU https://pubmed.ncbi.nlm.nih.gov/11180002 DMRM0JV DI DMRM0JV DMRM0JV DN Nalidixic acid DMRM0JV TI TT0IHXV DMRM0JV TN DNA topoisomerase II (TOP2) DMRM0JV MA Inhibitor DMRM0JV RN Activity of fluoroquinolone antibiotics against Plasmodium falciparum in vitro. Antimicrob Agents Chemother. 1988 Aug;32(8):1182-6. DMRM0JV RU https://pubmed.ncbi.nlm.nih.gov/2847647 DMRM3AW DI DMRM3AW DMRM3AW DN Acarbose DMRM3AW TI TTXWASR DMRM3AW TN Intestinal maltase-glucoamylase (MGAM) DMRM3AW MA Modulator DMRM3AW RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMRM3AW RU https://www.fda.gov/ DMRMCXW DI DMRMCXW DMRMCXW DN Zotarolimus DMRMCXW TI TTCJG29 DMRMCXW TN Serine/threonine-protein kinase mTOR (mTOR) DMRMCXW MA Modulator DMRMCXW RN Natural products to drugs: natural product-derived compounds in clinical trials. Nat Prod Rep. 2008 Jun;25(3):475-516. DMRMCXW RU https://pubmed.ncbi.nlm.nih.gov/18497896 DMRMDWA DI DMRMDWA DMRMDWA DN Estropipate DMRMDWA TI TTZAYWL DMRMDWA TN Estrogen receptor (ESR) DMRMDWA MA Modulator DMRMDWA RN US patent application no. 5,004,651, Stabilizing system for solid dosage forms. DMRMDWA RU http://www.google.com/patents/US5004651 DMRMFP4 DI DMRMFP4 DMRMFP4 DN Inamrinone Lactate DMRMFP4 TI TTZCG4L DMRMFP4 TN Phosphodiesterase 3 (PDE3) DMRMFP4 MA Inhibitor DMRMFP4 RN Effects of amrinone on hepatic ischemia-reperfusion injury in rats. J Hepatol. 2002 Jul;37(1):31-8. DMRMFP4 RU https://pubmed.ncbi.nlm.nih.gov/12076859 DMRMS0L DI DMRMS0L DMRMS0L DN Morphine DMRMS0L TI TTKWM86 DMRMS0L TN Opioid receptor mu (MOP) DMRMS0L MA Modulator DMRMS0L RN Antianalgesia: stereoselective action of dextro-morphine over levo-morphine on glia in the mouse spinal cord.J Pharmacol Exp Ther.2005 Sep;314(3):1101-8. DMRMS0L RU https://www.ncbi.nlm.nih.gov/pubmed/15901793 DMRMS1A DI DMRMS1A DMRMS1A DN Betamethasone Benzoate DMRMS1A TI TTYRL6O DMRMS1A TN Glucocorticoid receptor (NR3C1) DMRMS1A MA Modulator DMRMS1A RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMRMS1A RU https://www.fda.gov/ DMRQD04 DI DMRQD04 DMRQD04 DN Tramadol DMRQD04 TI TTWJBZ5 DMRQD04 TN 5-HT 2C receptor (HTR2C) DMRQD04 MA Modulator DMRQD04 RN The inhibitory effects of tramadol on 5-hydroxytryptamine type 2C receptors expressed in Xenopus oocytes. Anesth Analg. 2004 May;98(5):1401-6, table of contents. DMRQD04 RU https://pubmed.ncbi.nlm.nih.gov/15105221 DMRSKMZ DI DMRSKMZ DMRSKMZ DN Satumomab Pendetide DMRSKMZ TI TTX35ZM DMRSKMZ TN Tumor-associated glycoprotein 72 (TAG-72) DMRSKMZ MA Binder DMRSKMZ RN Indium-111 satumomab pendetide: the first FDA-approved monoclonal antibody for tumor imaging. J Nucl Med Technol. 1998 Sep;26(3):155-63; quiz 170-1. DMRSKMZ RU https://pubmed.ncbi.nlm.nih.gov/9755434 DMRSX53 DI DMRSX53 DMRSX53 DN nusinersen DMRSX53 TI TTSVGQ5 DMRSX53 TN SMN1 messenger RNA (SMN1 mRNA) DMRSX53 MA Modulator DMRSX53 RN 2016 FDA drug approvals. Nat Rev Drug Discov. 2017 Feb 2;16(2):73-76. DMRSX53 RU https://www.ncbi.nlm.nih.gov/pubmed/28148938 DMRSZA5 DI DMRSZA5 DMRSZA5 DN Cefacetrile DMRSZA5 TI TTJP4SM DMRSZA5 TN Bacterial Penicillin binding protein (Bact PBP) DMRSZA5 MA Binder DMRSZA5 RN Single dose 1 g ceftriaxone for urogenital and pharyngeal infection caused by Neisseria gonorrhoeae. Int J Urol. 2008 Sep;15(9):837-42. DMRSZA5 RU https://pubmed.ncbi.nlm.nih.gov/18665871 DMRTSGP DI DMRTSGP DMRTSGP DN Amiloride DMRTSGP TI TTRJYB6 DMRTSGP TN Acid-sensing ion channel 1 (ASIC1) DMRTSGP MA Modulator DMRTSGP RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMRTSGP RU https://www.fda.gov/ DMRV7H0 DI DMRV7H0 DMRV7H0 DN Bumetanide DMRV7H0 TI TTS087L DMRV7H0 TN Solute carrier family 12 member 1 (SLC12A1) DMRV7H0 MA Blocker DMRV7H0 RN Nerve Terminal GABAA Receptors Activate Ca2+/Calmodulin-dependent Signaling to Inhibit Voltage-gated Ca2+ Influx and Glutamate Release. J Biol Chem. 2009 Mar 27;284(13):8726-37. DMRV7H0 RU https://pubmed.ncbi.nlm.nih.gov/19141616 DMRVBWU DI DMRVBWU DMRVBWU DN Bentazepam DMRVBWU TI TTEX6LM DMRVBWU TN GABA(A) receptor gamma-3 (GABRG3) DMRVBWU MA Modulator DMRVBWU RN Prodynorphin gene deletion increased anxiety-like behaviours, impaired the anxiolytic effect of bromazepam and altered GABAA receptor subunits gene expression in the amygdala. J Psychopharmacol. 2011Jan;25(1):87-96. DMRVBWU RU https://pubmed.ncbi.nlm.nih.gov/20530587 DMS0AFE DI DMS0AFE DMS0AFE DN Desoxycorticosterone acetate DMS0AFE TI TT26PHO DMS0AFE TN Mineralocorticoid receptor (MR) DMS0AFE MA Modulator DMS0AFE RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMS0AFE RU https://www.fda.gov/ DMS104F DI DMS104F DMS104F DN Temsirolimus DMS104F TI TTCJG29 DMS104F TN Serine/threonine-protein kinase mTOR (mTOR) DMS104F MA Inhibitor DMS104F RN Advances in kinase targeting: current clinical use and clinical trials. Trends Pharmacol Sci. 2014 Nov;35(11):604-20. DMS104F RU https://pubmed.ncbi.nlm.nih.gov/25312588 DMS1GYT DI DMS1GYT DMS1GYT DN Mirabegron DMS1GYT TI TTMXGCW DMS1GYT TN Adrenergic receptor beta-3 (ADRB3) DMS1GYT MA Modulator DMS1GYT RN Nat Rev Drug Discov. 2013 Feb;12(2):87-90. DMS1GYT RU https://pubmed.ncbi.nlm.nih.gov/23370234 DMS2IUH DI DMS2IUH DMS2IUH DN Valganciclovir DMS2IUH TI TTIU7X1 DMS2IUH TN Herpes simplex virus DNA polymerase UL30 (HSV UL30) DMS2IUH MA Inhibitor DMS2IUH RN Drug targets in cytomegalovirus infection. Infect Disord Drug Targets. 2009 Apr;9(2):201-22. DMS2IUH RU https://pubmed.ncbi.nlm.nih.gov/19275707 DMS2J0Z DI DMS2J0Z DMS2J0Z DN Pexidartinib DMS2J0Z TI TT7MRDV DMS2J0Z TN Macrophage colony-stimulating factor 1 receptor (CSF1R) DMS2J0Z MA Inhibitor DMS2J0Z RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019 DMS2J0Z RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211810s000lbl.pdf DMS2J0Z DI DMS2J0Z DMS2J0Z DN Pexidartinib DMS2J0Z TI TTX41N9 DMS2J0Z TN Tyrosine-protein kinase Kit (KIT) DMS2J0Z MA Inhibitor DMS2J0Z RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019 DMS2J0Z RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211810s000lbl.pdf DMS2J0Z DI DMS2J0Z DMS2J0Z DN Pexidartinib DMS2J0Z TI TTGJCWZ DMS2J0Z TN Fms-like tyrosine kinase 3 (FLT-3) DMS2J0Z MA Inhibitor DMS2J0Z RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019 DMS2J0Z RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211810s000lbl.pdf DMS2M7O DI DMS2M7O DMS2M7O DN Deferiprone DMS2M7O TI TTUDR0C DMS2M7O TN Iron (Fe) DMS2M7O MA Modulator DMS2M7O RN 2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4. DMS2M7O RU https://pubmed.ncbi.nlm.nih.gov/22293555 DMS3508 DI DMS3508 DMS3508 DN Carboprost tromethamine DMS3508 TI TTT2ZAR DMS3508 TN Prostaglandin F2-alpha receptor (PTGFR) DMS3508 MA Modulator DMS3508 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMS3508 RU https://www.fda.gov/ DMS3GVE DI DMS3GVE DMS3GVE DN Desmopressin DMS3GVE TI TTYCILE DMS3GVE TN Vasopressin receptor (VR) DMS3GVE MA Modulator DMS3GVE RN Vasopressin V2 (SR121463A) and V1a (SR49059) receptor antagonists both inhibit desmopressin vasorelaxing activity. Eur J Pharmacol. 1999 Nov 3;383(3):287-90. DMS3GVE RU https://pubmed.ncbi.nlm.nih.gov/10594321 DMS3GVE DI DMS3GVE DMS3GVE DN Desmopressin DMS3GVE TI TTL9MHW DMS3GVE TN Vasopressin V1b receptor (V1BR) DMS3GVE MA Agonist DMS3GVE RN Design of potent and selective agonists for the human vasopressin V1b receptor based on modifications of [deamino-cys1]arginine vasopressin at position 4. J Med Chem. 2004 Apr 22;47(9):2375-88. DMS3GVE RU https://pubmed.ncbi.nlm.nih.gov/15084136 DMS3GVE DI DMS3GVE DMS3GVE DN Desmopressin DMS3GVE TI TTK8R02 DMS3GVE TN Vasopressin V2 receptor (V2R) DMS3GVE MA Agonist DMS3GVE RN Design of potent and selective agonists for the human vasopressin V1b receptor based on modifications of [deamino-cys1]arginine vasopressin at position 4. J Med Chem. 2004 Apr 22;47(9):2375-88. DMS3GVE RU https://pubmed.ncbi.nlm.nih.gov/15084136 DMS3GVE DI DMS3GVE DMS3GVE DN Desmopressin DMS3GVE TI TTSCIUP DMS3GVE TN Oxytocin receptor (OTR) DMS3GVE MA Agonist DMS3GVE RN Design of potent and selective agonists for the human vasopressin V1b receptor based on modifications of [deamino-cys1]arginine vasopressin at position 4. J Med Chem. 2004 Apr 22;47(9):2375-88. DMS3GVE RU https://pubmed.ncbi.nlm.nih.gov/15084136 DMS3GVE DI DMS3GVE DMS3GVE DN Desmopressin DMS3GVE TI TT4TFGN DMS3GVE TN Vasopressin V1a receptor (V1AR) DMS3GVE MA Agonist DMS3GVE RN Design of potent and selective agonists for the human vasopressin V1b receptor based on modifications of [deamino-cys1]arginine vasopressin at position 4. J Med Chem. 2004 Apr 22;47(9):2375-88. DMS3GVE RU https://pubmed.ncbi.nlm.nih.gov/15084136 DMS3GX2 DI DMS3GX2 DMS3GX2 DN Telmisartan DMS3GX2 TI TT8DBY3 DMS3GX2 TN Angiotensin II receptor type-1 (AGTR1) DMS3GX2 MA Antagonist DMS3GX2 RN Deletion of angiotensin II type I receptor reduces hepatic steatosis. J Hepatol. 2009 Jun;50(6):1226-35. DMS3GX2 RU https://pubmed.ncbi.nlm.nih.gov/19395110 DMS3YE9 DI DMS3YE9 DMS3YE9 DN Amantadine DMS3YE9 TI TTXT3PU DMS3YE9 TN Influenza M2 protein (Influ M) DMS3YE9 MA Inhibitor DMS3YE9 RN Discovery of spiro-piperidine inhibitors and their modulation of the dynamics of the M2 proton channel from influenza A virus. J Am Chem Soc. 2009 Jun 17;131(23):8066-76. DMS3YE9 RU https://pubmed.ncbi.nlm.nih.gov/19469531 DMS4BLQ DI DMS4BLQ DMS4BLQ DN Aminolevulinic acid hci DMS4BLQ TI TTJHKYD DMS4BLQ TN Delta-aminolevulinic acid dehydratase (ALAD) DMS4BLQ MA Inhibitor DMS4BLQ RN Exploring proteomes and analyzing protein processing by mass spectrometric identification of sorted N-terminal peptides. Nat Biotechnol. 2003 May;21(5):566-9. DMS4BLQ RU https://pubmed.ncbi.nlm.nih.gov/12665801 DMS51VC DI DMS51VC DMS51VC DN Clomiphene citrate DMS51VC TI TTZAYWL DMS51VC TN Estrogen receptor (ESR) DMS51VC MA Modulator DMS51VC RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMS51VC RU https://www.fda.gov/ DMS5IEB DI DMS5IEB DMS5IEB DN Docarpamine DMS5IEB TI TTEX248 DMS5IEB TN Dopamine D2 receptor (D2R) DMS5IEB MA Modulator DMS5IEB RN Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. DMS5IEB RU https://pubmed.ncbi.nlm.nih.gov/17309302 DMS60RB DI DMS60RB DMS60RB DN Levofloxacin DMS60RB TI TTN6J5F DMS60RB TN Bacterial DNA gyrase (Bact gyrase) DMS60RB MA Modulator DMS60RB RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMS60RB RU https://www.fda.gov/ DMS60RB DI DMS60RB DMS60RB DN Levofloxacin DMS60RB TI TTIXTO3 DMS60RB TN Staphylococcus Topoisomerase IV (Stap-coc parC) DMS60RB MA Modulator DMS60RB RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMS60RB RU https://www.fda.gov/ DMS7OU8 DI DMS7OU8 DMS7OU8 DN Elapegademase DMS7OU8 TI TTLP57V DMS7OU8 TN Adenosine deaminase (ADA) DMS7OU8 MA Modulator DMS7OU8 RN 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. DMS7OU8 RU https://pubmed.ncbi.nlm.nih.gov/30710142 DMS7T13 DI DMS7T13 DMS7T13 DN Meclizine DMS7T13 TI TTRANFM DMS7T13 TN Orphan nuclear receptor NR1I3 (NR1I3) DMS7T13 MA Modulator DMS7T13 RN Synthetic drugs and natural products as modulators of constitutive androstane receptor (CAR) and pregnane X receptor (PXR). Drug Metab Rev. 2006;38(1-2):51-73. DMS7T13 RU https://pubmed.ncbi.nlm.nih.gov/16684648 DMS8IFC DI DMS8IFC DMS8IFC DN Sorafenib DMS8IFC TI TTUTJGQ DMS8IFC TN Vascular endothelial growth factor receptor 2 (KDR) DMS8IFC MA Modulator DMS8IFC RN Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling.Mol Cancer Ther.2008 Oct;7(10):3129-40. DMS8IFC RU https://www.ncbi.nlm.nih.gov/pubmed/18852116 DMS8IFC DI DMS8IFC DMS8IFC DN Sorafenib DMS8IFC TI TTX41N9 DMS8IFC TN Tyrosine-protein kinase Kit (KIT) DMS8IFC MA Modulator DMS8IFC RN Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling.Mol Cancer Ther.2008 Oct;7(10):3129-40. DMS8IFC RU https://www.ncbi.nlm.nih.gov/pubmed/18852116 DMS8IFC DI DMS8IFC DMS8IFC DN Sorafenib DMS8IFC TI TTI7421 DMS8IFC TN Platelet-derived growth factor receptor beta (PDGFRB) DMS8IFC MA Modulator DMS8IFC RN Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling.Mol Cancer Ther.2008 Oct;7(10):3129-40. DMS8IFC RU https://www.ncbi.nlm.nih.gov/pubmed/18852116 DMS8IFC DI DMS8IFC DMS8IFC DN Sorafenib DMS8IFC TI TTGKNB4 DMS8IFC TN Epidermal growth factor receptor (EGFR) DMS8IFC MA Inhibitor DMS8IFC RN Nasopharyngeal carcinoma: Current treatment options and future directions. J Nasopharyng Carcinoma, 2014, 1(16): e16. DMS8IFC RU http://journalofnasopharyngealcarcinoma.org/JNPC/article/view/30/227 DMSA4B3 DI DMSA4B3 DMSA4B3 DN Desoxycorticosterone pivalate DMSA4B3 TI TT26PHO DMSA4B3 TN Mineralocorticoid receptor (MR) DMSA4B3 MA Binder DMSA4B3 RN Characterization of rat brain aldosterone receptors reveals high affinity for corticosterone. Endocrinology. 1983 Dec;113(6):2043-51. DMSA4B3 RU https://pubmed.ncbi.nlm.nih.gov/6227474 DMSA4HZ DI DMSA4HZ DMSA4HZ DN KU-0058948 DMSA4HZ TI TTVDSZ0 DMSA4HZ TN Poly [ADP-ribose] polymerase 1 (PARP1) DMSA4HZ MA Inhibitor DMSA4HZ RN Structural basis for inhibitor specificity in human poly(ADP-ribose) polymerase-3. J Med Chem. 2009 May 14;52(9):3108-11. DMSA4HZ RU https://pubmed.ncbi.nlm.nih.gov/19354255 DMSA8RU DI DMSA8RU DMSA8RU DN Abatacept DMSA8RU TI TTFZDNP DMSA8RU TN Activation B7-1 antigen (CD80) DMSA8RU MA Binder DMSA8RU RN Selective modulation of T-cell co-stimulation: a novel mode of action for the treatment of rheumatoid arthritis. Clin Exp Rheumatol. 2009 May-Jun;27(3):510-8. DMSA8RU RU https://pubmed.ncbi.nlm.nih.gov/19604448 DMSA8RU DI DMSA8RU DMSA8RU DN Abatacept DMSA8RU TI TTHGXBU DMSA8RU TN T-lymphocyte activation antigen CD86 (FUN1) DMSA8RU MA Binder DMSA8RU RN Selective modulation of T-cell co-stimulation: a novel mode of action for the treatment of rheumatoid arthritis. Clin Exp Rheumatol. 2009 May-Jun;27(3):510-8. DMSA8RU RU https://pubmed.ncbi.nlm.nih.gov/19604448 DMSB068 DI DMSB068 DMSB068 DN PF-04449913 DMSB068 TI TT8J1S3 DMSB068 TN Smoothened homolog (SMO) DMSB068 MA Modulator DMSB068 RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMSB068 RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMSB068 DI DMSB068 DMSB068 DN PF-04449913 DMSB068 TI TT4LXBC DMSB068 TN Hedgehog signaling pathway (HS pathway) DMSB068 MA Inhibitor DMSB068 RN 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. DMSB068 RU https://pubmed.ncbi.nlm.nih.gov/30710142 DMSB068 DI DMSB068 DMSB068 DN PF-04449913 DMSB068 TI TTCJG29 DMSB068 TN Serine/threonine-protein kinase mTOR (mTOR) DMSB068 MA Inhibitor DMSB068 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMSB068 RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DMSBRUW DI DMSBRUW DMSBRUW DN Decamethonium DMSBRUW TI TT54JVQ DMSBRUW TN Neuronal acetylcholine receptor alpha-1 (CHRNA1) DMSBRUW MA Modulator DMSBRUW RN Potency of nondepolarizing muscle relaxants on muscle-type acetylcholine receptors in denervated mouse skeletal muscle.Acta Pharmacol Sin.2010 Dec;31(12):1541-6. DMSBRUW RU https://www.ncbi.nlm.nih.gov/pubmed/21102480 DMSC4A7 DI DMSC4A7 DMSC4A7 DN Indomethacin DMSC4A7 TI TTVKILB DMSC4A7 TN Prostaglandin G/H synthase 2 (COX-2) DMSC4A7 MA Modulator DMSC4A7 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMSC4A7 RU https://www.fda.gov/ DMSCDY9 DI DMSCDY9 DMSCDY9 DN Mannitol DMSCDY9 TI TTTX5M8 DMSCDY9 TN Aspergillus Mannitol 2-dehydrogenase (Asperg M2DH) DMSCDY9 MA Activator DMSCDY9 RN Polyol-specific long-chain dehydrogenases/reductases of mannitol metabolism in Aspergillus fumigatus: biochemical characterization and pH studies o... Chem Biol Interact. 2009 Mar 16;178(1-3):274-82. DMSCDY9 RU https://pubmed.ncbi.nlm.nih.gov/18983992 DMSCDY9 DI DMSCDY9 DMSCDY9 DN Mannitol DMSCDY9 TI TTV0PE2 DMSCDY9 TN Aspergillus Mannitol-1-phosphate 5-dehydrogenase (Asperg mpdA) DMSCDY9 MA Activator DMSCDY9 RN Polyol-specific long-chain dehydrogenases/reductases of mannitol metabolism in Aspergillus fumigatus: biochemical characterization and pH studies o... Chem Biol Interact. 2009 Mar 16;178(1-3):274-82. DMSCDY9 RU https://pubmed.ncbi.nlm.nih.gov/18983992 DMSCIKZ DI DMSCIKZ DMSCIKZ DN Dopexamine DMSCIKZ TI TTEX248 DMSCIKZ TN Dopamine D2 receptor (D2R) DMSCIKZ MA Modulator DMSCIKZ RN Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. DMSCIKZ RU https://pubmed.ncbi.nlm.nih.gov/17309302 DMSD1UN DI DMSD1UN DMSD1UN DN Bevacizumab DMSD1UN TI TTOHSBA DMSD1UN TN Vascular endothelial growth factor A (VEGFA) DMSD1UN MA Inhibitor DMSD1UN RN FDA Approved Drug Products from FDA Official Website. 2004. Application Number: (ANDA) 125085. DMSD1UN RU https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125085 DMSE3I7 DI DMSE3I7 DMSE3I7 DN Gemcitabine DMSE3I7 TI TTBWDI0 DMSE3I7 TN Ribonucleoside-diphosphate reductase M2 (RRM2) DMSE3I7 MA Modulator DMSE3I7 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMSE3I7 RU https://www.fda.gov/ DMSEPK8 DI DMSEPK8 DMSEPK8 DN Brivaracetam DMSEPK8 TI TTT3P91 DMSEPK8 TN Synaptic vesicle glycoprotein 2A (SV2A) DMSEPK8 MA Inhibitor DMSEPK8 RN Pharmacological management of epilepsy: recent advances and future prospects. Drugs. 2008;68(14):1925-39. DMSEPK8 RU https://pubmed.ncbi.nlm.nih.gov/18778117 DMSF4PR DI DMSF4PR DMSF4PR DN Chlormerodrin DMSF4PR TI TTJUWVB DMSF4PR TN Succinate-semialdehyde dehydrogenase (ALDH5A1) DMSF4PR MA Modulator DMSF4PR RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMSF4PR RU https://www.fda.gov/ DMSFK9V DI DMSFK9V DMSFK9V DN Daclatasvir DMSFK9V TI TTCJ2X8 DMSFK9V TN Hepatitis C virus Non-structural 5A (HCV NS5A) DMSFK9V MA Inhibitor DMSFK9V RN 2011 Pipeline of Bristol-Myers Squibb. DMSFK9V RU http://www.bms.com/pages/default.aspx DMSFQ8I DI DMSFQ8I DMSFQ8I DN Meclocycline DMSFQ8I TI TTQ8KVI DMSFQ8I TN Staphylococcus 30S ribosomal subunit (Stap-coc pbp2) DMSFQ8I MA Binder DMSFQ8I RN Detection of tetracycline resistance genes by PCR methods. Methods Mol Biol. 2004;268:3-13. DMSFQ8I RU https://pubmed.ncbi.nlm.nih.gov/15156014 DMSHPW8 DI DMSHPW8 DMSHPW8 DN Tolterodine DMSHPW8 TI TTQ13Z5 DMSHPW8 TN Muscarinic acetylcholine receptor M3 (CHRM3) DMSHPW8 MA Antagonist DMSHPW8 RN Signal transduction underlying carbachol-induced contraction of human urinary bladder. J Pharmacol Exp Ther. 2004 Jun;309(3):1148-53. DMSHPW8 RU https://pubmed.ncbi.nlm.nih.gov/14769832 DMSI5CB DI DMSI5CB DMSI5CB DN Chloroquine DMSI5CB TI TTKY2NS DMSI5CB TN Duffy antigen chemokine receptor (ACKR1) DMSI5CB MA Modulator DMSI5CB RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMSI5CB RU https://www.fda.gov/ DMSIMD8 DI DMSIMD8 DMSIMD8 DN Cefuroxime DMSIMD8 TI TTJP4SM DMSIMD8 TN Bacterial Penicillin binding protein (Bact PBP) DMSIMD8 MA Binder DMSIMD8 RN Cefuroxime resistance in non-beta-lactamase Haemophilus influenzae is linked to mutations in ftsI. J Antimicrob Chemother. 2003 Mar;51(3):523-30. DMSIMD8 RU https://pubmed.ncbi.nlm.nih.gov/12615852 DMSIVND DI DMSIVND DMSIVND DN Hydroxychloroquine DMSIVND TI TTRJ1K4 DMSIVND TN Toll-like receptor 7 (TLR7) DMSIVND MA Antagonist DMSIVND RN TLR7/9 antagonists as therapeutics for immune-mediated inflammatory disorders. Inflamm Allergy Drug Targets. 2007 Dec;6(4):223-35. DMSIVND RU https://pubmed.ncbi.nlm.nih.gov/18220957 DMSJDTY DI DMSJDTY DMSJDTY DN Menadione DMSJDTY TI TT3MOS2 DMSJDTY TN Aldehyde oxidase (AOX1) DMSJDTY MA Inhibitor DMSJDTY RN Inhibition by SKF-525A of the aldehyde oxidase-mediated metabolism of the experimental antitumour agent acridine carboxamide. Biochem Pharmacol. 1993 May 25;45(10):2159-62. DMSJDTY RU https://pubmed.ncbi.nlm.nih.gov/8512597 DMSJDTY DI DMSJDTY DMSJDTY DN Menadione DMSJDTY TI TTPFZJ1 DMSJDTY TN Vasopressin V1 receptor (V1R) DMSJDTY MA Agonist DMSJDTY RN Evidence in hyponatremia related to inappropriate secretion of ADH that V1 receptor stimulation contributes to the increase in renal uric acid clearance. J Am Soc Nephrol. 1996 May;7(5):805-10. DMSJDTY RU https://pubmed.ncbi.nlm.nih.gov/8738818 DMSJVAM DI DMSJVAM DMSJVAM DN Amisulpride DMSJVAM TI TTEX248 DMSJVAM TN Dopamine D2 receptor (D2R) DMSJVAM MA Antagonist DMSJVAM RN Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia. CNS Drugs. 2006;20(5):389-409. DMSJVAM RU https://pubmed.ncbi.nlm.nih.gov/16696579 DMSL679 DI DMSL679 DMSL679 DN Gatifloxacin DMSL679 TI TTN6J5F DMSL679 TN Bacterial DNA gyrase (Bact gyrase) DMSL679 MA Modulator DMSL679 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMSL679 RU https://www.fda.gov/ DMSL679 DI DMSL679 DMSL679 DN Gatifloxacin DMSL679 TI TTIXTO3 DMSL679 TN Staphylococcus Topoisomerase IV (Stap-coc parC) DMSL679 MA Modulator DMSL679 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMSL679 RU https://www.fda.gov/ DMSLJP4 DI DMSLJP4 DMSLJP4 DN Ziconotide DMSLJP4 TI TT4FDG6 DMSLJP4 TN Voltage-gated calcium channel alpha Cav2.2 (CACNA1B) DMSLJP4 MA Blocker DMSLJP4 RN Emerging treatments for traumatic brain injury. Expert Opin Emerg Drugs. 2009 Mar;14(1):67-84. DMSLJP4 RU https://pubmed.ncbi.nlm.nih.gov/19249984 DMSM2KE DI DMSM2KE DMSM2KE DN Nitrofurazone DMSM2KE TI TTOVFH2 DMSM2KE TN Bacterial 30S ribosomal RNA (Bact 30S rRNA) DMSM2KE MA Inhibitor DMSM2KE RN The antibiotic Furvina targets the P-site of 30S ribosomal subunits and inhibits translation initiation displaying start codon bias. Nucleic Acids Res. 2012 Nov 1;40(20):10366-74. DMSM2KE RU https://pubmed.ncbi.nlm.nih.gov/22941660 DMSNVGB DI DMSNVGB DMSNVGB DN Echothiophate Iodide DMSNVGB TI TT1RS9F DMSNVGB TN Acetylcholinesterase (AChE) DMSNVGB MA Modulator DMSNVGB RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMSNVGB RU https://www.fda.gov/ DMSOAJ2 DI DMSOAJ2 DMSOAJ2 DN N-0923 DMSOAJ2 TI TTEX248 DMSOAJ2 TN Dopamine D2 receptor (D2R) DMSOAJ2 MA Agonist DMSOAJ2 RN Drugs used to treat Parkinson's disease, present status and future directions. CNS Neurol Disord Drug Targets. 2008 Oct;7(4):321-42. DMSOAJ2 RU https://pubmed.ncbi.nlm.nih.gov/18991661 DMSOQK1 DI DMSOQK1 DMSOQK1 DN Chloroprocaine DMSOQK1 TI TTWK8D0 DMSOQK1 TN Sodium pump subunit alpha-1 (ATP1A1) DMSOQK1 MA Blocker DMSOQK1 RN Inhibition of the Na,K-ATPase of canine renal medulla by several local anesthetics. Pharmacol Res. 2001 Apr;43(4):399-403. DMSOQK1 RU https://pubmed.ncbi.nlm.nih.gov/11352545 DMSOURV DI DMSOURV DMSOURV DN Formoterol DMSOURV TI TT2CJVK DMSOURV TN Adrenergic receptor beta-2 (ADRB2) DMSOURV MA Agonist DMSOURV RN Long-acting beta2-agonists for chronic obstructive pulmonary disease patients with poorly reversible airflow limitation. Cochrane Database Syst Rev. 2002;(3):CD001104. DMSOURV RU https://pubmed.ncbi.nlm.nih.gov/12137617 DMSOX7I DI DMSOX7I DMSOX7I DN Cocaine DMSOX7I TI TT3ROYC DMSOX7I TN Serotonin transporter (SERT) DMSOX7I MA Inhibitor DMSOX7I RN Differential involvement of the norepinephrine, serotonin and dopamine reuptake transporter proteins in cocaine-induced taste aversion. Pharmacol Biochem Behav. 2009 Jul;93(1):75-81. DMSOX7I RU https://pubmed.ncbi.nlm.nih.gov/19376154 DMSOX7I DI DMSOX7I DMSOX7I DN Cocaine DMSOX7I TI TTAWNKZ DMSOX7I TN Norepinephrine transporter (NET) DMSOX7I MA Inhibitor DMSOX7I RN Differential involvement of the norepinephrine, serotonin and dopamine reuptake transporter proteins in cocaine-induced taste aversion. Pharmacol Biochem Behav. 2009 Jul;93(1):75-81. DMSOX7I RU https://pubmed.ncbi.nlm.nih.gov/19376154 DMSOX7I DI DMSOX7I DMSOX7I DN Cocaine DMSOX7I TI TTVBI8W DMSOX7I TN Dopamine transporter (DAT) DMSOX7I MA Inhibitor DMSOX7I RN Differential involvement of the norepinephrine, serotonin and dopamine reuptake transporter proteins in cocaine-induced taste aversion. Pharmacol Biochem Behav. 2009 Jul;93(1):75-81. DMSOX7I RU https://pubmed.ncbi.nlm.nih.gov/19376154 DMSP4JX DI DMSP4JX DMSP4JX DN Cetraxate DMSP4JX TI TT5L2VC DMSP4JX TN Kallikrein-related peptidase (KLK) DMSP4JX MA Modulator DMSP4JX RN A new broad spectrum inhibitor of esteroproteases, 4-(2-carboxyethyl) phenyl-trans-4-aminomethyl cyclohexane carboxylate hydrochloride (DV 1006). Tohoku J Exp Med. 1972 Mar;106(3):233-48. DMSP4JX RU https://pubmed.ncbi.nlm.nih.gov/4261023 DMSPJG2 DI DMSPJG2 DMSPJG2 DN Ropivacaine DMSPJG2 TI TT90XZ8 DMSPJG2 TN Voltage-gated sodium channel alpha Nav1.8 (SCN10A) DMSPJG2 MA Modulator DMSPJG2 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMSPJG2 RU https://www.fda.gov/ DMSQ1JV DI DMSQ1JV DMSQ1JV DN LAS-34273 DMSQ1JV TI TTQ13Z5 DMSQ1JV TN Muscarinic acetylcholine receptor M3 (CHRM3) DMSQ1JV MA Antagonist DMSQ1JV RN Emerging drugs for the treatment of chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2006 May;11(2):275-91. DMSQ1JV RU https://pubmed.ncbi.nlm.nih.gov/16634702 DMSQ8MD DI DMSQ8MD DMSQ8MD DN Anagrelide DMSQ8MD TI TT06AWU DMSQ8MD TN Phosphodiesterase 3A (PDE3A) DMSQ8MD MA Inhibitor DMSQ8MD RN Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med. 2005 Jul 7;353(1):33-45. DMSQ8MD RU https://pubmed.ncbi.nlm.nih.gov/16000354 DMSQDLE DI DMSQDLE DMSQDLE DN Flecainide DMSQDLE TI TTN9VTF DMSQDLE TN Voltage-gated sodium channel alpha Nav1.9 (SCN11A) DMSQDLE MA Blocker DMSQDLE RN New antiarrhythmic agents for atrial fibrillation and atrial flutter. Expert Opin Emerg Drugs. 2005 May;10(2):311-22. DMSQDLE RU https://pubmed.ncbi.nlm.nih.gov/15934869 DMSQDLE DI DMSQDLE DMSQDLE DN Flecainide DMSQDLE TI TT05DLS DMSQDLE TN E3 ubiquitin-protein ligase COP1 (RFWD2) DMSQDLE MA Modulator DMSQDLE RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMSQDLE RU https://www.fda.gov/ DMSQVD6 DI DMSQVD6 DMSQVD6 DN Ceforanide DMSQVD6 TI TTJP4SM DMSQVD6 TN Bacterial Penicillin binding protein (Bact PBP) DMSQVD6 MA Binder DMSQVD6 RN The pharmacokinetics of the interstitial space in humans. BMC Clin Pharmacol. 2003 Jul 30;3:3. DMSQVD6 RU https://pubmed.ncbi.nlm.nih.gov/12890292 DMSQZE2 DI DMSQZE2 DMSQZE2 DN Asenapine DMSQZE2 TI TTXFI1K DMSQZE2 TN Hyaluronidase (HYAL) DMSQZE2 MA Modulator DMSQZE2 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMSQZE2 RU https://www.fda.gov/ DMSREPX DI DMSREPX DMSREPX DN Levobetaxolol DMSREPX TI TTR6W5O DMSREPX TN Adrenergic receptor beta-1 (ADRB1) DMSREPX MA Antagonist DMSREPX RN Binding affinities of ocular hypotensive beta-blockers levobetaxolol, levobunolol, and timolol at endogenous guinea pig beta-adrenoceptors. J Ocul Pharmacol Ther. 2004 Apr;20(2):93-9. DMSREPX RU https://pubmed.ncbi.nlm.nih.gov/15117564 DMSRZAO DI DMSRZAO DMSRZAO DN Eliglustat tartrate DMSRZAO TI TTPHEX3 DMSRZAO TN Ceramide glucosyltransferase (UGCG) DMSRZAO MA Modulator DMSRZAO RN 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81. DMSRZAO RU https://pubmed.ncbi.nlm.nih.gov/25633781 DMSTA36 DI DMSTA36 DMSTA36 DN Intedanib DMSTA36 TI TTVJ1D8 DMSTA36 TN Vascular endothelial growth factor receptor (VEGFR) DMSTA36 MA Modulator DMSTA36 RN 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81. DMSTA36 RU https://pubmed.ncbi.nlm.nih.gov/25633781 DMSTA36 DI DMSTA36 DMSTA36 DN Intedanib DMSTA36 TI TTRLW2X DMSTA36 TN Fibroblast growth factor receptor 1 (FGFR1) DMSTA36 MA Modulator DMSTA36 RN 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81. DMSTA36 RU https://pubmed.ncbi.nlm.nih.gov/25633781 DMSTA36 DI DMSTA36 DMSTA36 DN Intedanib DMSTA36 TI TTGJCWZ DMSTA36 TN Fms-like tyrosine kinase 3 (FLT-3) DMSTA36 MA Inhibitor DMSTA36 RN 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81. DMSTA36 RU https://pubmed.ncbi.nlm.nih.gov/25633781 DMSTA36 DI DMSTA36 DMSTA36 DN Intedanib DMSTA36 TI TTI2WET DMSTA36 TN Platelet-derived growth factor receptor (PDGFR) DMSTA36 MA Modulator DMSTA36 RN 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81. DMSTA36 RU https://pubmed.ncbi.nlm.nih.gov/25633781 DMSUVM1 DI DMSUVM1 DMSUVM1 DN Cefditoren DMSUVM1 TI TTJP4SM DMSUVM1 TN Bacterial Penicillin binding protein (Bact PBP) DMSUVM1 MA Binder DMSUVM1 RN Crystal structure of cefditoren complexed with Streptococcus pneumoniae penicillin-binding protein 2X: structural basis for its high antimicrobial ... Antimicrob Agents Chemother. 2007 Nov;51(11):3902-7. DMSUVM1 RU https://pubmed.ncbi.nlm.nih.gov/17724158 DMSVOCZ DI DMSVOCZ DMSVOCZ DN Pantoprazole DMSVOCZ TI TTLOKXP DMSVOCZ TN Gastric H(+)/K(+) ATPase (Proton pump) DMSVOCZ MA Modulator DMSVOCZ RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMSVOCZ RU https://www.fda.gov/ DMSVOZT DI DMSVOZT DMSVOZT DN Nifedipine DMSVOZT TI TTXHYV6 DMSVOZT TN Voltage-gated L-type calcium channel (L-CaC) DMSVOZT MA Modulator DMSVOZT RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMSVOZT RU https://www.fda.gov/ DMSWNJF DI DMSWNJF DMSWNJF DN Ravulizumab DMSWNJF TI TTKANGO DMSWNJF TN Complement C5 (CO5) DMSWNJF MA Inhibitor DMSWNJF RN 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. DMSWNJF RU https://pubmed.ncbi.nlm.nih.gov/30710142 DMSWUGE DI DMSWUGE DMSWUGE DN Telbivudine DMSWUGE TI TTT4SY6 DMSWUGE TN Hepatitis B virus Polymerase (HBV P) DMSWUGE MA Inhibitor DMSWUGE RN Nucleos(t)ide analogues for hepatitis B virus: strategies for long-term success. Best Pract Res Clin Gastroenterol. 2008;22(6):1081-92. DMSWUGE RU https://pubmed.ncbi.nlm.nih.gov/19187868 DMSWYF5 DI DMSWYF5 DMSWYF5 DN Quinine DMSWYF5 TI TT05DLS DMSWYF5 TN E3 ubiquitin-protein ligase COP1 (RFWD2) DMSWYF5 MA Modulator DMSWYF5 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMSWYF5 RU https://www.fda.gov/ DMSXKYG DI DMSXKYG DMSXKYG DN Gamma-homolinolenic acid DMSXKYG TI TT8NGED DMSXKYG TN Prostaglandin G/H synthase 1 (COX-1) DMSXKYG MA Inhibitor DMSXKYG RN Differential metabolism of dihomo-gamma-linolenic acid and arachidonic acid by cyclo-oxygenase-1 and cyclo-oxygenase-2: implications for cellular synthesis of prostaglandin E1 and prostaglandin E2. Biochem J. 2002 Jul 15;365(Pt 2):489-96. DMSXKYG RU https://pubmed.ncbi.nlm.nih.gov/11939906 DMSY4ZG DI DMSY4ZG DMSY4ZG DN Tenofovir disoproxil fumarate DMSY4ZG TI TT84ETX DMSY4ZG TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMSY4ZG MA Modulator DMSY4ZG RN Nat Rev Drug Discov. 2013 Feb;12(2):87-90. DMSY4ZG RU https://pubmed.ncbi.nlm.nih.gov/23370234 DMSYFM8 DI DMSYFM8 DMSYFM8 DN Cysteamine DMSYFM8 TI TTWF7UG DMSYFM8 TN Somatostatin (SST) DMSYFM8 MA Binder DMSYFM8 RN Somatostatin, Alzheimer's disease and cognition: an old story coming of age Prog Neurobiol. 2009 Oct;89(2):153-61. DMSYFM8 RU https://pubmed.ncbi.nlm.nih.gov/19595735 DMSYPNW DI DMSYPNW DMSYPNW DN Ranibizumab DMSYPNW TI TTOHSBA DMSYPNW TN Vascular endothelial growth factor A (VEGFA) DMSYPNW RN Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina. 2006 Oct;26(8):859-70. DMSYPNW RU https://pubmed.ncbi.nlm.nih.gov/17031284 DMSYRBX DI DMSYRBX DMSYRBX DN Atazanavir DMSYRBX TI TT5FNQT DMSYRBX TN Human immunodeficiency virus Protease (HIV PR) DMSYRBX MA Modulator DMSYRBX RN Hollow-fiber unit evaluation of a new human immunodeficiency virus type 1 protease inhibitor, BMS-232632, for determination of the linked pharmacod... J Infect Dis. 2001 Apr 1;183(7):1126-9. DMSYRBX RU https://pubmed.ncbi.nlm.nih.gov/11237841 DMSZLJR DI DMSZLJR DMSZLJR DN Avelumab DMSZLJR TI TT8ZLTI DMSZLJR TN Programmed cell death 1 ligand 1 (PD-L1) DMSZLJR RN Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells. Cancer Immunol Res. 2015 Oct;3(10):1148-57. DMSZLJR RU https://pubmed.ncbi.nlm.nih.gov/26014098 DMSZQAK DI DMSZQAK DMSZQAK DN Amphetamine DMSZQAK TI TTIU98M DMSZQAK TN Trace amine-associated receptor-1 (TAAR1) DMSZQAK MA Modulator DMSZQAK RN Methamphetamine and HIV-1-induced neurotoxicity: role of trace amine associated receptor 1 cAMP signaling in astrocytes. Neuropharmacology. 2014 Oct;85:499-507. DMSZQAK RU https://pubmed.ncbi.nlm.nih.gov/24950453 DMT1I52 DI DMT1I52 DMT1I52 DN Cycloserine DMT1I52 TI TT9IK2Z DMT1I52 TN N-methyl-D-aspartate receptor (NMDAR) DMT1I52 MA Agonist DMT1I52 RN How many modes of action should an antibiotic have Curr Opin Pharmacol. 2008 Oct;8(5):564-73. DMT1I52 RU https://pubmed.ncbi.nlm.nih.gov/18621146 DMT1I52 DI DMT1I52 DMT1I52 DN Cycloserine DMT1I52 TI TTCS3P1 DMT1I52 TN Mycobacterium D-alanine-D-alanine ligase A (MycB ddl) DMT1I52 MA Inhibitor DMT1I52 RN Self-protection mechanism in D-cycloserine-producing Streptomyces lavendulae. Gene cloning, characterization, and kinetics of its alanine racemase ... J Biol Chem. 2004 Oct 29;279(44):46143-52. DMT1I52 RU https://pubmed.ncbi.nlm.nih.gov/15302885 DMT1I52 DI DMT1I52 DMT1I52 DN Cycloserine DMT1I52 TI TT6TMZU DMT1I52 TN Mycobacterium Biosynthetic alanine racemase (MycB alr) DMT1I52 MA Inhibitor DMT1I52 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMT1I52 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMT1I52 DI DMT1I52 DMT1I52 DN Cycloserine DMT1I52 TI TTLD29N DMT1I52 TN Glutamate receptor ionotropic NMDA 1 (NMDAR1) DMT1I52 MA Inhibitor DMT1I52 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMT1I52 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMT2EJP DI DMT2EJP DMT2EJP DN Podofilox DMT2EJP TI TT0IHXV DMT2EJP TN DNA topoisomerase II (TOP2) DMT2EJP MA Modulator DMT2EJP RN Antitumor properties of podophyllotoxin and related compounds. Curr Pharm Des. 2000 Dec;6(18):1811-39. DMT2EJP RU https://pubmed.ncbi.nlm.nih.gov/11102564 DMT2FDC DI DMT2FDC DMT2FDC DN Desipramine DMT2FDC TI TTAWNKZ DMT2FDC TN Norepinephrine transporter (NET) DMT2FDC MA Inhibitor DMT2FDC RN Augmentation effect of combination therapy of aripiprazole and antidepressants on forced swimming test in mice. Psychopharmacology (Berl). 2009 Sep;206(1):97-107. DMT2FDC RU https://pubmed.ncbi.nlm.nih.gov/19517098 DMT2KRV DI DMT2KRV DMT2KRV DN Ciclosporin DMT2KRV TI TTA4LDE DMT2KRV TN Calcineurin (PPP3CA) DMT2KRV MA Inhibitor DMT2KRV RN Cyclosporine and tacrolimus for the treatment of rheumatoid arthritis. Curr Opin Rheumatol. 2007 May;19(3):238-45. DMT2KRV RU https://pubmed.ncbi.nlm.nih.gov/17414949 DMT3D5I DI DMT3D5I DMT3D5I DN Aflibercept DMT3D5I TI TTOHSBA DMT3D5I TN Vascular endothelial growth factor A (VEGFA) DMT3D5I MA Modulator DMT3D5I RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DMT3D5I RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DMT3D5I DI DMT3D5I DMT3D5I DN Aflibercept DMT3D5I TI TTPJQHE DMT3D5I TN Vascular endothelial growth factor B (VEGFB) DMT3D5I MA Modulator DMT3D5I RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DMT3D5I RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DMT3D5I DI DMT3D5I DMT3D5I DN Aflibercept DMT3D5I TI TT48I1Y DMT3D5I TN Placenta growth factor (PlGF) DMT3D5I MA Modulator DMT3D5I RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DMT3D5I RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DMT45MU DI DMT45MU DMT45MU DN Rosiglitazone XR DMT45MU TI TTZMAO3 DMT45MU TN Peroxisome proliferator-activated receptor gamma (PPAR-gamma) DMT45MU MA Agonist DMT45MU RN Clinical pipeline report, company report or official report of GlaxoSmithKline (2009). DMT45MU RU http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf DMT57WC DI DMT57WC DMT57WC DN Tetrahydrozoline DMT57WC TI TT2NUT5 DMT57WC TN Adrenergic receptor alpha-2C (ADRA2C) DMT57WC MA Modulator DMT57WC RN Prolonged cardiovascular effects after unintentional ingestion of tetrahydrozoline. Clin Toxicol (Phila). 2008 Feb;46(2):171-2. DMT57WC RU https://pubmed.ncbi.nlm.nih.gov/18259967 DMT5GNL DI DMT5GNL DMT5GNL DN Romidepsin DMT5GNL TI TT6R7JZ DMT5GNL TN Histone deacetylase 1 (HDAC1) DMT5GNL MA Inhibitor DMT5GNL RN Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92. DMT5GNL RU https://pubmed.ncbi.nlm.nih.gov/20118952 DMT5HA4 DI DMT5HA4 DMT5HA4 DN Ketamine DMT5HA4 TI TT9IK2Z DMT5HA4 TN N-methyl-D-aspartate receptor (NMDAR) DMT5HA4 MA Antagonist DMT5HA4 RN Ketamine modulates theta and gamma oscillations. J Cogn Neurosci. 2010 Jul;22(7):1452-64. DMT5HA4 RU https://pubmed.ncbi.nlm.nih.gov/19583475 DMT5RMB DI DMT5RMB DMT5RMB DN Cyclofenil DMT5RMB TI TTZAYWL DMT5RMB TN Estrogen receptor (ESR) DMT5RMB MA Modulator DMT5RMB RN Fluorine-substituted cyclofenil derivatives as estrogen receptor ligands: synthesis and structure-affinity relationship study of potential positron emission tomography agents for imaging estrogen receptors in breast cancer. J Med Chem. 2006 Apr 20;49(8):2496-511. DMT5RMB RU https://pubmed.ncbi.nlm.nih.gov/16610793 DMT6AM2 DI DMT6AM2 DMT6AM2 DN Ozanimod DMT6AM2 TI TT9JZCK DMT6AM2 TN Sphingosine-1-phosphate receptor 1 (S1PR1) DMT6AM2 MA Agonist DMT6AM2 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020 DMT6AM2 RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209899s000lbl.pdf DMT70RC DI DMT70RC DMT70RC DN Piperaquine DMT70RC TI TTZVSJ2 DMT70RC TN Sarcoplasmic/endoplasmic reticulum calcium ATPase (ATP2A) DMT70RC MA Inhibitor DMT70RC RN The fight against drug-resistant malaria: novel plasmodial targets and antimalarial drugs. Curr Med Chem. 2008;15(2):161-71. DMT70RC RU https://pubmed.ncbi.nlm.nih.gov/18220771 DMT73J8 DI DMT73J8 DMT73J8 DN Luliconazole DMT73J8 TI TTTSOUD DMT73J8 TN Candida Cytochrome P450 51 (Candi ERG11) DMT73J8 MA Inhibitor DMT73J8 RN Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651. DMT73J8 RU https://pubmed.ncbi.nlm.nih.gov/28919714 DMT81LZ DI DMT81LZ DMT81LZ DN Arn-509 DMT81LZ TI TTS64P2 DMT81LZ TN Androgen receptor (AR) DMT81LZ MA Inhibitor DMT81LZ RN 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. DMT81LZ RU https://pubmed.ncbi.nlm.nih.gov/30710142 DMT9FH3 DI DMT9FH3 DMT9FH3 DN Terlipressin DMT9FH3 TI TT4TFGN DMT9FH3 TN Vasopressin V1a receptor (V1AR) DMT9FH3 MA Stimulator DMT9FH3 RN Investigational vasopressin receptor modulators in the pipeline. Expert Opin Investig Drugs. 2009 Aug;18(8):1119-31. DMT9FH3 RU https://pubmed.ncbi.nlm.nih.gov/19589090 DMT9K8G DI DMT9K8G DMT9K8G DN Raltitrexed DMT9K8G TI TTU6BFZ DMT9K8G TN Candida Thymidylate synthase (Candi TMP1) DMT9K8G MA Inhibitor DMT9K8G RN DNA damage and homologous recombination signaling induced by thymidylate deprivation. Biochem Pharmacol. 2008 Oct 15;76(8):987-96. DMT9K8G RU https://pubmed.ncbi.nlm.nih.gov/18773878 DMTA5OE DI DMTA5OE DMTA5OE DN Azacitidine DMTA5OE TI TTHVCUP DMTA5OE TN DNA [cytosine-5]-methyltransferase (DNMT) DMTA5OE MA Inhibitor DMTA5OE RN The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid l... Leukemia. 2009 Jun;23(6):1019-28. DMTA5OE RU https://pubmed.ncbi.nlm.nih.gov/19194470 DMTAFY4 DI DMTAFY4 DMTAFY4 DN Oxacillin DMTAFY4 TI TTJP4SM DMTAFY4 TN Bacterial Penicillin binding protein (Bact PBP) DMTAFY4 MA Binder DMTAFY4 RN Novel anion liposome-encapsulated antisense oligonucleotide restores susceptibility of methicillin-resistant Staphylococcus aureus and rescues mice... Antimicrob Agents Chemother. 2009 Jul;53(7):2871-8. DMTAFY4 RU https://pubmed.ncbi.nlm.nih.gov/19433567 DMTAJQE DI DMTAJQE DMTAJQE DN Amphotericin B DMTAJQE TI TTQKWA4 DMTAJQE TN Fungal Cell membrane ergosterol (Fung CME) DMTAJQE MA Modulator DMTAJQE RN Comparative molecular dynamics simulations of amphotericin B-cholesterol/ergosterol membrane channels. Biochim Biophys Acta. 2002 Dec 23;1567(1-2):63-78. DMTAJQE RU https://pubmed.ncbi.nlm.nih.gov/12488039 DMTAREC DI DMTAREC DMTAREC DN Rimexolone DMTAREC TI TTPNQAC DMTAREC TN Estrogen-related receptor-alpha (ESRRA) DMTAREC MA Modulator DMTAREC RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 622). DMTAREC RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=622 DMTBGW8 DI DMTBGW8 DMTBGW8 DN Vardenafil DMTBGW8 TI TTJ0IQB DMTBGW8 TN Phosphodiesterase 5A (PDE5A) DMTBGW8 MA Binder DMTBGW8 RN The effect of vardenafil, a potent and highly selective phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction, on the cardiovascular response to exercise in patients with coronary artery disease. J Am Coll Cardiol. 2002 Dec 4;40(11):2006-12. DMTBGW8 RU https://pubmed.ncbi.nlm.nih.gov/12475462 DMTBKF3 DI DMTBKF3 DMTBKF3 DN Piperacillin DMTBKF3 TI TTJP4SM DMTBKF3 TN Bacterial Penicillin binding protein (Bact PBP) DMTBKF3 MA Binder DMTBKF3 RN In vitro antienterococcal activity explains associations between exposures to antimicrobial agents and risk of colonization by multiresistant enter... J Infect Dis. 2004 Dec 15;190(12):2162-6. DMTBKF3 RU https://pubmed.ncbi.nlm.nih.gov/15551215 DMTBW2O DI DMTBW2O DMTBW2O DN Propylhexedrine DMTBW2O TI TT2NUT5 DMTBW2O TN Adrenergic receptor alpha-2C (ADRA2C) DMTBW2O MA Modulator DMTBW2O RN Airway compromise and delayed death following attempted central vein injection of propylhexedrine. J Emerg Med. 1994 Nov-Dec;12(6):795-7. DMTBW2O RU https://pubmed.ncbi.nlm.nih.gov/7533806 DMTGBAX DI DMTGBAX DMTGBAX DN Pomalidomide DMTGBAX TI TTDIBYJ DMTGBAX TN Angiogenesis/myeloma cell growth (AMCG) DMTGBAX MA Modulator DMTGBAX RN Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651. DMTGBAX RU https://pubmed.ncbi.nlm.nih.gov/28919714 DMTGDN8 DI DMTGDN8 DMTGDN8 DN Levetiracetam DMTGDN8 TI TTPC4TU DMTGDN8 TN 5-HT 3A receptor (HTR3A) DMTGDN8 MA Antagonist DMTGDN8 RN Emerging therapies for fibromyalgia. Expert Opin Emerg Drugs. 2008 Mar;13(1):53-62. DMTGDN8 RU https://pubmed.ncbi.nlm.nih.gov/18321148 DMTGDN8 DI DMTGDN8 DMTGDN8 DN Levetiracetam DMTGDN8 TI TTT3P91 DMTGDN8 TN Synaptic vesicle glycoprotein 2A (SV2A) DMTGDN8 MA Modulator DMTGDN8 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMTGDN8 RU https://www.fda.gov/ DMTHWBI DI DMTHWBI DMTHWBI DN Nitrous oxide DMTHWBI TI TT9IK2Z DMTHWBI TN N-methyl-D-aspartate receptor (NMDAR) DMTHWBI MA Antagonist DMTHWBI RN Anaesthetic drugs: linking molecular actions to clinical effects. Curr Pharm Des. 2006;12(28):3665-79. DMTHWBI RU https://pubmed.ncbi.nlm.nih.gov/17073666 DMTI8YE DI DMTI8YE DMTI8YE DN Bosutinib DMTI8YE TI TT3PJMV DMTI8YE TN Tyrosine-protein kinase ABL1 (ABL) DMTI8YE MA Inhibitor DMTI8YE RN A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22. DMTI8YE RU https://pubmed.ncbi.nlm.nih.gov/17692029 DMTI8YE DI DMTI8YE DMTI8YE DN Bosutinib DMTI8YE TI TT6PKBN DMTI8YE TN Proto-oncogene c-Src (SRC) DMTI8YE MA Inhibitor DMTI8YE RN A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22. DMTI8YE RU https://pubmed.ncbi.nlm.nih.gov/17692029 DMTIGA0 DI DMTIGA0 DMTIGA0 DN Acrivastine DMTIGA0 TI TTTIBOJ DMTIGA0 TN Histamine H1 receptor (H1R) DMTIGA0 MA Antagonist DMTIGA0 RN Clinical pharmacology of new histamine H1 receptor antagonists. Clin Pharmacokinet. 1999 May;36(5):329-52. DMTIGA0 RU https://pubmed.ncbi.nlm.nih.gov/10384858 DMTIQF3 DI DMTIQF3 DMTIQF3 DN Treprostinil DMTIQF3 TI TTOFYT1 DMTIQF3 TN Prostacyclin receptor (PTGIR) DMTIQF3 MA Agonist DMTIQF3 RN Dosing considerations in the use of intravenous prostanoids in pulmonary arterial hypertension: an experience-based review. Am Heart J. 2009 Apr;157(4):625-35. DMTIQF3 RU https://pubmed.ncbi.nlm.nih.gov/19332188 DMTIUFA DI DMTIUFA DMTIUFA DN Celtura DMTIUFA TI TT3J5ZI DMTIUFA TN Cell mediated immunity response (CMIR) DMTIUFA RN A prospective observational safety study on MF59( ) adjuvanted cell culture-derived vaccine, Celtura( ) during the A/H1N1 (2009) influenza pandemic. Vaccine. 2012 Oct 5;30(45):6436-43. DMTIUFA RU https://pubmed.ncbi.nlm.nih.gov/22902681 DMTIVEN DI DMTIVEN DMTIVEN DN Metronidazole DMTIVEN TI TTS1W4A DMTIVEN TN Bacterial Deoxyribonucleic acid (Bact DNA) DMTIVEN MA Modulator DMTIVEN RN DNA breakage due to metronidazole treatment. Mutat Res. 2001 Jul 1;478(1-2):153-8. DMTIVEN RU https://www.ncbi.nlm.nih.gov/pubmed/11406179 DMTK234 DI DMTK234 DMTK234 DN Piroxicam DMTK234 TI TT8NGED DMTK234 TN Prostaglandin G/H synthase 1 (COX-1) DMTK234 MA Modulator DMTK234 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMTK234 RU https://www.fda.gov/ DMTK4LS DI DMTK4LS DMTK4LS DN Triptorelin DMTK4LS TI TT8R70G DMTK4LS TN Gonadotropin-releasing hormone receptor (GNRHR) DMTK4LS MA Modulator DMTK4LS RN Regulation of GnRH I receptor gene expression by the GnRH agonist triptorelin, estradiol, and progesterone in the gonadotroph-derived cell line alphaT3-1. Endocrine. 2006 Aug;30(1):139-44. DMTK4LS RU https://pubmed.ncbi.nlm.nih.gov/17185802 DMTKD7Q DI DMTKD7Q DMTKD7Q DN BIBW 2992 DMTKD7Q TI TT6EO5L DMTKD7Q TN Erbb2 tyrosine kinase receptor (HER2) DMTKD7Q MA Inhibitor DMTKD7Q RN Boehringer Ingelheim. Product Development Pipeline. June 2 2009. DMTKD7Q RU http://www.boehringer-ingelheim.com/corporate/research/pipeline.asp DMTKD7Q DI DMTKD7Q DMTKD7Q DN BIBW 2992 DMTKD7Q TI TTGKNB4 DMTKD7Q TN Epidermal growth factor receptor (EGFR) DMTKD7Q MA Inhibitor DMTKD7Q RN Boehringer Ingelheim. Product Development Pipeline. June 2 2009. DMTKD7Q RU http://www.boehringer-ingelheim.com/corporate/research/pipeline.asp DMTKU46 DI DMTKU46 DMTKU46 DN Bismuth DMTKU46 TI TTFNGC9 DMTKU46 TN Serum albumin (ALB) DMTKU46 MA Binder DMTKU46 RN Competitive binding of bismuth to transferrin and albumin in aqueous solution and in blood plasma. J Biol Chem. 2001 Mar 23;276(12):8829-35. DMTKU46 RU https://pubmed.ncbi.nlm.nih.gov/11110794 DMTL94F DI DMTL94F DMTL94F DN Maraviroc DMTL94F TI TT2CEJG DMTL94F TN C-C chemokine receptor type 5 (CCR5) DMTL94F MA Antagonist DMTL94F RN Rapamycin enhances aplaviroc anti-HIV activity: implications for the clinical development of novel CCR5 antagonists. Antiviral Res. 2009 Jul;83(1):86-9. DMTL94F RU https://pubmed.ncbi.nlm.nih.gov/19501260 DMTL94F DI DMTL94F DMTL94F DN Maraviroc DMTL94F TI TTJIH8Q DMTL94F TN CCR5 messenger RNA (CCR5 mRNA) DMTL94F MA Antagonist DMTL94F RN Molecular cloning and radioligand binding characterization of the chemokine receptor CCR5 from rhesus macaque and human. Biochem Pharmacol. 2005 Dec 19;71(1-2):163-72. DMTL94F RU https://pubmed.ncbi.nlm.nih.gov/16298345 DMTL9IP DI DMTL9IP DMTL9IP DN Meprednisone DMTL9IP TI TTYRL6O DMTL9IP TN Glucocorticoid receptor (NR3C1) DMTL9IP MA Modulator DMTL9IP RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMTL9IP RU https://www.fda.gov/ DMTM2IK DI DMTM2IK DMTM2IK DN Mercaptopurine DMTM2IK TI TTL7C8Q DMTM2IK TN Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1) DMTM2IK MA Inhibitor DMTM2IK RN Clinical pharmacology and pharmacogenetics of thiopurines. Eur J Clin Pharmacol. 2008 Aug;64(8):753-67. DMTM2IK RU https://pubmed.ncbi.nlm.nih.gov/18506437 DMTM2IK DI DMTM2IK DMTM2IK DN Mercaptopurine DMTM2IK TI TTZFTY4 DMTM2IK TN Amidophosphoribosyltransferase (PPAT) DMTM2IK MA Breaker DMTM2IK RN 6-mercaptopurine (6-MP) induces p53-mediated apoptosis of neural progenitor cells in the developing fetal rodent brain. Neurotoxicol Teratol. 2009 Jul-Aug;31(4):198-202. DMTM2IK RU https://pubmed.ncbi.nlm.nih.gov/19281843 DMTN5XI DI DMTN5XI DMTN5XI DN Chlordiazepoxide DMTN5XI TI TTPTXIN DMTN5XI TN Translocator protein (TSPO) DMTN5XI MA Modulator DMTN5XI RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMTN5XI RU https://www.fda.gov/ DMTNFCQ DI DMTNFCQ DMTNFCQ DN Levobunolol DMTNFCQ TI TTR6W5O DMTNFCQ TN Adrenergic receptor beta-1 (ADRB1) DMTNFCQ MA Antagonist DMTNFCQ RN Binding of beta-adrenoceptor antagonists to rat and rabbit lung: special reference to levobunolol. Arzneimittelforschung. 1984;34(5):579-84. DMTNFCQ RU https://pubmed.ncbi.nlm.nih.gov/6147147 DMTO13J DI DMTO13J DMTO13J DN Clonazepam DMTO13J TI TTNJYV2 DMTO13J TN Gamma-aminobutyric acid receptor (GAR) DMTO13J MA Agonist DMTO13J RN Glutamate- and GABA-based CNS therapeutics. Curr Opin Pharmacol. 2006 Feb;6(1):7-17. DMTO13J RU https://pubmed.ncbi.nlm.nih.gov/16377242 DMTP1DC DI DMTP1DC DMTP1DC DN Irbesartan DMTP1DC TI TT8DBY3 DMTP1DC TN Angiotensin II receptor type-1 (AGTR1) DMTP1DC MA Antagonist DMTP1DC RN Radioligand binding assays: application of [(125)I]angiotensin II receptor binding. Methods Mol Biol. 2009;552:131-41. DMTP1DC RU https://pubmed.ncbi.nlm.nih.gov/19513646 DMTP2NJ DI DMTP2NJ DMTP2NJ DN Desonide DMTP2NJ TI TTP3UTW DMTP2NJ TN Steroid hormone receptor ERR (ESRR) DMTP2NJ MA Modulator DMTP2NJ RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMTP2NJ RU https://www.fda.gov/ DMTPAM3 DI DMTPAM3 DMTPAM3 DN Metformin arginine-hemisuccinimide DMTPAM3 TI TTCBFJO DMTPAM3 TN Insulin receptor (INSR) DMTPAM3 MA Inhibitor DMTPAM3 RN Metformin (Glucophage) inhibits tyrosine phosphatase activity to stimulate the insulin receptor tyrosine kinase. Biochem Pharmacol. 2004 Jun 1;67(11):2081-91. DMTPAM3 RU https://pubmed.ncbi.nlm.nih.gov/15135305 DMTPIZC DI DMTPIZC DMTPIZC DN Conjugated estrogens a DMTPIZC TI TTZAYWL DMTPIZC TN Estrogen receptor (ESR) DMTPIZC MA Modulator DMTPIZC RN Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. DMTPIZC RU https://pubmed.ncbi.nlm.nih.gov/17309302 DMTQS9A DI DMTQS9A DMTQS9A DN Metaproterenol sulfate DMTQS9A TI TT2CJVK DMTQS9A TN Adrenergic receptor beta-2 (ADRB2) DMTQS9A MA Modulator DMTQS9A RN Male--female differences in the impact of beta-adrenoceptor stimulation on resistance to experimental metastasis: exploring the effects of age and ... J Neuroimmunol. 2008 Jan;193(1-2):113-9. DMTQS9A RU https://pubmed.ncbi.nlm.nih.gov/18037507 DMTS85L DI DMTS85L DMTS85L DN Capecitabine DMTS85L TI TTU6BFZ DMTS85L TN Candida Thymidylate synthase (Candi TMP1) DMTS85L MA Inhibitor DMTS85L RN UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan. Clin Cancer Res. 2005 Feb 1;11(3):1226-36. DMTS85L RU https://pubmed.ncbi.nlm.nih.gov/15709193 DMTSRI6 DI DMTSRI6 DMTSRI6 DN Oprelvekin DMTSRI6 TI TTZPLJS DMTSRI6 TN Interleukin 11 receptor alpha (IL11RA) DMTSRI6 MA Binder DMTSRI6 RN Oprelvekin: a review of its pharmacology and therapeutic potential in chemotherapy-induced thrombocytopenia. BioDrugs. 1998 Aug;10(2):159-71. DMTSRI6 RU https://pubmed.ncbi.nlm.nih.gov/18020592 DMTUKZH DI DMTUKZH DMTUKZH DN Deferoxamine mesylate DMTUKZH TI TTUDR0C DMTUKZH TN Iron (Fe) DMTUKZH MA Modulator DMTUKZH RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMTUKZH RU https://www.fda.gov/ DMTW3R8 DI DMTW3R8 DMTW3R8 DN Sulfadiazine DMTW3R8 TI TT4ILYC DMTW3R8 TN Bacterial Dihydropteroate synthetase (Bact folP) DMTW3R8 MA Inhibitor DMTW3R8 RN Sulfadiazine/hydroxypropyl-beta-cyclodextrin host-guest system: Characterization, phase-solubility and molecular modeling. Bioorg Med Chem. 2008 May 15;16(10):5788-94. DMTW3R8 RU https://pubmed.ncbi.nlm.nih.gov/18434167 DMTW6IU DI DMTW6IU DMTW6IU DN Methadone DMTW6IU TI TTN4QDT DMTW6IU TN Opioid receptor (OPR) DMTW6IU MA Agonist DMTW6IU RN Methadone treatment and its dangers. Medicina (Kaunas). 2009;45(5):419-25. DMTW6IU RU https://pubmed.ncbi.nlm.nih.gov/19535889 DMTWS9E DI DMTWS9E DMTWS9E DN Apremilast DMTWS9E TI TTO0FDJ DMTWS9E TN Cyclin-dependent kinase 6 (CDK6) DMTWS9E MA Inhibitor DMTWS9E RN Agreement signed with Prostagenics to develop prostate cancer treatment. Innovate Oncology, Inc. 2005. DMTWS9E RU http://www.newsrx.com/newsletters/Law-and-Health-Weekly/2005-05-14/05092005333475LH.html DMTWS9E DI DMTWS9E DMTWS9E DN Apremilast DMTWS9E TI TT0PG8F DMTWS9E TN Cyclin-dependent kinase 4 (CDK4) DMTWS9E MA Inhibitor DMTWS9E RN Agreement signed with Prostagenics to develop prostate cancer treatment. Innovate Oncology, Inc. 2005. DMTWS9E RU http://www.newsrx.com/newsletters/Law-and-Health-Weekly/2005-05-14/05092005333475LH.html DMTWS9E DI DMTWS9E DMTWS9E DN Apremilast DMTWS9E TI TTV5CGO DMTWS9E TN Phosphodiesterase 4 (PDE4) DMTWS9E MA Inhibitor DMTWS9E RN Highly selective phosphodiesterase 4 inhibitors for the treatment of allergic skin diseases and psoriasis. Inflamm Allergy Drug Targets. 2007 Mar;6(1):17-26. DMTWS9E RU https://pubmed.ncbi.nlm.nih.gov/17352685 DMTWUXR DI DMTWUXR DMTWUXR DN Chlormezanone DMTWUXR TI TTPTXIN DMTWUXR TN Translocator protein (TSPO) DMTWUXR MA Agonist DMTWUXR RN Successful treatment of anxiety with a single night-time dose of chlormezanone: double-blind comparison with diazepam. Curr Med Res Opin. 1982;8(1):33-8. DMTWUXR RU https://pubmed.ncbi.nlm.nih.gov/7105820 DMTX2BH DI DMTX2BH DMTX2BH DN Cefonicid DMTX2BH TI TTJP4SM DMTX2BH TN Bacterial Penicillin binding protein (Bact PBP) DMTX2BH MA Binder DMTX2BH RN Affinity of cefonicid, a long-acting cephalosporin, for the penicillin-binding proteins of Escherichia coli K-12. J Antibiot (Tokyo). 1984 May;37(5):572-6. DMTX2BH RU https://pubmed.ncbi.nlm.nih.gov/6376452 DMTY169 DI DMTY169 DMTY169 DN Norethindrone DMTY169 TI TTUV8G9 DMTY169 TN Progesterone receptor (PGR) DMTY169 MA Agonist DMTY169 RN Progesterone receptor ligand binding pocket flexibility: crystal structures of the norethindrone and mometasone furoate complexes. J Med Chem. 2004 Jun 17;47(13):3381-7. DMTY169 RU https://pubmed.ncbi.nlm.nih.gov/15189034 DMTY9LU DI DMTY9LU DMTY9LU DN Piperazine DMTY9LU TI TTNJYV2 DMTY9LU TN Gamma-aminobutyric acid receptor (GAR) DMTY9LU MA Antagonist DMTY9LU RN Cyclooctadepsipeptides--an anthelmintically active class of compounds exhibiting a novel mode of action. Int J Antimicrob Agents. 2003 Sep;22(3):318-31. DMTY9LU RU https://pubmed.ncbi.nlm.nih.gov/13678839 DMTYOPD DI DMTYOPD DMTYOPD DN Dinoprostone DMTYOPD TI TTT2ZAR DMTYOPD TN Prostaglandin F2-alpha receptor (PTGFR) DMTYOPD MA Antagonist DMTYOPD RN Evaluation of WO 2012/177618 A1 and US-2014/0179750 A1: novel small molecule antagonists of prostaglandin-E2 receptor EP2.Expert Opin Ther Pat. 2015 Jul;25(7):837-44. DMTYOPD RU https://www.ncbi.nlm.nih.gov/pubmed/25772215 DMTYOPD DI DMTYOPD DMTYOPD DN Dinoprostone DMTYOPD TI TT1ZAVI DMTYOPD TN Prostaglandin E2 receptor EP2 (PTGER2) DMTYOPD MA Antagonist DMTYOPD RN Evaluation of WO 2012/177618 A1 and US-2014/0179750 A1: novel small molecule antagonists of prostaglandin-E2 receptor EP2.Expert Opin Ther Pat. 2015 Jul;25(7):837-44. DMTYOPD RU https://www.ncbi.nlm.nih.gov/pubmed/25772215 DMTZC5G DI DMTZC5G DMTZC5G DN Bezlotoxumab DMTZC5G TI TTQH65V DMTZC5G TN Clostridium difficile Toxin B (CD toxB) DMTZC5G MA Modulator DMTZC5G RN 2016 FDA drug approvals. Nat Rev Drug Discov. 2017 Feb 2;16(2):73-76. DMTZC5G RU https://www.ncbi.nlm.nih.gov/pubmed/28148938 DMTZNQ9 DI DMTZNQ9 DMTZNQ9 DN Interferon alfa-n3 DMTZNQ9 TI TT95SOA DMTZNQ9 TN Interferon alpha (IFNA) DMTZNQ9 MA Modulator DMTZNQ9 RN Clinical pipeline report, company report or official report of Hemispherx Biopharma. DMTZNQ9 RU http://www.hemispherx.net/content/rnd/ DMU0YP6 DI DMU0YP6 DMU0YP6 DN Flumethasone Pivalate DMU0YP6 TI TTP3UTW DMU0YP6 TN Steroid hormone receptor ERR (ESRR) DMU0YP6 MA Modulator DMU0YP6 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMU0YP6 RU https://www.fda.gov/ DMU1GX0 DI DMU1GX0 DMU1GX0 DN Mitotane DMU1GX0 TI TTZAYWL DMU1GX0 TN Estrogen receptor (ESR) DMU1GX0 MA Binder DMU1GX0 RN Mitotane for adrenocortical carcinoma treatment. Curr Opin Investig Drugs. 2005 Apr;6(4):386-94. DMU1GX0 RU https://pubmed.ncbi.nlm.nih.gov/15898346 DMU1XOD DI DMU1XOD DMU1XOD DN Nafamostat DMU1XOD TI TTF8CQI DMU1XOD TN Tumor necrosis factor (TNF) DMU1XOD RN Clinical pipeline report, company report or official report of AstraZeneca (2009). DMU1XOD RU http://www.astrazeneca.com/_mshost3690701/content/resources/media/investors/AZN-Q2-2009/AZN-Q2-2009-Pipeline.pdf DMU1XOD DI DMU1XOD DMU1XOD DN Nafamostat DMU1XOD TI TTEMV5X DMU1XOD TN Serine protease unspecific (SP) DMU1XOD MA Inhibitor DMU1XOD RN Tryptase-positive mast cells correlate with angiogenesis in early breast cancer patients. Int J Oncol. 2009 Jul;35(1):115-20. DMU1XOD RU https://pubmed.ncbi.nlm.nih.gov/19513558 DMU3DNC DI DMU3DNC DMU3DNC DN Pentoxifylline DMU3DNC TI TTF8CQI DMU3DNC TN Tumor necrosis factor (TNF) DMU3DNC RN Targeted therapies in myelodysplastic syndromes: ASH 2003 review. Semin Hematol. 2004 Apr;41(2 Suppl 4):13-20. DMU3DNC RU https://pubmed.ncbi.nlm.nih.gov/15190511 DMU3FGB DI DMU3FGB DMU3FGB DN Dhaq diacetate DMU3FGB TI TT0IHXV DMU3FGB TN DNA topoisomerase II (TOP2) DMU3FGB MA Inhibitor DMU3FGB RN The hypoxia-activated ProDrug AQ4N penetrates deeply in tumor tissues and complements the limited distribution of mitoxantrone. Cancer Res. 2009 Feb 1;69(3):940-7. DMU3FGB RU https://pubmed.ncbi.nlm.nih.gov/19176397 DMU3IET DI DMU3IET DMU3IET DN Thiethylperazine DMU3IET TI TTEX248 DMU3IET TN Dopamine D2 receptor (D2R) DMU3IET MA Antagonist DMU3IET RN Antiemetic specificity of dopamine antagonists. Psychopharmacology (Berl). 1982;78(3):210-3. DMU3IET RU https://pubmed.ncbi.nlm.nih.gov/6130555 DMU4D5Y DI DMU4D5Y DMU4D5Y DN Benzquinamide DMU4D5Y TI TT0JLSD DMU4D5Y TN Multidrug resistance protein (MDR) DMU4D5Y MA Inhibitor DMU4D5Y RN Benzquinamide inhibits P-glycoprotein mediated drug efflux and potentiates anticancer agent cytotoxicity in multidrug resistant cells. Oncol Res. 1992;4(8-9):359-65. DMU4D5Y RU https://pubmed.ncbi.nlm.nih.gov/1362504 DMU4JLB DI DMU4JLB DMU4JLB DN Penicillin G Procaine DMU4JLB TI TTJP4SM DMU4JLB TN Bacterial Penicillin binding protein (Bact PBP) DMU4JLB MA Modulator DMU4JLB RN Bacterial Resistance to Penicillin G by Decreased Affinity of Penicillin-Binding Proteins: A Mathematical Model DMU4JLB RU https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2957969 DMU4ORS DI DMU4ORS DMU4ORS DN Magnesium DMU4ORS TI TT9IK2Z DMU4ORS TN N-methyl-D-aspartate receptor (NMDAR) DMU4ORS MA Antagonist DMU4ORS RN Emerging drugs for acute ischemic stroke. Expert Opin Emerg Drugs. 2009 Mar;14(1):33-42. DMU4ORS RU https://pubmed.ncbi.nlm.nih.gov/19249986 DMU54C3 DI DMU54C3 DMU54C3 DN Flutropium bromide DMU54C3 TI TTH18TF DMU54C3 TN Muscarinic acetylcholine receptor M5 (CHRM5) DMU54C3 MA Modulator DMU54C3 RN Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. DMU54C3 RU https://pubmed.ncbi.nlm.nih.gov/17309302 DMU54QB DI DMU54QB DMU54QB DN Treximet DMU54QB TI TTSQIFT DMU54QB TN 5-HT 1A receptor (HTR1A) DMU54QB MA Antagonist DMU54QB RN Clinical pipeline report, company report or official report of GlaxoSmithKline (2009). DMU54QB RU http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf DMU6OFP DI DMU6OFP DMU6OFP DN Dyclonine DMU6OFP TI TTZOVE0 DMU6OFP TN Voltage-gated sodium channel alpha Nav1.5 (SCN5A) DMU6OFP MA Blocker DMU6OFP RN Monoamine transporter and sodium channel mechanisms in the rapid pressor response to cocaine. Pharmacol Biochem Behav. 1998 Feb;59(2):305-12. DMU6OFP RU https://pubmed.ncbi.nlm.nih.gov/9476974 DMU764S DI DMU764S DMU764S DN Ritonavir DMU764S TI TT5FNQT DMU764S TN Human immunodeficiency virus Protease (HIV PR) DMU764S MA Inhibitor DMU764S RN Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV. Int J Antimicrob Agents. 2009 Apr;33(4):307-20. DMU764S RU https://pubmed.ncbi.nlm.nih.gov/19108994 DMU7SF8 DI DMU7SF8 DMU7SF8 DN Conjugated estrogens b DMU7SF8 TI TTZAYWL DMU7SF8 TN Estrogen receptor (ESR) DMU7SF8 MA Modulator DMU7SF8 RN Effect of MK-486 alone on Parkinsonism; studies on the clinical symptoms and catecholamine concentrations in the blood, urine and cerebrospinal fluid. No To Shinkei. 1977 Feb;29(2):205-13. DMU7SF8 RU https://pubmed.ncbi.nlm.nih.gov/326277 DMU7YEL DI DMU7YEL DMU7YEL DN Sufentanil DMU7YEL TI TTN4QDT DMU7YEL TN Opioid receptor (OPR) DMU7YEL MA Antagonist DMU7YEL RN mu-opioid receptor-stimulated synthesis of reactive oxygen species is mediated via phospholipase D2. J Neurochem. 2009 Aug;110(4):1288-96. DMU7YEL RU https://pubmed.ncbi.nlm.nih.gov/19519662 DMU8ANS DI DMU8ANS DMU8ANS DN Ximelegatran DMU8ANS TI TT6L509 DMU8ANS TN Coagulation factor IIa (F2) DMU8ANS MA Inhibitor DMU8ANS RN Emerging drugs in peripheral arterial disease. Expert Opin Emerg Drugs. 2006 Mar;11(1):75-90. DMU8ANS RU https://pubmed.ncbi.nlm.nih.gov/16503827 DMU8ANS DI DMU8ANS DMU8ANS DN Ximelegatran DMU8ANS TI TTMQO60 DMU8ANS TN Rho-associated protein kinase (ROCK) DMU8ANS MA Modulator DMU8ANS RN Pharmacological properties of Y-27632, a specific inhibitor of rho-associated kinases. Mol Pharmacol. 2000 May;57(5):976-83. DMU8ANS RU https://www.ncbi.nlm.nih.gov/pubmed/10779382 DMU8JGH DI DMU8JGH DMU8JGH DN Hydralazine DMU8JGH TI TT7HC21 DMU8JGH TN Membrane copper amine oxidase (AOC3) DMU8JGH MA Modulator DMU8JGH RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMU8JGH RU https://www.fda.gov/ DMU8KOD DI DMU8KOD DMU8KOD DN Anakinra DMU8KOD TI TTWOTEA DMU8KOD TN Interleukin 1 receptor type 1 (IL1R1) DMU8KOD MA Antagonist DMU8KOD RN IL-1 receptor antagonism and muscle gene expression in patients with type 2 diabetes. Eur Cytokine Netw. 2009 Jun 1;20(2):81-87. DMU8KOD RU https://pubmed.ncbi.nlm.nih.gov/19541594 DMU8V4S DI DMU8V4S DMU8V4S DN Moxifloxacin DMU8V4S TI TTN6J5F DMU8V4S TN Bacterial DNA gyrase (Bact gyrase) DMU8V4S MA Modulator DMU8V4S RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMU8V4S RU https://www.fda.gov/ DMU8V4S DI DMU8V4S DMU8V4S DN Moxifloxacin DMU8V4S TI TTIXTO3 DMU8V4S TN Staphylococcus Topoisomerase IV (Stap-coc parC) DMU8V4S MA Modulator DMU8V4S RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMU8V4S RU https://www.fda.gov/ DMU92F8 DI DMU92F8 DMU92F8 DN Promestriene DMU92F8 TI TTZAYWL DMU92F8 TN Estrogen receptor (ESR) DMU92F8 MA Modulator DMU92F8 RN Promestriene, a specific topic estrogen. Review of 40 years of vaginal atrophy treatment: is it safe even in cancer patients. Anticancer Drugs. 2013 Nov;24(10):989-98. DMU92F8 RU https://pubmed.ncbi.nlm.nih.gov/24080714 DMU9C8F DI DMU9C8F DMU9C8F DN Bavencio DMU9C8F TI TT8ZLTI DMU9C8F TN Programmed cell death 1 ligand 1 (PD-L1) DMU9C8F MA Inhibitor DMU9C8F RN ClinicalTrials.gov (NCT03403777) Avelumab in Refractory Testicular Germ Cell Cancer.. U.S. National Institutes of Health. DMU9C8F RU https://clinicaltrials.gov/ct2/show/NCT03403777 DMU9D2F DI DMU9D2F DMU9D2F DN Gabexate DMU9D2F TI TTEMV5X DMU9D2F TN Serine protease unspecific (SP) DMU9D2F MA Inhibitor DMU9D2F RN Tryptase-positive mast cells correlate with angiogenesis in early breast cancer patients. Int J Oncol. 2009 Jul;35(1):115-20. DMU9D2F RU https://pubmed.ncbi.nlm.nih.gov/19513558 DMU9MYJ DI DMU9MYJ DMU9MYJ DN Oxandrolone DMU9MYJ TI TTS64P2 DMU9MYJ TN Androgen receptor (AR) DMU9MYJ MA Agonist DMU9MYJ RN The effect of oxandrolone treatment on human osteoblastic cells. J Burns Wounds. 2007 Mar 7;6:e4. DMU9MYJ RU https://pubmed.ncbi.nlm.nih.gov/17364004 DMUBP9O DI DMUBP9O DMUBP9O DN Voglibose DMUBP9O TI TTXWASR DMUBP9O TN Intestinal maltase-glucoamylase (MGAM) DMUBP9O MA Inhibitor DMUBP9O RN Effects of changeover from voglibose to acarbose on postprandial triglycerides in type 2 diabetes mellitus patients. Adv Ther. 2009 Jun;26(6):660-6. DMUBP9O RU https://pubmed.ncbi.nlm.nih.gov/19568704 DMUCWEX DI DMUCWEX DMUCWEX DN Polidocanol - BioForm Medical/Chemische Fabrik Kreussler & Co DMUCWEX TI TT42M75 DMUCWEX TN Carbamoyl-phosphate synthetase I (CPS1) DMUCWEX MA Modulator DMUCWEX RN Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5. DMUCWEX RU https://pubmed.ncbi.nlm.nih.gov/21283092 DMUDIR8 DI DMUDIR8 DMUDIR8 DN Fludrocortisone DMUDIR8 TI TT26PHO DMUDIR8 TN Mineralocorticoid receptor (MR) DMUDIR8 MA Agonist DMUDIR8 RN Mineralocorticoid receptor-mediated inhibition of the hypothalamic-pituitary-adrenal axis in aged humans. J Gerontol A Biol Sci Med Sci. 2003 Oct;58(10):B900-5. DMUDIR8 RU https://pubmed.ncbi.nlm.nih.gov/14570856 DMUDIR8 DI DMUDIR8 DMUDIR8 DN Fludrocortisone DMUDIR8 TI TTS64P2 DMUDIR8 TN Androgen receptor (AR) DMUDIR8 MA Inhibitor DMUDIR8 RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMUDIR8 RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMUDJZM DI DMUDJZM DMUDJZM DN Dextromethorphan DMUDJZM TI TT5TPI6 DMUDJZM TN Opioid receptor sigma 1 (OPRS1) DMUDJZM MA Agonist DMUDJZM RN Dextromethorphan/quinidine: AVP 923, dextromethorphan/cytochrome P450-2D6 inhibitor, quinidine/dextromethorphan. Drugs R D. 2005;6(3):174-7. DMUDJZM RU https://pubmed.ncbi.nlm.nih.gov/15869321 DMUDWP9 DI DMUDWP9 DMUDWP9 DN Mepindolol DMUDWP9 TI TTMXGCW DMUDWP9 TN Adrenergic receptor beta-3 (ADRB3) DMUDWP9 MA Modulator DMUDWP9 RN Pharmacological studies on the intrinsic sympathomimetic activity of the beta-adrenoceptor antagonist mepindolol. Arzneimittelforschung. 1986 May;36(5):811-3. DMUDWP9 RU https://pubmed.ncbi.nlm.nih.gov/2873820 DMUFGAY DI DMUFGAY DMUFGAY DN Betazole DMUFGAY TI TTQHJ1K DMUFGAY TN Histamine H2 receptor (H2R) DMUFGAY MA Antagonist DMUFGAY RN Effect of nizatidine and cimetidine on betazole-stimulated gastric secretion of normal subjects: comparison of effects on acid, water, and pepsin. Am J Gastroenterol. 1988 Jan;83(1):32-6. DMUFGAY RU https://pubmed.ncbi.nlm.nih.gov/2892392 DMUHCF1 DI DMUHCF1 DMUHCF1 DN Fluoxymesterone DMUHCF1 TI TTS64P2 DMUHCF1 TN Androgen receptor (AR) DMUHCF1 MA Agonist DMUHCF1 RN An orally active selective androgen receptor modulator is efficacious on bone, muscle, and sex function with reduced impact on prostate. Endocrinology. 2007 Jan;148(1):363-73. DMUHCF1 RU https://pubmed.ncbi.nlm.nih.gov/17023534 DMUI0CH DI DMUI0CH DMUI0CH DN Tobramycin DMUI0CH TI TTOVFH2 DMUI0CH TN Bacterial 30S ribosomal RNA (Bact 30S rRNA) DMUI0CH MA Modulator DMUI0CH RN Mechanism of action of aminoglycoside antibiotics.Binding studies of tobramycin and its 6'-N-acetyl derivative to the bacterial ribosome and its subunits.Eur J Biochem.1979 Dec;102(1):73-81. DMUI0CH RU https://www.ncbi.nlm.nih.gov/pubmed/391568 DMUIASK DI DMUIASK DMUIASK DN Cosyntropin DMUIASK TI TTPWFDX DMUIASK TN Melanocortin receptor 2 (MC2R) DMUIASK MA Antagonist DMUIASK RN Hypothalamic-pituitary-adrenal axis dysfunction in hospitalized neonatal foals. J Vet Intern Med. 2009 Jul-Aug;23(4):901-12. DMUIASK RU https://pubmed.ncbi.nlm.nih.gov/19496914 DMUIE76 DI DMUIE76 DMUIE76 DN Acetaminophen DMUIE76 TI TTK0943 DMUIE76 TN Prostaglandin G/H synthase (COX) DMUIE76 MA Inhibitor DMUIE76 RN Mechanism of action of paracetamol. Am J Ther. 2005 Jan-Feb;12(1):46-55. DMUIE76 RU https://pubmed.ncbi.nlm.nih.gov/15662292 DMUIE76 DI DMUIE76 DMUIE76 DN Acetaminophen DMUIE76 TI TTAWNKZ DMUIE76 TN Norepinephrine transporter (NET) DMUIE76 MA Inhibitor DMUIE76 RN Augmentation effect of combination therapy of aripiprazole and antidepressants on forced swimming test in mice. Psychopharmacology (Berl). 2009 Sep;206(1):97-107. DMUIE76 RU https://pubmed.ncbi.nlm.nih.gov/19517098 DMUIE76 DI DMUIE76 DMUIE76 DN Acetaminophen DMUIE76 TI TT3ROYC DMUIE76 TN Serotonin transporter (SERT) DMUIE76 MA Inhibitor DMUIE76 RN Augmentation effect of combination therapy of aripiprazole and antidepressants on forced swimming test in mice. Psychopharmacology (Berl). 2009 Sep;206(1):97-107. DMUIE76 RU https://pubmed.ncbi.nlm.nih.gov/19517098 DMUJGR1 DI DMUJGR1 DMUJGR1 DN Sorivudine DMUJGR1 TI TT84ETX DMUJGR1 TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMUJGR1 MA Modulator DMUJGR1 RN Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. DMUJGR1 RU https://pubmed.ncbi.nlm.nih.gov/17309302 DMUKC5L DI DMUKC5L DMUKC5L DN Tivozanib DMUKC5L TI TT2Q6G1 DMUKC5L TN Vascular endothelial growth factor receptor 1 (FLT-1) DMUKC5L MA Inhibitor DMUKC5L RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services DMUKC5L RU https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-tivozanib-relapsed-or-refractory-advanced-renal-cell-carcinoma DMUKC5L DI DMUKC5L DMUKC5L DN Tivozanib DMUKC5L TI TTDCBX5 DMUKC5L TN Vascular endothelial growth factor receptor 3 (FLT-4) DMUKC5L MA Modulator DMUKC5L RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services DMUKC5L RU https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-tivozanib-relapsed-or-refractory-advanced-renal-cell-carcinoma DMUKC5L DI DMUKC5L DMUKC5L DN Tivozanib DMUKC5L TI TTUTJGQ DMUKC5L TN Vascular endothelial growth factor receptor 2 (KDR) DMUKC5L MA Modulator DMUKC5L RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services DMUKC5L RU https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-tivozanib-relapsed-or-refractory-advanced-renal-cell-carcinoma DMUL45H DI DMUL45H DMUL45H DN Naltrexone DMUL45H TI TTN4QDT DMUL45H TN Opioid receptor (OPR) DMUL45H MA Antagonist DMUL45H RN An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study. Arch Gen Psychiatry. 2008 Feb;65(2):135-44. DMUL45H RU https://pubmed.ncbi.nlm.nih.gov/18250251 DMUL5EW DI DMUL5EW DMUL5EW DN Posaconazole DMUL5EW TI TTTSOUD DMUL5EW TN Candida Cytochrome P450 51 (Candi ERG11) DMUL5EW MA Inhibitor DMUL5EW RN A new, broad-spectrum azole antifungal: posaconazole--mechanisms of action and resistance, spectrum of activity. Mycoses. 2006;49 Suppl 1:2-6. DMUL5EW RU https://pubmed.ncbi.nlm.nih.gov/16961575 DMUL7T1 DI DMUL7T1 DMUL7T1 DN Imidapril DMUL7T1 TI TTL69WB DMUL7T1 TN Angiotensin-converting enzyme (ACE) DMUL7T1 MA Modulator DMUL7T1 RN Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. DMUL7T1 RU https://pubmed.ncbi.nlm.nih.gov/17309302 DMULAI4 DI DMULAI4 DMULAI4 DN Carbimazole DMULAI4 TI TT52XDZ DMULAI4 TN Thyroid peroxidase (TPO) DMULAI4 MA Inhibitor DMULAI4 RN Diagnosis and treatment of thyrotoxicosis in childhood. A European questionnaire study. Eur J Endocrinol. 1994 Nov;131(5):467-73. DMULAI4 RU https://pubmed.ncbi.nlm.nih.gov/7952157 DMUM7HZ DI DMUM7HZ DMUM7HZ DN Fluorouracil DMUM7HZ TI TTU6BFZ DMUM7HZ TN Candida Thymidylate synthase (Candi TMP1) DMUM7HZ MA Inhibitor DMUM7HZ RN The efficacy of the combination therapy of 5-fluorouracil, cisplatin and leucovorin for hepatocellular carcinoma and its predictable factors. Cancer Chemother Pharmacol. 2004 Apr;53(4):296-304. DMUM7HZ RU https://pubmed.ncbi.nlm.nih.gov/14689231 DMUM7HZ DI DMUM7HZ DMUM7HZ DN Fluorouracil DMUM7HZ TI TTZPS91 DMUM7HZ TN Dihydrothymine dehydrogenase (DPYD) DMUM7HZ MA Inhibitor DMUM7HZ RN Enhancement of the antitumour activity of 5-fluorouracil (5-FU) by inhibiting dihydropyrimidine dehydrogenase activity (DPD) using 5-chloro-2,4-dihydroxypyridine (CDHP) in human tumour cells. Eur J Cancer. 2002 Jun;38(9):1271-7. DMUM7HZ RU https://pubmed.ncbi.nlm.nih.gov/12044515 DMUM7HZ DI DMUM7HZ DMUM7HZ DN Fluorouracil DMUM7HZ TI TTQY2EJ DMUM7HZ TN TERT messenger RNA (TERT mRNA) DMUM7HZ RN Design and development of antisense drugs. Expert Opin. Drug Discov. 2008 3(10):1189-1207. DMUM7HZ RU http://www.informahealthcare.com/doi/abs/10.1517/17460441.3.10.1177 DMUM7HZ DI DMUM7HZ DMUM7HZ DN Fluorouracil DMUM7HZ TI TTP1UKZ DMUM7HZ TN Thymidylate synthase messenger RNA (TYMS mRNA) DMUM7HZ RN Design and development of antisense drugs. Expert Opin. Drug Discov. 2008 3(10):1189-1207. DMUM7HZ RU http://www.informahealthcare.com/doi/abs/10.1517/17460441.3.10.1177 DMUMOEV DI DMUMOEV DMUMOEV DN Ansuvimab DMUMOEV TI TT2F0AU DMUMOEV TN Ebola virus Envelope glycoprotein (EV GP) DMUMOEV RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020 DMUMOEV RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761172s000lbl.pdf DMUMQZ0 DI DMUMQZ0 DMUMQZ0 DN Clidinium DMUMQZ0 TI TTZ9SOR DMUMQZ0 TN Muscarinic acetylcholine receptor M1 (CHRM1) DMUMQZ0 MA Antagonist DMUMQZ0 RN Accidental acute clidinium toxicity. Emerg Med J. 2009 Jun;26(6):460. DMUMQZ0 RU https://pubmed.ncbi.nlm.nih.gov/19465630 DMUMQZ0 DI DMUMQZ0 DMUMQZ0 DN Clidinium DMUMQZ0 TI TTOXS3C DMUMQZ0 TN Muscarinic acetylcholine receptor (CHRM) DMUMQZ0 MA Antagonist DMUMQZ0 RN Pharmacological comparison of the cloned human and rat M2 muscarinic receptor genes expressed in the murine fibroblast (B82) cell line. J Pharmacol Exp Ther. 1998 Feb;284(2):500-7. DMUMQZ0 RU https://pubmed.ncbi.nlm.nih.gov/9454790 DMUNSWV DI DMUNSWV DMUNSWV DN Cefradine DMUNSWV TI TTJP4SM DMUNSWV TN Bacterial Penicillin binding protein (Bact PBP) DMUNSWV MA Binder DMUNSWV RN Staphylococcus aureus PBP4 is essential for beta-lactam resistance in community-acquired methicillin-resistant strains. Antimicrob Agents Chemother. 2008 Nov;52(11):3955-66. DMUNSWV RU https://pubmed.ncbi.nlm.nih.gov/18725435 DMUNTE3 DI DMUNTE3 DMUNTE3 DN Estradiol DMUNTE3 TI TTZAYWL DMUNTE3 TN Estrogen receptor (ESR) DMUNTE3 MA Agonist DMUNTE3 RN Reprint of Are all estrogens the same Maturitas. 2008 Sep-Oct;61(1-2):195-201. DMUNTE3 RU https://pubmed.ncbi.nlm.nih.gov/19434891 DMUOK4C DI DMUOK4C DMUOK4C DN Lisinopril DMUOK4C TI TTL69WB DMUOK4C TN Angiotensin-converting enzyme (ACE) DMUOK4C MA Inhibitor DMUOK4C RN Involvement of vascular angiotensin II-forming enzymes in the progression of aortic abdominal aneurysms in angiotensin II- infused ApoE-deficient m... J Atheroscler Thromb. 2009 Jun;16(3):164-71. DMUOK4C RU https://pubmed.ncbi.nlm.nih.gov/19556720 DMUOT9V DI DMUOT9V DMUOT9V DN Taxol DMUOT9V TI TTJGNVC DMUOT9V TN Apoptosis regulator Bcl-2 (BCL-2) DMUOT9V MA Modulator DMUOT9V RN Paclitaxel directly binds to Bcl-2 and functionally mimics activity of Nur77. Cancer Res. 2009 Sep 1;69(17):6906-14. DMUOT9V RU https://pubmed.ncbi.nlm.nih.gov/19671798 DMUOT9V DI DMUOT9V DMUOT9V DN Taxol DMUOT9V TI TTYFKSZ DMUOT9V TN Tubulin beta (TUBB) DMUOT9V MA Modulator DMUOT9V RN Paclitaxel directly binds to Bcl-2 and functionally mimics activity of Nur77. Cancer Res. 2009 Sep 1;69(17):6906-14. DMUOT9V RU https://pubmed.ncbi.nlm.nih.gov/19671798 DMUPE07 DI DMUPE07 DMUPE07 DN Nicotinamide DMUPE07 TI TTVDSZ0 DMUPE07 TN Poly [ADP-ribose] polymerase 1 (PARP1) DMUPE07 MA Binder DMUPE07 RN beta-1,2,3-Triazolyl-nucleosides as nicotinamide riboside mimics. Nucleosides Nucleotides Nucleic Acids. 2009 Mar;28(3):238-59. DMUPE07 RU https://pubmed.ncbi.nlm.nih.gov/19333861 DMUPFLI DI DMUPFLI DMUPFLI DN Deutetrabenazine DMUPFLI TI TTNZRI3 DMUPFLI TN Synaptic vesicle amine transporter (SLC18A2) DMUPFLI MA Modulator DMUPFLI RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMUPFLI RU https://www.fda.gov/ DMUPOGR DI DMUPOGR DMUPOGR DN Lumacaftor + Ivacaftor DMUPOGR TI TTFPKRB DMUPOGR TN cAMP-dependent chloride channel F508 deletion (CFTR del F508) DMUPOGR MA Enhancer DMUPOGR RN Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357. DMUPOGR RU https://pubmed.ncbi.nlm.nih.gov/30728472 DMUPOGR DI DMUPOGR DMUPOGR DN Lumacaftor + Ivacaftor DMUPOGR TI TTRLZHP DMUPOGR TN cAMP-dependent chloride channel (CFTR) DMUPOGR MA Enhancer DMUPOGR RN Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357. DMUPOGR RU https://pubmed.ncbi.nlm.nih.gov/30728472 DMUQ0E8 DI DMUQ0E8 DMUQ0E8 DN Tepotinib DMUQ0E8 TI TTNDSF4 DMUQ0E8 TN Proto-oncogene c-Met (MET) DMUQ0E8 MA Modulator DMUQ0E8 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2021 DMUQ0E8 RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214096s000lbl.pdf DMUR64T DI DMUR64T DMUR64T DN Lesinurad DMUR64T TI TTA592U DMUR64T TN Urate anion exchanger 1 (URAT1) DMUR64T MA Modulator DMUR64T RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1031). DMUR64T RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1031 DMUR94J DI DMUR94J DMUR94J DN Certoparin sodium DMUR94J TI TTCIHJA DMUR94J TN Coagulation factor Xa (F10) DMUR94J MA Modulator DMUR94J RN Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. DMUR94J RU https://pubmed.ncbi.nlm.nih.gov/17309302 DMUSLW3 DI DMUSLW3 DMUSLW3 DN Carbetocin DMUSLW3 TI TTSCIUP DMUSLW3 TN Oxytocin receptor (OTR) DMUSLW3 MA Agonist DMUSLW3 RN Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin V1a, V1b, V2 and OT receptors: research tools and potential therapeutic agents. Prog Brain Res. 2008;170:473-512. DMUSLW3 RU https://pubmed.ncbi.nlm.nih.gov/18655903 DMUSZHD DI DMUSZHD DMUSZHD DN Hydrochlorothiazide DMUSZHD TI TTL69WB DMUSZHD TN Angiotensin-converting enzyme (ACE) DMUSZHD MA Modulator DMUSZHD RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMUSZHD RU https://www.fda.gov/ DMUTEX3 DI DMUTEX3 DMUTEX3 DN Amiodarone DMUTEX3 TI TT1VOHK DMUTEX3 TN Potassium channel unspecific (KC) DMUTEX3 MA Modulator DMUTEX3 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMUTEX3 RU https://www.fda.gov/ DMUTL7O DI DMUTL7O DMUTL7O DN Cloxacillin DMUTL7O TI TTJP4SM DMUTL7O TN Bacterial Penicillin binding protein (Bact PBP) DMUTL7O MA Binder DMUTL7O RN Development of a receptor-based microplate assay for the detection of beta-lactam antibiotics in different food matrices. Anal Chim Acta. 2007 Mar 14;586(1-2):296-303. DMUTL7O RU https://pubmed.ncbi.nlm.nih.gov/17386727 DMUTYR2 DI DMUTYR2 DMUTYR2 DN Epoprostenol DMUTYR2 TI TTOFYT1 DMUTYR2 TN Prostacyclin receptor (PTGIR) DMUTYR2 MA Agonist DMUTYR2 RN Novel signaling pathways promote a paracrine wave of prostacyclin-induced vascular smooth muscle differentiation. J Mol Cell Cardiol. 2009 May;46(5):682-94. DMUTYR2 RU https://pubmed.ncbi.nlm.nih.gov/19302827 DMUTZ8S DI DMUTZ8S DMUTZ8S DN Interferon Alfa-2a, Recombinant DMUTZ8S TI TTGJVQM DMUTZ8S TN Fibroblast growth factor receptor 2 (FGFR2) DMUTZ8S MA Binder DMUTZ8S RN DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6. DMUTZ8S RU https://pubmed.ncbi.nlm.nih.gov/18048412 DMUV8OR DI DMUV8OR DMUV8OR DN Indecainide DMUV8OR TI TTZOVE0 DMUV8OR TN Voltage-gated sodium channel alpha Nav1.5 (SCN5A) DMUV8OR MA Blocker DMUV8OR RN Electrophysiological studies of indecainide hydrochloride, a new antiarrhythmic agent, in canine cardiac tissues. J Cardiovasc Pharmacol. 1984 Jul-Aug;6(4):614-21. DMUV8OR RU https://pubmed.ncbi.nlm.nih.gov/6206315 DMUWAM2 DI DMUWAM2 DMUWAM2 DN Pyronaridine DMUWAM2 TI TTZVSJ2 DMUWAM2 TN Sarcoplasmic/endoplasmic reticulum calcium ATPase (ATP2A) DMUWAM2 MA Inhibitor DMUWAM2 RN The fight against drug-resistant malaria: novel plasmodial targets and antimalarial drugs. Curr Med Chem. 2008;15(2):161-71. DMUWAM2 RU https://pubmed.ncbi.nlm.nih.gov/18220771 DMUWBIJ DI DMUWBIJ DMUWBIJ DN Propiverine DMUWBIJ TI TTH18TF DMUWBIJ TN Muscarinic acetylcholine receptor M5 (CHRM5) DMUWBIJ MA Antagonist DMUWBIJ RN Affinity profiles of various muscarinic antagonists for cloned human muscarinic acetylcholine receptor (mAChR) subtypes and mAChRs in rat heart and submandibular gland. Life Sci. 1999;64(25):2351-8. DMUWBIJ RU https://pubmed.ncbi.nlm.nih.gov/10374898 DMUXP52 DI DMUXP52 DMUXP52 DN Clobetasol DMUXP52 TI TT9V5JH DMUXP52 TN Phospholipase A2 (PLA2G1B) DMUXP52 MA Inhibitor DMUXP52 RN Utilization of epidermal phospholipase A2 inhibition to monitor topical steroid action. Br J Dermatol. 1984 Jul;111 Suppl 27:195-203. DMUXP52 RU https://pubmed.ncbi.nlm.nih.gov/6743552 DMUY2OR DI DMUY2OR DMUY2OR DN Cynarin DMUY2OR TI TTLOQ79 DMUY2OR TN Taste receptor (TASR) DMUY2OR MA Modulator DMUY2OR RN Medicinal plants in therapy. Bull World Health Organ. 1985;63(6):965-81. DMUY2OR RU https://pubmed.ncbi.nlm.nih.gov/3879679 DMUY35B DI DMUY35B DMUY35B DN Progesterone DMUY35B TI TTUV8G9 DMUY35B TN Progesterone receptor (PGR) DMUY35B MA Agonist DMUY35B RN Clinical pipeline report, company report or official report of lipocine. DMUY35B RU http://www.lipocine.com/pipeline/lpcn-1107/ DMUYNEI DI DMUYNEI DMUYNEI DN Amoxicillin DMUYNEI TI TTXT4D5 DMUYNEI TN Bacterial Cell membrane (Bact CM) DMUYNEI MA Modulator DMUYNEI RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMUYNEI RU https://www.fda.gov/ DMUZNIG DI DMUZNIG DMUZNIG DN Troleandomycin DMUZNIG TI TTUWYEA DMUZNIG TN Bacterial 50S ribosomal RNA (Bact 50S rRNA) DMUZNIG MA Binder DMUZNIG RN Depression of colony formation by human thymus-derived lymphocytes with rifampin and other antimicrobial agents. J Infect Dis. 1981 Jun;143(6):832-5. DMUZNIG RU https://pubmed.ncbi.nlm.nih.gov/6972981 DMUZPJ5 DI DMUZPJ5 DMUZPJ5 DN Cisatracurium DMUZPJ5 TI TTUPDWN DMUZPJ5 TN Cholinergic receptor unspecific (CHR) DMUZPJ5 MA Antagonist DMUZPJ5 RN Bradycardia produced by pyridostigmine and physostigmine. Can J Anaesth. 1997 Dec;44(12):1286-92. DMUZPJ5 RU https://pubmed.ncbi.nlm.nih.gov/9429048 DMUZPJ5 DI DMUZPJ5 DMUZPJ5 DN Cisatracurium DMUZPJ5 TI TTF4E0J DMUZPJ5 TN Neuronal acetylcholine receptor alpha-2 (CHRNA2) DMUZPJ5 MA Antagonist DMUZPJ5 RN Pharmacological characteristics of the inhibition of nondepolarizing neuromuscular blocking agents at human adult muscle nicotinic acetylcholine receptor. Anesthesiology. 2009 Jun;110(6):1244-52. DMUZPJ5 RU https://pubmed.ncbi.nlm.nih.gov/19417616 DMV05SW DI DMV05SW DMV05SW DN As-1670542 DMV05SW TI TTIHYA4 DMV05SW TN Thrombopoietin receptor (MPL) DMV05SW MA Agonist DMV05SW RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1722). DMV05SW RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1722 DMV0RNS DI DMV0RNS DMV0RNS DN Deflazacort DMV0RNS TI TTYRL6O DMV0RNS TN Glucocorticoid receptor (NR3C1) DMV0RNS MA Modulator DMV0RNS RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMV0RNS RU https://www.fda.gov/ DMV23GL DI DMV23GL DMV23GL DN Lidoflazine DMV23GL TI TTAXZ0K DMV23GL TN Voltage-gated sodium channel alpha Nav1.3 (SCN3A) DMV23GL MA Inhibitor DMV23GL RN Synthesis and pharmacological evaluation of phenylacetamides as sodium-channel blockers. J Med Chem. 1994 Jan 21;37(2):268-74. DMV23GL RU https://pubmed.ncbi.nlm.nih.gov/8295214 DMV23GL DI DMV23GL DMV23GL DN Lidoflazine DMV23GL TI TTLXAKE DMV23GL TN Solute carrier family 29 member 1 (SLC29A1) DMV23GL MA Inhibitor DMV23GL RN Synthesis, flow cytometric evaluation, and identification of highly potent dipyridamole analogues as equilibrative nucleoside transporter 1 inhibit... J Med Chem. 2007 Aug 9;50(16):3906-20. DMV23GL RU https://pubmed.ncbi.nlm.nih.gov/17636949 DMV23GL DI DMV23GL DMV23GL DN Lidoflazine DMV23GL TI TTRK8B9 DMV23GL TN Sodium channel unspecific (NaC) DMV23GL MA Inhibitor DMV23GL RN Synthesis and pharmacological evaluation of phenylacetamides as sodium-channel blockers. J Med Chem. 1994 Jan 21;37(2):268-74. DMV23GL RU https://pubmed.ncbi.nlm.nih.gov/8295214 DMV26S8 DI DMV26S8 DMV26S8 DN Levomilnacipran DMV26S8 TI TTAWNKZ DMV26S8 TN Norepinephrine transporter (NET) DMV26S8 MA Modulator DMV26S8 RN Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92. DMV26S8 RU https://pubmed.ncbi.nlm.nih.gov/20118952 DMV26S8 DI DMV26S8 DMV26S8 DN Levomilnacipran DMV26S8 TI TT3ROYC DMV26S8 TN Serotonin transporter (SERT) DMV26S8 MA Modulator DMV26S8 RN Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92. DMV26S8 RU https://pubmed.ncbi.nlm.nih.gov/20118952 DMV2JNY DI DMV2JNY DMV2JNY DN Cephapirin DMV2JNY TI TTJP4SM DMV2JNY TN Bacterial Penicillin binding protein (Bact PBP) DMV2JNY MA Binder DMV2JNY RN The formation of functional penicillin-binding proteins. J Biol Chem. 1975 Aug 25;250(16):6578-85. DMV2JNY RU https://pubmed.ncbi.nlm.nih.gov/808545 DMV3YMX DI DMV3YMX DMV3YMX DN Vedolizmab DMV3YMX TI TTLT9XQ DMV3YMX TN Integrin beta-7 (ITGB7) DMV3YMX MA Antagonist DMV3YMX RN Clinical pipeline report, company report or official report of Takeda (2009). DMV3YMX RU http://www.takeda.com/pdf/usr/default/10_1_34992_2.pdf DMV3YMX DI DMV3YMX DMV3YMX DN Vedolizmab DMV3YMX TI TT4BT06 DMV3YMX TN Integrin alpha-4 (ITGA4) DMV3YMX MA Antagonist DMV3YMX RN Clinical pipeline report, company report or official report of Takeda (2009). DMV3YMX RU http://www.takeda.com/pdf/usr/default/10_1_34992_2.pdf DMV4KOA DI DMV4KOA DMV4KOA DN GW642444 DMV4KOA TI TT2CJVK DMV4KOA TN Adrenergic receptor beta-2 (ADRB2) DMV4KOA MA Agonist DMV4KOA RN Clinical pipeline report, company report or official report of GlaxoSmithKline (2009). DMV4KOA RU http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf DMV62ED DI DMV62ED DMV62ED DN Fotemustine DMV62ED TI TTR7UJ3 DMV62ED TN Cytoplasmic thioredoxin reductase (TXNRD1) DMV62ED MA Inhibitor DMV62ED RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMV62ED RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMV67QO DI DMV67QO DMV67QO DN Ibalizumab DMV67QO TI TTN2JFW DMV67QO TN T-cell surface glycoprotein CD4 (CD4) DMV67QO MA Modulator DMV67QO RN 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. DMV67QO RU https://pubmed.ncbi.nlm.nih.gov/30710142 DMV74ZH DI DMV74ZH DMV74ZH DN Pizotyline DMV74ZH TI TT85JO3 DMV74ZH TN 5-HT receptor (5HTR) DMV74ZH MA Modulator DMV74ZH RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DMV74ZH RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DMV7IM6 DI DMV7IM6 DMV7IM6 DN Histamine Phosphate DMV7IM6 TI TT7CXIM DMV7IM6 TN Histamine receptor (HR) DMV7IM6 MA Modulator DMV7IM6 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMV7IM6 RU https://www.fda.gov/ DMV7YFT DI DMV7YFT DMV7YFT DN Darolutamide DMV7YFT TI TTS64P2 DMV7YFT TN Androgen receptor (AR) DMV7YFT MA Antagonist DMV7YFT RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019 DMV7YFT RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212099Orig1s000lbl.pdf DMV96ZH DI DMV96ZH DMV96ZH DN Anapsos DMV96ZH TI TTXL3MF DMV96ZH TN Lymphoid cell adhesion molecule expression (LCDME) DMV96ZH MA Modulator DMV96ZH RN Anapsos (Polypodium leucotomos) modulates lymphoid cells and the expression of adhesion molecules. Pharmacol Res. 2002 Aug;46(2):185-90. DMV96ZH RU https://pubmed.ncbi.nlm.nih.gov/12220959 DMV9ADG DI DMV9ADG DMV9ADG DN Pilocarpine DMV9ADG TI TTH18TF DMV9ADG TN Muscarinic acetylcholine receptor M5 (CHRM5) DMV9ADG MA Agonist DMV9ADG RN Retinoic acid prevents virus-induced airway hyperreactivity and M2 receptor dysfunction via anti-inflammatory and antiviral effects. Am J Physiol Lung Cell Mol Physiol. 2009 Aug;297(2):L340-6. DMV9ADG RU https://pubmed.ncbi.nlm.nih.gov/19465517 DMVAIH4 DI DMVAIH4 DMVAIH4 DN Hylenex DMVAIH4 TI TTYTVXF DMVAIH4 TN Hyaluronic acid (HA) DMVAIH4 MA Modulator DMVAIH4 RN Targeting the tumor microenvironment in cancer: why hyaluronidase deserves a second look. Cancer Discov. 2011 September; 1(4): 291-296. DMVAIH4 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3204883/ DMVAZP9 DI DMVAZP9 DMVAZP9 DN Tenoxicam DMVAZP9 TI TTVKILB DMVAZP9 TN Prostaglandin G/H synthase 2 (COX-2) DMVAZP9 MA Inhibitor DMVAZP9 RN The use and safety profile of non-steroidal antiinflammatory drugs among Turkish patients with osteoarthritis. Turk J Gastroenterol. 2005 Sep;16(3):138-42. DMVAZP9 RU https://pubmed.ncbi.nlm.nih.gov/16245223 DMVE3TK DI DMVE3TK DMVE3TK DN Bromocriptine DMVE3TK TI TTEX248 DMVE3TK TN Dopamine D2 receptor (D2R) DMVE3TK MA Agonist DMVE3TK RN Silymarin BIO-C, an extract from Silybum marianum fruits, induces hyperprolactinemia in intact female rats. Phytomedicine. 2009 Sep;16(9):839-44. DMVE3TK RU https://pubmed.ncbi.nlm.nih.gov/19303749 DMVEK07 DI DMVEK07 DMVEK07 DN Magnesium Sulfate DMVEK07 TI TT9IK2Z DMVEK07 TN N-methyl-D-aspartate receptor (NMDAR) DMVEK07 MA Antagonist DMVEK07 RN Magnesium sulfate diminishes the effects of amide local anesthetics in rat sciatic-nerve block. Reg Anesth Pain Med. 2007 Jul-Aug;32(4):288-95. DMVEK07 RU https://pubmed.ncbi.nlm.nih.gov/17720112 DMVGPMX DI DMVGPMX DMVGPMX DN Fosfomycin DMVGPMX TI TTICX3S DMVGPMX TN Bacterial UDP-N-acetylglucosamine carboxyvinyltransferase (Bact murA) DMVGPMX MA Inhibitor DMVGPMX RN Evidence that the fosfomycin target Cys115 in UDP-N-acetylglucosamine enolpyruvyl transferase (MurA) is essential for product release. J Biol Chem. 2005 Feb 4;280(5):3757-63. DMVGPMX RU https://pubmed.ncbi.nlm.nih.gov/15531591 DMVHJLX DI DMVHJLX DMVHJLX DN Perospirone DMVHJLX TI TTYSN63 DMVHJLX TN 5-HT 2 receptor (5HT2R) DMVHJLX MA Modulator DMVHJLX RN Pharmacological effects of zotepine and other antipsychotics on the central 5-HT2 receptors. Pharmacopsychiatry. 1993 Mar;26(2):53-8. DMVHJLX RU https://pubmed.ncbi.nlm.nih.gov/7690975 DMVIKJZ DI DMVIKJZ DMVIKJZ DN Cinryze DMVIKJZ TI TTVQ6R9 DMVIKJZ TN C1 esterase inhibitor (SERPING1) DMVIKJZ MA Modulator DMVIKJZ RN 2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6. DMVIKJZ RU https://pubmed.ncbi.nlm.nih.gov/19180096 DMVIKJZ DI DMVIKJZ DMVIKJZ DN Cinryze DMVIKJZ TI TT7LRQH DMVIKJZ TN Complement C1s component (C1S) DMVIKJZ MA Modulator DMVIKJZ RN 2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6. DMVIKJZ RU https://pubmed.ncbi.nlm.nih.gov/19180096 DMVJS2K DI DMVJS2K DMVJS2K DN Monobenzone DMVJS2K TI TTULVH8 DMVJS2K TN Tyrosinase (TYR) DMVJS2K MA Inhibitor DMVJS2K RN Identification of an Alkylhydroquinone from Rhus succedanea as an Inhibitor of Tyrosinase and Melanogenesis. J Agric Food Chem. 2009 Mar 25;57(6):2200-5. DMVJS2K RU https://pubmed.ncbi.nlm.nih.gov/19159217 DMVKA4O DI DMVKA4O DMVKA4O DN Mianserin DMVKA4O TI TTYSN63 DMVKA4O TN 5-HT 2 receptor (5HT2R) DMVKA4O MA Antagonist DMVKA4O RN 5-HT reuptake and 5-HT2 receptors modulate capsaicin-evoked hypothermia in rats. Neurosci Lett. 2008 Jan 17;430(3):191-6. DMVKA4O RU https://pubmed.ncbi.nlm.nih.gov/18155835 DMVLHNI DI DMVLHNI DMVLHNI DN Tridihexethyl DMVLHNI TI TTH18TF DMVLHNI TN Muscarinic acetylcholine receptor M5 (CHRM5) DMVLHNI MA Binder DMVLHNI RN Effect of anticholinergic agents upon acquired nystagmus: a double-blind study of trihexyphenidyl and tridihexethyl chloride. Neurology. 1991 Nov;41(11):1737-41. DMVLHNI RU https://pubmed.ncbi.nlm.nih.gov/1944902 DMVLMW6 DI DMVLMW6 DMVLMW6 DN Ketanserin DMVLMW6 TI TTYSN63 DMVLMW6 TN 5-HT 2 receptor (5HT2R) DMVLMW6 MA Antagonist DMVLMW6 RN Nordexfenfluramine causes more severe pulmonary vasoconstriction than dexfenfluramine. Am J Physiol Lung Cell Mol Physiol. 2004 Mar;286(3):L531-8. DMVLMW6 RU https://pubmed.ncbi.nlm.nih.gov/14607779 DMVM6QR DI DMVM6QR DMVM6QR DN Lacosamide DMVM6QR TI TTZCW3T DMVM6QR TN Dihydropyrimidinase related protein 2 (DPYSL2) DMVM6QR MA Modulator DMVM6QR RN 2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6. DMVM6QR RU https://pubmed.ncbi.nlm.nih.gov/19180096 DMVM6QR DI DMVM6QR DMVM6QR DN Lacosamide DMVM6QR TI TTN9VTF DMVM6QR TN Voltage-gated sodium channel alpha Nav1.9 (SCN11A) DMVM6QR MA Inhibitor DMVM6QR RN Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357. DMVM6QR RU https://pubmed.ncbi.nlm.nih.gov/30728472 DMVM6QR DI DMVM6QR DMVM6QR DN Lacosamide DMVM6QR TI TTIG65Q DMVM6QR TN Voltage-gated sodium channel (Nav) DMVM6QR MA Inhibitor DMVM6QR RN Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357. DMVM6QR RU https://pubmed.ncbi.nlm.nih.gov/30728472 DMVMQ1L DI DMVMQ1L DMVMQ1L DN Nafronyl DMVMQ1L TI TT85JO3 DMVMQ1L TN 5-HT receptor (5HTR) DMVMQ1L MA Modulator DMVMQ1L RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DMVMQ1L RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DMVMY7K DI DMVMY7K DMVMY7K DN Arepanrix DMVMY7K TI TT3J5ZI DMVMY7K TN Cell mediated immunity response (CMIR) DMVMY7K RN Comparison of Pandemrix and Arepanrix, two pH1N1 AS03-adjuvanted vaccines differentially associated with narcolepsy development. Brain Behav Immun. 2015 Jul;47:44-57. DMVMY7K RU https://pubmed.ncbi.nlm.nih.gov/25452148 DMVN2E6 DI DMVN2E6 DMVN2E6 DN Vinpocetine DMVN2E6 TI TTHQENC DMVN2E6 TN Phosphodiesterase 1 (PDE1) DMVN2E6 MA Inhibitor DMVN2E6 RN Effects of phosphodiesterase inhibitors on contraction induced by endothelin-1 of isolated human prostatic tissue. Urology. 2009 Jun;73(6):1397-401. DMVN2E6 RU https://pubmed.ncbi.nlm.nih.gov/19285714 DMVN5OH DI DMVN5OH DMVN5OH DN Minocycline DMVN5OH TI TTQ8KVI DMVN5OH TN Staphylococcus 30S ribosomal subunit (Stap-coc pbp2) DMVN5OH MA Binder DMVN5OH RN Functional, biophysical, and structural bases for antibacterial activity of tigecycline. Antimicrob Agents Chemother. 2006 Jun;50(6):2156-66. DMVN5OH RU https://pubmed.ncbi.nlm.nih.gov/16723578 DMVO0UB DI DMVO0UB DMVO0UB DN Alfentanil DMVO0UB TI TTKWM86 DMVO0UB TN Opioid receptor mu (MOP) DMVO0UB MA Agonist DMVO0UB RN Concentration-effect relationship of intravenous alfentanil and ketamine on peripheral neurosensory thresholds, allodynia and hyperalgesia of neuropathic pain. Pain. 2001 Mar;91(1-2):177-87. DMVO0UB RU https://pubmed.ncbi.nlm.nih.gov/11240090 DMVO4ED DI DMVO4ED DMVO4ED DN Ethoxzolamide DMVO4ED TI TTANPDJ DMVO4ED TN Carbonic anhydrase II (CA-II) DMVO4ED MA Inhibitor DMVO4ED RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMVO4ED RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMVO4ED DI DMVO4ED DMVO4ED DN Ethoxzolamide DMVO4ED TI TTHQPL7 DMVO4ED TN Carbonic anhydrase I (CA-I) DMVO4ED MA Modulator DMVO4ED RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMVO4ED RU https://www.fda.gov/ DMVOIK1 DI DMVOIK1 DMVOIK1 DN Rosoxacin DMVOIK1 TI TT0IHXV DMVOIK1 TN DNA topoisomerase II (TOP2) DMVOIK1 MA Inhibitor DMVOIK1 RN Inhibition of Micrococcus luteus DNA gyrase by norfloxacin and 10 other quinolone carboxylic acids. Antimicrob Agents Chemother. 1986 Apr;29(4):598-601. DMVOIK1 RU https://pubmed.ncbi.nlm.nih.gov/3010848 DMVONE6 DI DMVONE6 DMVONE6 DN Epidermal growth factor DMVONE6 TI TTED8JB DMVONE6 TN Epidermal growth factor (EGF) DMVONE6 MA Modulator DMVONE6 RN Repurposing of the epidermal growth factor. Journal of Commercial Biotechnology (2011) 17, 45-52. DMVONE6 RU http://www.palgrave-journals.com/jcb/journal/v17/n1/full/jcb201028a.html DMVONE6 DI DMVONE6 DMVONE6 DN Epidermal growth factor DMVONE6 TI TTGKNB4 DMVONE6 TN Epidermal growth factor receptor (EGFR) DMVONE6 MA Modulator DMVONE6 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1797). DMVONE6 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1797 DMVP5YE DI DMVP5YE DMVP5YE DN Doxorubicin DMVP5YE TI TTQY2EJ DMVP5YE TN TERT messenger RNA (TERT mRNA) DMVP5YE RN Design and development of antisense drugs. Expert Opin. Drug Discov. 2008 3(10):1189-1207. DMVP5YE RU http://www.informahealthcare.com/doi/abs/10.1517/17460441.3.10.1177 DMVP5YE DI DMVP5YE DMVP5YE DN Doxorubicin DMVP5YE TI TT0IHXV DMVP5YE TN DNA topoisomerase II (TOP2) DMVP5YE MA Modulator DMVP5YE RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMVP5YE RU https://www.fda.gov/ DMVPUQI DI DMVPUQI DMVPUQI DN Hydroflumethiazide DMVPUQI TI TTS087L DMVPUQI TN Solute carrier family 12 member 1 (SLC12A1) DMVPUQI MA Blocker DMVPUQI RN DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6. DMVPUQI RU https://pubmed.ncbi.nlm.nih.gov/18048412 DMVPWLZ DI DMVPWLZ DMVPWLZ DN Terbutyline DMVPWLZ TI TTVIREA DMVPWLZ TN Adrenergic receptor (ADR) DMVPWLZ MA Modulator DMVPWLZ RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DMVPWLZ RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DMVPZBE DI DMVPZBE DMVPZBE DN Iloprost DMVPZBE TI TT1ZAVI DMVPZBE TN Prostaglandin E2 receptor EP2 (PTGER2) DMVPZBE MA Agonist DMVPZBE RN Exploration of prostanoid receptor subtype regulating estradiol and prostaglandin E2 induction of spinophilin in developing preoptic area neurons. Neuroscience. 2007 May 25;146(3):1117-27. DMVPZBE RU https://pubmed.ncbi.nlm.nih.gov/17408863 DMVR628 DI DMVR628 DMVR628 DN Vindesine DMVR628 TI TTYFKSZ DMVR628 TN Tubulin beta (TUBB) DMVR628 MA Binder DMVR628 RN Antiproliferating activity of the mitotic inhibitor pironetin against vindesine- and paclitaxel-resistant human small cell lung cancer H69 cells. Anticancer Res. 2007 Mar-Apr;27(2):729-36. DMVR628 RU https://pubmed.ncbi.nlm.nih.gov/17465195 DMVRH9C DI DMVRH9C DMVRH9C DN Lomefloxacin DMVRH9C TI TT0IHXV DMVRH9C TN DNA topoisomerase II (TOP2) DMVRH9C MA Inhibitor DMVRH9C RN Inhibition of human topoisomerase IIalpha by fluoroquinolones and ultraviolet A irradiation. Toxicol Sci. 2002 Sep;69(1):16-22. DMVRH9C RU https://pubmed.ncbi.nlm.nih.gov/12215656 DMVRIC2 DI DMVRIC2 DMVRIC2 DN Zileuton DMVRIC2 TI TT2J34L DMVRIC2 TN Arachidonate 5-lipoxygenase (5-LOX) DMVRIC2 MA Inhibitor DMVRIC2 RN 5-lipoxygenase inhibitor zileuton attenuates ischemic brain damage: involvement of matrix metalloproteinase 9. Neurol Res. 2009 Oct;31(8):848-52. DMVRIC2 RU https://pubmed.ncbi.nlm.nih.gov/19309543 DMVRLT7 DI DMVRLT7 DMVRLT7 DN Fludarabine DMVRLT7 TI TTLP57V DMVRLT7 TN Adenosine deaminase (ADA) DMVRLT7 MA Inhibitor DMVRLT7 RN Purine nucleoside analogs in indolent non-Hodgkin's lymphoma. Oncology (Williston Park). 2000 Jun;14(6 Suppl 2):13-5. DMVRLT7 RU https://pubmed.ncbi.nlm.nih.gov/10887639 DMVRYT2 DI DMVRYT2 DMVRYT2 DN Nabilone DMVRYT2 TI TTMSFAW DMVRYT2 TN Cannabinoid receptor 2 (CB2) DMVRYT2 MA Inhibitor DMVRYT2 RN Novel 1',1'-chain substituted hexahydrocannabinols: 9-hydroxy-3-(1-hexyl-cyclobut-1-yl)-hexahydrocannabinol (AM2389) a highly potent cannabinoid r... J Med Chem. 2010 Oct 14;53(19):6996-7010. DMVRYT2 RU https://pubmed.ncbi.nlm.nih.gov/20925434 DMVRYT2 DI DMVRYT2 DMVRYT2 DN Nabilone DMVRYT2 TI TT6OEDT DMVRYT2 TN Cannabinoid receptor 1 (CB1) DMVRYT2 MA Inhibitor DMVRYT2 RN Novel 1',1'-chain substituted hexahydrocannabinols: 9-hydroxy-3-(1-hexyl-cyclobut-1-yl)-hexahydrocannabinol (AM2389) a highly potent cannabinoid r... J Med Chem. 2010 Oct 14;53(19):6996-7010. DMVRYT2 RU https://pubmed.ncbi.nlm.nih.gov/20925434 DMVS9WQ DI DMVS9WQ DMVS9WQ DN Nitisinone DMVS9WQ TI TT8DSFC DMVS9WQ TN Hydroxyphenylpyruvate dioxygenase (HPD) DMVS9WQ MA Inhibitor DMVS9WQ RN Experience of nitisinone for the pharmacological treatment of hereditary tyrosinaemia type 1. Expert Opin Pharmacother. 2008 May;9(7):1229-36. DMVS9WQ RU https://pubmed.ncbi.nlm.nih.gov/18422479 DMVTHER DI DMVTHER DMVTHER DN Lincomycin DMVTHER TI TTUWYEA DMVTHER TN Bacterial 50S ribosomal RNA (Bact 50S rRNA) DMVTHER MA Inhibitor DMVTHER RN Specific inhibition of 50S ribosomal subunit formation in Staphylococcus aureus cells by 16-membered macrolide, lincosamide, and streptogramin B antibiotics. Curr Microbiol. 2000 Aug;41(2):126-35. DMVTHER RU https://pubmed.ncbi.nlm.nih.gov/10856379 DMVTHWQ DI DMVTHWQ DMVTHWQ DN Silver sulfadiazine DMVTHWQ TI TT4ILYC DMVTHWQ TN Bacterial Dihydropteroate synthetase (Bact folP) DMVTHWQ MA Binder DMVTHWQ RN Comparative evaluation of transdermal formulations of norfloxacin with silver sulfadiazine cream, USP, for burn wound healing property. J Burns Wounds. 2006 Jun 7;5:e4. DMVTHWQ RU https://pubmed.ncbi.nlm.nih.gov/16921417 DMVTU5Q DI DMVTU5Q DMVTU5Q DN Delafloxacin Meglumine DMVTU5Q TI TTIXTO3 DMVTU5Q TN Staphylococcus Topoisomerase IV (Stap-coc parC) DMVTU5Q MA Inhibitor DMVTU5Q RN 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85. DMVTU5Q RU https://pubmed.ncbi.nlm.nih.gov/29348678 DMVTU5Q DI DMVTU5Q DMVTU5Q DN Delafloxacin Meglumine DMVTU5Q TI TTZ82MR DMVTU5Q TN Plasmodium DNA gyrase (Malaria gyrase) DMVTU5Q MA Inhibitor DMVTU5Q RN 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85. DMVTU5Q RU https://pubmed.ncbi.nlm.nih.gov/29348678 DMVWHTG DI DMVWHTG DMVWHTG DN Afamelanotide DMVWHTG TI TT0MV2T DMVWHTG TN Melanocortin receptor 1 (MC1R) DMVWHTG MA Modulator DMVWHTG RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019 DMVWHTG RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210797s000lbl.pdf DMVXFYE DI DMVXFYE DMVXFYE DN Vinorelbine DMVXFYE TI TTML2WA DMVXFYE TN Tubulin (TUB) DMVXFYE MA Inhibitor DMVXFYE RN Vinca alkaloid and MDR1. Gan To Kagaku Ryoho. 2008 Jul;35(7):1086-9. DMVXFYE RU https://pubmed.ncbi.nlm.nih.gov/18633246 DMVY4GN DI DMVY4GN DMVY4GN DN Testolactone DMVY4GN TI TTSZLWK DMVY4GN TN Aromatase (CYP19A1) DMVY4GN MA Inhibitor DMVY4GN RN Aromatase inhibitors for male infertility. J Urol. 2002 Feb;167(2 Pt 1):624-9. DMVY4GN RU https://pubmed.ncbi.nlm.nih.gov/11792932 DMVYSLE DI DMVYSLE DMVYSLE DN Cefalotin DMVYSLE TI TTLP6GN DMVYSLE TN Bacterial DD-carboxypeptidase (Bact vanYB) DMVYSLE MA Inhibitor DMVYSLE RN Binding of cephalothin and cefotaxime to D-ala-D-ala-peptidase reveals a functional basis of a natural mutation in a low-affinity penicillin-binding protein and in extended-spectrum beta-lactamases. Biochemistry. 1995 Jul 25;34(29):9532-40. DMVYSLE RU https://pubmed.ncbi.nlm.nih.gov/7626623 DMVYXR8 DI DMVYXR8 DMVYXR8 DN Sumatriptan DMVYXR8 TI TT6MSOK DMVYXR8 TN 5-HT 1D receptor (HTR1D) DMVYXR8 MA Agonist DMVYXR8 RN Irritable bowel syndrome: new agents targeting serotonin receptor subtypes. Drugs. 2001;61(3):317-32. DMVYXR8 RU https://pubmed.ncbi.nlm.nih.gov/11293643 DMVZQ2M DI DMVZQ2M DMVZQ2M DN Probucol DMVZQ2M TI TTJW1GN DMVZQ2M TN ATP-binding cassette transporter A1 (ABCA1) DMVZQ2M MA Modulator DMVZQ2M RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMVZQ2M RU https://www.fda.gov/ DMW1OQ0 DI DMW1OQ0 DMW1OQ0 DN Clobazam - Lundbeck DMW1OQ0 TI TT1MPAY DMW1OQ0 TN GABA(A) receptor alpha-1 (GABRA1) DMW1OQ0 MA Antagonist DMW1OQ0 RN DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6. DMW1OQ0 RU https://pubmed.ncbi.nlm.nih.gov/18048412 DMW1OQ0 DI DMW1OQ0 DMW1OQ0 DN Clobazam - Lundbeck DMW1OQ0 TI TTEX6LM DMW1OQ0 TN GABA(A) receptor gamma-3 (GABRG3) DMW1OQ0 MA Modulator DMW1OQ0 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMW1OQ0 RU https://www.fda.gov/ DMW2GEJ DI DMW2GEJ DMW2GEJ DN Mepolizumab DMW2GEJ TI TTPREZD DMW2GEJ TN Interleukin-5 (IL5) DMW2GEJ MA Modulator DMW2GEJ RN Mepolizumab: 240563, anti-IL-5 monoclonal antibody - GlaxoSmithKline, anti-interleukin-5 monoclonal antibody - GlaxoSmithKline, SB 240563. Drugs R D. 2008;9(2):125-30. DMW2GEJ RU https://www.ncbi.nlm.nih.gov/pubmed/18298130 DMW4M97 DI DMW4M97 DMW4M97 DN Clevidipine butyrate DMW4M97 TI TT5HONZ DMW4M97 TN Calcium channel unspecific (CaC) DMW4M97 MA Modulator DMW4M97 RN 2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6. DMW4M97 RU https://pubmed.ncbi.nlm.nih.gov/19180096 DMW4M97 DI DMW4M97 DMW4M97 DN Clevidipine butyrate DMW4M97 TI TTXHYV6 DMW4M97 TN Voltage-gated L-type calcium channel (L-CaC) DMW4M97 MA Inhibitor DMW4M97 RN Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357. DMW4M97 RU https://pubmed.ncbi.nlm.nih.gov/30728472 DMW4X37 DI DMW4X37 DMW4X37 DN Diphenylpyraline DMW4X37 TI TTTIBOJ DMW4X37 TN Histamine H1 receptor (H1R) DMW4X37 MA Antagonist DMW4X37 RN Transport mechanism of an H1-antagonist at the blood-brain barrier: transport mechanism of mepyramine using the carotid injection technique. Biol Pharm Bull. 1994 May;17(5):676-9. DMW4X37 RU https://pubmed.ncbi.nlm.nih.gov/7920432 DMW51AX DI DMW51AX DMW51AX DN Anisodamine DMW51AX TI TTR6W5O DMW51AX TN Adrenergic receptor beta-1 (ADRB1) DMW51AX MA Modulator DMW51AX RN Medicinal plants in therapy. Bull World Health Organ. 1985;63(6):965-81. DMW51AX RU https://pubmed.ncbi.nlm.nih.gov/3879679 DMW542E DI DMW542E DMW542E DN Orphenadrine DMW542E TI TT9IK2Z DMW542E TN N-methyl-D-aspartate receptor (NMDAR) DMW542E MA Antagonist DMW542E RN Involvement of voltage-gated sodium channels blockade in the analgesic effects of orphenadrine. Pain. 2009 Apr;142(3):225-35. DMW542E RU https://pubmed.ncbi.nlm.nih.gov/19217209 DMW5ML9 DI DMW5ML9 DMW5ML9 DN Tecovirimat DMW5ML9 TI TTG7UOF DMW5ML9 TN Variola virus Envelope phospholipase F13 (VARV p37) DMW5ML9 MA Inhibitor DMW5ML9 RN Tecovirimat, a p37 envelope protein inhibitor for the treatment of smallpox infection.IDrugs. 2010 Mar;13(3):181-91. Review DMW5ML9 RU https://pubmed.ncbi.nlm.nih.gov/20191435 DMW649X DI DMW649X DMW649X DN Eletriptan DMW649X TI TTK8CXU DMW649X TN 5-HT 1B receptor (HTR1B) DMW649X MA Modulator DMW649X RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMW649X RU https://www.fda.gov/ DMW649X DI DMW649X DMW649X DN Eletriptan DMW649X TI TT6MSOK DMW649X TN 5-HT 1D receptor (HTR1D) DMW649X MA Modulator DMW649X RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMW649X RU https://www.fda.gov/ DMW67MU DI DMW67MU DMW67MU DN Botulinum Toxin Type A DMW67MU TI TTYQWA0 DMW67MU TN Synaptosomal-associated protein 25 (SNAP25) DMW67MU MA Inhibitor DMW67MU RN Evaluation of the therapeutic usefulness of botulinum neurotoxin B, C1, E, and F compared with the long lasting type A. Basis for distinct duration... J Biol Chem. 2003 Jan 10;278(2):1363-71. DMW67MU RU https://pubmed.ncbi.nlm.nih.gov/12381720 DMW6F0S DI DMW6F0S DMW6F0S DN Mizoribine DMW6F0S TI TTL7C8Q DMW6F0S TN Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1) DMW6F0S MA Inhibitor DMW6F0S RN VX-497: a novel, selective IMPDH inhibitor and immunosuppressive agent. J Pharm Sci. 2001 May;90(5):625-37. DMW6F0S RU https://pubmed.ncbi.nlm.nih.gov/11288107 DMW6GVL DI DMW6GVL DMW6GVL DN Nadolol DMW6GVL TI TTR6W5O DMW6GVL TN Adrenergic receptor beta-1 (ADRB1) DMW6GVL MA Modulator DMW6GVL RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMW6GVL RU https://www.fda.gov/ DMW6ZJI DI DMW6ZJI DMW6ZJI DN Levocetirizine dihydrochloride DMW6ZJI TI TTTIBOJ DMW6ZJI TN Histamine H1 receptor (H1R) DMW6ZJI MA Antagonist DMW6ZJI RN Update on prescription and over-the-counter histamine inverse agonists in rhinitis therapy. Curr Allergy Asthma Rep. 2009 Mar;9(2):140-8. DMW6ZJI RU https://pubmed.ncbi.nlm.nih.gov/19210904 DMW83TP DI DMW83TP DMW83TP DN Pimozide DMW83TP TI TTEX248 DMW83TP TN Dopamine D2 receptor (D2R) DMW83TP MA Antagonist DMW83TP RN [The benzamides tiapride, sulpiride, and amisulpride in treatment for Tourette's syndrome]. Nervenarzt. 2007 Mar;78(3):264, 266-8, 270-1. DMW83TP RU https://pubmed.ncbi.nlm.nih.gov/16924461 DMW8KI7 DI DMW8KI7 DMW8KI7 DN Insulin Susp Isophane Recombinant Human DMW8KI7 TI TTZOPHG DMW8KI7 TN Insulin (INS) DMW8KI7 MA Modulator DMW8KI7 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMW8KI7 RU https://www.fda.gov/ DMW8QNG DI DMW8QNG DMW8QNG DN Brolucizumab DMW8QNG TI TTOHSBA DMW8QNG TN Vascular endothelial growth factor A (VEGFA) DMW8QNG MA Inhibitor DMW8QNG RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019 DMW8QNG RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761125s000lbl.pdf DMW8QNG DI DMW8QNG DMW8QNG DN Brolucizumab DMW8QNG TI TT9HKJA DMW8QNG TN Vascular endothelial growth factor (VEGF) DMW8QNG MA Inhibitor DMW8QNG RN Brolucizumab: First Approval. Drugs. 2019 Dec;79(18):1997-2000. DMW8QNG RU https://pubmed.ncbi.nlm.nih.gov/31768932 DMWA24P DI DMWA24P DMWA24P DN IPI-145 DMWA24P TI TTGBPJE DMWA24P TN PI3-kinase delta (PIK3CD) DMWA24P MA Modulator DMWA24P RN PI3K-delta and PI3K-gamma inhibition by IPI-145 abrogates immune responses and suppresses activity in autoimmune and inflammatory disease models. Chem Biol. 2013 Nov 21;20(11):1364-74. DMWA24P RU https://pubmed.ncbi.nlm.nih.gov/24211136 DMWA24P DI DMWA24P DMWA24P DN IPI-145 DMWA24P TI TTHBTOP DMWA24P TN PI3-kinase gamma (PIK3CG) DMWA24P MA Modulator DMWA24P RN PI3K-delta and PI3K-gamma inhibition by IPI-145 abrogates immune responses and suppresses activity in autoimmune and inflammatory disease models. Chem Biol. 2013 Nov 21;20(11):1364-74. DMWA24P RU https://pubmed.ncbi.nlm.nih.gov/24211136 DMWA2DZ DI DMWA2DZ DMWA2DZ DN Berotralstat DMWA2DZ TI TTMF8H9 DMWA2DZ TN Plasma kallikrein (KLKB1) DMWA2DZ MA Inhibitor DMWA2DZ RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020 DMWA2DZ RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/214094s000lbl.pdf DMWBHRY DI DMWBHRY DMWBHRY DN Olmesartan medoxomil DMWBHRY TI TT8DBY3 DMWBHRY TN Angiotensin II receptor type-1 (AGTR1) DMWBHRY MA Antagonist DMWBHRY RN Mechanism of diastolic stiffening of the failing myocardium and its prevention by angiotensin receptor and calcium channel blockers. J Cardiovasc Pharmacol. 2009 Jul;54(1):47-56. DMWBHRY RU https://pubmed.ncbi.nlm.nih.gov/19528815 DMWBQKU DI DMWBQKU DMWBQKU DN Olprinone DMWBQKU TI TTZCG4L DMWBQKU TN Phosphodiesterase 3 (PDE3) DMWBQKU MA Inhibitor DMWBQKU RN Olprinone: a phosphodiesterase III inhibitor with positive inotropic and vasodilator effects. Cardiovasc Drug Rev. 2002 Fall;20(3):163-74. DMWBQKU RU https://pubmed.ncbi.nlm.nih.gov/12397365 DMWCOSR DI DMWCOSR DMWCOSR DN Quinethazone DMWCOSR TI TTUNARX DMWCOSR TN Carbonic anhydrase (CA) DMWCOSR MA Inhibitor DMWCOSR RN Carbonic anhydrase inhibitors. Interaction of indapamide and related diuretics with 12 mammalian isozymes and X-ray crystallographic studies for th... Bioorg Med Chem Lett. 2008 Apr 15;18(8):2567-73. DMWCOSR RU https://pubmed.ncbi.nlm.nih.gov/18374572 DMWCQP4 DI DMWCQP4 DMWCQP4 DN Interferon alfa-2B DMWCQP4 TI TTSIUJ9 DMWCQP4 TN Interferon-alpha 2 (IFNA2) DMWCQP4 MA Modulator DMWCQP4 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMWCQP4 RU https://www.fda.gov/ DMWCRN1 DI DMWCRN1 DMWCRN1 DN Ispaghula DMWCRN1 TI TTH18TF DMWCRN1 TN Muscarinic acetylcholine receptor M5 (CHRM5) DMWCRN1 MA Antagonist DMWCRN1 RN Emerging drugs for irritable bowel syndrome. Expert Opin Emerg Drugs. 2006 May;11(2):293-313. DMWCRN1 RU https://pubmed.ncbi.nlm.nih.gov/16634703 DMWE2N4 DI DMWE2N4 DMWE2N4 DN Auranofin DMWE2N4 TI TTP3UTW DMWE2N4 TN Steroid hormone receptor ERR (ESRR) DMWE2N4 MA Modulator DMWE2N4 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMWE2N4 RU https://www.fda.gov/ DMWE60C DI DMWE60C DMWE60C DN Rufinamide DMWE60C TI TTRK8B9 DMWE60C TN Sodium channel unspecific (NaC) DMWE60C MA Blocker DMWE60C RN Emerging drugs for epilepsy. Expert Opin Emerg Drugs. 2007 Sep;12(3):407-22. DMWE60C RU https://pubmed.ncbi.nlm.nih.gov/17874969 DMWF5R4 DI DMWF5R4 DMWF5R4 DN Melphalan flufenamide DMWF5R4 TI TTUTN1I DMWF5R4 TN Human Deoxyribonucleic acid (hDNA) DMWF5R4 MA Binder DMWF5R4 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2021 DMWF5R4 RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214383s000lbl.pdf DMWFHMZ DI DMWFHMZ DMWFHMZ DN Aminoglutethimide DMWFHMZ TI TTSYVO6 DMWFHMZ TN Cholesterol desmolase (CYP11A1) DMWFHMZ MA Inhibitor DMWFHMZ RN Breakdown of Th cell immune responses and steroidogenic CYP11A1 expression in CD4+ T cells in a murine model implanted with B16 melanoma. Cell Immunol. 2000 Nov 25;206(1):7-15. DMWFHMZ RU https://pubmed.ncbi.nlm.nih.gov/11161433 DMWFHMZ DI DMWFHMZ DMWFHMZ DN Aminoglutethimide DMWFHMZ TI TTSZLWK DMWFHMZ TN Aromatase (CYP19A1) DMWFHMZ MA Inhibitor DMWFHMZ RN Aminoglutethimide-induced protein free radical formation on myeloperoxidase: a potential mechanism of agranulocytosis. Chem Res Toxicol. 2007 Jul;20(7):1038-45. DMWFHMZ RU https://pubmed.ncbi.nlm.nih.gov/17602675 DMWFJTR DI DMWFJTR DMWFJTR DN Linagliptin DMWFJTR TI TTDIGC1 DMWFJTR TN Dipeptidyl peptidase 4 (DPP-4) DMWFJTR MA Inhibitor DMWFJTR RN Boehringer Ingelheim. Product Development Pipeline. June 2 2009. DMWFJTR RU http://www.boehringer-ingelheim.com/corporate/research/pipeline.asp DMWH7NQ DI DMWH7NQ DMWH7NQ DN Alprostadil DMWH7NQ TI TT1ZAVI DMWH7NQ TN Prostaglandin E2 receptor EP2 (PTGER2) DMWH7NQ MA Agonist DMWH7NQ RN Emerging drugs for diabetic foot ulcers. Expert Opin Emerg Drugs. 2006 Nov;11(4):709-24. DMWH7NQ RU https://pubmed.ncbi.nlm.nih.gov/17064227 DMWH7NQ DI DMWH7NQ DMWH7NQ DN Alprostadil DMWH7NQ TI TT2O84V DMWH7NQ TN Thromboxane A2 receptor (TBXA2R) DMWH7NQ MA Modulator DMWH7NQ RN Flow after prostaglandin E1 is mediated by receptor-coupled adenylyl cyclase in human anterior segments. Invest Ophthalmol Vis Sci. 1999 Oct;40(11):2622-6. DMWH7NQ RU https://pubmed.ncbi.nlm.nih.gov/10509658 DMWH9CN DI DMWH9CN DMWH9CN DN Ridogrel DMWH9CN TI TT2O84V DMWH9CN TN Thromboxane A2 receptor (TBXA2R) DMWH9CN MA Binder DMWH9CN RN Chronic ouabain treatment exacerbates blood pressure elevation in spontaneously hypertensive rats: the role of vascular mechanisms. J Hypertens. 2009 Jun;27(6):1233-42. DMWH9CN RU https://pubmed.ncbi.nlm.nih.gov/19337130 DMWIJTN DI DMWIJTN DMWIJTN DN Voclosporin DMWIJTN TI TTA4LDE DMWIJTN TN Calcineurin (PPP3CA) DMWIJTN MA Inhibitor DMWIJTN RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2021 DMWIJTN RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/213716s000lbl.pdf DMWIX23 DI DMWIX23 DMWIX23 DN Metaraminol DMWIX23 TI TTEX248 DMWIX23 TN Dopamine D2 receptor (D2R) DMWIX23 MA Agonist DMWIX23 RN Alpha1-adrenoceptor stimulation enhances experimental gastric carcinogenesis induced by N-methyl-N'-nitro-N-nitrosoguanidine in Wistar rats. Int J Cancer. 1998 Jul 29;77(3):467-9. DMWIX23 RU https://pubmed.ncbi.nlm.nih.gov/9663612 DMWLC57 DI DMWLC57 DMWLC57 DN Brentuximab vedotin DMWLC57 TI TT2GM5R DMWLC57 TN Lymphocyte activation antigen CD30 (TNFRSF8) DMWLC57 MA Modulator DMWLC57 RN 2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4. DMWLC57 RU https://pubmed.ncbi.nlm.nih.gov/22293555 DMWLTU2 DI DMWLTU2 DMWLTU2 DN PSMA-11 Ga-68 DMWLTU2 TI TT9G4N0 DMWLTU2 TN Glutamate carboxypeptidase II (GCPII) DMWLTU2 MA Binder DMWLTU2 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020 DMWLTU2 RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212642s000lbl.pdf DMWMCN0 DI DMWMCN0 DMWMCN0 DN Erenumab DMWMCN0 TI TTY6O0Q DMWMCN0 TN Calcitonin gene-related peptide receptor (CGRPR) DMWMCN0 MA Modulator DMWMCN0 RN 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. DMWMCN0 RU https://pubmed.ncbi.nlm.nih.gov/30710142 DMWMPD4 DI DMWMPD4 DMWMPD4 DN Vorinostat DMWMPD4 TI TT6R7JZ DMWMPD4 TN Histone deacetylase 1 (HDAC1) DMWMPD4 MA Inhibitor DMWMPD4 RN Protein methyltransferases as a target class for drug discovery. Nat Rev Drug Discov. 2009 Sep;8(9):724-32. DMWMPD4 RU https://pubmed.ncbi.nlm.nih.gov/19721445 DMWMPRG DI DMWMPRG DMWMPRG DN Tetrodotoxin DMWMPRG TI TTZOVE0 DMWMPRG TN Voltage-gated sodium channel alpha Nav1.5 (SCN5A) DMWMPRG MA Blocker DMWMPRG RN Halothane attenuates the cerebroprotective action of several Na+ and Ca2+ channel blockers via reversal of their ion channel blockade. Eur J Pharmacol. 2002 Oct 4;452(2):175-81. DMWMPRG RU https://pubmed.ncbi.nlm.nih.gov/12354567 DMWMPRG DI DMWMPRG DMWMPRG DN Tetrodotoxin DMWMPRG TI TTRK8B9 DMWMPRG TN Sodium channel unspecific (NaC) DMWMPRG MA Antagonist DMWMPRG RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMWMPRG RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DMWMPRG DI DMWMPRG DMWMPRG DN Tetrodotoxin DMWMPRG TI TTIG65Q DMWMPRG TN Voltage-gated sodium channel (Nav) DMWMPRG MA Inhibitor DMWMPRG RN Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357. DMWMPRG RU https://pubmed.ncbi.nlm.nih.gov/30728472 DMWNHPC DI DMWNHPC DMWNHPC DN Aminolevulinic Acid Hydrochloride DMWNHPC TI TTNFMS9 DMWNHPC TN Protoporphyrinogen oxidase (PPOX) DMWNHPC MA Modulator DMWNHPC RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMWNHPC RU https://www.fda.gov/ DMWNRZT DI DMWNRZT DMWNRZT DN Basiliximab DMWNRZT TI TT10Y9E DMWNRZT TN Interleukin 2 receptor alpha (IL2RA) DMWNRZT MA Modulator DMWNRZT RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMWNRZT RU https://www.fda.gov/ DMWO3N6 DI DMWO3N6 DMWO3N6 DN Indeloxazine DMWO3N6 TI TTGP7BY DMWO3N6 TN Monoamine oxidase type B (MAO-B) DMWO3N6 MA Modulator DMWO3N6 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DMWO3N6 RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DMWOSKJ DI DMWOSKJ DMWOSKJ DN Zolpidem DMWOSKJ TI TTEX6LM DMWOSKJ TN GABA(A) receptor gamma-3 (GABRG3) DMWOSKJ MA Modulator (allosteric modulator) DMWOSKJ RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 415). DMWOSKJ RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=415 DMWOSKJ DI DMWOSKJ DMWOSKJ DN Zolpidem DMWOSKJ TI TT1MPAY DMWOSKJ TN GABA(A) receptor alpha-1 (GABRA1) DMWOSKJ MA Modulator DMWOSKJ RN Zolpidem, a selective GABA(A) receptor alpha1 subunit agonist, induces comparable Fos expression in oxytocinergic neurons of the hypothalamic paraventricular and accessory but not supraoptic nuclei in the rat.Brain Res Bull.2006 Dec 11;71(1-3):200-7. DMWOSKJ RU https://www.ncbi.nlm.nih.gov/pubmed/17113947 DMWP1BH DI DMWP1BH DMWP1BH DN Tazemetostat DMWP1BH TI TT9MZCQ DMWP1BH TN Enhancer of zeste homolog 2 (EZH2) DMWP1BH MA Inhibitor DMWP1BH RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020 DMWP1BH RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf DMWQ16I DI DMWQ16I DMWQ16I DN Primaquine DMWQ16I TI TT698WO DMWQ16I TN Plasmodium Deoxyribonucleic acid (Malaria DNA) DMWQ16I RN Primaquine-induced differential gene expression analysis in mice liver using DNA microarrays. Toxicology. 2007 Sep 24;239(1-2):96-107. DMWQ16I RU https://pubmed.ncbi.nlm.nih.gov/17686563 DMWQ4MZ DI DMWQ4MZ DMWQ4MZ DN Gilteritinib DMWQ4MZ TI TTGJCWZ DMWQ4MZ TN Fms-like tyrosine kinase 3 (FLT-3) DMWQ4MZ MA Inhibitor DMWQ4MZ RN 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. DMWQ4MZ RU https://pubmed.ncbi.nlm.nih.gov/30710142 DMWQ4MZ DI DMWQ4MZ DMWQ4MZ DN Gilteritinib DMWQ4MZ TI TTZPY6J DMWQ4MZ TN Tyrosine-protein kinase UFO (AXL) DMWQ4MZ MA Inhibitor DMWQ4MZ RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMWQ4MZ RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMWS3FH DI DMWS3FH DMWS3FH DN Fondaparinux sodium DMWS3FH TI TTCIHJA DMWS3FH TN Coagulation factor Xa (F10) DMWS3FH MA Inhibitor DMWS3FH RN Biochemistry and clinical pharmacology of new anticoagulant agents. Pathophysiol Haemost Thromb. 2002 Sep-Dec;32(5-6):218-24. DMWS3FH RU https://pubmed.ncbi.nlm.nih.gov/13679646 DMWSA0V DI DMWSA0V DMWSA0V DN Patisiran DMWSA0V TI TTPOYU7 DMWSA0V TN Transthyretin messenger RNA (TTR mRNA) DMWSA0V RN Clinical pipeline report, company report or official report of Alnylam Pharmaceuticals, Inc. DMWSA0V RU http://www.alnylam.com/product-pipeline/ttr-amyloidosis-fac/ DMWSMND DI DMWSMND DMWSMND DN Cevimeline DMWSMND TI TTQ13Z5 DMWSMND TN Muscarinic acetylcholine receptor M3 (CHRM3) DMWSMND MA Agonist DMWSMND RN Degradation of submandibular gland AQP5 by parasympathetic denervation of chorda tympani and its recovery by cevimeline, an M3 muscarinic receptor ... Am J Physiol Gastrointest Liver Physiol. 2008 Jul;295(1):G112-G123. DMWSMND RU https://pubmed.ncbi.nlm.nih.gov/18450949 DMWT905 DI DMWT905 DMWT905 DN Mefloquine DMWT905 TI TTT28H3 DMWT905 TN Plasmodium 80S ribosome (Malaria 80S) DMWT905 MA Binder DMWT905 RN An ultrastructural study of the effects of mefloquine on malaria parasites. Am J Trop Med Hyg. 1987 Jan;36(1):9-14. DMWT905 RU https://pubmed.ncbi.nlm.nih.gov/3544894 DMWTAOI DI DMWTAOI DMWTAOI DN Estramustine DMWTAOI TI TTSBFYK DMWTAOI TN Estramustine binding protein (EMBP) DMWTAOI MA Binder DMWTAOI RN Estramustine binding protein in primary tumours and metastases of malignant melanoma. Melanoma Res. 1994 Dec;4(6):401-5. DMWTAOI RU https://pubmed.ncbi.nlm.nih.gov/7703721 DMWTVAN DI DMWTVAN DMWTVAN DN Rauwolfia serpentina root DMWTVAN TI TTZIFHC DMWTVAN TN Voltage-gated calcium channel alpha Cav1.2 (CACNA1C) DMWTVAN MA Inhibitor DMWTVAN RN Alpha- and beta-adrenoceptors: from the gene to the clinic. 2. Structure-activity relationships and therapeutic applications. J Med Chem. 1995 Sep 15;38(19):3681-716. DMWTVAN RU https://pubmed.ncbi.nlm.nih.gov/7562902 DMWU0I2 DI DMWU0I2 DMWU0I2 DN Pralsetinib DMWU0I2 TI TT4DXQT DMWU0I2 TN Proto-oncogene c-Ret (RET) DMWU0I2 MA Inhibitor DMWU0I2 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020 DMWU0I2 RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213721s000lbl.pdf DMWUFQ4 DI DMWUFQ4 DMWUFQ4 DN Ramucirumab DMWUFQ4 TI TTUTJGQ DMWUFQ4 TN Vascular endothelial growth factor receptor 2 (KDR) DMWUFQ4 MA Modulator DMWUFQ4 RN 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81. DMWUFQ4 RU https://pubmed.ncbi.nlm.nih.gov/25633781 DMWUIJE DI DMWUIJE DMWUIJE DN Tolmetin DMWUIJE TI TTVKILB DMWUIJE TN Prostaglandin G/H synthase 2 (COX-2) DMWUIJE MA Inhibitor DMWUIJE RN Maternal toxicity of nonsteroidal anti-inflammatory drugs as an important factor affecting prenatal development. Reprod Toxicol. 2009 Sep;28(2):239-44. DMWUIJE RU https://pubmed.ncbi.nlm.nih.gov/19379806 DMWUMRL DI DMWUMRL DMWUMRL DN Interferon gamma-1b DMWUMRL TI TT13TL0 DMWUMRL TN Interferon gamma receptor (IFNGR2) DMWUMRL MA Binder DMWUMRL RN Genetic polymorphisms in the promoter of the interferon gamma receptor 1 gene are associated with atopic cataracts. Invest Ophthalmol Vis Sci. 2007 Feb;48(2):583-9. DMWUMRL RU https://pubmed.ncbi.nlm.nih.gov/17251453 DMWV2AG DI DMWV2AG DMWV2AG DN Ceftibuten DMWV2AG TI TTJP4SM DMWV2AG TN Bacterial Penicillin binding protein (Bact PBP) DMWV2AG MA Binder DMWV2AG RN Neisseria gonorrhoeae and emerging resistance to extended spectrum cephalosporins. Curr Opin Infect Dis. 2009 Feb;22(1):87-91. DMWV2AG RU https://pubmed.ncbi.nlm.nih.gov/19532086 DMWV3TZ DI DMWV3TZ DMWV3TZ DN Finasteride DMWV3TZ TI TT2A0DR DMWV3TZ TN Oxo-5-alpha-steroid 4-dehydrogenase (SRD5A) DMWV3TZ MA Inhibitor DMWV3TZ RN The role of 5-alpha reductase inhibitors in prostate pathophysiology: Is there an additional advantage to inhibition of type 1 isoenzyme Can Urol Assoc J. 2009 Jun;3(3 Suppl 2):S109-14. DMWV3TZ RU https://pubmed.ncbi.nlm.nih.gov/19543428 DMWV3TZ DI DMWV3TZ DMWV3TZ DN Finasteride DMWV3TZ TI TTT02K8 DMWV3TZ TN Steroid 5-alpha-reductase 2 (SRD5A2) DMWV3TZ MA Inhibitor DMWV3TZ RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMWV3TZ RU http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf DMWVCF3 DI DMWVCF3 DMWVCF3 DN Fusidic acid DMWVCF3 TI TT6HP1T DMWVCF3 TN Streptococcus Elongation factor G (Stre-coc fusA) DMWVCF3 MA Inhibitor DMWVCF3 RN Genetic determinants of resistance to fusidic acid among clinical bacteremia isolates of Staphylococcus aureus. Antimicrob Agents Chemother. 2009 May;53(5):2059-65. DMWVCF3 RU https://pubmed.ncbi.nlm.nih.gov/19289529 DMWVIGP DI DMWVIGP DMWVIGP DN Digitoxin DMWVIGP TI TTQ38E9 DMWVIGP TN Sodium/potassium-transporting ATPase (SPT ATPase) DMWVIGP MA Inhibitor DMWVIGP RN Treatment of congestive heart failure--current status of use of digitoxin. Eur J Clin Invest. 2001;31 Suppl 2:10-7. DMWVIGP RU https://pubmed.ncbi.nlm.nih.gov/11525233 DMWX5CO DI DMWX5CO DMWX5CO DN Nicotine DMWX5CO TI TTJSZTB DMWX5CO TN Nicotinic acetylcholine receptor (nAChR) DMWX5CO MA Antagonist DMWX5CO RN Atypical antipsychotics as noncompetitive inhibitors of alpha4beta2 and alpha7 neuronal nicotinic receptors. Neuropharmacology. 2009 Aug;57(2):183-91. DMWX5CO RU https://pubmed.ncbi.nlm.nih.gov/19481556 DMWX683 DI DMWX683 DMWX683 DN Mupirocin DMWX683 TI TT6KYJ5 DMWX683 TN Bacterial Isoleucyl-tRNA synthetase (Bact ileS) DMWX683 MA Modulator DMWX683 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMWX683 RU https://www.fda.gov/ DMWXLYZ DI DMWXLYZ DMWXLYZ DN Darifenacin DMWXLYZ TI TTQ13Z5 DMWXLYZ TN Muscarinic acetylcholine receptor M3 (CHRM3) DMWXLYZ MA Antagonist DMWXLYZ RN M(1) and M(3) muscarinic receptors are involved in the release of urinary bladder-derived relaxant factor. Pharmacol Res. 2009 May;59(5):300-5. DMWXLYZ RU https://pubmed.ncbi.nlm.nih.gov/19416629 DMWXLYZ DI DMWXLYZ DMWXLYZ DN Darifenacin DMWXLYZ TI TTOXS3C DMWXLYZ TN Muscarinic acetylcholine receptor (CHRM) DMWXLYZ MA Antagonist DMWXLYZ RN Characterisation of [3H]-darifenacin as a novel radioligand for the study of muscarinic M3 receptors. J Recept Signal Transduct Res. 1997 Jan-May;17(1-3):177-84. DMWXLYZ RU https://pubmed.ncbi.nlm.nih.gov/9029489 DMX0E5B DI DMX0E5B DMX0E5B DN Bimatoprost DMX0E5B TI TT9B4N3 DMX0E5B TN Prostaglandin receptor (PTGR) DMX0E5B MA Modulator DMX0E5B RN Bimatoprost-induced calcium signaling in human T-cells does not involve prostanoid FP or TP receptors. Curr Eye Res. 2009 Mar;34(3):184-95. DMX0E5B RU https://pubmed.ncbi.nlm.nih.gov/19274525 DMX0EZJ DI DMX0EZJ DMX0EZJ DN Prothionamide DMX0EZJ TI TTVTX4N DMX0EZJ TN Bacterial Fatty acid synthetase I (Bact inhA) DMX0EZJ MA Inhibitor DMX0EZJ RN Mechanism of thioamide drug action against tuberculosis and leprosy. J Exp Med. 2007 Jan 22;204(1):73-8. DMX0EZJ RU https://pubmed.ncbi.nlm.nih.gov/17227913 DMX0K3Q DI DMX0K3Q DMX0K3Q DN Epinastine DMX0K3Q TI TTTIBOJ DMX0K3Q TN Histamine H1 receptor (H1R) DMX0K3Q MA Antagonist DMX0K3Q RN Influence of epinastine hydrochloride, an H1-receptor antagonist, on the function of mite allergen-pulsed murine bone marrow-derived dendritic cell... Mediators Inflamm. 2009;2009:738038. DMX0K3Q RU https://pubmed.ncbi.nlm.nih.gov/19381339 DMX2358 DI DMX2358 DMX2358 DN Adapalene DMX2358 TI TTOD7B3 DMX2358 TN Retinoic acid receptor (RAR) DMX2358 MA Binder DMX2358 RN A review of adapalene in the treatment of acne vulgaris. J Adolesc Health. 2008 Nov;43(5):421-4. DMX2358 RU https://pubmed.ncbi.nlm.nih.gov/18848668 DMX38HQ DI DMX38HQ DMX38HQ DN Apomorphine DMX38HQ TI TTEX248 DMX38HQ TN Dopamine D2 receptor (D2R) DMX38HQ MA Agonist DMX38HQ RN Dopamine D(2/3) receptor occupancy of apomorphine in the nonhuman primate brain--a comparative PET study with [11C]raclopride and [11C]MNPA. Synapse. 2009 May;63(5):378-89. DMX38HQ RU https://pubmed.ncbi.nlm.nih.gov/19173265 DMX4GND DI DMX4GND DMX4GND DN Meperidine DMX4GND TI TTQ8AFT DMX4GND TN Adrenergic receptor Alpha-2 (ADRA2) DMX4GND MA Agonist DMX4GND RN Meperidine, remifentanil and tramadol but not sufentanil interact with alpha(2)-adrenoceptors in alpha(2A)-, alpha(2B)- and alpha(2C)-adrenoceptor ... Eur J Pharmacol. 2008 Mar 17;582(1-3):70-7. DMX4GND RU https://pubmed.ncbi.nlm.nih.gov/18234187 DMX6OE3 DI DMX6OE3 DMX6OE3 DN Dabrafenib DMX6OE3 TI TTWCGQT DMX6OE3 TN Serine/threonine-protein kinase B-raf (BRAF) DMX6OE3 MA Inhibitor DMX6OE3 RN Clinical pipeline report, company report or official report of GlaxoSmithKline (2011). DMX6OE3 RU http://www.gsk.com/ DMX6RTG DI DMX6RTG DMX6RTG DN Trospium DMX6RTG TI TTH18TF DMX6RTG TN Muscarinic acetylcholine receptor M5 (CHRM5) DMX6RTG MA Antagonist DMX6RTG RN Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. DMX6RTG RU https://pubmed.ncbi.nlm.nih.gov/17016423 DMX7A5V DI DMX7A5V DMX7A5V DN Faropenem DMX7A5V TI TT4ILYC DMX7A5V TN Bacterial Dihydropteroate synthetase (Bact folP) DMX7A5V MA Inhibitor DMX7A5V RN Emerging drugs for bacterial urinary tract infections. Expert Opin Emerg Drugs. 2005 May;10(2):275-98. DMX7A5V RU https://pubmed.ncbi.nlm.nih.gov/15934867 DMX7LKS DI DMX7LKS DMX7LKS DN Isovanillin DMX7LKS TI TT3MOS2 DMX7LKS TN Aldehyde oxidase (AOX1) DMX7LKS MA Inhibitor DMX7LKS RN Contribution of aldehyde oxidizing enzymes on the metabolism of 3,4-dimethoxy-2-phenylethylamine to 3,4-dimethoxyphenylacetic acid by guinea pig li... Cell Physiol Biochem. 2006;17(1-2):47-56. DMX7LKS RU https://pubmed.ncbi.nlm.nih.gov/16543721 DMX7V28 DI DMX7V28 DMX7V28 DN Insulin-aspart DMX7V28 TI TTZOPHG DMX7V28 TN Insulin (INS) DMX7V28 MA Modulator DMX7V28 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMX7V28 RU https://www.fda.gov/ DMX8CVY DI DMX8CVY DMX8CVY DN Pivampicillin DMX8CVY TI TTJP4SM DMX8CVY TN Bacterial Penicillin binding protein (Bact PBP) DMX8CVY MA Binder DMX8CVY RN Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. DMX8CVY RU https://pubmed.ncbi.nlm.nih.gov/17016423 DMX8M26 DI DMX8M26 DMX8M26 DN Hyaluronate sodium DMX8M26 TI TTG8DNU DMX8M26 TN Hyaluronic acid receptor (LYVE1) DMX8M26 MA Modulator DMX8M26 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4954). DMX8M26 RU http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4954 DMX9K8F DI DMX9K8F DMX9K8F DN Carbachol DMX9K8F TI TTF4E0J DMX9K8F TN Neuronal acetylcholine receptor alpha-2 (CHRNA2) DMX9K8F MA Antagonist DMX9K8F RN Synergy between pairs of competitive antagonists at adult human muscle acetylcholine receptors. Anesth Analg. 2008 Aug;107(2):525-33. DMX9K8F RU https://pubmed.ncbi.nlm.nih.gov/18633030 DMX9PIA DI DMX9PIA DMX9PIA DN Live attenuated influenza vaccine DMX9PIA TI TT3J5ZI DMX9PIA TN Cell mediated immunity response (CMIR) DMX9PIA RN Flu myths: dispelling the myths associated with live attenuated influenza vaccine. Mayo Clin Proc. 2008 Jan;83(1):77-84. DMX9PIA RU https://pubmed.ncbi.nlm.nih.gov/18174020 DMXBLMP DI DMXBLMP DMXBLMP DN Riociguat DMXBLMP TI TTWNFC2 DMXBLMP TN Soluble guanylyl cyclase (GUCY2D) DMXBLMP MA Modulator DMXBLMP RN Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651. DMXBLMP RU https://pubmed.ncbi.nlm.nih.gov/28919714 DMXBQAM DI DMXBQAM DMXBQAM DN Miglitol DMXBQAM TI TTXWASR DMXBQAM TN Intestinal maltase-glucoamylase (MGAM) DMXBQAM MA Inhibitor DMXBQAM RN Drug therapy of postprandial hyperglycaemia. Drugs. 1999 Jan;57(1):19-29. DMXBQAM RU https://pubmed.ncbi.nlm.nih.gov/9951949 DMXC1K9 DI DMXC1K9 DMXC1K9 DN Alpha 1-PI DMXC1K9 TI TT3NKIB DMXC1K9 TN Pancreatic elastase 1 (CELA1) DMXC1K9 MA Inhibitor DMXC1K9 RN Elastase inhibitors. J Soc Biol. 2001;195(2):143-50. DMXC1K9 RU https://pubmed.ncbi.nlm.nih.gov/11723826 DMXC1K9 DI DMXC1K9 DMXC1K9 DN Alpha 1-PI DMXC1K9 TI TTN9D8E DMXC1K9 TN Glutamate receptor ionotropic NMDA 2B (NMDAR2B) DMXC1K9 MA Antagonist DMXC1K9 RN NMDA receptor stimulation induces reversible fission of the neuronal endoplasmic reticulum. PLoS One. 2009;4(4):e5250. DMXC1K9 RU https://pubmed.ncbi.nlm.nih.gov/19381304 DMXCM7H DI DMXCM7H DMXCM7H DN Cerivastatin DMXCM7H TI TTPADOQ DMXCM7H TN HMG-CoA reductase (HMGCR) DMXCM7H MA Inhibitor DMXCM7H RN Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127. DMXCM7H RU https://pubmed.ncbi.nlm.nih.gov/19249983 DMXDZAQ DI DMXDZAQ DMXDZAQ DN Bepotastine DMXDZAQ TI TTTIBOJ DMXDZAQ TN Histamine H1 receptor (H1R) DMXDZAQ MA Antagonist DMXDZAQ RN Mast cells play a critical role in the pathogenesis of viral myocarditis. Circulation. 2008 Jul 22;118(4):363-72. DMXDZAQ RU https://pubmed.ncbi.nlm.nih.gov/18606918 DMXE76K DI DMXE76K DMXE76K DN Delamanid DMXE76K TI TTXT4D5 DMXE76K TN Bacterial Cell membrane (Bact CM) DMXE76K MA Inhibitor DMXE76K RN Compassionate use of delamanid in adults and children for drug-resistant tuberculosis: 5-year update. Eur Respir J. 2021 May 20;57(5):2002483. DMXE76K RU https://pubmed.ncbi.nlm.nih.gov/33243846 DMXEACF DI DMXEACF DMXEACF DN Idarucizumab DMXEACF TI TTFDXCO DMXEACF TN Dabigatran (Dabi) DMXEACF MA Binder DMXEACF RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2015 DMXEACF RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/761025lbl.pdf DMXGDFK DI DMXGDFK DMXGDFK DN Fenbufen DMXGDFK TI TTVKILB DMXGDFK TN Prostaglandin G/H synthase 2 (COX-2) DMXGDFK MA Inhibitor DMXGDFK RN Fenbufen based 3-[5-(substituted aryl)-1,3,4-oxadiazol-2-yl]-1-(biphenyl-4-yl)propan-1-ones as safer antiinflammatory and analgesic agents. Eur J Med Chem. 2009 Sep;44(9):3798-804. DMXGDFK RU https://pubmed.ncbi.nlm.nih.gov/19457595 DMXGDFK DI DMXGDFK DMXGDFK DN Fenbufen DMXGDFK TI TT8NGED DMXGDFK TN Prostaglandin G/H synthase 1 (COX-1) DMXGDFK MA Inhibitor DMXGDFK RN Fenbufen based 3-[5-(substituted aryl)-1,3,4-oxadiazol-2-yl]-1-(biphenyl-4-yl)propan-1-ones as safer antiinflammatory and analgesic agents. Eur J Med Chem. 2009 Sep;44(9):3798-804. DMXGDFK RU https://pubmed.ncbi.nlm.nih.gov/19457595 DMXGJEI DI DMXGJEI DMXGJEI DN Chlophedianol DMXGJEI TI TTTIBOJ DMXGJEI TN Histamine H1 receptor (H1R) DMXGJEI MA Antagonist DMXGJEI RN Identification and differentiation of alkylamine antihistamines and their metabolites in urine by computerized gas chromatography-mass spectrometry. J Chromatogr. 1988 Aug 19;430(1):31-41. DMXGJEI RU https://pubmed.ncbi.nlm.nih.gov/2905706 DMXGQYZ DI DMXGQYZ DMXGQYZ DN Fleroxacin DMXGQYZ TI TT0IHXV DMXGQYZ TN DNA topoisomerase II (TOP2) DMXGQYZ MA Inhibitor DMXGQYZ RN Fleroxacin overview. Chemotherapy. 1996 Mar;42 Suppl 1:1-9. DMXGQYZ RU https://pubmed.ncbi.nlm.nih.gov/8861529 DMXIQYS DI DMXIQYS DMXIQYS DN Iodipamide DMXIQYS TI TTFNGC9 DMXIQYS TN Serum albumin (ALB) DMXIQYS MA Binder DMXIQYS RN Determining binding sites of drugs on human serum albumin using FIA-QCM. Biosens Bioelectron. 2008 Sep 15;24(1):48-54. DMXIQYS RU https://pubmed.ncbi.nlm.nih.gov/18436441 DMXJ7O8 DI DMXJ7O8 DMXJ7O8 DN Vitamin C DMXJ7O8 TI TTK982E DMXJ7O8 TN Collagen (CO) DMXJ7O8 MA Activator DMXJ7O8 RN Effects of vitamin C on dark circles of the lower eyelids: quantitative evaluation using image analysis and echogram. Skin Res Technol. 2009 May;15(2):214-7. DMXJ7O8 RU https://pubmed.ncbi.nlm.nih.gov/19626722 DMXJ7O8 DI DMXJ7O8 DMXJ7O8 DN Vitamin C DMXJ7O8 TI TTOP832 DMXJ7O8 TN Solute carrier family 23 member 2 (SLC23A2) DMXJ7O8 MA Modulator DMXJ7O8 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1042). DMXJ7O8 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1042 DMXJ7O8 DI DMXJ7O8 DMXJ7O8 DN Vitamin C DMXJ7O8 TI TT6XAGK DMXJ7O8 TN Solute carrier family 23 member 1 (SLC23A1) DMXJ7O8 MA Modulator DMXJ7O8 RN Decreased expression of the vitamin C transporter SVCT1 by ascorbic acid in a human intestinal epithelial cell line. Br J Nutr. 2002 Feb;87(2):97-100. DMXJ7O8 RU https://pubmed.ncbi.nlm.nih.gov/11895172 DMXKJ6C DI DMXKJ6C DMXKJ6C DN Torasemide DMXKJ6C TI TTS087L DMXKJ6C TN Solute carrier family 12 member 1 (SLC12A1) DMXKJ6C MA Blocker DMXKJ6C RN Genetic variation in the renal sodium transporters NKCC2, NCC, and ENaC in relation to the effects of loop diuretic drugs. Clin Pharmacol Ther. 2007 Sep;82(3):300-9. DMXKJ6C RU https://pubmed.ncbi.nlm.nih.gov/17460608 DMXKZT3 DI DMXKZT3 DMXKZT3 DN Buclizine DMXKZT3 TI TTTIBOJ DMXKZT3 TN Histamine H1 receptor (H1R) DMXKZT3 MA Antagonist DMXKZT3 RN Toxicologic and clinical appraisal of buclizine, a new antihistaminic compound. J Allergy. 1956 Jan;27(1):63-7. DMXKZT3 RU https://pubmed.ncbi.nlm.nih.gov/13294975 DMXLBCQ DI DMXLBCQ DMXLBCQ DN Sodium phenylbutyrate DMXLBCQ TI TTBH0VX DMXLBCQ TN Histone deacetylase (HDAC) DMXLBCQ MA Inhibitor DMXLBCQ RN Histone Deacetylase inhibitors: new promise in the treatment of immune and inflammatory diseases. Curr Drug Targets. 2010 Nov;11(11):1430-8. DMXLBCQ RU https://pubmed.ncbi.nlm.nih.gov/20583972 DMXLBCQ DI DMXLBCQ DMXLBCQ DN Sodium phenylbutyrate DMXLBCQ TI TTFJ8Q1 DMXLBCQ TN Protein kinase C alpha (PRKCA) DMXLBCQ MA Modulator DMXLBCQ RN Polo-like kinase inhibitor Ro5203280 has potent antitumor activity in nasopharyngeal carcinoma.Mol Cancer Ther. 2013 Aug;12(8):1393-401. DMXLBCQ RU https://pubmed.ncbi.nlm.nih.gov/23686835 DMXLKHV DI DMXLKHV DMXLKHV DN Oxycodone DMXLKHV TI TT27RFC DMXLKHV TN Opioid receptor delta (OPRD1) DMXLKHV MA Agonist DMXLKHV RN Oxycodone: a pharmacological and clinical review. Clin Transl Oncol. 2007 May;9(5):298-307. DMXLKHV RU https://pubmed.ncbi.nlm.nih.gov/17525040 DMXLKHV DI DMXLKHV DMXLKHV DN Oxycodone DMXLKHV TI TTKWM86 DMXLKHV TN Opioid receptor mu (MOP) DMXLKHV MA Modulator DMXLKHV RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 319). DMXLKHV RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=319 DMXLSH3 DI DMXLSH3 DMXLSH3 DN Tapentadol hydrochloride DMXLSH3 TI TTKWM86 DMXLSH3 TN Opioid receptor mu (MOP) DMXLSH3 MA Modulator DMXLSH3 RN 2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6. DMXLSH3 RU https://pubmed.ncbi.nlm.nih.gov/19180096 DMXLSH3 DI DMXLSH3 DMXLSH3 DN Tapentadol hydrochloride DMXLSH3 TI TTAWNKZ DMXLSH3 TN Norepinephrine transporter (NET) DMXLSH3 MA Modulator DMXLSH3 RN 2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6. DMXLSH3 RU https://pubmed.ncbi.nlm.nih.gov/19180096 DMXLT8C DI DMXLT8C DMXLT8C DN Sulfisoxazole DMXLT8C TI TT4ILYC DMXLT8C TN Bacterial Dihydropteroate synthetase (Bact folP) DMXLT8C MA Inhibitor DMXLT8C RN Inhibition of recombinant Pneumocystis carinii dihydropteroate synthetase by sulfa drugs. Antimicrob Agents Chemother. 1995 Aug;39(8):1756-63. DMXLT8C RU https://pubmed.ncbi.nlm.nih.gov/7486915 DMXLVDT DI DMXLVDT DMXLVDT DN Lasmiditan DMXLVDT TI TT0MI3F DMXLVDT TN 5-HT 1F receptor (HTR1F) DMXLVDT MA Agonist DMXLVDT RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019 DMXLVDT RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211280s000lbl.pdf DMXLYQF DI DMXLYQF DMXLYQF DN Belatacept DMXLYQF TI TTQ13FT DMXLYQF TN T-cell-specific surface glycoprotein CD28 (CD28) DMXLYQF MA Inhibitor DMXLYQF RN New developments in immunosuppressive therapy for heart transplantation. Expert Opin Emerg Drugs. 2009 Mar;14(1):1-21. DMXLYQF RU https://pubmed.ncbi.nlm.nih.gov/19265486 DMXNR04 DI DMXNR04 DMXNR04 DN Unoprostone DMXNR04 TI TT9B4N3 DMXNR04 TN Prostaglandin receptor (PTGR) DMXNR04 MA Modulator DMXNR04 RN Comparison of the vasoactive effects of the docosanoid unoprostone and selected prostanoids on isolated perfused retinal arterioles. Invest Ophthalmol Vis Sci. 2001 Jun;42(7):1499-504. DMXNR04 RU https://pubmed.ncbi.nlm.nih.gov/11381053 DMXNZM4 DI DMXNZM4 DMXNZM4 DN Oxazepam DMXNZM4 TI TTPTXIN DMXNZM4 TN Translocator protein (TSPO) DMXNZM4 MA Agonist DMXNZM4 RN Effects of the combination of metyrapone and oxazepam on cocaine and food self-administration in rats. Pharmacol Biochem Behav. 2008 Nov;91(1):181-9. DMXNZM4 RU https://pubmed.ncbi.nlm.nih.gov/18692521 DMXOELT DI DMXOELT DMXOELT DN Midazolam DMXOELT TI TTPTXIN DMXOELT TN Translocator protein (TSPO) DMXOELT MA Modulator DMXOELT RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMXOELT RU https://www.fda.gov/ DMXQKSL DI DMXQKSL DMXQKSL DN Dinoprost Tromethamine DMXQKSL TI TTOFYT1 DMXQKSL TN Prostacyclin receptor (PTGIR) DMXQKSL MA Antagonist DMXQKSL RN Palmitoylation of the human prostacyclin receptor. Functional implications of palmitoylation and isoprenylation. J Biol Chem. 2003 Feb 28;278(9):6947-58. DMXQKSL RU https://pubmed.ncbi.nlm.nih.gov/12488443 DMXQS7K DI DMXQS7K DMXQS7K DN Cenestin DMXQS7K TI TTZAYWL DMXQS7K TN Estrogen receptor (ESR) DMXQS7K MA Agonist DMXQS7K RN Estrogen replacement therapy and cardioprotection: mechanisms and controversies. Braz J Med Biol Res. 2002 Mar;35(3):271-6. DMXQS7K RU https://pubmed.ncbi.nlm.nih.gov/11887204 DMXSVGI DI DMXSVGI DMXSVGI DN Loncastuximab tesirine DMXSVGI TI TTW640A DMXSVGI TN B-lymphocyte surface antigen B4 (CD19) DMXSVGI MA Inhibitor DMXSVGI RN Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma. Blood. 2021 May 13;137(19):2634-2645. DMXSVGI RU https://pubmed.ncbi.nlm.nih.gov/33211842 DMXTCVF DI DMXTCVF DMXTCVF DN Radium-223-Dichloride DMXTCVF TI TTUTN1I DMXTCVF TN Human Deoxyribonucleic acid (hDNA) DMXTCVF MA Modulator DMXTCVF RN Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651. DMXTCVF RU https://pubmed.ncbi.nlm.nih.gov/28919714 DMXTMBJ DI DMXTMBJ DMXTMBJ DN Azelastine DMXTMBJ TI TTTIBOJ DMXTMBJ TN Histamine H1 receptor (H1R) DMXTMBJ MA Antagonist DMXTMBJ RN Intact cell binding for in vitro prediction of sedative and non-sedative histamine H1-receptor antagonists based on receptor internalization. J Pharmacol Sci. 2008 May;107(1):66-79. DMXTMBJ RU https://pubmed.ncbi.nlm.nih.gov/18446005 DMXVU6D DI DMXVU6D DMXVU6D DN Diphemanil Methylsulfate DMXVU6D TI TTZ9SOR DMXVU6D TN Muscarinic acetylcholine receptor M1 (CHRM1) DMXVU6D MA Modulator DMXVU6D RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMXVU6D RU https://www.fda.gov/ DMXW92T DI DMXW92T DMXW92T DN Ixekizumab DMXW92T TI TTG0MT6 DMXW92T TN Interleukin-17 (IL17) DMXW92T MA Modulator DMXW92T RN Brodalumab and ixekizumab, anti-interleukin-17-receptor antibodies for psoriasis: a critical appraisal. Br J Dermatol. 2012 Oct;167(4):710-3; discussion 714-5. DMXW92T RU https://pubmed.ncbi.nlm.nih.gov/23013312 DMXWOCP DI DMXWOCP DMXWOCP DN Ethotoin DMXWOCP TI TTZOVE0 DMXWOCP TN Voltage-gated sodium channel alpha Nav1.5 (SCN5A) DMXWOCP MA Blocker DMXWOCP RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMXWOCP RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMXY30O DI DMXY30O DMXY30O DN Dipyridamole DMXY30O TI TTJ0IQB DMXY30O TN Phosphodiesterase 5A (PDE5A) DMXY30O MA Modulator DMXY30O RN Anti-platelet therapy: phosphodiesterase inhibitors.Br J Clin Pharmacol.2011 Oct;72(4):634-46. DMXY30O RU https://www.ncbi.nlm.nih.gov/pubmed/21649691 DMXYJ9C DI DMXYJ9C DMXYJ9C DN Busulfan DMXYJ9C TI TTUTN1I DMXYJ9C TN Human Deoxyribonucleic acid (hDNA) DMXYJ9C MA Modulator DMXYJ9C RN DNA intrastrand cross-link at the 5'-GA-3' sequence formed by busulfan and its role in the cytotoxic effect. Cancer Sci. 2004 May;95(5):454-8. DMXYJ9C RU https://www.ncbi.nlm.nih.gov/pubmed/15132775 DMXYJOB DI DMXYJOB DMXYJOB DN Phentolamine DMXYJOB TI TTEX248 DMXYJOB TN Dopamine D2 receptor (D2R) DMXYJOB MA Antagonist DMXYJOB RN Nesfatin-1 exerts cardiovascular actions in brain: possible interaction with the central melanocortin system. Am J Physiol Regul Integr Comp Physiol. 2009 Aug;297(2):R330-6. DMXYJOB RU https://pubmed.ncbi.nlm.nih.gov/19474390 DMXYTN9 DI DMXYTN9 DMXYTN9 DN Phenmetrazine DMXYTN9 TI TTVBI8W DMXYTN9 TN Dopamine transporter (DAT) DMXYTN9 MA Inhibitor DMXYTN9 RN Interaction of the anorectic medication, phendimetrazine, and its metabolites with monoamine transporters in rat brain. Eur J Pharmacol. 2002 Jun 28;447(1):51-7. DMXYTN9 RU https://pubmed.ncbi.nlm.nih.gov/12106802 DMXYTN9 DI DMXYTN9 DMXYTN9 DN Phenmetrazine DMXYTN9 TI TTAWNKZ DMXYTN9 TN Norepinephrine transporter (NET) DMXYTN9 MA Inhibitor DMXYTN9 RN Interaction of the anorectic medication, phendimetrazine, and its metabolites with monoamine transporters in rat brain. Eur J Pharmacol. 2002 Jun 28;447(1):51-7. DMXYTN9 RU https://pubmed.ncbi.nlm.nih.gov/12106802 DMXZ84M DI DMXZ84M DMXZ84M DN Malathion DMXZ84M TI TT1RS9F DMXZ84M TN Acetylcholinesterase (AChE) DMXZ84M MA Inhibitor DMXZ84M RN Acetylcholinesterase activity in Corbicula fluminea Mull., as a biomarker of organophosphate pesticide pollution in Pinacanauan River, Philippines. Environ Monit Assess. 2010 Jun;165(1-4):331-40. DMXZ84M RU https://pubmed.ncbi.nlm.nih.gov/19444631 DMXZOCG DI DMXZOCG DMXZOCG DN Phenobarbital DMXZOCG TI TTNJYV2 DMXZOCG TN Gamma-aminobutyric acid receptor (GAR) DMXZOCG MA Antagonist DMXZOCG RN DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6. DMXZOCG RU https://pubmed.ncbi.nlm.nih.gov/18048412 DMXZRW0 DI DMXZRW0 DMXZRW0 DN DTI-015 DMXZRW0 TI TTUTN1I DMXZRW0 TN Human Deoxyribonucleic acid (hDNA) DMXZRW0 MA Binder DMXZRW0 RN Carmustine-induced toxicity, DNA crosslinking and O6-methylguanine-DNA methyltransferase activity in two human lung cancer cell lines. Eur J Cancer. 1991;27(12):1658-62. DMXZRW0 RU https://pubmed.ncbi.nlm.nih.gov/1664221 DMY0EKH DI DMY0EKH DMY0EKH DN Nemonapride DMY0EKH TI TTEX248 DMY0EKH TN Dopamine D2 receptor (D2R) DMY0EKH MA Agonist DMY0EKH RN The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22. DMY0EKH RU https://pubmed.ncbi.nlm.nih.gov/17667958 DMY0KGJ DI DMY0KGJ DMY0KGJ DN Chlorprothixene DMY0KGJ TI TTEX248 DMY0KGJ TN Dopamine D2 receptor (D2R) DMY0KGJ MA Antagonist DMY0KGJ RN Potential utility of histamine H3 receptor antagonist pharmacophore in antipsychotics. Bioorg Med Chem Lett. 2009 Jan 15;19(2):538-42. DMY0KGJ RU https://pubmed.ncbi.nlm.nih.gov/19091563 DMY0M8J DI DMY0M8J DMY0M8J DN Sargramostim DMY0M8J TI TT6MP2Z DMY0M8J TN GMCSFR-alpha (CSF2RA) DMY0M8J MA Binder DMY0M8J RN Stem cell transplantation and hematopoietic growth factors. Curr Hematol Rep. 2002 Nov;1(2):103-9. DMY0M8J RU https://pubmed.ncbi.nlm.nih.gov/12901131 DMY18XK DI DMY18XK DMY18XK DN Penicillin G Sodium DMY18XK TI TTJP4SM DMY18XK TN Bacterial Penicillin binding protein (Bact PBP) DMY18XK MA Modulator DMY18XK RN Bacterial Resistance to Penicillin G by Decreased Affinity of Penicillin-Binding Proteins: A Mathematical Model DMY18XK RU https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2957969 DMY2KX9 DI DMY2KX9 DMY2KX9 DN Alendronate DMY2KX9 TI TTIKWV4 DMY2KX9 TN Geranyltranstransferase (FDPS) DMY2KX9 MA Modulator DMY2KX9 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMY2KX9 RU https://www.fda.gov/ DMY4D87 DI DMY4D87 DMY4D87 DN Quazepam DMY4D87 TI TTPTXIN DMY4D87 TN Translocator protein (TSPO) DMY4D87 MA Modulator DMY4D87 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMY4D87 RU https://www.fda.gov/ DMY4UMW DI DMY4UMW DMY4UMW DN Atovaquone DMY4UMW TI TT3PQ2Y DMY4UMW TN Plasmodium Dihydroorotate dehydrogenase (Malaria DHOdehase) DMY4UMW MA Inhibitor DMY4UMW RN Inhibitor binding in a class 2 dihydroorotate dehydrogenase causes variations in the membrane-associated N-terminal domain. Protein Sci. 2004 Apr;13(4):1031-42. DMY4UMW RU https://pubmed.ncbi.nlm.nih.gov/15044733 DMY5JEP DI DMY5JEP DMY5JEP DN Mezlocillin DMY5JEP TI TT85JMW DMY5JEP TN Bacterial Penicillin binding protein 3 (Bact mrcA) DMY5JEP MA Binder DMY5JEP RN Bactericidal effect of piperacillin alone and combined. Presse Med. 1986 Dec 20;15(46):2297-302. DMY5JEP RU https://pubmed.ncbi.nlm.nih.gov/2949271 DMY60I8 DI DMY60I8 DMY60I8 DN Cefixime DMY60I8 TI TTJP4SM DMY60I8 TN Bacterial Penicillin binding protein (Bact PBP) DMY60I8 MA Binder DMY60I8 RN Genetics of chromosomally mediated intermediate resistance to ceftriaxone and cefixime in Neisseria gonorrhoeae. Antimicrob Agents Chemother. 2009 Sep;53(9):3744-51. DMY60I8 RU https://pubmed.ncbi.nlm.nih.gov/19528266 DMY62FC DI DMY62FC DMY62FC DN Tezacaftor And Ivacaftor DMY62FC TI TTRLZHP DMY62FC TN cAMP-dependent chloride channel (CFTR) DMY62FC MA Binder DMY62FC RN 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. DMY62FC RU https://pubmed.ncbi.nlm.nih.gov/30710142 DMY6T31 DI DMY6T31 DMY6T31 DN Isoflurane DMY6T31 TI TTAN6JD DMY6T31 TN Glutamate receptor AMPA (GRIA) DMY6T31 MA Agonist DMY6T31 RN Transmembrane residues define the action of isoflurane at the GABAA receptor alpha-3 subunit. Brain Res. 2005 Jan 25;1032(1-2):30-5. DMY6T31 RU https://pubmed.ncbi.nlm.nih.gov/15680938 DMY7ESM DI DMY7ESM DMY7ESM DN Recombinant Factor IX DMY7ESM TI TTFEZ5Q DMY7ESM TN Coagulation factor IX (F9) DMY7ESM MA Modulator DMY7ESM RN BAX326 (RIXUBIS): a novel recombinant factor IX for the control and prevention of bleeding episodes in adults and children with hemophilia B. Ther Adv Hematol. 2014 Oct;5(5):168-80. DMY7ESM RU https://pubmed.ncbi.nlm.nih.gov/25324957 DMY7PED DI DMY7PED DMY7PED DN Cisapride DMY7PED TI TT07C3Y DMY7PED TN 5-HT 4 receptor (HTR4) DMY7PED MA Agonist DMY7PED RN Metoclopramide stimulates catecholamine- and granin-derived peptide secretion from pheochromocytoma cells through activation of serotonin type 4 (5... Endocr Relat Cancer. 2009 Mar;16(1):281-90. DMY7PED RU https://pubmed.ncbi.nlm.nih.gov/18948374 DMY85QW DI DMY85QW DMY85QW DN Bazedoxifene DMY85QW TI TTZAYWL DMY85QW TN Estrogen receptor (ESR) DMY85QW MA Modulator DMY85QW RN Bazedoxifene, a selective estrogen receptor modulator: effects on the endometrium, ovaries, and breast from a randomized controlled trial in osteoporotic postmenopausal women. Menopause. 2009 Nov-Dec;16(6):1109-15. DMY85QW RU https://pubmed.ncbi.nlm.nih.gov/19543129 DMY9BMK DI DMY9BMK DMY9BMK DN Rocuronium DMY9BMK TI TTF4E0J DMY9BMK TN Neuronal acetylcholine receptor alpha-2 (CHRNA2) DMY9BMK MA Antagonist DMY9BMK RN Pharmacological characteristics of the inhibition of nondepolarizing neuromuscular blocking agents at human adult muscle nicotinic acetylcholine receptor. Anesthesiology. 2009 Jun;110(6):1244-52. DMY9BMK RU https://pubmed.ncbi.nlm.nih.gov/19417616 DMY9TCW DI DMY9TCW DMY9TCW DN Bromazepam DMY9TCW TI TTAN6JD DMY9TCW TN Glutamate receptor AMPA (GRIA) DMY9TCW MA Binder DMY9TCW RN Glutamatergic and GABAergic modulations of ultrasonic vocalizations during maternal separation distress in mouse pups. Psychopharmacology (Berl). 2009 May;204(1):61-71. DMY9TCW RU https://pubmed.ncbi.nlm.nih.gov/19099296 DMYBV3G DI DMYBV3G DMYBV3G DN Paricalcitol DMYBV3G TI TTK59TV DMYBV3G TN Vitamin D3 receptor (VDR) DMYBV3G MA Agonist DMYBV3G RN New acquisitions in therapy of secondary hyperparathyroidism in chronic kidney disease and peritoneal dialysis patients: role of vitamin D receptor... Contrib Nephrol. 2009;163:219-226. DMYBV3G RU https://pubmed.ncbi.nlm.nih.gov/19494617 DMYCXKL DI DMYCXKL DMYCXKL DN Capmatinib DMYCXKL TI TTNDSF4 DMYCXKL TN Proto-oncogene c-Met (MET) DMYCXKL MA Modulator DMYCXKL RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020 DMYCXKL RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213591s000lbl.pdf DMYE5LJ DI DMYE5LJ DMYE5LJ DN DEOXYCYTIDINE DMYE5LJ TI TTP3QRF DMYE5LJ TN Thymidine kinase 1 (TK1) DMYE5LJ MA Inhibitor DMYE5LJ RN Species- or isozyme-specific enzyme inhibitors. 5. Differential effects of thymidine substituents on affinity for rat thymidine kinase isozymes. J Med Chem. 1982 Jun;25(6):644-9. DMYE5LJ RU https://pubmed.ncbi.nlm.nih.gov/7097717 DMYFBMS DI DMYFBMS DMYFBMS DN 99mTc-fanolesomab DMYFBMS TI TTNV1KZ DMYFBMS TN Fucosyltransferase IV (CD15) DMYFBMS RN 2004 approvals: the demise of the blockbuster. Nat Rev Drug Discov. 2005 Feb;4(2):93-4. DMYFBMS RU https://pubmed.ncbi.nlm.nih.gov/15756752 DMYGHX5 DI DMYGHX5 DMYGHX5 DN Moxidectin DMYGHX5 TI TTSNVHO DMYGHX5 TN Onchocerca Glutamate-gated chloride channel (Onchoc GluCl) DMYGHX5 MA Modulator DMYGHX5 RN 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. DMYGHX5 RU https://pubmed.ncbi.nlm.nih.gov/30710142 DMYGHX5 DI DMYGHX5 DMYGHX5 DN Moxidectin DMYGHX5 TI TTNJYV2 DMYGHX5 TN Gamma-aminobutyric acid receptor (GAR) DMYGHX5 MA Modulator DMYGHX5 RN 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. DMYGHX5 RU https://pubmed.ncbi.nlm.nih.gov/30710142 DMYGJQO DI DMYGJQO DMYGJQO DN Ponatinib DMYGJQO TI TTGJCWZ DMYGJQO TN Fms-like tyrosine kinase 3 (FLT-3) DMYGJQO MA Modulator DMYGJQO RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DMYGJQO RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DMYGJQO DI DMYGJQO DMYGJQO DN Ponatinib DMYGJQO TI TT3PJMV DMYGJQO TN Tyrosine-protein kinase ABL1 (ABL) DMYGJQO MA Modulator DMYGJQO RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DMYGJQO RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DMYGJQO DI DMYGJQO DMYGJQO DN Ponatinib DMYGJQO TI TTX41N9 DMYGJQO TN Tyrosine-protein kinase Kit (KIT) DMYGJQO MA Modulator DMYGJQO RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DMYGJQO RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DMYGJQO DI DMYGJQO DMYGJQO DN Ponatinib DMYGJQO TI TT4DXQT DMYGJQO TN Proto-oncogene c-Ret (RET) DMYGJQO MA Modulator DMYGJQO RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DMYGJQO RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DMYHBKN DI DMYHBKN DMYHBKN DN Exenatide DMYHBKN TI TTVIMDE DMYHBKN TN Glucagon-like peptide 1 receptor (GLP1R) DMYHBKN MA Binder DMYHBKN RN Improved glycemic control and reduction of cardiometabolic risk factors in subjects with type 2 diabetes and metabolic syndrome treated with exenatide in a clinical practice setting. Diabetes TechnolTher. 2009 Jun;11(6):353-9. DMYHBKN RU https://pubmed.ncbi.nlm.nih.gov/19459763 DMYHDCA DI DMYHDCA DMYHDCA DN Pranlukast DMYHDCA TI TTGKOY9 DMYHDCA TN Leukotriene CysLT1 receptor (CYSLTR1) DMYHDCA MA Antagonist DMYHDCA RN Beneficial effects of leukotriene receptor antagonists in the prevention of cedar pollinosis in a community setting. J Investig Allergol Clin Immunol. 2009;19(3):195-203. DMYHDCA RU https://pubmed.ncbi.nlm.nih.gov/19610262 DMYHN59 DI DMYHN59 DMYHN59 DN Axicabtagene ciloleucel DMYHN59 TI TTW640A DMYHN59 TN B-lymphocyte surface antigen B4 (CD19) DMYHN59 MA CAR-T-Cell-Therapy DMYHN59 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services DMYHN59 RU https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/yescarta-axicabtagene-ciloleucel DMYILBE DI DMYILBE DMYILBE DN Modafinil DMYILBE TI TTVBI8W DMYILBE TN Dopamine transporter (DAT) DMYILBE MA Modulator DMYILBE RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMYILBE RU https://www.fda.gov/ DMYK490 DI DMYK490 DMYK490 DN Nepafenac DMYK490 TI TTK0943 DMYK490 TN Prostaglandin G/H synthase (COX) DMYK490 MA Inhibitor DMYK490 RN Topical nepafenac inhibits ocular neovascularization. Invest Ophthalmol Vis Sci. 2003 Jan;44(1):409-15. DMYK490 RU https://pubmed.ncbi.nlm.nih.gov/12506103 DMYKUNR DI DMYKUNR DMYKUNR DN Moxalactam Disodium DMYKUNR TI TT85JMW DMYKUNR TN Bacterial Penicillin binding protein 3 (Bact mrcA) DMYKUNR MA Modulator DMYKUNR RN Moxalactam (6059-S), a new 1-oxa-beta-lactam: binding affinity for penicillin-binding proteins of Escherichia coli K-12. DMYKUNR RU https://www.ncbi.nlm.nih.gov/pmc/articles/PMC283783 DMYLMU0 DI DMYLMU0 DMYLMU0 DN Isosorbide mononitrate DMYLMU0 TI TT6HPVC DMYLMU0 TN Guanylate cyclase (GC) DMYLMU0 MA Stimulator DMYLMU0 RN Nitric oxide and nitric oxide synthase isoforms in the normal, hypertrophic, and failing heart. Mol Cell Biochem. 2010 Jan;333(1-2):191-201. DMYLMU0 RU https://pubmed.ncbi.nlm.nih.gov/19618122 DMYLOVR DI DMYLOVR DMYLOVR DN Aciclovir DMYLOVR TI TTIU7X1 DMYLOVR TN Herpes simplex virus DNA polymerase UL30 (HSV UL30) DMYLOVR MA Modulator DMYLOVR RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMYLOVR RU https://www.fda.gov/ DMYLOVR DI DMYLOVR DMYLOVR DN Aciclovir DMYLOVR TI TTHPJTK DMYLOVR TN Varicella-zoster virus DNA polymerase (VZV ORF28) DMYLOVR MA Modulator DMYLOVR RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMYLOVR RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMYM974 DI DMYM974 DMYM974 DN Arformoterol DMYM974 TI TT2CJVK DMYM974 TN Adrenergic receptor beta-2 (ADRB2) DMYM974 MA Agonist DMYM974 RN Arformoterol tartrate in the treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease. Drugs Today (Barc). 2009 Jan;45(1):3-9. DMYM974 RU https://pubmed.ncbi.nlm.nih.gov/19271027 DMYN59P DI DMYN59P DMYN59P DN Vildagliptin DMYN59P TI TTDIGC1 DMYN59P TN Dipeptidyl peptidase 4 (DPP-4) DMYN59P MA Inhibitor DMYN59P RN Emerging drug candidates of dipeptidyl peptidase IV (DPP IV) inhibitor class for the treatment of Type 2 Diabetes. Curr Drug Targets. 2009 Jan;10(1):71-87. DMYN59P RU https://pubmed.ncbi.nlm.nih.gov/19149538 DMYN8MA DI DMYN8MA DMYN8MA DN Tianeptine DMYN8MA TI TT3ROYC DMYN8MA TN Serotonin transporter (SERT) DMYN8MA MA Inhibitor DMYN8MA RN Emerging treatments for depression. Expert Opin Pharmacother. 2006 Dec;7(17):2323-39. DMYN8MA RU https://pubmed.ncbi.nlm.nih.gov/17109609 DMYNMDP DI DMYNMDP DMYNMDP DN Tocainide DMYNMDP TI TT05DLS DMYNMDP TN E3 ubiquitin-protein ligase COP1 (RFWD2) DMYNMDP MA Modulator DMYNMDP RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMYNMDP RU https://www.fda.gov/ DMYOAKS DI DMYOAKS DMYOAKS DN Teduglutide DMYOAKS TI TT1YWO5 DMYOAKS TN Glucagon-like peptide 2 receptor (GLP2R) DMYOAKS MA Modulator DMYOAKS RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DMYOAKS RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DMYP4XC DI DMYP4XC DMYP4XC DN Norgestimate DMYP4XC TI TTUV8G9 DMYP4XC TN Progesterone receptor (PGR) DMYP4XC MA Agonist DMYP4XC RN Pharmacological profile of progestins. Maturitas. 2008 Sep-Oct;61(1-2):151-7. DMYP4XC RU https://pubmed.ncbi.nlm.nih.gov/19434887 DMYQCWT DI DMYQCWT DMYQCWT DN Tecartus DMYQCWT TI TTW640A DMYQCWT TN B-lymphocyte surface antigen B4 (CD19) DMYQCWT RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. DMYQCWT RU https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/tecartus-brexucabtagene-autoleucel DMYQDBO DI DMYQDBO DMYQDBO DN Ademetionine DMYQDBO TI TTX2N1T DMYQDBO TN Transferase unspecific (TF) DMYQDBO MA Modulator DMYQDBO RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2013 DMYQDBO RU https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/205123Orig1s000MedR.pdf DMYQVGN DI DMYQVGN DMYQVGN DN Premarin/Trimegestone DMYQVGN TI TTZAYWL DMYQVGN TN Estrogen receptor (ESR) DMYQVGN MA Modulator DMYQVGN RN The Haunting of Medical Journals: How Ghostwriting Sold RT PLoS Med. 2010 September; 7(9): e1000335. DMYQVGN RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2935455/ DMYRBO1 DI DMYRBO1 DMYRBO1 DN Umbralisib DMYRBO1 TI TTA8PLI DMYRBO1 TN Casein kinase I epsilon (CSNK1E) DMYRBO1 MA Inhibitor DMYRBO1 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2021 DMYRBO1 RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/213176s000lbl.pdf DMYRBO1 DI DMYRBO1 DMYRBO1 DN Umbralisib DMYRBO1 TI TTGBPJE DMYRBO1 TN PI3-kinase delta (PIK3CD) DMYRBO1 MA Inhibitor DMYRBO1 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2021 DMYRBO1 RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/213176s000lbl.pdf DMYRX8B DI DMYRX8B DMYRX8B DN Ardeparin DMYRX8B TI TT4QPUL DMYRX8B TN Antithrombin-III (ATIII) DMYRX8B MA Modulator DMYRX8B RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMYRX8B RU https://www.fda.gov/ DMYSCIL DI DMYSCIL DMYSCIL DN Prolastin DMYSCIL TI TTZBFA0 DMYSCIL TN Protease unspecific (PRO) DMYSCIL MA Inhibitor DMYSCIL RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DMYSCIL RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DMYT0OG DI DMYT0OG DMYT0OG DN Vigabatrin DMYT0OG TI TTT2LD9 DMYT0OG TN GABA transaminase (ABAT) DMYT0OG MA Inhibitor DMYT0OG RN Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92. DMYT0OG RU https://pubmed.ncbi.nlm.nih.gov/20118952 DMYT2FP DI DMYT2FP DMYT2FP DN Cellulose Sodium Phosphate DMYT2FP TI TT8X5NO DMYT2FP TN Calcium (Ca) DMYT2FP MA Modulator DMYT2FP RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMYT2FP RU https://www.fda.gov/ DMYTE6L DI DMYTE6L DMYTE6L DN Enoxacin DMYTE6L TI TT0IHXV DMYTE6L TN DNA topoisomerase II (TOP2) DMYTE6L MA Inhibitor DMYTE6L RN Clinical pharmacokinetics of the newer antibacterial 4-quinolones. Clin Pharmacokinet. 1988 Feb;14(2):96-121. DMYTE6L RU https://pubmed.ncbi.nlm.nih.gov/3282749 DMYTXVR DI DMYTXVR DMYTXVR DN Cefoxitin DMYTXVR TI TTJP4SM DMYTXVR TN Bacterial Penicillin binding protein (Bact PBP) DMYTXVR MA Binder DMYTXVR RN Staphylococcus aureus PBP4 is essential for beta-lactam resistance in community-acquired methicillin-resistant strains. Antimicrob Agents Chemother. 2008 Nov;52(11):3955-66. DMYTXVR RU https://pubmed.ncbi.nlm.nih.gov/18725435 DMYURI6 DI DMYURI6 DMYURI6 DN Raltegravir DMYURI6 TI TT5FH9Y DMYURI6 TN Human immunodeficiency virus Integrase (HIV IN) DMYURI6 MA Modulator DMYURI6 RN 2007 FDA drug approvals: a year of flux. Nat Rev Drug Discov. 2008 Feb;7(2):107-9. DMYURI6 RU https://pubmed.ncbi.nlm.nih.gov/18246607 DMYVP5G DI DMYVP5G DMYVP5G DN Insulin recombinant DMYVP5G TI TTCBFJO DMYVP5G TN Insulin receptor (INSR) DMYVP5G MA Binder DMYVP5G RN Knockouts model the 100 best-selling drugs--will they model the next 100 Nat Rev Drug Discov. 2003 Jan;2(1):38-51. DMYVP5G RU https://pubmed.ncbi.nlm.nih.gov/12509758 DMYWQ0O DI DMYWQ0O DMYWQ0O DN Tetrabenazine DMYWQ0O TI TTNZRI3 DMYWQ0O TN Synaptic vesicle amine transporter (SLC18A2) DMYWQ0O MA Blocker DMYWQ0O RN Dopamine signaling is required for depolarization-induced slow current in cerebellar Purkinje cells. J Neurosci. 2009 Jul 1;29(26):8530-8. DMYWQ0O RU https://pubmed.ncbi.nlm.nih.gov/19571144 DMYX7NI DI DMYX7NI DMYX7NI DN Acetohydroxamic Acid DMYX7NI TI TTAS2UO DMYX7NI TN Bacterial Urease (Bact ureC) DMYX7NI MA Inhibitor DMYX7NI RN Enzymatic, immunological and phylogenetic characterization of Brucella suis urease. BMC Microbiol. 2008 Jul 19;8:121. DMYX7NI RU https://pubmed.ncbi.nlm.nih.gov/18638408 DMYXBV3 DI DMYXBV3 DMYXBV3 DN Dulaglutide DMYXBV3 TI TTVIMDE DMYXBV3 TN Glucagon-like peptide 1 receptor (GLP1R) DMYXBV3 MA Agonist DMYXBV3 RN 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81. DMYXBV3 RU https://pubmed.ncbi.nlm.nih.gov/25633781 DMYZ0P1 DI DMYZ0P1 DMYZ0P1 DN Eluxadoline DMYZ0P1 TI TTKWM86 DMYZ0P1 TN Opioid receptor mu (MOP) DMYZ0P1 MA Modulator DMYZ0P1 RN Molecular characterization of eluxadoline as a potential ligand targeting mu-delta opioid receptor heteromers.Biochem Pharmacol.2014 Dec 1;92(3):448-56. DMYZ0P1 RU https://www.ncbi.nlm.nih.gov/pubmed/25261794 DMYZ0P1 DI DMYZ0P1 DMYZ0P1 DN Eluxadoline DMYZ0P1 TI TT27RFC DMYZ0P1 TN Opioid receptor delta (OPRD1) DMYZ0P1 MA Modulator DMYZ0P1 RN Molecular characterization of eluxadoline as a potential ligand targeting mu-delta opioid receptor heteromers.Biochem Pharmacol.2014 Dec 1;92(3):448-56. DMYZ0P1 RU https://www.ncbi.nlm.nih.gov/pubmed/25261794 DMYZ57N DI DMYZ57N DMYZ57N DN Albendazole DMYZ57N TI TTYFKSZ DMYZ57N TN Tubulin beta (TUBB) DMYZ57N MA Binder DMYZ57N RN Flubendazole interferes with a wide spectrum of cell homeostatic mechanisms in Echinococcus granulosus protoscoleces. Parasitol Int. 2009 Sep;58(3):270-7. DMYZ57N RU https://pubmed.ncbi.nlm.nih.gov/19336257 DMYZFXN DI DMYZFXN DMYZFXN DN Lornoxicam DMYZFXN TI TTK0943 DMYZFXN TN Prostaglandin G/H synthase (COX) DMYZFXN MA Modulator DMYZFXN RN The analgesic NSAID lornoxicam inhibits cyclooxygenase (COX)-1/-2, inducible nitric oxide synthase (iNOS), and the formation of interleukin (IL)-6 in vitro. Inflamm Res. 1999 Jul;48(7):369-79. DMYZFXN RU https://pubmed.ncbi.nlm.nih.gov/10450786 DMYZITL DI DMYZITL DMYZITL DN Cephaloglycin DMYZITL TI TTJP4SM DMYZITL TN Bacterial Penicillin binding protein (Bact PBP) DMYZITL MA Modulator DMYZITL RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMYZITL RU https://www.fda.gov/ DMZ0P95 DI DMZ0P95 DMZ0P95 DN Ga-68-DOTATOC DMZ0P95 TI TTZ6T9E DMZ0P95 TN Somatostatin receptor type 2 (SSTR2) DMZ0P95 MA Binder DMZ0P95 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019 DMZ0P95 RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210828s000lbl.pdf DMZ0Q1G DI DMZ0Q1G DMZ0Q1G DN Permethrin DMZ0Q1G TI TTRK8B9 DMZ0Q1G TN Sodium channel unspecific (NaC) DMZ0Q1G MA Blocker DMZ0Q1G RN In vitro assays for repellents and deterrents for ticks: differing effects of products when tested with attractant or arrestment stimuli. Med Vet Entomol. 2003 Dec;17(4):370-8. DMZ0Q1G RU https://pubmed.ncbi.nlm.nih.gov/14651650 DMZ1WXJ DI DMZ1WXJ DMZ1WXJ DN Vitamin B1 DMZ1WXJ TI TT8RHGB DMZ1WXJ TN Bacterial Pyruvate decarboxylase (Bact aceE) DMZ1WXJ MA Cofactor DMZ1WXJ RN Vitamins and cofactors: highlights of ESBOC 2009. Nat Chem Biol. 2009 Aug;5(8):530-3. DMZ1WXJ RU https://pubmed.ncbi.nlm.nih.gov/19620989 DMZ2WL4 DI DMZ2WL4 DMZ2WL4 DN Cefpiramide DMZ2WL4 TI TTJP4SM DMZ2WL4 TN Bacterial Penicillin binding protein (Bact PBP) DMZ2WL4 MA Binder DMZ2WL4 RN Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. DMZ2WL4 RU https://pubmed.ncbi.nlm.nih.gov/17016423 DMZ30JT DI DMZ30JT DMZ30JT DN Oxantel pamoate DMZ30JT TI TTHDSE2 DMZ30JT TN Bacterial Fumarate reductase flavoprotein (Bact frdA) DMZ30JT MA Inhibitor DMZ30JT RN Fumarate reductase is essential for Helicobacter pylori colonization of the mouse stomach. Microb Pathog. 2000 Nov;29(5):279-87. DMZ30JT RU https://pubmed.ncbi.nlm.nih.gov/11031122 DMZ36RN DI DMZ36RN DMZ36RN DN Mazindol DMZ36RN TI TTAWNKZ DMZ36RN TN Norepinephrine transporter (NET) DMZ36RN MA Modulator DMZ36RN RN Binding of [3H]mazindol to cardiac norepinephrine transporters: kinetic and equilibrium studies. Naunyn Schmiedebergs Arch Pharmacol. 2004 Jul;370(1):9-16. DMZ36RN RU https://pubmed.ncbi.nlm.nih.gov/15300361 DMZ4P3A DI DMZ4P3A DMZ4P3A DN Telithromycin DMZ4P3A TI TTUWYEA DMZ4P3A TN Bacterial 50S ribosomal RNA (Bact 50S rRNA) DMZ4P3A MA Binder DMZ4P3A RN An examination of the differential sensitivity to ketolide antibiotics in ermB strains of Streptococcus pyogenes and Streptococcus pneumoniae. Curr Microbiol. 2004 Oct;49(4):239-47. DMZ4P3A RU https://pubmed.ncbi.nlm.nih.gov/15386111 DMZ5RGV DI DMZ5RGV DMZ5RGV DN Naproxen DMZ5RGV TI TTVKILB DMZ5RGV TN Prostaglandin G/H synthase 2 (COX-2) DMZ5RGV MA Inhibitor DMZ5RGV RN Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers. J Clin Pharmacol. 2000 Oct;40(10):1109-20. DMZ5RGV RU https://pubmed.ncbi.nlm.nih.gov/11028250 DMZ5RGV DI DMZ5RGV DMZ5RGV DN Naproxen DMZ5RGV TI TT8NGED DMZ5RGV TN Prostaglandin G/H synthase 1 (COX-1) DMZ5RGV MA Inhibitor DMZ5RGV RN Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers. J Clin Pharmacol. 2000 Oct;40(10):1109-20. DMZ5RGV RU https://pubmed.ncbi.nlm.nih.gov/11028250 DMZ65K8 DI DMZ65K8 DMZ65K8 DN Pilsicainide DMZ65K8 TI TTRK8B9 DMZ65K8 TN Sodium channel unspecific (NaC) DMZ65K8 MA Modulator DMZ65K8 RN A sodium channel blocker, pilsicainide, produces atrial post-repolarization refractoriness through the reduction of sodium channel availability. Tohoku J Exp Med. 2011;225(1):35-42. DMZ65K8 RU https://pubmed.ncbi.nlm.nih.gov/21869589 DMZ6VEY DI DMZ6VEY DMZ6VEY DN Sulfacetamide DMZ6VEY TI TT915ZD DMZ6VEY TN Candida Mannose-6-phosphate isomerase (Candi PMI1) DMZ6VEY MA Inhibitor DMZ6VEY RN Antifungal Activity of Ag(I) and Zn(II) Complexes of Sulfacetamide Derivatives. Met Based Drugs. 2000;7(1):49-54. DMZ6VEY RU https://pubmed.ncbi.nlm.nih.gov/18475922 DMZ7XNQ DI DMZ7XNQ DMZ7XNQ DN Tacrolimus DMZ7XNQ TI TTA4LDE DMZ7XNQ TN Calcineurin (PPP3CA) DMZ7XNQ MA Inhibitor DMZ7XNQ RN Emerging drugs for ocular allergy. Expert Opin Emerg Drugs. 2005 Aug;10(3):505-20. DMZ7XNQ RU https://pubmed.ncbi.nlm.nih.gov/16083326 DMZ80SB DI DMZ80SB DMZ80SB DN Azatadine DMZ80SB TI TTTIBOJ DMZ80SB TN Histamine H1 receptor (H1R) DMZ80SB MA Antagonist DMZ80SB RN Comparative effects of loratadine and azatadine in the treatment of seasonal allergic rhinitis. Asian Pac J Allergy Immunol. 1990 Dec;8(2):103-7. DMZ80SB RU https://pubmed.ncbi.nlm.nih.gov/1982614 DMZ905C DI DMZ905C DMZ905C DN Mozavaptan DMZ905C TI TTPFZJ1 DMZ905C TN Vasopressin V1 receptor (V1R) DMZ905C MA Antagonist DMZ905C RN Vasopressin (ADH). Nippon Rinsho. 1992 Dec;50(12):2893-900. DMZ905C RU https://pubmed.ncbi.nlm.nih.gov/1337114 DMZ905C DI DMZ905C DMZ905C DN Mozavaptan DMZ905C TI TTL9MHW DMZ905C TN Vasopressin V1b receptor (V1BR) DMZ905C MA Inhibitor DMZ905C RN New analgesic drugs derived from phencyclidine. J Med Chem. 1981 May;24(5):496-9. DMZ905C RU https://pubmed.ncbi.nlm.nih.gov/7241506 DMZ905C DI DMZ905C DMZ905C DN Mozavaptan DMZ905C TI TTK8R02 DMZ905C TN Vasopressin V2 receptor (V2R) DMZ905C MA Inhibitor DMZ905C RN Nonpeptide vasopressin receptor antagonists: development of selective and orally active V1a, V2 and V1b receptor ligands. Prog Brain Res. 2002;139:197-210. DMZ905C RU https://pubmed.ncbi.nlm.nih.gov/12436936 DMZ905C DI DMZ905C DMZ905C DN Mozavaptan DMZ905C TI TT4TFGN DMZ905C TN Vasopressin V1a receptor (V1AR) DMZ905C MA Inhibitor DMZ905C RN Nonpeptide vasopressin antagonists: a new group of hormone blockers entering the scene. Exp Clin Endocrinol Diabetes. 1999;107(3):157-65. DMZ905C RU https://pubmed.ncbi.nlm.nih.gov/10376439 DMZ9BMU DI DMZ9BMU DMZ9BMU DN Colistimethate DMZ9BMU TI TT4ILYC DMZ9BMU TN Bacterial Dihydropteroate synthetase (Bact folP) DMZ9BMU MA Binder DMZ9BMU RN Polymyxin B sulfate and colistin: old antibiotics for emerging multiresistant gram-negative bacteria. Ann Pharmacother. 1999 Sep;33(9):960-7. DMZ9BMU RU https://pubmed.ncbi.nlm.nih.gov/10492501 DMZ9FAO DI DMZ9FAO DMZ9FAO DN Somatomedin-1 DMZ9FAO TI TTHRID2 DMZ9FAO TN Insulin-like growth factor I receptor (IGF1R) DMZ9FAO MA Modulator DMZ9FAO RN 2005 approvals: Safety first. Nature Reviews Drug Discovery 5, 92-93 (February 2006). DMZ9FAO RU http://www.nature.com/nrd/journal/v11/n1/full/nrd3645.html DMZA017 DI DMZA017 DMZA017 DN Tetracycline DMZA017 TI TTQ8KVI DMZA017 TN Staphylococcus 30S ribosomal subunit (Stap-coc pbp2) DMZA017 MA Binder DMZA017 RN The glycylcyclines: a comparative review with the tetracyclines. Drugs. 2004;64(1):63-88. DMZA017 RU https://pubmed.ncbi.nlm.nih.gov/14723559 DMZA5PQ DI DMZA5PQ DMZA5PQ DN Glipizide DMZA5PQ TI TTG140O DMZA5PQ TN Inward rectifier potassium channel Kir1.2 (KCNJ10) DMZA5PQ MA Blocker DMZA5PQ RN Triggering and amplification of insulin secretion by dimethyl alpha-ketoglutarate, a membrane permeable alpha-ketoglutarate analogue. Eur J Pharmacol. 2009 Apr 1;607(1-3):41-6. DMZA5PQ RU https://pubmed.ncbi.nlm.nih.gov/19233162 DMZAL7W DI DMZAL7W DMZAL7W DN Promazine DMZAL7W TI TTH18TF DMZAL7W TN Muscarinic acetylcholine receptor M5 (CHRM5) DMZAL7W MA Binder DMZAL7W RN Muscarinic cholinergic and histamine H1 receptor binding of phenothiazine drug metabolites. Life Sci. 1988;43(5):405-12. DMZAL7W RU https://pubmed.ncbi.nlm.nih.gov/2899826 DMZBU15 DI DMZBU15 DMZBU15 DN Tripelennamine DMZBU15 TI TTTIBOJ DMZBU15 TN Histamine H1 receptor (H1R) DMZBU15 MA Antagonist DMZBU15 RN Involvement of histamine H1 and H2 receptors in the regulation of STAT-1 phosphorylation: inverse agonism exhibited by the receptor antagonists. Int Immunopharmacol. 2005 Jul;5(7-8):1299-309. DMZBU15 RU https://pubmed.ncbi.nlm.nih.gov/15914334 DMZC1HS DI DMZC1HS DMZC1HS DN Ivacaftor DMZC1HS TI TTRLZHP DMZC1HS TN cAMP-dependent chloride channel (CFTR) DMZC1HS MA Modulator DMZC1HS RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DMZC1HS RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DMZC6GT DI DMZC6GT DMZC6GT DN Elliptinium acetate DMZC6GT TI TTABD5E DMZC6GT TN DNA replication (DNA repli) DMZC6GT MA Modulator DMZC6GT RN Stationary potential of the brain: Part II. Clinical studies. Neurol Med Chir (Tokyo). 1979 Jul;19(7):655-64. DMZC6GT RU https://pubmed.ncbi.nlm.nih.gov/91123 DMZD5QR DI DMZD5QR DMZD5QR DN Cytarabine DMZD5QR TI TTIU7X1 DMZD5QR TN Herpes simplex virus DNA polymerase UL30 (HSV UL30) DMZD5QR MA Inhibitor DMZD5QR RN Chromatin-associated proteins HMGB1/2 and PDIA3 trigger cellular response to chemotherapy-induced DNA damage. Mol Cancer Ther. 2009 Apr;8(4):864-72. DMZD5QR RU https://pubmed.ncbi.nlm.nih.gov/19372559 DMZDCS0 DI DMZDCS0 DMZDCS0 DN Bezafibrate DMZDCS0 TI TTJ584C DMZDCS0 TN Peroxisome proliferator-activated receptor alpha (PPARA) DMZDCS0 MA Agonist DMZDCS0 RN Bezafibrate at clinically relevant doses decreases serum/liver triglycerides via down-regulation of sterol regulatory element-binding protein-1c in... Mol Pharmacol. 2009 Apr;75(4):782-92. DMZDCS0 RU https://pubmed.ncbi.nlm.nih.gov/19124612 DMZDF0B DI DMZDF0B DMZDF0B DN Aceclofenac DMZDF0B TI TTK0943 DMZDF0B TN Prostaglandin G/H synthase (COX) DMZDF0B MA Modulator DMZDF0B RN Aceclofenac spares cyclooxygenase 1 as a result of limited but sustained biotransformation to diclofenac. Clin Pharmacol Ther. 2003 Sep;74(3):222-35. DMZDF0B RU https://pubmed.ncbi.nlm.nih.gov/12966366 DMZDN4W DI DMZDN4W DMZDN4W DN L-alanine DMZDN4W TI TTT2LD9 DMZDN4W TN GABA transaminase (ABAT) DMZDN4W MA Inhibitor DMZDN4W RN DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6. DMZDN4W RU https://pubmed.ncbi.nlm.nih.gov/18048412 DMZEONG DI DMZEONG DMZEONG DN Finafloxacin DMZEONG TI TTN6J5F DMZEONG TN Bacterial DNA gyrase (Bact gyrase) DMZEONG MA Modulator DMZEONG RN 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81. DMZEONG RU https://pubmed.ncbi.nlm.nih.gov/25633781 DMZEONG DI DMZEONG DMZEONG DN Finafloxacin DMZEONG TI TTIXTO3 DMZEONG TN Staphylococcus Topoisomerase IV (Stap-coc parC) DMZEONG MA Modulator DMZEONG RN 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81. DMZEONG RU https://pubmed.ncbi.nlm.nih.gov/25633781 DMZEPFJ DI DMZEPFJ DMZEPFJ DN Demeclocycline DMZEPFJ TI TTQ8KVI DMZEPFJ TN Staphylococcus 30S ribosomal subunit (Stap-coc pbp2) DMZEPFJ MA Binder DMZEPFJ RN Detection of tetracycline resistance genes by PCR methods. Methods Mol Biol. 2004;268:3-13. DMZEPFJ RU https://pubmed.ncbi.nlm.nih.gov/15156014 DMZFICR DI DMZFICR DMZFICR DN Bevantolol DMZFICR TI TTEX248 DMZFICR TN Dopamine D2 receptor (D2R) DMZFICR MA Antagonist DMZFICR RN Determination of bevantolol in human plasma by high performance liquid chromatography using solid phase extraction technique. Arch Pharm Res. 2007 Jul;30(7):890-7. DMZFICR RU https://pubmed.ncbi.nlm.nih.gov/17703743 DMZG5WL DI DMZG5WL DMZG5WL DN Emapalumab DMZG5WL TI TT93WF5 DMZG5WL TN Interferon-gamma (IFNG) DMZG5WL MA Modulator DMZG5WL RN 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. DMZG5WL RU https://pubmed.ncbi.nlm.nih.gov/30710142 DMZGXUM DI DMZGXUM DMZGXUM DN Estazolam DMZGXUM TI TTPTXIN DMZGXUM TN Translocator protein (TSPO) DMZGXUM MA Agonist DMZGXUM RN Design and synthesis of new 2-substituted-5-(2-benzylthiophenyl)-1,3,4-oxadiazoles as benzodiazepine receptor agonists. Bioorg Med Chem Lett. 2005 Jun 15;15(12):3126-9. DMZGXUM RU https://pubmed.ncbi.nlm.nih.gov/15876530 DMZHPNE DI DMZHPNE DMZHPNE DN Cimetropium bromide DMZHPNE TI TTH18TF DMZHPNE TN Muscarinic acetylcholine receptor M5 (CHRM5) DMZHPNE MA Modulator DMZHPNE RN Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. DMZHPNE RU https://pubmed.ncbi.nlm.nih.gov/17309302 DMZHUO5 DI DMZHUO5 DMZHUO5 DN Phenylephrine DMZHUO5 TI TTEX248 DMZHUO5 TN Dopamine D2 receptor (D2R) DMZHUO5 MA Agonist DMZHUO5 RN MMP-2 induced vein relaxation via inhibition of [Ca2+]e-dependent mechanisms of venous smooth muscle contraction. Role of RGD peptides. J Surg Res. 2010 Apr;159(2):755-64. DMZHUO5 RU https://pubmed.ncbi.nlm.nih.gov/19482300 DMZI2UF DI DMZI2UF DMZI2UF DN Sulphadoxine DMZI2UF TI TT4ILYC DMZI2UF TN Bacterial Dihydropteroate synthetase (Bact folP) DMZI2UF MA Binder DMZI2UF RN The fight against drug-resistant malaria: novel plasmodial targets and antimalarial drugs. Curr Med Chem. 2008;15(2):161-71. DMZI2UF RU https://pubmed.ncbi.nlm.nih.gov/18220771 DMZI2UF DI DMZI2UF DMZI2UF DN Sulphadoxine DMZI2UF TI TTGP7BY DMZI2UF TN Monoamine oxidase type B (MAO-B) DMZI2UF MA Inhibitor DMZI2UF RN Novel monoamine oxidase inhibitors, 3-(2-aminoethoxy)-1,2-benzisoxazole derivatives, and their differential reversibility. Jpn J Pharmacol. 2002 Feb;88(2):174-82. DMZI2UF RU https://pubmed.ncbi.nlm.nih.gov/11928718 DMZI3WO DI DMZI3WO DMZI3WO DN Etomidate DMZI3WO TI TTEX6LM DMZI3WO TN GABA(A) receptor gamma-3 (GABRG3) DMZI3WO MA Modulator DMZI3WO RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMZI3WO RU https://www.fda.gov/ DMZJYBW DI DMZJYBW DMZJYBW DN Metocurine Iodide DMZJYBW TI TTL1ATN DMZJYBW TN Neuronal acetylcholine receptor alpha-4/beta-2 (CHRNA4/B2) DMZJYBW MA Modulator DMZJYBW RN NMR study of general anesthetic interaction with nAChR beta2 subunit.Biophys J.2008 Mar 1;94(5):1681-8. DMZJYBW RU https://www.ncbi.nlm.nih.gov/pubmed/17993502 DMZKXB7 DI DMZKXB7 DMZKXB7 DN Butylscopolamine DMZKXB7 TI TTH18TF DMZKXB7 TN Muscarinic acetylcholine receptor M5 (CHRM5) DMZKXB7 MA Modulator DMZKXB7 RN Comparison of pharmacological effects of L- and DL-n-butyl-scopolamine in rat uterus. Yao Xue Xue Bao. 1994;29(1):24-7. DMZKXB7 RU https://pubmed.ncbi.nlm.nih.gov/8036897 DMZKYIV DI DMZKYIV DMZKYIV DN Amsacrine DMZKYIV TI TT0IHXV DMZKYIV TN DNA topoisomerase II (TOP2) DMZKYIV MA Inhibitor DMZKYIV RN Design of two etoposide-amsacrine conjugates: topoisomerase II and tubuline polymerization inhibition and relation to cytotoxicity. Anticancer Drug Des. 2000 Dec;15(6):413-21. DMZKYIV RU https://pubmed.ncbi.nlm.nih.gov/11716434 DMZL3IV DI DMZL3IV DMZL3IV DN Alemtuzumab DMZL3IV TI TTQT5S9 DMZL3IV TN Cambridge pathology 1 antigen (CD52) DMZL3IV RN Identifying alemtuzumab as an anti-myeloid cell antiangiogenic therapy for the treatment of ovarian cancer. J Transl Med. 2009 Jun 19;7:49. DMZL3IV RU https://pubmed.ncbi.nlm.nih.gov/19545375 DMZLBUO DI DMZLBUO DMZLBUO DN Lucanthone DMZLBUO TI TT0IHXV DMZLBUO TN DNA topoisomerase II (TOP2) DMZLBUO MA Inhibitor DMZLBUO RN Clonogenicity of human leukemic cells protected from cell-lethal agents by heat shock protein 70. Cell Stress Chaperones. 2005 Spring;10(1):37-45. DMZLBUO RU https://pubmed.ncbi.nlm.nih.gov/15832946 DMZLGRB DI DMZLGRB DMZLGRB DN Pimecrolimus DMZLGRB TI TTA4LDE DMZLGRB TN Calcineurin (PPP3CA) DMZLGRB MA Inhibitor DMZLGRB RN Treatment of chronic blepharokeratoconjunctivitis with local calcineurin inhibitors. Ophthalmologe. 2009 Jul;106(7):635-8. DMZLGRB RU https://pubmed.ncbi.nlm.nih.gov/19499228 DMZLHKJ DI DMZLHKJ DMZLHKJ DN Adenine DMZLHKJ TI TTUTN1I DMZLHKJ TN Human Deoxyribonucleic acid (hDNA) DMZLHKJ MA Binder DMZLHKJ RN Escherichia coli DNA adenine methyltransferase: intrasite processivity and substrate-induced dimerization and activation. Biochemistry. 2009 Aug 11;48(31):7399-410. DMZLHKJ RU https://pubmed.ncbi.nlm.nih.gov/19580332 DMZM84R DI DMZM84R DMZM84R DN Ethynodiol diacetate DMZM84R TI TTUV8G9 DMZM84R TN Progesterone receptor (PGR) DMZM84R MA Binder DMZM84R RN Contribution of functional groups of 19-nor-progestogens to binding to progesterone and estradiol-17beta receptors in rabbit uterus. Endocrinology. 1977 Jun;100(6):1579-84. DMZM84R RU https://pubmed.ncbi.nlm.nih.gov/858280 DMZMSCT DI DMZMSCT DMZMSCT DN Cilostazol DMZMSCT TI TT06AWU DMZMSCT TN Phosphodiesterase 3A (PDE3A) DMZMSCT MA Inhibitor DMZMSCT RN A new generation of phosphodiesterase inhibitors: multiple molecular forms of phosphodiesterase and the potential for drug selectivity. J Med Chem. 1985 May;28(5):537-45. DMZMSCT RU https://pubmed.ncbi.nlm.nih.gov/2985781 DMZMSCT DI DMZMSCT DMZMSCT DN Cilostazol DMZMSCT TI TTZCG4L DMZMSCT TN Phosphodiesterase 3 (PDE3) DMZMSCT MA Modulator DMZMSCT RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMZMSCT RU https://www.fda.gov/ DMZMSPF DI DMZMSPF DMZMSPF DN Bicalutamide DMZMSPF TI TTS64P2 DMZMSPF TN Androgen receptor (AR) DMZMSPF MA Antagonist DMZMSPF RN Androgen receptor overexpression induces tamoxifen resistance in human breast cancer cells. Breast Cancer Res Treat. 2010 May;121(1):1-11. DMZMSPF RU https://pubmed.ncbi.nlm.nih.gov/19533338 DMZOLBI DI DMZOLBI DMZOLBI DN Carbamazepine DMZOLBI TI TTRK8B9 DMZOLBI TN Sodium channel unspecific (NaC) DMZOLBI MA Modulator DMZOLBI RN Sidedness of carbamazepine accessibility to voltage-gated sodium channels. Mol Pharmacol. 2014 Feb;85(2):381-7. DMZOLBI RU https://pubmed.ncbi.nlm.nih.gov/24319110 DMZPHIK DI DMZPHIK DMZPHIK DN Beclomethasone DMZPHIK TI TTP3UTW DMZPHIK TN Steroid hormone receptor ERR (ESRR) DMZPHIK MA Modulator DMZPHIK RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMZPHIK RU https://www.fda.gov/ DMZPXRC DI DMZPXRC DMZPXRC DN Carzinophilin DMZPXRC TI TTY1GPO DMZPXRC TN Human Deoxyribonucleic acid major groove (hDNA maj) DMZPXRC MA Modulator DMZPXRC RN Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. DMZPXRC RU https://pubmed.ncbi.nlm.nih.gov/17309302 DMZQOUX DI DMZQOUX DMZQOUX DN Trastuzumab DMZQOUX TI TT6EO5L DMZQOUX TN Erbb2 tyrosine kinase receptor (HER2) DMZQOUX RN Her2/neu is not a commonly expressed therapeutic target in melanoma -- a large cohort tissue microarray study. Melanoma Res. 2004 Jun;14(3):207-10. DMZQOUX RU https://pubmed.ncbi.nlm.nih.gov/15179190 DMZR15V DI DMZR15V DMZR15V DN Selpercatinib DMZR15V TI TT4DXQT DMZR15V TN Proto-oncogene c-Ret (RET) DMZR15V MA Inhibitor DMZR15V RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020 DMZR15V RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213246s000lbl.pdf DMZR26N DI DMZR26N DMZR26N DN Ciprofloxacin+dexamethasone DMZR26N TI TT0IHXV DMZR26N TN DNA topoisomerase II (TOP2) DMZR26N MA Binder DMZR26N RN Emerging therapies for the treatment and prevention of otitis media. Expert Opin Emerg Drugs. 2006 May;11(2):251-64. DMZR26N RU https://pubmed.ncbi.nlm.nih.gov/16634700 DMZREFQ DI DMZREFQ DMZREFQ DN Eslicarbazepine DMZREFQ TI TTRK8B9 DMZREFQ TN Sodium channel unspecific (NaC) DMZREFQ MA Blocker DMZREFQ RN Progress report on new antiepileptic drugs: a summary of the Ninth Eilat Conference (EILAT IX). Epilepsy Res. 2009 Jan;83(1):1-43. DMZREFQ RU https://pubmed.ncbi.nlm.nih.gov/19008076 DMZREFQ DI DMZREFQ DMZREFQ DN Eslicarbazepine DMZREFQ TI TTN9VTF DMZREFQ TN Voltage-gated sodium channel alpha Nav1.9 (SCN11A) DMZREFQ MA Inhibitor DMZREFQ RN Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357. DMZREFQ RU https://pubmed.ncbi.nlm.nih.gov/30728472 DMZREFQ DI DMZREFQ DMZREFQ DN Eslicarbazepine DMZREFQ TI TTIG65Q DMZREFQ TN Voltage-gated sodium channel (Nav) DMZREFQ MA Inhibitor DMZREFQ RN Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357. DMZREFQ RU https://pubmed.ncbi.nlm.nih.gov/30728472 DMZSDGX DI DMZSDGX DMZSDGX DN Dicyclomine DMZSDGX TI TTZ9SOR DMZSDGX TN Muscarinic acetylcholine receptor M1 (CHRM1) DMZSDGX MA Antagonist DMZSDGX RN [Characterization of muscarinic receptors in undifferentiated thyroid cells in Fisher rats]. Endocrinol Nutr. 2009 Mar;56(3):106-11. DMZSDGX RU https://pubmed.ncbi.nlm.nih.gov/19627722 DMZSWQC DI DMZSWQC DMZSWQC DN Flunisolide DMZSWQC TI TTYRL6O DMZSWQC TN Glucocorticoid receptor (NR3C1) DMZSWQC MA Agonist DMZSWQC RN The glucocorticoid receptor heterocomplex gene STIP1 is associated with improved lung function in asthmatic subjects treated with inhaled corticost... J Allergy Clin Immunol. 2009 Jun;123(6):1376-83.e7. DMZSWQC RU https://pubmed.ncbi.nlm.nih.gov/19254810 DMZT2P0 DI DMZT2P0 DMZT2P0 DN Abobotulinum toxin A DMZT2P0 TI TTZJD1B DMZT2P0 TN Acetylcholine release (Ach rele) DMZT2P0 MA Modulator DMZT2P0 RN Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92. DMZT2P0 RU https://pubmed.ncbi.nlm.nih.gov/20118952 DMZT4N7 DI DMZT4N7 DMZT4N7 DN Leucovorin/5-fluorouracil DMZT4N7 TI TTU6BFZ DMZT4N7 TN Candida Thymidylate synthase (Candi TMP1) DMZT4N7 MA Inhibitor DMZT4N7 RN Decreased levels of UMP kinase as a mechanism of fluoropyrimidine resistance. Mol Cancer Ther. 2009 May;8(5):1037-44. DMZT4N7 RU https://pubmed.ncbi.nlm.nih.gov/19383847 DMZTGN2 DI DMZTGN2 DMZTGN2 DN Methylnaltrexone bromide DMZTGN2 TI TTD0CIQ DMZTGN2 TN Melanocortin receptor 4 (MC4R) DMZTGN2 MA Agonist DMZTGN2 RN Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60. DMZTGN2 RU https://pubmed.ncbi.nlm.nih.gov/16083333 DMZTGN2 DI DMZTGN2 DMZTGN2 DN Methylnaltrexone bromide DMZTGN2 TI TTKWM86 DMZTGN2 TN Opioid receptor mu (MOP) DMZTGN2 MA Modulator DMZTGN2 RN 2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6. DMZTGN2 RU https://pubmed.ncbi.nlm.nih.gov/19180096 DMZTXCH DI DMZTXCH DMZTXCH DN Remifentanil DMZTXCH TI TTKWM86 DMZTXCH TN Opioid receptor mu (MOP) DMZTXCH MA Agonist DMZTXCH RN The pro-nociceptive effects of remifentanil or surgical injury in mice are associated with a decrease in delta-opioid receptor mRNA levels: Prevent... Pain. 2009 Jan;141(1-2):88-96. DMZTXCH RU https://pubmed.ncbi.nlm.nih.gov/19058913 DMZU5JP DI DMZU5JP DMZU5JP DN Flunarizine DMZU5JP TI TTZPWGN DMZU5JP TN Voltage-gated calcium channel alpha Cav3.2 (CACNA1H) DMZU5JP MA Blocker DMZU5JP RN Positive allosteric interaction of structurally diverse T-type calcium channel antagonists. Cell Biochem Biophys. 2009;55(2):81-93. DMZU5JP RU https://pubmed.ncbi.nlm.nih.gov/19582593 DMZU5JP DI DMZU5JP DMZU5JP DN Flunarizine DMZU5JP TI TTX4QDJ DMZU5JP TN Voltage-gated calcium channel alpha Cav2.1 (CACNA1A) DMZU5JP MA Inhibitor DMZU5JP RN Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357. DMZU5JP RU https://pubmed.ncbi.nlm.nih.gov/30728472 DMZUR4N DI DMZUR4N DMZUR4N DN Triclosan DMZUR4N TI TTNX2CS DMZUR4N TN Plasmodium Enoyl-ACP reductase (Malaria fabI) DMZUR4N MA Binder DMZUR4N RN Novel molecular targets for antimalarial drug development. Chem Biol Drug Des. 2008 Apr;71(4):287-97. DMZUR4N RU https://pubmed.ncbi.nlm.nih.gov/18298458 DMZUW6P DI DMZUW6P DMZUW6P DN Factor viia DMZUW6P TI TTF0EGX DMZUW6P TN Coagulation factor VII (F7) DMZUW6P MA Modulator DMZUW6P RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2363). DMZUW6P RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2363 DMZV2PJ DI DMZV2PJ DMZV2PJ DN Acetophenazine DMZV2PJ TI TTEX248 DMZV2PJ TN Dopamine D2 receptor (D2R) DMZV2PJ MA Antagonist DMZV2PJ RN Atypical antipsychotics: mechanism of action. Can J Psychiatry. 2002 Feb;47(1):27-38. DMZV2PJ RU https://pubmed.ncbi.nlm.nih.gov/11873706 DMZVMKF DI DMZVMKF DMZVMKF DN Alfuzosin DMZVMKF TI TT34BHT DMZVMKF TN Adrenergic receptor alpha-1D (ADRA1D) DMZVMKF MA Antagonist DMZVMKF RN Alfuzosin: a review of the therapeutic use of the prolonged-release formulation given once daily in the management of benign prostatic hyperplasia. Drugs. 2002;62(4):633-53. DMZVMKF RU https://pubmed.ncbi.nlm.nih.gov/11893233 DMZW9HA DI DMZW9HA DMZW9HA DN Olsalazine DMZW9HA TI TTPZ7AG DMZW9HA TN Oxidoreductase unspecific (OR) DMZW9HA MA Modulator DMZW9HA RN Reaction mechanism of azoreductases suggests convergent evolution with quinone oxidoreductases. Protein Cell. 2010 Aug;1(8):780-90. DMZW9HA RU https://pubmed.ncbi.nlm.nih.gov/21203919 DMZYLFC DI DMZYLFC DMZYLFC DN Viomycin sulfate DMZYLFC TI TTIA0J5 DMZYLFC TN Bacterial 70S ribosomal RNA (Bact 70S rRNA) DMZYLFC MA Modulator DMZYLFC RN The antibiotic viomycin traps the ribosome in an intermediate state of translocation.Nat Struct Mol Biol.2007 Jun;14(6):493-7. DMZYLFC RU https://www.ncbi.nlm.nih.gov/pubmed/17515906 nan DI nan nan DN nan nan TI TTIHYA4 nan TN Thrombopoietin receptor (MPL) nan MA Agonist nan RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1722). nan RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1722 DM5GFIK DI DM5GFIK DM5GFIK DN Icotinib hydrochloride DM5GFIK TI TTGKNB4 DM5GFIK TN Epidermal growth factor receptor (EGFR) DM5GFIK MA Antagonist DM5GFIK RN Phase I study of icotinib hydrochloride (BPI-2009H), an oral EGFR tyrosine kinase inhibitor, in patients with advanced NSCLC and other solid tumors. Lung Cancer. 2011 Aug;73(2):195-202. DM5GFIK RU https://pubmed.ncbi.nlm.nih.gov/21144613 DM5GIWZ DI DM5GIWZ DM5GIWZ DN Mirogabalin DM5GIWZ TI TTFK1JQ DM5GIWZ TN Voltage-gated calcium channel alpha-2/delta-1 (CACNA2D1) DM5GIWZ MA Modulator DM5GIWZ RN Efficacy and safety of mirogabalin (DS-5565) for the treatment of diabetic peripheral neuropathic pain: a randomized, double-blind, placebo- and active comparator-controlled, adaptive proof-of-concept phase 2 study. Diabetes Care. 2014 Dec;37(12):3253-61. DM5GIWZ RU https://pubmed.ncbi.nlm.nih.gov/25231896 DMBZ27L DI DMBZ27L DMBZ27L DN Favipiravir DMBZ27L TI TT79JGK DMBZ27L TN Mycobacterium RNA polymerase (MycB RNAP) DMBZ27L MA Modulator DMBZ27L RN Favipiravir (T-705), a novel viral RNA polymerase inhibitor.Antiviral Res.2013 Nov;100(2):446-54. DMBZ27L RU https://www.ncbi.nlm.nih.gov/pubmed/24084488 DMDWYUN DI DMDWYUN DMDWYUN DN HBI-8000 DMDWYUN TI TT6R7JZ DMDWYUN TN Histone deacetylase 1 (HDAC1) DMDWYUN MA Modulator DMDWYUN RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMDWYUN RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMDWYUN DI DMDWYUN DMDWYUN DN HBI-8000 DMDWYUN TI TTBH0VX DMDWYUN TN Histone deacetylase (HDAC) DMDWYUN MA Inhibitor DMDWYUN RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMDWYUN RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMRCOU5 DI DMRCOU5 DMRCOU5 DN Dicycloplatin DMRCOU5 TI TTUTN1I DMRCOU5 TN Human Deoxyribonucleic acid (hDNA) DMRCOU5 MA Inhibitor DMRCOU5 RN Dicycloplatin, a novel platinum analog in chemotherapy: synthesis of chinese pre-clinical and clinical profile and emerging mechanistic studies. Anticancer Res. 2014 Jan;34(1):455-63. DMRCOU5 RU https://pubmed.ncbi.nlm.nih.gov/24403501 DMY67U8 DI DMY67U8 DMY67U8 DN Trapidil DMY67U8 TI TTST7KB DMY67U8 TN Fibroblast growth factor receptor 3 (FGFR3) DMY67U8 MA Inhibitor DMY67U8 RN Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127. DMY67U8 RU https://pubmed.ncbi.nlm.nih.gov/19249983 DMY67U8 DI DMY67U8 DMY67U8 DN Trapidil DMY67U8 TI TTI2WET DMY67U8 TN Platelet-derived growth factor receptor (PDGFR) DMY67U8 MA Inhibitor DMY67U8 RN Osteitis fibrosa is mediated by Platelet-Derived Growth Factor-A via a phosphoinositide 3-kinase-dependent signaling pathway in a rat model for chr... Endocrinology. 2008 Nov;149(11):5735-46. DMY67U8 RU https://pubmed.ncbi.nlm.nih.gov/18635661 DM2M47Y DI DM2M47Y DM2M47Y DN TKM-ApoB DM2M47Y TI TTN1IE2 DM2M47Y TN APOB messenger RNA (APOB mRNA) DM2M47Y RN Current Progress of siRNA/shRNA Therapeutics in Clinical Trials. Biotechnol J. 2011 September; 6(9): 1130-1146. DM2M47Y RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3388104/ DM2VOQ3 DI DM2VOQ3 DM2VOQ3 DN Mosapride DM2VOQ3 TI TT07C3Y DM2VOQ3 TN 5-HT 4 receptor (HTR4) DM2VOQ3 MA Agonist DM2VOQ3 RN The in vitro pharmacological profile of TD-5108, a selective 5-HT(4) receptor agonist with high intrinsic activity. Naunyn Schmiedebergs Arch Pharmacol. 2008 Jul;378(1):125-37. DM2VOQ3 RU https://pubmed.ncbi.nlm.nih.gov/18415081 DM3S8XC DI DM3S8XC DM3S8XC DN Dihydrotestosterone DM3S8XC TI TTKPW01 DM3S8XC TN Androgen receptor messenger RNA (AR mRNA) DM3S8XC MA Agonist DM3S8XC RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 628). DM3S8XC RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=628 DM3S8XC DI DM3S8XC DM3S8XC DN Dihydrotestosterone DM3S8XC TI TTS64P2 DM3S8XC TN Androgen receptor (AR) DM3S8XC MA Modulator DM3S8XC RN Inhibition of the dihydrotestosterone-activated androgen receptor by nuclear receptor corepressor. Mol Endocrinol. 2002 Jul;16(7):1492-501. DM3S8XC RU https://www.ncbi.nlm.nih.gov/pubmed/12089345 DM3YH4I DI DM3YH4I DM3YH4I DN D-Serine DM3YH4I TI TTLD29N DM3YH4I TN Glutamate receptor ionotropic NMDA 1 (NMDAR1) DM3YH4I MA Inhibitor DM3YH4I RN Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. DM3YH4I RU https://pubmed.ncbi.nlm.nih.gov/11752352 DM3YH4I DI DM3YH4I DM3YH4I DN D-Serine DM3YH4I TI TTF45NW DM3YH4I TN Strychnine-binding glycine receptor (GLRA1) DM3YH4I MA Inhibitor DM3YH4I RN Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. DM3YH4I RU https://pubmed.ncbi.nlm.nih.gov/11752352 DM4OQRD DI DM4OQRD DM4OQRD DN HIF-1alpha DM4OQRD TI TTQHWNA DM4OQRD TN Hypoxia-inducible factor 1 alpha (HIF-1A) DM4OQRD MA Inhibitor DM4OQRD RN A RNA antagonist of hypoxia-inducible factor-1alpha, EZN-2968, inhibits tumor cell growth. Mol Cancer Ther. 2008 Nov;7(11):3598-608. DM4OQRD RU https://pubmed.ncbi.nlm.nih.gov/18974394 DM4OQRD DI DM4OQRD DM4OQRD DN HIF-1alpha DM4OQRD TI TT0LF7H DM4OQRD TN Fibroblast growth factor receptor (FGFR) DM4OQRD MA Antagonist DM4OQRD RN Tumor angiogenesis as a therapeutic target. Drug Discov Today. 2001 Oct 1;6(19):1005-1024. DM4OQRD RU https://pubmed.ncbi.nlm.nih.gov/11576867 DM4TX7J DI DM4TX7J DM4TX7J DN Talipexole DM4TX7J TI TTEX248 DM4TX7J TN Dopamine D2 receptor (D2R) DM4TX7J MA Agonist DM4TX7J RN Effects of talipexole on emesis-related changes in abdominal afferent vagal activity and ileal serotonin metabolism in rats. Res Commun Mol Pathol Pharmacol. 1997 Jan;95(1):67-82. DM4TX7J RU https://pubmed.ncbi.nlm.nih.gov/9055350 DM5FABJ DI DM5FABJ DM5FABJ DN LAROPIPRANT DM5FABJ TI TTPADOQ DM5FABJ TN HMG-CoA reductase (HMGCR) DM5FABJ MA Inhibitor DM5FABJ RN A novel c-Met inhibitor, MK8033, synergizes with carboplatin plus paclitaxel to inhibit ovarian cancer cell growth. Oncol Rep. 2013 May;29(5):2011-8. DM5FABJ RU https://pubmed.ncbi.nlm.nih.gov/23467907 DM5FABJ DI DM5FABJ DM5FABJ DN LAROPIPRANT DM5FABJ TI TT2O84V DM5FABJ TN Thromboxane A2 receptor (TBXA2R) DM5FABJ MA Inhibitor DM5FABJ RN Discovery of a potent and selective prostaglandin D2 receptor antagonist, [(3R)-4-(4-chloro-benzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydroc... J Med Chem. 2007 Feb 22;50(4):794-806. DM5FABJ RU https://pubmed.ncbi.nlm.nih.gov/17300164 DM5FABJ DI DM5FABJ DM5FABJ DN LAROPIPRANT DM5FABJ TI TTNVEIR DM5FABJ TN Prostaglandin D2 receptor (PTGDR) DM5FABJ MA Inhibitor DM5FABJ RN Discovery of a potent and selective prostaglandin D2 receptor antagonist, [(3R)-4-(4-chloro-benzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydroc... J Med Chem. 2007 Feb 22;50(4):794-806. DM5FABJ RU https://pubmed.ncbi.nlm.nih.gov/17300164 DM5FABJ DI DM5FABJ DM5FABJ DN LAROPIPRANT DM5FABJ TI TTOFYT1 DM5FABJ TN Prostacyclin receptor (PTGIR) DM5FABJ MA Inhibitor DM5FABJ RN Discovery of a potent and selective prostaglandin D2 receptor antagonist, [(3R)-4-(4-chloro-benzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydroc... J Med Chem. 2007 Feb 22;50(4):794-806. DM5FABJ RU https://pubmed.ncbi.nlm.nih.gov/17300164 DM5FABJ DI DM5FABJ DM5FABJ DN LAROPIPRANT DM5FABJ TI TTQDMX5 DM5FABJ TN Prostaglandin D2 receptor 2 (PTGDR2) DM5FABJ MA Inhibitor DM5FABJ RN Discovery of a potent and selective prostaglandin D2 receptor antagonist, [(3R)-4-(4-chloro-benzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydroc... J Med Chem. 2007 Feb 22;50(4):794-806. DM5FABJ RU https://pubmed.ncbi.nlm.nih.gov/17300164 DM5FABJ DI DM5FABJ DM5FABJ DN LAROPIPRANT DM5FABJ TI TTT2ZAR DM5FABJ TN Prostaglandin F2-alpha receptor (PTGFR) DM5FABJ MA Inhibitor DM5FABJ RN Discovery of a potent and selective prostaglandin D2 receptor antagonist, [(3R)-4-(4-chloro-benzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydroc... J Med Chem. 2007 Feb 22;50(4):794-806. DM5FABJ RU https://pubmed.ncbi.nlm.nih.gov/17300164 DM5FABJ DI DM5FABJ DM5FABJ DN LAROPIPRANT DM5FABJ TI TT1ZAVI DM5FABJ TN Prostaglandin E2 receptor EP2 (PTGER2) DM5FABJ MA Inhibitor DM5FABJ RN Discovery of a potent and selective prostaglandin D2 receptor antagonist, [(3R)-4-(4-chloro-benzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydroc... J Med Chem. 2007 Feb 22;50(4):794-806. DM5FABJ RU https://pubmed.ncbi.nlm.nih.gov/17300164 DM6VFO1 DI DM6VFO1 DM6VFO1 DN Pregnenolone DM6VFO1 TI TTPNQAC DM6VFO1 TN Estrogen-related receptor-alpha (ESRRA) DM6VFO1 MA Agonist DM6VFO1 RN Suppression of adrenal function by low-dose prednisone: assessment with 24-hour urinary steroid hormone profiles--a review of five cases. Altern Med Rev. 2006 Mar;11(1):40-6. DM6VFO1 RU https://pubmed.ncbi.nlm.nih.gov/16597193 DM8EKSV DI DM8EKSV DM8EKSV DN Anti-MIF antibodies DM8EKSV TI TT2AST1 DM8EKSV TN Macrophage migration inhibitory factor (MIF) DM8EKSV MA Inhibitor DM8EKSV RN Neutralization of Macrophage Migration Inhibitory Factor (MIF) by Fully Human Antibodies Correlates with Their Specificity for the beta-Sheet Structure of MIF. J Biol Chem. 2012 March 2; 287(10): 7446-7455. DM8EKSV RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3293543/ DM8NWFD DI DM8NWFD DM8NWFD DN Hypericum DM8NWFD TI TTAWNKZ DM8NWFD TN Norepinephrine transporter (NET) DM8NWFD MA Inhibitor DM8NWFD RN The experimental and clinical pharmacology of St John's Wort (Hypericum perforatum L.). Mol Psychiatry. 1999 Jul;4(4):333-8. DM8NWFD RU https://pubmed.ncbi.nlm.nih.gov/10483049 DM92S6N DI DM92S6N DM92S6N DN Levamlodipine DM92S6N TI TTXHYV6 DM92S6N TN Voltage-gated L-type calcium channel (L-CaC) DM92S6N MA Modulator DM92S6N RN Effects of (S)-amlodipine and (R)-amlodipine on L-type calcium channel current of rat ventricular myocytes and cytosolic calcium of aortic smooth muscle cells. Pharmazie. 2008 Jun;63(6):470-4. DM92S6N RU https://pubmed.ncbi.nlm.nih.gov/18604992 DMB0FWL DI DMB0FWL DMB0FWL DN Dihydrocodeine DMB0FWL TI TTN4QDT DMB0FWL TN Opioid receptor (OPR) DMB0FWL MA Modulator DMB0FWL RN Affinities of dihydrocodeine and its metabolites to opioid receptors. Pharmacol Toxicol. 2002 Aug;91(2):57-63. DMB0FWL RU https://pubmed.ncbi.nlm.nih.gov/12420793 DMB7WYM DI DMB7WYM DMB7WYM DN ATOSIBAN DMB7WYM TI TT4TFGN DMB7WYM TN Vasopressin V1a receptor (V1AR) DMB7WYM MA Inhibitor DMB7WYM RN The discovery of GSK221149A: a potent and selective oxytocin antagonist. Bioorg Med Chem Lett. 2008 Jan 1;18(1):90-4. DMB7WYM RU https://pubmed.ncbi.nlm.nih.gov/18032036 DMB7WYM DI DMB7WYM DMB7WYM DN ATOSIBAN DMB7WYM TI TTSCIUP DMB7WYM TN Oxytocin receptor (OTR) DMB7WYM MA Inhibitor DMB7WYM RN Pyridobenzodiazepines: a novel class of orally active, vasopressin V2 receptor selective agonists. Bioorg Med Chem Lett. 2006 Feb 15;16(4):954-9. DMB7WYM RU https://pubmed.ncbi.nlm.nih.gov/16297621 DMB7WYM DI DMB7WYM DMB7WYM DN ATOSIBAN DMB7WYM TI TTL9MHW DMB7WYM TN Vasopressin V1b receptor (V1BR) DMB7WYM MA Inhibitor DMB7WYM RN The discovery of GSK221149A: a potent and selective oxytocin antagonist. Bioorg Med Chem Lett. 2008 Jan 1;18(1):90-4. DMB7WYM RU https://pubmed.ncbi.nlm.nih.gov/18032036 DMB7WYM DI DMB7WYM DMB7WYM DN ATOSIBAN DMB7WYM TI TTK8R02 DMB7WYM TN Vasopressin V2 receptor (V2R) DMB7WYM MA Inhibitor DMB7WYM RN The discovery of GSK221149A: a potent and selective oxytocin antagonist. Bioorg Med Chem Lett. 2008 Jan 1;18(1):90-4. DMB7WYM RU https://pubmed.ncbi.nlm.nih.gov/18032036 DMBPN7T DI DMBPN7T DMBPN7T DN Rupatadine DMBPN7T TI TTQL5VC DMBPN7T TN Platelet-activating factor receptor (PTAFR) DMBPN7T MA Inhibitor DMBPN7T RN Designed multiple ligands. An emerging drug discovery paradigm. J Med Chem. 2005 Oct 20;48(21):6523-43. DMBPN7T RU https://pubmed.ncbi.nlm.nih.gov/16220969 DMBPN7T DI DMBPN7T DMBPN7T DN Rupatadine DMBPN7T TI TTTIBOJ DMBPN7T TN Histamine H1 receptor (H1R) DMBPN7T MA Inhibitor DMBPN7T RN Designed multiple ligands. An emerging drug discovery paradigm. J Med Chem. 2005 Oct 20;48(21):6523-43. DMBPN7T RU https://pubmed.ncbi.nlm.nih.gov/16220969 DMC5Q8X DI DMC5Q8X DMC5Q8X DN Berberine DMC5Q8X TI TTUJFD0 DMC5Q8X TN Telomerase reverse transcriptase (TERT) DMC5Q8X MA Inhibitor DMC5Q8X RN Stage specificity of Plasmodium falciparum telomerase and its inhibition by berberine. Parasitol Int. 2002 Mar;51(1):99-103. DMC5Q8X RU https://pubmed.ncbi.nlm.nih.gov/11880232 DMDN4A1 DI DMDN4A1 DMDN4A1 DN Glitazone DMDN4A1 TI TTZMAO3 DMDN4A1 TN Peroxisome proliferator-activated receptor gamma (PPAR-gamma) DMDN4A1 MA Agonist DMDN4A1 RN Peroxisome proliferator-activated receptor alpha activators improve insulin sensitivity and reduce adiposity. J Biol Chem. 2000 Jun 2;275(22):16638-42. DMDN4A1 RU https://pubmed.ncbi.nlm.nih.gov/10828060 DMF8CJ9 DI DMF8CJ9 DMF8CJ9 DN Pyridine DMF8CJ9 TI TTKNWZ4 DMF8CJ9 TN Thromboxane-A synthase (TBXAS1) DMF8CJ9 MA Inhibitor DMF8CJ9 RN Highly selective inhibitors of thromboxane synthetase. 2. Pyridine derivatives. J Med Chem. 1981 Oct;24(10):1149-55. DMF8CJ9 RU https://pubmed.ncbi.nlm.nih.gov/7199089 DMHEAB1 DI DMHEAB1 DMHEAB1 DN Neupro DMHEAB1 TI TTWFZ1N DMHEAB1 TN Dopamine receptor (DR) DMHEAB1 MA Agonist DMHEAB1 RN Rotigotine Transdermal Patch: A Review in Parkinson's Disease. CNS Drugs. 2019 Jul;33(7):707-718. DMHEAB1 RU https://pubmed.ncbi.nlm.nih.gov/31243728 DMIGKA1 DI DMIGKA1 DMIGKA1 DN Ozagrel DMIGKA1 TI TTQBR95 DMIGKA1 TN Stress-activated protein kinase 2a (p38 alpha) DMIGKA1 MA Inhibitor DMIGKA1 RN Clinical pipeline report, company report or official report of GlaxoSmithKline (2009). DMIGKA1 RU http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf DMIV8CT DI DMIV8CT DMIV8CT DN Parecoxib DMIV8CT TI TTSZDQU DMIV8CT TN Lactotransferrin (LTF) DMIV8CT MA Inhibitor DMIV8CT RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMIV8CT RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMKV32D DI DMKV32D DMKV32D DN Xylometazoline DMKV32D TI TT2NUT5 DMKV32D TN Adrenergic receptor alpha-2C (ADRA2C) DMKV32D MA Modulator DMKV32D RN Alpha-adrenoceptor agonistic activity of oxymetazoline and xylometazoline. Fundam Clin Pharmacol. 2010 Dec;24(6):729-39. DMKV32D RU https://pubmed.ncbi.nlm.nih.gov/20030735 DMN2Q5I DI DMN2Q5I DMN2Q5I DN Diacerein DMN2Q5I TI TTRYK0X DMN2Q5I TN Interleukin-1 beta (IL1B) DMN2Q5I MA Inhibitor DMN2Q5I RN Non-surgical treatment of osteoarthritis of large joints - new aspects. Wien Med Wochenschr. 2009;159(3-4):76-86. DMN2Q5I RU https://pubmed.ncbi.nlm.nih.gov/19247594 DMOSJD0 DI DMOSJD0 DMOSJD0 DN Sivelestat sodium hydrate DMOSJD0 TI TTPLTSQ DMOSJD0 TN Neutrophil elastase (NE) DMOSJD0 MA Inhibitor DMOSJD0 RN Emerging therapies for treatment of acute lung injury and acute respiratory distress syndrome. Expert Opin Emerg Drugs. 2007 Sep;12(3):461-77. DMOSJD0 RU https://pubmed.ncbi.nlm.nih.gov/17874973 DMOSJD0 DI DMOSJD0 DMOSJD0 DN Sivelestat sodium hydrate DMOSJD0 TI TTEMV5X DMOSJD0 TN Serine protease unspecific (SP) DMOSJD0 MA Inhibitor DMOSJD0 RN Emerging drugs for the treatment of chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2006 May;11(2):275-91. DMOSJD0 RU https://pubmed.ncbi.nlm.nih.gov/16634702 DMTV7XH DI DMTV7XH DMTV7XH DN SPN-812 DMTV7XH TI TTAWNKZ DMTV7XH TN Norepinephrine transporter (NET) DMTV7XH MA Antagonist DMTV7XH RN New Insights into the Mechanism of Action of Viloxazine: Serotonin and Norepinephrine Modulating Properties. J Exp Pharmacol. 2020 Aug 25;12:285-300. DMTV7XH RU https://pubmed.ncbi.nlm.nih.gov/32943948 DMTV7XH DI DMTV7XH DMTV7XH DN SPN-812 DMTV7XH TI TT0K1SC DMTV7XH TN 5-HT 2B receptor (HTR2B) DMTV7XH MA Antagonist DMTV7XH RN New Insights into the Mechanism of Action of Viloxazine: Serotonin and Norepinephrine Modulating Properties. J Exp Pharmacol. 2020 Aug 25;12:285-300. DMTV7XH RU https://pubmed.ncbi.nlm.nih.gov/32943948 DMVILAD DI DMVILAD DMVILAD DN MOTILIN DMVILAD TI TT953CX DMVILAD TN Motilin receptor (MLNR) DMVILAD MA Inhibitor DMVILAD RN Discovery of a new class of macrocyclic antagonists to the human motilin receptor. J Med Chem. 2006 Nov 30;49(24):7190-7. DMVILAD RU https://pubmed.ncbi.nlm.nih.gov/17125271 DMVPLNC DI DMVPLNC DMVPLNC DN Ingrezza DMVPLNC TI TTNZRI3 DMVPLNC TN Synaptic vesicle amine transporter (SLC18A2) DMVPLNC MA Antagonist DMVPLNC RN VMAT2 Inhibitors and the Path to Ingrezza (Valbenazine). Prog Med Chem. 2018;57(1):87-111. DMVPLNC RU https://pubmed.ncbi.nlm.nih.gov/29680151 DMVXLOD DI DMVXLOD DMVXLOD DN Imrecoxib DMVXLOD TI TT8NGED DMVXLOD TN Prostaglandin G/H synthase 1 (COX-1) DMVXLOD MA Inhibitor DMVXLOD RN Synthesis and anti-inflammatory activity of the major metabolites of imrecoxib. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2270-2. DMVXLOD RU https://pubmed.ncbi.nlm.nih.gov/19286379 DMVXLOD DI DMVXLOD DMVXLOD DN Imrecoxib DMVXLOD TI TTVKILB DMVXLOD TN Prostaglandin G/H synthase 2 (COX-2) DMVXLOD MA Inhibitor DMVXLOD RN Synthesis and anti-inflammatory activity of the major metabolites of imrecoxib. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2270-2. DMVXLOD RU https://pubmed.ncbi.nlm.nih.gov/19286379 DMVZL26 DI DMVZL26 DMVZL26 DN 3,4-Dihydroxycinnamic Acid DMVZL26 TI TT2AST1 DMVZL26 TN Macrophage migration inhibitory factor (MIF) DMVZL26 MA Inhibitor DMVZL26 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMVZL26 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMVZL26 DI DMVZL26 DMVZL26 DN 3,4-Dihydroxycinnamic Acid DMVZL26 TI TT2J34L DMVZL26 TN Arachidonate 5-lipoxygenase (5-LOX) DMVZL26 MA Inhibitor DMVZL26 RN Phenidone protects the nigral dopaminergic neurons from LPS-induced neurotoxicity. Neurosci Lett. 2008 Nov 7;445(1):1-6. DMVZL26 RU https://pubmed.ncbi.nlm.nih.gov/18760329 DMWDEN0 DI DMWDEN0 DMWDEN0 DN Amylin DMWDEN0 TI TTD0CIQ DMWDEN0 TN Melanocortin receptor 4 (MC4R) DMWDEN0 MA Agonist DMWDEN0 RN Novel anti-obesity drugs. Expert Opin Investig Drugs. 2000 Jun;9(6):1317-26. DMWDEN0 RU https://pubmed.ncbi.nlm.nih.gov/11060745 DMWL182 DI DMWL182 DMWL182 DN Beraprost DMWL182 TI TTOFYT1 DMWL182 TN Prostacyclin receptor (PTGIR) DMWL182 MA Agonist DMWL182 RN Prostaglandin I2 IP Receptor Agonist, Beraprost, Prevents Transient Global Cerebral Ischemia Induced Hippocampal CA1 Injury in Aging Mice. J Neurol Disord. 2014;2:1000174. DMWL182 RU https://pubmed.ncbi.nlm.nih.gov/25584359 DMXBYQR DI DMXBYQR DMXBYQR DN Silymarin DMXBYQR TI TT2J34L DMXBYQR TN Arachidonate 5-lipoxygenase (5-LOX) DMXBYQR MA Inhibitor DMXBYQR RN Anti-inflammatory and anti-arthritic activities of silymarin acting through inhibition of 5-lipoxygenase. Phytomedicine. 2000 Mar;7(1):21-4. DMXBYQR RU https://pubmed.ncbi.nlm.nih.gov/10782486 DMY2AEF DI DMY2AEF DMY2AEF DN PAI-1 DMY2AEF TI TTGY7WI DMY2AEF TN Urokinase-type plasminogen activator (PLAU) DMY2AEF MA Inhibitor DMY2AEF RN Urokinase-type plasminogen activator and its inhibitor PAI-1: predictors of poor response to tamoxifen therapy in recurrent breast cancer. J Natl Cancer Inst. 1995 May 17;87(10):751-6. DMY2AEF RU https://pubmed.ncbi.nlm.nih.gov/7563153 DMYGEH7 DI DMYGEH7 DMYGEH7 DN Ceftolozane sulfate DMYGEH7 TI TTJP4SM DMYGEH7 TN Bacterial Penicillin binding protein (Bact PBP) DMYGEH7 MA Modulator DMYGEH7 RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMYGEH7 RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMYOC29 DI DMYOC29 DMYOC29 DN Hirudin DMYOC29 TI TT6L509 DMYOC29 TN Coagulation factor IIa (F2) DMYOC29 MA Inhibitor DMYOC29 RN Probing the hirudin-thrombin interaction by incorporation of noncoded amino acids and molecular dynamics simulation. Biochemistry. 2002 Nov 19;41(46):13556-69. DMYOC29 RU https://pubmed.ncbi.nlm.nih.gov/12427016 DMZ5Y1P DI DMZ5Y1P DMZ5Y1P DN Dichloroacetate DMZ5Y1P TI TTCZOF2 DMZ5Y1P TN Pyruvate dehydrogenase kinase 1 (PDHK1) DMZ5Y1P MA Inhibitor DMZ5Y1P RN Comparison of Antitumor Effects of Combined and Separate Treatment with NO Synthase Inhibitor T1023 and PDK1 Inhibitor Dichloroacetate. Bull Exp Biol Med. 2019 Nov;168(1):92-94. DMZ5Y1P RU https://pubmed.ncbi.nlm.nih.gov/31768777 DMXIRA0 DI DMXIRA0 DMXIRA0 DN RLX030 DMXIRA0 TI TTMAHD1 DMXIRA0 TN Relaxin receptor 1 (RXFP1) DMXIRA0 MA Modulator DMXIRA0 RN Design of the RELAXin in acute heart failure study. Am Heart J. 2012 Feb;163(2):149-55.e1. DMXIRA0 RU https://pubmed.ncbi.nlm.nih.gov/22305830 DMOML9Q DI DMOML9Q DMOML9Q DN Pancrecarb DMOML9Q TI TTCGSZ4 DMOML9Q TN Pancreatic alpha-amylase (AMY2A) DMOML9Q MA Modulator DMOML9Q RN Clinical pipeline report, company report or official report of Digestive Care. DMOML9Q RU http://www.digestivecare.com/release102708.shtm DMOML9Q DI DMOML9Q DMOML9Q DN Pancrecarb DMOML9Q TI TT7MRGU DMOML9Q TN Chymotrypsin (CTR) DMOML9Q MA Modulator DMOML9Q RN US patent application no. 2012,0251,516, PHARMACEUTICAL COMPOSITION FOR TREATING CANCER COMPRISING TRYPSINOGEN AND/OR CHYMOTRYPSINOGEN AND AN ACTIVE AGENT SELECTED FROM A SELENIUM COMPOUND, A VANILLOID COMPOUND AND A CYTOPLASMIC GLYCOLYSIS REDUCTION AGENT. DMOML9Q RU http://www.patentbuddy.com/Patent/20120251516?ft=true&sr=true DMOML9Q DI DMOML9Q DMOML9Q DN Pancrecarb DMOML9Q TI TTXMY0J DMOML9Q TN Pancreatic triacylglycerol lipase (PNLIP) DMOML9Q MA Modulator DMOML9Q RN Clinical pipeline report, company report or official report of Digestive Care. DMOML9Q RU http://www.digestivecare.com/release102708.shtm DM26I8H DI DM26I8H DM26I8H DN TK-DLI DM26I8H TI TTP3QRF DM26I8H TN Thymidine kinase 1 (TK1) DM26I8H MA Modulator DM26I8H RN Company report (Takara Bio) DM26I8H RU http://www.takara-bio.com/news_e/2008/10/07.htm DMBRFUQ DI DMBRFUQ DMBRFUQ DN B-cell lymphoma vaccine DMBRFUQ TI TT6MP2Z DMBRFUQ TN GMCSFR-alpha (CSF2RA) DMBRFUQ RN Idiotypevaccinetherapy (BiovaxID) infollicularlymphomain first complete remission: Phase III clinical trial results, Journal of Clinical Oncology, Vol 27, No 18S (June 20 Supplement), 2009: 2. DMBRFUQ RU http://meeting.ascopubs.org/cgi/content/abstract/27/18S/2?maxtoshow=&HITS=10&hits=10&RESULTFORMAT=&fulltext=Idiotype+vaccine+therapy+(BiovaxID)+in+follicular+lymphoma+&searchid=1&FIRSTINDEX=0&volume=27&issue=18S&resourcetype=HWCIT DMF2O4T DI DMF2O4T DMF2O4T DN (S)-FLURBIPROFEN DMF2O4T TI TT9W8GU DMF2O4T TN Gamma-secretase (GS) DMF2O4T MA Inhibitor DMF2O4T RN The geminal dimethyl analogue of Flurbiprofen as a novel Abeta42 inhibitor and potential Alzheimer's disease modifying agent. Bioorg Med Chem Lett. 2006 Apr 15;16(8):2219-23. DMF2O4T RU https://pubmed.ncbi.nlm.nih.gov/16455248 DMF2O4T DI DMF2O4T DMF2O4T DN (S)-FLURBIPROFEN DMF2O4T TI TT8JRS7 DMF2O4T TN Beta-secretase (BACE) DMF2O4T MA Inhibitor DMF2O4T RN The geminal dimethyl analogue of Flurbiprofen as a novel Abeta42 inhibitor and potential Alzheimer's disease modifying agent. Bioorg Med Chem Lett. 2006 Apr 15;16(8):2219-23. DMF2O4T RU https://pubmed.ncbi.nlm.nih.gov/16455248 DMF2O4T DI DMF2O4T DMF2O4T DN (S)-FLURBIPROFEN DMF2O4T TI TTWN3F4 DMF2O4T TN Presenilin 2 (PSEN2) DMF2O4T MA Inhibitor DMF2O4T RN The geminal dimethyl analogue of Flurbiprofen as a novel Abeta42 inhibitor and potential Alzheimer's disease modifying agent. Bioorg Med Chem Lett. 2006 Apr 15;16(8):2219-23. DMF2O4T RU https://pubmed.ncbi.nlm.nih.gov/16455248 DMF2O4T DI DMF2O4T DMF2O4T DN (S)-FLURBIPROFEN DMF2O4T TI TTVKILB DMF2O4T TN Prostaglandin G/H synthase 2 (COX-2) DMF2O4T MA Inhibitor DMF2O4T RN 2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors. J Med Chem. 2005 Jun 30;48(13):4312-31. DMF2O4T RU https://pubmed.ncbi.nlm.nih.gov/15974585 DMF2O4T DI DMF2O4T DMF2O4T DN (S)-FLURBIPROFEN DMF2O4T TI TT8NGED DMF2O4T TN Prostaglandin G/H synthase 1 (COX-1) DMF2O4T MA Inhibitor DMF2O4T RN 2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors. J Med Chem. 2005 Jun 30;48(13):4312-31. DMF2O4T RU https://pubmed.ncbi.nlm.nih.gov/15974585 DMF2O4T DI DMF2O4T DMF2O4T DN (S)-FLURBIPROFEN DMF2O4T TI TTZ3S8C DMF2O4T TN Presenilin 1 (PSEN1) DMF2O4T MA Inhibitor DMF2O4T RN The geminal dimethyl analogue of Flurbiprofen as a novel Abeta42 inhibitor and potential Alzheimer's disease modifying agent. Bioorg Med Chem Lett. 2006 Apr 15;16(8):2219-23. DMF2O4T RU https://pubmed.ncbi.nlm.nih.gov/16455248 DMLRKJX DI DMLRKJX DMLRKJX DN Neugranin DMLRKJX TI TT5TQ2W DMLRKJX TN Granulocyte colony-stimulating factor (CSF3) DMLRKJX MA Modulator DMLRKJX RN Development and Characterization of a Novel Fusion Protein of a Mutated Granulocyte Colony-Stimulating Factor and Human Serum Albumin in Pichia pastoris. PLoS One. 2014; 9(12): e115840. DMLRKJX RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4275271/ DMP5O1U DI DMP5O1U DMP5O1U DN GSK2696273 DMP5O1U TI TTLP57V DMP5O1U TN Adenosine deaminase (ADA) DMP5O1U MA Modulator DMP5O1U RN Clinical pipeline report, company report or official report of GlaxoSmithKline. DMP5O1U RU https://www.gsk.com/en-gb/media/press-releases/2015/gsk-fondazione-telethon-and-ospedale-san-raffaele-announce-eu-regulatory-submission-for-gene-therapy-to-treat-rare-disease-ada-scid/ DMUY09W DI DMUY09W DMUY09W DN SK-NBP601 DMUY09W TI TT1290U DMUY09W TN Coagulation factor VIII (F8) DMUY09W MA Inhibitor DMUY09W RN Clinical pipeline report, company report or official report of SK Chemicals. DMUY09W RU http://www.skchemicals.com/en/about/rd_result.asp DMXSDJU DI DMXSDJU DMXSDJU DN MPL-containing Pollinex allergy desensitization vaccine DMXSDJU TI TTISGCA DMXSDJU TN Toll-like receptor 4 (TLR4) DMXSDJU RN Allergy Therapeutics PLC. News Announcement. Allergy Therapeutics. Clinical Trials. Allergy Therapeutics PLC. 11 October 2006. DMXSDJU RU http://miranda.hemscott.com/ir/agy/ir.jsp?page=news_regulatory&article=36483600159086 DMYA6TR DI DMYA6TR DMYA6TR DN Human coagulation factor X DMYA6TR TI TTCIHJA DMYA6TR TN Coagulation factor Xa (F10) DMYA6TR MA Modulator DMYA6TR RN Semuloparin for the prevention of venous thromboembolic events in cancer patients. Drugs Today (Barc). 2012 Jul;48(7):451-7. DMYA6TR RU https://pubmed.ncbi.nlm.nih.gov/22844656 DM02BVQ DI DM02BVQ DM02BVQ DN ARQ-087 DM02BVQ TI TTRLW2X DM02BVQ TN Fibroblast growth factor receptor 1 (FGFR1) DM02BVQ MA Inhibitor DM02BVQ RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1808). DM02BVQ RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1808 DM02BVQ DI DM02BVQ DM02BVQ DN ARQ-087 DM02BVQ TI TT0LF7H DM02BVQ TN Fibroblast growth factor receptor (FGFR) DM02BVQ MA Antagonist DM02BVQ RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM02BVQ RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM06KRC DI DM06KRC DM06KRC DN Oregovomab DM06KRC TI TTC1PS3 DM06KRC TN Ovarian carcinoma antigen CA125 (MUC16) DM06KRC RN MUC16 (CA125): tumor biomarker to cancer therapy, a work in progress. Mol Cancer. 2014; 13: 129. DM06KRC RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4046138/ DM0762O DI DM0762O DM0762O DN Fenfluramine DM0762O TI TT85JO3 DM0762O TN 5-HT receptor (5HTR) DM0762O MA Antagonist DM0762O RN Pharmacotherapy for obesity. Drugs. 2005;65(10):1391-418. DM0762O RU https://pubmed.ncbi.nlm.nih.gov/15977970 DM07653 DI DM07653 DM07653 DN SULTHIAME DM07653 TI TTANPDJ DM07653 TN Carbonic anhydrase II (CA-II) DM07653 MA Inhibitor DM07653 RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DM07653 RU https://pubmed.ncbi.nlm.nih.gov/10592235 DM08XIN DI DM08XIN DM08XIN DN EPIANDROSTERONE DM08XIN TI TTKN8W0 DM08XIN TN Glucose-6-phosphate dehydrogenase (G6PD) DM08XIN MA Inhibitor DM08XIN RN Inhibition of Trypanosoma brucei glucose-6-phosphate dehydrogenase by human steroids and their effects on the viability of cultured parasites. Bioorg Med Chem. 2009 Mar 15;17(6):2483-9. DM08XIN RU https://pubmed.ncbi.nlm.nih.gov/19231202 DM097UP DI DM097UP DM097UP DN CBT-1 DM097UP TI TT3OT40 DM097UP TN Multidrug resistance protein 1 (ABCB1) DM097UP MA Modulator DM097UP RN A pharmacodynamic study of the P-glycoprotein antagonist CBT-1 in combination with paclitaxel in solid tumors. Oncologist.2012;17(4):512. DM097UP RU https://www.ncbi.nlm.nih.gov/pubmed/22416063 DM09M3H DI DM09M3H DM09M3H DN BAY 94-9027 DM09M3H TI TT1290U DM09M3H TN Coagulation factor VIII (F8) DM09M3H MA Modulator DM09M3H RN Phase I study of BAY 94-9027, a PEGylated B-domain-deleted recombinant factor VIII with an extended half-life, in subjects with hemophilia A. J Thromb Haemost. 2014 Apr;12(4):488-96. DM09M3H RU https://pubmed.ncbi.nlm.nih.gov/24843882 DM09RKB DI DM09RKB DM09RKB DN LC-150444 DM09RKB TI TTDIGC1 DM09RKB TN Dipeptidyl peptidase 4 (DPP-4) DM09RKB MA Inhibitor DM09RKB RN Clinical pipeline report, company report or official report of ShangHai APIs Chemical. DM09RKB RU http://www.apischemical.com/APIsproducts4/850649-62-6,Alogliptin(SYR-322).htm DM09TVB DI DM09TVB DM09TVB DN Zimura DM09TVB TI TTKANGO DM09TVB TN Complement C5 (CO5) DM09TVB MA Inhibitor DM09TVB RN C5 Inhibitor Avacincaptad Pegol for Geographic Atrophy Due to Age-Related Macular Degeneration: A Randomized Pivotal Phase 2/3 Trial. Ophthalmology. 2021 Apr;128(4):576-586. DM09TVB RU https://pubmed.ncbi.nlm.nih.gov/32882310 DM0AEDT DI DM0AEDT DM0AEDT DN BIIB067 DM0AEDT TI TT6RVLG DM0AEDT TN Superoxide dismutase Cu-Zn (SOD Cu-Zn) DM0AEDT MA Inhibitor DM0AEDT RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM0AEDT RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DM0DIEZ DI DM0DIEZ DM0DIEZ DN UNI-rhIL-11 DM0DIEZ TI TTZPLJS DM0DIEZ TN Interleukin 11 receptor alpha (IL11RA) DM0DIEZ MA Modulator DM0DIEZ RN Clinical study of rhIL-11 for prevention and treatment of chemotherapy-induced thrombocytopenia. Ai Zheng. 2002 Aug;21(8):892-5. DM0DIEZ RU https://pubmed.ncbi.nlm.nih.gov/12478901 DM0EQ9X DI DM0EQ9X DM0EQ9X DN Av 133 DM0EQ9X TI TTNZRI3 DM0EQ9X TN Synaptic vesicle amine transporter (SLC18A2) DM0EQ9X MA Enhancer DM0EQ9X RN Brain imaging of vesicular monoamine transporter type 2 in healthy aging subjects by 18F-FP-(+)-DTBZ PET. PLoS One. 2013 Sep 30;8(9):e75952. DM0EQ9X RU https://pubmed.ncbi.nlm.nih.gov/24098749 DM0GUV2 DI DM0GUV2 DM0GUV2 DN DE-766 DM0GUV2 TI TTGKNB4 DM0GUV2 TN Epidermal growth factor receptor (EGFR) DM0GUV2 MA Modulator DM0GUV2 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1797). DM0GUV2 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1797 DM0HIU5 DI DM0HIU5 DM0HIU5 DN Solanezumab DM0HIU5 TI TTE4KHA DM0HIU5 TN Amyloid beta A4 protein (APP) DM0HIU5 MA Modulator DM0HIU5 RN Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. N Engl J Med. 2014 Jan 23;370(4):311-21. DM0HIU5 RU https://pubmed.ncbi.nlm.nih.gov/24450890 DM0JA9N DI DM0JA9N DM0JA9N DN Cyrtominetin DM0JA9N TI TT5FLYB DM0JA9N TN Staphylococcus Alpha-hemolysin (Stap-coc hly) DM0JA9N MA Modulator DM0JA9N RN Molecular insight into the inhibition mechanism of cyrtominetin to alpha-hemolysin by molecular dynamics simulation. Eur J Med Chem. 2013 Apr;62:320-8. DM0JA9N RU https://pubmed.ncbi.nlm.nih.gov/23376250 DM0LQ94 DI DM0LQ94 DM0LQ94 DN GnRH DM0LQ94 TI TT8R70G DM0LQ94 TN Gonadotropin-releasing hormone receptor (GNRHR) DM0LQ94 MA Modulator DM0LQ94 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 256). DM0LQ94 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=256 DM0MI81 DI DM0MI81 DM0MI81 DN Bevacizumab + Erlotinib DM0MI81 TI TTGKNB4 DM0MI81 TN Epidermal growth factor receptor (EGFR) DM0MI81 MA Inhibitor DM0MI81 RN Clinical pipeline report, company report or official report of Roche (2009). DM0MI81 RU http://www.roche.com/research_and_development/pipeline/roche_pharma_pipeline.htm DM0MI81 DI DM0MI81 DM0MI81 DN Bevacizumab + Erlotinib DM0MI81 TI TTOHSBA DM0MI81 TN Vascular endothelial growth factor A (VEGFA) DM0MI81 MA Inhibitor DM0MI81 RN Clinical pipeline report, company report or official report of Roche (2009). DM0MI81 RU http://www.roche.com/research_and_development/pipeline/roche_pharma_pipeline.htm DM0Q6CM DI DM0Q6CM DM0Q6CM DN CIGB-300 DM0Q6CM TI TTZ5NI7 DM0Q6CM TN Casein kinase II (CSNK2) DM0Q6CM MA Modulator DM0Q6CM RN Synergistic interactions of the anti-casein kinase 2 CIGB-300 peptide and chemotherapeutic agents in lung and cervical preclinical cancer models. Mol Clin Oncol. 2014 Nov;2(6):935-944. DM0Q6CM RU https://pubmed.ncbi.nlm.nih.gov/25279177 DM0QNF4 DI DM0QNF4 DM0QNF4 DN TRx0237 DM0QNF4 TI TTS87KH DM0QNF4 TN Microtubule-associated protein tau (MAPT) DM0QNF4 MA Inhibitor DM0QNF4 RN Mechanisms of Anticholinesterase Interference with Tau Aggregation Inhibitor Activity in a Tau-Transgenic Mouse Model. Curr Alzheimer Res. 2020;17(3):285-296. DM0QNF4 RU https://pubmed.ncbi.nlm.nih.gov/32091331 DM0QV27 DI DM0QV27 DM0QV27 DN NN5401 DM0QV27 TI TTCBFJO DM0QV27 TN Insulin receptor (INSR) DM0QV27 MA Modulator DM0QV27 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1800). DM0QV27 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1800 DM0TWCY DI DM0TWCY DM0TWCY DN PF-04950615 DM0TWCY TI TTBRG7E DM0TWCY TN Proprotein convertase subtilisin/kexin type 9 (PCSK9) DM0TWCY RN Phase 3 data for PCSK9 inhibitor wows. Nat Biotechnol. 2013 Dec;31(12):1057-8. DM0TWCY RU https://pubmed.ncbi.nlm.nih.gov/24316621 DM0ZOGX DI DM0ZOGX DM0ZOGX DN Linopirdine DM0ZOGX TI TTIVDM3 DM0ZOGX TN Voltage-gated potassium channel Kv7.3 (KCNQ3) DM0ZOGX MA Modulator DM0ZOGX RN The M-channel blocker linopirdine is an agonist of the capsaicin receptor TRPV1. J Pharmacol Sci. 2010;114(3):332-40. DM0ZOGX RU https://pubmed.ncbi.nlm.nih.gov/21099148 DM103O8 DI DM103O8 DM103O8 DN Ligelizumab DM103O8 TI TTYJQTF DM103O8 TN Immunoglobulin E (IgE) DM103O8 MA Inhibitor DM103O8 RN Clinical pipeline report, company report or official report of Novartis. DM103O8 RU https://www.novartis.com/our-science/novartis-global-pipeline?search_api_views_fulltext=Ligelizumab&field_pipeline_filing_date=All DM13V0P DI DM13V0P DM13V0P DN Rivoceranib DM13V0P TI TTUTJGQ DM13V0P TN Vascular endothelial growth factor receptor 2 (KDR) DM13V0P MA Antagonist DM13V0P RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM13V0P RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM15ZIB DI DM15ZIB DM15ZIB DN Mosunetuzumab DM15ZIB TI TTUN7MC DM15ZIB TN T-cell surface glycoprotein CD3 (CD3) DM15ZIB MA Inhibitor DM15ZIB RN Mitigating the risk of cytokine release syndrome in a Phase I trial of CD20/CD3 bispecific antibody mosunetuzumab in NHL: impact of translational system modeling. NPJ Syst Biol Appl. 2020 Aug 28;6(1):28. DM15ZIB RU https://pubmed.ncbi.nlm.nih.gov/32859946 DM15ZIB DI DM15ZIB DM15ZIB DN Mosunetuzumab DM15ZIB TI TTUE541 DM15ZIB TN Leukocyte surface antigen Leu-16 (CD20) DM15ZIB MA Inhibitor DM15ZIB RN Mitigating the risk of cytokine release syndrome in a Phase I trial of CD20/CD3 bispecific antibody mosunetuzumab in NHL: impact of translational system modeling. NPJ Syst Biol Appl. 2020 Aug 28;6(1):28. DM15ZIB RU https://pubmed.ncbi.nlm.nih.gov/32859946 DM180DM DI DM180DM DM180DM DN ARGX-113 DM180DM TI TTKLPHO DM180DM TN Neonatal Fc receptor (FCGRT) DM180DM MA Antagonist DM180DM RN Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis. Neurology. 2019 Jun 4;92(23):e2661-e2673. DM180DM RU https://pubmed.ncbi.nlm.nih.gov/31118245 DM1874J DI DM1874J DM1874J DN TRC105 DM1874J TI TTB30LE DM1874J TN Endoglin CD105 (ENG) DM1874J MA Modulator DM1874J RN An open-label phase Ib dose-escalation study of TRC105 (anti-endoglin antibody) with bevacizumab in patients with advanced cancer. Clin Cancer Res. 2014 Dec 1;20(23):5918-26. DM1874J RU https://pubmed.ncbi.nlm.nih.gov/25261556 DM18B72 DI DM18B72 DM18B72 DN Rosiglitazone + simvastatin DM18B72 TI TTZMAO3 DM18B72 TN Peroxisome proliferator-activated receptor gamma (PPAR-gamma) DM18B72 MA Agonist DM18B72 RN Clinical pipeline report, company report or official report of GlaxoSmithKline (2009). DM18B72 RU http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf DM1975O DI DM1975O DM1975O DN Cilnidipine DM1975O TI TTXHYV6 DM1975O TN Voltage-gated L-type calcium channel (L-CaC) DM1975O MA Blocker DM1975O RN N- and L-type calcium channel antagonist improves glomerular dynamics, reverses severe nephrosclerosis, and inhibits apoptosis and proliferation in an l-NAME/SHR model. J Hypertens. 2002 May;20(5):993-1000. DM1975O RU https://pubmed.ncbi.nlm.nih.gov/12011661 DM1975O DI DM1975O DM1975O DN Cilnidipine DM1975O TI TT4FDG6 DM1975O TN Voltage-gated calcium channel alpha Cav2.2 (CACNA1B) DM1975O MA Blocker DM1975O RN N- and L-type calcium channel antagonist improves glomerular dynamics, reverses severe nephrosclerosis, and inhibits apoptosis and proliferation in an l-NAME/SHR model. J Hypertens. 2002 May;20(5):993-1000. DM1975O RU https://pubmed.ncbi.nlm.nih.gov/12011661 DM19CFZ DI DM19CFZ DM19CFZ DN DIMS-0150 DM19CFZ TI TTKLNRV DM19CFZ TN NFKB messenger RNA (NFKB mRNA) DM19CFZ RN News and Analysis. Nature Reviews Drug Discovery 12, 179 (March 2013). DM19CFZ RU http://www.nature.com/nrd/journal/v12/n3/full/nrd3963.html DM1ARHT DI DM1ARHT DM1ARHT DN BYM338 DM1ARHT TI TTX2DRI DM1ARHT TN Activin receptor type IIA (ACVR2A) DM1ARHT MA Inhibitor DM1ARHT RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM1ARHT RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DM1BXMY DI DM1BXMY DM1BXMY DN LY2605541 DM1BXMY TI TTZOPHG DM1BXMY TN Insulin (INS) DM1BXMY MA Modulator DM1BXMY RN LY2605541--a preferential hepato-specific insulin analogue. Diabetes. 2014 Feb;63(2):390-2. DM1BXMY RU https://pubmed.ncbi.nlm.nih.gov/24464715 DM1C95G DI DM1C95G DM1C95G DN DARE-BV1 DM1C95G TI TTUWYEA DM1C95G TN Bacterial 50S ribosomal RNA (Bact 50S rRNA) DM1C95G RN Characterization of Escherichia coli 50S ribosomal protein L31. FEMS Microbiol Lett. 1999 Nov 15;180(2):345-9. DM1C95G RU https://pubmed.ncbi.nlm.nih.gov/10556732 DM1EO3G DI DM1EO3G DM1EO3G DN Odanacatib DM1EO3G TI TTDZN01 DM1EO3G TN Cathepsin K (CTSK) DM1EO3G MA Inhibitor DM1EO3G RN A novel c-Met inhibitor, MK8033, synergizes with carboplatin plus paclitaxel to inhibit ovarian cancer cell growth. Oncol Rep. 2013 May;29(5):2011-8. DM1EO3G RU https://pubmed.ncbi.nlm.nih.gov/23467907 DM1IZ5D DI DM1IZ5D DM1IZ5D DN Talabostat DM1IZ5D TI TTGPQ0F DM1IZ5D TN Prolyl endopeptidase FAP (FAP) DM1IZ5D MA Inhibitor DM1IZ5D RN Phase II trial of single agent Val-boroPro (Talabostat) inhibiting Fibroblast Activation Protein in patients with metastatic colorectal cancer. Cancer Biol Ther. 2007 Nov;6(11):1691-9. DM1IZ5D RU https://pubmed.ncbi.nlm.nih.gov/18032930 DM1IZ5D DI DM1IZ5D DM1IZ5D DN Talabostat DM1IZ5D TI TTJGLZF DM1IZ5D TN Dipeptidyl peptidase 8 (DPP-8) DM1IZ5D MA Inhibitor DM1IZ5D RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM1IZ5D RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM1IZ5D DI DM1IZ5D DM1IZ5D DN Talabostat DM1IZ5D TI TTNDUL7 DM1IZ5D TN Dipeptidyl peptidase 9 (DPP-9) DM1IZ5D MA Inhibitor DM1IZ5D RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM1IZ5D RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM1JCW8 DI DM1JCW8 DM1JCW8 DN Xaliproden DM1JCW8 TI TTSQIFT DM1JCW8 TN 5-HT 1A receptor (HTR1A) DM1JCW8 MA Antagonist DM1JCW8 RN Pharma & Vaccines. Product Development Pipeline. April 29 2009. DM1JCW8 RU http://en.sanofi-aventis.com/binaries/RD_Phase_III_EN_tcm28-24007.pdf DM1K78U DI DM1K78U DM1K78U DN Apricitabine DM1K78U TI TT84ETX DM1K78U TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DM1K78U MA Modulator DM1K78U RN Multiple-dose pharmacokinetics of apricitabine, a novel nucleoside reverse transcriptase inhibitor, in patients with HIV-1 infection. Clin Drug Investig. 2008;28(2):129-38. DM1K78U RU https://www.ncbi.nlm.nih.gov/pubmed/18211121 DM1NQDW DI DM1NQDW DM1NQDW DN SGI110 DM1NQDW TI TT6S2FE DM1NQDW TN DNA [cytosine-5]-methyltransferase 1 (DNMT1) DM1NQDW MA Modulator DM1NQDW RN Immunomodulatory action of the DNA methyltransferase inhibitor SGI-110 in epithelial ovarian cancer cells and xenografts. Epigenetics. 2015;10(3):237-46. DM1NQDW RU https://pubmed.ncbi.nlm.nih.gov/25793777 DM1NTVQ DI DM1NTVQ DM1NTVQ DN Tadekinig alfa DM1NTVQ TI TTRICUF DM1NTVQ TN Interleukin-18 (IL18) DM1NTVQ MA Inhibitor DM1NTVQ RN Clinical pipeline report, company report or official report of AB2 Bio. DM1NTVQ RU http://www.ab2bio.com/en/products.36.html DM1ODMR DI DM1ODMR DM1ODMR DN SR46349B DM1ODMR TI TTJQOD7 DM1ODMR TN 5-HT 2A receptor (HTR2A) DM1ODMR MA Modulator DM1ODMR RN SR46349-B, a 5-HT(2A/2C) receptor antagonist, potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens. Neuropsychopharmacology. 2002 Sep;27(3):430-41. DM1ODMR RU https://www.ncbi.nlm.nih.gov/pubmed/12225700 DM1ODMR DI DM1ODMR DM1ODMR DN SR46349B DM1ODMR TI TTWJBZ5 DM1ODMR TN 5-HT 2C receptor (HTR2C) DM1ODMR MA Modulator DM1ODMR RN SR46349-B, a 5-HT(2A/2C) receptor antagonist, potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens. Neuropsychopharmacology. 2002 Sep;27(3):430-41. DM1ODMR RU https://www.ncbi.nlm.nih.gov/pubmed/12225700 DM1PI9G DI DM1PI9G DM1PI9G DN NN8717 DM1PI9G TI TTAXGIP DM1PI9G TN Coagulation factor XIII (F13B) DM1PI9G MA Modulator DM1PI9G RN Topical recombinant thrombin at a concentration of 1000 IU/mL reliably shortens in vivo TTH and delivers durable hemostasis in the presence of heparin anticoagulation and clopidogrel platelet inhibition in a rabbit model of vascular bleeding. Ann Surg Innov Res. 2009; 3: 14. DM1PI9G RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2786906/ DM1PRT6 DI DM1PRT6 DM1PRT6 DN M710 DM1PRT6 TI TT9HKJA DM1PRT6 TN Vascular endothelial growth factor (VEGF) DM1PRT6 MA Inhibitor DM1PRT6 RN ClinicalTrials.gov (NCT03610646) Comparative Study to Evaluate the Efficacy and Safety of MYL-1701P and Eylea in Subjects With Diabetic Macular Edema. U.S. National Institutes of Health. DM1PRT6 RU https://clinicaltrials.gov/ct2/show/NCT03610646 DM1RMF5 DI DM1RMF5 DM1RMF5 DN Acadesine DM1RMF5 TI TTLAFZV DM1RMF5 TN AMP-activated protein kinase (AMPK) DM1RMF5 MA Modulator DM1RMF5 RN Acadesine, an adenosine-regulating agent with the potential for widespread indications. Expert Opin Pharmacother. 2008 Aug;9(12):2137-44. DM1RMF5 RU https://pubmed.ncbi.nlm.nih.gov/18671468 DM1RWMY DI DM1RWMY DM1RWMY DN Plasma derived factor VIII PEGylated liposomal DM1RWMY TI TT1290U DM1RWMY TN Coagulation factor VIII (F8) DM1RWMY MA Modulator DM1RWMY RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2607). DM1RWMY RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2607 DM1SMAI DI DM1SMAI DM1SMAI DN Eperisone DM1SMAI TI TTCRJKY DM1SMAI TN Voltage-gated calcium channel (Cav) DM1SMAI MA Modulator DM1SMAI RN Suppression of calcium current in a snail neurone by eperisone and its analogues. Eur J Pharmacol. 1989 Sep 22;168(3):299-305. DM1SMAI RU https://pubmed.ncbi.nlm.nih.gov/2555204 DM1T6ZN DI DM1T6ZN DM1T6ZN DN Pacritinib DM1T6ZN TI TTGJCWZ DM1T6ZN TN Fms-like tyrosine kinase 3 (FLT-3) DM1T6ZN MA Modulator DM1T6ZN RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1807). DM1T6ZN RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1807 DM1T6ZN DI DM1T6ZN DM1T6ZN DN Pacritinib DM1T6ZN TI TTRMX3V DM1T6ZN TN Janus kinase 2 (JAK-2) DM1T6ZN MA Modulator DM1T6ZN RN National Cancer Institute Drug Dictionary (drug id 609888). DM1T6ZN RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=609888 DM1TJXA DI DM1TJXA DM1TJXA DN Chloride DM1TJXA TI TTTSOUD DM1TJXA TN Candida Cytochrome P450 51 (Candi ERG11) DM1TJXA MA Modulator DM1TJXA RN Isavuconazonium: first global approval. Drugs. 2015 May;75(7):817-22. DM1TJXA RU https://pubmed.ncbi.nlm.nih.gov/25902926 DM1WEHC DI DM1WEHC DM1WEHC DN Buparlisib DM1WEHC TI TTGBPJE DM1WEHC TN PI3-kinase delta (PIK3CD) DM1WEHC MA Inhibitor DM1WEHC RN Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov. 2009 Aug;8(8):627-44. DM1WEHC RU https://pubmed.ncbi.nlm.nih.gov/19644473 DM1WEHC DI DM1WEHC DM1WEHC DN Buparlisib DM1WEHC TI TTHBTOP DM1WEHC TN PI3-kinase gamma (PIK3CG) DM1WEHC MA Inhibitor DM1WEHC RN Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov. 2009 Aug;8(8):627-44. DM1WEHC RU https://pubmed.ncbi.nlm.nih.gov/19644473 DM1WEHC DI DM1WEHC DM1WEHC DN Buparlisib DM1WEHC TI TTTHBCA DM1WEHC TN PI3-kinase beta (PIK3CB) DM1WEHC MA Inhibitor DM1WEHC RN Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov. 2009 Aug;8(8):627-44. DM1WEHC RU https://pubmed.ncbi.nlm.nih.gov/19644473 DM1WEHC DI DM1WEHC DM1WEHC DN Buparlisib DM1WEHC TI TTEUNMR DM1WEHC TN PI3-kinase alpha (PIK3CA) DM1WEHC MA Inhibitor DM1WEHC RN Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov. 2009 Aug;8(8):627-44. DM1WEHC RU https://pubmed.ncbi.nlm.nih.gov/19644473 DM1WMOK DI DM1WMOK DM1WMOK DN Generx DM1WMOK TI TTCEKVZ DM1WMOK TN Fibroblast growth factor-4 (FGF4) DM1WMOK MA Replacement DM1WMOK RN Effects of Ad5FGF-4 in patients with angina: an analysis of pooled data from the AGENT-3 and AGENT-4 trials. J Am Coll Cardiol. 2007 Sep 11;50(11):1038-46. DM1WMOK RU https://pubmed.ncbi.nlm.nih.gov/17825712 DM1WNGJ DI DM1WNGJ DM1WNGJ DN DFP-10917 DM1WNGJ TI TTABD5E DM1WNGJ TN DNA replication (DNA repli) DM1WNGJ MA Inhibitor DM1WNGJ RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM1WNGJ RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM1YVLM DI DM1YVLM DM1YVLM DN FST-201 DM1YVLM TI TTYRL6O DM1YVLM TN Glucocorticoid receptor (NR3C1) DM1YVLM MA Agonist DM1YVLM RN A combination povidone-iodine 0.4%/dexamethasone 0.1% ophthalmic suspension in the treatment of adenoviral conjunctivitis. Adv Ther. 2009 Aug;26(8):776-83. DM1YVLM RU https://pubmed.ncbi.nlm.nih.gov/19756415 DM20KYR DI DM20KYR DM20KYR DN Ruxolitinib DM20KYR TI TTWKB01 DM20KYR TN HUMAN janus kinase 1 (JAK-1) DM20KYR MA Inhibitor DM20KYR RN The Use of Anti-Inflammatory Drugs in the Treatment of People With Severe Coronavirus Disease 2019 (COVID-19): The Perspectives of Clinical Immunologists From China. Clin Immunol. 2020 May;214:108393. DM20KYR RU https://pubmed.ncbi.nlm.nih.gov/32222466 DM20KYR DI DM20KYR DM20KYR DN Ruxolitinib DM20KYR TI TT0F5HE DM20KYR TN HUMAN janus kinase 2 (JAK-2) DM20KYR MA Inhibitor DM20KYR RN The Use of Anti-Inflammatory Drugs in the Treatment of People With Severe Coronavirus Disease 2019 (COVID-19): The Perspectives of Clinical Immunologists From China. Clin Immunol. 2020 May;214:108393. DM20KYR RU https://pubmed.ncbi.nlm.nih.gov/32222466 DM23BUP DI DM23BUP DM23BUP DN PF-05280014 DM23BUP TI TT6EO5L DM23BUP TN Erbb2 tyrosine kinase receptor (HER2) DM23BUP MA Antagonist DM23BUP RN Comparative nonclinical assessments of the proposed biosimilar PF-05280014 and trastuzumab (Herceptin( )). BioDrugs. 2014 Oct;28(5):451-9. DM23BUP RU https://pubmed.ncbi.nlm.nih.gov/25001079 DM25TMP DI DM25TMP DM25TMP DN Rubraca rucaparib DM25TMP TI TTEBCY8 DM25TMP TN Poly [ADP-ribose] polymerase (PARP) DM25TMP MA Inhibitor DM25TMP RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM25TMP RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM29XGY DI DM29XGY DM29XGY DN HMPL-004 DM29XGY TI TTBD054 DM29XGY TN Inflammation pathogenesis (IP) DM29XGY MA Antagonist DM29XGY RN Clinical pipeline report, company report or official report of Hutchison Medi Pharma. DM29XGY RU http://www.hmplglobal.com/en/hmpl-004/ DM2ATZB DI DM2ATZB DM2ATZB DN Deoxynojirimycin DM2ATZB TI TTXWASR DM2ATZB TN Intestinal maltase-glucoamylase (MGAM) DM2ATZB MA Inhibitor DM2ATZB RN Nitrogen-in-the-ring pyranoses and furanoses: structural basis of inhibition of mammalian glycosidases. J Med Chem. 1994 Oct 28;37(22):3701-6. DM2ATZB RU https://pubmed.ncbi.nlm.nih.gov/7966130 DM2ATZB DI DM2ATZB DM2ATZB DN Deoxynojirimycin DM2ATZB TI TTHCF4J DM2ATZB TN Alpha-glucosidase (GLA) DM2ATZB MA Inhibitor DM2ATZB RN Nitrogen-in-the-ring pyranoses and furanoses: structural basis of inhibition of mammalian glycosidases. J Med Chem. 1994 Oct 28;37(22):3701-6. DM2ATZB RU https://pubmed.ncbi.nlm.nih.gov/7966130 DM2ATZB DI DM2ATZB DM2ATZB DN Deoxynojirimycin DM2ATZB TI TTLPC70 DM2ATZB TN Lysosomal alpha-glucosidase (GAA) DM2ATZB MA Inhibitor DM2ATZB RN In vitro inhibition of glycogen-degrading enzymes and glycosidases by six-membered sugar mimics and their evaluation in cell cultures. Bioorg Med Chem. 2008 Aug 1;16(15):7330-6. DM2ATZB RU https://pubmed.ncbi.nlm.nih.gov/18595718 DM2EJM3 DI DM2EJM3 DM2EJM3 DN AKB-6548 DM2EJM3 TI TTJQFBG DM2EJM3 TN HIF-prolyl hydroxylase (HPH) DM2EJM3 MA Modulator DM2EJM3 RN DOI: 10.1038/nrd4422 DM2EJM3 RU http://www.nature.com/nrd/journal/v13/n11/fig_tab/nrd4422_T2.html DM2F9YO DI DM2F9YO DM2F9YO DN Anakinra DM2F9YO TI TTT7FOP DM2F9YO TN HUMAN interleukin-1 receptor 1 (IL1R1) DM2F9YO MA Antagonist DM2F9YO RN FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (BLA) 125166. DM2F9YO RU http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Addlsearch_drug_name DM2FV5N DI DM2FV5N DM2FV5N DN Darunavir + cobicistat DM2FV5N TI TT1D53B DM2FV5N TN COVID-19 3C-like protease (3CLpro) DM2FV5N MA Inhibitor DM2FV5N RN Coronavirus puts drug repurposing on the fast track. Nat Biotechnol. 2020 Apr;38(4):379-381. DM2FV5N RU https://pubmed.ncbi.nlm.nih.gov/32205870 DM2GF14 DI DM2GF14 DM2GF14 DN PF-06410293 DM2GF14 TI TTF8CQI DM2GF14 TN Tumor necrosis factor (TNF) DM2GF14 RN Apoptosis and the FLIP and NF-kappa B proteins as pharmacodynamic criteria for biosimilar TNF-alpha antagonists. Biologics. 2014 Jul 31;8:211-20. DM2GF14 RU https://pubmed.ncbi.nlm.nih.gov/25114503 DM2GHCR DI DM2GHCR DM2GHCR DN Rebamipide DM2GHCR TI TT5Y4EM DM2GHCR TN N-formyl peptide receptor (FPR1) DM2GHCR MA Antagonist DM2GHCR RN Rebamipide suppresses formyl-methionyl-leucyl-phenylalanine (fMLP)-induced superoxide production by inhibiting fMLP-receptor binding in human neutrophils. J Pharmacol Exp Ther. 2001 Apr;297(1):388-94. DM2GHCR RU https://pubmed.ncbi.nlm.nih.gov/11259567 DM2H8FZ DI DM2H8FZ DM2H8FZ DN TAK-700 DM2H8FZ TI TTRA5BZ DM2H8FZ TN Steroid 17-alpha-monooxygenase (S17AH) DM2H8FZ MA Modulator DM2H8FZ RN Orteronel (TAK-700), a novel non-steroidal 17,20-lyase inhibitor: effects on steroid synthesis in human and monkey adrenal cells and serum steroid levels in cynomolgus monkeys. J Steroid Biochem Mol Biol. 2012 Apr;129(3-5):115-28. DM2H8FZ RU https://pubmed.ncbi.nlm.nih.gov/22249003 DM2J4YB DI DM2J4YB DM2J4YB DN ABP 501 DM2J4YB TI TTF8CQI DM2J4YB TN Tumor necrosis factor (TNF) DM2J4YB RN Case study: biosimilar anti TNFalpha (Adalimumab) analysis of Fc effector functions. BMC Proc. 2013; 7(Suppl 6): P30. DM2J4YB RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3980296/ DM2OBNW DI DM2OBNW DM2OBNW DN Bococizumab DM2OBNW TI TTBRG7E DM2OBNW TN Proprotein convertase subtilisin/kexin type 9 (PCSK9) DM2OBNW RN The dyslipidaemia market. Nat Rev Drug Discov. 2014 Nov;13(11):807-8. DM2OBNW RU https://pubmed.ncbi.nlm.nih.gov/25323928 DM2R15Q DI DM2R15Q DM2R15Q DN DENBUFYLLINE DM2R15Q TI TTZ97H5 DM2R15Q TN Phosphodiesterase 4A (PDE4A) DM2R15Q MA Inhibitor DM2R15Q RN Pyrazolopyrimidine-2,4-dione sulfonamides: novel and selective calcitonin inducers. J Med Chem. 2002 May 23;45(11):2342-5. DM2R15Q RU https://pubmed.ncbi.nlm.nih.gov/12014973 DM2R15Q DI DM2R15Q DM2R15Q DN DENBUFYLLINE DM2R15Q TI TTSKMI8 DM2R15Q TN Phosphodiesterase 4D (PDE4D) DM2R15Q MA Inhibitor DM2R15Q RN Pyrazolopyrimidine-2,4-dione sulfonamides: novel and selective calcitonin inducers. J Med Chem. 2002 May 23;45(11):2342-5. DM2R15Q RU https://pubmed.ncbi.nlm.nih.gov/12014973 DM2R15Q DI DM2R15Q DM2R15Q DN DENBUFYLLINE DM2R15Q TI TTVIAT9 DM2R15Q TN Phosphodiesterase 4B (PDE4B) DM2R15Q MA Inhibitor DM2R15Q RN Pyrazolopyrimidine-2,4-dione sulfonamides: novel and selective calcitonin inducers. J Med Chem. 2002 May 23;45(11):2342-5. DM2R15Q RU https://pubmed.ncbi.nlm.nih.gov/12014973 DM2RTGP DI DM2RTGP DM2RTGP DN Alpha-glucosidase DM2RTGP TI TTXWASR DM2RTGP TN Intestinal maltase-glucoamylase (MGAM) DM2RTGP MA Modulator DM2RTGP RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2627). DM2RTGP RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2627 DM2TNJ1 DI DM2TNJ1 DM2TNJ1 DN Molgramostim DM2TNJ1 TI TT6MP2Z DM2TNJ1 TN GMCSFR-alpha (CSF2RA) DM2TNJ1 MA Agonist DM2TNJ1 RN Clinical pipeline report, company report or official report of gensci-china. DM2TNJ1 RU http://www.gensci-china.com/gensci/cp1_somatropinAQ.asp?MaxID=3 DM2XSG0 DI DM2XSG0 DM2XSG0 DN GMA105 DM2XSG0 TI TTVIMDE DM2XSG0 TN Glucagon-like peptide 1 receptor (GLP1R) DM2XSG0 MA Inhibitor DM2XSG0 RN Clinical pipeline report, company report or official report of Gmax Biopharm. DM2XSG0 RU http://www.gmaxbiopharm.com/wap_product_detailen/id/3.html DM2YQK8 DI DM2YQK8 DM2YQK8 DN AR-301 DM2YQK8 TI TT5FLYB DM2YQK8 TN Staphylococcus Alpha-hemolysin (Stap-coc hly) DM2YQK8 MA Inhibitor DM2YQK8 RN Clinical pipeline report, company report or official report of Aridis Pharmaceuticals. DM2YQK8 RU https://www.aridispharma.com/ar-301/ DM3274D DI DM3274D DM3274D DN Fostamatinib disodium DM3274D TI TTOU65C DM3274D TN Tyrosine-protein kinase SYK (SYK) DM3274D MA Inhibitor DM3274D RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM3274D RU http://phrma-docs.phrma.org/sites/default/files/pdf/medicines-in-development-drug-list-rare-diseases.pdf DM34GOF DI DM34GOF DM34GOF DN REL-1017 DM34GOF TI TT9IK2Z DM34GOF TN N-methyl-D-aspartate receptor (NMDAR) DM34GOF MA Antagonist DM34GOF RN N-Methyl-D-aspartate receptor antagonist d-methadone produces rapid, mTORC1-dependent antidepressant effects. Neuropsychopharmacology. 2019 Dec;44(13):2230-2238. DM34GOF RU https://pubmed.ncbi.nlm.nih.gov/31454827 DM35GBS DI DM35GBS DM35GBS DN Favipiravir DM35GBS TI TTV1095 DM35GBS TN COVID-19 RNA-directed RNA polymerase (RdRp) DM35GBS MA Inhibitor DM35GBS RN Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial. medRxiv. Posted April 15, 2020. DM35GBS RU https://doi.org/10.1101/2020.03.17.20037432 DM35T1O DI DM35T1O DM35T1O DN Epristeride DM35T1O TI TT2A0DR DM35T1O TN Oxo-5-alpha-steroid 4-dehydrogenase (SRD5A) DM35T1O MA Inhibitor DM35T1O RN Discovery of a novel hybrid from finasteride and epristeride as 5alpha-reductase inhibitor. Bioorg Med Chem Lett. 2011 Jan 1;21(1):475-8. DM35T1O RU https://pubmed.ncbi.nlm.nih.gov/21094046 DM36C17 DI DM36C17 DM36C17 DN Blonanserin DM36C17 TI TTEX248 DM36C17 TN Dopamine D2 receptor (D2R) DM36C17 MA Antagonist DM36C17 RN The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22. DM36C17 RU https://pubmed.ncbi.nlm.nih.gov/17667958 DM36C17 DI DM36C17 DM36C17 DN Blonanserin DM36C17 TI TTJQOD7 DM36C17 TN 5-HT 2A receptor (HTR2A) DM36C17 MA Antagonist DM36C17 RN The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22. DM36C17 RU https://pubmed.ncbi.nlm.nih.gov/17667958 DM376WT DI DM376WT DM376WT DN NKTR 214 DM376WT TI TT9721Y DM376WT TN Interleukin 2 receptor beta (IL2RB) DM376WT MA Agonist DM376WT RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM376WT RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DM3A701 DI DM3A701 DM3A701 DN IDP-122 DM3A701 TI TTP3UTW DM3A701 TN Steroid hormone receptor ERR (ESRR) DM3A701 MA Agonist DM3A701 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM3A701 RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DM3BK2Y DI DM3BK2Y DM3BK2Y DN OTL-103 DM3BK2Y TI TTE8T73 DM3BK2Y TN Wiskott-Aldrich syndrome protein (WAS) DM3BK2Y MA Replacement DM3BK2Y RN Clinical pipeline report, company report or official report of Orchard Therapeutics. DM3BK2Y RU https://www.orchard-tx.com/approach/pipeline/ DM3BO8G DI DM3BO8G DM3BO8G DN SUVN-G3031 DM3BO8G TI TT9JNIC DM3BO8G TN Histamine H3 receptor (H3R) DM3BO8G MA Antagonist DM3BO8G RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM3BO8G RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DM3DG5C DI DM3DG5C DM3DG5C DN THX-TS01 DM3DG5C TI TT94IAG DM3DG5C TN Cannabinoid receptor (CB) DM3DG5C MA Modulator DM3DG5C RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM3DG5C RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DM3FIC2 DI DM3FIC2 DM3FIC2 DN ABT-761 DM3FIC2 TI TT2J34L DM3FIC2 TN Arachidonate 5-lipoxygenase (5-LOX) DM3FIC2 MA Inhibitor DM3FIC2 RN Treatment with 5-lipoxygenase inhibitor VIA-2291 (Atreleuton) in patients with recent acute coronary syndrome. Circ Cardiovasc Imaging. 2010 May;3(3):298-307. DM3FIC2 RU https://pubmed.ncbi.nlm.nih.gov/20190281 DM3FPAQ DI DM3FPAQ DM3FPAQ DN Anifrolumab DM3FPAQ TI TTMQB37 DM3FPAQ TN Interferon alpha/beta receptor 2 (IFNAR2) DM3FPAQ MA Antagonist DM3FPAQ RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM3FPAQ RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DM3G74J DI DM3G74J DM3G74J DN Tamibarotene DM3G74J TI TTISP28 DM3G74J TN Retinoic acid receptor beta (RARB) DM3G74J MA Modulator DM3G74J RN Tamibarotene: a candidate retinoid drug for Alzheimer's disease. Biol Pharm Bull. 2012;35(8):1206-12. DM3G74J RU https://pubmed.ncbi.nlm.nih.gov/22863914 DM3G74J DI DM3G74J DM3G74J DN Tamibarotene DM3G74J TI TTW38KT DM3G74J TN Retinoic acid receptor alpha (RARA) DM3G74J MA Modulator DM3G74J RN Tamibarotene: a candidate retinoid drug for Alzheimer's disease. Biol Pharm Bull. 2012;35(8):1206-12. DM3G74J RU https://pubmed.ncbi.nlm.nih.gov/22863914 DM3GTAL DI DM3GTAL DM3GTAL DN Maribavir DM3GTAL TI TTXQ04B DM3GTAL TN Cytomegalovirus Ganciclovir kinase (CMV UL97) DM3GTAL MA Inhibitor DM3GTAL RN The human cytomegalovirus UL97 protein kinase, an antiviral drug target, is required at the stage of nuclear egress. J Virol. 2003 Jan;77(2):905-14. DM3GTAL RU https://pubmed.ncbi.nlm.nih.gov/12502806 DM3H2U4 DI DM3H2U4 DM3H2U4 DN Patrome DM3H2U4 TI TTN451K DM3H2U4 TN Aromatic-L-amino-acid decarboxylase (DDC) DM3H2U4 MA Modulator DM3H2U4 RN The aromatic-L-amino acid decarboxylase inhibitor carbidopa is selectively cytotoxic to human pulmonary carcinoid and small cell lung carcinoma cells. Clin Cancer Res. 2000 Nov;6(11):4365-72. DM3H2U4 RU https://pubmed.ncbi.nlm.nih.gov/11106255 DM3IWS8 DI DM3IWS8 DM3IWS8 DN Laquinimod DM3IWS8 TI TTSXVID DM3IWS8 TN Nuclear factor NF-kappa-B (NFKB) DM3IWS8 MA Modulator DM3IWS8 RN Reduced astrocytic NF- B activation by laquinimod protects from cuprizone-induced demyelination. Acta Neuropathol. 2012 Sep;124(3):411-24. DM3IWS8 RU https://pubmed.ncbi.nlm.nih.gov/22766690 DM3L2GT DI DM3L2GT DM3L2GT DN O6-Benzylguanine alkylade DM3L2GT TI TTJ8DV7 DM3L2GT TN O-6-methylguanine-DNA-alkyltransferase (MGMT) DM3L2GT MA Modulator DM3L2GT RN Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma. J Clin Oncol. 2009 Mar 10;27(8):1262-7. DM3L2GT RU https://pubmed.ncbi.nlm.nih.gov/19204199 DM3MAYQ DI DM3MAYQ DM3MAYQ DN BMS-986205 DM3MAYQ TI TTZJYKH DM3MAYQ TN Indoleamine 2,3-dioxygenase 1 (IDO1) DM3MAYQ MA Inhibitor DM3MAYQ RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM3MAYQ RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM3MXT8 DI DM3MXT8 DM3MXT8 DN BI 201335 DM3MXT8 TI TT5FNQT DM3MXT8 TN Human immunodeficiency virus Protease (HIV PR) DM3MXT8 MA Inhibitor DM3MXT8 RN 2011 Pipeline of Boehringer Ingelheim Pharma. DM3MXT8 RU http://www.boehringer-ingelheim.com/ DM3OU54 DI DM3OU54 DM3OU54 DN ICI 118,551 DM3OU54 TI TT2CJVK DM3OU54 TN Adrenergic receptor beta-2 (ADRB2) DM3OU54 MA Antagonist DM3OU54 RN Selective beta 2-adrenoceptor antagonists: derivatives of ICI 118,551 and a binary aryloxypropanolamine. J Pharm Pharmacol. 1988 Nov;40(11):803-5. DM3OU54 RU https://pubmed.ncbi.nlm.nih.gov/2907563 DM3PA8H DI DM3PA8H DM3PA8H DN THVD-201 DM3PA8H TI TTOXS3C DM3PA8H TN Muscarinic acetylcholine receptor (CHRM) DM3PA8H MA Agonist DM3PA8H RN Future therapies: Early trials and basic science. Can Urol Assoc J. 2013 Sep-Oct; 7(9-10 Suppl 4): S179-S180. DM3PA8H RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3919188/ DM3PS2E DI DM3PS2E DM3PS2E DN Squalamine DM3PS2E TI TT9HKJA DM3PS2E TN Vascular endothelial growth factor (VEGF) DM3PS2E MA Modulator DM3PS2E RN Clinical pipeline report, company report or official report of Ohr Pharmaceutical. DM3PS2E RU http://www.ohrpharmaceutical.com/research/squalamine DM3PS2E DI DM3PS2E DM3PS2E DN Squalamine DM3PS2E TI TTGKIED DM3PS2E TN Fibroblast growth factor-2 (FGF2) DM3PS2E MA Modulator DM3PS2E RN Clinical pipeline report, company report or official report of Ohr Pharmaceutical. DM3PS2E RU http://www.ohrpharmaceutical.com/research/squalamine DM3PS2E DI DM3PS2E DM3PS2E DN Squalamine DM3PS2E TI TTSM78N DM3PS2E TN Platelet-derived growth factor A (PDGFA) DM3PS2E MA Inhibitor DM3PS2E RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM3PS2E RU http://phrma-docs.phrma.org/files/dmfile/mid-diabetes-drug-list.pdf DM3PSUF DI DM3PSUF DM3PSUF DN MK-3102 DM3PSUF TI TTDIGC1 DM3PSUF TN Dipeptidyl peptidase 4 (DPP-4) DM3PSUF MA Modulator DM3PSUF RN Omarigliptin (MK-3102): a novel long-acting DPP-4 inhibitor for once-weekly treatment of type 2 diabetes. J Med Chem. 2014 Apr 24;57(8):3205-12. DM3PSUF RU https://pubmed.ncbi.nlm.nih.gov/24660890 DM3QLK2 DI DM3QLK2 DM3QLK2 DN Atamestane + Toremifene DM3QLK2 TI TTSZLWK DM3QLK2 TN Aromatase (CYP19A1) DM3QLK2 MA Modulator DM3QLK2 RN Toremifene-atamestane; alone or in combination: predictions from the preclinical intratumoral aromatase model. J Steroid Biochem Mol Biol. 2008 Jan;108(1-2):1-7. DM3QLK2 RU https://pubmed.ncbi.nlm.nih.gov/17942301 DM3RWXL DI DM3RWXL DM3RWXL DN Resveratrol DM3RWXL TI TT8NGED DM3RWXL TN Prostaglandin G/H synthase 1 (COX-1) DM3RWXL MA Modulator DM3RWXL RN Resveratrol is a peroxidase-mediated inactivator of COX-1 but not COX-2: a mechanistic approach to the design of COX-1 selective agents. J Biol Chem. 2004 May 21;279(21):22727-37. DM3RWXL RU https://pubmed.ncbi.nlm.nih.gov/15020596 DM3RWXL DI DM3RWXL DM3RWXL DN Resveratrol DM3RWXL TI TTUF2HO DM3RWXL TN NAD-dependent deacetylase sirtuin-1 (SIRT1) DM3RWXL MA Inhibitor DM3RWXL RN Sirtuin modulators: an updated patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):5-15. DM3RWXL RU https://www.ncbi.nlm.nih.gov/pubmed/25435179 DM3UQ9K DI DM3UQ9K DM3UQ9K DN Acolbifene DM3UQ9K TI TTZAYWL DM3UQ9K TN Estrogen receptor (ESR) DM3UQ9K MA Modulator DM3UQ9K RN Bioactivation of the selective estrogen receptor modulator acolbifene to quinone methides. Chem Res Toxicol. 2005 Feb;18(2):174-82. DM3UQ9K RU https://pubmed.ncbi.nlm.nih.gov/15720121 DM3WP0N DI DM3WP0N DM3WP0N DN Al3818 DM3WP0N TI TT6PKBN DM3WP0N TN Proto-oncogene c-Src (SRC) DM3WP0N MA Inhibitor DM3WP0N RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM3WP0N RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM3YEV0 DI DM3YEV0 DM3YEV0 DN 131I-labelled aCD45 DM3YEV0 TI TTUS45N DM3YEV0 TN Leukocyte common antigen (PTPRC) DM3YEV0 RN 131I-anti-CD45 antibody plus busulfan and cyclophosphamide before allogeneic hematopoietic cell transplantation for treatment of acute myeloid leukemia in first remission. Blood. 2006 Mar 1;107(5):2184-91. DM3YEV0 RU https://pubmed.ncbi.nlm.nih.gov/16254140 DM3YXP8 DI DM3YXP8 DM3YXP8 DN Remacemide DM3YXP8 TI TT9IK2Z DM3YXP8 TN N-methyl-D-aspartate receptor (NMDAR) DM3YXP8 MA Agonist DM3YXP8 RN Glutamate- and GABA-based CNS therapeutics. Curr Opin Pharmacol. 2006 Feb;6(1):7-17. DM3YXP8 RU https://pubmed.ncbi.nlm.nih.gov/16377242 DM3ZL7D DI DM3ZL7D DM3ZL7D DN Edotecarin DM3ZL7D TI TTGTQHC DM3ZL7D TN DNA topoisomerase I (TOP1) DM3ZL7D MA Inhibitor DM3ZL7D RN Edotecarin: a novel topoisomerase I inhibitor. Clin Colorectal Cancer. 2005 May;5(1):27-36. DM3ZL7D RU https://pubmed.ncbi.nlm.nih.gov/15929804 DM407I6 DI DM407I6 DM407I6 DN BAY 853934 DM407I6 TI TTJQFBG DM407I6 TN HIF-prolyl hydroxylase (HPH) DM407I6 MA Inhibitor DM407I6 RN Discovery of Molidustat (BAY 85-3934): A Small-Molecule Oral HIF-Prolyl Hydroxylase (HIF-PH) Inhibitor for the Treatment of Renal Anemia. ChemMedChem. 2018 May 23;13(10):988-1003. DM407I6 RU https://pubmed.ncbi.nlm.nih.gov/29485740 DM408GM DI DM408GM DM408GM DN S-474474 DM408GM TI TT8DBY3 DM408GM TN Angiotensin II receptor type-1 (AGTR1) DM408GM MA Blocker DM408GM RN Clinical pipeline report, company report or official report of Shionogi (2011). DM408GM RU http://www.shionogi.co.jp/index_e.html DM42GP9 DI DM42GP9 DM42GP9 DN Bicifadine DM42GP9 TI TTAWNKZ DM42GP9 TN Norepinephrine transporter (NET) DM42GP9 MA Modulator DM42GP9 RN Preclinical Evaluation of the Abuse Potential of the Analgesic Bicifadine DM42GP9 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202431 DM42GP9 DI DM42GP9 DM42GP9 DN Bicifadine DM42GP9 TI TT3ROYC DM42GP9 TN Serotonin transporter (SERT) DM42GP9 MA Modulator DM42GP9 RN Preclinical Evaluation of the Abuse Potential of the Analgesic Bicifadine DM42GP9 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202431 DM42PFT DI DM42PFT DM42PFT DN E-3810 DM42PFT TI TTRLW2X DM42PFT TN Fibroblast growth factor receptor 1 (FGFR1) DM42PFT MA Inhibitor DM42PFT RN E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models. Cancer Res. 2011 Feb 15;71(4):1396-405. DM42PFT RU https://pubmed.ncbi.nlm.nih.gov/21212416 DM42PFT DI DM42PFT DM42PFT DN E-3810 DM42PFT TI TTGJVQM DM42PFT TN Fibroblast growth factor receptor 2 (FGFR2) DM42PFT MA Inhibitor DM42PFT RN E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models. Cancer Res. 2011 Feb 15;71(4):1396-405. DM42PFT RU https://pubmed.ncbi.nlm.nih.gov/21212416 DM42PFT DI DM42PFT DM42PFT DN E-3810 DM42PFT TI TTUTJGQ DM42PFT TN Vascular endothelial growth factor receptor 2 (KDR) DM42PFT MA Inhibitor DM42PFT RN E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models. Cancer Res. 2011 Feb 15;71(4):1396-405. DM42PFT RU https://pubmed.ncbi.nlm.nih.gov/21212416 DM42PFT DI DM42PFT DM42PFT DN E-3810 DM42PFT TI TT8FYO9 DM42PFT TN Platelet-derived growth factor receptor alpha (PDGFRA) DM42PFT MA Inhibitor DM42PFT RN E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models. Cancer Res. 2011 Feb 15;71(4):1396-405. DM42PFT RU https://pubmed.ncbi.nlm.nih.gov/21212416 DM42PFT DI DM42PFT DM42PFT DN E-3810 DM42PFT TI TTST7KB DM42PFT TN Fibroblast growth factor receptor 3 (FGFR3) DM42PFT MA Inhibitor DM42PFT RN E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models. Cancer Res. 2011 Feb 15;71(4):1396-405. DM42PFT RU https://pubmed.ncbi.nlm.nih.gov/21212416 DM42PFT DI DM42PFT DM42PFT DN E-3810 DM42PFT TI TTDCBX5 DM42PFT TN Vascular endothelial growth factor receptor 3 (FLT-4) DM42PFT MA Inhibitor DM42PFT RN E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models. Cancer Res. 2011 Feb 15;71(4):1396-405. DM42PFT RU https://pubmed.ncbi.nlm.nih.gov/21212416 DM42PFT DI DM42PFT DM42PFT DN E-3810 DM42PFT TI TTI7421 DM42PFT TN Platelet-derived growth factor receptor beta (PDGFRB) DM42PFT MA Inhibitor DM42PFT RN E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models. Cancer Res. 2011 Feb 15;71(4):1396-405. DM42PFT RU https://pubmed.ncbi.nlm.nih.gov/21212416 DM42PFT DI DM42PFT DM42PFT DN E-3810 DM42PFT TI TT2Q6G1 DM42PFT TN Vascular endothelial growth factor receptor 1 (FLT-1) DM42PFT MA Inhibitor DM42PFT RN E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models. Cancer Res. 2011 Feb 15;71(4):1396-405. DM42PFT RU https://pubmed.ncbi.nlm.nih.gov/21212416 DM45DS8 DI DM45DS8 DM45DS8 DN NKTR-181 DM45DS8 TI TTKWM86 DM45DS8 TN Opioid receptor mu (MOP) DM45DS8 MA Agonist DM45DS8 RN A Review of Abuse-Deterrent Opioids For Chronic Nonmalignant Pain. P T. 2012 July; 37(7): 412-418. DM45DS8 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3411218/ DM49IGE DI DM49IGE DM49IGE DN Remdesivir DM49IGE TI TTOA6YT DM49IGE TN MERS-CoV RNA-directed RNA polymerase (RdRp) DM49IGE MA Inhibitor DM49IGE RN Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun. 2020 Jan 10;11(1):222. DM49IGE RU https://pubmed.ncbi.nlm.nih.gov/31924756 DM49IGE DI DM49IGE DM49IGE DN Remdesivir DM49IGE TI TTKXI53 DM49IGE TN SARS-CoV RNA-directed RNA polymerase (RdRp) DM49IGE MA Inhibitor DM49IGE RN Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun. 2020 Jan 10;11(1):222. DM49IGE RU https://pubmed.ncbi.nlm.nih.gov/31924756 DM49IGE DI DM49IGE DM49IGE DN Remdesivir DM49IGE TI TTV1095 DM49IGE TN COVID-19 RNA-directed RNA polymerase (RdRp) DM49IGE MA Inhibitor DM49IGE RN Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020 Mar;30(3):269-271. DM49IGE RU https://pubmed.ncbi.nlm.nih.gov/32020029 DM4CGH5 DI DM4CGH5 DM4CGH5 DN verubecestat DM4CGH5 TI TT8JRS7 DM4CGH5 TN Beta-secretase (BACE) DM4CGH5 MA Modulator DM4CGH5 RN BACE1 inhibitor drugs in clinical trials for Alzheimer's disease. Alzheimers Res Ther. 2014 Dec 24;6(9):89. DM4CGH5 RU https://pubmed.ncbi.nlm.nih.gov/25621019 DM4CGH5 DI DM4CGH5 DM4CGH5 DN verubecestat DM4CGH5 TI TTJUNZF DM4CGH5 TN Beta-secretase 1 (BACE1) DM4CGH5 MA Inhibitor DM4CGH5 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM4CGH5 RU http://phrma-docs.phrma.org/files/dmfile/MID-Update_Alzheimers-Disease_2017-Drug-List.pdf DM4CSDH DI DM4CSDH DM4CSDH DN CS-8958 DM4CSDH TI TT50QJ3 DM4CSDH TN Influenza Neuraminidase (Influ NA) DM4CSDH MA Inhibitor DM4CSDH RN Developing new antiviral agents for influenza treatment: what does the future hold Clin Infect Dis. 2009 Jan 1;48 Suppl 1:S3-13. DM4CSDH RU https://pubmed.ncbi.nlm.nih.gov/19067613 DM4E9PK DI DM4E9PK DM4E9PK DN AM-111 DM4E9PK TI TTR2TXZ DM4E9PK TN Jun N terminal kinase (JNK) DM4E9PK MA Modulator DM4E9PK RN The JNK inhibitor XG-102 protects against TNBS-induced colitis.PLoS One.2012;7(3):e30985. DM4E9PK RU https://www.ncbi.nlm.nih.gov/pubmed/22427801 DM4EGPN DI DM4EGPN DM4EGPN DN Lanperisone DM4EGPN TI TT84DRB DM4EGPN TN Voltage-gated sodium channel alpha Nav1.4 (SCN4A) DM4EGPN MA Modulator DM4EGPN RN Tolperisone-type drugs inhibit spinal reflexes via blockade of voltage-gated sodium and calcium channels. J Pharmacol Exp Ther. 2005 Dec;315(3):1237-46. DM4EGPN RU https://pubmed.ncbi.nlm.nih.gov/16126840 DM4FHQR DI DM4FHQR DM4FHQR DN Canfosfamide DM4FHQR TI TT40K12 DM4FHQR TN Glutathione S-transferase P (GSTP1) DM4FHQR MA Modulator DM4FHQR RN Mechanism of glutathione transferase P1-1-catalyzed activation of the prodrug canfosfamide (TLK286, TELCYTA). Biochemistry. 2013 Nov 12;52(45):8069-78. DM4FHQR RU https://pubmed.ncbi.nlm.nih.gov/24066958 DM4FPM3 DI DM4FPM3 DM4FPM3 DN Amediplase DM4FPM3 TI TTGY7WI DM4FPM3 TN Urokinase-type plasminogen activator (PLAU) DM4FPM3 MA Activator DM4FPM3 RN Emerging drugs in peripheral arterial disease. Expert Opin Emerg Drugs. 2006 Mar;11(1):75-90. DM4FPM3 RU https://pubmed.ncbi.nlm.nih.gov/16503827 DM4GWL7 DI DM4GWL7 DM4GWL7 DN Gefapixant DM4GWL7 TI TT2THBD DM4GWL7 TN P2X purinoceptor 3 (P2RX3) DM4GWL7 MA Inhibitor DM4GWL7 RN Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357. DM4GWL7 RU https://pubmed.ncbi.nlm.nih.gov/30728472 DM4GXW3 DI DM4GXW3 DM4GXW3 DN Ataluren DM4GXW3 TI TT2TNRM DM4GXW3 TN Dystrophin nonsense mutant (DMD) DM4GXW3 MA Modulator DM4GXW3 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7341). DM4GXW3 RU http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7341 DM4HK8Z DI DM4HK8Z DM4HK8Z DN ASTX727 DM4HK8Z TI TTHVCUP DM4HK8Z TN DNA [cytosine-5]-methyltransferase (DNMT) DM4HK8Z MA Inhibitor DM4HK8Z RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM4HK8Z RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM4HQ52 DI DM4HQ52 DM4HQ52 DN APL-2 DM4HQ52 TI TTJGY7A DM4HQ52 TN Complement C3 (CO3) DM4HQ52 MA Inhibitor DM4HQ52 RN Anti-ageing pipeline starts to mature.Nat Rev Drug Discov. 2018 Sep;17(9):609-612. DM4HQ52 RU https://pubmed.ncbi.nlm.nih.gov/30072728 DM4HYMS DI DM4HYMS DM4HYMS DN ABT-888 DM4HYMS TI TTEBCY8 DM4HYMS TN Poly [ADP-ribose] polymerase (PARP) DM4HYMS MA Modulator DM4HYMS RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DM4HYMS RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DM4K9WH DI DM4K9WH DM4K9WH DN R1678 DM4K9WH TI TTHJTF7 DM4K9WH TN Glycine transporter GlyT-1 (SLC6A9) DM4K9WH MA Blocker DM4K9WH RN Clinical pipeline report, company report or official report of Roche (2009). DM4K9WH RU http://www.roche.com/research_and_development/pipeline/roche_pharma_pipeline.htm DM4N1SP DI DM4N1SP DM4N1SP DN Shigamabs DM4N1SP TI TT1HYOF DM4N1SP TN Bacterial Shiga toxin 2 subunit B (Bact stxII) DM4N1SP MA Modulator DM4N1SP RN Antibacterial antibodies gain traction. Nat Rev Drug Discov. 2015 Nov;14(11):737-8. DM4N1SP RU https://www.ncbi.nlm.nih.gov/pubmed/26514853 DM4NX0C DI DM4NX0C DM4NX0C DN Fevipiprant DM4NX0C TI TTQDMX5 DM4NX0C TN Prostaglandin D2 receptor 2 (PTGDR2) DM4NX0C MA Antagonist DM4NX0C RN Fevipiprant in the treatment of asthma. Expert Opin Investig Drugs. 2018 Feb;27(2):199-207. DM4NX0C RU https://pubmed.ncbi.nlm.nih.gov/29363343 DM4OAIU DI DM4OAIU DM4OAIU DN LMI070 DM4OAIU TI TT8QL6X DM4OAIU TN Survival motor neuron protein (SMN1) DM4OAIU MA Modulator DM4OAIU RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM4OAIU RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DM4OHMP DI DM4OHMP DM4OHMP DN A-3309 DM4OHMP TI TTPI1M5 DM4OHMP TN Ileal sodium/bile acid cotransporter (SLC10A2) DM4OHMP MA Inhibitor DM4OHMP RN Elobixibat for the treatment of constipation. Expert Opin Investig Drugs. 2013 Feb;22(2):277-84. DM4OHMP RU https://pubmed.ncbi.nlm.nih.gov/23215781 DM4P5UJ DI DM4P5UJ DM4P5UJ DN VM-501 DM4P5UJ TI TTGUYTR DM4P5UJ TN Interleukin-11 (IL11) DM4P5UJ MA Agonist DM4P5UJ RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800033052) DM4P5UJ RU http://adisinsight.springer.com/drugs/800033052 DM4SKYI DI DM4SKYI DM4SKYI DN PAMAQUESIDE DM4SKYI TI TT61VTP DM4SKYI TN Cholesterol uptake (Chole uptake) DM4SKYI MA Modulator DM4SKYI RN Comparison of synthetic saponin cholesterol absorption inhibitors in rabbits: evidence for a non-stoichiometric, intestinal mechanism of action. J Lipid Res. 1999 Mar;40(3):464-74. DM4SKYI RU https://pubmed.ncbi.nlm.nih.gov/10064735 DM4TOEQ DI DM4TOEQ DM4TOEQ DN Spartalizumab DM4TOEQ TI TTNBFWK DM4TOEQ TN Programmed cell death protein 1 (PD-1) DM4TOEQ RN Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730. DM4TOEQ RU https://pubmed.ncbi.nlm.nih.gov/30247903 DM4U5NF DI DM4U5NF DM4U5NF DN ISIS-TTR DM4U5NF TI TTPOYU7 DM4U5NF TN Transthyretin messenger RNA (TTR mRNA) DM4U5NF RN Clinical pipeline report, company report or official report of ISIS Pharmaceuticals (2011). DM4U5NF RU http://www.isispharm.com/index.htm DM4VJ5Q DI DM4VJ5Q DM4VJ5Q DN ATG-Fresenius S DM4VJ5Q TI TTXQYT6 DM4VJ5Q TN T-cells (T-cells) DM4VJ5Q RN Clinical pipeline report, company report or official report of Neovii Biotech. DM4VJ5Q RU http://www.neoviibiotech.com/products-and-pipeline/atg-fresenius.html DM4W8RE DI DM4W8RE DM4W8RE DN Melagatran DM4W8RE TI TT6L509 DM4W8RE TN Coagulation factor IIa (F2) DM4W8RE MA Inhibitor DM4W8RE RN Orally active thrombin inhibitors. Part 2: optimization of the P2-moiety. Bioorg Med Chem Lett. 2006 May 15;16(10):2648-53. DM4W8RE RU https://pubmed.ncbi.nlm.nih.gov/16460939 DM4W8RE DI DM4W8RE DM4W8RE DN Melagatran DM4W8RE TI TTP86E2 DM4W8RE TN Plasminogen (PLG) DM4W8RE MA Inhibitor DM4W8RE RN Orally active thrombin inhibitors. Part 1: optimization of the P1-moiety. Bioorg Med Chem Lett. 2006 May 15;16(10):2641-7. DM4W8RE RU https://pubmed.ncbi.nlm.nih.gov/16517159 DM4W8RE DI DM4W8RE DM4W8RE DN Melagatran DM4W8RE TI TT2WR1T DM4W8RE TN Cationic trypsinogen (PRSS1) DM4W8RE MA Inhibitor DM4W8RE RN Orally active thrombin inhibitors. Part 1: optimization of the P1-moiety. Bioorg Med Chem Lett. 2006 May 15;16(10):2641-7. DM4W8RE RU https://pubmed.ncbi.nlm.nih.gov/16517159 DM4W8RE DI DM4W8RE DM4W8RE DN Melagatran DM4W8RE TI TTCIHJA DM4W8RE TN Coagulation factor Xa (F10) DM4W8RE MA Inhibitor DM4W8RE RN Orally active thrombin inhibitors. Part 1: optimization of the P1-moiety. Bioorg Med Chem Lett. 2006 May 15;16(10):2641-7. DM4W8RE RU https://pubmed.ncbi.nlm.nih.gov/16517159 DM4XBM7 DI DM4XBM7 DM4XBM7 DN DiaPep-277 DM4XBM7 TI TT9HL5R DM4XBM7 TN Mitochondrial matrix protein P1 (HSPD1) DM4XBM7 MA Modulator DM4XBM7 RN Therapy with the hsp60 peptide DiaPep277 in C-peptide positive type 1 diabetes patients. Diabetes Metab Res Rev. 2007 May;23(4):269-75. DM4XBM7 RU https://pubmed.ncbi.nlm.nih.gov/17024692 DM4XSQ2 DI DM4XSQ2 DM4XSQ2 DN FG-4592 DM4XSQ2 TI TT9ISBX DM4XSQ2 TN HIF-prolyl hydroxylase 2 (HPH-2) DM4XSQ2 MA Inhibitor DM4XSQ2 RN Crystalline forms of a prolyl hydroxylase inhibitor. US9115085. DM4XSQ2 RU http://www.freepatentsonline.com/US9115085.html DM4XSQ2 DI DM4XSQ2 DM4XSQ2 DN FG-4592 DM4XSQ2 TI TTMHFRY DM4XSQ2 TN HIF-prolyl hydroxylase 1 (HPH-1) DM4XSQ2 MA Inhibitor DM4XSQ2 RN The latest advances in kidney diseases and related disorders. Drug News Perspect. 2007 Dec;20(10):647-54. DM4XSQ2 RU https://pubmed.ncbi.nlm.nih.gov/18301799 DM4Y1SP DI DM4Y1SP DM4Y1SP DN Carisbamate DM4Y1SP TI TTRK8B9 DM4Y1SP TN Sodium channel unspecific (NaC) DM4Y1SP MA Blocker DM4Y1SP RN Progress report on new antiepileptic drugs: a summary of the Ninth Eilat Conference (EILAT IX). Epilepsy Res. 2009 Jan;83(1):1-43. DM4Y1SP RU https://pubmed.ncbi.nlm.nih.gov/19008076 DM4Y7WV DI DM4Y7WV DM4Y7WV DN GRASPA DM4Y7WV TI TT4WT91 DM4Y7WV TN Asparaginase (ASRGL1) DM4Y7WV MA Modulator DM4Y7WV RN l-asparaginase loaded red blood cells in refractory or relapsing acute lymphoblastic leukaemia in children and adults: results of the GRASPALL 2005-01 randomized trial. Br J Haematol. 2011 Apr;153(1):58-65. DM4Y7WV RU https://pubmed.ncbi.nlm.nih.gov/21332712 DM4YDAJ DI DM4YDAJ DM4YDAJ DN Sildenafil DM4YDAJ TI TTRYFSB DM4YDAJ TN HUMAN phosphodiesterase type 5 (PDE5) DM4YDAJ MA Inhibitor DM4YDAJ RN Nitric oxide inhibits the replication cycle of severe acute respiratory syndrome coronavirus. J Virol. 2005 Feb;79(3):1966-9. doi: 10.1128/JVI.79.3.1966-1969.2005. DM4YDAJ RU https://pubmed.ncbi.nlm.nih.gov/15650225 DM4YGWA DI DM4YGWA DM4YGWA DN Esonarimod DM4YGWA TI TTGD6BY DM4YGWA TN TNF-alpha/IL-1 beta production (TNFA/IL1B produ) DM4YGWA MA Modulator DM4YGWA RN KE-758, an active metabolite of the new anti-rheumatic drug KE-298, suppresses production of tumor necrosis factor-alpha and interleukin-1 beta in THP-1, a human monocyte cell line. Drugs Exp Clin Res. 2002;28(5):197-205. DM4YGWA RU https://pubmed.ncbi.nlm.nih.gov/12635495 DM4Z9QI DI DM4Z9QI DM4Z9QI DN Olokizumab DM4Z9QI TI TTT1V78 DM4Z9QI TN Interleukin-6 (IL6) DM4Z9QI MA Modulator DM4Z9QI RN Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: outcomes of a randomised Phase IIb study. Ann Rheum Dis. 2014 September; 73(9): 1607-1615. DM4Z9QI RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4145439/ DM50SNX DI DM50SNX DM50SNX DN Bucelipase alfa DM50SNX TI TTTRNQW DM50SNX TN Bile-salt-activated lipase (CEL) DM50SNX MA Modulator DM50SNX RN ClinicalTrials.gov (NCT00743483) Efficacy of Bucelipase Alfa (BSSL) in Patients With Cystic Fibrosis and Pancreatic Insufficiency. U.S. National Institutes of Health. DM50SNX RU https://clinicaltrials.gov/ct2/show/NCT00743483 DM51JW4 DI DM51JW4 DM51JW4 DN BIIB037 DM51JW4 TI TTE4KHA DM51JW4 TN Amyloid beta A4 protein (APP) DM51JW4 MA Modulator DM51JW4 RN Passive anti-amyloid immunotherapy in Alzheimer's disease: What are the most promising targets . Immun Ageing. 2013; 10: 18. DM51JW4 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3681567/ DM52QEZ DI DM52QEZ DM52QEZ DN Zalutumumab DM52QEZ TI TTGKNB4 DM52QEZ TN Epidermal growth factor receptor (EGFR) DM52QEZ RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1797). DM52QEZ RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1797 DM53J6B DI DM53J6B DM53J6B DN PDR001 DM53J6B TI TTNBFWK DM53J6B TN Programmed cell death protein 1 (PD-1) DM53J6B MA Antagonist DM53J6B RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM53J6B RU http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf DM57B9J DI DM57B9J DM57B9J DN Biferonex DM57B9J TI TT4TZ8J DM57B9J TN Interferon-beta (IFNB1) DM57B9J MA Modulator DM57B9J RN Improving compliance with interferon-beta therapy in patients with multiple sclerosis. CNS Drugs. 2009;23(6):453-62. DM57B9J RU https://pubmed.ncbi.nlm.nih.gov/19480465 DM5DAP3 DI DM5DAP3 DM5DAP3 DN PGF2ALPHA-IE DM5DAP3 TI TTT2ZAR DM5DAP3 TN Prostaglandin F2-alpha receptor (PTGFR) DM5DAP3 MA Modulator DM5DAP3 RN Role of nitric oxide in PGF2 alpha-induced ocular hyperemia. Exp Eye Res. 1994 Oct;59(4):401-7. DM5DAP3 RU https://pubmed.ncbi.nlm.nih.gov/7532135 DM5DRMY DI DM5DRMY DM5DRMY DN P1101 DM5DRMY TI TT95SOA DM5DRMY TN Interferon alpha (IFNA) DM5DRMY MA Inhibitor DM5DRMY RN Molecular responses and chromosomal aberrations in patients with polycythemia vera treated with peg-proline-interferon alpha-2b. Am J Hematol. 2015 Apr;90(4):288-94. DM5DRMY RU https://pubmed.ncbi.nlm.nih.gov/25545244 DM5E73H DI DM5E73H DM5E73H DN Revusiran DM5E73H TI TTPOYU7 DM5E73H TN Transthyretin messenger RNA (TTR mRNA) DM5E73H RN Clinical pipeline report, company report or official report of Alnylam Pharmaceuticals, Inc. DM5E73H RU http://www.alnylam.com/product-pipeline/ttr-amyloidosis-fac/ DM5FZH4 DI DM5FZH4 DM5FZH4 DN ProstaVac DM5FZH4 TI TTS78AZ DM5FZH4 TN Prostate specific antigen (KLK3) DM5FZH4 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2373). DM5FZH4 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2373 DM5H0R9 DI DM5H0R9 DM5H0R9 DN Enzastaurin DM5H0R9 TI TTYPXQF DM5H0R9 TN Protein kinase C beta (PRKCB) DM5H0R9 MA Modulator DM5H0R9 RN The oral protein-kinase C beta inhibitor enzastaurin (LY317615) suppresses signalling through the AKT pathway, inhibits proliferation and induces apoptosis in multiple myeloma cell lines. Leuk Lymphoma. 2008 Jul;49(7):1374-83. DM5H0R9 RU https://pubmed.ncbi.nlm.nih.gov/18452078 DM5H0R9 DI DM5H0R9 DM5H0R9 DN Enzastaurin DM5H0R9 TI TTWTSCV DM5H0R9 TN RAC-alpha serine/threonine-protein kinase (AKT1) DM5H0R9 MA Inhibitor DM5H0R9 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM5H0R9 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM5H0R9 DI DM5H0R9 DM5H0R9 DN Enzastaurin DM5H0R9 TI TTHBTOP DM5H0R9 TN PI3-kinase gamma (PIK3CG) DM5H0R9 MA Inhibitor DM5H0R9 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM5H0R9 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM5K6J4 DI DM5K6J4 DM5K6J4 DN AJM-300 DM5K6J4 TI TT6S84X DM5K6J4 TN Integrin alpha-4/beta-1 (ITGA4/B1) DM5K6J4 MA Modulator DM5K6J4 RN Oral treatment with a novel small molecule alpha 4 integrin antagonist, AJM300, prevents the development of experimental colitis in mice. J Crohns Colitis. 2013 Dec;7(11):e533-42. DM5K6J4 RU https://pubmed.ncbi.nlm.nih.gov/23623333 DM5KL8E DI DM5KL8E DM5KL8E DN IBI-308 DM5KL8E TI TTNBFWK DM5KL8E TN Programmed cell death protein 1 (PD-1) DM5KL8E RN Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730. DM5KL8E RU https://pubmed.ncbi.nlm.nih.gov/30247903 DM5L8QT DI DM5L8QT DM5L8QT DN INO-1001 DM5L8QT TI TTEBCY8 DM5L8QT TN Poly [ADP-ribose] polymerase (PARP) DM5L8QT MA Modulator DM5L8QT RN Therapeutic injection of PARP inhibitor INO-1001 preserves cardiac function in porcine myocardial ischemia and reperfusion without reducing infarct size. Shock. 2010 May;33(5):507-12. DM5L8QT RU https://pubmed.ncbi.nlm.nih.gov/20395771 DM5LQHB DI DM5LQHB DM5LQHB DN CCX-168 DM5LQHB TI TTHXFA1 DM5LQHB TN C5a anaphylatoxin chemotactic receptor (C5AR1) DM5LQHB MA Antagonist DM5LQHB RN Clinical pipeline report, company report or official report of ChemoCentryx. DM5LQHB RU http://www.chemocentryx.com/pipeline/orphan-and-rare-diseases/ DM5N1OB DI DM5N1OB DM5N1OB DN Asp-2151 DM5N1OB TI TTKCVJR DM5N1OB TN Herpes simplex virus Helicase-primase (HSV UL8) DM5N1OB MA Inhibitor DM5N1OB RN Efficacy of ASP2151, a helicase-primase inhibitor, against thymidine kinase-deficient herpes simplex virus type 2 infection in vitro and in vivo. Antiviral Res. 2012 Feb;93(2):301-4. DM5N1OB RU https://pubmed.ncbi.nlm.nih.gov/22155691 DM5PRLA DI DM5PRLA DM5PRLA DN Fasinumab DM5PRLA TI TTDN3LF DM5PRLA TN Nerve growth factor (NGF) DM5PRLA MA Inhibitor DM5PRLA RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM5PRLA RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DM5S4DL DI DM5S4DL DM5S4DL DN Forigerimod DM5S4DL TI TTPVYKI DM5S4DL TN Signal transduction unspecific (ST) DM5S4DL MA Modulator DM5S4DL RN Spliceosomal peptide P140 for immunotherapy of systemic lupus erythematosus: results of an early phase II clinical trial. Arthritis Rheum. 2008 Dec;58(12):3873-83. DM5S4DL RU https://pubmed.ncbi.nlm.nih.gov/19035498 DM5S4LX DI DM5S4LX DM5S4LX DN Mirvetuximab soravtansine DM5S4LX TI TTVC37M DM5S4LX TN Folate receptor alpha (FOLR1) DM5S4LX MA Antagonist DM5S4LX RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM5S4LX RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM5ST9Z DI DM5ST9Z DM5ST9Z DN Zolbetuximab DM5ST9Z TI TT6PKBX DM5ST9Z TN Claudin-18 (CLDN18) DM5ST9Z RN FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma. Ann Oncol. 2021 May;32(5):609-619. DM5ST9Z RU https://pubmed.ncbi.nlm.nih.gov/33610734 DM5T4IS DI DM5T4IS DM5T4IS DN VP-102 DM5T4IS TI TTHTKNY DM5T4IS TN Serine/threonine PP2A-alpha (PPP2CA) DM5T4IS MA Inhibitor DM5T4IS RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM5T4IS RU http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf DM5T4IS DI DM5T4IS DM5T4IS DN VP-102 DM5T4IS TI TTLA7IX DM5T4IS TN Protein phosphatase 1A (PPM1A) DM5T4IS MA Inhibitor DM5T4IS RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM5T4IS RU http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf DM5VH6U DI DM5VH6U DM5VH6U DN Serlopitant DM5VH6U TI TTZPO1L DM5VH6U TN Substance-P receptor (TACR1) DM5VH6U MA Antagonist DM5VH6U RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM5VH6U RU http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf DM5WCV4 DI DM5WCV4 DM5WCV4 DN JX-594 DM5WCV4 TI TTNYZG2 DM5WCV4 TN Granulocyte-macrophage colony-stimulating factor (CSF2) DM5WCV4 MA Modulator DM5WCV4 RN Systemic armed oncolytic and immunologic therapy for cancer with JX-594, a targeted poxvirus expressing GM-CSF. Mol Ther. 2006 Sep;14(3):361-70. DM5WCV4 RU https://pubmed.ncbi.nlm.nih.gov/16905462 DM5X7DJ DI DM5X7DJ DM5X7DJ DN Chlorpromazine DM5X7DJ TI TTAIY2U DM5X7DJ TN HUMAN clathrin-mediated endocytosis (RME) DM5X7DJ MA Inhibitor DM5X7DJ RN Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016 May;15(5):327-47. DM5X7DJ RU https://pubmed.ncbi.nlm.nih.gov/26868298 DM5X849 DI DM5X849 DM5X849 DN MEDI4736 DM5X849 TI TT8ZLTI DM5X849 TN Programmed cell death 1 ligand 1 (PD-L1) DM5X849 MA Modulator DM5X849 RN National Cancer Institute Drug Dictionary (drug id 740856). DM5X849 RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=740856 DM5XUQL DI DM5XUQL DM5XUQL DN CPI-613 DM5XUQL TI TTH8T6I DM5XUQL TN Alpha-ketoglutarate dehydrogenase (OGDH) DM5XUQL MA Modulator DM5XUQL RN A strategically designed small molecule attacks alpha-ketoglutarate dehydrogenase in tumor cells through a redox process. Cancer Metab. 2014 Mar 10;2(1):4. DM5XUQL RU https://pubmed.ncbi.nlm.nih.gov/24612826 DM5Y4Q2 DI DM5Y4Q2 DM5Y4Q2 DN Azithromycin + hydroxychloroquine DM5Y4Q2 TI TTD16BI DM5Y4Q2 TN HUMAN pH-dependent viral fusion/replication (pH-DVF/R) DM5Y4Q2 MA Inhibitor DM5Y4Q2 RN Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020 Mar;30(3):269-271. DM5Y4Q2 RU https://pubmed.ncbi.nlm.nih.gov/32020029 DM5Y4Q2 DI DM5Y4Q2 DM5Y4Q2 DN Azithromycin + hydroxychloroquine DM5Y4Q2 TI TTZGK1R DM5Y4Q2 TN HUMAN glycosylation of host receptor (GHR) DM5Y4Q2 MA Inhibitor DM5Y4Q2 RN Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020 Mar;30(3):269-271. DM5Y4Q2 RU https://pubmed.ncbi.nlm.nih.gov/32020029 DM5Y4Q2 DI DM5Y4Q2 DM5Y4Q2 DN Azithromycin + hydroxychloroquine DM5Y4Q2 TI TT3A1EZ DM5Y4Q2 TN HUMAN toll-like receptor 7/9 signalling pathway (TLR7/9 pathway) DM5Y4Q2 MA Inhibitor DM5Y4Q2 RN Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nat Rev Rheumatol. 2020 Mar;16(3):155-166. DM5Y4Q2 RU https://pubmed.ncbi.nlm.nih.gov/32034323 DM60TVK DI DM60TVK DM60TVK DN CQA 206-291 DM60TVK TI TTEX248 DM60TVK TN Dopamine D2 receptor (D2R) DM60TVK MA Agonist DM60TVK RN The antiparkinsonian activity of CQA 206-291, a new D2 dopamine receptor agonist. Clin Neuropharmacol. 1989 Feb;12(1):55-9. DM60TVK RU https://pubmed.ncbi.nlm.nih.gov/2565766 DM624TW DI DM624TW DM624TW DN Omecamtiv mecarbil DM624TW TI TT9WOBN DM624TW TN Cardiac myosin (MYBPC3) DM624TW MA Modulator DM624TW RN CK-1827452, a sarcomere-directed cardiac myosin activator for acute and chronic heart disease. IDrugs. 2009 Apr;12(4):243-51. DM624TW RU https://pubmed.ncbi.nlm.nih.gov/19350469 DM62E7C DI DM62E7C DM62E7C DN CPL-7075 DM62E7C TI TTF8CQI DM62E7C TN Tumor necrosis factor (TNF) DM62E7C MA Inhibitor DM62E7C RN Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26. DM62E7C RU https://pubmed.ncbi.nlm.nih.gov/17355217 DM62QTW DI DM62QTW DM62QTW DN RTB101 DM62QTW TI TT4GO0F DM62QTW TN CREB-regulated transcription coactivator 1 (TORC1) DM62QTW MA Inhibitor DM62QTW RN Anti-ageing pipeline starts to mature.Nat Rev Drug Discov. 2018 Sep;17(9):609-612. DM62QTW RU https://pubmed.ncbi.nlm.nih.gov/30072728 DM64QG9 DI DM64QG9 DM64QG9 DN Diquafosol DM64QG9 TI TTOZHQC DM64QG9 TN P2Y purinoceptor 2 (P2RY2) DM64QG9 MA Agonist DM64QG9 RN Emerging drugs for the treatment of chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2006 May;11(2):275-91. DM64QG9 RU https://pubmed.ncbi.nlm.nih.gov/16634702 DM64WYC DI DM64WYC DM64WYC DN Atx-101 DM64WYC TI TTLG1PD DM64WYC TN Proliferating cell nuclear antigen (PCNA) DM64WYC MA Immunomodulator DM64WYC RN Targeting proliferating cell nuclear antigen and its protein interactions induces apoptosis in multiple myeloma cells. PLoS One. 2013 Jul 31;8(7):e70430. DM64WYC RU https://pubmed.ncbi.nlm.nih.gov/23936203 DM67P0F DI DM67P0F DM67P0F DN CS-038 DM67P0F TI TTZMAO3 DM67P0F TN Peroxisome proliferator-activated receptor gamma (PPAR-gamma) DM67P0F MA Modulator DM67P0F RN Determination of chiglitazar, a dual alpha/gamma peroxisome proliferator-activated receptor (PPAR) agonist, in human plasma by liquid chromatograph... Pharmazie. 2007 Nov;62(11):825-9. DM67P0F RU https://www.ncbi.nlm.nih.gov/pubmed/18065097 DM67P0F DI DM67P0F DM67P0F DN CS-038 DM67P0F TI TTJ584C DM67P0F TN Peroxisome proliferator-activated receptor alpha (PPARA) DM67P0F MA Modulator DM67P0F RN Determination of chiglitazar, a dual alpha/gamma peroxisome proliferator-activated receptor (PPAR) agonist, in human plasma by liquid chromatograph... Pharmazie. 2007 Nov;62(11):825-9. DM67P0F RU https://www.ncbi.nlm.nih.gov/pubmed/18065097 DM6BU57 DI DM6BU57 DM6BU57 DN Eraxis/Vfend DM6BU57 TI TTZMS1L DM6BU57 TN Fungal Papulacandin B resistance protein 1 (Fung FKS1) DM6BU57 MA Inhibitor DM6BU57 RN Pfizer. Product Development Pipeline. March 31 2009. DM6BU57 RU http://media.pfizer.com/files/research/pipeline/2009_0331/pipeline_2009_0331.pdf DM6BZCV DI DM6BZCV DM6BZCV DN Sivelestat DM6BZCV TI TTPLTSQ DM6BZCV TN Neutrophil elastase (NE) DM6BZCV MA Inhibitor DM6BZCV RN Neutrophil elastase inhibitor (sivelestat) reduces the levels of inflammatory mediators by inhibiting NF-kB. Inflamm Res. 2009 Apr;58(4):198-203. DM6BZCV RU https://pubmed.ncbi.nlm.nih.gov/19169649 DM6BZCV DI DM6BZCV DM6BZCV DN Sivelestat DM6BZCV TI TT3NKIB DM6BZCV TN Pancreatic elastase 1 (CELA1) DM6BZCV MA Inhibitor DM6BZCV RN Sivelestat (selective neutrophil elastase inhibitor) improves the mortality rate of sepsis associated with both acute respiratory distress syndrome... Shock. 2010 Jan;33(1):14-8. DM6BZCV RU https://pubmed.ncbi.nlm.nih.gov/19487982 DM6CHNJ DI DM6CHNJ DM6CHNJ DN Camptothecin DM6CHNJ TI TTGTQHC DM6CHNJ TN DNA topoisomerase I (TOP1) DM6CHNJ MA Modulator DM6CHNJ RN Topoisomerase I inhibitors: camptothecins and beyond. Nat Rev Cancer. 2006 Oct;6(10):789-802. DM6CHNJ RU https://pubmed.ncbi.nlm.nih.gov/16990856 DM6ENSJ DI DM6ENSJ DM6ENSJ DN Tralokinumab DM6ENSJ TI TTMPZ7V DM6ENSJ TN Interleukin 13 receptor alpha-2 (IL13RA2) DM6ENSJ MA Modulator DM6ENSJ RN Targeting interleukin-13 with tralokinumab attenuates lung fibrosis and epithelial damage in a humanized SCID idiopathic pulmonary fibrosis model.Am J Respir Cell Mol Biol.2014 May;50(5):985-94. DM6ENSJ RU https://www.ncbi.nlm.nih.gov/pubmed/24325475 DM6ENSJ DI DM6ENSJ DM6ENSJ DN Tralokinumab DM6ENSJ TI TT0GVCH DM6ENSJ TN Interleukin-13 (IL13) DM6ENSJ MA Inhibitor DM6ENSJ RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM6ENSJ RU http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf DM6HXTS DI DM6HXTS DM6HXTS DN Anamorelin DM6HXTS TI TTWDC17 DM6HXTS TN Growth hormone secretagogue receptor 1 (GHSR) DM6HXTS MA Stimulator DM6HXTS RN Pharmacodynamic hormonal effects of anamorelin, a novel oral ghrelin mimetic and growth hormone secretagogue in healthy volunteers. Growth Horm IGF Res. 2009 Jun;19(3):267-73. DM6HXTS RU https://pubmed.ncbi.nlm.nih.gov/19196529 DM6HXTS DI DM6HXTS DM6HXTS DN Anamorelin DM6HXTS TI TTHCF4J DM6HXTS TN Alpha-glucosidase (GLA) DM6HXTS MA Modulator DM6HXTS RN Absorption, elimination, and metabolism of CS-1036, a novel -amylase inhibitor in rats and monkeys, and the relationship between gastrointestinal distribution and suppression of glucose absorption.Drug Metab Dispos.2013 Apr;41(4):878-87. DM6HXTS RU https://www.ncbi.nlm.nih.gov/pubmed/23378626 DM6KRLW DI DM6KRLW DM6KRLW DN BQ788 DM6KRLW TI TT3ZTGU DM6KRLW TN Endothelin B receptor (EDNRB) DM6KRLW MA Antagonist DM6KRLW RN BQ788, an endothelin ET(B) receptor antagonist, attenuates stab wound injury-induced reactive astrocytes in rat brain. Glia. 1999 May;26(3):268-71. DM6KRLW RU https://pubmed.ncbi.nlm.nih.gov/10340767 DM6L4ZT DI DM6L4ZT DM6L4ZT DN SB-742457 DM6L4ZT TI TTJS8PY DM6L4ZT TN 5-HT 6 receptor (HTR6) DM6L4ZT MA Antagonist DM6L4ZT RN 5-HT6 receptors and Alzheimer's disease. Alzheimers Res Ther. 2013; 5(2): 15. DM6L4ZT RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3706851/ DM6L5ZQ DI DM6L5ZQ DM6L5ZQ DN Vercirnon DM6L5ZQ TI TTIPS8B DM6L5ZQ TN C-C chemokine receptor type 9 (CCR9) DM6L5ZQ MA Modulator DM6L5ZQ RN GSK-1605786, a selective small-molecule antagonist of the CCR9 chemokine receptor for the treatment of Crohn's disease. IDrugs. 2010 Jul;13(7):472-81. DM6L5ZQ RU https://pubmed.ncbi.nlm.nih.gov/20582872 DM6LVCQ DI DM6LVCQ DM6LVCQ DN LY-CoV555 DM6LVCQ TI TTZ3COY DM6LVCQ TN COVID-19 spike glycoprotein (S) DM6LVCQ MA Inhibitor DM6LVCQ RN Neutralizing Antibody LY-CoV555 for Outpatient Covid-19. Reply. N Engl J Med. 2021 Jan 14;384(2):189. DM6LVCQ RU https://pubmed.ncbi.nlm.nih.gov/33378611 DM6P8HU DI DM6P8HU DM6P8HU DN Dutasteride + tamsulosin DM6P8HU TI TTNGILX DM6P8HU TN Adrenergic receptor alpha-1A (ADRA1A) DM6P8HU MA Antagonist DM6P8HU RN Clinical pipeline report, company report or official report of GlaxoSmithKline (2009). DM6P8HU RU http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf DM6P8HU DI DM6P8HU DM6P8HU DN Dutasteride + tamsulosin DM6P8HU TI TT2A0DR DM6P8HU TN Oxo-5-alpha-steroid 4-dehydrogenase (SRD5A) DM6P8HU MA Inhibitor DM6P8HU RN Clinical pipeline report, company report or official report of GlaxoSmithKline (2009). DM6P8HU RU http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf DM6PMNR DI DM6PMNR DM6PMNR DN Ulocuplumab DM6PMNR TI TTBID49 DM6PMNR TN C-X-C chemokine receptor type 4 (CXCR4) DM6PMNR MA Antagonist DM6PMNR RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM6PMNR RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DM6QOVN DI DM6QOVN DM6QOVN DN HKI-272 DM6QOVN TI TTUTJGQ DM6QOVN TN Vascular endothelial growth factor receptor 2 (KDR) DM6QOVN MA Inhibitor DM6QOVN RN Dual irreversible kinase inhibitors: quinazoline-based inhibitors incorporating two independent reactive centers with each targeting different cyst... Bioorg Med Chem. 2007 Jun 1;15(11):3635-48. DM6QOVN RU https://pubmed.ncbi.nlm.nih.gov/17416531 DM6QOVN DI DM6QOVN DM6QOVN DN HKI-272 DM6QOVN TI TTR5TV4 DM6QOVN TN ERBB2 messenger RNA (HER2 mRNA) DM6QOVN MA Inhibitor DM6QOVN RN Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling. Proc Natl Acad Sci U S A. 2007 Dec 11;104(50):19936-41. DM6QOVN RU https://pubmed.ncbi.nlm.nih.gov/18077425 DM6QOVN DI DM6QOVN DM6QOVN DN HKI-272 DM6QOVN TI TTGKNB4 DM6QOVN TN Epidermal growth factor receptor (EGFR) DM6QOVN MA Inhibitor DM6QOVN RN Dual irreversible kinase inhibitors: quinazoline-based inhibitors incorporating two independent reactive centers with each targeting different cyst... Bioorg Med Chem. 2007 Jun 1;15(11):3635-48. DM6QOVN RU https://pubmed.ncbi.nlm.nih.gov/17416531 DM6QOVN DI DM6QOVN DM6QOVN DN HKI-272 DM6QOVN TI TT6EO5L DM6QOVN TN Erbb2 tyrosine kinase receptor (HER2) DM6QOVN MA Inhibitor DM6QOVN RN A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22. DM6QOVN RU https://pubmed.ncbi.nlm.nih.gov/17692029 DM6QZIA DI DM6QZIA DM6QZIA DN Solithromycin DM6QZIA TI TTUWYEA DM6QZIA TN Bacterial 50S ribosomal RNA (Bact 50S rRNA) DM6QZIA MA Modulator DM6QZIA RN Company report (cempra) DM6QZIA RU http://www.cempra.com/products/Solithromycin-cem-101/ DM6R2XF DI DM6R2XF DM6R2XF DN FKB238 DM6R2XF TI TT9HKJA DM6R2XF TN Vascular endothelial growth factor (VEGF) DM6R2XF MA Inhibitor DM6R2XF RN Clinical pipeline report, company report or official report of Fujifilm. DM6R2XF RU https://fujifilmkyowakirin-biologics.com/en/pipeline/ DM6RUKX DI DM6RUKX DM6RUKX DN BVT.2733 DM6RUKX TI TTN7BL9 DM6RUKX TN Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1) DM6RUKX MA Inhibitor DM6RUKX RN Selective inhibition of 11 beta-hydroxysteroid dehydrogenase type 1 improves hepatic insulin sensitivity in hyperglycemic mice strains. Endocrinology. 2003 Nov;144(11):4755-62. DM6RUKX RU https://pubmed.ncbi.nlm.nih.gov/12960099 DM6RWBN DI DM6RWBN DM6RWBN DN Beperminogene perplasmid DM6RWBN TI TTNDSF4 DM6RWBN TN Proto-oncogene c-Met (MET) DM6RWBN MA Modulator DM6RWBN RN Beperminogene perplasmid for the treatment of critical limb ischemia. Expert Rev Cardiovasc Ther. 2014 Oct;12(10):1145-56. DM6RWBN RU https://pubmed.ncbi.nlm.nih.gov/25190335 DM6S4R2 DI DM6S4R2 DM6S4R2 DN DA-3031 DM6S4R2 TI TT5TQ2W DM6S4R2 TN Granulocyte colony-stimulating factor (CSF3) DM6S4R2 MA Modulator DM6S4R2 RN A randomized, multi-center, open-label, phase II study of once-per-cycle DA-3031, a biosimilar pegylated G-CSF, compared with daily filgrastim in patients receiving TAC chemotherapy for early-stage breast cancer.Invest New Drugs.2013 Oct;31(5):1300-6. DM6S4R2 RU https://www.ncbi.nlm.nih.gov/pubmed/23677653 DM6V34C DI DM6V34C DM6V34C DN Marimastat DM6V34C TI TTMTWOS DM6V34C TN Matrix metalloproteinase-7 (MMP-7) DM6V34C MA Inhibitor DM6V34C RN Metalloelastase (MMP-12) induced inflammatory response in mice airways: effects of dexamethasone, rolipram and marimastat. Eur J Pharmacol. 2007 Mar 15;559(1):75-81. DM6V34C RU https://pubmed.ncbi.nlm.nih.gov/17234180 DM6V34C DI DM6V34C DM6V34C DN Marimastat DM6V34C TI TTMX39J DM6V34C TN Matrix metalloproteinase-1 (MMP-1) DM6V34C MA Inhibitor DM6V34C RN Metalloelastase (MMP-12) induced inflammatory response in mice airways: effects of dexamethasone, rolipram and marimastat. Eur J Pharmacol. 2007 Mar 15;559(1):75-81. DM6V34C RU https://pubmed.ncbi.nlm.nih.gov/17234180 DM6V34C DI DM6V34C DM6V34C DN Marimastat DM6V34C TI TTLM12X DM6V34C TN Matrix metalloproteinase-2 (MMP-2) DM6V34C MA Inhibitor DM6V34C RN Metalloelastase (MMP-12) induced inflammatory response in mice airways: effects of dexamethasone, rolipram and marimastat. Eur J Pharmacol. 2007 Mar 15;559(1):75-81. DM6V34C RU https://pubmed.ncbi.nlm.nih.gov/17234180 DM6WZG8 DI DM6WZG8 DM6WZG8 DN AXS-05 DM6WZG8 TI TT9IK2Z DM6WZG8 TN N-methyl-D-aspartate receptor (NMDAR) DM6WZG8 MA Antagonist DM6WZG8 RN Clinical pipeline report, company report or official report of Axsome Therapeutics. DM6WZG8 RU https://axsome.com/axs-pipeline/about-axs-05/ DM71CK8 DI DM71CK8 DM71CK8 DN Beloranib DM71CK8 TI TTZL0OI DM71CK8 TN Methionine aminopeptidase 2 (METAP2) DM71CK8 MA Inhibitor DM71CK8 RN 2011 Pipeline of Zafgen. DM71CK8 RU http://www.zafgen.com/approach-pipeline.html DM71GPM DI DM71GPM DM71GPM DN Grippol Plus DM71GPM TI TT3J5ZI DM71GPM TN Cell mediated immunity response (CMIR) DM71GPM RN Clinical pipeline report, company report or official report of Petrovax. DM71GPM RU http://petrovax.com/medication/catalog/grippallplus/ DM71ZL6 DI DM71ZL6 DM71ZL6 DN TZTX-001 DM71ZL6 TI TTZAYWL DM71ZL6 TN Estrogen receptor (ESR) DM71ZL6 MA Modulator DM71ZL6 RN Clinical pipeline report, company report or official report of Pharmabiz. DM71ZL6 RU http://www.pharmabiz.com/PrintArticle.aspx?aid=77569&sid=2 DM735FA DI DM735FA DM735FA DN IMO-2125 DM735FA TI TTSHG0T DM735FA TN Toll-like receptor 9 (TLR9) DM735FA MA Agonist DM735FA RN Clinical pipeline report, company report or official report of Idera Pharmaceuticals (2011). DM735FA RU http://www.iderapharma.com/ DM76GZ0 DI DM76GZ0 DM76GZ0 DN Angiotensin-(1-7) DM76GZ0 TI TTOISYB DM76GZ0 TN Proto-oncogene Mas (MAS) DM76GZ0 MA Agonist DM76GZ0 RN New therapeutic pathways in the RAS. J Renin Angiotensin Aldosterone Syst. 2012 Dec;13(4):505-8. DM76GZ0 RU https://pubmed.ncbi.nlm.nih.gov/23166114 DM7BCWT DI DM7BCWT DM7BCWT DN Imiglitazar DM7BCWT TI TTZMAO3 DM7BCWT TN Peroxisome proliferator-activated receptor gamma (PPAR-gamma) DM7BCWT MA Modulator DM7BCWT RN A novel oxyiminoalkanoic acid derivative, TAK-559, activates human peroxisome proliferator-activated receptor subtypes. Eur J Pharmacol. 2004 Jul 8;495(1):17-26. DM7BCWT RU https://pubmed.ncbi.nlm.nih.gov/15219816 DM7BCWT DI DM7BCWT DM7BCWT DN Imiglitazar DM7BCWT TI TTJ584C DM7BCWT TN Peroxisome proliferator-activated receptor alpha (PPARA) DM7BCWT MA Modulator DM7BCWT RN A novel oxyiminoalkanoic acid derivative, TAK-559, activates human peroxisome proliferator-activated receptor subtypes. Eur J Pharmacol. 2004 Jul 8;495(1):17-26. DM7BCWT RU https://pubmed.ncbi.nlm.nih.gov/15219816 DM7BSRH DI DM7BSRH DM7BSRH DN Tramiprosate DM7BSRH TI TTE4KHA DM7BSRH TN Amyloid beta A4 protein (APP) DM7BSRH MA Antagonist DM7BSRH RN Targeting soluble Abeta peptide with Tramiprosate for the treatment of brain amyloidosis. Neurobiol Aging. 2007 Apr;28(4):537-47. DM7BSRH RU https://pubmed.ncbi.nlm.nih.gov/16675063 DM7EBH9 DI DM7EBH9 DM7EBH9 DN ALX-0081 DM7EBH9 TI TT3SZBT DM7EBH9 TN von Willebrand factor (VWF) DM7EBH9 MA Binder DM7EBH9 RN Clinical pipeline report, company report or official report of Ablynx DM7EBH9 RU http://hugin.info/137912/R/1338761/319541.pdf DM7EOBQ DI DM7EOBQ DM7EOBQ DN Entacapone+levodopa+carbidopa DM7EOBQ TI TTKWFB8 DM7EOBQ TN Catechol-O-methyl-transferase (COMT) DM7EOBQ MA Inhibitor DM7EOBQ RN Emerging drugs for restless legs syndrome. Expert Opin Emerg Drugs. 2005 Aug;10(3):537-52. DM7EOBQ RU https://pubmed.ncbi.nlm.nih.gov/16083328 DM7EOBQ DI DM7EOBQ DM7EOBQ DN Entacapone+levodopa+carbidopa DM7EOBQ TI TTEX248 DM7EOBQ TN Dopamine D2 receptor (D2R) DM7EOBQ MA Agonist DM7EOBQ RN Emerging drugs for restless legs syndrome. Expert Opin Emerg Drugs. 2005 Aug;10(3):537-52. DM7EOBQ RU https://pubmed.ncbi.nlm.nih.gov/16083328 DM7EVUF DI DM7EVUF DM7EVUF DN ABL001 DM7EVUF TI TTS7G69 DM7EVUF TN Fusion protein Bcr-Abl (Bcr-Abl) DM7EVUF MA Inhibitor DM7EVUF RN Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure. N Engl J Med. 2019 Dec 12;381(24):2315-2326. DM7EVUF RU https://pubmed.ncbi.nlm.nih.gov/31826340 DM7F2VG DI DM7F2VG DM7F2VG DN SA-237 DM7F2VG TI TT0E5SK DM7F2VG TN Interleukin 6 receptor (IL6R) DM7F2VG MA Antagonist DM7F2VG RN IBC's 23rd Annual Antibody Engineering, 10th Annual Antibody Therapeutics International Conferences and the 2012 Annual Meeting of The Antibody Society: December 3-6, 2012, San Diego, CA. MAbs. 2013 March 1; 5(2): 178-201. DM7F2VG RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3893229/ DM7HQNX DI DM7HQNX DM7HQNX DN Renzapride DM7HQNX TI TT07C3Y DM7HQNX TN 5-HT 4 receptor (HTR4) DM7HQNX MA Modulator DM7HQNX RN Pharmacology and metabolism of renzapride : a novel therapeutic agent for the potential treatment of irritable bowel syndrome. Drugs R D. 2008;9(1):37-63. DM7HQNX RU https://www.ncbi.nlm.nih.gov/pubmed/18095752 DM7HQNX DI DM7HQNX DM7HQNX DN Renzapride DM7HQNX TI TTNXLKE DM7HQNX TN 5-HT 3 receptor (5HT3R) DM7HQNX MA Modulator DM7HQNX RN Pharmacology and metabolism of renzapride : a novel therapeutic agent for the potential treatment of irritable bowel syndrome. Drugs R D. 2008;9(1):37-63. DM7HQNX RU https://www.ncbi.nlm.nih.gov/pubmed/18095752 DM7JFDO DI DM7JFDO DM7JFDO DN Recombinant von Willebrand factor/recombinant Factor VIII complex DM7JFDO TI TT3SZBT DM7JFDO TN von Willebrand factor (VWF) DM7JFDO MA Modulator DM7JFDO RN 6 Factor VIII Concentrates, Factor VIII/von Willebrand Factor Concentrates, Factor IX Concentrates, Activated Prothrombin Complex Concentrates. Transfus Med Hemother. 2009 December; 36(6): 409-418. DM7JFDO RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2997296/ DM7JFDO DI DM7JFDO DM7JFDO DN Recombinant von Willebrand factor/recombinant Factor VIII complex DM7JFDO TI TT1290U DM7JFDO TN Coagulation factor VIII (F8) DM7JFDO MA Modulator DM7JFDO RN 6 Factor VIII Concentrates, Factor VIII/von Willebrand Factor Concentrates, Factor IX Concentrates, Activated Prothrombin Complex Concentrates. Transfus Med Hemother. 2009 December; 36(6): 409-418. DM7JFDO RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2997296/ DM7KI4E DI DM7KI4E DM7KI4E DN Oblimersen DM7KI4E TI TTJGNVC DM7KI4E TN Apoptosis regulator Bcl-2 (BCL-2) DM7KI4E MA Inhibitor DM7KI4E RN Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127. DM7KI4E RU https://pubmed.ncbi.nlm.nih.gov/19249983 DM7NJYC DI DM7NJYC DM7NJYC DN BGB-A317 DM7NJYC TI TTNBFWK DM7NJYC TN Programmed cell death protein 1 (PD-1) DM7NJYC MA Inhibitor DM7NJYC RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM7NJYC RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DM7NV1I DI DM7NV1I DM7NV1I DN SPD-465 DM7NV1I TI TTIU98M DM7NV1I TN Trace amine-associated receptor-1 (TAAR1) DM7NV1I MA Agonist DM7NV1I RN Methamphetamine and HIV-1-induced neurotoxicity: role of trace amine associated receptor 1 cAMP signaling in astrocytes. Neuropharmacology. 2014 Oct;85:499-507. DM7NV1I RU https://pubmed.ncbi.nlm.nih.gov/24950453 DM7OSHC DI DM7OSHC DM7OSHC DN Pinaverium bromide DM7OSHC TI TTXHYV6 DM7OSHC TN Voltage-gated L-type calcium channel (L-CaC) DM7OSHC MA Blocker DM7OSHC RN Emerging drugs for irritable bowel syndrome. Expert Opin Emerg Drugs. 2006 May;11(2):293-313. DM7OSHC RU https://pubmed.ncbi.nlm.nih.gov/16634703 DM7QI29 DI DM7QI29 DM7QI29 DN Crenezumab DM7QI29 TI TTE4KHA DM7QI29 TN Amyloid beta A4 protein (APP) DM7QI29 MA Modulator DM7QI29 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2402). DM7QI29 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2402 DM7R145 DI DM7R145 DM7R145 DN Otesaconazole DM7R145 TI TTTSOUD DM7R145 TN Candida Cytochrome P450 51 (Candi ERG11) DM7R145 MA Inhibitor DM7R145 RN Efficacy of the clinical agent VT-1161 against fluconazole-sensitive and -resistant Candida albicans in a murine model of vaginal candidiasis. Antimicrob Agents Chemother. 2015 Sep;59(9):5567-73. DM7R145 RU https://pubmed.ncbi.nlm.nih.gov/26124165 DM7R3N5 DI DM7R3N5 DM7R3N5 DN Mirikizumab DM7R3N5 TI TTRTK6Y DM7R3N5 TN Interleukin-12 alpha (IL12A) DM7R3N5 MA Inhibitor DM7R3N5 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM7R3N5 RU http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf DM7V9LH DI DM7V9LH DM7V9LH DN Blisibimod DM7V9LH TI TTWMIDN DM7V9LH TN B-cell-activating factor (TNFSF13B) DM7V9LH MA Inhibitor DM7V9LH RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM7V9LH RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DM7WORZ DI DM7WORZ DM7WORZ DN LY-686017 DM7WORZ TI TTZPO1L DM7WORZ TN Substance-P receptor (TACR1) DM7WORZ MA Antagonist DM7WORZ RN Stress-related neuropeptides and alcoholism: CRH, NPY and beyond. Alcohol. 2009 November; 43(7): 491-498. DM7WORZ RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2804869/ DM7WYXJ DI DM7WYXJ DM7WYXJ DN P-1101 DM7WYXJ TI TTSIUJ9 DM7WYXJ TN Interferon-alpha 2 (IFNA2) DM7WYXJ MA Modulator DM7WYXJ RN Effects of PEG-interferon-alpha-2A on Schistosoma mansoni infection in mice. J Parasitol. 2010 Aug;96(4):703-8. DM7WYXJ RU https://pubmed.ncbi.nlm.nih.gov/20486736 DM7YNV9 DI DM7YNV9 DM7YNV9 DN Iclaprim DM7YNV9 TI TT9B4N3 DM7YNV9 TN Prostaglandin receptor (PTGR) DM7YNV9 MA Modulator DM7YNV9 RN Novel ocular antihypertensive compounds in clinical trials. Clin Ophthalmol. 2011; 5: 667-677. DM7YNV9 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3104796/ DM7YNV9 DI DM7YNV9 DM7YNV9 DN Iclaprim DM7YNV9 TI TTV8DM2 DM7YNV9 TN Bacterial Dihydrofolate reductase (Bact DHFR) DM7YNV9 MA Modulator DM7YNV9 RN Iclaprim: a novel dihydrofolate reductase inhibitor for skin and soft tissue infections.Future Microbiol.2009 Mar;4(2):131-44. DM7YNV9 RU https://www.ncbi.nlm.nih.gov/pubmed/19257839 DM7YNV9 DI DM7YNV9 DM7YNV9 DN Iclaprim DM7YNV9 TI TTYZVDJ DM7YNV9 TN Dihydrofolate reductase (DHFR) DM7YNV9 MA Inhibitor DM7YNV9 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM7YNV9 RU http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf DM7ZFBA DI DM7ZFBA DM7ZFBA DN M100907 DM7ZFBA TI TTJQOD7 DM7ZFBA TN 5-HT 2A receptor (HTR2A) DM7ZFBA MA Antagonist DM7ZFBA RN Antagonism of 5-hydroxytryptamine(2a) receptors attenuates the behavioral effects of cocaine in rats. J Pharmacol Exp Ther. 2001 Apr;297(1):357-63. DM7ZFBA RU https://pubmed.ncbi.nlm.nih.gov/11259563 DM7ZFBA DI DM7ZFBA DM7ZFBA DN M100907 DM7ZFBA TI TTQ6VDM DM7ZFBA TN Voltage-gated potassium channel Kv11.1 (KCNH2) DM7ZFBA MA Inhibitor DM7ZFBA RN Non-basic ligands for aminergic GPCRs: the discovery and development diaryl sulfones as selective, orally bioavailable 5-HT2A receptor antagonists ... Bioorg Med Chem Lett. 2010 Jun 15;20(12):3708-12. DM7ZFBA RU https://pubmed.ncbi.nlm.nih.gov/20493697 DM7ZFBA DI DM7ZFBA DM7ZFBA DN M100907 DM7ZFBA TI TTWJBZ5 DM7ZFBA TN 5-HT 2C receptor (HTR2C) DM7ZFBA MA Inhibitor DM7ZFBA RN Non-basic ligands for aminergic GPCRs: the discovery and development diaryl sulfones as selective, orally bioavailable 5-HT2A receptor antagonists ... Bioorg Med Chem Lett. 2010 Jun 15;20(12):3708-12. DM7ZFBA RU https://pubmed.ncbi.nlm.nih.gov/20493697 DM7ZOAE DI DM7ZOAE DM7ZOAE DN GFT-505 DM7ZOAE TI TT2JWF6 DM7ZOAE TN Peroxisome proliferator-activated receptor delta (PPARD) DM7ZOAE MA Modulator DM7ZOAE RN Dual peroxisome proliferator-activated receptor / agonist GFT505 improves hepatic and peripheral insulin sensitivity in abdominally obese subjects.Diabetes Care.2013 Oct;36(10):2923-30. DM7ZOAE RU https://www.ncbi.nlm.nih.gov/pubmed/23715754 DM7ZOAE DI DM7ZOAE DM7ZOAE DN GFT-505 DM7ZOAE TI TTJ584C DM7ZOAE TN Peroxisome proliferator-activated receptor alpha (PPARA) DM7ZOAE MA Modulator DM7ZOAE RN Dual peroxisome proliferator-activated receptor / agonist GFT505 improves hepatic and peripheral insulin sensitivity in abdominally obese subjects.Diabetes Care.2013 Oct;36(10):2923-30. DM7ZOAE RU https://www.ncbi.nlm.nih.gov/pubmed/23715754 DM803GL DI DM803GL DM803GL DN CIPEMASTAT DM803GL TI TTGA1IV DM803GL TN Matrix metalloproteinase-8 (MMP-8) DM803GL MA Modulator DM803GL RN Matrix metalloproteinase inhibition lowers mortality and brain injury in experimental pneumococcal meningitis. Infect Immun. 2014 Apr;82(4):1710-8. DM803GL RU https://pubmed.ncbi.nlm.nih.gov/24491581 DM803GL DI DM803GL DM803GL DN CIPEMASTAT DM803GL TI TTMX39J DM803GL TN Matrix metalloproteinase-1 (MMP-1) DM803GL MA Modulator DM803GL RN Matrix metalloproteinase inhibition lowers mortality and brain injury in experimental pneumococcal meningitis. Infect Immun. 2014 Apr;82(4):1710-8. DM803GL RU https://pubmed.ncbi.nlm.nih.gov/24491581 DM823WQ DI DM823WQ DM823WQ DN FP-1201 DM823WQ TI TT4TZ8J DM823WQ TN Interferon-beta (IFNB1) DM823WQ MA Modulator DM823WQ RN The effect of intravenous interferon-beta-1a (FP-1201) on lung CD73 expression and on acute respiratory distress syndrome mortality: an open-label study.Lancet Respir Med. 2014 Feb;2(2):98-107. DM823WQ RU https://www.ncbi.nlm.nih.gov/pubmed/24503265 DM83EBP DI DM83EBP DM83EBP DN Alisporivir DM83EBP TI TTATDGJ DM83EBP TN Calcium signal-modulating cyclophilin ligand (CAML) DM83EBP MA Inhibitor DM83EBP RN DEB025 (Alisporivir) inhibits hepatitis C virus replication by preventing a cyclophilin A induced cis-trans isomerisation in domain II of NS5A. PLoS One. 2010 Oct 27;5(10):e13687. DM83EBP RU https://pubmed.ncbi.nlm.nih.gov/21060866 DM83SEB DI DM83SEB DM83SEB DN Faricimab DM83SEB TI TTOHSBA DM83SEB TN Vascular endothelial growth factor A (VEGFA) DM83SEB RN Faricimab: an investigational agent targeting the Tie-2/angiopoietin pathway and VEGF-A for the treatment of retinal diseases. Expert Opin Investig Drugs. 2021 Mar;30(3):193-200. DM83SEB RU https://pubmed.ncbi.nlm.nih.gov/33471572 DM83SEB DI DM83SEB DM83SEB DN Faricimab DM83SEB TI TTKLQTJ DM83SEB TN Angiopoietin-2 (ANGPT2) DM83SEB RN Faricimab: an investigational agent targeting the Tie-2/angiopoietin pathway and VEGF-A for the treatment of retinal diseases. Expert Opin Investig Drugs. 2021 Mar;30(3):193-200. DM83SEB RU https://pubmed.ncbi.nlm.nih.gov/33471572 DM84AD1 DI DM84AD1 DM84AD1 DN Arofylline DM84AD1 TI TTV5CGO DM84AD1 TN Phosphodiesterase 4 (PDE4) DM84AD1 MA Inhibitor DM84AD1 RN Emerging drugs for the treatment of chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2006 May;11(2):275-91. DM84AD1 RU https://pubmed.ncbi.nlm.nih.gov/16634702 DM84LO5 DI DM84LO5 DM84LO5 DN MK-8109 DM84LO5 TI TTVC37M DM84LO5 TN Folate receptor alpha (FOLR1) DM84LO5 MA Modulator DM84LO5 RN A current review of folate receptor alpha as a potential tumor target in non-small-cell lung cancer. Drug Des Devel Ther. 2015; 9: 4989-4996. DM84LO5 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4560517/ DM8D13S DI DM8D13S DM8D13S DN MABp1 DM8D13S TI TTPM6HI DM8D13S TN Interleukin-1 alpha (IL1A) DM8D13S MA Inhibitor DM8D13S RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM8D13S RU http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf DM8E51L DI DM8E51L DM8E51L DN FASORACETAM DM8E51L TI TTAN6JD DM8E51L TN Glutamate receptor AMPA (GRIA) DM8E51L MA Modulator DM8E51L RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DM8E51L RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DM8FSPV DI DM8FSPV DM8FSPV DN JTZ-951 DM8FSPV TI TTJQFBG DM8FSPV TN HIF-prolyl hydroxylase (HPH) DM8FSPV MA Modulator DM8FSPV RN DOI: 10.1038/nrneph.2015.82 DM8FSPV RU http://www.nature.com/nrneph/journal/v11/n7/fig_tab/nrneph.2015.82_T1.html DM8GFEV DI DM8GFEV DM8GFEV DN Atacicept DM8GFEV TI TTOI1RM DM8GFEV TN A proliferation-inducing ligand (APRIL) DM8GFEV MA Modulator DM8GFEV RN Atacicept: a new B lymphocyte-targeted therapy for multiple sclerosis. Nervenarzt. 2009 Dec;80(12):1462-72. DM8GFEV RU https://pubmed.ncbi.nlm.nih.gov/19779889 DM8HCFD DI DM8HCFD DM8HCFD DN Sarilumab DM8HCFD TI TTDVAKP DM8HCFD TN HUMAN interleukin-6 receptor (IL6R) DM8HCFD MA Blocker DM8HCFD RN IL-6 as a keystone cytokine in health and disease. Nat Immunol. 2015 May;16(5):448-57. DM8HCFD RU https://pubmed.ncbi.nlm.nih.gov/25898198 DM8HVNR DI DM8HVNR DM8HVNR DN Recombinant acidic fibroblast growth factor DM8HVNR TI TT5HU6Z DM8HVNR TN Fibroblast growth factor (FGF) DM8HVNR MA Modulator DM8HVNR RN Molecular characterization of recombinant human acidic fibroblast growth factor produced in E. coli: comparative studies with human basic fibroblast growth factor. Mol Endocrinol. 1990 Jun;4(6):869-79. DM8HVNR RU https://pubmed.ncbi.nlm.nih.gov/1700280 DM8J29L DI DM8J29L DM8J29L DN PF-04965842 DM8J29L TI TTJSQEF DM8J29L TN Tyrosine-protein kinase (PTK) DM8J29L MA Inhibitor DM8J29L RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM8J29L RU http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf DM8JWNA DI DM8JWNA DM8JWNA DN NVP-LAQ824 DM8JWNA TI TT6R7JZ DM8JWNA TN Histone deacetylase 1 (HDAC1) DM8JWNA MA Inhibitor DM8JWNA RN NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma. Blood. 2003 Oct 1;102(7):2615-22. DM8JWNA RU https://pubmed.ncbi.nlm.nih.gov/12816865 DM8JWNA DI DM8JWNA DM8JWNA DN NVP-LAQ824 DM8JWNA TI TTBH0VX DM8JWNA TN Histone deacetylase (HDAC) DM8JWNA MA Inhibitor DM8JWNA RN Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127. DM8JWNA RU https://pubmed.ncbi.nlm.nih.gov/19249983 DM8K5Z6 DI DM8K5Z6 DM8K5Z6 DN Motexafin lutetium DM8K5Z6 TI TTS78AZ DM8K5Z6 TN Prostate specific antigen (KLK3) DM8K5Z6 MA Modulator DM8K5Z6 RN Motexafin lutetium-photodynamic therapy of prostate cancer: short- and long-term effects on prostate-specific antigen. Clin Cancer Res. 2008 Aug 1;14(15):4869-76. DM8K5Z6 RU https://pubmed.ncbi.nlm.nih.gov/18676760 DM8L3JU DI DM8L3JU DM8L3JU DN Fosclin DM8L3JU TI TTLH4J3 DM8L3JU TN Plasmodium DOXP reductoisomerase (Malaria DXR) DM8L3JU MA Inhibitor DM8L3JU RN Fosmidomycin-clindamycin for Plasmodium falciparum Infections in African children. J Infect Dis. 2004 Mar 1;189(5):901-8. DM8L3JU RU https://pubmed.ncbi.nlm.nih.gov/14976608 DM8L7JD DI DM8L7JD DM8L7JD DN Zoniporide hydrochloride DM8L7JD TI TTGSEFH DM8L7JD TN Sodium/hydrogen exchanger 1 (SLC9A1) DM8L7JD MA Inhibitor DM8L7JD RN Zoniporde: a potent and selective inhibitor of the human sodium-hydrogen exchanger isoform 1 (NHE-1). Cardiovasc Drug Rev. 2003 Spring;21(1):17-32. DM8L7JD RU https://pubmed.ncbi.nlm.nih.gov/12595915 DM8M2N3 DI DM8M2N3 DM8M2N3 DN Glycyrrhizin DM8M2N3 TI TTN7BL9 DM8M2N3 TN Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1) DM8M2N3 MA Inhibitor DM8M2N3 RN Discovery of novel dual functional agent as PPARgamma agonist and 11beta-HSD1 inhibitor for the treatment of diabetes. Bioorg Med Chem. 2009 Aug 1;17(15):5722-32. DM8M2N3 RU https://pubmed.ncbi.nlm.nih.gov/19574056 DM8QIRN DI DM8QIRN DM8QIRN DN AMT-011 DM8QIRN TI TTOF3WZ DM8QIRN TN Lipoprotein lipase (LPL) DM8QIRN MA Modulator DM8QIRN RN Alipogene tiparvovec for the treatment of lipoprotein lipase deficiency. Drugs Today (Barc). 2013 Mar;49(3):161-70. DM8QIRN RU https://pubmed.ncbi.nlm.nih.gov/23527320 DM8RBHJ DI DM8RBHJ DM8RBHJ DN Esomeprazole magnesium + Aspirin DM8RBHJ TI TTF1QVM DM8RBHJ TN Gastric H(+)/K(+) ATPase alpha (ATP4A) DM8RBHJ MA Inhibitor DM8RBHJ RN Clinical pipeline report, company report or official report of AstraZeneca (2009). DM8RBHJ RU http://www.astrazeneca.com/_mshost3690701/content/resources/media/investors/AZN-Q2-2009/AZN-Q2-2009-Pipeline.pdf DM8RLJ5 DI DM8RLJ5 DM8RLJ5 DN RAD-1901 DM8RLJ5 TI TTZAYWL DM8RLJ5 TN Estrogen receptor (ESR) DM8RLJ5 MA Modulator DM8RLJ5 RN RAD1901: a novel, orally bioavailable selective estrogen receptor degrader that demonstrates antitumor activity in breast cancer xenograft models. Anticancer Drugs. 2015 Oct;26(9):948-56. DM8RLJ5 RU https://pubmed.ncbi.nlm.nih.gov/26164151 DM8SYTE DI DM8SYTE DM8SYTE DN AIR-insulin DM8SYTE TI TTF89GD DM8SYTE TN Interleukin-2 (IL2) DM8SYTE MA Modulator DM8SYTE RN The AIR inhaled insulin system: system components and pharmacokinetic/glucodynamic data. Diabetes Technol Ther. 2007 Jun;9 Suppl 1:S41-7. DM8SYTE RU https://pubmed.ncbi.nlm.nih.gov/17563303 DM8VO16 DI DM8VO16 DM8VO16 DN KH-902 DM8VO16 TI TTVJ1D8 DM8VO16 TN Vascular endothelial growth factor receptor (VEGFR) DM8VO16 MA Modulator DM8VO16 RN Effects of intravitreal injection of KH902, a vascular endothelial growth factor receptor decoy, on the retinas of streptozotocin-induced diabetic rats. Diabetes Obes Metab. 2012 Jul;14(7):644-53. DM8VO16 RU https://pubmed.ncbi.nlm.nih.gov/22340191 DM8Y12A DI DM8Y12A DM8Y12A DN PH-80 DM8Y12A TI TTOASGR DM8Y12A TN Neuroepithelial receptor (NR) DM8Y12A MA Modulator DM8Y12A RN Patents by Assignee Pherin Corporation. DM8Y12A RU http://patents.justia.com/assignee/pherin-corporation DM8Y4JS DI DM8Y4JS DM8Y4JS DN AC220 DM8Y4JS TI TTGJCWZ DM8Y4JS TN Fms-like tyrosine kinase 3 (FLT-3) DM8Y4JS MA Inhibitor DM8Y4JS RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM8Y4JS RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM8Z0I3 DI DM8Z0I3 DM8Z0I3 DN MF-101 DM8Z0I3 TI TTOM3J0 DM8Z0I3 TN Estrogen receptor beta (ESR2) DM8Z0I3 MA Antagonist DM8Z0I3 RN MF101, a selective estrogen receptor beta modulator for the treatment of menopausal hot flushes: a phase II clinical trial. Menopause. 2009 May-Jun;16(3):458-65. DM8Z0I3 RU https://pubmed.ncbi.nlm.nih.gov/19182698 DM90AG2 DI DM90AG2 DM90AG2 DN Ularitide DM90AG2 TI TTJME02 DM90AG2 TN Atrial natriuretic peptide receptor A (NPR1) DM90AG2 MA Modulator DM90AG2 RN Ularitide for the treatment of acute decompensated heart failure: from preclinical to clinical studies. Eur Heart J. 2015 Mar 21;36(12):715-23. DM90AG2 RU https://pubmed.ncbi.nlm.nih.gov/25670819 DM91LGU DI DM91LGU DM91LGU DN Abexinostat DM91LGU TI TTBH0VX DM91LGU TN Histone deacetylase (HDAC) DM91LGU MA Modulator DM91LGU RN Phase 1 study of the oral histone deacetylase inhibitor abexinostat in patients with Hodgkin lymphoma, non-Hodgkin lymphoma, or chronic lymphocytic leukaemia. Invest New Drugs. 2015 Apr;33(2):423-31. DM91LGU RU https://pubmed.ncbi.nlm.nih.gov/25600050 DM936V7 DI DM936V7 DM936V7 DN GS-9674 DM936V7 TI TTS4UGC DM936V7 TN Farnesoid X-activated receptor (FXR) DM936V7 MA Agonist DM936V7 RN The Nonsteroidal Farnesoid X Receptor Agonist Cilofexor (GS-9674) Improves Markers of Cholestasis and Liver Injury in Patients With Primary Sclerosing Cholangitis. Hepatology. 2019 Sep;70(3):788-801. DM936V7 RU https://pubmed.ncbi.nlm.nih.gov/30661255 DM942HP DI DM942HP DM942HP DN Brivanib DM942HP TI TTUTJGQ DM942HP TN Vascular endothelial growth factor receptor 2 (KDR) DM942HP MA Modulator DM942HP RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DM942HP RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DM94Y6O DI DM94Y6O DM94Y6O DN BMN-701 DM94Y6O TI TTLPC70 DM94Y6O TN Lysosomal alpha-glucosidase (GAA) DM94Y6O MA Modulator DM94Y6O RN Clinical pipeline report, company report or official report of BioMarin Pharma. DM94Y6O RU https://www.bmrn.com/pipeline/igf2-gaa-for-pompe-disease.php DM95IPS DI DM95IPS DM95IPS DN Tivanisiran DM95IPS TI TT50OG3 DM95IPS TN TRPV1 messenger RNA (TRPV1 mRNA) DM95IPS MA Inhibitor DM95IPS RN Tivanisiran, a novel siRNA for the treatment of dry eye disease. Expert Opin Investig Drugs. 2018 Apr;27(4):421-426. DM95IPS RU https://pubmed.ncbi.nlm.nih.gov/29569947 DM97S10 DI DM97S10 DM97S10 DN DP-b99 DM97S10 TI TT6X50U DM97S10 TN Matrix metalloproteinase-9 (MMP-9) DM97S10 MA Inhibitor DM97S10 RN DP-b99 modulates matrix metalloproteinase activity and neuronal plasticity. PLoS One. 2014 Jun 11;9(6):e99789. DM97S10 RU https://pubmed.ncbi.nlm.nih.gov/24918931 DM9CEI5 DI DM9CEI5 DM9CEI5 DN Bevacizumab + Trastuzumab DM9CEI5 TI TTOHSBA DM9CEI5 TN Vascular endothelial growth factor A (VEGFA) DM9CEI5 MA Inhibitor DM9CEI5 RN Clinical pipeline report, company report or official report of Roche (2009). DM9CEI5 RU http://www.roche.com/research_and_development/pipeline/roche_pharma_pipeline.htm DM9CEI5 DI DM9CEI5 DM9CEI5 DN Bevacizumab + Trastuzumab DM9CEI5 TI TT6EO5L DM9CEI5 TN Erbb2 tyrosine kinase receptor (HER2) DM9CEI5 RN Clinical pipeline report, company report or official report of Roche (2009). DM9CEI5 RU http://www.roche.com/research_and_development/pipeline/roche_pharma_pipeline.htm DM9CEI5 DI DM9CEI5 DM9CEI5 DN Bevacizumab + Trastuzumab DM9CEI5 TI TTS4UGC DM9CEI5 TN Farnesoid X-activated receptor (FXR) DM9CEI5 MA Antagonist DM9CEI5 RN Lithocholic acid decreases expression of bile salt export pump through farnesoid X receptor antagonist activity. J Biol Chem. 2002 Aug 30;277(35):31441-7. DM9CEI5 RU https://pubmed.ncbi.nlm.nih.gov/12052824 DM9CMI3 DI DM9CMI3 DM9CMI3 DN H5N1 influenza vaccine DM9CMI3 TI TT3J5ZI DM9CMI3 TN Cell mediated immunity response (CMIR) DM9CMI3 RN Characterization of a whole, inactivated influenza (H5N1) vaccine. Influenza and Other Respiratory Viruses Volume 2, Issue 6, pages 261-266, November 2008. DM9CMI3 RU http://onlinelibrary.wiley.com/doi/10.1111/j.1750-2659.2008.00066.x/full DM9DEYL DI DM9DEYL DM9DEYL DN SD-6010 DM9DEYL TI TTF10I9 DM9DEYL TN Nitric-oxide synthase inducible (NOS2) DM9DEYL MA Inhibitor DM9DEYL RN A 2-year randomised, double-blind, placebo-controlled, multicentre study of oral selective iNOS inhibitor, cindunistat (SD-6010), in patients with symptomatic osteoarthritis of the knee. Ann Rheum Dis. 2013 Feb;72(2):187-95. DM9DEYL RU https://pubmed.ncbi.nlm.nih.gov/23144445 DM9EXGI DI DM9EXGI DM9EXGI DN Bevacizumab + Rituximab DM9EXGI TI TTUE541 DM9EXGI TN Leukocyte surface antigen Leu-16 (CD20) DM9EXGI RN Clinical pipeline report, company report or official report of Roche (2009). DM9EXGI RU http://www.roche.com/research_and_development/pipeline/roche_pharma_pipeline.htm DM9EXGI DI DM9EXGI DM9EXGI DN Bevacizumab + Rituximab DM9EXGI TI TTOHSBA DM9EXGI TN Vascular endothelial growth factor A (VEGFA) DM9EXGI MA Inhibitor DM9EXGI RN Clinical pipeline report, company report or official report of Roche (2009). DM9EXGI RU http://www.roche.com/research_and_development/pipeline/roche_pharma_pipeline.htm DM9EZM0 DI DM9EZM0 DM9EZM0 DN LNP023 DM9EZM0 TI TTA0P7K DM9EZM0 TN Complement factor B (CFB) DM9EZM0 MA Inhibitor DM9EZM0 RN Discovery of 4-((2 S,4 S)-4-Ethoxy-1-((5-methoxy-7-methyl-1 H-indol-4-yl)methyl)piperidin-2-yl)benzoic Acid (LNP023), a Factor B Inhibitor Specifically Designed To Be Applicable to Treating a Diverse Array of Complement Mediated Diseases. J Med Chem. 2020 Jun 11;63(11):5697-5722. DM9EZM0 RU https://pubmed.ncbi.nlm.nih.gov/32073845 DM9FAJM DI DM9FAJM DM9FAJM DN D-5519 DM9FAJM TI TTPNQAC DM9FAJM TN Estrogen-related receptor-alpha (ESRRA) DM9FAJM MA Modulator DM9FAJM RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007199) DM9FAJM RU http://adisinsight.springer.com/drugs/800007199 DM9G5XD DI DM9G5XD DM9G5XD DN IB-MECA DM9G5XD TI TTJFY5U DM9G5XD TN Adenosine A3 receptor (ADORA3) DM9G5XD MA Agonist DM9G5XD RN A role for central A3-adenosine receptors. Mediation of behavioral depressant effects. FEBS Lett. 1993 Dec 20;336(1):57-60. DM9G5XD RU https://pubmed.ncbi.nlm.nih.gov/8262217 DM9GSVQ DI DM9GSVQ DM9GSVQ DN Tasquinimod DM9GSVQ TI TT0TMQG DM9GSVQ TN Calgranulin B (S100A9) DM9GSVQ MA Modulator DM9GSVQ RN Mechanisms of action of tasquinimod on the tumour microenvironment. Cancer Chemother Pharmacol. 2014; 73(1): 1-8. DM9GSVQ RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3889691/ DM9HUYP DI DM9HUYP DM9HUYP DN ZANOTERONE DM9HUYP TI TTS64P2 DM9HUYP TN Androgen receptor (AR) DM9HUYP MA Inhibitor DM9HUYP RN Antiandrogenic steroidal sulfonyl heterocycles. Utility of electrostatic complementarity in defining bioisosteric sulfonyl heterocycles. J Med Chem. 1992 May 15;35(10):1663-70. DM9HUYP RU https://pubmed.ncbi.nlm.nih.gov/1588549 DM9J0KD DI DM9J0KD DM9J0KD DN K-103-IP DM9J0KD TI TTK0943 DM9J0KD TN Prostaglandin G/H synthase (COX) DM9J0KD MA Modulator DM9J0KD RN ClinicalTrials.gov (NCT02089425) An Efficacy and Safety Study for the Treatment of Mild to Moderate Acute Pain Associated With Ankle Strain or Sprain.. U.S. National Institutes of Health. DM9J0KD RU https://clinicaltrials.gov/ct2/show/NCT02089425 DM9J5Q4 DI DM9J5Q4 DM9J5Q4 DN VAL-083 DM9J5Q4 TI TTUTN1I DM9J5Q4 TN Human Deoxyribonucleic acid (hDNA) DM9J5Q4 MA Modulator DM9J5Q4 RN Effect of 1,2:5,6-dianhydrogalactitol and 1,2:5,6-dianhydro-3,4-diacetylgalactitol on DNA synthesis in the cells of melanoma B16, bone marrow, small intestine epithelium, spleen and liver of mice. Biull Eksp Biol Med. 1984 Sep;98(9):301-3. DM9J5Q4 RU https://pubmed.ncbi.nlm.nih.gov/6487788 DM9K3LM DI DM9K3LM DM9K3LM DN MPDL-3280A DM9K3LM TI TT8ZLTI DM9K3LM TN Programmed cell death 1 ligand 1 (PD-L1) DM9K3LM MA Modulator DM9K3LM RN Targeted immunotherapy for non-small cell lung cancer. World J Clin Oncol. 2014 May 10; 5(2): 39-47. DM9K3LM RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4014795/ DM9L1AC DI DM9L1AC DM9L1AC DN SYR-472 DM9L1AC TI TTDIGC1 DM9L1AC TN Dipeptidyl peptidase 4 (DPP-4) DM9L1AC MA Inhibitor DM9L1AC RN SYR-472, a novel once-weekly dipeptidyl peptidase-4 (DPP-4) inhibitor, in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2014 Feb;2(2):125-32. DM9L1AC RU https://pubmed.ncbi.nlm.nih.gov/24622716 DM9LH10 DI DM9LH10 DM9LH10 DN Vadastuximab talirine DM9LH10 TI TTJVYO3 DM9LH10 TN Myeloid cell surface antigen CD33 (CD33) DM9LH10 MA Antagonist DM9LH10 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM9LH10 RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DM9PVHX DI DM9PVHX DM9PVHX DN P2B-001 DM9PVHX TI TT4C8EA DM9PVHX TN Dopamine D3 receptor (D3R) DM9PVHX MA Inhibitor DM9PVHX RN Pharmacology of pramipexole, a dopamine D3-preferring agonist useful in treating Parkinson's disease. Clin Neuropharmacol. 1998 May-Jun;21(3):141-51. DM9PVHX RU https://pubmed.ncbi.nlm.nih.gov/9617505 DM9PVHX DI DM9PVHX DM9PVHX DN P2B-001 DM9PVHX TI TTGP7BY DM9PVHX TN Monoamine oxidase type B (MAO-B) DM9PVHX MA Inhibitor DM9PVHX RN Rasagiline (TVP-1012): a new selective monoamine oxidase inhibitor for Parkinson's disease. Am J Geriatr Pharmacother. 2006 Dec;4(4):330-46. DM9PVHX RU https://pubmed.ncbi.nlm.nih.gov/17296539 DM9PVHX DI DM9PVHX DM9PVHX DN P2B-001 DM9PVHX TI TTEX248 DM9PVHX TN Dopamine D2 receptor (D2R) DM9PVHX MA Inhibitor DM9PVHX RN Pharmacology of pramipexole, a dopamine D3-preferring agonist useful in treating Parkinson's disease. Clin Neuropharmacol. 1998 May-Jun;21(3):141-51. DM9PVHX RU https://pubmed.ncbi.nlm.nih.gov/9617505 DM9QPOU DI DM9QPOU DM9QPOU DN Epoetin zeta DM9QPOU TI TTAUX24 DM9QPOU TN Erythropoietin Receptor (EPOR) DM9QPOU MA Modulator DM9QPOU RN Long-term safety and tolerability of epoetin zeta, administered intravenously, for maintenance treatment of renal anemia. Adv Ther. 2008 Nov;25(11):1215-28. DM9QPOU RU https://pubmed.ncbi.nlm.nih.gov/18931828 DM9R2SD DI DM9R2SD DM9R2SD DN Alilusem DM9R2SD TI TTYJL7K DM9R2SD TN Sodium/potassium transport (Na/K trans) DM9R2SD MA Modulator DM9R2SD RN US patent application no. 8,067,031, Compositions and systems for forming crosslinked biomaterials and associated methods of preparation and use. DM9R2SD RU http://www.google.lv/patents/US8067031 DM9R5J6 DI DM9R5J6 DM9R5J6 DN Tezepelumab DM9R5J6 TI TTHMW3T DM9R5J6 TN Thymic stromal lymphopoietin (TSLP) DM9R5J6 RN Tezepelumab in Adults with Uncontrolled Asthma. N Engl J Med. 2017 Sep 7;377(10):936-946. DM9R5J6 RU https://pubmed.ncbi.nlm.nih.gov/28877011 DM9SKW8 DI DM9SKW8 DM9SKW8 DN AZD5363 DM9SKW8 TI TTAZ05C DM9SKW8 TN RAC-gamma serine/threonine-protein kinase (AKT3) DM9SKW8 MA Modulator DM9SKW8 RN The novel AKT inhibitor afuresertib shows favorable safety, pharmacokinetics, and clinical activity in multiple myeloma. Blood. 2014 Oct 2;124(14):2190-5. DM9SKW8 RU https://pubmed.ncbi.nlm.nih.gov/25075128 DM9SKW8 DI DM9SKW8 DM9SKW8 DN AZD5363 DM9SKW8 TI TTWTSCV DM9SKW8 TN RAC-alpha serine/threonine-protein kinase (AKT1) DM9SKW8 MA Inhibitor DM9SKW8 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM9SKW8 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM9T8OF DI DM9T8OF DM9T8OF DN RQ-00000004 DM9T8OF TI TTLOKXP DM9T8OF TN Gastric H(+)/K(+) ATPase (Proton pump) DM9T8OF MA Modulator DM9T8OF RN N-(2-hydroxyethyl)-N,2-dimethyl-8-{[(4R)-5-methyl-3,4-dihydro-2H-chromen-4-yl]amino}imidazo[1,2-a]pyridine-6-carboxamide (PF-03716556), a novel, potent, and selective acid pump antagonist for the treatment of gastroesophageal reflux disease. J Pharmacol Exp Ther. 2009 Feb;328(2):671-9. DM9T8OF RU https://pubmed.ncbi.nlm.nih.gov/18981288 DM9Y3B5 DI DM9Y3B5 DM9Y3B5 DN CMX-001 DM9Y3B5 TI TTATL6Y DM9Y3B5 TN DNA-dependent DNA polymerase (DPOL) DM9Y3B5 MA Inhibitor DM9Y3B5 RN Detection of Molluscum Contagiosum Virus (MCV) DNA in the Plasma of an Immunocompromised Patient and Possible Reduction of MCV DNA With CMX-001. J Infect Dis. 2012 March 1; 205(5): 794-797. DM9Y3B5 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3274371/ DM9Y3EG DI DM9Y3EG DM9Y3EG DN Guadecitabine DM9Y3EG TI TT6S2FE DM9Y3EG TN DNA [cytosine-5]-methyltransferase 1 (DNMT1) DM9Y3EG MA Inhibitor DM9Y3EG RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM9Y3EG RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM9YI2C DI DM9YI2C DM9YI2C DN ErepoXen DM9YI2C TI TTAUX24 DM9YI2C TN Erythropoietin Receptor (EPOR) DM9YI2C MA Agonist DM9YI2C RN Combination erythropoietin-hydroxyurea therapy in sickle cell disease: experience from the National Institutes of Health and a literature review. Haematologica. 2006 Aug;91(8):1076-83. DM9YI2C RU https://pubmed.ncbi.nlm.nih.gov/16885048 DM9Z4N5 DI DM9Z4N5 DM9Z4N5 DN RA101495 DM9Z4N5 TI TTKANGO DM9Z4N5 TN Complement C5 (CO5) DM9Z4N5 MA Inhibitor DM9Z4N5 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM9Z4N5 RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DMA0WEK DI DMA0WEK DMA0WEK DN Coprexa DMA0WEK TI TT6RVLG DMA0WEK TN Superoxide dismutase Cu-Zn (SOD Cu-Zn) DMA0WEK MA Inhibitor DMA0WEK RN Copper binding by tetrathiomolybdate attenuates angiogenesis and tumor cell proliferation through the inhibition of superoxide dismutase 1. Clin Cancer Res. 2006 Aug 15;12(16):4974-82. DMA0WEK RU https://pubmed.ncbi.nlm.nih.gov/16914587 DMA16IL DI DMA16IL DMA16IL DN NU-100 DMA16IL TI TT4TZ8J DMA16IL TN Interferon-beta (IFNB1) DMA16IL MA Modulator DMA16IL RN PEGylated interferon beta-1a in the treatment of multiple sclerosis - an update. Biologics. 2013; 7: 131-138. DMA16IL RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3686537/ DMA25NO DI DMA25NO DMA25NO DN MK-4214 DMA25NO TI TT5TQ2W DMA25NO TN Granulocyte colony-stimulating factor (CSF3) DMA25NO MA Modulator DMA25NO RN DOI: 10.1038/nbt0710-636a DMA25NO RU http://www.nature.com/nbt/journal/v28/n7/full/nbt0710-636a.html DMA2NYS DI DMA2NYS DMA2NYS DN Lampalizumab DMA2NYS TI TT8D13I DMA2NYS TN Complement factor D (CFD) DMA2NYS MA Inhibitor DMA2NYS RN In Vivo Stability Profiles of Anti-factor D Molecules Support Long-Acting Delivery Approaches. Mol Pharm. 2019 Jan 7;16(1):86-95. DMA2NYS RU https://pubmed.ncbi.nlm.nih.gov/30444371 DMA86FL DI DMA86FL DMA86FL DN Avastin+/-Tarceva DMA86FL TI TTOHSBA DMA86FL TN Vascular endothelial growth factor A (VEGFA) DMA86FL MA Inhibitor DMA86FL RN Clinical pipeline report, company report or official report of Genentech (2009). DMA86FL RU http://www.gene.com/gene/pipeline/status/ DMA86FL DI DMA86FL DMA86FL DN Avastin+/-Tarceva DMA86FL TI TT3PQ2Y DMA86FL TN Plasmodium Dihydroorotate dehydrogenase (Malaria DHOdehase) DMA86FL MA Inhibitor DMA86FL RN Kinetics of inhibition of human and rat dihydroorotate dehydrogenase by atovaquone, lawsone derivatives, brequinar sodium and polyporic acid. Chem Biol Interact. 2000 Jan 3;124(1):61-76. DMA86FL RU https://pubmed.ncbi.nlm.nih.gov/10658902 DMA86FL DI DMA86FL DMA86FL DN Avastin+/-Tarceva DMA86FL TI TTG8HIM DMA86FL TN Dual specificity protein phosphatase 1 (DUSP1) DMA86FL MA Inhibitor DMA86FL RN Bioactivities of simplified adociaquinone B and naphthoquinone derivatives against Cdc25B, MKP-1, and MKP-3 phosphatases. Bioorg Med Chem. 2009 Mar 15;17(6):2276-81. DMA86FL RU https://pubmed.ncbi.nlm.nih.gov/19028102 DMA86FL DI DMA86FL DMA86FL DN Avastin+/-Tarceva DMA86FL TI TT2J34L DMA86FL TN Arachidonate 5-lipoxygenase (5-LOX) DMA86FL MA Inhibitor DMA86FL RN Simple analogues of anthralin: unusual specificity of structure and antiproliferative activity. J Med Chem. 1997 Nov 7;40(23):3773-80. DMA86FL RU https://pubmed.ncbi.nlm.nih.gov/9371243 DMA86FL DI DMA86FL DMA86FL DN Avastin+/-Tarceva DMA86FL TI TTR0SWN DMA86FL TN M-phase inducer phosphatase 2 (MPIP2) DMA86FL MA Inhibitor DMA86FL RN Bioactivities of simplified adociaquinone B and naphthoquinone derivatives against Cdc25B, MKP-1, and MKP-3 phosphatases. Bioorg Med Chem. 2009 Mar 15;17(6):2276-81. DMA86FL RU https://pubmed.ncbi.nlm.nih.gov/19028102 DMA86FL DI DMA86FL DMA86FL DN Avastin+/-Tarceva DMA86FL TI TTZJYKH DMA86FL TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMA86FL MA Inhibitor DMA86FL RN Indoleamine 2,3-dioxygenase is the anticancer target for a novel series of potent naphthoquinone-based inhibitors. J Med Chem. 2008 Mar 27;51(6):1706-18. DMA86FL RU https://pubmed.ncbi.nlm.nih.gov/18318466 DMA86FL DI DMA86FL DMA86FL DN Avastin+/-Tarceva DMA86FL TI TTJNTSI DMA86FL TN Rotamase Pin1 (PIN1) DMA86FL MA Inhibitor DMA86FL RN Overexpression of PIN1 Enhances Cancer Growth and Aggressiveness with Cyclin D1 Induction in EBV-Associated Nasopharyngeal Carcinoma.PLoS One. 2016 Jun 3;11(6):e0156833. DMA86FL RU https://pubmed.ncbi.nlm.nih.gov/27258148 DMACVEI DI DMACVEI DMACVEI DN SPI-2012 DMACVEI TI TT5TQ2W DMACVEI TN Granulocyte colony-stimulating factor (CSF3) DMACVEI MA Modulator DMACVEI RN Company report (Sppirx) DMACVEI RU http://www.sppirx.com/338-spectrum-products-development-spi2012.html DMACYW6 DI DMACYW6 DMACYW6 DN NKTR-214 DMACYW6 TI TT9721Y DMACYW6 TN Interleukin 2 receptor beta (IL2RB) DMACYW6 MA Agonist DMACYW6 RN Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy. Nat Commun. 2020 Jan 31;11(1):661. DMACYW6 RU https://pubmed.ncbi.nlm.nih.gov/32005826 DMAD2OZ DI DMAD2OZ DMAD2OZ DN Palovarotene DMAD2OZ TI TT1Q3IE DMAD2OZ TN Retinoic acid receptor gamma (RARG) DMAD2OZ MA Agonist DMAD2OZ RN Randomised controlled trial for emphysema with a selective agonist of the gamma-type retinoic acid receptor. Eur Respir J. 2012 Aug;40(2):306-12. DMAD2OZ RU https://pubmed.ncbi.nlm.nih.gov/22282548 DMAFPHB DI DMAFPHB DMAFPHB DN TRYPTAMINE DMAFPHB TI TTGP7BY DMAFPHB TN Monoamine oxidase type B (MAO-B) DMAFPHB MA Inhibitor DMAFPHB RN Binding of beta-carbolines at imidazoline I2 receptors: a structure-affinity investigation. Bioorg Med Chem Lett. 2004 Feb 23;14(4):999-1002. DMAFPHB RU https://pubmed.ncbi.nlm.nih.gov/15013009 DMAFPHB DI DMAFPHB DMAFPHB DN TRYPTAMINE DMAFPHB TI TTJQOD7 DMAFPHB TN 5-HT 2A receptor (HTR2A) DMAFPHB MA Inhibitor DMAFPHB RN Central serotonin receptors as targets for drug research. J Med Chem. 1987 Jan;30(1):1-12. DMAFPHB RU https://pubmed.ncbi.nlm.nih.gov/3543362 DMAFPHB DI DMAFPHB DMAFPHB DN TRYPTAMINE DMAFPHB TI TT3WG5C DMAFPHB TN Monoamine oxidase type A (MAO-A) DMAFPHB MA Inhibitor DMAFPHB RN Binding of beta-carbolines at imidazoline I2 receptors: a structure-affinity investigation. Bioorg Med Chem Lett. 2004 Feb 23;14(4):999-1002. DMAFPHB RU https://pubmed.ncbi.nlm.nih.gov/15013009 DMAFUIR DI DMAFUIR DMAFUIR DN DWP-431 DMAFUIR TI TTP3IGX DMAFUIR TN Bone morphogenetic protein 2 (BMP2) DMAFUIR MA Modulator DMAFUIR RN Complications with the use of bone morphogenetic protein 2 (BMP-2) in spine surgery. Spine J. 2014 Mar 1;14(3):552-9. DMAFUIR RU https://pubmed.ncbi.nlm.nih.gov/24412416 DMAJM12 DI DMAJM12 DMAJM12 DN LATIN T1D DMAJM12 TI TTVIMDE DMAJM12 TN Glucagon-like peptide 1 receptor (GLP1R) DMAJM12 MA Agonist DMAJM12 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 249). DMAJM12 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=249 DMALFKX DI DMALFKX DMALFKX DN Savolitinib DMALFKX TI TTNDSF4 DMALFKX TN Proto-oncogene c-Met (MET) DMALFKX MA Inhibitor DMALFKX RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMALFKX RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMAMTGI DI DMAMTGI DMAMTGI DN SD-101 DMAMTGI TI TTSHG0T DMAMTGI TN Toll-like receptor 9 (TLR9) DMAMTGI RN Novel drugs targeting Toll-like receptors for antiviral therapy. Future Virol. 2014 September; 9(9): 811-829. DMAMTGI RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4303062/ DMANKTO DI DMANKTO DMANKTO DN Vatreptacog alfa (activated) DMANKTO TI TTF0EGX DMANKTO TN Coagulation factor VII (F7) DMANKTO MA Modulator DMANKTO RN Recombinant factor VIIa analog (vatreptacog alfa [activated]) for treatment of joint bleeds in hemophilia patients with inhibitors: a randomized controlled trial. J Thromb Haemost. 2012 Jan;10(1):81-9. DMANKTO RU https://pubmed.ncbi.nlm.nih.gov/22470921 DMAPRWV DI DMAPRWV DMAPRWV DN SaxaDapa FDC DMAPRWV TI TTDIGC1 DMAPRWV TN Dipeptidyl peptidase 4 (DPP-4) DMAPRWV MA Modulator DMAPRWV RN Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for type 2 diabetes. Cardiol Rev. 2010 Jul-Aug;18(4):213-7. DMAPRWV RU https://pubmed.ncbi.nlm.nih.gov/20539105 DMAPRWV DI DMAPRWV DMAPRWV DN SaxaDapa FDC DMAPRWV TI TTN7Y4P DMAPRWV TN Sodium/glucose cotransporter 2 (SLC5A4) DMAPRWV MA Modulator DMAPRWV RN Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for type 2 diabetes. Cardiol Rev. 2010 Jul-Aug;18(4):213-7. DMAPRWV RU https://pubmed.ncbi.nlm.nih.gov/20539105 DMAR1YS DI DMAR1YS DMAR1YS DN BMS-986165 DMAR1YS TI TTBYWP2 DMAR1YS TN TYK2 tyrosine kinase (TYK2) DMAR1YS MA Inhibitor DMAR1YS RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMAR1YS RU http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf DMAR9ND DI DMAR9ND DMAR9ND DN Bupropion+Naltrexone DMAR9ND TI TTVBI8W DMAR9ND TN Dopamine transporter (DAT) DMAR9ND MA Inhibitor DMAR9ND RN Anti-obesity drugs. Expert Opin Pharmacother. 2008 Jun;9(8):1339-50. DMAR9ND RU https://pubmed.ncbi.nlm.nih.gov/18473708 DMAR9ND DI DMAR9ND DMAR9ND DN Bupropion+Naltrexone DMAR9ND TI TTAWNKZ DMAR9ND TN Norepinephrine transporter (NET) DMAR9ND MA Inhibitor DMAR9ND RN Anti-obesity drugs. Expert Opin Pharmacother. 2008 Jun;9(8):1339-50. DMAR9ND RU https://pubmed.ncbi.nlm.nih.gov/18473708 DMAR9ND DI DMAR9ND DMAR9ND DN Bupropion+Naltrexone DMAR9ND TI TTN4QDT DMAR9ND TN Opioid receptor (OPR) DMAR9ND MA Antagonist DMAR9ND RN Anti-obesity drugs. Expert Opin Pharmacother. 2008 Jun;9(8):1339-50. DMAR9ND RU https://pubmed.ncbi.nlm.nih.gov/18473708 DMASPWR DI DMASPWR DMASPWR DN CM-2395 DMASPWR TI TT4C8EA DMASPWR TN Dopamine D3 receptor (D3R) DMASPWR MA Agonist DMASPWR RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031127) DMASPWR RU http://adisinsight.springer.com/drugs/800031127 DMASPWR DI DMASPWR DMASPWR DN CM-2395 DMASPWR TI TT5TPI6 DMASPWR TN Opioid receptor sigma 1 (OPRS1) DMASPWR MA Agonist DMASPWR RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031127) DMASPWR RU http://adisinsight.springer.com/drugs/800031127 DMASPWR DI DMASPWR DMASPWR DN CM-2395 DMASPWR TI TTSQIFT DMASPWR TN 5-HT 1A receptor (HTR1A) DMASPWR MA Agonist DMASPWR RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031127) DMASPWR RU http://adisinsight.springer.com/drugs/800031127 DMASPWR DI DMASPWR DMASPWR DN CM-2395 DMASPWR TI TTE0A2F DMASPWR TN Dopamine D4 receptor (D4R) DMASPWR MA Agonist DMASPWR RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031127) DMASPWR RU http://adisinsight.springer.com/drugs/800031127 DMATC14 DI DMATC14 DMATC14 DN Tozadenant DMATC14 TI TTM2AOE DMATC14 TN Adenosine A2a receptor (ADORA2A) DMATC14 MA Antagonist DMATC14 RN Tozadenant (SYN115) in patients with Parkinson's disease who have motor fluctuations on levodopa: a phase 2b, double-blind, randomised trial. Lancet Neurol. 2014 Aug;13(8):767-76. DMATC14 RU https://pubmed.ncbi.nlm.nih.gov/25008546 DMAXTFO DI DMAXTFO DMAXTFO DN H1N1 influenza vaccine DMAXTFO TI TT3J5ZI DMAXTFO TN Cell mediated immunity response (CMIR) DMAXTFO RN Clinical pipeline report, company report or official report of Sanofi Pasteur. DMAXTFO RU http://www.sanofipasteur.com/en/articles/sanofi-pasteur-s-a-h1n1-vaccine-humenza-recommended-by-european-medicines-agency.aspx DMAYC76 DI DMAYC76 DMAYC76 DN Levomequitazine DMAYC76 TI TT7CXIM DMAYC76 TN Histamine receptor (HR) DMAYC76 MA Antagonist DMAYC76 RN Oxidation of histamine H1 antagonist mequitazine is catalyzed by cytochrome P450 2D6 in human liver microsomes. J Pharmacol Exp Ther. 1998 Feb;284(2):437-42. DMAYC76 RU https://pubmed.ncbi.nlm.nih.gov/9454781 DMAYO46 DI DMAYO46 DMAYO46 DN AEZS-108 DMAYO46 TI TT8R70G DMAYO46 TN Gonadotropin-releasing hormone receptor (GNRHR) DMAYO46 MA Modulator DMAYO46 RN Stability of cytotoxic luteinizing hormone-releasing hormone conjugate (AN-152) containing doxorubicin 14-O-hemiglutarate in mouse and human serum in vitro: implications for the design of preclinicalstudies. Proc Natl Acad Sci U S A. 2000 Jan 18;97(2):829-34. DMAYO46 RU https://pubmed.ncbi.nlm.nih.gov/10639165 DMAYTIH DI DMAYTIH DMAYTIH DN S-06911 DMAYTIH TI TTK59TV DMAYTIH TN Vitamin D3 receptor (VDR) DMAYTIH MA Inhibitor DMAYTIH RN Evidence for tissue- and cell-type selective activation of the vitamin D receptor by Ro-26-9228, a noncalcemic analog of vitamin D3. J Cell Biochem. 2003 Feb 1;88(2):267-73. DMAYTIH RU https://pubmed.ncbi.nlm.nih.gov/12520525 DMB06MU DI DMB06MU DMB06MU DN HC-1119 DMB06MU TI TTS64P2 DMB06MU TN Androgen receptor (AR) DMB06MU MA Inhibitor DMB06MU RN Clinical pipeline report, company report or official report of Hinova Pharmaceuticals. DMB06MU RU http://www.hinovapharma.com/en/chanpinxianguan.html DMB147A DI DMB147A DMB147A DN BAX-817 DMB147A TI TTF0EGX DMB147A TN Coagulation factor VII (F7) DMB147A MA Inhibitor DMB147A RN Clinical pipeline report, company report or official report of Baxter. DMB147A RU http://investor.baxter.com/phoenix.zhtml?c=86121&p=irol-newsArticle&id=2025563 DMB24H7 DI DMB24H7 DMB24H7 DN Motavizumab DMB24H7 TI TT57ID8 DMB24H7 TN Respiratory syncytial virus protein F (RSV F) DMB24H7 MA Modulator DMB24H7 RN Motavizumab. Correction in: MAbs. 2010 Sep-Oct; 2(5): 591. DMB24H7 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2759493/ DMB2C0E DI DMB2C0E DMB2C0E DN Elagolix DMB2C0E TI TT8R70G DMB2C0E TN Gonadotropin-releasing hormone receptor (GNRHR) DMB2C0E MA Antagonist DMB2C0E RN Elagolix, a novel, orally bioavailable GnRH antagonist under investigation for the treatment of endometriosis-related pain. Womens Health (Lond Engl). 2015 Jan;11(1):19-28. DMB2C0E RU https://pubmed.ncbi.nlm.nih.gov/25581052 DMB34TZ DI DMB34TZ DMB34TZ DN Grippol TC DMB34TZ TI TT3J5ZI DMB34TZ TN Cell mediated immunity response (CMIR) DMB34TZ RN Clinical pipeline report, company report or official report of Petrovax. DMB34TZ RU http://petrovax.com/medication/catalog/grippallplus/ DMB4JPG DI DMB4JPG DMB4JPG DN CNTX-4975 DMB4JPG TI TTMI6F5 DMB4JPG TN Transient receptor potential cation channel V1 (TRPV1) DMB4JPG MA Agonist DMB4JPG RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMB4JPG RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DMB9587 DI DMB9587 DMB9587 DN Amocarzine DMB9587 TI TT1RS9F DMB9587 TN Acetylcholinesterase (AChE) DMB9587 MA Inhibitor DMB9587 RN Activity, mechanism of action and pharmacokinetics of 2-tert-butylbenzothiazole and CGP 6140 (amocarzine) antifilarial drugs. Acta Trop. 1992 Aug;51(3-4):195-211. DMB9587 RU https://pubmed.ncbi.nlm.nih.gov/1359747 DMBD4K3 DI DMBD4K3 DMBD4K3 DN Selinexor DMBD4K3 TI TTCJUR4 DMBD4K3 TN Exportin-1 (XPO1) DMBD4K3 MA Inhibitor DMBD4K3 RN Inhibition of CRM1-dependent nuclear export sensitizes malignant cells to cytotoxic and targeted agents. Semin Cancer Biol. 2014 August; 0: 62-73. DMBD4K3 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4108511/ DMBEL3Q DI DMBEL3Q DMBEL3Q DN GDC-0853 DMBEL3Q TI TTGM6VW DMBEL3Q TN Tyrosine-protein kinase BTK (ATK) DMBEL3Q MA Inhibitor DMBEL3Q RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMBEL3Q RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DMBER0Q DI DMBER0Q DMBER0Q DN Hu5F9-G4 DMBER0Q TI TT28S46 DMBER0Q TN Leukocyte surface antigen CD47 (CD47) DMBER0Q MA Inhibitor DMBER0Q RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMBER0Q RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMBFE4K DI DMBFE4K DMBFE4K DN Tirapazamine DMBFE4K TI TT0IHXV DMBFE4K TN DNA topoisomerase II (TOP2) DMBFE4K MA Modulator DMBFE4K RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMBFE4K RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMBH4FL DI DMBH4FL DMBH4FL DN BI 655066 DMBH4FL TI TTC1GLB DMBH4FL TN Interleukin-23 (IL23) DMBH4FL RN Anti-IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: Safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol. 2015 Jul;136(1):116-124.e7. DMBH4FL RU https://pubmed.ncbi.nlm.nih.gov/25769911 DMBIZ7H DI DMBIZ7H DMBIZ7H DN ICT-107 DMBIZ7H TI TTMPZ7V DMBIZ7H TN Interleukin 13 receptor alpha-2 (IL13RA2) DMBIZ7H RN Clinical pipeline report, company report or official report of ImmunoCellular Therapeutics. DMBIZ7H RU http://www.imuc.com/pipeline/ict-107 DMBJTVL DI DMBJTVL DMBJTVL DN Isotretinoin DMBJTVL TI TTNHMO8 DMBJTVL TN COVID-19 papain-like proteinase (PL-PRO) DMBJTVL MA Inhibitor DMBJTVL RN ClinicalTrials.gov (NCT04361422) Isotretinoin in Treatment of COVID-19. U.S. National Institutes of Health. DMBJTVL RU https://clinicaltrials.gov/ct2/show/NCT04361422 DMBKWAF DI DMBKWAF DMBKWAF DN Peg-G-CSF DMBKWAF TI TTC70AJ DMBKWAF TN Granulocyte colony-stimulating factor receptor (G-CSF-R) DMBKWAF MA Stimulator DMBKWAF RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1719). DMBKWAF RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1719 DMBPY9Z DI DMBPY9Z DMBPY9Z DN MBG453 DMBPY9Z TI TT1RWL7 DMBPY9Z TN Hepatitis A virus cellular receptor 2 (TIM3) DMBPY9Z RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMBPY9Z RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMBQK0X DI DMBQK0X DMBQK0X DN Algenpantucel-L DMBQK0X TI TTPJ1I3 DMBQK0X TN Galactosyltransferase (GALT) DMBQK0X RN Recent Treatment Advances and Novel Therapies in Pancreas Cancer: A Review. J Gastrointest Cancer. 2014; 45(2): 190-201. DMBQK0X RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4024386/ DMBRQF5 DI DMBRQF5 DMBRQF5 DN ApoC-III DMBRQF5 TI TT3GKN5 DMBRQF5 TN Lipase unspecific (LIP) DMBRQF5 MA Inhibitor DMBRQF5 RN An ABC of apolipoprotein C-III: a clinically useful new cardiovascular risk factor Int J Clin Pract. 2008 May;62(5):799-809. DMBRQF5 RU https://pubmed.ncbi.nlm.nih.gov/18201179 DMBS3UG DI DMBS3UG DMBS3UG DN CORT-125134 DMBS3UG TI TTYRL6O DMBS3UG TN Glucocorticoid receptor (NR3C1) DMBS3UG MA Antagonist DMBS3UG RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMBS3UG RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMBWO5T DI DMBWO5T DMBWO5T DN ODT-8 DMBWO5T TI TTJX3UE DMBWO5T TN Somatostatin receptor type 3 (SSTR3) DMBWO5T MA Inhibitor DMBWO5T RN Somatostatin receptor 1 selective analogues: 3. Dicyclic peptides. J Med Chem. 2005 Jan 27;48(2):515-22. DMBWO5T RU https://pubmed.ncbi.nlm.nih.gov/15658865 DMBWO5T DI DMBWO5T DMBWO5T DN ODT-8 DMBWO5T TI TT2BC4G DMBWO5T TN Somatostatin receptor type 5 (SSTR5) DMBWO5T MA Inhibitor DMBWO5T RN Somatostatin receptor 1 selective analogues: 3. Dicyclic peptides. J Med Chem. 2005 Jan 27;48(2):515-22. DMBWO5T RU https://pubmed.ncbi.nlm.nih.gov/15658865 DMBWO5T DI DMBWO5T DMBWO5T DN ODT-8 DMBWO5T TI TTZ6T9E DMBWO5T TN Somatostatin receptor type 2 (SSTR2) DMBWO5T MA Inhibitor DMBWO5T RN Somatostatin receptor 1 selective analogues: 3. Dicyclic peptides. J Med Chem. 2005 Jan 27;48(2):515-22. DMBWO5T RU https://pubmed.ncbi.nlm.nih.gov/15658865 DMBWO5T DI DMBWO5T DMBWO5T DN ODT-8 DMBWO5T TI TTAE1BR DMBWO5T TN Somatostatin receptor type 4 (SSTR4) DMBWO5T MA Inhibitor DMBWO5T RN Somatostatin receptor 1 selective analogues: 3. Dicyclic peptides. J Med Chem. 2005 Jan 27;48(2):515-22. DMBWO5T RU https://pubmed.ncbi.nlm.nih.gov/15658865 DMBWO5T DI DMBWO5T DMBWO5T DN ODT-8 DMBWO5T TI TTIND6G DMBWO5T TN Somatostatin receptor type 1 (SSTR1) DMBWO5T MA Inhibitor DMBWO5T RN Somatostatin receptor 1 selective analogues: 3. Dicyclic peptides. J Med Chem. 2005 Jan 27;48(2):515-22. DMBWO5T RU https://pubmed.ncbi.nlm.nih.gov/15658865 DMBXR23 DI DMBXR23 DMBXR23 DN BMN-110 DMBXR23 TI TTT9YPO DMBXR23 TN N-acetylgalactosamine 6 sulfatase (GALNS) DMBXR23 MA Modulator DMBXR23 RN Efficacy and safety of enzyme replacement therapy with BMN 110 (elosulfase alfa) for Morquio A syndrome (mucopolysaccharidosis IVA): a phase 3 randomised placebo-controlled study. J Inherit Metab Dis. 2014 Nov;37(6):979-90. DMBXR23 RU https://pubmed.ncbi.nlm.nih.gov/24810369 DMBY31K DI DMBY31K DMBY31K DN Rivoglitazone DMBY31K TI TTZMAO3 DMBY31K TN Peroxisome proliferator-activated receptor gamma (PPAR-gamma) DMBY31K MA Agonist DMBY31K RN A randomized-controlled trial to investigate the effects of rivoglitazone, a novel PPAR gamma agonist on glucose-lipid control in type 2 diabetes. Diabetes Obes Metab. 2011 Sep;13(9):806-13. DMBY31K RU https://pubmed.ncbi.nlm.nih.gov/21492364 DMBY56U DI DMBY56U DMBY56U DN EXISULIND DMBY56U TI TTJ0IQB DMBY56U TN Phosphodiesterase 5A (PDE5A) DMBY56U MA Modulator DMBY56U RN Exisulind induction of apoptosis involves guanosine 3',5'-cyclic monophosphate phosphodiesterase inhibition, protein kinase G activation, and attenuated beta-catenin. Cancer Res. 2000 Jul 1;60(13):3338-42. DMBY56U RU https://pubmed.ncbi.nlm.nih.gov/10910034 DMC4X7L DI DMC4X7L DMC4X7L DN CMS-024-02 DMC4X7L TI TTBH0VX DMC4X7L TN Histone deacetylase (HDAC) DMC4X7L MA Modulator DMC4X7L RN US patent application no. 2012,0302,505, Cyclodextrin-based polymers for therapeutic delivery. DMC4X7L RU http://www.google.com/patents/US20120302505 DMC7W6R DI DMC7W6R DMC7W6R DN Selumetinib DMC7W6R TI TTROQ37 DMC7W6R TN MAPK/ERK kinase kinase (MAP3K) DMC7W6R MA Modulator DMC7W6R RN Intrinsic resistance to selumetinib, a selective inhibitor of MEK1/2, by cAMP-dependent protein kinase A activation in human lung and colorectal cancer cells.Br J Cancer.2012 May 8;106(10):1648-59. DMC7W6R RU https://www.ncbi.nlm.nih.gov/pubmed/22569000 DMC7W6R DI DMC7W6R DMC7W6R DN Selumetinib DMC7W6R TI TTIDAPM DMC7W6R TN ERK activator kinase 1 (MEK1) DMC7W6R MA Inhibitor DMC7W6R RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMC7W6R RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMC7W6R DI DMC7W6R DMC7W6R DN Selumetinib DMC7W6R TI TTTW2NY DMC7W6R TN ERK activator kinase 2 (MEK2) DMC7W6R MA Inhibitor DMC7W6R RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMC7W6R RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMCA6BW DI DMCA6BW DMCA6BW DN Pixykine DMCA6BW TI TT6MP2Z DMCA6BW TN GMCSFR-alpha (CSF2RA) DMCA6BW MA Modulator DMCA6BW RN Phase I/II trial of PIXY321 (granulocyte-macrophage colony stimulating factor/interleukin-3 fusion protein) for treatment of inherited and acquired... Br J Haematol. 1998 Nov;103(2):304-7. DMCA6BW RU https://www.ncbi.nlm.nih.gov/pubmed/9827896 DMCA7FN DI DMCA7FN DMCA7FN DN Exatecan DMCA7FN TI TTGTQHC DMCA7FN TN DNA topoisomerase I (TOP1) DMCA7FN MA Inhibitor DMCA7FN RN Phase I study of topoisomerase I inhibitor exatecan mesylate (DX-8951f) given as weekly 24-hour infusions three of every four weeks. Clin Cancer Res. 2001 Dec;7(12):3963-70. DMCA7FN RU https://pubmed.ncbi.nlm.nih.gov/11751488 DMCDZ15 DI DMCDZ15 DMCDZ15 DN Evacetrapib DMCDZ15 TI TTFQAYR DMCDZ15 TN Cholesteryl ester transfer protein (CETP) DMCDZ15 MA Inhibitor DMCDZ15 RN The dyslipidaemia market. Nat Rev Drug Discov. 2014 Nov;13(11):807-8. DMCDZ15 RU https://pubmed.ncbi.nlm.nih.gov/25323928 DMCF6SX DI DMCF6SX DMCF6SX DN TAK-491 DMCF6SX TI TT8DBY3 DMCF6SX TN Angiotensin II receptor type-1 (AGTR1) DMCF6SX MA Modulator DMCF6SX RN 2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4. DMCF6SX RU https://pubmed.ncbi.nlm.nih.gov/22293555 DMCGWBJ DI DMCGWBJ DMCGWBJ DN Epigallocatechin gallate DMCGWBJ TI TTHPFTS DMCGWBJ TN Plasmodium Beta-hydroxyacyl-ACP dehydratase (Malaria FabZ) DMCGWBJ MA Inhibitor DMCGWBJ RN Inhibition of Plasmodium falciparum fatty acid biosynthesis: evaluation of FabG, FabZ, and FabI as drug targets for flavonoids. J Med Chem. 2006 Jun 1;49(11):3345-53. DMCGWBJ RU https://pubmed.ncbi.nlm.nih.gov/16722653 DMCGWBJ DI DMCGWBJ DMCGWBJ DN Epigallocatechin gallate DMCGWBJ TI TT7AOUD DMCGWBJ TN Fatty acid synthase (FASN) DMCGWBJ MA Inhibitor DMCGWBJ RN Inhibition of Plasmodium falciparum fatty acid biosynthesis: evaluation of FabG, FabZ, and FabI as drug targets for flavonoids. J Med Chem. 2006 Jun 1;49(11):3345-53. DMCGWBJ RU https://pubmed.ncbi.nlm.nih.gov/16722653 DMCGWBJ DI DMCGWBJ DMCGWBJ DN Epigallocatechin gallate DMCGWBJ TI TT84ETX DMCGWBJ TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMCGWBJ MA Inhibitor DMCGWBJ RN Simplified catechin-gallate inhibitors of HIV-1 reverse transcriptase. Bioorg Med Chem Lett. 2001 Oct 22;11(20):2763-7. DMCGWBJ RU https://pubmed.ncbi.nlm.nih.gov/11591519 DMCGWBJ DI DMCGWBJ DMCGWBJ DN Epigallocatechin gallate DMCGWBJ TI TTBE4IR DMCGWBJ TN Plasmodium Oxoacyl-[acyl-carrier protein] reductase (Malaria fabG) DMCGWBJ MA Inhibitor DMCGWBJ RN Inhibition of Plasmodium falciparum fatty acid biosynthesis: evaluation of FabG, FabZ, and FabI as drug targets for flavonoids. J Med Chem. 2006 Jun 1;49(11):3345-53. DMCGWBJ RU https://pubmed.ncbi.nlm.nih.gov/16722653 DMCGWBJ DI DMCGWBJ DMCGWBJ DN Epigallocatechin gallate DMCGWBJ TI TTJ4QE7 DMCGWBJ TN Matrix metalloproteinase-14 (MMP-14) DMCGWBJ MA Inhibitor DMCGWBJ RN Regioselective synthesis of methylated epigallocatechin gallate via nitrobenzenesulfonyl (Ns) protecting group. Bioorg Med Chem Lett. 2009 Aug 1;19(15):4171-4. DMCGWBJ RU https://pubmed.ncbi.nlm.nih.gov/19524436 DMCGWBJ DI DMCGWBJ DMCGWBJ DN Epigallocatechin gallate DMCGWBJ TI TTNX2CS DMCGWBJ TN Plasmodium Enoyl-ACP reductase (Malaria fabI) DMCGWBJ MA Inhibitor DMCGWBJ RN Green tea catechins potentiate triclosan binding to enoyl-ACP reductase from Plasmodium falciparum (PfENR). J Med Chem. 2007 Feb 22;50(4):765-75. DMCGWBJ RU https://pubmed.ncbi.nlm.nih.gov/17263522 DMCGWBJ DI DMCGWBJ DMCGWBJ DN Epigallocatechin gallate DMCGWBJ TI TTLM12X DMCGWBJ TN Matrix metalloproteinase-2 (MMP-2) DMCGWBJ MA Inhibitor DMCGWBJ RN Regioselective synthesis of methylated epigallocatechin gallate via nitrobenzenesulfonyl (Ns) protecting group. Bioorg Med Chem Lett. 2009 Aug 1;19(15):4171-4. DMCGWBJ RU https://pubmed.ncbi.nlm.nih.gov/19524436 DMCGWBJ DI DMCGWBJ DMCGWBJ DN Epigallocatechin gallate DMCGWBJ TI TTE14XG DMCGWBJ TN Squalene monooxygenase (SQLE) DMCGWBJ MA Inhibitor DMCGWBJ RN Ellagitannins and hexahydroxydiphenoyl esters as inhibitors of vertebrate squalene epoxidase. J Nat Prod. 2001 Aug;64(8):1010-4. DMCGWBJ RU https://pubmed.ncbi.nlm.nih.gov/11520216 DMCGWBJ DI DMCGWBJ DMCGWBJ DN Epigallocatechin gallate DMCGWBJ TI TTPLTSQ DMCGWBJ TN Neutrophil elastase (NE) DMCGWBJ MA Inhibitor DMCGWBJ RN Evaluation of human neutrophil elastase inhibitory effect of iridoid glycosides from Hedyotis diffusa. Bioorg Med Chem Lett. 2010 Jan 15;20(2):513-5. DMCGWBJ RU https://pubmed.ncbi.nlm.nih.gov/20004577 DMCHA27 DI DMCHA27 DMCHA27 DN Almonertinib DMCHA27 TI TTGKNB4 DMCHA27 TN Epidermal growth factor receptor (EGFR) DMCHA27 MA Inhibitor DMCHA27 RN Safety, Efficacy, and Pharmacokinetics of Almonertinib (HS-10296) in Pretreated Patients With EGFR-Mutated Advanced NSCLC: A Multicenter, Open-label, Phase 1 Trial. J Thorac Oncol. 2020 Dec;15(12):1907-1918. DMCHA27 RU https://pubmed.ncbi.nlm.nih.gov/32916310 DMCJRL1 DI DMCJRL1 DMCJRL1 DN MGN-1703 DMCJRL1 TI TTSHG0T DMCJRL1 TN Toll-like receptor 9 (TLR9) DMCJRL1 MA Agonist DMCJRL1 RN Maintenance treatment with the immunomodulator MGN1703, a Toll-like receptor 9 (TLR9) agonist, in patients with metastatic colorectal carcinoma and disease control after chemotherapy: a randomised, double-blind, placebo-controlled trial. J Cancer Res Clin Oncol. 2014 Sep;140(9):1615-24. DMCJRL1 RU https://pubmed.ncbi.nlm.nih.gov/24816725 DMCJY35 DI DMCJY35 DMCJY35 DN MIN-101 DMCJY35 TI TTJQOD7 DMCJY35 TN 5-HT 2A receptor (HTR2A) DMCJY35 MA Antagonist DMCJY35 RN Pharmacological profile of the new potent neuroleptic ocaperidone (R 79,598). J Pharmacol Exp Ther. 1992 Jan;260(1):146-59. DMCJY35 RU https://pubmed.ncbi.nlm.nih.gov/1370538 DMCJY35 DI DMCJY35 DMCJY35 DN MIN-101 DMCJY35 TI TT9NXW4 DMCJY35 TN Sigma intracellular receptor 2 (TMEM97) DMCJY35 MA Antagonist DMCJY35 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMCJY35 RU http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf DMCKPG4 DI DMCKPG4 DMCKPG4 DN ABC294640 DMCKPG4 TI TTCN0M9 DMCKPG4 TN Sphingosine kinase 2 (SPHK2) DMCKPG4 MA Modulator DMCKPG4 RN Targeting the sphingosine-1-phosphate axis in cancer, inflammation and beyond. Nat Rev Drug Discov. 2013 Sep;12(9):688-702. DMCKPG4 RU https://pubmed.ncbi.nlm.nih.gov/23954895 DMCMDVR DI DMCMDVR DMCMDVR DN Triptolide DMCMDVR TI TTSXVID DMCMDVR TN Nuclear factor NF-kappa-B (NFKB) DMCMDVR MA Inhibitor DMCMDVR RN Functional p53 is required for triptolide-induced apoptosis and AP-1 and nuclear factor-kappaB activation in gastric cancer cells. Oncogene. 2001 Nov 29;20(55):8009-18. DMCMDVR RU https://pubmed.ncbi.nlm.nih.gov/11753684 DMCMIJ1 DI DMCMIJ1 DMCMIJ1 DN NT0202 DMCMIJ1 TI TTIU98M DMCMIJ1 TN Trace amine-associated receptor-1 (TAAR1) DMCMIJ1 MA Agonist DMCMIJ1 RN Methamphetamine and HIV-1-induced neurotoxicity: role of trace amine associated receptor 1 cAMP signaling in astrocytes. Neuropharmacology. 2014 Oct;85:499-507. DMCMIJ1 RU https://pubmed.ncbi.nlm.nih.gov/24950453 DMCMJRA DI DMCMJRA DMCMJRA DN EGF816 DMCMJRA TI TTGKNB4 DMCMJRA TN Epidermal growth factor receptor (EGFR) DMCMJRA MA Inhibitor DMCMJRA RN Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC. Cancer Discov. 2013 Dec;3(12):1404-15. DMCMJRA RU https://pubmed.ncbi.nlm.nih.gov/24065731 DMCRGY4 DI DMCRGY4 DMCRGY4 DN Karenitecin DMCRGY4 TI TTGTQHC DMCRGY4 TN DNA topoisomerase I (TOP1) DMCRGY4 MA Inhibitor DMCRGY4 RN Characterization of protein kinase chk1 essential for the cell cycle checkpoint after exposure of human head and neck carcinoma A253 cells to a novel topoisomerase I inhibitor BNP1350. Mol Pharmacol.2000 Mar;57(3):453-9. DMCRGY4 RU https://pubmed.ncbi.nlm.nih.gov/10692484 DMCRGY4 DI DMCRGY4 DMCRGY4 DN Karenitecin DMCRGY4 TI TT2GPK3 DMCRGY4 TN DNA topoisomerase (TOP) DMCRGY4 MA Inhibitor DMCRGY4 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMCRGY4 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMCWM03 DI DMCWM03 DMCWM03 DN Unfractionated heparin DMCWM03 TI TT4QPUL DMCWM03 TN Antithrombin-III (ATIII) DMCWM03 MA Modulator DMCWM03 RN Heparin with low affinity to antithrombin III inhibits the activation of prothrombin in normal plasma. Thromb Res. 1982 Nov 15;28(4):487-97. DMCWM03 RU https://pubmed.ncbi.nlm.nih.gov/7164033 DMD1FTP DI DMD1FTP DMD1FTP DN PRO-140 DMD1FTP TI TT2CEJG DMD1FTP TN C-C chemokine receptor type 5 (CCR5) DMD1FTP MA Antagonist DMD1FTP RN Agonist-induced internalization of CC chemokine receptor 5 as a mechanism to inhibit HIV replication. J Pharmacol Exp Ther. 2011 Jun;337(3):655-62. DMD1FTP RU https://pubmed.ncbi.nlm.nih.gov/21389095 DMD2O0L DI DMD2O0L DMD2O0L DN UX-001 DMD2O0L TI TT50QJ3 DMD2O0L TN Influenza Neuraminidase (Influ NA) DMD2O0L MA Inhibitor DMD2O0L RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMD2O0L RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMD2O0L DI DMD2O0L DMD2O0L DN UX-001 DMD2O0L TI TTQ8J1V DMD2O0L TN Bacterial Deoxy-manno-octulosonate cytidylyltransferase (Bact kdsB) DMD2O0L MA Inhibitor DMD2O0L RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMD2O0L RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMD5QRS DI DMD5QRS DMD5QRS DN Ranirestat DMD5QRS TI TTFBNVI DMD5QRS TN Aldose reductase (AKR1B1) DMD5QRS MA Inhibitor DMD5QRS RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2768). DMD5QRS RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2768 DMD6AUX DI DMD6AUX DMD6AUX DN Tat-NR2B9c DMD6AUX TI TT9PB26 DMD6AUX TN Presynaptic density protein 95 (DLG4) DMD6AUX MA Inhibitor DMD6AUX RN Treatment of stroke wit